Upload
others
View
3
Download
0
Embed Size (px)
Citation preview
*Special sy
Session‐B
Poster Ti
clinic dra
treatmen
Poster Ty
Submissi
Primary A
Email: zla
Addition
Shardool
Grant Ca
Karla Mil
Purpose:
undertre
account f
higher m
hip fractu
VA and p
Bone Hea
services t
Methods
a physici
and two
risk facto
Corporat
risk facto
exposure
receive c
protocols
scans, ed
treatmen
ymbols that w
Board # ‐ 1‐0
itle: Implem
amatically in
nt
ype: Descrip
ion Category
Author: Zac
anderson@g
al Authors:
l Patel
nnon
ler
: Osteoporos
eated both n
for 29 perce
mortality rate
ure. The de
particularly p
alth Team (B
to rural Vete
s: Adapted f
an‐led team
APPs, includ
ors, we oper
te Data Ware
ors included
e to high risk
care by the B
s. As approp
ducation on
nt if identifie
2018ASProf
ere not spelled
001
entation of
creases the
ptive Report
y: Ambulato
hary Anders
gmail.com
sis is a silent
ationally an
ent of fragilit
e than wome
livery of oste
poor for rura
BHT), to prov
erans.
rom the Pat
m and include
ding a Clinica
ationalized e
ehouse (CDW
Osteoporos
k medication
BHT, and on
priate, enrol
bone health
ed as either o
SHPMidyfessional
d‐out per the g
a primary pr
number of r
ory Care
son; Departm
t, treatable,
d within the
ty fractures,
en, with one
eoporosis se
al Veterans.
vide efficien
ient‐Aligned
es two progr
al Pharmacy
evidence‐ba
W), a reposit
sis Self‐asses
ns. Veterans
acceptance
lled Veteran
hy lifestyle, a
osteoporosi
yearClinlPoster
guidelines wer
revention, p
rural veteran
ment of Vete
chronic con
e Veteran Aff
25 percent
in three old
ervices is sub
To meet thi
t, evidence‐
d Care Team
ram support
Specialist. T
sed screenin
tory of medi
ssment Tool
s at risk were
evaluated b
s received D
additional fra
s or high‐ris
nicalMeAbstrac
re translated i
population‐b
ns receiving
erans Affairs
dition that i
fairs (VA) He
of total cost
der men dyin
b‐optimal na
is critical nee
‐based prima
(PACT) mod
t assistants, t
To identify V
ng guideline
ical and pha
(OST) score,
e sent enrol
by clinical nu
Dual‐energy
acture risk a
k osteopeni
eetingcts
into unknown
based virtual
osteoporosi
s;
s underdiag
ealthcare sys
ts, and have
ng within on
ationally and
ed, we deve
ary preventi
del, the Rura
two clinical
Veterans wit
es into querie
rmacy recor
, sex, age, an
lment letter
urse educato
X‐ray Absor
assessment,
a. Advanced
characters.
osteoporos
is screening
nosed and
stem. Men
a significant
ne year after
d throughou
eloped a Rur
on osteopor
al BHT consis
nurse educa
th osteoporo
es to the VH
rds. Capture
nd/or chron
rs, invited to
ors via stand
ptiometry (D
and triage fo
d practice
sis
and
tly
r a
t the
al
rosis
sts of
ators,
osis
HA
d
ic
o
ard
DXA)
or
*Special sy
providers
laborato
pharmac
monitore
the Rura
utilized t
choosing
establish
Results:
with 1,24
1,132 (91
participa
accepted
significan
and to re
choosing
Conclusio
Veterans
delivery o
procedur
adapted
outside t
managem
of care.
ymbols that w
s, then evalu
ry evaluatio
cological the
ed therapy a
l BHT betwe
o compare t
g to participa
hment of the
During the f
41 (34.6 perc
1.2 percent;
ting Veteran
d pharmacol
ntly more lik
eceive pharm
g not to part
on: Enrollme
s will receive
of primary p
res without a
to provide o
the VA. Due
ment, Clinica
2018ASProf
ere not spelled
uated the Ve
ns for secon
rapies, and w
at scheduled
een 12/1/201
the proporti
ate and thos
e BHT.
first 15 mont
cent; 95 per
95 percent
ns, 318 (25.6
ogical thera
kely to comp
macological t
icipate.
ent in the Ru
e appropriate
prevention se
adding work
other preven
to their pro
al Pharmacis
SHPMidyfessional
d‐out per the g
eteran’s nee
dary causes
when indica
intervals. F
16 and 02/0
on of osteop
e who did n
ths of implem
cent CI, 33.1
CI, 89.51 to
6 percent; 95
py. Veteran
plete a DXA s
therapy (25.
ural BHT sign
e screening
ervices for o
kload to the
ntative servic
oven benefit
sts are highly
yearClinlPoster
guidelines wer
ed for osteop
s of bone los
ted, initiate
For this study
1/2018. A n
porosis scree
ot participat
mentation, t
10 to 36.22)
92.67) enro
5 percent CI,
ns choosing t
scan (91.2 ve
6 versus 2.4
nificantly inc
and treatme
osteoporosis
primary car
ces, as well
at improvin
y qualified a
nicalMeAbstrac
re translated i
porosis phar
s, discussed
d pharmaco
y, we includ
non‐experim
ening and tr
te, both befo
the Rural BH
Veterans ac
ollees comple
, 23.27 to 28
to participat
ersus 2.6 per
4 percent, P
creases the l
ent for osteo
s provides un
re team and
as instituted
ng patient ou
nd easily inc
eetingcts
into unknown
rmacotherap
risks/benef
ological thera
ded Veterans
mental cohor
reatment in
ore and afte
HT contacted
ccepting enr
eting a DXA
8.13) met cr
te in the Rur
rcent, P less
less than 0.0
likelihood th
oporosis. Th
nique proces
could poten
d in other ca
utcomes in c
corporated i
characters.
py, performe
fits of
apy and
s contacted
rt design was
Veterans
er the
d 3,582 Vete
rollment and
scan. Of tho
iteria for an
ral BHT were
than 0.0001
0001) than t
hat rural
his model fo
sses and
ntially be
are settings
chronic disea
nto this mod
ed
by
s
erans,
d
ose
d
e
1)
those
r the
ase
del
*Special sy
Session‐B
Poster Ti
Pharmac
Poster Ty
Submissi
Primary A
Email: m
Addition
Daniel An
Purpose:
standard
by Decem
and inpa
These sta
CMS. Thi
Methods
assigned
Ambulato
awarene
awarene
Pharmac
was prov
Environm
and asse
storage a
complete
ongoing
Results: A
to‐face p
hazardou
ymbols that w
Board # ‐ 1‐0
itle: Preparin
copeia (USP)
ype: Descrip
ion Category
Author: Mo
sarwar04@g
al Authors:
nzalone
: The U.S. Ph
ds for handlin
mber 1, 2019
tient areas o
andards will
s makes und
s: An Ambula
as the Instit
ory Outpatie
ss and readi
ss. Initial ste
cies. USP 800
vided on app
mental Healt
ss for any st
areas within
ed based on
based on pe
All pharmac
pharmacy hu
us drugs. Sta
2018ASProf
ere not spelled
002
ng outpatien
800
ptive Report
y: Ambulato
nazzah Sarw
gmail.com
harmacopeia
ng of hazard
9. There has
of Pharmacy
be enforcea
derstanding
atory Care O
tutional Lead
ent Care pha
iness. Based
eps were tak
0 champions
propriate rec
th Services a
tructural cha
the pharma
the NIOSH l
ending chang
cy staff was e
uddles about
aff was furth
SHPMidyfessional
d‐out per the g
nt pharmacie
ory Care
war; Universi
al Conventio
dous drugs in
been lots o
y, but not mu
able by the F
what they e
Outpatient P
der for USP 8
armacies ass
on those re
ken to provid
s were select
ceiving, stora
nd Facilities
anges necess
acies. An ass
list of hazard
ges.
educated thr
t upcoming c
er educated
yearClinlPoster
guidelines wer
es at an acad
ity of Illinois
on published
n healthcare
f conversati
uch specific
FDA, state ph
entail in an o
harmacist w
800. An initi
sociated with
esults, steps
de education
ted from eac
age, and han
s Manageme
sary in the P
essment of
dous drugs.
rough depar
changes in re
d about the i
nicalMeAbstrac
re translated i
demic cente
s at Chicago;
Chapter 80
e settings and
on regarding
to an outpat
harmacy boa
outpatient p
was chosen a
ial Gap Analy
h the Acade
were taken
n to the Amb
ch respectiv
ndling of haz
ent was invo
Pharmacies, s
risk templat
Updates to
rtment meet
eceiving, sto
importance
eetingcts
into unknown
er for United
0 in Februar
d will be leg
g preparatio
tient pharm
ards, Joint C
harmacy of v
as the design
ysis was con
mic Center t
for appropr
bulatory Car
ve pharmacy
zardous drug
lved to prov
specifically t
te was create
Policies and
tings, in‐serv
orage, and h
of assessme
characters.
d States
ry 2016. It se
gally enforce
on in the hos
acy setting.
Commission
vital importa
nated person
nducted for 7
to assess
riate departm
re Outpatien
y and educat
gs.
vide consulta
to receiving
ed and
Procedures
vices, and fa
andling of
ent of risk fo
ets
able
spital
and
ance.
n and
7
ment
nt
tion
ation
and
s is
ace‐
rms
*Special sy
for all ha
were edu
storage w
departm
entire de
visited by
with live
resulted
with pha
and prov
Conclusio
educatio
and Phar
staff will
awarene
according
standard
and proc
ymbols that w
zardous dru
ucated first t
was further e
ent with sup
epartment st
y the USP 80
demonstrat
in more ove
rmacy team
vide a visual.
on: This met
n on USP 80
rmacy Mana
lead to incre
ss of employ
g to USP 800
ds within eac
cedures.
2018ASProf
ere not spelled
ugs, including
to facilitate t
educated to
pport from P
taff. After de
00 designate
tion. This les
erall buy‐in. S
m members t
thod ensure
00 in a timely
gers lead to
eased comp
yee safety. T
0 standards
ch respective
SHPMidyfessional
d‐out per the g
g different d
team buy‐in
ensure und
Pharmacy Ad
epartment w
ed person an
ssened the a
Sample asse
o demonstra
s that outpa
y and efficie
overall mor
pliance, decre
The compreh
lead to a be
e pharmacy
yearClinlPoster
guidelines wer
dosage forms
and then pr
erstanding.
dministration
wide in‐servi
nd staff mem
nxiety of sta
essment of ri
ate all requi
atient pharm
nt manner.
re buy‐in fro
eased anxiet
hensive one‐
tter underst
and ensure
nicalMeAbstrac
re translated i
s of the sam
rimary staff
In‐services w
n to further
ces were giv
mbers receiv
aff regarding
isk forms we
red steps in
macies receiv
Support from
om Pharmacy
ty regarding
‐on‐one trai
tanding of h
compliance
eetingcts
into unknown
me drug. Pha
involved in
were provid
ensure buy‐
ven, each ph
ed one‐on‐o
g upcoming
ere complet
handling of
ve the neede
m Pharmacy
y staff. More
g changes, an
ning to com
ow to imple
with new ph
characters.
rmacy mana
receiving an
ed to the en
‐in from the
harmacy was
one educatio
changes and
ed and share
f hazardous d
ed and requ
y Administra
e buy‐in from
nd a heighte
mplete tasks
ement such
harmacy po
agers
nd
ntire
s
on
d
ed
drugs
ired
ation
m
ened
licies
*Special sy
Session‐B
Poster Ti
managem
Poster Ty
Submissi
Primary A
Email: m
Addition
Yong Mo
Suna Chu
Lisa Lea
Ivy Tonnu
Purpose:
include C
patients
assess th
eye exam
outcome
was to de
outcome
Methods
improvem
between
period w
they hav
excluded
diabetes,
Patients
managed
consults.
than 10 g
ymbols that w
Board # ‐ 1‐0
itle: Evaluati
ment
ype: Evaluat
ion Category
Author: Mic
_webb44@y
al Authors:
oon
ung
u‐Mihara
: Within the
Clinical Pharm
referred by
he quality of
ms, and annu
es between t
escribe the r
es achieved b
s: This is an i
ment projec
October 1 ‐
was 18 month
e been refer
d if they had
, received di
who met inc
d by their PC
Data collec
groups], diab
2018ASProf
ere not spelled
003
ion of patien
tive Study
y: Ambulato
chelle Webb
yahoo.com
Veterans He
macy Specia
Primary Car
diabetes ca
ual A1c. This
those manag
referred diab
by CPS comp
institutional
t. Patients w
‐ October 31
hs post index
rred to a CPS
a diagnosis
iabetes care
clusion and e
CP solely and
ted included
betes‐relate
SHPMidyfessional
d‐out per the g
nts referred
ory Care
; VA Long Be
ealth Admin
alists (CPS) w
re Providers
re such as co
project com
ged by PCP a
betes popula
pared to PCP
review boa
were screene
1, 2015. The
x date. From
S within 18 m
of pre‐diabe
outside of t
exclusion cri
d 2) patients
d baseline A
d complicat
yearClinlPoster
guidelines wer
to a clinical
each Healthc
istration (VH
who have pre
(PCP). VHA a
ompletion o
mpared the d
and those re
ation. The se
P.
rd approved
ed to include
index date w
m the screen
months prio
etes, co‐man
the institutio
iteria were c
managed by
1c [grouped
ions [neurop
nicalMeAbstrac
re translated i
pharmacy s
care System
HA), Patient
escriptive au
also has per
of annual foo
diabetic pati
eferred to a C
econdary ob
d, retrospect
e those who
was set as th
ed cohort, p
r to the inde
naged by the
on, or expire
categorized
y CPS via ref
into less th
pathy, neph
eetingcts
into unknown
pecialist for
m;
Aligned Car
uthority and
rformance m
ot exams, an
ients’ charac
CPS. The pri
bjective was
tive chart re
o had PCP vis
he first visit
patients wer
ex date; pati
e endocrinol
ed during the
into two coh
ferrals evide
an 9, 9 – 9.9
ropathy, ret
characters.
r diabetes
re Teams (PA
manage dia
measures to h
nnual/bienni
cteristics and
mary object
to assess A1
view, quality
sit(s) for diab
date. The st
re excluded i
ients were a
logist(s) for
e study perio
horts: 1) pat
enced by ref
9, and greate
tinopathy], a
ACT)
abetic
help
al
d
tive
1c
y‐
betes
udy
if
lso
od.
tients
erral
er
and
*Special sy
diabetes
were the
and A1c
used as a
Results:
PCP grou
patients
comparis
for the A
significan
complica
PCP grou
more like
0.005). B
percent r
in those w
compare
Conclusio
CPS for d
more pat
on insulin
completi
CPS achie
ymbols that w
medication
e percentage
change betw
appropriate.
Of 972 patie
up and 112 p
with A1c les
sons were st
A1c less than
nt baseline c
ations, diagn
up (15.2 vers
ely to have c
Both the CPS
reduction in
with baselin
ed to PCP we
on: Of the p
diabetes man
tients with b
n. Patients m
ng an annua
eved a simila
2018ASProf
ere not spelled
regimens [d
e of patients
ween baselin
ents screene
patients in CP
ss than 9 and
tatistically si
9, between
characteristic
osis of cardi
sus 6.5, 26.3
completed a
and PCP ach
those with
ne A1c greate
ere not statis
atients with
nagement. T
baseline diab
managed by
al A1c. Finall
ar mean A1c
SHPMidyfessional
d‐out per the g
diet only, ora
that comple
ne and end o
ed, 546 patie
PS group. A
d more perc
gnificant (49
9 – 9.9, and
cs were grea
iovascular d
versus 27.7
n annual A1
hieved statis
baseline A1c
er than 10.
stically signif
h elevated A1
Those referre
betes compl
CPS were m
y, it appeare
c reduction c
yearClinlPoster
guidelines wer
al medicatio
eted an ann
of study peri
ents were inc
t baseline, t
entage of pa
9 versus 95,
d greater tha
ater presenc
isease, and i
, and 13 ver
c (92 percen
stically signif
c 9‐9.9, and
However, m
ficant.
1c greater th
ed appeared
ications, dia
more likely to
ed that at 18
compared to
nicalMeAbstrac
re translated i
ons, on insuli
ual A1c chec
iod. T‐Test o
cluded in the
the CPS grou
atients with
21 versus 3,
an 10, respe
ce of patient
insulin users
rsus 47 perce
nt compared
ficant reduc
an average
mean A1c red
han 9, a vast
d to be more
gnosis of ca
o meet the p
8 month foll
o PCP.
eetingcts
into unknown
in]. Outcom
ck during the
or Chi‐Squar
e study with
up had less p
A1c greater
, and 30 vers
ctively. Oth
ts with 2 or m
s in the CPS
ent, respect
d to 81 perce
ctions in A1c
3.2 percent
ductions ach
t majority w
e complicate
rdiovascular
performance
ow up, patie
characters.
me measures
e study perio
re tests were
h 434 patien
percentage o
r than 9, all
sus 2 percen
her statistica
more diabet
compared to
ively). CPS w
ent, P equals
averaging a
reduction in
hieved by CP
ere referred
ed by having
r disease, an
e measure of
ents referred
s
od
e
ts in
of
nt)
lly
tes
o
were
s
a 1.2
n A1c
PS
d to a
g
nd/or
f
d to
*Special sy
Session‐B
Poster Ti
anticoag
Poster Ty
Submissi
Primary A
Email: kn
Addition
Travis Lin
Jeffrey Ja
Clare Fre
Purpose:
anticoag
and treat
anticoag
This stud
Methods
care syst
for at lea
bleeding
or discha
receiving
hours aft
from rem
older, ag
uncontro
dysfunct
inflamma
concomit
potentia
ymbols that w
Board # ‐ 1‐0
itle: Evaluati
ulants
ype: Evaluat
ion Category
Author: Kait
nshumate@y
al Authors:
nneman
ansen
eund
: Oral antico
ulants (DOA
tment of ven
ulation is he
dy aims to de
s: This pilot,
em. Patients
ast 90 days w
event comp
arge associat
g edoxaban,
ter a proced
maining iden
e 75 or olde
olled hyperte
ion, liver dis
atory drug (N
tant antiplat
l predictors
2018ASProf
ere not spelled
004
ing potentia
tive Study
y: Cardiology
tlen Shumat
yahoo.com
oagulation, e
AC), is the rec
nous thromb
emorrhage. B
etermine risk
retrospectiv
s with an act
with a medic
prised the ca
ted with any
receiving da
ure. Control
tified DOAC
er, history of
ension, histo
sease, gastro
NSAID) use,
telet use. Un
significantly
SHPMidyfessional
d‐out per the g
l predictors
y / Anticoag
e; Saint Lou
either in the
commended
boembolism
Bleeding risk
k factors ass
ve case‐cont
tive outpatie
cation posses
ase cohort. A
y diagnosis c
abigatran 75
l patients we
recipients. T
f prior bleed,
ory of stroke
ointestinal d
concomitan
nivariate ana
y associated
yearClinlPoster
guidelines wer
of bleeding
gulation
is VA Health
form of vita
d therapy for
m. The major
k schemas ex
sociated with
trol analysis
ent order fo
ssion ratio o
A bleeding ev
ode for blee
mg twice da
ere randoml
The chosen
, anemia, th
e, tobacco us
isorder, con
t NSAID with
alysis and log
with bleedin
nicalMeAbstrac
re translated i
events in pa
h Care System
min k antag
r stroke prev
safety conc
xist but are v
h bleeding e
was conduc
r apixaban,
of at least 80
vent was de
eding. Patien
aily, or if a b
y selected in
variables fo
rombocytop
se, alcohol a
comitant no
h proton pu
gistic regres
ng event occ
eetingcts
into unknown
atients takin
m;
gonists or dir
vention in at
ern while re
validated in
events while
cted at a sing
rivaroxaban
0 percent, pl
efined as eith
nts were exc
leed occurre
n a 1:4 case‐
r evaluation
penia, diabet
abuse, malig
on‐steroidal
mp inhibitor
ssion were u
currence. Th
characters.
ng direct ora
rect oral
trial fibrillati
eceiving oral
warfarin on
taking DOA
gle VA healt
n, or dabigat
us documen
her an admis
cluded if
ed within 72
‐control ratio
were: age 6
tes mellitus,
nancy, kidne
anti‐
r use, and
sed to ident
his study was
l
ion
nly.
ACs.
h
ran
nted
ssion
2
o
65 or
,
ey
tify
s
*Special sy
approved
Health Ca
Results: A
met inclu
the contr
was eval
significan
between
DOAC, D
identified
anemia,
entered i
interval (
(1.05‐8.3
3.93);p=0
populatio
Conclusio
bleeding
were ass
may aid i
DOACs.
ymbols that w
d by the inst
are System a
A total of 68
usion criteria
rol cohort. O
uated across
nt difference
groups in p
OAC dosed a
d the follow
and history
into the regr
(1.42‐5.98);p
35);p=0.039)
0.045) were
on.
on: This is th
events in pa
ociated with
in identificat
2018ASProf
ere not spelled
titutional rev
and was exe
8 bleeds wer
a. Of the rem
Overall, the b
s the type of
es amongst t
atients age
according to
ing as signifi
of stroke. Ag
ression. Hist
p=0.004), liv
, and anemi
identified a
he first indep
atients recei
h a bleeding
tion of facto
SHPMidyfessional
d‐out per the g
view board a
empt from in
re discovere
maining 1,09
bleed rate w
f DOAC the p
the various D
65 or greate
o the packag
icant possibl
ge 65 or gre
tory of prior
er disease (O
a (Odds rati
s independe
pendent tria
iving a DOAC
event in pat
ors associate
yearClinlPoster
guidelines wer
at the Depar
nformed con
d, however
94 patients, 2
was 5.9 perce
patient rece
DOACs, how
er, age 75 or
e insert, and
le predictors
ater, per pro
bleed (Odds
Odds ratio 2
o 1.99, 95 p
ently associa
al to analyze
C. History of
tients receiv
d with highe
nicalMeAbstrac
re translated i
rtment of Ve
nsent.
only 50 pati
200 were ra
ent. Baseline
eived. In gen
wever signific
r greater, DO
d kidney dys
s: history of
otocol, and t
s ratio 2.91,
.97, 95 perc
ercent confi
ated with ble
the predicti
f prior bleed,
ving a DOAC
er bleeding r
eetingcts
into unknown
eterans Affai
ents with bl
ndomly cho
e demograph
eral, there w
cant differen
OAC indicatio
sfunction. Un
prior bleed,
the listed va
95 percent
cent confide
idence inter
eeding event
ive role of va
, anemia, an
. The results
rates in patie
characters.
irs Saint Lou
eeding even
sen to make
hic informat
were not
nces were fo
on, duration
nivariate ana
, liver diseas
riables were
confidence
nce interval
val (1.02‐
ts in this
arious facto
nd liver disea
s of this anal
ents receivin
uis
nts
e up
tion
ound
on
alysis
se,
e
rs on
ase
lysis
ng
*Special sy
Session‐B
Poster Ti
healthca
Poster Ty
Submissi
Primary A
Email: ch
Addition
Kelly Mo
Tara Butl
Purpose:
and digo
who rem
(GDT). Al
digoxin t
digoxin u
in vetera
evaluate
Methods
impleme
included
October
reviews t
Compute
determin
diagnosis
failure m
Results: T
inactive d
managem
ymbols that w
Board # ‐ 1‐0
itle: Medicat
re system
ype: Evaluat
ion Category
Author: Chr
hristopher.w
al Authors:
ran
ler
: Digoxin sho
xin should o
main symptom
lso, digoxin l
herapy. Retr
use. The prim
ns with AFib
appropriate
s: This MUE
ntation. A p
all veterans
23, 2016 an
to pharmaci
erized Patien
ned to not be
s, AFib/atria
medications,
The MUE inc
digoxin ther
ment of AFib
2018ASProf
ere not spelled
005
tion use eva
tive Study
y: Cardiology
ristopher Wi
wilson122006
ould not be u
only be used
matic after t
laboratory m
rospective c
mary objectiv
b and/or con
eness of digo
was approve
atient list w
s in the healt
d October 2
sts within th
nt Record Sy
e taking digo
l flutter diag
concomitan
cluded a rev
apy. The ma
b. Digoxin wa
SHPMidyfessional
d‐out per the g
aluation of d
y / Anticoag
lson; Sherid
used as mon
in heart fail
treatment w
monitoring s
linical trials
ve of this M
ngestive hea
oxin monitor
ed by the Ph
as generate
thcare syste
2, 2017. Pat
he healthcar
ystem (CPRS)
oxin. The fol
gnosis, digox
t AFib medic
view of 98 ve
ajority of vet
as found to b
yearClinlPoster
guidelines wer
igoxin utiliza
gulation
an VA Medic
notherapy fo
ure with red
with appropri
hould occur
have provid
UE was to ev
rt failure (CH
ring.
harmacy and
d from Micr
m with a dig
tients were d
e system. Pa
). Veterans w
lowing data
xin prescript
cations, and
eterans. Eigh
terans (75.5
be prescribe
nicalMeAbstrac
re translated i
ation at a ru
cal Center;
or rate contr
duced ejecti
iate guidelin
r at least ann
ded evidence
valuate pres
HF). A secon
d Therapeuti
rosoft SQL on
goxin prescr
distributed f
atient charts
were exclude
were collec
ion informat
lab monitor
ht veterans w
percent) we
ed as monot
eetingcts
into unknown
ral Veterans
rol in atrial f
on fraction (
ne directed m
nually in pati
e of increase
scribing prac
ndary object
ics (P&T) Co
n October 2
iption issued
for retrospec
s were acces
ed upon cha
cted: age, se
tion, concom
ring informa
were exclud
ere receiving
herapy for A
characters.
s Affairs
ibrillation (A
(HFrEF) patie
medical ther
ients receivi
ed mortality
ctices of digo
ive was to
mmittee pri
3, 2017 that
d between
ctive chart
ssed through
art review if
ex, heart failu
mitant heart
ation.
ed due to
g digoxin for
AFib rate con
AFib),
ents
rapy
ng
with
oxin
ior to
t
h the
ure
t
r
ntrol
*Special sy
in 7 patie
was miss
had a dia
Digoxin u
chart rev
(Scr), pot
patients
deemed
only 25 p
Conclusio
enzyme (
based be
considere
digoxin t
digoxin t
and reco
prescribe
ymbols that w
ents (7.7 per
sing in 12 pa
agnosis of he
use was dee
views in 73 p
tassium (K),
(41.1 percen
appropriate
patients (27.
on: Patients
(ACE) inhibit
eta blocker. P
ed for aldost
herapy with
roughs to at
mmendatio
ers via notes
2018ASProf
ere not spelled
rcent). A tota
tients (41.4
eart failure w
med approp
patients (75.
and magnes
nt) had a dig
e (based on a
8 percent).
with HFrEF
tor or an ang
Patients wit
terone anta
in this healt
t least annua
ns for optim
s entered int
SHPMidyfessional
d‐out per the g
al of 29 patie
percent) of
with preserv
priate based
5 percent). T
sium (Mg) dr
goxin trough
at least annu
may benefit
giotensin II r
h an ejection
gonist thera
thcare system
ally. Results
mizing digoxin
to patient’s c
yearClinlPoster
guidelines wer
ents (32.2 p
patients wit
ed ejection
on clinical ju
The majority
rawn within
drawn in th
ual monitori
t from the a
receptor bloc
n fraction le
apy. The grea
m involves in
of this MUE
n use and la
charts.
nicalMeAbstrac
re translated i
ercent) had
th HFrEF. On
fraction wit
udgement o
y of veterans
the past yea
he past year.
ng of Scr, K,
ddition of an
cker (ARB) in
ss than 35 p
atest area fo
ncreasing th
were prese
boratory mo
eetingcts
into unknown
HFrEF. Appr
nly 2 patient
hout a diagn
of pharmacis
s had a seru
ar. However
. Digoxin mo
MG, and dig
n angiotensi
n addition to
percent shou
or improvem
he monitorin
ented to the
onitoring we
characters.
ropriate GDT
s (0.22 perce
nosis of AFib
sts performin
m creatinine
r, only 37
onitoring wa
goxin trough
in‐convertin
o an evidenc
uld also be
ment regardi
ng frequency
P&T commi
ere provided
T
ent)
b.
ng
e
s
h) in
g
ce
ng
y of
ttee,
d to
*Special sy
Session‐B
Poster Ti
populatio
Poster Ty
Submissi
Primary A
Email: sia
Addition
Lorrie Str
Randell M
Allen She
Purpose:
populatio
dashboa
Pharmac
Pharmac
however
the partn
remote a
services f
Methods
in Septem
pharmac
introduct
and subs
populatio
clinical p
compute
cell phon
prescript
Other act
ymbols that w
Board # ‐ 1‐0
itle: Implem
on managem
ype: Descrip
ion Category
Author: Sian
an.carr‐lope
al Authors:
rohecker
Miyahara
ek
: Veterans A
on managem
rds facilitate
cy dashboard
cy need intro
r space and a
nership betw
access to ele
for Veterans
s: A collabor
mber of 201
cists, provide
tory pharma
sequently ap
on health ex
harmacy spe
erized patien
nes. Student
tion drug mo
tivities inclu
2018ASProf
ere not spelled
006
enting a Vet
ment
ptive Report
y: Chronic /
n Carr‐Lopez
Affairs (VA) N
ment dashbo
e manageme
ds facilitate l
oductory pra
availability a
ween a VA Pr
ectronic med
s.
ration betwe
5. Pharmacy
e population
acy practice
pproved as a
xperiences a
ecialists. Stu
nt record sys
s focus on th
onitoring pro
de ordering
SHPMidyfessional
d‐out per the g
terans Affair
Managed Ca
z; VA Northe
Northern Cal
oards to iden
ent of chroni
laboratory m
actice experi
t medical fa
rimary Care
dical records
een NCHCS a
y students, u
n manageme
experience
required co
re conducte
udents are gr
stem (CPRS)
he VA opioid
ogram (PDM
laboratory t
yearClinlPoster
guidelines wer
rs collaborat
are
ern California
ifornia Healt
ntify Veteran
ic conditions
monitoring o
ences that p
cilities may
Service and
for student
and Universit
under the dir
ent services f
(IPPE) electi
ourse beginn
ed at the univ
ranted remo
and use per
d safety initia
MP) activities
tests for me
nicalMeAbstrac
re translated i
tion with a s
a Health Car
th Care Syst
ns requiring
s such as dia
of specific me
prepare stud
limit access
a School of
ts to provide
ty of the Pac
rect supervis
for Veterans
ve course w
ning April 20
versity by st
ote access pr
rsonally own
ative, specif
s and review
edication saf
eetingcts
into unknown
chool of pha
re System;
em (NCHCS)
intervention
abetes and c
edications.
dents for adv
ibility. This p
Pharmacy t
e population
cific (UOP) w
sion of VA c
s within NCH
was piloted in
18 with 60 s
tudents prec
rivileges to t
ned laptops a
fically perfor
w of urine dru
fety, calling p
characters.
armacy for
) utilizes
ns. Primary C
chronic pain.
Schools of
vanced prac
poster descr
hat utilizes
manageme
was establish
linical
HCS. An
n August 201
students. Th
cepted by VA
the VA
and VA prov
rming
ug screen re
patients with
Care
.
tice,
ribes
nt
hed
16
he
A
vided
sults.
h
*Special sy
upcomin
facilitatin
documen
additiona
first day
health ac
dashboa
Results: T
staff trav
HR office
was exce
have assu
missed im
develope
reminder
appointm
student a
opioid th
week. Th
improvem
NCHCS w
Vaccine a
Hepatitis
Conclusio
utilizing r
while add
are provi
educatin
team to a
ymbols that w
g appointme
ng annual he
nt progress n
al signers to
of the cours
ctivities and
rd metrics a
Three proce
vel to UOP to
e and reducin
essive for VA
umed these
mmunization
ed a report t
r for immun
ment and pro
activities are
herapy within
his has enabl
ment of the
was not meet
and Meningo
s B and appr
on: The colla
remote acce
dressing the
ided real‐wo
g patients, n
address qua
2018ASProf
ere not spelled
ents to educ
emoglobin A
notes in CPR
the progres
se regarding
again on at
re monitore
ess improvem
o conduct fin
ng travel tim
A staff, two U
responsibili
ns at their p
that identifie
izations. Thi
ovide educa
e available in
n NCHCS. St
led over 99%
quarterly PD
ting immuni
ococcal Vacc
oaching the
aboration be
ess to CPRS m
e limitations
orld introduc
navigating CP
lity measure
SHPMidyfessional
d‐out per the g
cate about th
A1C testing fo
RS, and comm
ss note. Stud
their experi
the end of t
ed.
ment activiti
ngerprinting
me for stude
UOP staff be
ties. The ori
rior appoint
es Veterans w
s enables th
tion about t
n two domai
udents com
% completion
DMP measu
zation goals
cine. Studen
goal for HPV
etween a VA
meets many
for work spa
ctory experie
PRS and doc
es and suppo
yearClinlPoster
guidelines wer
he importan
or patients w
municate wi
dents compl
ience and co
the IPPE. Add
es were imp
g and picture
nts. Becaus
came VA wit
ginal immun
ment. The V
with upcom
he students t
he benefits
ns. Over 4,7
plete approx
n of the ann
re from 39%
s for Human
nts’ efforts re
V.
A Primary Ca
objectives.
ace and com
ences with p
cumenting p
ort populatio
nicalMeAbstrac
re translated i
nce of pendin
with diabete
th other hea
lete a baseli
ompetence p
ditionally, ch
plemented. V
e taking, red
e paperwor
thout comp
nization repo
VA clinical ap
ing appointm
to call vetera
of immuniza
700 Veterans
ximately 300
nual PDMP re
% to 58% bet
Papilloma V
esulted in m
are Service a
VA’s teachin
mputers at th
population m
rogress note
on health ac
eetingcts
into unknown
ng immuniza
es mellitus. S
alth care pro
ne assessme
performing p
hanges in th
VA Human R
ucing foot tr
k for studen
ensation em
ort identifie
pplications c
ments and a
ans prior to
ations. The
s are prescri
0 PDMP pro
equirement
tween April a
Vaccine (HPV
meeting the m
nd a School
ng mission is
he medical f
management
es. NCHCS h
ctivities.
characters.
ations, and
Students
oviders by ad
ent during th
population
e clinical
Resources (H
raffic into th
nt onboardin
mployees and
d Veterans w
oordinator
an active clin
the
outcomes o
ibed chronic
gress notes
and an
and June 20
V), Hepatitis
measure for
of Pharmac
s accomplish
acility. Stude
t including
as an additio
dding
he
HR)
he VA
ng
d
who
nical
of
c
per
018.
B
cy
hed
ents
onal
*Special sy
Session‐B
Poster Ti
patients
Poster Ty
Submissi
Primary A
Email: ts
Addition
Shawn D
Bernadea
Brien Tho
Kelly Mo
Purpose:
than a th
medicati
consisten
availabili
appointm
titration
improvem
clinical p
Methods
Committ
Almanac
hyperten
or diasto
with or w
excluded
pain, alco
enrolled
following
ymbols that w
Board # ‐ 1‐0
itle: Expansi
at a Veteran
ype: Evaluat
ion Category
Author: Tale
teir@gmail.
al Authors:
alton
ane Roth
ompson
ran
: Hypertensi
hird of the ve
on dose adju
nt follow up
ty due to an
ments to opt
and to ensu
ment projec
harmacy ser
s: This quaili
ee and deem
, a performa
nsion, were a
olic blood pre
without diab
d during initi
ohol withdra
in the Pharm
g data was c
2018ASProf
ere not spelled
007
on of clinica
ns Affairs he
tive Study
y: Chronic /
er Steir; She
com
on is the mo
eteran popu
ustments, fr
are often re
nnual follow
timize care. T
re adequate
t is to impro
rvices.
ty improvem
med IRB app
ance measur
above blood
essure great
etes, and wr
al chart revi
awal, acute m
macotherapy
ollected dur
SHPMidyfessional
d‐out per the g
al pharmacy
althcare sys
Managed Ca
ridan VA He
ost common
lation. To ad
requent lab m
equired. Prim
up appointm
These interm
e blood pres
ove hyperten
ment project
proval was n
re tool, patie
d pressure go
ter than 90 m
ritten conse
ew if they h
mental healt
y Clinic, or d
ring intial ch
yearClinlPoster
guidelines wer
services for
tem: a quali
are
althcare Sys
chronic con
dequately tr
monitoring,
mary care pr
ment, inhibi
mittent appo
sure control
nsion contro
t was approv
ot required.
ents were in
oal (systolic
mmHg), had
nt from the
ad an acute
th decompe
diagnosed wi
art review: c
nicalMeAbstrac
re translated i
the manage
ty improvem
stem;
ndition amon
reat hyperte
non‐pharma
roviders ofte
iting the abi
ointments ar
l. The prima
ol through th
ved by the P
Based on d
cluded if the
blood press
a diagnosis
provider an
cause of hy
ensation), me
ith congestiv
comorbiditie
eetingcts
into unknown
ement of hyp
ment project
ng veterans,
nsive patien
acologic trea
en have limit
lity for inter
re crucial fo
ry objective
he expansion
Pharmacy an
ata within th
ey had a dia
ure greater
of ischemic
nd patient. P
ypertension (
edical emerg
ve heart fail
es, allergies,
characters.
pertensive
t
, affecting m
nts, multiple
atment, and
ted clinic
rmittent
r medication
of this qual
n of establish
nd Therapeut
he Primary C
gnosis of
than 140 mm
c heart disea
atients were
(i.e. uncontr
gency, alrea
ure. The
vitals, labs,
more
d
n
ity
hed
tics
Care
mHg
ase,
e
rolled
dy
and
*Special sy
past anti
chart rev
pharmac
outcome
based on
hyperten
the VA/D
Results:
hyperten
were ma
percent.
(11), and
systolic b
completi
diastolic
visit whe
percent o
goal at th
titrated u
their med
included
Conclusio
patient’s
to ensure
professio
according
allow tim
national
larger po
ymbols that w
hypertensiv
view was com
cy interventio
es. The prima
n the Depart
nsion. The se
DoD guidelin
Seventeen p
nsion. The av
les. The ave
At baseline
d angiotensin
blood pressu
on of the inv
blood press
en blood pre
of patients m
he completio
up and one m
dications an
two with lis
on: Pharmac
blood press
e proper blo
onals as the
g to recomm
mely and acc
metrics. Fur
opulation at
2018ASProf
ere not spelled
e medicatio
mpleted to c
ons, and me
ary outcome
ment of Vet
econdary out
es, medicati
patient were
verage age o
rage athero
patient mos
n II receptor
ure was 150.
vention win
ure was 75.4
ssure was ch
met blood pr
on of clinic. T
medication w
d six patient
sinopril, one
cist interven
sures and im
ood pressure
majority of p
mended proc
urate assess
rther expans
this facility
SHPMidyfessional
d‐out per the g
ns trialed. U
collect vitals,
edication adh
e was the pe
teran Affairs
tcomes inclu
ion adheren
e enrolled int
of patient se
sclerotic car
st patients w
blocker (AR
9 mm Hg an
dow, the ave
4 mm Hg. Tw
hecked man
ressure at go
Three medic
was tapered
ts required p
with hydroc
ntion led to a
mproved bloo
e checks are
patients wer
cedures. Add
sment of the
sion of this p
yearClinlPoster
guidelines wer
Upon comple
, labs, medic
herence to a
ercentage of
/Departmen
uded approp
ce, and adve
to the Pharm
en in clinic w
rdiovascular
were taking a
RBs) (7). Prio
nd diastolic b
erage systol
welve patien
ually in clini
oal and 17.6
cations were
d off. Eleven
pharmacist i
chlorothiazid
accurate ass
od pressure
being perfo
re meeting g
ditionally, pr
e patient and
project may a
nicalMeAbstrac
re translated i
etion of the i
cation chang
analyze the p
patients tha
nt of Defens
priate medic
erse effects
macotherapy
was 71.4 yea
disease (AS
aspirin (16),
or to clinic e
blood pressu
ic blood pre
nts were con
c by the pha
6 percent did
e initiated in
patients rep
ntervention
de and one t
essment and
control. Co
rmed in clin
goal when p
roper docum
d to ensure t
allow for im
eetingcts
into unknown
intervention
ges, adverse
primary and
at met goal
e (VA/DoD)
cations presc
of medicatio
y Clinic to be
ars old. All p
CVD) 10‐yea
statins (16),
nrollment, t
ure was 81.9
essure was 1
nsidered at g
armacist. Ult
d not meet b
n clinic, one m
ported being
n. Adverse dr
to beta bloc
d document
ontinued edu
ic by healthc
ressures we
mentation is
the facility is
proved outc
characters.
n window, a
e effects, oth
secondary
blood pressu
guidelines f
cribed follow
ons.
e managed f
atient enrol
ar risk was 3
, beta blocke
he average
9 mm Hg. At
134.9 mm Hg
goal upon in
timately, 82.
blood pressu
medication w
g adherent t
rug reaction
kers.
tation of
ucation is ne
care
ere checked
essential to
s meeting
comes in the
final
her
ure
or
wing
for
led
6
ers
the
g and
itial
.4
ure
was
o
s
eeded
e
*Special sy
Session‐B
Poster Ti
healthca
Poster Ty
Submissi
Primary A
Email: ts
Addition
Kelly Mo
Tara Bult
Purpose:
postmen
that are d
bisphosp
additiona
extended
fractures
Therefor
therapy a
as appro
Methods
Committ
veterans
between
appropri
chart rev
Compute
determin
race; hei
bone min
kidney fu
ymbols that w
Board # ‐ 1‐0
itle: Medicat
re system
ype: Evaluat
ion Category
Author: Tale
teir@gmail.
al Authors:
ran
ter
: Literature s
opausal wo
diagnosed w
phonate ther
al benefit. St
d duration d
s, non‐verteb
e, this MUE
and recomm
priate.
s: This medic
ee. A patien
in a rural VA
3/14/2017
ate use of b
views to pha
erized Patien
ned not to be
ght; weight;
neral density
unction, liver
2018ASProf
ere not spelled
008
tion use eva
tive Study
y: Chronic /
er Steir; She
com
supports bis
men with os
with osteopo
rapy has bee
tudies have
oes not lead
bral fracture
was conduc
mendations t
cation use ev
nt list was ge
A healthcare
and 3/14/20
isphosphona
rmacists wit
nt Record Sy
e taking a bi
prescription
y; indication
r function, c
SHPMidyfessional
d‐out per the g
aluation of b
Managed Ca
ridan VA He
phosphonat
steoporosis a
orosis receive
en associate
found that u
d to a statist
es, or clinical
cted to asses
to providers
valuation wa
enerated fro
e system wit
018. Educati
ate therapy.
thin this faci
ystem (CPRS)
sphosphona
ns character
for use and
alcium, vitam
yearClinlPoster
guidelines wer
isphosphona
are
althcare Sys
tes use for th
and men wit
e the most b
d with incre
utilization of
ically signific
l fractures.
ssed the app
were made
as approved
m Microsoft
th an active b
ion was prov
. Patients we
lity. Patient
). Veterans w
ate. The follo
ristics; calciu
d documenta
min D and TS
nicalMeAbstrac
re translated i
ate therapy
stem;
he preventio
th osteoporo
benefit. Long
ased risk of
f bisphospho
cant increas
propriatenes
to deprescr
d by Pharma
t SQL on 3/1
bisphosphon
vided to pha
ere then dist
charts were
were exclude
owing data w
um and vitam
ation on cov
SH; history o
eetingcts
into unknown
within a Vet
on of fractur
osis. Specific
g‐term utiliz
side effects
onate therap
e in clinical v
ss of active b
ribe bisphosp
cy and Thera
14/2018 that
nate prescri
armacists reg
tributed for
e accessed th
ed upon cha
were collect
min D supple
er sheet; lab
of fractures
characters.
teran Affairs
res in
cally, patien
zation of
without
py for an
vertebral
bisphosphon
phonate the
apeutics
t included al
ption issued
garding
retrospectiv
hrough the
art review if
ed: age; sex
ementation;
bs including
and side eff
s
ts
nate
erapy
l
d
ve
x;
fects.
*Special sy
Recomm
vitamin D
entered i
Results: A
34.3 perc
problem
bisphosp
ordered
bisphosp
lacked ca
initiating
supplem
supplem
appropri
currently
recomme
Conclusio
warrante
renewal
reminder
monitori
bisphosp
poor ren
ymbols that w
endations fo
D supplemen
into patient
A majority o
cent of patie
. Bone mine
phonate ther
at next follo
phonate ther
alcium suppl
g calcium sup
entation in 3
entation due
ate in 65.7 p
y on treatme
endation to
on: Continue
ed. Encourag
of bisphosph
rs to prompt
ng data and
phonate ther
al function a
2018ASProf
ere not spelled
or continuat
ntation and f
charts.
of patients w
ents have an
ral density d
rapy, howev
ow up in 62.9
rapy are also
ementation
pplementati
37.1 percent
e to history
percent of pa
ent and to co
stop bispho
ed assessme
ge providers
honate ther
t providers t
allow for m
rapy in patie
and low risk
SHPMidyfessional
d‐out per the g
tion or disco
future moni
were receivin
n indication f
data was ava
ver a follow u
9 percent of
o receiving v
(65.7 perce
on in 62.9 p
t of patients
of kidney sto
atients at th
ontinue in 60
sphonate th
ent of active
and pharma
apy to ensur
to order upd
monitoring of
ents that are
of fracture.
yearClinlPoster
guidelines wer
ntinuation o
toring was p
ng bisphosph
for bisphosp
ailable for re
up bone min
patients. A
vitamin D sup
ent). Addition
ercent of pa
s. One patien
ones. Bispho
e start of th
0 percent of
herapy was m
bisphospho
acists to asse
re the need
dated bone m
f bisphospho
e inappropria
nicalMeAbstrac
re translated i
of bisphosph
provided to
honates for
phonate ther
eview in 80 p
neral density
majority of
pplementati
nally, pharm
atients and in
nt was not st
osphonate t
herapy, 68.6
f patients. T
made in 31.4
onate therap
ess bisphosp
for continue
mineral dens
onate therap
ate including
eetingcts
into unknown
honate ther
prescribers v
primary oste
rapy listed a
percent of pa
y was recom
patient rece
ion (62.9 pe
macists recom
nitiating vita
tarted on ca
herapy was
percent of p
Therefore the
4 percent of
py upon rene
phonate the
ed use. Utiliz
sity scans co
py. Discoura
g those with
characters.
apy, calcium
via notes
eoporosis. O
s an active
atients rece
mended to
eiving
rcent), howe
mmended
amin D
alcium
deemed
patients
e
patients.
ewal is
erapy upon
zation of clin
ould increase
ge the use o
osteopenia
m and
Only
iving
be
ever
nical
e
of
,
*Special sy
Session‐B
Poster Ti
atherosc
Poster Ty
Submissi
Primary A
Email: m
Addition
Raju Kon
Balakesh
Purpose:
mortality
have wit
most dra
substant
establish
evaluatin
Methods
wards, su
months.
physical
to gather
Blood Pre
introduce
each pat
sample. Q
to determ
of the pr
time, usu
scores w
developi
ymbols that w
Board # ‐ 1‐0
itle: Estimat
lerosis cardi
ype: Evaluat
ion Category
Author: Mit
iitra38@gm
al Authors:
eri
hava Ramaia
: Cardiovasc
y in both eco
nessed majo
amatic advan
ially reduce
hed CVD. The
ng risk factor
s: Prospectiv
urgical ward
The require
examination
r informatio
essure (BP),
ed to QRISK
ient was det
QRISK and A
mine an indi
obability tha
ually 10 year
ere used to
ng CVD in th
2018ASProf
ere not spelled
009
ion of cardio
ovascular di
tive Study
y: Clinical Se
ra Bakhshes
mail.com
h
ular disease
onomically w
or strides in
nce has been
the likelihoo
e purpose of
rs using QRIS
ve observatio
s, and high i
ed data was
n of the med
n from patie
family histo
and ASCVD
termined an
ASCVD risk as
vidual's cha
at a person w
rs. Results ha
classify indiv
he next few y
SHPMidyfessional
d‐out per the g
ovascular dis
isease (ASCV
ervices Mana
sh; KARNATA
s (CVD) are
well‐develop
the prevent
n the demon
od of recurre
f this study is
SK and ASCV
onal study c
intensive car
collected in
dication with
ents. The age
ory and thera
risk score ca
d risk score
ssessment to
nces of deve
will develop
ave altogeth
viduals acco
years of the
yearClinlPoster
guidelines wer
sease (CVD)
VD) risk asse
agement
AKA COLLEG
currently on
ed as well a
ion of CVDs
nstration tha
ent major co
s to predict
VD risk asses
onducted in
re unit (HICU
form case s
h patient is a
e, sex, social
apeutic man
alculators an
was observe
ools, are am
eloping card
cardiovascu
her, 257 case
ording to Low
individual’s
nicalMeAbstrac
re translated i
events by u
essments too
E OF PHARM
ne of the ma
s developing
through mo
at aggressive
oronary synd
the incidenc
ssment tools
n intensive ca
U) of tertiary
sheets, treat
also verified.
l status, labo
nagement we
nd the risk fo
ed for each
mong a numb
iovascular d
ular disease
es analyzed.
w, Moderate
life.
eetingcts
into unknown
se of QRISK
ols in Indian
MACY;
ajor causes o
g countries.
odification o
e medical th
dromes in pa
ce of CVD ev
s.
are unit (ICU
y‐care hospi
ment chart,
. A questionn
oratory data
ere recorded
or developm
risk factor in
ber of scorin
disease by giv
within a spe
QRISK and A
e and High ri
characters.
a
patient.
of disability a
The past ye
f its causes.
erapy will
atients with
vent by
U), medical
tal in India f
lab master,
naire was us
a, weight, he
d. The data w
ment of CVD
n the study
g systems us
ving an estim
ecified amou
ASCVD risk
sk factor for
and
ars
The
for 6
the
sed
eight,
was
in
sed
mate
unt of
r
*Special sy
Results: A
80) as Lo
for ASCV
48 perce
factors u
Pressure
individua
equals 33
had high
score. No
Diabetics
ASCVD a
Conclusio
assessme
individua
probabili
Risk facto
individua
The estim
care.
ymbols that w
As per QRIS
ow risk, 32 pe
D and 24 pe
nt (n equals
sing QRISK a
, out of 44 p
al had High r
3) among sa
er risk accor
on‐Diabetic
s with 67 pe
nd 50 perce
on: Risk of d
ent tools, wh
al's chances
ity that a pe
or assessme
al CVD event
mated absolu
2018ASProf
ere not spelled
K and ASCVD
ercent (n eq
ercent (n equ
123) as Hig
and ASCVD r
patients with
risk score for
mple and al
rding to QRIS
patients wer
rcent (n equ
nt (n equals
developing C
hich are amo
of developin
rson will dev
nt tools can
ts (coronary,
ute CVD eve
SHPMidyfessional
d‐out per the g
D scales, the
uals 82) as M
uals 62) as Lo
h risk for QR
risk tool asse
h Stage 2 BP
r developing
l of them ha
SK than Non
re having low
uals 23) out o
17) accordi
CVD event w
ong a numbe
ng cardiovas
velop CVD w
be convenie
, cerebrovas
ent rates can
yearClinlPoster
guidelines wer
e percentage
Moderate ris
ow risk, 28 p
RISK. Ris
essments. W
had high ris
g CVD events
ad high risk a
n‐Smokers w
wer risk acco
of 46 of Non
ng to QRISK.
as predicted
er of scoring
scular diseas
within a spec
ently used to
scular, perip
n be used to
nicalMeAbstrac
re translated i
e was respec
sk, 37 perce
percent (n eq
sk scores we
When compa
sk. 40 percen
s. Obese ind
according to
with 40 perce
ording to AS
n‐Diabetic ha
.
d clinically Q
g systems us
se by giving a
cified amoun
o assess gen
heral arteria
quantify risk
eetingcts
into unknown
ctively 31 pe
nt (n equals
quals 72) as
re compared
red accordin
nt (n equels1
ividuals wer
QRISK and A
ent (n equals
SCVD and QR
aving low ris
QRISK and AS
sed to determ
an estimate
nt of time, us
neral CVD ris
al disease an
k and to guid
characters.
ercent (n equ
95) as High
Moderate r
d for each ri
ng to their B
18) of the
re 13 percen
ASCVD. Smo
s 29) high ris
RISK than
sk according
SCVD risk
mine an
of the
sually 10 yea
sk and risk of
nd heart failu
de preventiv
uals
risk
risk,
isk
lood
nt (n
okers
sk
to
ars.
f
ure).
ve
*Special sy
Session‐B
Poster Ti
and meta
Poster Ty
Submissi
Primary A
Email: fa
Addition
Raju Kon
Balakesh
Purpose:
seriously
every yea
smoking,
preventa
assess th
the chan
Score (FR
Methods
hospital,
diabetes
chart, lab
prepared
the detai
Pressure
FRS and
(includin
10 years
risk facto
day epide
atherosc
ymbols that w
Board # ‐ 1‐0
itle: Assessm
abolic syndr
ype: Evaluat
ion Category
Author: Fate
tima.dehdar
al Authors:
eri
hava Ramaia
: Heart attac
y affect half o
ar are cause
, high levels
able if meani
he role of Ris
ces of increa
RS).
s: Prospectiv
India for six
and geriatri
b master, the
d questionna
ils like inpati
(BP), family
MetS risk sc
g mortality)
to come in t
ors score tha
emic which
lerosis and s
2018ASProf
ere not spelled
010
ment of the r
ome risk too
tive Study
y: Clinical Se
emeh Dehda
ri1991@gma
h
cks, stroke, a
of the popul
d by one or
of blood lipi
ingful action
sk Scores in i
ased risks fo
ve observatio
x months. Th
ic patients. T
e physical ex
aire to gathe
ient number
y history and
ore calculato
caused by c
the life of th
at was obser
predicts CVD
sudden deat
SHPMidyfessional
d‐out per the g
risk factors f
ol
ervices Mana
ari; Karnatak
ail.com
and other pr
ation. The m
more cardio
ids, physical
n is taken aga
indication of
or future card
onal study c
he newly adm
The required
xamination o
er informatio
r, age, sex, s
d therapeutic
ors.FRS is de
coronary hea
he individual
rved for each
D mortality;
th independe
yearClinlPoster
guidelines wer
for cardiovas
agement
ka College O
reventable c
majority of th
ovascular ris
inactivity an
ainst these r
f Metabolic
diovascular
onducted in
mitted case
d data was c
of the medic
on of patient
ocial status,
c manageme
esigned to p
art disease a
, taking into
h risk factor
the incidenc
ent of other
nicalMeAbstrac
re translated i
scular event
Of Pharmacy;
ardiovascula
he heart atta
sk factors like
nd most of t
risk factors.
Syndrome (M
disease even
n medicine w
charts diagn
ollected in f
cation with p
t data collec
, laboratory
ent. Then th
redict the ris
and non‐fata
o account the
in the study
ce and progr
r cardiovascu
eetingcts
into unknown
ts by framing
;
ar diseases (
acks and str
e hypertens
these CVD ev
The study is
MetS) and u
nts using Fra
wards of tert
nosed with h
form case sh
patient is als
ction was use
data, weigh
e data was i
sk of heart p
al myocardia
e presence o
y sample. Me
ression of ca
ular risks.
characters.
gham risk sc
(CVD) kill or
okes that oc
ion, diabete
vents are
s intended to
understandin
amingham R
tiary‐care
hypertension
heets, treatm
so verified. A
ed to collect
t, height, Blo
introduced t
problems
al infarction f
or absence o
etS is a mod
arotid
ore
ccur
es,
o
ng
Risk
n,
ment
A
t all
ood
to
for
of
ern
*Special sy
Results: A
patients
(n equals
MetS wa
CVD even
equals 22
were 13
Non‐Diab
equals 32
equals 12
showed t
equals 18
Conclusio
10‐year a
prospect
identifica
fighting t
predictin
Regimen
ymbols that w
After analys
using FRS cl
s 147) as Low
s Present in
nt according
2) of the ind
percent (n e
betic patient
2) out of 46
29) out of 21
the significa
8) out of 23
on: Framing
absolute risk
tive associat
ation of the
the growing
ng stage of th
that can su
2018ASProf
ere not spelled
sing 260 case
assifying the
w risk, 6 perc
65 percent
g to their Blo
ividuals had
equals 33) am
ts were havi
Non‐Diabet
10 Diabetics
nce of the ro
individuals w
gham risk eq
k of develop
ion of the M
metabolic a
epidemic of
he CVD and
it the major
SHPMidyfessional
d‐out per the g
es, they wer
em accordin
cent (n equa
(n equals 16
ood Pressure
d high risk sc
mong sampl
ng lower ris
ic individual
having high
ole of HDL in
with HDL lev
uations coul
ing CVD. Des
MetS with car
bnormalities
f disease. Th
combine the
ity of CVD pa
yearClinlPoster
guidelines wer
e compared
g to their ris
als 15)as Mo
67) of the sa
e, out of 44 p
ore for deve
e and all of t
k according
s in the sam
h risk. Studyi
n preventing
vels lower th
ld stratify lif
spite its high
rdiovascular
s and taking
his research f
e results in o
atients base
nicalMeAbstrac
re translated i
with risk fa
sk score. The
oderate risk,
mple. Study
patients with
eloping CVD
them had hi
to FRS than
mple having l
ng the effec
g cardiovascu
han 35mg/dL
fetime risk fo
h prevalence
r and overall
appropriate
focused on t
order to com
ed on a clinic
eetingcts
into unknown
ctors and ris
e percentage
37 percent
ying the risk
h Stage 2 BP
events. Obe
igh risk acco
Diabetics w
ow risk and
ct of Lipid pr
ular events,
L showed hig
or CVD by th
e, little is kno
mortality. E
e interventio
the role of R
me up with T
cal trial.
characters.
sk score in
e was 57 per
(n equals 95
for develop
P, 50 percent
ese individua
ording to FRS
with 70 perce
61 percent
ofile, results
78percent (
gher risk.
he estimatio
own of the
Early
on would he
Risk Factors i
Therapeutic
rcent
5).
ing
t (n
als
S.
ent (n
(n
s
(n
n of
elp in
in
*Special sy
Session‐B
Poster Ti
and coun
Poster Ty
Submissi
Primary A
Email: tjo
Addition
Purpose:
has beco
costs. In
Meds2Be
process.
medicati
to determ
counselin
Methods
team of t
pharmac
pharmac
program
doing an
opportun
counselin
physician
program
Once the
reviewed
and deliv
for little t
ymbols that w
Board # ‐ 1‐0
itle: Optimiz
nseling prior
ype: Descrip
ion Category
Author: Tay
ones19@mid
al Authors:
: Encouragin
ome a nation
2016 the Un
eds program
The program
on educatio
mine the imp
ng on transit
s: This progr
three clinica
cy students t
cists perform
by using an
extensive a
nity to demo
ng points are
ns, case man
except thos
e patient is s
d by both clin
vered to bed
to no cost u
2018ASProf
ere not spelled
011
zing transitio
to hospital
ptive Report
y: Clinical Se
ylor Jones; U
dwestern.ed
ng patient co
nal focus to h
niversity of C
m to help ass
m delivers di
n by the pha
pact of imple
tions of care
am operate
l pharmacist
to coordinate
m a clinical re
electronic h
ssessment o
onstrate the
e most impo
nagers, and s
se going to lo
uccessfully e
nical pharma
dside. If a pat
sing the hos
SHPMidyfessional
d‐out per the g
ons in care th
discharge
ervices Mana
niversity of
du
ompliance an
help minimiz
Chicago Med
ist with the
ischarge pre
armacist. Th
ementing be
e.
s as a separa
ts work with
e discharge
eview of eac
health record
of the patien
ir knowledge
ortant to disc
social worke
ong‐term ca
enrolled in t
acists and st
tient is unin
spital’s 340B
yearClinlPoster
guidelines wer
hrough impl
agement
Chicago Hos
nd proper m
ze adverse h
dicine Pharm
medication
escriptions to
e purpose o
edside medi
ate entity in
h Advanced M
prescription
h patient’s m
d (EHR) syst
nt’s medical
e and collect
cuss given th
ers are encou
re facilities,
he program
tudent pharm
sured, a coo
plan.
nicalMeAbstrac
re translated i
ementing be
spital;
medication us
health outco
macy Departm
component
o patient’s b
of this descri
cation delive
the hospita
Medication
n processing
medication t
em. Student
history. Stu
tively decide
he chosen m
uraged to en
hospice cen
and the pat
macists, the
ordinator is a
eetingcts
into unknown
edside medi
se during tra
omes and red
ment implem
of the trans
bedside alon
ptive, retros
ery and pha
al’s outpatien
Access Coor
and deliver
therapy enro
t pharmacist
udents are gi
e with the p
medication re
nroll patient
nters or tran
tient’s chart
prescription
able to prov
characters.
ication deliv
ansitions of
duce medica
mented a
sitions in car
g with provi
spective stud
rmacist
nt pharmacy
rdinators an
y. The clinic
olled in the
ts also join in
iven an
harmacist w
egimen. Nur
s into the
splant patie
s have been
ns are then f
ide medicat
very
care
al
re
iding
dy is
y. A
d
al
n
what
rses,
ents.
filled
ions
*Special sy
After dat
with the
within th
cycle.
Results:
patients
weekend
Monday
the hosp
transition
outcome
has been
continue
outcome
Conclusio
after disc
experien
prior to d
satisfacti
ymbols that w
ta from the p
pharmacy m
he program.
Over the cou
being servic
d has led the
through Sat
ital and pati
ns of care. A
es such as a l
n a significan
es to grow da
es.
on: Many pa
charge, such
ce with a me
discharge re
ion and an in
2018ASProf
ere not spelled
program is c
manager and
This concep
urse of the p
ced a week. T
e program to
turday. Over
ients being d
Although the
ower readm
nt increase in
ata will be co
atients face
h as treatme
edication. Im
sulted in low
ncrease in to
SHPMidyfessional
d‐out per the g
collected and
d team to ad
pt of quality i
program, en
The increase
o extend hou
rall, the posit
discharged h
ere has not b
mission rate,
n the outpat
ollected to s
barriers that
nt cost, lack
mplementati
wer medicat
otal revenue
yearClinlPoster
guidelines wer
d analyzed, a
dress issues
improvemen
rollment has
e in patient d
urs of operat
tive feedbac
has shown th
been any dat
increased re
tient pharma
show if there
t can preven
of transpor
ion of bedsid
ion costs for
e for the out
nicalMeAbstrac
re translated i
a 15‐minute
s or challeng
nt (QI) adopt
s increased t
demand and
tion from M
ck from heal
he program t
ta to suppor
efills, or less
acy’s total re
e is an impac
nt them from
rtation, and/
de medicatio
r patient's, a
patient phar
eetingcts
into unknown
meeting is h
ges and sugg
ts the Plan‐D
to roughly 2
d discharges
onday throu
lthcare prov
to be useful
rt an improve
s adverse dru
evenue. As t
ct being mad
m filling their
/or having a
on delivery a
an increase i
rmacy.
characters.
held biweek
gest solution
Do‐Study‐Ac
200 to 400
during the
ugh Friday to
iders located
during
ement in he
ug events th
he program
de on health
r prescriptio
negative pa
and counsel
n patient
kly
s
ct
o
d in
ealth
here
h
ons
st
ing
*Special sy
Session‐B
Poster Ti
pharmac
Poster Ty
Submissi
Primary A
Email: al
Addition
Linda Pha
Sharya B
Purpose:
guideline
Currently
documen
Assessme
was to de
integrate
Veterans
Methods
pulmona
practices
assessme
chart rev
COPD ass
specific G
evaluatio
documen
from clin
tools con
III, the Ph
documen
ymbols that w
Board # ‐ 1‐0
itle: Targetin
cy‐collaborat
ype: Descrip
ion Category
Author: Aud
ee@pacific.
al Authors:
am
ourdet
: The Global
es is the gold
y, the study
ntation of CO
ent Test (CA
evelop, selec
e the most u
s pulmonary
s: This qualit
ary services.
s in a Vetera
ent of COPD
view of selec
sessment an
GOLD‐recom
on of exacer
ntation tools
nic providers
nsisted of a p
harmacy Ser
ntation tools
2018ASProf
ere not spelled
012
ng best chro
tive quality i
ptive Report
y: Clinical Se
drey Lee; Un
edu
Initiative fo
d standard fo
institution d
OPD, such as
AT). The goa
ct, and imple
pdated GOL
clinic and to
ty improvem
It consisted
ns pulmona
clinical prac
cted clinic pa
nd documen
mmended ass
bations, spir
s were devel
, and integra
patient intak
rvice educate
s. Following
SHPMidyfessional
d‐out per the g
nic obstruct
mprovemen
ervices Mana
niversity of th
r Chronic Ob
or best pract
does not use
s validated s
l of this pha
ement stand
LD guideline
o assess the
ment project
of three pha
ry clinic, Pha
ctices in the
atients was c
tation pract
sessment pr
rometry, and
loped and se
ation of the
ke questionn
ed the clinic
disseminati
yearClinlPoster
guidelines wer
tive lung dise
nt project at
agement
he Pacific an
bstructive Lu
tices in COP
e standardiz
symptom ass
rmacy‐collab
dardized ass
recommend
use and imp
involved co
ases: Phase
ase II: develo
pulmonary
conducted b
ices pre‐too
ractices was
d tobacco us
elected base
2017 GOLD
naire and an
c providers o
ion of the to
nicalMeAbstrac
re translated i
ease (COPD)
a Veterans
nd VA Medic
ung Disease
D assessmen
ed tools for
sessment qu
borative qua
sessment an
dations for u
pact of these
llaboration b
I: pre‐tool a
opment of to
clinic. Duri
by Pharmacy
ol implement
collected, p
se. During P
ed upon resu
guideline re
electronic n
on use of the
ools, usage o
eetingcts
into unknown
) documenta
health care
cal Center Sa
(GOLD) con
nt and mana
assessment
uestionnaire
ality improve
d document
use by provid
e tools on cl
between the
assessment o
ools, and Ph
ng Phase I, a
y Service to e
tation. Docu
particularly u
Phase II, asse
ults of a char
ecommenda
note templat
e assessmen
of the tools b
characters.
ation practic
system
an Francisco
sensus
agement.
t and
s like the CO
ement proje
tation tools t
ders in a
inical practic
e pharmacy
of COPD clin
hase III: post
a retrospect
evaluate cur
umentation
use of CAT,
essment and
rt review, in
tions. These
te. During P
t and
by the clinic
ces: a
;
OPD
ect
that
ce.
and
ical
‐tool
ive
rent
of
d
put
e
Phase
*Special sy
providers
and post
Service a
Results: A
question
Prior to i
template
included
percent)
assessme
were col
percent)
spiromet
Conclusio
documen
pulmona
pharmac
impact o
ymbols that w
s and patien
‐tool implem
as part of a s
A total of 14
naires were
mplementat
e (Phase I), a
use of CAT s
contained d
ent on tobac
lected and r
notes includ
try results an
on: This pha
ntation of sp
ary clinic. Fu
cy services w
n clinical pra
2018ASProf
ere not spelled
nts and docu
mentation w
even‐week p
4 pulmonary
distributed
tion of the c
sampling of
score while
documentati
cco use. Afte
eviewed. Ei
ded assessm
nd assessme
armacist coll
pecific GOLD
urther collab
will be condu
actice and C
SHPMidyfessional
d‐out per the g
mentation o
were collecte
pilot assessm
y clinic provid
to COPD pa
linic patient
f 14 clinic no
10 notes (77
ion of spirom
er implemen
ght (40 perc
ment of exace
ent of tobacc
aborative qu
‐recommen
orative educ
cted to enha
OPD manag
yearClinlPoster
guidelines wer
of GOLD‐rec
d, evaluated
ment.
ders receive
tients, in wh
t intake ques
otes were re
7 percent) ad
metry, and 1
ntation of Ph
cent) notes i
erbations, an
co use.
uality improv
ded clinical
cational effo
ance usage o
ement.
nicalMeAbstrac
re translated i
ommended
d, and comp
ed training. A
hich 51 (77 p
stionnaire an
eviewed. No
ddressed ex
13 (100 perce
hase III, a sa
included a C
nd 20 (100 p
vement proj
assessment
orts between
of documen
eetingcts
into unknown
assessment
pared by the
A total of 66
percent) wer
nd COPD ele
one of the no
xacerbations
ent) notes in
mpling of 20
CAT score wh
percent) not
ject lead to
measures a
n the pulmo
tation tools
characters.
t practices p
Pharmacy
patient inta
re returned.
ectronic note
otes (0 perce
s, 12 notes (9
ncluded
0 clinic note
hile 16 (80
tes included
increased
at a Veterans
nary and
and assess t
re‐
ake
e
ent)
92
s
s
their
*Special sy
Session‐B
Poster Ti
providers
Poster Ty
Submissi
Primary A
Email: he
Addition
Julie Gro
Michael T
Kimberly
Anthony
Purpose:
(CRVA) In
veteran h
Office of
CPS in ad
positions
improvin
health.
Methods
designed
standard
Compreh
track the
A consult
and durin
redesign,
Program
(mentors
CPPO dev
ymbols that w
Board # ‐ 1‐0
itle: Increasi
s
ype: Descrip
ion Category
Author: Hea
eather.ourth
al Authors:
ppi
Tran
y Quicci‐Robe
Morreale
: Launched i
nitiative emp
healthcare n
Rural Healt
dvanced prac
s at 63 VA fa
ng access in 3
s: The PBM C
d to ensure C
dize and ope
hensive data
e workload, m
tative visit p
ng these visi
, and optimi
was develo
s) to accelera
veloped and
2018ASProf
ere not spelled
013
ing access to
ptive Report
y: Clinical Se
ather Ourth;
erts
n October 2
ployed a mu
needs. Pharm
h (ORH) and
ctice provide
cilities and t
3 areas of id
Clinical Phar
CRVA initiativ
rationalize im
abase system
metrics, and
process to pr
its the team
zation of cli
ped that ma
ate and stan
d presented
SHPMidyfessional
d‐out per the g
o care for ru
ervices Mana
Departmen
016, the Clin
ulti‐dimensio
macy Benefi
d was awarde
er roles. Fun
their rural ou
entified nee
rmacy Practi
ve success t
mplementat
ms were esta
d interventio
romote prac
focuses on
nical pharm
atches new c
ndardize pro
Clinical Phar
yearClinlPoster
guidelines wer
ral veterans
agement
nt of Veteran
nical Pharma
onal approac
its Managem
ed $136 mill
nding was pr
utpatient cli
ed: primary
ce Office (CP
hat included
tion of this e
ablished to m
ns of every
tice sharing
pharmacist
acy services
clinicians wit
oject practice
rmacy Leade
nicalMeAbstrac
re translated i
by leveragin
ns Affairs;
acy Specialis
ch to increas
ment Service
lion over 5 y
rovided for t
nics. The CP
care, pain m
PPO) develo
d forming a s
enterprise‐w
measure faci
pharmacist
and project
professiona
s. A compreh
th establishe
e implement
ership Boot C
eetingcts
into unknown
ng clinical ph
st (CPS) Rura
se access to
e (PBM) part
years to expa
the placeme
PS positions
management
oped an infra
steering com
wide initiative
ility CPS hirin
involved wit
t successes w
l practice, C
hensive CPS
ed seasoned
tation across
Camps throu
characters.
harmacist
al Veteran Ac
support rura
tnered with t
and the use
ent of 180 CP
are focused
t, and menta
astructure
mmittee to
e (EWI).
ng status an
th the progr
was deploye
PS practice
Mentorship
d practitione
s all sites. Fi
ugh a series
ccess
al
the
of
PS
d on
al
d
am.
d
rs
nally,
of
*Special sy
virtual te
which we
impleme
through
The Clini
program
pain and
Results: T
from Oct
encounte
practice
have bee
31,307 e
state inte
managem
FY19. The
group me
clinical p
a gap ana
rated the
who rate
Conclusio
access to
would ha
the impr
both the
develop
pharmac
ymbols that w
eleconferenc
ere face‐to‐f
ntation, pro
a succession
cal Pharmac
through the
mental hea
This EWI has
tober 1, 201
ers for 102,1
area, CPS pe
en 41,041 en
ncounters fo
erventions to
ment. CPPO
e mentoring
entoring pro
ractice topic
alysis assess
eir knowledg
ed their know
on: The imp
o care for ov
ave not have
oved patien
CPS as well
lasting infras
cy practice in
2018ASProf
ere not spelled
ces from Sep
face program
omotion, and
n of topic spe
cy Boot Cam
e developme
lth CPS.
s demonstra
7 thru May 3
159 veterans
erformed 12
ncounters fo
or 13,571 ve
otaling 300,
conducted
g program ha
ogram. The f
cs determine
sment. A po
ge as “No/M
wledge as “M
lementation
er 100,000 v
e been delive
t access, the
as Clinical P
structure an
nitiatives.
SHPMidyfessional
d‐out per the g
ptember to O
ms. The Lead
d maintenan
ecific presen
ps provided
ent of two cu
ated significa
30, 2018, CP
s of which 69
5,371 encou
r 16,436 vet
eterans. In a
243 in prima
21 consultat
as paired 54
five Clinical
ed to have th
ost‐training a
Minimal” decr
Mastery” inc
n of this CPS
veterans in t
ered withou
e project has
Pharmacy Ch
nd cultural ch
yearClinlPoster
guidelines wer
October 201
dership Boot
nce of expan
ntations to fa
clinical train
urriculums, o
ant increase
PS providers
9% were con
unters for 41
terans and in
addition, the
ary care, 96,
tive visits in
mentor/me
Pharmacy B
he largest kn
analysis show
reased by 83
creased by 3
rural health
the initial ye
t these adva
s been instru
hampions at
hange which
nicalMeAbstrac
re translated i
17 and Clinic
t Camp serie
ded Clinical
acility Clinic
ning for the
one for prim
s in access t
have perfor
nsidered rur
1,101 vetera
n pain mana
e CRVA CPS h
,943 in ment
FY18 with m
entee match
Boot Camp p
nowledge ga
wed the per
3% and the p
34%.
h program ha
ar of the pro
ance practice
umental in im
the 63 facili
h will help su
eetingcts
into unknown
al Pharmacy
es focused o
Pharmacy p
al Pharmacy
CPS hired as
mary care CP
to care. Dur
rmed 268,73
ral. In the pr
ans. In ment
agement the
have docum
tal health an
more anticip
hes and is ex
rograms tra
aps for parti
rcentage of p
percentage o
as significan
ogram. This
e pharmacis
mproving th
ities involved
upport futur
characters.
y Boot Camp
n the
programs
y Champions
s part of the
PS and one fo
ing the perio
34 patient ca
rimary care
tal health th
ere have bee
ented disea
nd 74,212 in
ated during
panding into
ined 186 CP
cipants base
participants
of participan
tly improved
is care that
sts. In additio
he training of
d and has he
re clinical
ps
s.
e
or
od
are
ere
en
se
pain
o a
PS in
ed on
who
nts
d
on to
f
elped
*Special sy
Session‐B
Poster Ti
Poster Ty
Submissi
Primary A
Email: m
Addition
Patricia C
Purpose:
activator
hemodia
significan
significan
significan
related t
heparin t
avoidanc
Methods
period is
impleme
patients
before (p
excluded
receives
graft for
catheter
catheter
documen
incidence
of incide
ymbols that w
Board # ‐ 1‐0
itle: Evaluati
ype: Evaluat
ion Category
Author: Mu
ustafa.lee@
al Authors:
Chun
: Catheter lo
r (tPA), are u
lysis (HD) pa
nt difference
nt reduction
nt cost incre
hrombosis a
twice weekly
ce after prot
s: This is an i
from Novem
ntation of th
18 years or
period 1) and
d if undergoi
chronic dialy
HD. Thromb
lock solutio
lock solutio
nted by rena
es of cathete
nces of cath
2018ASProf
ere not spelled
014
ion of interd
tive Study
y: Clinical To
stafa Lee; Ve
@va.gov
ocking solutio
used to minim
atients using
e between h
in complica
ase. The prim
and bacterem
y and tPA we
ocol convers
institutional
mber 1, 2015
he change to
greater und
d after (perio
ng acute dia
ysis at an ou
bosis was de
n used per H
n used per w
al attending.
er malfuncti
eter‐related
SHPMidyfessional
d‐out per the g
dialytic cathe
opics / Thera
eterans Affa
ons, namely
mize cathete
g chronic cen
eparin and s
ations was se
mary object
mia after pro
eekly. The se
sion.
review boa
5 to October
o the individ
ergoing chro
od 2) the pro
alysis, receiv
utside facility
fined as tPA
HD session d
week during
The primary
on due to th
d bacteremia
yearClinlPoster
guidelines wer
eter lock pro
apeutics
airs Long Bea
y heparin, so
er‐related th
ntral venous
sodium citra
een in hepar
ive was to e
otocol conve
econdary ob
rd approved
r 31, 2017. T
dual patients
onic hemodi
oposed chan
ing dialysis d
y, or using a
A protocol vio
during period
period 2) or
y objective m
hrombosis as
a. Secondary
nicalMeAbstrac
re translated i
otocol conve
ach Healthca
odium citrate
hrombosis a
s catheters (C
ate in cathet
rin versus tP
valuate the
ersion from t
bjective was
d, quality ass
The index da
s, and closes
ialysis using
nge was incl
during a hos
n arterioven
olation (grea
d 1 and grea
r catheter ex
measures we
s defined in
y objective in
eetingcts
into unknown
ersion in a di
are System;
e, and tissue
nd bacterem
CVC). Studie
ter‐related c
A, however,
incidence of
tPA three tim
to determin
sessment stu
ate is the dat
st to Novemb
a CVC at lea
uded. Patien
spital admiss
nous fistula o
ater than 4m
ater than 4m
xchanges du
ere the num
the study, a
ncluded calc
characters.
ialysis unit
e plasminoge
mia in
es show no
omplication
, with a
f catheter‐
mes per wee
ne cost
udy. The stu
te of
ber 1, 2016.
ast one mon
nts were
sion, but
or arteriove
mg of tPA
mg of tPA
ue to clot as
mber of
and the num
culation of c
en
s. A
ek to
dy
All
th
nous
mber
ost
*Special sy
savings b
applied a
Results: A
inclusion
differenc
equals 0.
number o
versus 7
to clot, a
2, respec
was appr
the study
Conclusio
thrombo
venous c
significan
ymbols that w
before and a
as appropria
Among the 3
n and exclusi
ce in primary
.94), numbe
of catheter‐
patients had
nd 3 versus
ctively. For t
roximately $
y period reac
on: The find
osis or cathet
atheter. In a
nt cost‐savin
2018ASProf
ere not spelled
fter the prot
te.
314 patients
on criteria. W
y outcomes o
r of cathete
related bact
d a tPA proto
1 patients h
he secondar
$223,000 and
ched $370,0
ings suggest
ter‐related b
addition, rep
ngs.
SHPMidyfessional
d‐out per the g
tocol conver
s receiving H
When comp
of number o
r exchanges
teremia (3 ve
ocol violatio
had a cathete
ry outcome,
d the estima
000.
t the protoco
bacteremia i
placing tPA w
yearClinlPoster
guidelines wer
rsion. Descri
HD during th
pared betwee
of tPA protoc
due to clot
ersus 2, p‐va
on, 1 versus 0
er‐related ba
the realized
ated cost sav
ol conversio
n patients u
with heparin
nicalMeAbstrac
re translated i
iptive statist
e study peri
en period 1
col violation
(1 versus 0,
alue equals 0
0 patients ha
acteremia b
d cost saving
vings after th
on did not aff
undergoing c
n was more c
eetingcts
into unknown
tics and pair
od, 19 patie
and period
ns (20 versus
p‐value equ
0.58). Of the
ad a cathete
between per
gs for the stu
he protocol
ffect the num
chronic HD u
cost‐effectiv
characters.
ed t‐test we
ents met the
2, there was
s 18, p‐value
uals 0.33), an
e 19 patients
er exchange
iod 1 and pe
udy populati
conversion f
mber of cath
using a centr
ve, generatin
ere
s no
e
nd
s, 8
due
eriod
on
for
heter
ral
ng
*Special sy
Session‐B
Poster Ti
patients
Poster Ty
Submissi
Primary A
Email: ivy
Addition
Emily Ch
Katherine
Douglas
Purpose:
recently
FDA indic
considere
currently
(Remicad
investiga
calculate
Methods
Patients
gastroen
receive c
not recei
were eva
reactions
relevant
(defined
and bioc
conversio
escalatio
ymbols that w
Board # ‐ 1‐0
itle: Switchin
with inflamm
ype: Evaluat
ion Category
Author: Ivy
y.tonnu‐mih
al Authors:
ang
e Le
Nguyen
: Inflectra (in
approved bi
cation for m
ed interchan
y is no public
de) to inflixim
ate the safety
e the potenti
s: This is an i
with IBD car
terology clin
continuous c
ive Remicad
aluated at 6
s, steroid uti
endpoints w
as Simple En
hemical rem
on dose was
on at 6‐mont
2018ASProf
ere not spelled
015
ng to inflixim
matory bow
tive Study
y: Clinical To
Tonnu‐Miha
nfliximab‐dy
iosimilar to t
oderate to s
ngeable with
cation evalua
mab‐dyyb bi
y and efficac
ial cost savin
institutional
red for by th
nic were con
care by the a
e for at least
months or lo
ilization, and
were clinical
ndoscopic Sc
mission (defin
s set at millig
th evaluation
SHPMidyfessional
d‐out per the g
mab‐dyyb res
el disease (I
opics / Thera
ara; VA Long
v
yyb), an anti‐
the biologic
severe irritab
h biologics. T
ating the int
iosimilar (Inf
cy of switchi
ngs when sw
review boa
he Veterans A
nverted from
aforemention
t 90 days pr
onger after c
d hospital ad
remission (d
core‐Crohn’s
ned as stable
gram to milli
n. A subgrou
yearClinlPoster
guidelines wer
sults in no d
BD)
apeutics
g Beach Heal
‐tumor necro
agent Remic
ble bowel di
To our know
terchangeab
flectra). The
ing from Rem
witching from
rd approved
Affairs Long
m Remicade t
ned clinic, w
ior to the co
conversion.
dmissions re
determined
s Disease sco
e or improvi
igram, we al
up analysis w
nicalMeAbstrac
re translated i
differences in
lthcare Syste
osis factor‐a
cade (inflixim
isease (IBD).
wledge, in th
bility betwee
e primary ob
micade to In
m biologics to
d, retrospect
Beach Heal
to Inflectra.
were newly in
onversion we
Safety endp
lated to IBD
by GI attend
ore 0 to 2; M
ing C‐Reactiv
lso examine
was conduct
eetingcts
into unknown
n clinical out
em;
alpha (anti‐T
mab). Both
. Of note, bio
he United Sta
en infliximab
bjective of th
nflectra. We
o its compar
tive chart re
thcare Syste
Patients wh
nitiated on I
ere excluded
points were
D. Efficacy an
ding), endos
Mayo endosc
ve Protein re
d the need f
ted to exam
characters.
tcomes amo
TNF‐alpha), is
agents rece
osimilars are
ates, there
b biologic
his study is to
also aim to
rable biosim
view study.
em
ho did not
nflectra, or
d. Endpoints
infusion
nd clinically
scopic remiss
copic score 0
esults). As
for dose
ine safety an
ong
s a
ived
e not
o
milar.
did
s
sion
0, 1),
nd
*Special sy
efficacy o
therapy v
with the
the Vete
test was
Results: A
followed
revealed
had Rem
concomit
months a
percent)
remission
required
hospitaliz
experien
yearly ca
Conclusio
patients
conversio
outcome
immunos
steroid u
cost savi
further s
ymbols that w
outcome diff
versus those
conversion
rans Health
performed f
Among the 6
by GI clinic,
the average
icade as the
tant immuno
after conver
achieved bi
n. Our data a
a new cours
zation. The
ced infusion
lculated cos
on: We used
who switche
on is safe an
es. Infusion
suppressive
utilization or
ngs. Future
upport the u
2018ASProf
ere not spelled
ferences bet
e who were
by estimatin
Administrat
for sub‐anal
61 patients i
, 17 met crit
e age was 47
eir first anti‐T
osuppressiv
sion, 13 pat
ochemical re
also showed
se of steroid
sub‐group a
n reactions (4
st savings wa
d multiple pa
ed from Rem
nd effective.
reactions on
therapy. Fu
hospitalizat
studies with
use of biosim
SHPMidyfessional
d‐out per the g
tween patie
not. Finally,
ng the yearly
tion by its pr
ysis.
identified w
eria and we
7.6 years (sta
TNF alpha th
e therapy ‐ e
ients (76.5 p
emission; an
d 4 patients e
d therapy or
analysis foun
4 out of 9 pa
as $68,629 fo
arameters to
micade thera
Over 70 pe
nly occurred
urthermore,
tion. Finally,
h longer follo
milar therapi
yearClinlPoster
guidelines wer
nts who we
, we calculat
y projected d
rime vendor.
ith IBD, on lo
re included
andard devia
herapy; 47.1
either 6‐mer
percent) wer
nd 12 patien
experienced
increase in
nd only those
atients witho
or the study
o evaluate th
apy for chron
rcent of pat
in those wh
no converte
the convers
ow‐up interv
ies.
nicalMeAbstrac
re translated i
re on conco
ted the cost‐
drug costs u
. Descriptive
ong‐term in
in analysis. B
ation 14.3);
1 percent (8
rcaptopurine
re in clinical
nts (70.6 perc
d infusion re
existing ster
e who were
out concom
y cohort.
he safety an
nic IBD. Our
tients achiev
ho were not
ed patient ex
sion yielded
vals and larg
eetingcts
into unknown
mitant imm
‐minimizatio
sing the dru
e analysis w
fliximab infu
Baseline cha
82.4 percen
patients) we
e or methot
remission; 1
cent) were i
actions; no p
roid doses; a
not on conc
itant therap
nd efficacy of
r findings su
ved multiple
on concomi
xperienced a
nearly $70,0
ger cohorts i
characters.
unosuppres
on associate
ug prices set
was conducte
usion, and
aracteristics
nt (14 patien
ere on
rexate. At 6
15 patients (
n endoscop
patients
and there wa
comitant the
py). Overall, t
f Inflectra us
ggest this
desired
tant
an increase
000 in yearly
is warranted
sive
d
for
ed, t‐
ts)
6
(88.2
ic
as no
erapy
the
se in
in
y
d to
*Special sy
Session‐B
Poster Ti
commun
Poster Ty
Submissi
Primary A
Email: so
Addition
Emily Lea
Ji Eun Kim
Terri Fos
Purpose:
significan
diabetes
lowering
generally
for poten
to evalua
treatmen
Methods
inhibitor
was cros
were exc
prior to t
the milita
Demogra
blood pre
effects. T
Board.
ymbols that w
Board # ‐ 1‐0
itle: Clinical
ity setting
ype: Evaluat
ion Category
Author: Son
onya.babaya
al Authors:
af
m
ter
: Sodium‐glu
ntly reduce h
. Additional
blood press
y well‐tolera
ntial failures
ate efficacy,
nt facility.
s: Computer
prescription
s referenced
cluded from
the start of t
ary treatmen
aphic data, b
essure, weig
This study re
2018ASProf
ere not spelled
016
consideratio
tive Study
y: Drug Infor
nya Babayan
ucose co‐tran
hemoglobin
ly, they exh
sure. Althou
ted with low
in medicati
safety, and
rized outpati
ns dispensed
d to prescrib
this retrosp
the study pe
nt facility. A
baseline and
ght, concurre
eceived clea
SHPMidyfessional
d‐out per the g
ons of sodiu
rmation/Dru
; Veterans A
nsporter‐2 (
A1C and pro
ibit other fav
ugh clinical t
w discontinu
on persisten
medication
ient prescrip
d between th
ber clinic loca
ective chart
riod and if t
A retrospecti
follow‐up d
ent anti‐hyp
rance for su
yearClinlPoster
guidelines wer
m‐glucose c
ug Use Evalu
Affairs ‐ Rose
SGLT2) inhib
ovide cardio
vorable prop
rials have sh
ation rates,
nce in clinica
persistence
ption records
he dates of J
ation and m
review if th
he prescript
ive chart rev
data were co
perglycemic m
ubmission by
nicalMeAbstrac
re translated i
o‐transporte
uation
eburg;
bitors have b
ovascular ben
perties inclu
hown that th
their side ef
al practice. T
of SGLT2 in
s were searc
July 1, 2014
edication th
ey were pre
tion was writ
view of 119 p
ollected to in
medications
y the Public A
eetingcts
into unknown
er 2 inhibito
been demon
nefit in patie
uding weight
hese medica
ffect profile
The purpose
hibitors at o
ched to iden
to July 31, 2
herapy start
escribed SGL
tten by a pro
patients was
nclude: hem
s, and docum
Affairs Office
characters.
or use in a
nstrated to
ents with
t loss and
tions are
raises conce
e of this stud
our military
ntify SGLT2
2017. The da
date. Patien
LT2 inhibitor
ovider outsi
s performed
moglobin A1C
mented side
er/QI Review
ern
dy is
ata
nts
s
de of
d.
C,
w
*Special sy
Results: A
from 30 t
over 95 p
prescribe
these me
patients)
patients,
loss of gr
patients
however
adherenc
genitour
Conclusio
growing
review co
pressure
but was n
DISCLAIM
The view
policy of
ymbols that w
A total of 11
to 78 years w
patients had
ed SGLT2 inh
edications by
). This review
greater tha
reater than 1
continued w
r, 48 patients
ce, and lost t
inary infecti
on: The use
evidence of
onfirms the
and weight
not solely at
MER
ws expressed
Departmen
2018ASProf
ere not spelled
19 patient ch
with the me
diagnosis o
hibitor was e
y a clinical p
w showed h
n 5 mmHg r
1kg in 82 pat
with SGLT2 in
s discontinu
to follow‐up
on and poly
of SGLT‐2 in
cardiovascu
positive ben
. Concern fo
ttributed to
in this abstr
t of the Arm
SHPMidyfessional
d‐out per the g
harts were re
dian age of 5
f hypertensi
empagliflozin
harmacist (6
emoglobin A
eduction in
tients. Med
nhibitors as
ed use durin
p. Of the thi
uria only 11
nhibitors in t
ular benefit i
nefit of the S
or medicatio
side effects.
ract are thos
my, Departme
yearClinlPoster
guidelines wer
eviewed ret
58. Of the in
ion and/or h
n. More tha
69 patients)
A1C reductio
systolic bloo
ication pers
part of their
ng the study
rty‐six patie
of them dis
the treatmen
n patients w
SGLT2 inhibit
n persistenc
se of the Au
ent of Defen
nicalMeAbstrac
re translated i
rospectively
ncluded pati
hyperlipidem
an half of the
followed by
on of greate
od pressure
sistence eval
r medication
y period due
nts that rep
scontinued t
nt of diabete
with diabete
tors in lowe
ce in clinical
thors and do
nse, or the U
eetingcts
into unknown
y. The baseli
ents, 82 pat
mia. The mos
e patients w
y endocrinol
r than 0.2 pe
in 60 patien
luation reve
n therapy for
to side effe
orted side e
herapy due
es is on the r
s. This retro
ring hemogl
practice wa
o not reflect
U.S. Governm
characters.
ne age range
tients were m
st commonly
were prescrib
ogists (24
ercent in 85
nts, and weig
aled that 71
r diabetes;
cts, non‐
effects includ
to intoleran
rise due to t
ospective ch
obin A1c, bl
s also confir
t the official
ment.
ed
male,
y
bed
ght
1
ding
nce.
the
art
ood
rmed
*Special sy
Session‐B
Poster Ti
Poster Ty
Submissi
Primary A
Email: ka
Addition
Jaesong K
Eunsun S
Kyenghe
Purpose:
of Food a
prescript
combina
drugs tog
purpose
personal
Methods
recomme
2017 in a
and the e
analyze t
avoid com
of contro
number o
medical r
Results: A
kinds of c
cases wa
(35.9%) a
ymbols that w
Board # ‐ 1‐0
itle: Analysis
ype: Descrip
ion Category
Author: Kyu
alee313@yu
al Authors:
Kim
Son
e Kwon
: In accordan
and Drug Saf
tion control t
tion since 20
gether. Yet,
of guiding sa
injury and m
s: This study
ended to use
a single terti
emergency s
the prescript
mbined pres
ol. For safety
of days of ho
records and
Among the p
combination
s 306. Of th
and the incid
2018ASProf
ere not spelled
017
s of prescrip
ptive Report
y: Drug Infor
unga Lee; Yo
hs.ac
nce with the
fety(MFDS)
through a co
006. Howeve
follow‐up st
afe drug use
monitoring p
was conduc
e together d
ary general
situations su
tion status, w
scription, nu
y evaluation,
ospital stay w
analyzed us
prohibited d
ns prescribed
e total presc
dence of adv
SHPMidyfessional
d‐out per the g
tions that ar
rmation/Dru
nsei Univers
e Drug utiliza
in 2004, a si
omputer pro
er, in order t
tudies are lac
e by analyzin
performance
cted for pati
during the ho
hospital in K
uch as cardio
we collected
umber of day
, data on mo
were collect
sing IBM SPS
drug combin
d in the hosp
criptions, the
verse events
yearClinlPoster
guidelines wer
re not recom
ug Use Evalu
sity Healthca
ation review
ngle tertiary
ogram for dr
to treat cert
cking. There
ng the status
e rate which
ents who re
ospitalizatio
Korea. The ca
opulmonary
d data on the
ys together,
onitoring pe
ted. The data
SS Statistics v
ations anno
pital for the
e actual follo
s was 42 case
nicalMeAbstrac
re translated i
mmended fo
uation
are System;
program de
y general ho
rugs prohibit
tain patients
efore, this st
s of prescript
was selectiv
eceived med
n period fro
ases were no
resuscitatio
e combinatio
and reasons
rformance, i
a were retro
ver. 23.0(IBM
unced by th
past one ye
ow‐up moni
es (13.7%). H
eetingcts
into unknown
or use togeth
eveloped by
spital has be
ted to be use
s, it is inevita
udy was con
tion includin
vely allowed
ications that
m August 1,
ot administe
n were exclu
on of medic
s for request
interaction r
ospectively c
M Co., Armo
e MFDS, the
ear and the t
toring rate w
However, 17
characters.
her
Korea Minis
een conduct
ed in
able to use t
nducted for t
ng incidence
d.
t are not
, 2016 to Jul
ered togethe
uded. In ord
ines, reason
ting cancella
rate, and
collected usi
onk, NY, USA
ere were 17
total numbe
was 110 case
76 cases (57
stry
ting
he
the
e of
y 31,
er
er to
ns to
ation
ng
A).
r of
es
.5%)
*Special sy
were not
for childr
medicati
cases (12
recomme
Although
this study
pharmac
elderly.
Conclusio
considere
considera
particula
adverse d
also post
This will
compreh
ymbols that w
t identified b
ren under 18
ons due to r
2.1%) respec
ended to use
h follow‐up m
y. Therefore
cist, to increa
on: Drugs th
ed in conjun
ation. In add
r, it is neces
drug reactio
t‐manageme
serve as the
hensive stud
2018ASProf
ere not spelled
because mon
8 years old a
relatively hig
ctively, accou
e together a
monitoring s
e, additional
ase it. In par
hat are not re
nction with t
dition, patien
ssary to focu
ons. This stud
ent status su
basis for sa
ies.
SHPMidyfessional
d‐out per the g
nitoring was
and geriatric
gh risk of adv
unting for 50
announced b
should be ac
measures a
rticular, it is
ecommende
he patient's
nts should b
s on childre
dy has signif
uch as monit
fer drug use
yearClinlPoster
guidelines wer
s not perform
s aged 65 ye
verse drug r
0.3%. The co
by MFDS is h
ccompanied,
re needed, s
necessary to
ed to use tog
clinical situ
be monitored
n and the el
icance in an
oring perfor
e. Further mu
nicalMeAbstrac
re translated i
med. In addi
ears or older
eactions we
ombination o
ighly likely t
, a low moni
such as follo
o concentrat
gether are h
ation, taking
d continuou
derly who a
alyzing not o
rmance rate
ulti center st
eetingcts
into unknown
tion, the pre
r who requir
ere 117 cases
of drugs tha
to cause har
toring rate w
ow‐up check
te on childre
highly risky a
g risks and b
sly for the p
re relatively
only prescrip
and sympto
tudies are n
characters.
escription ra
red careful u
s (38.2%) an
t are not
m to patient
was observe
k by the
en and the
nd should b
benefits into
prescriptions
y vulnerable
ption status
om incidence
eeded for m
ate
use of
nd 37
ts.
ed in
e
s. In
to
but
e.
more
*Special sy
Session‐B
Poster Ti
knowledg
Lebanon
Poster Ty
Submissi
Primary A
Email: 21
Addition
Reem Sa
Zeina Far
Dalal Ham
Purpose:
psycholo
provide a
different
improvem
knowledg
participa
Methods
in a priva
with acne
question
test com
After the
vulgaris b
handout,
develope
vulgaris p
counselin
improvem
ymbols that w
Board # ‐ 1‐0
itle: Effect o
ge improvem
, 2018
ype: Descrip
ion Category
Author: Hib
1230690@st
al Authors:
yed
rah
mmoudi
: Acne vulga
ogical impact
appropriate
t counseling
ment in know
ge retention
nts with the
s: An interve
ate universit
e vulgaris, w
naires and t
posed of mu
e pre‐test, pa
by one of tw
, or website‐
ed for the stu
pathophysio
ng by either
ment. Moreo
2018ASProf
ere not spelled
018
f face‐to‐fac
ment and ret
ptive Report
y: Drug Infor
a Saty; Leba
tudents.liu.e
ris is a comm
t. Proper cou
education. T
methods, fa
wledge abou
n one month
e two counse
entional stud
y in Bekaa g
were selected
tests, includi
ultiple‐choic
articipants w
wo methods:
‐based coun
udy. Both co
ology, risk fac
of the two m
over, a parti
SHPMidyfessional
d‐out per the g
ce and webs
tention amo
rmation/Dru
nese Interna
edu.lb
mon skin dis
unseling is n
The objectiv
ace‐to‐face c
ut acne vulg
h after the co
eling method
dy was cond
governorate,
d. Two clinic
ng a questio
e questions
were random
face‐to‐face
nseling using
ounseling me
ctors, medic
methods, a p
icipant satisf
yearClinlPoster
guidelines wer
ite‐based co
ong universit
ug Use Evalu
ational Univ
order of ado
eeded to all
ves of this stu
counseling v
aris among
ounseling; an
ds.
ucted on firs
, Lebanon, in
cal pharmaci
onnaire for d
to detect ba
mly assigned
e counseling
an in‐house
ethods offer
cations, and
post‐test wa
faction ques
nicalMeAbstrac
re translated i
ounseling me
ty students i
uation
versity;
olescents tha
eviate acne
udy were to
ersus websit
university st
nd to evalua
st and secon
n 2018. Stud
ists conduct
demographic
aseline know
to receive c
g by the clini
e website ab
red the same
education. I
as administe
stionnaire w
eetingcts
into unknown
ethods in ac
in Bekaa gov
at has major
vulgaris sign
o compare th
te‐based co
tudents; to d
ate satisfacti
nd year univ
dents, from d
ed the study
c data, follow
wledge abou
counseling a
ical pharmac
bout acne vu
e informatio
Immediately
red to asses
was used to e
characters.
cne vulgaris
vernorate,
r physical an
ns and to
he effect of t
unseling, on
detect
ion of
ersity stude
different ma
y, using a set
wed by a pre
ut acne vulga
bout acne
cists, aided b
ulgaris specia
on about acn
y following t
ss knowledge
evaluate eac
nd
two
n the
nts
ajors,
t of
e‐
aris.
by a
ally
ne
he
e
h of
*Special sy
the two m
retention
analyses
Results:
with a m
learning
No assoc
post‐test
website‐
to‐face c
There wa
knowledg
mean sco
As a who
percent c
face‐to fa
group.
Conclusio
and com
despite f
methods
The webs
tradition
populatio
allow ret
ymbols that w
methods. On
n. Pre‐ and p
for indepen
One‐hundre
ean age of 2
methods, w
ciation was f
t scores show
based couns
ounseling m
as no signific
ge after one
ore of 14.0 ±
ole, 70% of p
considered t
ace group w
on: The face
parable in im
face‐to‐face
s may be use
site‐based m
al methods.
on, the webs
tention of kn
2018ASProf
ere not spelled
ne month lat
post‐tests we
ndent and pa
ed‐and‐twelv
20.0 ± 1.5 ye
ith reading a
ound betwe
wed improve
seling metho
method from
cant differen
e month was
± 6.0 and fac
participants w
that the stud
were more sa
e‐to‐face and
mproving kn
counseling m
ed by pharm
method offer
Given the w
site‐based c
nowledge ab
SHPMidyfessional
d‐out per the g
ter, the post
ere correcte
aired groups
ve students w
ears. Eighty p
and listening
een type of c
ement (P‐va
od scores ha
9.8 ± 4.0 to
nce between
s observed in
ce‐to‐face co
were satisfie
dy helped th
atisfied with
d the websit
owledge ab
method bein
acists to suc
rs a promisin
wide use of t
ounseling ca
bout commo
yearClinlPoster
guidelines wer
t‐test was re
ed and grade
were perfo
were recruit
percent felt t
g together, c
counseling a
lue <0.05) in
ad a mean ris
15.3 ± 4.2 i
n the two co
n both webs
ounseling me
ed with the c
hem underst
the counsel
te‐based cou
out acne vu
ng considere
ccessfully de
ng opportun
the Internet
an support p
n disorders
nicalMeAbstrac
re translated i
epeated to d
ed out of 24.
rmed using
ted for the s
that they lea
compared to
nd baseline
n both group
se from 9.7
n the pre‐ an
unseling me
site‐based co
ethod with a
counseling s
and acne. H
ling session
unseling met
lgaris among
ed more enjo
eliver inform
nity for coun
and techno
pharmacist c
like acne vu
eetingcts
into unknown
determine kn
. Descriptive
SPSS version
study, 85% w
arn better u
o computer‐
characterist
ps in all ques
± 4.0 to 16.1
nd post‐test
ethods. The r
ounseling me
a mean scor
sessions. Sev
owever, par
compared to
thods were
g university
oyable by pa
ation about
seling, and i
logy among
counseling to
ulgaris.
characters.
nowledge
e and univari
n 17.
were females
sing face‐to‐
based meth
tics. Pre‐ and
stions. The
1 ± 4.0, and
ts respective
retention of
ethod with a
e of 15.0 ± 5
venty‐seven
rticipants in
o the websit
both effectiv
students,
articipants. B
acne vulgar
is as effectiv
such
o provide an
iate
s,
‐face
ods.
d
face‐
ely.
f
a
5.0.
the
te
ve
Both
ris.
ve as
nd
*Special sy
Session‐B
Poster Ti
managem
Poster Ty
Submissi
Primary A
Email: ry
Addition
Yuichi Sa
Shoji Yam
Purpose:
morbidit
institutio
disease (
October
managem
factors a
Methods
2007 and
physician
based on
we provi
of antifu
candidias
cultures
out endo
duration
received
was exam
was perf
ymbols that w
Board # ‐ 1‐0
itle: Prognos
ment of cand
ype: Evaluat
ion Category
Author: Ryu
yuichi_hirano
al Authors:
kamoto
mamoto
: Candidemia
y. Detailed i
on’s practica
ID) consulta
2015. Few s
ment of cand
nd evaluate
s: A total of
d December
ns and infect
n the results
ded the follo
ngal therapy
sis guideline
to confirm t
ophthalmitis
of therapy w
these bund
mined by Ka
ormed to id
2018ASProf
ere not spelled
019
stic factors a
didemia: a te
tive Study
y: Infectious
uichi Hirano;
a is an impo
nvestigation
l data are es
tions by an
tudies have
didemia. The
the impact
121 patients
2016 were e
tious disease
of blood cu
owing items
y based on t
es, 2; remova
he clearance
, 5; an adeq
were evalua
les were def
plan‐Meier p
entify factor
SHPMidyfessional
d‐out per the g
and the impa
ertiary hosp
s Disease / H
Aomori Pre
f.aomori.jp
rtant nosoco
ns on the pro
ssential for b
antifungal st
been condu
e objectives
of ID consul
s diagnosed
enrolled in t
e‐specialized
lture tests w
s to physician
he Infectiou
al of a centra
e of Candida
uate duratio
ted using th
fined as the
plots and th
rs associated
yearClinlPoster
guidelines wer
act of infecti
ital experien
HIV
fectural Cen
omial infect
ognostic fact
better mana
tewardship
ucted on the
of the prese
tations on t
with candid
the present s
d pharmacist
were perform
ns as a bund
s Disease So
al venous ca
a species, 4;
on of therapy
he IDSA cand
ID consultat
e Log‐rank t
d with death
nicalMeAbstrac
re translated i
ious disease
nce in Japan
ntral Hospita
ion due to it
tors of cand
gement. In o
(AFS) team w
e impact of ID
ent study we
he managem
demia in our
study. Our A
ts. Prospect
med. Among
dle: 1; initiat
ociety of Am
atheter (CVC
ophthalmol
y. The dosag
didiasis guide
tion group. T
test. A multiv
h. P values le
eetingcts
into unknown
e consultatio
al;
ts high mort
idemia base
our hospital
were implem
D consultati
ere to identi
ment of cand
hospital bet
AFS team con
ive audits an
g patients wi
ion of an ad
merica (IDSA)
C), 3; follow‐u
ogical consu
ge of antifun
elines. Fiftee
The 30‐day m
variate Cox h
ess than 0.05
characters.
ons on the
ality and
ed on each
, infectious
mented from
ons on the
fy prognosti
didemia.
tween Janua
nsists of
nd feedback
th candidem
equate dosa
) published
up blood
ultations to r
ngal agents a
en patients w
mortality rat
hazard analy
5 were
m
ic
ary
k
mia,
age
rule
and
who
te
ysis
*Special sy
considere
institutio
Results: T
114 patie
therapy w
fluconazo
itraconaz
Between
the appro
consultat
consultat
consultat
(ID consu
observed
according
therapy,
significan
surgical w
Conclusio
Our ID co
no signifi
prompt a
outcome
ymbols that w
ed to be sign
on.
The 30‐day
ents. The me
was 2 (range
ole 28.9%, m
zole 2.5%, an
n patients wi
opriate dosa
tions 44.4%)
tions 100% v
tions 80% vs
ultations 60%
d in the 30‐d
g to the Log
an advance
nt factors fo
wards were
on: Approxim
onsultations
icant differe
administratio
es among pa
2018ASProf
ere not spelled
nificant. The
mortality rat
edian numbe
e of 0‐9 days
micafungin 5
nd caspofun
th and witho
age of antifu
), follow‐up
vs. without I
s. without ID
% vs. withou
day mortality
‐rank test (P
d age, lung d
r a high mor
associated w
mately 50%
using bundl
ences were o
on of antifun
tients with c
SHPMidyfessional
d‐out per the g
e study proto
te was 33%.
er of days fro
s). The propo
1.2%, liposo
gin 2.5%.
out ID consu
ungal therap
blood cultur
D consultati
D consultatio
ut ID consult
y rate (ID con
P value of 0.3
diseases, and
rtality rate, w
with a lower
of patients
les contribut
observed in m
ngal therapy
candidemia.
yearClinlPoster
guidelines wer
ocol was app
Systemic an
om blood cu
ortion of eac
omal amphot
ultations, sig
y (ID consult
res to confir
ions 56.5%),
ons 41.4%), a
ations 15.1%
nsultations 2
38). Candida
d mechanica
whereas C. p
mortality ra
received mic
ted to the be
mortality rat
y and remov
nicalMeAbstrac
re translated i
proved by th
ntifungal age
ultures to th
ch antifunga
tericin B 6.6
gnificant diff
tations 86.6
m the cleara
, ophthalmo
and an appro
%). No signif
20% vs. with
a albicans, th
al ventilation
parapsilosis,
ate.
cafungin as a
etter manag
tes. In terms
val of CVC we
eetingcts
into unknown
he ethics com
ents were ad
e initiation o
al agent was
6%, voricona
ferences wer
6% vs. withou
ance of Cand
ological cons
opriate dura
ficant differe
hout ID cons
he absence o
n were ident
the remova
an initial ant
gement of th
s of practica
ere essentia
characters.
mmittee in o
dministered
of antifunga
as follows:
zole 2.5%,
re observed
ut ID
dida species
ultations (ID
ation of ther
ences were
ultations 30
of antifunga
tified as
al of CVC, an
tifungal ther
herapy; how
l procedures
l for favorab
our
to
l
in
(ID
D
rapy
0.3%)
l
d
rapy.
wever,
s, the
ble
*Special sy
Session‐B
Poster Ti
increase
Poster Ty
Submissi
Primary A
Email: je
Addition
Cheree S
Xai Yang
Purpose:
and Vete
to the ge
care prov
provider
tested, a
improve
technicia
Methods
from labo
defined w
outreach
duplicate
lancet de
reusable
device w
kits onlin
sensitivit
Pharmac
POC test
patient lo
ymbols that w
Board # ‐ 1‐0
itle: Pharma
antibody te
ype: Descrip
ion Category
Author: Jen
nnifer.siilata
al Authors:
Sosin
: Patients bo
erans are at a
eneral popul
viders. Our
education,
nd commun
test rates, a
ans to increa
s: Pharmacis
oratory serv
when the tes
h visits. Patie
e testing. Sp
evice. The P
test stands,
was used for e
ne and hands
ty tests with
cy staff was g
was conduc
og. If a patie
2018ASProf
ere not spelled
020
acy‐impleme
sting in vete
ptive Report
y: Infectious
nifer Siilata;
orn between
a 25 percent
ation. HCV a
HCV staff us
patient educ
nity educatio
a POC antibo
ase testing a
st from HCV
vice to estab
sts could be
ent’s electro
pecimens co
OC kits purc
, and specim
every patien
s‐on use. La
statistic agr
given access
cted results w
ent had a ne
SHPMidyfessional
d‐out per the g
ented hepati
eran birth co
s Disease / H
Departmen
n 1945 to 196
t higher cha
antibody tes
sed multiple
cation throu
on by speakin
ody test prot
mong rural,
clinic worke
lish POC tes
used such a
onic chart wa
llected are c
chased includ
men collectio
nt. Pharmac
aboratory co
reement of 9
to entering
were ready
egative resul
yearClinlPoster
guidelines wer
tis C virus (H
ohort popula
HIV
nt of Veteran
65 are consi
nce of havin
sting is not r
campaigns t
ugh letters an
ng at various
tocol was im
homeless an
ed in collabo
ting protoco
as at health f
as checked b
capillary fing
de single use
on loops. Int
cy staff were
onducted val
95 percent c
results into
in 20 to 40 m
t, no further
nicalMeAbstrac
re translated i
HCV) point o
ation
ns Affairs;
idered a high
ng contracte
routinely do
to increase V
nd phone ca
s Veteran‐sp
mplemented
nd patients
oration with
ol for HCV. A
fairs, stand d
before testin
gerstick who
e test device
ternal quality
e trained and
lidation verif
confidence le
o patient’s el
minutes and
r action was
eetingcts
into unknown
of care (POC)
h risk popula
d the diseas
ne through p
Veteran test
alls urging th
ponsored ev
for pharmac
without tran
ancillary tes
A policy was
down events
ng was cond
le blood tak
e, developer
y control bu
d certified to
fication usin
evel prior to
ectronic cha
d recorded o
s needed oth
characters.
) test protoc
ation for HCV
se as compar
patients’ pri
ting includin
hem to get
vents. To fur
cists and clin
nsportation.
sting coordin
s established
s, and home
ucted to pre
ken by using
r solution,
uilt in to the
o use the PO
ng specificity
field use.
art. Once th
n approved
her than to n
col to
V
red
mary
ng
rther
nical
.
nator
d that
eless
event
a
OC
y and
he
notify
*Special sy
the patie
confirm a
Results:
in the bir
patients
Of the pa
Conclusio
come to
facilities,
to no add
all Vetera
initiate th
liked. Th
attend th
sent to p
POC test
continue
done twi
There are
has been
testing w
ymbols that w
ent. If a posi
active infect
In fiscal year
rth cohort. T
have been t
atients teste
on: HCV POC
the laborato
, increased a
dress or pho
ans regardle
he POC testi
here are still
hese staffed
patients in ad
ing could be
e to do outre
ce weekly, b
e additional
n a success w
would not ha
2018ASProf
ere not spelled
itive antibod
tion.
r 2018, there
There have b
ested. This
ed, zero have
C protocol a
ory, increase
awareness an
one number
ess if they we
ing, the quan
many more
outreach ev
dvance, only
e improved if
each among
but in 2018,
outreach ev
with an incre
ve been don
SHPMidyfessional
d‐out per the g
dy resulted, t
e are 1899 p
been four ev
represents t
e been posit
llowed an in
ed convenien
nd educatio
listed, and i
ere in the bi
ntity of patie
patients in t
vents. Altho
y a few of the
f staff could
the homeles
outreach wa
vents planne
ease in the n
ne at all.
yearClinlPoster
guidelines wer
then follow‐
patients nee
vents attend
two percent
ive.
ncrease in te
nce for patie
n for patient
ncreased tes
rth cohort.
ents reached
the birth co
ough invitatio
e patients w
attend mor
ss populatio
as stopped d
ed through F
umber of pa
nicalMeAbstrac
re translated i
‐up HCV RNA
ding to be te
ded thus far
t of the popu
esting among
ents who live
ts whose co
sting, educa
Because lim
d was not as
hort that ne
on letters ab
who received
re outreach e
on. In 2017,
due to chang
Fiscal Year 20
atients being
eetingcts
into unknown
A viral load w
ested out of
in which a to
ulation need
g patients w
e far from th
ntact have b
ation and aw
mited staff w
s many as we
eed to be tes
bout local ar
d the letters
events regu
HCV homele
ges in staffin
018. Overal
g tested, for
characters.
was needed
f the total 12
otal of 41
ding to be te
who are unab
he laborator
been limited
wareness am
as used to
e would hav
sted who do
rea events w
would show
larly and
ess outreach
ng priorities.
l, the progra
whom with
to
2,798
sted.
ble to
ry
d due
ong
ve
not
were
w up.
h was
.
am
out
*Special sy
Session‐B
Poster Ti
type 2 di
Poster Ty
Submissi
Primary A
Email: am
Addition
Marlene
Purpose:
treatmen
(HbA1c)
the impa
neuropat
2 diabete
Methods
patients
to identif
Patients
Providen
Patients
follow‐up
hospice o
achievem
HbA1c, w
paired t‐t
detect a
1.2% and
date to e
progress
macrova
ymbols that w
Board # ‐ 1‐0
itle: Effect o
abetes mell
ype: Evaluat
ion Category
Author: Am
my_stamand
al Authors:
Callahan
: The primar
nt of Hepatit
in patients w
act of therap
thy) and ma
es mellitus in
s: A retrospe
with chronic
fy patients t
were includ
nce Veterans
were exclud
p, or died be
or palliative
ment of susta
which was an
test. We est
0.37% differ
d an alpha le
either death
ion of micro
scular comp
2018ASProf
ere not spelled
021
f successful
itus in Unite
tive Study
y: Infectious
y St. Amand
ry objective o
tis C with an
with type 2 d
py on microv
crovascular
n the vetera
ective cohort
c Hepatitis C
reated from
ed in the stu
s Affairs Med
ded from the
efore sustain
services at t
ained virolog
nalyzed for t
timated that
rence in HbA
evel of 0.05.
or the end o
ovascular com
plications (st
SHPMidyfessional
d‐out per the g
hepatitis C t
ed States vet
s Disease / H
d; Providence
du
of this study
tiviral pharm
diabetes me
vascular com
complicatio
n population
t analysis wa
C and T2DM.
m January 1, 2
udy if they co
dical Center
e study if the
ned virologic
time of enro
gic response
the 24‐mont
t a sample si
A1c pre‐ and
As a second
of the study
mplications
roke, myoca
yearClinlPoster
guidelines wer
treatment o
terans
HIV
e Veterans A
y was to dete
macotherapy
llitus (T2DM
mplications (r
ns (stroke, m
n with Hepa
as conducte
The local H
2005 to June
ompleted an
and had a d
ey did not co
c response co
ollment. Pati
e. The prima
th period pre
ze of 90 pat
d post‐ treatm
ary analysis,
period and
(retinopathy
ardial infarct
nicalMeAbstrac
re translated i
on glycemic c
Affairs Medic
ermine the i
y on the cha
M). In additio
retinopathy,
myocardial i
titis C.
d through e
epatitis C cli
e 30, 2016 in
ntiviral Hepa
diagnosis of t
omplete anti
ould be asse
ients were c
ry outcome
e‐treatment
ients would
ment assum
, patients w
assessed for
y, nephropa
tion, death).
eetingcts
into unknown
control and c
cal Center;
impact of su
ange in hemo
on, this study
, nephropath
nfarction, an
lectronic cha
inical case re
n the pharm
atitis C treat
type 2 diabe
iviral therap
essed, or we
characterized
was the cha
t and post‐tr
provide 80%
ming a standa
ere followed
r the inciden
thy, neurop
characters.
complication
uccessful
oglobin A1c
y investigate
hy, and
nd death) of
art review in
egistry was u
macy liver clin
ment at the
etes mellitus
py, were lost
ere enrolled
d based upo
ange in mea
reatment usi
% power to
ard deviation
d from the in
nce or
athy), and
ns of
ed
f type
n
used
nic.
s.
to
in
on
n
ing a
n of
ndex
*Special sy
Results: A
study. Fo
post‐trea
The chan
as oppos
achieve S
patients
HbA1c of
study pe
diabetes
numerica
Conclusio
statistica
month pe
baseline
a greater
data. Enr
potentia
ymbols that w
A total of 72
or all patient
atment HbA1
nge in mean
sed to those
SVR, the HbA
is too small
f greater tha
riod of near
care team h
ally higher in
on: Treatme
ally significan
eriod post‐t
HbA1c grea
r reduction i
rollment in m
l confoundin
2018ASProf
ere not spelled
2 patients m
ts, the avera
1c was 6.91%
HbA1c was
who did not
A1c actually
(n = 6) to dr
an or equal t
ly 1.0%. Pat
had a greate
n the group o
ent of Hepat
nt reduction
reatment. T
ter than or e
n HbA1c, alt
metabolic cli
ng variable.
SHPMidyfessional
d‐out per the g
et inclusion
ge pre‐treat
% ± 0.99; ‐0.
greater in pa
t achieve vir
rose on ave
raw any mea
to 7.0% show
tients enrolle
r reduction
of patients w
itis C with an
in HbA1c fr
he reduction
equal to 7.0%
though the s
inic, diabete
yearClinlPoster
guidelines wer
and exclusio
tment HbA1c
.39% ± 1.23%
atients who
ral suppressi
erage by nea
aningful conc
wed a greate
ed in metab
in mean HbA
who did not
ntiviral thera
om the 24‐m
n in HbA1c w
%. Sustained
size of the po
es care team
nicalMeAbstrac
re translated i
on criteria a
c was 7.29%
% [95% CI ‐0
achieved a
ion. In the gr
rly 0.5%. Ho
clusions. Pat
er reduction
olic clinic, e
A1c. Macrov
achieve a su
apy was asso
month perio
was greater
d virologic re
opulation lim
, or endocrin
eetingcts
into unknown
nd were eva
% ± 1.12 and
0.67 to ‐0.11
sustained vi
roup of patie
owever, this
tients with a
in mean Hb
ndocrinolog
vascular com
ustained viro
ociated with
d pre‐treatm
among patie
esponse was
mits interpre
nology clinic
characters.
aluated in th
the average
], p‐value < 0
irologic resp
ents who did
group of
a higher base
bA1c over th
gy clinic, or
mplications w
ologic respo
h a minor bu
ment to the
ents with a
s associated
etation of th
c represents
he
e
0.01.
ponse
d not
eline
e
were
nse.
ut
24‐
with
his
a
*Special sy
Session‐B
Poster Ti
deperson
Poster Ty
Submissi
Primary A
Email: ke
Addition
Daniel He
Shawn D
Purpose:
Affairs (V
an “All Em
changes
action pl
deperson
this inter
quarterly
Methods
concerns
split into
three to
and topic
custome
size, acco
care, act
cook‐off)
massage
adequate
cancelled
ymbols that w
Board # ‐ 1‐0
itle: Quarter
nalization re
ype: Descrip
ion Category
Author: Kell
elly.moran@
al Authors:
eser
alton
: Organizatio
VA) to help b
mployee Sur
in the facilit
an for areas
nalization ar
rvention was
y pharmacy t
s: Pharmacy
s with burn o
two blocks
four speake
cs were chos
r service, ch
ountability, p
ive listening
) and treats f
s as part of t
e coverage o
d clinic durin
2018ASProf
ere not spelled
022
rly training d
duction
ptive Report
y: Leadershi
ly Moran; Sh
@va.gov
onal satisfac
build a collab
rvey” (AES) a
ty and work g
identified in
e two areas
s to improve
training day
supervisors
out and depe
which were
rs from diffe
sen based on
oice, food a
promotion o
, and a lab t
for the staff
the training
of essential f
ng training ti
SHPMidyfessional
d‐out per the g
days: manag
p Developm
heridan VAH
tion and em
borative, inc
as a tool to a
group. Each
n the AES wh
in the AES t
e AES results
s.
implemente
ersonalizatio
each three
erent discipl
n employee
s medicine,
opportunitie
our. In addi
f (ice cream s
day. Pharm
functions in
me. Team b
yearClinlPoster
guidelines wer
ement strat
ment
CS;
mployee enga
lusive and re
assess emplo
h year work g
hich need im
that indicate
s in burnout
ed quarterly
on from the
hours in len
ines along w
suggestions
battlefield a
s, ethics, du
tion, superv
sundaes, esp
macy staff wa
pharmacy, a
building activ
nicalMeAbstrac
re translated i
egy to engag
agement is a
esults‐orient
oyee satisfac
groups are e
mprovement
e employee w
and deperso
y a “Pharmac
2016 AES. T
gth. Each tr
with a team b
s. Training t
acupuncture
uress and cod
visors organi
presso bar, s
as split into t
and Clinical P
vities includ
eetingcts
into unknown
ge staff in b
a high priorit
ted culture.
ction and m
encouraged
t. Burnout a
withdrawal.
onalization b
cy Training D
The training
raining sessi
building acti
opics includ
e, self‐care, h
de procedur
ized lunch (c
smoothies)
two groups t
Pharmacy Sp
ed walking a
characters.
urnout and
ty for Vetera
The VA utili
ake positive
to create an
and
The purpos
by implemen
Day” to addr
sessions we
on included
ivity. Activit
ed meditatio
health at eve
res, recovery
chili and coo
as well as
to ensure
pecialists
and history t
ans
zes
e
n
se of
nting
ress
ere
ties
on,
ery
y
okie
tour
*Special sy
of campu
complete
Results: T
complete
were wo
positive l
percent o
year the
workplac
deperson
the AES.
number i
satisfacti
including
outside”,
our every
Conclusio
workgrou
training d
providing
obtain co
other ite
ymbols that w
us, building a
e an evaluat
The first pha
ed to date. T
rthwhile. N
learning exp
of the pharm
employees a
ce and work
nalization de
In addition,
is more favo
ion remaine
g “great line
, and “I reall
yday routine
on: Pharmac
up within fiv
day is a nove
g a break fro
ontinuing ed
ms in the Al
2018ASProf
ere not spelled
a snowman
ion form at t
armacy train
Training day
inety‐nine p
perience and
macy staff ag
are encoura
place climat
ecreased fro
, burnout de
orable in bot
d the same b
up – I really
y enjoy train
e. Thank you
cy training d
ve months af
el approach
om the every
ducation for
l Employee S
SHPMidyfessional
d‐out per the g
and Easter e
the end of e
ning day star
evaluations
percent of em
d the content
greed/strong
ged to take
te on a scale
m fiscal yea
ecreased fro
th of these a
between FY
y learned a lo
ning day and
u for doing t
days decreas
fter receivin
to effectivel
yday pharma
the training
Survey.
yearClinlPoster
guidelines wer
egg hunt. Ph
each session
rted in June
overwhelm
mployees ag
t of the train
gly agreed th
the AES whi
of zero to fi
r (FY) 2016 t
m 2.57 in FY
reas. Workg
2016 to FY2
ot from this
d look forwa
these.”
ed burnout
g the 2016 A
ly addressing
acy routine.
sessions as
nicalMeAbstrac
re translated i
harmacy staf
.
2017 with a
ming felt the
greed/strong
ning was app
he training m
ich asks a va
ive. After tw
to FY2017, 3
Y 2016 to 2.1
group satisfa
2017. Emplo
training”, “lo
ard to them.
and deperso
AES results.
g concerns i
In the futur
well as inclu
eetingcts
into unknown
ff was encou
total of fou
pharmacy tr
gly agreed th
propriate. N
met their exp
ariety of que
wo pharmacy
3.29 to 2.32
12 in FY2017
action and o
oyee feedba
oved the act
Gives us a g
onalization i
Utilizing qua
dentified in
re, pharmacy
ude topics th
characters.
uraged to
r training da
raining days
he training w
Ninety‐six
pectation. E
estions abou
y training da
respectively
7. A lower
organization
ack is positiv
tivity getting
good break f
n the pharm
arterly pharm
the AES wh
y supervisor
hat address
ays
was a
ach
t the
ys,
y on
ve,
g
from
macy
macy
ile
s will
*Special sy
Session‐B
Poster Ti
Poster Ty
Submissi
Primary A
Email: m
Addition
Laida Elb
Teresa Ca
Fernando
María Isa
Purpose:
importan
achieve r
evaluate
secondar
patient's
Methods
cytostati
the ethic
Data coll
professio
Oncology
per day,
administ
Main var
dispensa
(visual an
if during
high adh
ymbols that w
Board # ‐ 1‐0
itle: Therape
ype: Evaluat
ion Category
Author: Ma
ariamatsal@
al Authors:
berdín Pazos
alleja Chuclá
o Busto Fern
abel Martín
: Compliance
nt for the suc
remission of
the adheren
ry objective
characterist
s: Prospectiv
c drugs in Ph
c committee
ected: relate
on), disease
y Group (ECO
frequency, f
ers: patient,
riable: % com
tions, 2)Mo
nalog scale o
the entire st
erence and
2018ASProf
ere not spelled
023
eutic adhere
tive Study
y: Oncology
ria Mateos S
@gmail.com
á
nández
Herranz
e of oral cyto
ccess of the
f the disease
nce to treatm
was to analy
tics, treatme
ve observatio
harmacy Ser
and informe
ed to patien
(diagnosis, s
OG), concom
fasting or foo
, supervised
mpliance. Me
risky‐Green
of 1‐10, from
tudy period:
3)Self‐asses
SHPMidyfessional
d‐out per the g
ence study to
/ Hematolo
Salvador; Xe
ostatic drugs
treatment.
e and avoid r
ment with o
yze the varia
ent and dise
onal study. A
rvice were in
ed consent w
t (sex, date
stage, date o
mitant diseas
od intake, al
administrat
easurement
Test, 3)Self‐
m worst to be
: 1)Measure
sment by th
yearClinlPoster
guidelines wer
o oral oncolo
gy
rencia Xestió
s of oncolog
The continu
relapses. The
ral cytostati
ables that ca
ase.
Adult patien
ncluded (Ma
was obtaine
of birth, livin
of diagnosis,
ses, mental d
lternative th
tion or by ca
t of adherenc
‐assessment
est complian
ment of adh
e patient 10
nicalMeAbstrac
re translated i
ogical medic
ón Integrada
gical patients
uity of the tre
e main objec
ic drugs in ca
an influence
nts who start
rch‐May 20
d for all sub
ng alone vs n
treatment l
disease) and
herapy, adve
regiver).
ce methods
t by the patie
nce). Patient
herence 100
0.
eetingcts
into unknown
cations
a A Coruña;
s at the amb
eatment con
ctive of the s
ancer patien
in adherenc
t treatment
17). Study w
jects.
not, toxic ha
line, Eastern
d treatment
erse effects (
: 1)Registrat
ent of their o
ts were cons
0%, 2)Morisk
characters.
bulatory leve
ntributes to
study was to
nts. The
ce related to
with oral
was approved
abits,
n Cooperativ
(drugs, tabl
(AE), medica
tion of
own adhere
sidered adhe
ky‐Green Tes
el is
o
o the
d by
ve
ets
ation
ence
erent
st
*Special sy
Statistics
accuracy
absolute
test or M
qualitativ
different
<0.05). S
Results:
patients.
system c
n=3(4.0%
and thyro
45.9%, IV
metastat
patients
14/74 me
pazopani
afatinib,
patients:
once a da
therapy.
caregiver
Adheren
(p=0.015
significan
Conclusio
bibliogra
The phar
contribut
his family
ymbols that w
s: Sample siz
y +/‐10%). Qu
value and p
Mann‐Whitne
ve variables:
t variables as
PSS softwar
74 patients.
41.9% activ
ancers n=7(9
%) and other
oid carcinom
V 54.1%. Tre
tic 35.1%, ot
ECOG=2‐3. 4
ental health
ib=2, osimer
axitinib and
1‐6 tablets/
ay, 71.6% tw
37.8% no AE
r/supervised
ce results: 7
5). Medicatio
nce was foun
on: The perc
phy. Sex and
rmacist must
te to an imp
y.
2018ASProf
ere not spelled
e determina
uantitative v
percentage (
ey test (acco
: Chi square
ssociated wi
e 19.0.
41/74 men.
ve work. Diag
9.5%), kidne
rs n=7(9.4%)
ma, prostate
atment line
thers metast
41.9% witho
patients. Tr
rtinib n=2, n
sorafenib. 4
/day, 39.1%
wice daily. Fo
E; 48.6%: 1‐2
d.
74.3% patien
on administe
nd in the oth
centage of a
d who admin
t be actively
provement o
SHPMidyfessional
d‐out per the g
ation (80% c
variables: me
95% confide
ording to nor
test or Fisch
th lack of ad
. 63.2+/‐11.5
gnostic: colo
ey cancer n=
(ovarian ca
cancer, neu
: adjuvant/n
tatic lines 17
out concomit
reatment: Ca
=1: imatinib
48.6% (36/74
patients: 7‐
ood: 71.6%;
2 AE; 13.5%
nts (55/74) 1
ers: 77.6% pa
her variables
dherent pat
nisters the m
y involved in
f therapeuti
yearClinlPoster
guidelines wer
ompliance s
ean +/‐ stan
ence interva
rmal Kolgom
her exact tes
dherence, lo
5 years old.
on/rectal can
7(9.5%), bre
ncer, melan
uroendocrine
neoadjuvant
7.6%. 33 pati
tant disease
apecitabine
b, enzalutam
4) concomit
16 tablets/d
fasting 14.9
: >=3 AE. 9.5
00%adheren
atient vs 42.
s evaluated.
tients was si
medication in
the detectio
ic complianc
nicalMeAbstrac
re translated i
similar to the
dard deviati
l). Comparis
morov‐Smirn
st. To determ
gistic regres
14.9% lived
ncer n=46(6
east cancer n
oma, gastro
e tumor, sof
therapy 47.
ients ECOG=
es, 32.4% 1‐2
n=49, temo
mide, everolim
ant intraven
day. Frecuen
%; indiffere
5% medicatio
nt. Sex: 85.4
.9% others (
milar to that
nfluence com
on of non‐ad
ce through e
eetingcts
into unknown
e published,
ion. Qualitat
son of means
ov test). Ass
mine the ass
ssion models
alone. 10.8%
2.2%), centr
n=4(5.4%), lu
ointestinal st
ft tissue sarc
.3%, first‐line
=0, 37 patien
2 diseases, 2
zolomide n=
mus, olapari
nous antineo
ncy of admin
nt 13.5%. 5.
on administ
4% men vs 60
p=0.045). No
t published
mpliance wi
dherent pati
education of
characters.
p<0.05,
tive variable
s: Student's
sociation of
sociation of
s were used
% smoking
ral nervous
ung cancer
tromal tumo
coma). Stage
e treatment
nts ECOG=1,
25.7% 3 or m
=7, sunitinib
ib, dabrafen
oplastic. 60.9
istration: 28
4% alternati
ered by
0.6% women
o statistical
in the
th treatmen
ients and
the patient
es:
T
(p
ors
e II/III
t of
4
more.
n=6,
ib,
9%
8.4%
ive
n
nt.
and
*Special sy
Session‐B
Poster Ti
Veterans
Poster Ty
Submissi
Primary A
Email: sh
Addition
Zachary A
Amy Bec
Benjamin
Michael
Purpose:
orthoped
mental h
operative
Salt Lake
Report (F
sorts foll
proportio
Methods
coordina
orthoped
and 06/0
care from
repositor
Veterans
pain scor
the FUR.
visit at ea
calculate
ymbols that w
Board # ‐ 1‐0
itle: Custom
s undergoing
ype: Descrip
ion Category
Author: Sha
hardool.pate
al Authors:
Anderson
kstead
n Brooke
Buys
: Chronic po
dic surgery. T
health diagno
e clinical pro
e City Health
FUR), a healt
ow‐up dates
on of Vetera
s: We perfor
tion after di
dic surgical p
01/2018, and
m TPS. The d
ry of medica
s with a com
res in the ele
The second
ach interval,
ed using the
2018ASProf
ere not spelled
024
ized health
g orthopedic
ptive Report
y: Pain Mana
rdool Patel;
st‐surgical p
The risk is es
oses. Develo
ogress, opioi
care System
th informati
s for pre‐spe
ans completi
rmed a retro
ischarge from
procedure at
d included th
ata source f
al and pharm
pleted follow
ectronic med
ary outcome
, based on su
Clopper‐Pea
SHPMidyfessional
d‐out per the g
information
c surgery
agement / P
Salt Lake Ci
pain (CPSP) a
specially hig
oping CPSP c
d usage and
m Transitiona
on technolo
ecified interv
ng follow‐up
ospective coh
m surgery. W
t the VA Salt
hose that we
for this inves
macy records
w‐up visit, d
dical record,
e was the pr
urgical proce
arson exact t
yearClinlPoster
guidelines wer
technology
Palliative Car
ty VA Medic
affects up to
h in Veteran
can lead to p
d CPSP risk fa
al Pain Servic
ogy (HIT). The
vals to priori
p at each int
hort study to
We identified
t Lake City H
ere assigned
stigation is t
s. The prima
defined by en
, at each of t
roportion of
edure. Confi
test for both
nicalMeAbstrac
re translated i
y effectively d
re
cal Center;
58 percent
ns due to the
prolonged op
actors, the V
ce (TPS) dev
e FUR calcul
itize care de
terval.
o evaluate t
d all Veteran
ealthcare Sy
d to receive p
he VA Corpo
ry outcome
ntry of both
the pre‐spec
Veterans w
idence interv
h the primar
eetingcts
into unknown
directs care
of patients f
e prevalence
pioid therap
Veterans Adm
eloped the F
lates and ch
elivery. We in
he role of th
ns discharge
ystem betwe
peri‐operativ
orate Data W
was the pro
a TPS progr
cified interva
with a comple
val (CI) estim
ry and secon
characters.
delivery in
following
e of concurre
y. To track p
ministration
Follow‐Up
ronologically
nvestigated
he FUR on ca
d from an
een 01/17/2
ve and follow
Warehouse,
oportion of
ress note and
als as shown
eted follow‐
mates were
ndary outcom
ent
post‐
n (VA)
y
the
are
2018
w‐up
a
d
n on
up
me.
*Special sy
Results: T
surgical p
For the p
2: 82 per
percent (
percent (
percent (
percent (
completi
confiden
complete
Conclusio
progress
high prop
between
optimizin
in other s
ymbols that w
The investig
procedures:
primary outc
rcent (95 per
(95 percent
(95 percent
(95 percent
(95 percent
on rates at e
ce intervals
ed follow‐up
on: A custom
, opioid use
portion of Ve
HIT and ded
ng care deliv
service lines
2018ASProf
ere not spelled
gation cohort
12 ankle, 14
come, we ob
rcent CI: 73 t
CI: 64 to 82)
CI: 58 to 78)
CI: 64 to 85)
CI: 53 to 90)
each interva
did not high
p.
mizable HIT
and pain sco
eterans with
dicated pop
very. Our mo
s within VA, a
SHPMidyfessional
d‐out per the g
t is comprise
4 hip, 38 kne
bserved the f
to 89); day‐7
); day‐14: 79
); day‐30: 78
); day‐90: 69
). In the seco
al, based on
hlight any sp
has allowed
ores for Vete
h completed
ulation‐heal
odel of TPS a
and beyond
yearClinlPoster
guidelines wer
ed of 96 Vet
ee, 29 should
following pro
7: 82 percen
9 percent (95
8 percent (95
9 percent (95
ondary outco
surgical proc
pecific surgic
TPS to effic
erans under
d follow‐up a
th programs
and the FUR
.
nicalMeAbstrac
re translated i
terans, accou
der and 7 ot
oportions fo
nt (95 percen
5 percent CI
5 percent CI
5 percent CI
ome, we obs
cedure. How
cal procedure
iently and e
rgoing ortho
at each evalu
s holds imm
can be repli
eetingcts
into unknown
unting for 10
ther orthope
or completed
nt CI: 73 to 8
: 69 to 86); d
: 67 to 86); d
: 54 to 81); d
served varia
wever, the o
e(s) as outlie
ffectively tra
pedic surge
uation interv
ense potent
icated to dir
characters.
00 orthoped
edic procedu
d follow‐up;
89); day‐10:
day‐21: 69
day‐60: 75
day‐120: 75
ations in
verlap of
ers for
ack clinical
ry. We repo
val. The syne
tial for
rect care del
dic
ures.
day‐
74
rt a
ergy
ivery
*Special sy
Session‐B
Poster Ti
response
Poster Ty
Submissi
Primary A
Email: la
Addition
Maria Ma
Maria Ou
Eduardo
María Isa
Purpose:
have bee
studies s
the studi
with pso
ustekinu
Methods
and mon
All patien
least 6 m
consent w
45 mg ev
dosage re
year. The
of the dr
quantifie
Data coll
previous
mg/Kg), c
ymbols that w
Board # ‐ 1‐0
itle: Therape
e.
ype: Evaluat
ion Category
Author: Laid
ida.elberdin
al Authors:
ateos Salvad
uteda Macía
Fonseca Cap
abel Martín
: In recent ye
en carried ou
hown a rela
es on clinica
riasis are pa
mab in patie
s: Observatio
nitored in the
nts should p
months (good
was obtaine
very 12 week
egimen indu
e serum leve
ug (Ctrough
ed by capture
ected: sex, a
treatment w
concomitant
2018ASProf
ere not spelled
025
eutic drug m
tive Study
y: Pharmaco
da Elberdín P
@gmail.com
dor
s
pdevila
Herranz
ears, studies
ut in rheuma
tionship bet
al relevance
rticularly sca
ents with mo
onal retrosp
e Pharmacy
resent a Pso
d responders
ed for all sub
ks if weight <
uction. Patie
els of ustekin
), after phar
e ELISA imm
age, weight,
with biologis
t treatment
SHPMidyfessional
d‐out per the g
monitoring of
okinetics
Pazos; Xeren
m
s about ther
atoid arthriti
tween clinica
of therapeu
arce. Our ob
oderate to se
ective study
Service was
oriasis Area S
s). The ethic
bjects before
<100 kg, and
nts should h
numab were
rmacist inter
munoassay (T
date diagno
st drugs, dur
(immunosu
yearClinlPoster
guidelines wer
f ustekinuma
ncia Xestión
apeutic drug
is, inflamma
al response a
utic drug mo
bjective is to
evere plaqu
y of all psoria
carried out
Severity Inde
cs committee
e entry in the
d 90 mg eve
have been tr
e assessed im
rview. The co
Triturus® ana
osis psoriasis
ration of ust
ppressive dr
nicalMeAbstrac
re translated i
ab in psorias
Integrada A
g monitoring
atory bowel
and serum c
nitoring for
analyze the
e psoriasis w
atic patients
from Septe
ex (PASI) les
e approved t
e study. Pati
ry 12 weeks
reated with u
mmediately p
oncentration
alyzer).
s, diagnosis
ekinumab tr
rugs, topical
eetingcts
into unknown
sis patients w
A Coruña;
g for biopha
disease and
concentratio
ustekinuma
e trough con
with good re
s treated wit
mber 2017 ‐
ss than 3 ma
this study. T
ients receive
s if weight> 1
ustekinumab
prior to the
ns of ustekin
psoriatic art
reatment, do
corticostero
characters.
with good
rmaceutical
psoriasis. Th
ons. Howeve
ab in patient
centrations
esponse.
th ustekinum
‐ February 2
intained for
The informed
ed ustekinum
100 kg after
b for at least
administrat
numab were
thritis (PA),
osage (mg a
oid and/or o
s
hese
er,
s
of
mab
018.
at
d
mab
t 1
ion
e
nd
oral,
*Special sy
retinoids
time (PA
Statistics
(median/
Results:
100 Kg. T
tumor ne
Treatme
2.0) mg/
26.6); PA
mcg/ml;
vs 0.90 (0
patients
45 mg m
negative
ratio (mg
Conclusio
between
a negativ
significan
usefulne
ymbols that w
s) PASI scale
SIe), ustekin
s: descriptive
/range) and
29 patients
Time since d
ecrosis facto
nt time: 67.3
Kg. Concom
ASIe 0.0 (0.0‐
Comparison
0.24 ‐ 2.8) m
were higher
edian 0.75 v
correlation
g/kg), but no
on: Drug con
ustekinuma
ve correlatio
nce between
ss of therap
2018ASProf
ere not spelled
before start
numab conce
e analysis of
qualitative (
(62.1% men
iagnosis 23 (
or (anti‐TNF)
3 (6.0‐108) m
itant treatm
‐3.0), 24/29
n ustekinuma
mcg/ml (p> 0
r than publis
vs 0.21‐0.26
was found b
o statistical s
ncentration
ab concentra
on between t
n ustekinum
eutic drug m
SHPMidyfessional
d‐out per the g
t of ustekinu
entration.
variables (S
(percentage
). Age: 51 (3
(4‐58) years
drugs (19/2
months. Dos
ment: 1‐acitre
patients PAS
ab concentr
.05). The co
shed in summ
mcg/ml; 90
between ust
significance w
was detecte
ation and do
them. Furthe
ab concentr
monitoring in
yearClinlPoster
guidelines wer
umab treatm
PSS version
).
35‐79) years
. 10.3% PA.
20 etanercep
sage: 23 pati
etin, 1‐meth
SIe 0.0. Uste
ation dose 4
ncentration
mary of prod
mg dose, m
tekinumab c
was found (c
ed in all patie
osage admin
er researchs
ration and cl
n psoriasis p
nicalMeAbstrac
re translated i
ment (PASIu)
19.0); quan
old. Weight
72.4% previ
pt, 8/20 adal
ients 45 mg,
hotrexate. PA
ekinumab co
45 mg vs 90
s of ustekinu
duct charact
median 0.90 v
oncentratio
correlation c
ents. No rela
nistered. How
s are needed
inical respon
atients treat
eetingcts
into unknown
and at bloo
titative varia
t 80 (51‐117
ously treate
limumab, 4/
, 6 patients 9
ASI values: P
oncentration
mg: 0.75 (0.
umab obtain
teristics at st
vs 0.47‐0.49
ns and the d
coefficient ‐0
ationship wa
wever, there
d to determi
nse, and hen
ted with ust
characters.
od extraction
ables
) Kg, 6 patie
ed with anti‐
/20 inflixima
90 mg; 1.6 (1
PASIu 10.7 (4
n 0.75 (0.22
.22 ‐ 5) mcg/
ned in our
teady state:
mcg/ml. A
dose/weight
0.32, p> 0.05
as found
e seems to e
ne the clinic
nce the
tekinumab.
n
nts>
b).
1.0‐
4.7‐
‐ 5.0)
/ml
dose
t
5).
exists
cal
*Special sy
Session‐B
Poster Ti
Poster Ty
Submissi
Primary A
Email: gu
Addition
Purpose:
evidence
further s
student p
with the
and lead
be benef
Methods
beginnin
in the co
objective
provided
an oppor
grades of
individua
the sessi
performa
Students
qualitativ
An alpha
p‐value o
ranges of
approved
ymbols that w
Board # ‐ 1‐0
itle: Introdu
ype: Evaluat
ion Category
Author: Jaso
uyj@findlay.
al Authors:
: Student en
e that sugges
hown that e
performance
lead instruc
to enhance
ficial to try to
s: An optiona
g of the sem
urse had the
es of the cou
d students w
rtunity to ge
f individuals
als who did n
on and enga
ance in the c
s were sent a
ve feedback
of 0.05 and
of less than 0
f final course
d this study.
2018ASProf
ere not spelled
026
ctory overvi
tive Study
y: Preceptin
on Guy; Univ
edu
gagement h
sts it helps in
engagement
e. The purpo
ctor at the be
d performan
o implemen
al individual
mester in the
e option to e
urse, timeline
ith time to a
et to know th
who chose
not participa
aging with th
course.
a survey at t
on the sessi
d a power of
0.05 represe
e scores wer
SHPMidyfessional
d‐out per the g
ew session a
g/Preceptor
versity of Fin
has been at t
ncrease stud
and interac
ose of this re
eginning of t
nce in the ph
t in other co
course over
e Introductio
email the lea
e for the cou
ask question
he instructor
to participat
ate in the ses
he faculty m
he midpoint
ion. The sur
80 percent
ented statist
re calculated
yearClinlPoster
guidelines wer
and its effec
r Skills/Educa
ndlay;
the forefront
dent perform
tion specific
esearch was
the semeste
harmacy cur
ourses or on
rview sessio
on to Pharma
ad instructor
urse, and ass
ns they had r
r at the begi
te in the ses
ssion (n equ
ember via a
t of the seme
rvey used a 5
were used in
ical significa
d and compa
nicalMeAbstrac
re translated i
ct on student
ation and Tr
t of pharma
mance and k
cally with ins
s to identify
er could be u
rriculum. If s
APPEs.
on was offere
acy Practice
r to setup a
sessment cr
regarding th
nning of the
ssion (n equa
uals 60) to de
one‐on‐one
ester via Sur
5‐point Like
n the study.
ance. To red
ared betwee
eetingcts
into unknown
t performan
raining
cy education
knowledge. L
structors can
if a course o
useful for stu
successful th
ed to studen
II course. S
time to mee
riteria/expec
e course and
e semester.
als 50) were
etermine if p
e session enh
rvey Monkey
rt scale for a
A t‐test was
duce the risk
en groups. T
characters.
nce
n recently d
Literature ha
n help increa
overview ses
udent educa
his process c
nts at the
Students enr
et to discuss
ctations. Thi
d also provid
Final course
e compared t
participating
hanced
y to provide
all 5 question
s utilized and
k of selection
he Universit
ue to
as
ase
ssion
tion
could
rolled
the
is
ded
e
to
g in
e
ns.
d a
n bias
ty IRB
*Special sy
Results:
course sc
session h
complete
hundred
the cours
course, t
helped m
instructo
Student f
Conclusio
Practice
and incre
applied t
student p
ymbols that w
Students wh
core of 87.7
had a mean f
ed the surve
percent of s
se overview
hat they wo
motivate the
or. The cours
final course
on: The cou
II course. Th
eased studen
to other area
performance
2018ASProf
ere not spelled
ho chose to p
percent, wh
final score o
ey out of 50 e
student resp
session was
ould recomm
m to succee
se overview
scores range
rse overview
he course ov
nt reported
as of the cur
e as well as s
SHPMidyfessional
d‐out per the g
participate i
hile students
f 85.2 perce
eligible. Stu
pondents agr
s beneficial,
mend the ses
ed, and that t
session too
ed from C m
w session wa
verview sess
engagemen
rriculum incl
student eng
yearClinlPoster
guidelines wer
n the course
s who did no
ent (p equals
dent feedba
reed or stro
that the ses
ssion be used
the session
k on averag
minus to A in
as highly effe
sion significa
t in the cour
uding APPE
agement an
nicalMeAbstrac
re translated i
e overview s
ot participate
s 0.02). Ther
ack was over
ngly agreed
ssion improv
d in other co
helped esta
e 17 minute
both group
ective in the
antly enhanc
rse. These s
rotations to
d rapport w
eetingcts
into unknown
session had a
e in the cour
re were 22 s
rwhelmingly
on the follo
ved their eng
ourses, that
blish rappor
es to comple
s.
e Introductio
ced student
same princip
o potentially
with precepto
characters.
a mean final
rse overview
students wh
y positive. O
owing topics
gagement in
the session
rt with the
ete per stude
on to Pharma
performanc
ples could be
increase
ors.
l
w
o
One
: that
the
ent.
acy
e
e
*Special sy
Session‐B
Poster Ti
populatio
Poster Ty
Submissi
Primary A
Email: da
Addition
Nader Na
Jessica V
Rachel Ro
Purpose:
individua
also asso
studied t
chart rev
of postsy
is hypoth
Methods
Inclusion
on doxaz
appointm
prescribe
alpha‐an
doxazosi
first pres
differenc
average s
effects. C
until end
ymbols that w
Board # ‐ 1‐0
itle: Doxazos
on
ype: Descrip
ion Category
Author: Dav
avid.charlest
al Authors:
assar
incent
ose
: Noradrene
als with past
ociated with
to reduce ex
view is to eva
ynaptic alpha
hesized to be
s: This retros
n criteria con
zosin from Se
ment with th
ed solely for
tagonists, (3
n or did not
scription. Th
ces in nightm
sleep length
Chart review
d of therapy,
2018ASProf
ere not spelled
027
sin for the tr
ptive Report
y: Psychiatry
vid Charlesth
rgic activity,
trauma rela
a reduced q
cessive nora
aluate the u
a‐1 adrenerg
e a potential
spective cha
nsisted of (1)
eptember 1,
he initiating p
prostate, bl
3) document
fill the pres
he primary e
mares and ni
h per night, a
ws were con
or until the
SHPMidyfessional
d‐out per the g
reatment of
y / Neurolog
ham; Vetera
ov
, such as nig
ated events.
quality and le
adrenergic b
se of doxazo
gic receptors
lly effective
art review inc
) reported sy
, 2015 to Jan
provider. Ex
ladder, or hy
ted allergy o
cription, and
ndpoints of
ght sweats.
average opti
ducted begi
last visit pri
yearClinlPoster
guidelines wer
nightmares
gy
ns Affairs, C
htmares and
Many vete
ength of slee
brain activity
osin in a vete
s in both the
and tolerab
cluded veter
ymptoms of
nuary 31, 20
xclusion crite
ypertension,
or anaphylax
d (5) did to f
this retrosp
The second
mal dose of
nning with t
ior to July 31
nicalMeAbstrac
re translated i
and night sw
entral Califo
d night swea
rans report
ep. Prazosin
y. The purpo
eran popula
e brain and p
le treatmen
rans prescrib
nightmares
017, and (3) a
eria consiste
, (2) concom
xis to doxazo
follow up wi
pective chart
dary endpoin
f doxazosin,
the date of in
1, 2017 whe
eetingcts
into unknown
weats in a v
ornia Health
ats, common
these sympt
n has previou
ose of this re
tion. Doxaz
peripheral n
t alternative
bed doxazos
s or night sw
at least one
ed of (1) dox
mitant non‐u
osin, (4) repo
th the provi
t review wer
nts were per
and incidenc
nitial doxazo
n data colle
characters.
eteran
Care System
nly affect
toms which
usly been
etrospective
zosin, an inh
ervous syste
e to prazosin
sin at our fac
weats, (2) sta
follow‐up
xazosin
roselective
ort of not tak
der after the
re percent
rcent increas
ce of advers
osin prescrip
ction ended
m;
are
ibitor
em,
n.
cility.
rted
king
e
se in
se
ption
.
*Special sy
Results:
inclusion
average
initially r
27 perce
night inc
5.3 mg (r
The most
lighthead
experien
Conclusio
veteran p
substanc
Health Ca
ymbols that w
During the r
n criteria. Ni
reduction in
eported for
nt (0.9 less n
reased by 0.
range: 0.5 to
t common a
dedness (23
ced serious
on: Doxazos
population,
ce use. Addi
are System a
2018ASProf
ere not spelled
review perio
ghtmares w
nightmares
64 veterans
nights per w
.2 hours (ran
o 20 mg/day
dverse effec
percent), dr
adverse effe
sin appears t
regardless o
tional studie
as well as in
SHPMidyfessional
d‐out per the g
d, 225 chart
ere present
s was 38 per
s. With doxa
week). For th
nge: 0 to 5 h
), and adver
cts reported
rowsiness (2
ects.
to be effectiv
of mental he
es may furth
other popu
yearClinlPoster
guidelines wer
ts were scree
for 94 veter
cent (1.1 les
azosin, night
he secondary
ours per nig
rse effects oc
with doxazo
21 percent),
ve for reduc
alth diagnos
her elucidate
lations.
nicalMeAbstrac
re translated i
ened, and 1
rans. With d
ss nights per
t sweats wer
y outcomes,
ght), the ave
ccurred in 5
osin within t
and dizzines
cing nightma
sis, co‐occur
e its utility w
eetingcts
into unknown
32 of those
doxazosin th
r week). Nig
re reduced b
, average sle
erage dose o
5 percent of
this review w
ss (16 percen
ares and nigh
rring sleep d
within the Ve
characters.
charts met t
herapy, the
ght sweats w
by an averag
eep length p
f doxazosin
f individuals
were
nt). No vete
ht sweats in
isorders, or
eterans Affai
the
were
ge of
er
was
.
erans
this
rs
*Special sy
Session‐B
Poster Ti
disorder
Poster Ty
Submissi
Primary A
Email: ch
Addition
Shawn D
David Dix
Catherin
Purpose:
untreate
managem
pharmac
consump
objective
patients
Methods
to implem
Alcohol U
receiving
Test (AU
they had
mental h
to 3, hos
condition
use disor
mental h
quantity
drinks pe
ymbols that w
Board # ‐ 1‐0
itle: Implem
at a rural Ve
ype: Evaluat
ion Category
Author: Chr
hristopher.w
al Authors:
alton
xon
e Scalley
: Alcohol use
d. Pharmaci
ment of AUD
cist directed
ption freque
e examined p
who recalle
s: This projec
mentation a
Use Disorder
g drug therap
DIT‐C) score
an active pr
health provid
pitalization
n, recent or
rder (other t
health provid
was tracked
er week, drin
2018ASProf
ere not spelled
028
entation of
eterans Affa
tive Study
y: Psychiatry
ristopher Wi
wilson122006
e disorder (A
sts are in a u
D. This qualit
treatment o
ncy and qua
patient acce
d being offe
ct was appro
nd did not r
r Data Resou
py for treatm
e of 4‐9 recor
rescription f
der outside t
in the 6 mon
current subs
than nicotine
ders for enro
d using the Q
nks/drinking
SHPMidyfessional
d‐out per the g
clinical phar
irs healthcar
y / Neurolog
lson; Sherid
AUD) is a com
unique role t
ty improvem
of AUD. The
antity in vete
ess to AUD p
red an AUD
oved by the
equire IRB a
urce was use
ment of AUD
rded in 2017
for AUD pha
the VA, an A
nths prior to
stance use d
e or cannabi
ollment. Onc
Quick Drinkin
g day, and da
yearClinlPoster
guidelines wer
rmacy servic
re system: a
gy
an VA Medic
mmon disea
to offer first
ment project
primary obje
erans enrolle
harmacothe
medication
Pharmacy a
approval. The
ed to identify
D and had an
7. Patients w
rmacothera
UDIT‐C scor
o clinic imple
disorder prog
is). A pharm
ce enrolled,
ng Screen (Q
ays per week
nicalMeAbstrac
re translated i
ces in the ma
a quality imp
cal Center;
se among ve
t line pharm
evaluated t
ective was t
ed in the AU
erapy by com
prior to clin
and Therape
e VA Academ
y patients w
n Alcohol Us
were exclude
py, AUD in r
re of greater
ementation f
gramming, o
macist sent co
alcohol cons
QDS) to evalu
k drinking gr
eetingcts
into unknown
anagement o
provement p
eterans that
acotherapy
he impact o
to measure e
D clinic. A se
mparing the
nic versus th
utics (P&T) C
mic Detailing
with AUD wh
e Disorder Id
ed from entr
remission, pr
r than 9 or le
for an unsta
or a co‐occu
onsults to p
sumption fre
uate days dr
reater than o
characters.
of alcohol us
project
t often goes
to veterans
f clinical
effect on alc
econdary
number of
ose that did
Committee p
g Service (AD
o were not
dentification
ry into clinic
rimary care
ess than or e
ble medical
rring substa
rimary care
equency and
rinking per w
or equal to 5
se
for
ohol
not.
prior
DS)
n
if
or
equal
nce
or
d
week,
5
*Special sy
drinks pe
Managem
stopped
statistics
Results: A
enrolled
A total of
once (dis
baseline
risk drink
pain rela
per week
drinks pe
decrease
clinic enr
on follow
managed
Conclusio
quantity
ongoing
patients
prospect
health se
ymbols that w
er day. Patie
ment format
after 4 mon
.
A total of 50
in clinic as c
f 19 patients
scharged or
average AU
king. The ma
ted conditio
k was decrea
er drinking d
ed from 3.05
rollment out
w‐up using n
d on follow‐u
on: The pha
and increas
process imp
continue to
tive enrollme
ettings.
2018ASProf
ere not spelled
nts were see
t, and educa
ths of clinic
0 patients m
consultation
s were enrol
lost to follow
DIT‐C score
ajority of pat
on, or nicotin
ased from 5.
ay was decr
5 to 2.28. On
t of the 19 p
altrexone th
up using brie
rmacy led A
ed patient e
provement to
be managed
ent of patien
SHPMidyfessional
d‐out per the g
en in clinic fo
ation was pro
time and wa
et criteria fo
was decline
lled into the
w‐up), and 7
of patients s
tients seen i
ne use disord
.42 to 5.19, d
reased from
ly 1 patient
atients seen
herapy in add
ef interventi
UD clinic de
education re
o optimize p
d in clinic. Fu
nts with pos
yearClinlPoster
guidelines wer
ollowing the
ovided regar
as analyzed
or entry into
ed (25 patien
AUD clinic.
7 patients we
seen in clinic
n clinic had
der. During t
drinks per w
3.84 to 3.64
recalled bei
n at least onc
dition to brie
on alone.
creased alco
garding AUD
patient care w
uture plans f
itive AUDIT‐
nicalMeAbstrac
re translated i
e Addiction‐F
rding pharm
using descri
o clinic. Thirt
nts declined
Of this num
ere seen at l
c was 5.6 rep
a comorbid
the interven
week was dec
4, and days p
ing offered a
ce in clinic. O
ef intervent
ohol consum
D medication
were identif
for clinic exp
‐C screens in
eetingcts
into unknown
Focused Me
macotherapy
iptive and in
y‐one patien
and 6 provi
mber, 12 pati
least twice i
presenting m
diagnosis of
ntion window
creased from
per week bin
an AUD med
One patient
ion, and 6 p
mption frequ
ns. Multiple
fied. Current
pansion may
n primary car
characters.
edical
. Data collec
nferential
nts were not
ders decline
ents were se
n clinic. The
moderate to
f depression
w, days drink
m 23.32 to 2
nge drinking
dication prio
was manage
atients were
uency and
areas for
tly enrolled
y include
re or menta
ction
t
ed).
een
o high
, a
king
21.62,
g was
r to
ed
e
l
*Special sy
Session‐B
Poster Ti
pharmac
study
Poster Ty
Submissi
Primary A
Email: jh
Addition
Raju kon
balakesh
Mustafa
Purpose:
world. Th
well as p
effective
study via
administ
analysing
Methods
administ
on each d
nursing u
100 dose
aware of
the medi
immedia
number a
medicati
hospital
case. The
ymbols that w
Board # ‐ 1‐0
itle: Effectiv
cist at a terti
ype: Evaluat
ion Category
Author: Bad
asar555@gm
al Authors:
eri
va Ramaiah
Ali
: Medication
hey are asso
rolong hosp
methods th
a direct obse
ering the me
g the data an
s: The comp
ration and it
day upon ob
unit prior to
es per day by
f the clinical
ication chart
tely. In med
as that obse
on profile, la
protocol file
en, the obse
2018ASProf
ere not spelled
029
e methods t
ary care hos
tive Study
y: Safety / Q
dr ali Gassar;
mail.com
n error is a c
ociated with
italisation. T
hat can detec
ervation met
edications a
nd finally rep
lete study w
ts related er
bservation, t
medication
y the nurses
pharmacist
t to confirm
ication char
erved using d
ab master, h
es were thor
rver analyse
SHPMidyfessional
d‐out per the g
to detect me
spital in Bang
Quality
; KARNATAK
ommon vita
life threaten
The purpose
ct the medic
thod which w
nd medicati
porting it to
was primarily
rrors. Direct
he clinical p
administrat
. During this
observation
the errors. T
rt review pro
direct observ
hospital form
oughly inves
ed the collec
yearClinlPoster
guidelines wer
edication err
galore: a sin
A COLLEGE O
al problem in
ning complic
of this stud
cation errors
was done by
on chart rev
the concern
y focused on
observation
harmacist a
ion. The obs
s process, th
n. The observ
The error wa
ocess, the ch
vation meth
mulary, drug
stigated to id
cted data an
nicalMeAbstrac
re translated i
rors in surgic
gle blinded
OF PHARMA
n all healthca
cations, rise
y was to de
s. Two meth
y directly obs
view method
ned clinician
the errors t
n was used to
s an observe
server witne
he nurses we
ved data we
as further di
harts with th
od were bei
storage and
dentify for a
nd finally rep
eetingcts
into unknown
cal wards by
prospective
ACY;
are systems
in patient tr
etermine and
hods were in
serving the n
d was done b
s.
that occurs d
o detect me
er was prese
essed the ad
ere blinded
ere then cros
iscussed wit
he same hosp
ing studied.
d labelling , d
any associate
ported the e
characters.
y clinical
observation
around the
reatment co
d compare t
ncluded in th
nurses while
by collecting
during drug
edication err
ent at the
dministration
and were n
ss checked w
h the clinicia
pital referen
The case sh
databases an
ed errors in
rrors for the
nal
st as
he
his
e
g and
ors
n of
ot
with
ans
nce
heet,
nd
the
e
*Special sy
concerne
was dem
method.
patients
Results: A
the study
observat
review m
error wa
290 erro
(24.2 per
errors, 13
(51.2 per
method d
review. D
prescribe
percent)
use of ina
Conclusio
chart rev
capture h
compare
capture t
method w
ymbols that w
ed clinicians.
monstrated b
This study i
irrespective
A total dose
y, the male p
ion method
method invol
s document
rs (75.7 perc
rcent). The t
323 errors (4
rcent) by me
detected 22
Direct observ
ed) storage a
. Whereas th
appropriate
on: Two det
view) proved
higher numb
ed to the m
the superfici
was more ef
2018ASProf
ere not spelled
. All the erro
ased on the
ncluded all p
of the diagn
es of 12572 i
patients (77
covered a t
ved 6752 (5
ed in 383 (3
cent ) and th
type of erro
48.7 percent
edication cha
.7 percent o
vation meth
at patient be
he medicatio
abbreviatio
ection meth
d to be effici
ber of medic
edication ch
ial informati
ffective met
SHPMidyfessional
d‐out per the g
ors were furt
nature, typ
patients adm
nosis.
n 558 patien
percent) we
otal of 5820
3.7percent)
percent ) do
he medicatio
rs observed
t) were dete
art review m
of errors com
od showed
edside (29.7
on chart rev
on (21percen
hods to obse
ent and relia
cation errors
hart review. T
on related t
hod to detec
yearClinlPoster
guidelines wer
ther classifie
e and numb
mitted to the
nts were obs
ere higher co
0 (46.2 perce
doses. Out
oses, in whic
on chart revi
by both the
ected by dire
method. Subs
mpared to 20
effective in o
percent) fo
iew demons
nt ) as well a
erve medicat
able . The di
s primarily re
The medicat
to medicatio
ct medicatio
nicalMeAbstrac
re translated i
ed and the e
ber of the er
e surgical wa
served over
ompared to
ent) doses an
of 12572 do
ch direct obs
iew method
e methods w
ect observat
sequently, t
0.5 percent e
observing un
llowed by dr
strated its ef
s drug drug
tion errors (o
rect observa
elated to adm
tion chart re
on error. Ove
on errors.
eetingcts
into unknown
effectiveness
rrors reporte
ard both adu
a period of s
female patie
nd the medi
oses, the adm
servation m
accounted f
were distingu
ion method
he direct ob
errors by me
nauthorised
rug duplicat
ffectiveness
interactions
observation
ation metho
ministration
eview metho
er all, the dir
characters.
s of the meth
ed by respec
ult and geria
six months.
ents. The dir
cation chart
ministration
ethod share
for 93 errors
uish. Out of 2
and 1390 e
bservation
edication ch
d drug (drug
ion (18.2
in identifyin
s (19.6 perce
and medica
od was able t
n errors
od was able
rect observa
hod
ctive
tric
In
rect
t
e was
s
2713
rrors
art
not
ng
ent).
ation
to
to
ation
*Special sy
Session‐B
Poster Ti
hospital‐
Poster Ty
Submissi
Primary A
Email: kia
Addition
Raju Kon
Balakesh
Purpose:
and Drug
analgesic
anesthet
uncertain
experien
Methods
admitted
usage. Th
predefine
as tools t
who wer
inclusive
The stud
patients.
adverse d
informat
causality
causality
Hartwig s
appropri
ymbols that w
Board # ‐ 1‐0
itle: Prospec
clinical phar
ype: Evaluat
ion Category
Author: Kian
anahamed@
al Authors:
eri
hava Ramaia
: The purpos
g Administra
c medication
tics and anal
nty around l
ced by the p
s: The study
d adult patie
he patient d
ed data colle
to review th
re taking at l
criteria. 126
y involved 2
Adverse dru
drug reactio
ion were rec
, action take
assessment
scale. The da
ate software
2018ASProf
ere not spelled
030
ctive study o
rmacist inter
tive Study
y: Safety / Q
na Hamed; K
@yahoo.com
h
se of this stu
ation (FDA) m
ns also to ide
gesic with o
iability and p
patient or to
was conduc
nt was rand
emographic
ection form.
e prescriptio
east two dru
62 prescripti
00 patients,
ug interactio
on reporting
corded: type
en, and even
t by WHO (w
ata were sto
e.
SHPMidyfessional
d‐out per the g
on off‐label u
rvention
Quality
Karnataka co
m
udy was to fi
medication p
entify advers
ther therapy
physicians m
o receive infe
cted in all wa
omly selecte
s and all me
. The Microm
on and case
ugs and had
ion reviewed
, of which 92
ons occurred
form. For ea
e of adverse
nt outcome,
world health
ored confide
yearClinlPoster
guidelines wer
use of anesth
ollege of pha
nd out the lo
prescribing a
se drug reac
y drug as off
may be less l
erior therapy
ards at a tert
ed on daily b
edically relev
medex, Med
charts. All p
hospital sta
d in which 2
2 patients re
d due to dru
ach adverse
event, serio
and was ana
organization
ntially and s
nicalMeAbstrac
re translated i
hetics and a
armacy;
oose links b
and utilizatio
ction associa
f‐label use o
ikely to repo
y.
tiary care ho
basis and rev
vant informa
scape and re
patients rece
ay of at least
00 of them
ecruited wer
g‐drug inter
drug reactio
ousness, ons
alyzed using
n) and Nara
subjected to
eetingcts
into unknown
nalgesic in a
etween off‐
on of anesth
ated betwee
of medicines
ort adverse e
ospital in Ind
viewed for t
ation was no
eferences bo
eiving off‐lab
t 48 hours co
had off‐labe
re male and
raction was r
on, the follow
set and reso
g the followi
njo scales an
o further ana
characters.
a tertiary car
label use Fo
etic and
n off‐label
creates
events
dia. The new
the off‐label
oted in a
ooks were u
bel medicati
onsidered as
el use.
108 were fe
recorded in
wing
lution, sever
ng methods
nd severity b
alysis using
re
od
wly
used
ion
s
emale
an
rity,
:
by
*Special sy
Results:
prescript
anesthet
anesthet
atracuriu
pain; pro
anaphyla
midazola
during m
a mechan
Among a
followed
The off‐la
legs synd
pain; tram
regional
naproxen
Out of 20
interactio
proprano
Conclusio
indicated
fentanyl
highly pr
lidocaine
respectiv
There wa
lidocaine
fluoxetin
blockade
ymbols that w
During six m
tions had off
tics followed
tic drug follo
um 12(10 pe
opofol: chron
axis, bradyar
am: refractor
mechanical ve
nically venti
nalgesics, tr
by acetami
abel indicati
drome; Sulfa
madol: intra
anesthesia;
n: menorrha
00 prescripti
on and drug
olol, midazo
on: The stud
d for off‐labe
and adrenal
escribed ana
e, atracurium
vely was iden
as 4 percent
e, atracurium
ne respective
e, hypertens
2018ASProf
ere not spelled
month 1262 p
f‐label use. M
d by analgesi
owed by adre
rcentage). T
nic migraine
rrhythmia, ca
ry status epi
entilation; p
lated patien
ramadol was
nophen 13(1
ons were ac
salazine: Cro
avenous tram
azathioprine
agia, systemi
ions, Study s
s involved w
lam and clar
dy showed th
el use.
lin was highl
algesics off‐l
m, tramadol
ntified which
age incidenc
m, tramadol
ely causing b
ion and hype
SHPMidyfessional
d‐out per the g
patient pres
Major patien
ics. fentanyl
enalin 17 (14
The off‐label
; ketamine:
ardiac arrest
ilepticus; atr
ethidine: ca
nt.
s highly pres
15.7 percent
cetaminophe
ohn disease;
madol contro
e: Crohn dis
ic lupus eryt
shows result
were adrenal
rithromycin,
hat the quie
ly prescribed
label drugs.
with propra
h are associa
ce of advers
with propra
bradycardia,
erthermia re
yearClinlPoster
guidelines wer
criptions we
nts (n equals
20 (17 perc
4.5 percenta
indications
bronchospa
t, hyperkale
racurium: in
ncer pain, ch
scribed drug
tage), and su
en: migraine
; Codeine: m
olled shiveri
ease; diclofe
hematosus;
ting of 8 (4 p
line, lidocain
clindamycin
t often the a
d anesthetic
while comp
nolol, midaz
ated with AD
e drug react
nolol, midaz
respiratory
espectively.
nicalMeAbstrac
re translated i
ere scrutinize
s117; 58.5 pe
entage) was
age), pethidi
were lidoca
asm, opioid w
mia, septic s
duction of n
hronic shive
which was a
ulfasalazine
e, osteoarthr
migraine, ma
ng during ce
enac: fever,
percentage)
ne, atracuriu
n and fluoxe
anesthetic a
cs and trama
aring the pr
zolam, clinda
DR.
tions which i
zolam, clarit
depression,
eetingcts
into unknown
ed, in which
ercentage) r
s highly pres
ine 16(14 pe
ine: manage
withdrawal;
shock, local
neuromuscu
ering; fentan
about 15 (18
11(13.3 per
ritis; Gabape
anagement o
esarean sect
post‐episiot
ADRs due to
um, tramado
etine respect
nd analgesic
adol and ace
revalence of
amycin and
includes dru
hromycin, c
, increased n
characters.
h 200
received
scribed
ercentage), a
ement of can
adrenalin:
anesthesia;
lar blockade
yl: analgesia
8 percentage
centage).
entin: Restle
of cancer rel
tion under
tomy pain;
o drug
ol with
tively.
cs were
taminophen
ADR adrena
fluoxetine
ugs adrenalin
lindamycin a
neuromuscu
and
ncer
e
a for
e)
ess
ated
n was
alin,
n,
and
lar
*Special sy
Session‐B
Poster Ti
overrides
Poster Ty
Submissi
Primary A
Email: m
Addition
Purpose:
related c
system fo
Methods
are class
pharmac
clinicians
overridin
We evalu
period(20
frequenc
alert with
Results: A
medicati
medicati
12.0 per
alerts we
While, in
not have
classes th
drugs(22
ymbols that w
Board # ‐ 1‐0
itle: Evaluati
s in the inpa
ype: Evaluat
ion Category
Author: Min
kkang1363@
al Authors:
: The aim of
linical decisi
or preventio
s: In Asan M
ified “cautio
cists and phy
s. They can e
ng the alert,
uated ADRs a
017). Factor
cy of overrid
hin each pat
A total of 4,
ons that we
ons) by asse
medications
ere “no reaso
n the “prohib
this allergy/
hat triggered
.3%), nonste
2018ASProf
ere not spelled
031
ion of adver
tient setting
tive Study
y: Safety / Q
nkyoung Kan
@gmail.com
this study w
ion support(
on of ADRs, a
edical Cente
on” and “pro
ysicians. Whe
either discon
which requi
alerts for inp
rs that were
e reasons, a
tient and cla
101(90%) of
re classified
essment of A
s. In the “cau
onable alter
bition” group
/tolerates”(2
d overridden
eroidal anti‐
SHPMidyfessional
d‐out per the g
se drug reac
g
Quality
ng; Aasn Med
was to analyz
(CDS) alert o
and suggest
er, medicatio
ohibition” aft
en medicatio
ntinue the or
res entering
patients with
measured w
nd characte
ssified in tw
f 4,551 alerts
as “caution
ADR. The ave
ution” group
rnatives”(39.
p, they were
24.5%), “des
n alerts were
inflammato
yearClinlPoster
guidelines wer
ctions relate
dical Center
ze character
overrides, as
methods fo
ons with AD
ter conducti
ons with AD
rder or cont
g a free‐text
hin in our he
were drug an
eristics of AD
wo categories
s were overr
”(295 medic
erage numbe
p, clinicians’
.7%), “aware
e “no reason
sensitization
e antimicrob
ry drugs (NS
nicalMeAbstrac
re translated i
ed clinical de
r;
ristics of adv
sess the effe
r decreasing
Rs reported
ng causality
DRs are order
inue with th
reason.
ealth system
nd drug class
DRs. We ana
s according t
ridden in 25
cations) and
er of ADRs a
most comm
e/premedica
nable alterna
n protocol/sk
bial agents(4
SAIDs)(7.4%)
eetingcts
into unknown
ecision suppo
verse drug re
ectiveness o
g preventabl
by health‐sy
y assessment
red, ADRs al
he medicatio
m during a 1 y
s that trigge
lyzed the fir
to the ADRs
9 patients w
“prohibition
alerts is 15.8
mon reasons
ation/will m
atives”(28.6%
kin test”(22.
42.0%), antic
) in the “cau
characters.
ort alert
eactions(ADR
of ADRs alert
le ADRs.
ystem provid
t of ADRsa b
ert informed
on order by
year
red alerts,
st overridde
assessment
with 342
n”(47
per patient
for overridi
onitor”(21.7
%), “patient
.4%). Drug
cancer
tion” group.
Rs)
t
ders
by
d the
en
t.
and
ng
7%).
does
. In
*Special sy
the “proh
experien
Conclusio
alert wer
tolerates
and frequ
for increa
alerting s
ymbols that w
hibition” gro
ced ADRs at
on: Override
re repeated
s ADRs. The h
uent nonexa
asing the sp
system.
2018ASProf
ere not spelled
oup, overridd
ttributed to t
es of ADRs a
same patien
high rate of
act match ale
ecificity of a
SHPMidyfessional
d‐out per the g
den drug cla
the overridd
lerts were c
nts and med
alert overrid
erts. Based o
lerting and t
yearClinlPoster
guidelines wer
asses were s
den drug and
ommon but
ications bec
dden was att
on these find
thereby imp
nicalMeAbstrac
re translated i
imilar. Only
d it was not
low rate of
cause of not
tributable to
dings, we ha
proving the c
eetingcts
into unknown
1 patient of
serious.
re‐experien
reassessing
o no reasona
ave made re
clinical utility
characters.
f 259 patient
nced ADRs. A
when patie
able alternat
ecommendat
y of the ADR
ts
ADRs
nts
tives
tions
Rs
*Special sy
Session‐B
Poster Ti
inpatient
Poster Ty
Submissi
Primary A
Email: ch
Addition
Melissa M
Isabel Sa
Richard R
Purpose:
anonymo
the patie
previous
events re
heighten
standard
regular in
Methods
analyzed
Center fo
were rev
in more d
either or
relevant
500. Med
associate
patient s
ymbols that w
Board # ‐ 1‐0
itle: Interdis
t concentrat
ype: Descrip
ion Category
Author: Chr
hristopher.si
al Authors:
Moriarty
nvanson‐Ka
Rooney
: The institut
ously reporte
ent, or near m
year, the te
elated to inp
ned risk for s
dized proced
nsulin U‐500
s: As part of
and scored
or Patient Sa
viewed; med
detail. Using
dering, adm
steps from t
dication eve
ed action pla
afety.
2018ASProf
ere not spelled
032
ciplinary me
ed regular in
ptive Report
y: Safety / Q
ristopher Sie
rceski
tion’s interd
ed medicatio
miss events
eam noted a
patient utiliza
erious harm
ures for ord
0 to enhance
the Medicat
using the Sa
afety. All me
ication even
g event desc
ministering, o
the patient a
nt informati
ans to enact
SHPMidyfessional
d‐out per the g
edication eve
nsulin U‐500
Quality
gler; Jesse B
gov
disciplinary M
on errors. Er
that were ca
n increase in
ation of con
m associated
ering, prepa
e patient saf
tion Event T
afety Assess
dication eve
nts involving
riptions, me
or dispensing
admission to
ion guided t
systematic i
yearClinlPoster
guidelines wer
ent team’s p
0
Brown VA M
Medication E
rrors are cat
aught prior t
n the numbe
centrated re
with errone
aring, dispen
ety.
Team review
ment Code a
ents reporte
g concentrate
dication eve
g, and a proc
o administra
he developm
improvemen
nicalMeAbstrac
re translated i
process impr
edical Cente
Event Team
tegorized as
to reaching t
er of near m
egular insuli
eous use, ste
nsing, and ad
process, the
as recomme
d between 4
ed regular in
ents were ch
cess flowcha
tion of conc
ment of a roo
nts to preve
eetingcts
into unknown
rovement fo
er;
meets week
actual even
the patient.
iss and actu
n U‐500. Giv
eps were tak
dministering
e reported e
ended by the
4/1/2017 an
nsulin U‐500
haracterized
art was creat
centrated re
ot cause sta
nt recurrenc
characters.
or handling o
kly to review
nts that reac
During the
al medicatio
ven the
ken to introd
g concentrat
errors are
e National
nd 3/31/2018
0 were asses
as errors of
ted to includ
gular insulin
tement and
ce and impro
of
w
hed
on
duce
ed
8
ssed
f
de all
n U‐
ove
*Special sy
Results: T
which th
The even
vulnerab
500. To a
process.
checklist
pharmac
orders w
service, i
insulin U
Conclusio
insulin U
standard
events.
ymbols that w
There were
ree were ass
nts were vari
bilities in the
address the v
An ordering
for pharma
cy dispensing
were impleme
npatient nu
‐500 to enha
on: Through
‐500‐related
dized process
2018ASProf
ere not spelled
424 medica
sociated wit
iable with re
ordering, pr
variability, c
g checklist w
cists, and an
g log and ind
ented for be
rses were gi
ance knowle
h identificatio
d errors, the
s improveme
SHPMidyfessional
d‐out per the g
tion events
th concentra
espect to cha
reparing, an
hecklists we
as created fo
n administra
dependent p
eneficial red
ven an educ
edge and pro
on and evalu
Medication
ents to optim
yearClinlPoster
guidelines wer
during the t
ated regular
aracterizatio
d administe
ere created f
or physician
tion checklis
pharmacy do
undancy. In
cational in‐se
omote awar
uation of ne
n Event Team
mize patient
nicalMeAbstrac
re translated i
ime frame o
insulin U‐50
on, and were
ering of conc
for each serv
ns, a prepara
st for nurses
ouble‐check
coordinatio
ervice regar
reness.
ar miss and
m implement
t safety and
eetingcts
into unknown
of 4/1/2017
00 in the inp
e suggestive
centrated reg
vice involved
ation and dis
s. Additional
of all concen
on with Nurs
ding concen
actual conc
ted systema
avoid poten
characters.
to 3/31/201
atient settin
of systemat
gular insulin
d in the inpa
spensing
lly, an inpati
ntrated insu
ing Educatio
ntrated regu
entrated reg
atic and
ntial medicat
18, of
ng.
tic
n U‐
atient
ent
ulin
on
lar
gular
tion
*Special sy
Session‐B
Poster Ti
in ectopi
Poster Ty
Submissi
Primary A
Email: bt
Addition
Pallivalap
Wessam
Mahmou
Moza Al
Purpose:
uterine a
surgery.
administ
methotre
and effic
assessed
Methods
was appr
of all wo
period of
that is “s
all those
EP was d
MTX was
absence
IU. The o
dose, wh
progress
ymbols that w
Board # ‐ 1‐0
itle: Assessin
c pregnancy
ype: Descrip
ion Category
Author: Binn
thomas28@
al Authors:
ppila Abdulr
Elkassem
ud Mohamm
Hail
: An ectopic
activity. Med
Current prac
er single dos
exate regime
acy of single
the b‐hCG l
s: The study
roved by the
men diagno
f nine month
single dose”
patients wh
iagnosed by
s indicated fo
of fetal card
overall succe
hile the failur
ing βHcG va
2018ASProf
ere not spelled
033
ng the suitab
y at a tertiary
ptive Report
y: Women's
ny Thomas;
hamad.qa
ouf
med Gasim
pregnancy (
dical interven
ctice at Wom
se intramusc
ens is limited
e‐dose MTX
evels and co
took place a
e medical res
sed with EP
hs. Women's
protocol at
ho were trea
y the obstetr
or all patien
diac activity a
ess rate was
re was defin
alues, or sev
SHPMidyfessional
d‐out per the g
bility and eff
y care Obste
Health
Hamad Med
(EP) is a cond
ntion with m
men’s Hospit
cular metho
d in Qatar. T
50 mg/m2 B
orrelate them
at a 220 bed
search cente
and treated
s Hospital co
a dose of 50
ated with MT
rician based
ts hemodyn
and β‐hum
determined
ned if the pat
vere abdomin
yearClinlPoster
guidelines wer
ficacy of a si
etric setting
dical Corpora
dition in wh
methotrexate
tal is driven
trexate (MT
The study wa
BSA used in t
m with succ
ded obstetr
er at Hamad
d with MTX w
omplies to si
0 mg/m2 of
TX and lost f
d on clinical f
amically sta
an chorionic
by normaliz
tient encoun
nal pain afte
nicalMeAbstrac
re translated i
ngle dose in
in Qatar.
ation;
ich the impl
e is well esta
by internati
TX). Data abo
as designed
the treatme
cess rates.
ric teaching h
d Medical Co
were retrosp
ingle dose M
body surfac
follow up for
findings and
ble, tubal m
c gonadotro
zation of βH
ntered hemo
er two doses
eetingcts
into unknown
ntramuscular
antation occ
ablished as a
ionally accep
out the effic
to evaluate
nt of EP. Thi
hospital in Q
orporation. M
pectively rev
MTX protoco
ce area. The
r the next vis
correlated
mass of less t
pin (βHcG) l
HcG after firs
odynamic in
s of MTX.
characters.
r methotrex
curs outside
an alternativ
pted protoco
acy of differ
the suitabili
is study furth
Qatar. The st
Medical reco
viewed for a
ol by Stovall e
study exclud
sit.
with ultraso
han .5 cm,
ess than 500
st or second
stability,
ate
e the
ve to
ol, to
rent
ity
her
tudy
ords
et.al.
ded
ound.
00
*Special sy
Results:
intramus
these pat
women t
one or m
7% had β
contraind
a βHcG<
Approxim
therapeu
prearran
MTX (P=
associate
the study
Conclusio
intramus
tubal pre
success.
ymbols that w
Seventy‐thre
scular MTX a
tients had m
treated were
more previou
βHcG levels >
dication to t
15 IU betw
mately 95% o
utic managem
gement βHc
0.023). Grav
ed with the s
y period.
on: The use
scular MTX c
egnancy. Tim
2018ASProf
ere not spelled
ee patients f
at Women’s
multigravida
e between 3
us EP. The me
> IU 5000. Se
he MTX trea
een Day 5 a
of the EP wa
ment with M
cG levels we
vida status, p
success rate
of MTX duri
can be a safe
mely detectio
SHPMidyfessional
d‐out per the g
from more t
Hospital ove
and 25% use
31 ‐ 35 years
ean pretreat
eventeen pe
atment. Alm
nd Day 7 an
as treated be
MTX was mo
re significan
previous his
of the treat
ing EP is safe
e alternative
on, low (βHc
yearClinlPoster
guidelines wer
than 11 diffe
er a period o
ed assisted t
. Twenty pe
tment levels
ercentage of
ost 60.5% o
d an additio
elow 10 wee
re than 75%
ntly lower in
tory of EP, lo
tment. No m
e and effecti
to surgery f
cG) levels an
nicalMeAbstrac
re translated i
erent nation
of 9 months.
techniques f
rcentages of
s of (βHcG) w
f the patient
f the patient
onal 18% req
eks gestation
%. The study
those who r
ocation of E
major adverse
ive. Our stud
for hemodyn
d proper fol
eetingcts
into unknown
alities were
. Approxima
for conceptio
f the patient
was 2527.7 o
ts treated ha
ts had succe
quired secon
n. The overa
findings rev
responded t
P was not fo
e effects we
dy suggested
namically sta
llow up are p
characters.
treated with
tely 80% of
on. Majority
ts had histor
of which alm
ad relative
essfully achie
d dose.
ll success ra
vealed that t
to the single
ound to be
ere noted du
d that
able unruptu
predictors o
h
y of
ry of
most
eved
te of
he
dose
uring
ured
f
*Special sy
Session‐B
Poster Ti
Poster Ty
Submissi
Resource
Primary A
Email: am
Addition
Jennifer S
Hui‐Jie Le
Paul Bush
Purpose:
tool to as
pharmac
been ass
currently
aim of th
and dete
Methods
electroni
within th
obtained
and the u
personal
Exhaustio
Scores <
logistic re
weekly a
availabili
ymbols that w
Board # ‐ 4‐0
itle: Incidenc
ype: Evaluat
ion Category
es
Author: Am
manda.m.ba
al Authors:
Schultheis
ee
h
: The Maslac
ssess burnou
cists indicate
ociated with
y unknown w
his study was
ermine poten
s: IRB approv
ic qualtrics s
he ASHP mem
d. The surve
unmodified,
ized results,
on Scores >
33 in any of
egression wa
t work and a
ty of resour
2018ASProf
ere not spelled
001
ce of burnou
tive Study
y: Administr
anda Ball; D
ch Burnout I
ut among he
ed burnout is
h higher risk
whether criti
s to determi
ntial risk fact
val was obta
survey was d
mbership se
y included d
22‐question
based on th
27; Deperso
f the three su
as performe
at home, nu
ces for resili
SHPMidyfessional
d‐out per the g
ut in critical
rative Practic
Duke Univers
u
nventory fo
ealth care wo
s as high as 5
for burnout
ical care pha
ne the preva
tors for the
ained and jo
distributed v
rvices datab
demographic
n, MBI‐HHS s
heir respons
onalization S
ubscales we
ed to assess f
mber of ICU
ency or burn
yearClinlPoster
guidelines wer
care pharma
ce/Managem
sity Hospital;
r Human Ser
orkers. A re
50%. The in
t compared t
armacists ex
alence of bu
developmen
intly approv
ia email to c
base. Particip
c questions,
survey. Upo
es, indicatin
cores > 10; o
re considere
for risk facto
U patient bed
nout at insti
nicalMeAbstrac
re translated i
acists
ment/Financ
;
rvices Surve
ecent survey
tensive care
to other hea
perience a h
urnout amon
nt burnout.
ved by ASHP
critical care p
pation was v
institutiona
on completio
ng their risk o
or Reduced
ed at risk of
ors using yea
ds, average o
itution.
eetingcts
into unknown
cial Managem
y (MBI‐HHS)
y of health‐sy
e unit (ICU) e
alth care per
higher rate o
ng critical ca
for distribut
pharmacists
voluntary an
l and staffin
on, responde
of burnout.
Personal Ac
burnout. M
ars in practic
orders verifi
characters.
ment/Huma
) is a validate
ystem
environment
rsonnel. It is
of burnout. T
re pharmaci
tion. An
s, as designat
d consent w
g characteri
ents receive
Emotional
hievement
Multi‐variate
ce, hours wo
ed daily,
n
ed
t has
s
The
ists
ted
was
istics,
ed
e
orked
*Special sy
Results:
(62%), Ca
proportio
Common
and the E
24 (IQR 1
Approxim
outcome
subscales
institutio
significan
Conclusio
were not
not awar
significan
concerne
given hig
of and pr
ymbols that w
Of 3196 surv
aucasian (80
on of respon
n primary wo
Emergency D
16‐30). Medi
mately 73% o
e, 123/193 (6
s. Only 14.5
on. Using mu
ntly associat
on: In this su
tably earlier
re of institut
ntly associat
ed about or e
gh rates of b
rovide resou
2018ASProf
ere not spelled
veys sent, re
0%), and mar
ndents had b
ork areas inc
Department
ian medicati
of responde
64%) respon
5% of respon
ultivariable l
ed with burn
urvey of crit
in their care
ional resour
ed with burn
experiencing
urnout in ot
urces for pre
SHPMidyfessional
d‐out per the g
esponse rate
rried/partne
been practic
cluded mixed
(14%) with
ion orders v
nts, worked
dents met t
ndents ident
logistic regre
nout.
ical care pha
eer, tended t
rces for burn
nout. It is im
g burnout m
her critical c
venting burn
yearClinlPoster
guidelines wer
e was 6.2%.
ered (62%). T
ing for less t
d Medical/S
a median nu
erified per s
longer than
he criteria fo
ified resourc
ession, no si
armacists, bu
to work mor
nout. No sing
mportant to c
may have bee
care profess
nout within
nicalMeAbstrac
re translated i
A majority o
The median
than 5 years
urgical units
umber of pa
shift were 80
n 50 hours pe
or burnout o
ces for burn
ngle risk fac
urnout was
re than 40 h
gle risk facto
consider tha
en more like
ions, It is ess
critical care
eetingcts
into unknown
of responde
age was 34
s (43%) and 6
s (25%), Med
tient care be
0 (IQR 25‐15
er week. Fo
on one of th
out were av
ctor was dete
as high as 64
hours per we
or was deter
at pharmacis
ely to respon
sential to cr
pharmacy.
characters.
nts were fem
years. A lar
6‐15 years (3
dical ICU (20
eds covered
0).
or the primar
e three burn
vailable at th
ermined to b
4%. Respond
eek, and we
rmined to be
sts who are m
nd. However
eate awaren
male
rge
32%).
0%),
of
ry
nout
heir
be
dents
re
e
more
r,
ness
*Special sy
Session‐B
Poster Ti
key stake
Poster Ty
Submissi
Resource
Primary A
Email: do
Addition
Julie McC
Michael
James M
James M
Purpose:
Seasoned
more rob
develope
Administ
residency
Health‐Sy
perspect
Methods
commun
design a
The prog
residents
Leaders i
local coll
utilized t
our ASHP
and we lo
ymbols that w
Board # ‐ 4‐0
itle: Innovat
eholders
ype: Descrip
ion Category
es
Author: Dom
ominick.case
al Authors:
Coy
Millard
yres
ilner
: Evidence d
d leaders at
bust success
ed an innova
tration (MHA
y candidates
ystem Pharm
ive of key st
s: With a foc
ity hospitals
unique Hea
gram advoca
s to learn th
in 2015 and
ege of pharm
he PGY2 sta
P Accreditati
ook to make
2018ASProf
ere not spelled
002
ive residenc
ptive Report
y: Administr
minick Casel
elnova@prov
emonstrates
the America
ion manage
ative residen
A) that appe
s. This descr
macy Admin
takeholders.
cus on succe
s within a he
lth‐System P
ted for a PG
rough leade
our first res
macy during
ndards from
ion Survey. O
e continuous
SHPMidyfessional
d‐out per the g
cy and fellow
rative Practic
nova; Provid
vidence.org
s that we ar
an Society of
ment strate
ncy and fello
als to our he
iptive report
istration Res
ssion manag
ealth‐system
Pharmacy Ad
GY1/PGY2/M
rship experi
ident began
g the PGY1 a
m ASHP and w
Our program
s improveme
yearClinlPoster
guidelines wer
wship progra
ce/Managem
dence Health
e facing a sh
f Health‐Syst
gies to mitig
wship progr
ealth‐system
t will demon
sidency and
gement with
m), we worke
dministratio
MHA, followe
ence. The pr
the program
nd PGY2 yea
will refine ou
m has match
ents to make
nicalMeAbstrac
re translated i
am narrows
ment/Financ
h and Servic
hortage of tr
tem Pharma
gate this lead
ram with a M
m, our partne
nstrate value
Fellowship
hin our local
ed with a loc
n residency
ed by a final t
rogram was
m in 2016. T
ars, at no co
ur program
ed a residen
e it a sustain
eetingcts
into unknown
leadership g
cial Managem
ces;
rained pharm
acists (ASHP
dership shor
Masters in H
er college of
e and outline
Program fro
service area
cal college of
and fellows
third fellows
approved b
The MHA is c
ost to the res
with recent
nt each year
ned success.
characters.
gap; a view f
ment/Huma
macy leaders
) recommen
rtage. We ha
ealth
f pharmacy,
e the new
om the
a (two
f pharmacy t
hip program
ship year for
by Executive
completed a
sident. We
feedback fr
for three ye
from
n
s.
nd
ave
and
to
m.
r
t a
om
ears,
*Special sy
Results:
fellowshi
which wi
their fina
the pote
goals and
will desc
and adm
Conclusio
leadersh
Residenc
demonst
gap with
overview
program
educatio
ymbols that w
We will dem
ip program w
ll be discuss
ancial and ed
ntial for incr
d objectives,
ribe the ben
inistrative fe
on: With mo
ip team, we
cy and Fellow
trated and re
succession
w demonstra
with key sta
nal benefits
2018ASProf
ere not spelled
monstrate ou
which also o
sed as well. W
ducational b
reased capac
, and expans
nefits from th
ellows, and a
ore pharmac
successfully
wship Progra
efined. Creat
planning thr
tes how des
akeholder pe
.
SHPMidyfessional
d‐out per the g
ur rationale f
offers an MH
We will sum
enefits. Wit
city of staff,
sion of pharm
he view of o
also from ou
cy leaders ne
y implement
am spanning
tive solution
rough reside
signing a hig
erspectives i
yearClinlPoster
guidelines wer
for designing
A. New resid
marize signi
h improved
enhanceme
macy service
our organizat
ur local partn
eeded, and i
ted a new He
g over three
ns such as th
ency and fell
hly function
in mind can
nicalMeAbstrac
re translated i
g a compreh
dency progr
ificant reside
quality and
ent of achiev
es through t
tion, prospe
nering colleg
mmense sup
ealth System
years. Bene
his program w
owship prog
ning residenc
lead to sust
eetingcts
into unknown
hensive resid
rams bring n
ency project
service in m
vement of se
this new pro
ctive candid
ge of pharm
pport from o
m Pharmacy
efits are bein
will narrow
gram develo
cy and fellow
tainable fina
characters.
dency and
ew challeng
ts, to include
mind, we disc
enior leaders
gram. Finall
dates, reside
acy.
our executiv
Administrat
ng realized,
the leadersh
opment. This
wship trainin
ncial and
ges,
e
cuss
ship
y, we
ents
ve
tion
hip
s
ng
*Special sy
Session‐B
Poster Ti
the settin
Poster Ty
Submissi
Resource
Primary A
Email: ch
Addition
Purpose:
limited re
personne
fluid, and
project a
software
Methods
recorded
11/20/17
drug pro
were eva
waste. A
model gi
compoun
determin
be comp
Costs of w
(Week 1)
labor sav
census w
as fluctua
calculate
ymbols that w
Board # ‐ 4‐0
itle: Sterile c
ng of drug sh
ype: Evaluat
ion Category
es
Author: Tho
hranowskit@
al Authors:
: The profess
esources. In
el budgets w
d supply sho
ssesses the
e by tracking
s: All expired
d in 7 day “W
7 (Week 2).
duct. Workf
aluated and
An effort was
ven current
nded were d
ned at the di
ounded in a
wasted med
) and 11/22/
vings given t
was recorded
ating census
ed based upo
2018ASProf
ere not spelled
003
compoundin
hortages thr
tive Study
y: Administr
omas Chrano
@deborah.or
sion of phar
nternally, the
within one’s i
ortages have
impact of IV
wasted com
d pharmacy
Waste Week”
The first we
flow softwar
modified in
s made to m
staffing sch
determined u
iscretion of t
n electronic
dication were
/17 (Week 2
he variability
d during thes
s could affec
on average m
SHPMidyfessional
d‐out per the g
ng workflow
rough the us
rative Practic
owski; Debor
rg
macy is und
ese challeng
institution.
had a profo
V workflow a
mpounded st
prepared co
” intervals 6/
eek served a
re was then
a manner th
move as close
edules. Prio
using paper
the compou
c queue strea
e calculated
), respective
y of compou
se waste we
ct total amou
midnight cen
yearClinlPoster
guidelines wer
optimizatio
se of IV work
ce/Managem
rah Heart an
er constant
ges may inclu
More recen
ound impact
adjustment t
terile produc
ompounded
/19/17 to 6/
s a baseline
implemente
hat would ha
e as possible
or to the use
profiles and
nder. The s
amlining a v
from our m
ely. Compou
unding time
eks to stand
unt of waste
nsus 1/1/201
nicalMeAbstrac
re translated i
n to conserv
kflow softwa
ment/Financ
nd Lung Cent
pressure to
ude tasks su
tly, external
on our abili
through the
cts before a
sterile prod
/26/17 (Wee
to measure
ed 10/9/17,
ave the grea
e towards a “
e of the work
d printed lab
software is d
ery manual
medication w
nding time w
between pr
dardize wast
ed products.
18‐3/31/201
eetingcts
into unknown
ve fluids and
are
cial Managem
ter;
provide opt
ch as meetin
l challenges
ity to care fo
use of IV wo
nd after imp
ucts were co
ek 1) and 11/
wasted com
and workflo
atest impact
“just in time
kflow softwa
bels. The wo
designed to
and cumber
wholesaler as
was not use
roducts. Mid
te as “cost p
Cost saving
18.
characters.
d reduce was
ment/Huma
timal care w
ng drug and
such as drug
or patients.
orkflow
plementatio
ollected and
/13/17 to
mpounded st
ow processe
to reduce
e” compound
are, items to
orkflow was o
display item
rsome proce
s of 6/30/17
d to calculat
dnight patie
er patient d
gs per year w
ste in
n
with
g,
This
n.
d
terile
s
ding
o be
often
ms to
ess.
te
nt
ay”
was
*Special sy
Results:
recorded
was reco
Week 2 d
patient d
than $32
Conclusio
compoun
conserva
ymbols that w
During Wee
d as $1444.5
orded. As a r
due to reduc
day. This rep
2,000.
on: The use
nding waste
ation of fluid
2018ASProf
ere not spelled
k 1, the tota
2. During W
result, a tota
ced waste. T
presents an a
of IV workfl
at our instit
s during wid
SHPMidyfessional
d‐out per the g
al dollar amo
Week 2, a tot
al cost saving
The differen
annual cost
ow software
tution. This
despread sho
yearClinlPoster
guidelines wer
ount of wast
tal dollar am
gs of $828.6
ce was calcu
savings to th
e resulted in
led to signif
ortages.
nicalMeAbstrac
re translated i
ted compoun
mount of was
68 was obser
ulated to be
he pharmacy
n significant
ficant cost sa
eetingcts
into unknown
nded sterile
sted medicat
rved betwee
a cost savin
y drug budg
reduction of
avings as we
characters.
products w
tion of $615
en Week 1 a
ngs of $1.51
get of greate
f sterile
ell as
as
5.84
nd
per
r
*Special sy
Session‐B
Poster Ti
Poster Ty
Submissi
Resource
Primary A
Email: cy
Addition
Lynn Stiv
Victoria S
Nehemia
Leah We
Purpose:
case man
Past prac
creating
medicati
receive c
standard
reduce th
Methods
were dist
medicati
determin
members
medicati
affordab
medicati
administ
complian
ymbols that w
Board # ‐ 4‐0
itle: Courtes
ype: Descrip
ion Category
es
Author: Cyn
ynthia.coffey
al Authors:
vers
Sisitka
ah Thrash
st
: Providing a
nagement, h
ctices allowe
an atmosph
ons. New re
consistent tr
dized guidelin
he financial
s: A multidis
tributed at o
ons over an
ne those mo
s developed
ons. Most af
ility were co
ons were als
ration when
nce. Provide
2018ASProf
ere not spelled
004
sy medicatio
ptive Report
y: Administr
nthia Coffey;
access to me
hospital adm
ed for patien
ere of behav
egulations on
eatment bas
nes to provid
burden of co
ciplinary tea
other health
11 month p
st frequentl
a color‐cod
ffordable m
oded yellow,
so identified
n prescribed
rs were edu
SHPMidyfessional
d‐out per the g
on assistance
rative Practic
Cardinal He
m
edications to
ministrators, a
nts to simply
viors where
n nondiscrim
sed on stand
de courtesy
ourtesy med
am was form
care centers
period was a
y dispensed
ed formular
edications fo
and the exp
d as medicat
due to subs
cated to pre
yearClinlPoster
guidelines wer
e
ce/Managem
ealth Inc. & R
o indigent pa
and hospita
y state their
patients put
mination and
dardized pra
medications
dications on
med and inve
s. The intern
ssessed and
and with th
ry for easy id
or the patien
pensive med
ions that wo
sequent cost
escribe medi
nicalMeAbstrac
re translated i
ment/Financ
Riverside Re
atients is cos
l‐based phar
inability to p
t other prior
d accessibility
actices. This
s to patients
the health s
estigated ho
nal annual ex
d analyzed by
he greatest e
dentification
nt were cod
dications we
ould need ap
t for refills a
ications in th
eetingcts
into unknown
cial Managem
egional Medi
stly and is a c
rmacies enc
pay for a me
rities ahead
y require th
project deve
s unable to p
system by 35
w courtesy
xpense of co
y therapeuti
expense. The
n of approve
ed green, m
re coded red
pproval by se
nd the likeli
he green list
characters.
ment/Huma
ical Center;
challenge th
ounter daily
edication,
of purchasin
at each pati
eloped
pay as well a
5 percent.
medications
ourtesy
ic category t
e pharmacy
d courtesy
moderate
d. The red co
enior hospit
hood for no
t, when poss
n
hat
y.
ng
ent
as
s
to
team
oded
tal
n‐
sible,
*Special sy
to provid
of return
Next was
process w
promotin
interview
might be
program
courtesy
Results:
reflect di
of medic
meetings
cost of co
reduction
Conclusio
medicati
prescript
health‐sy
Conclusio
medicati
prescript
health‐sy
ymbols that w
de the best o
ning to the e
s to determi
was develop
ng patient fin
wed patients
e willing to h
s and free tr
medication
Data was co
iscussion abo
ations to the
s. The cost sa
ourtesy med
n during the
on: Impleme
ons to patie
tions and res
ystem.
on: Impleme
ons to patie
tions and res
ystem.
2018ASProf
ere not spelled
opportunity
mergency d
ne criteria to
ped to includ
nancial resp
s to discuss
elp pay for m
rials were ex
s.
ollected and
out medicat
e hospital. C
avings comp
dication expe
e 7 month pe
entation of s
nts unable t
sources for o
entation of s
nts unable t
sources for o
SHPMidyfessional
d‐out per the g
towards fac
epartment r
o qualify a p
de scripting t
onsibility. D
options such
medications
xplored prior
analyzed we
tion affordab
Continued ed
paring the tim
enditure wa
eriod.
standardized
to pay result
obtaining ref
standardized
to pay result
obtaining ref
yearClinlPoster
guidelines wer
ilitating affo
refills.
patient for co
that informs
uring the im
h as friends,
. Additional
r to determi
eekly for pat
bility and op
ducation wa
me period o
s decreased
d guidelines
ted in improv
fills as well a
d guidelines
ted in improv
fills as well a
nicalMeAbstrac
re translated i
ordable med
ourtesy med
s patients of
mplantation,
family, and
options suc
ning if the p
tient insuran
ptions, presc
s given and
of May to De
by just over
and a proce
ved access t
as a reduced
and a proce
ved access t
as a reduced
eetingcts
into unknown
ication man
dications. An
the discoun
the case m
community
h as patient
patient is elig
nce status, d
ribed medic
shared durin
ecember 201
r $100,000,
ess for distrib
to affordable
d financial bu
ess for distrib
to affordable
d financial bu
characters.
agement ins
n interview
nt prices offe
anager
y resources t
t assistance
gible to rece
documentati
cations, and
ng weekly
16 to 2017. T
a 54 percen
buting court
e new
urden to the
buting court
e new
urden to the
stead
ered
that
eive
on to
cost
The
t
esy
e
tesy
e
*Special sy
Session‐B
Poster Ti
rate and
Poster Ty
Submissi
Resource
Primary A
Email: cy
Addition
Victoria S
Logan Va
Eric Ston
Cynthia W
Purpose:
discharge
approxim
discharge
to impro
maximizi
was to in
decrease
delivery a
Methods
bedside p
hospital d
stop at e
discharge
the beds
insight in
alternate
based ph
ymbols that w
Board # ‐ 4‐0
itle: Improvi
expedite pa
ype: Descrip
ion Category
es
Author: Cyn
ynthia.coffey
al Authors:
Sisitka
an Wagenen
e
Williams
: Hospital‐ba
e prescriptio
mately 60 pe
e prescriptio
ve patient sa
ing revenue
ncrease utiliz
e the numbe
and patient
s: The workf
program. Sta
discharge tim
ach nurse’s
e patients. T
ide program
nto their per
e methods fo
harmacy wer
2018ASProf
ere not spelled
005
ng bedside
atient discha
ptive Report
y: Administr
nthia Coffey;
ased outpati
ons. Well‐run
rcent of disc
ons were fille
atisfaction b
in a hospita
zation of the
r of paper p
discharge.
flow of the o
andard roun
mes. During
station to co
The staff mem
m. A survey
ception of th
or filling disc
re explored.
SHPMidyfessional
d‐out per the g
medication
rges
rative Practic
Cardinal He
m
ient pharma
n bedside m
charge presc
ed in the out
by delivering
l‐based outp
e hospital‐ba
rescriptions
outpatient ph
nding times w
rounds, pha
ollect writte
mber also us
was also dev
he bedside p
charge presc
Opportunit
yearClinlPoster
guidelines wer
delivery pro
ce/Managem
ealth Inc. & R
cies are und
edication de
criptions. At
tpatient pha
g medication
patient phar
ased outpati
by encoura
harmacy wa
were implem
armacy staff
n prescriptio
sed this time
veloped and
program and
criptions and
ies identified
nicalMeAbstrac
re translated i
ogram to incr
ment/Financ
Riverside Re
derutilized b
elivery progr
this commu
armacy. The
ns and exped
rmacy. The p
ent pharma
ging electro
as reorganize
mented base
f deliver fille
ons and inqu
e to promot
d distributed
d identify are
d potential b
d included r
eetingcts
into unknown
rease prescr
cial Managem
egional Medi
y inpatient p
rams can cap
unity hospita
purpose of
diting discha
primary goal
cy. A second
onic prescrib
ed to dedica
ed on an ana
d prescriptio
uire about p
e and enroll
d to nursing
eas for impr
barriers to us
esolving pay
characters.
ription captu
ment/Huma
ical Center;
providers wr
pture
al only 5% of
this project
arge while
l of the proje
dary goal wa
ing to exped
te staff to th
alysis of peak
ons to patie
ending
l patients int
staff to gain
rovement. N
sing the hos
yment barrie
ure
n
riting
f
was
ect
as to
dite
he
k
nts,
to
Next,
pital‐
ers
*Special sy
and elect
electroni
identified
medicati
prescript
upcomin
prescribe
Results: T
to 41% (8
outpatie
year. In a
percent t
the phar
Conclusio
a bedside
number o
utilizatio
turnarou
ymbols that w
tronic prescr
ic prescriptio
d that provid
ons to the b
tions, introd
g legislation
ed electronic
This project
8.2 fold incre
nt pharmacy
addition, the
to 87 percen
macy was ac
on: Impleme
e discharge
of prescripti
n of electron
und time and
2018ASProf
ere not spelled
ribing of me
ons revealed
ders were no
bedside. The
uced the ph
n which will r
cally.
has resulted
ease) of all d
y. The increa
e proportion
nt and the go
chieved.
enting strate
medication
ons filled by
nic prescribi
d increased p
SHPMidyfessional
d‐out per the g
dications. A
d a pivotal co
ot electronic
team educa
armacy’s pr
require any c
d in an incre
discharge pre
ase contribu
of prescript
oal of reduci
egies and pro
program wa
y the hospita
ng. These im
profit for the
yearClinlPoster
guidelines wer
n analysis on
omponent to
cally prescrib
ated the pro
ocess to res
controlled s
ease from a 5
escriptions b
ted to $544,
tions transm
ing the num
ocesses to im
as associated
al‐based out
mprovement
e institution
nicalMeAbstrac
re translated i
n the numbe
o this proces
bing medica
viders relate
olve payme
ubstance co
5% discharge
being filled b
,031 of gros
mitted electro
ber of writte
mprove the
d with a sign
tpatient pha
ts led to dec
.
eetingcts
into unknown
er of written
ss improvem
tions slowin
ed to the de
nt barriers, a
ontaining an
e prescriptio
by the hospi
s revenue ov
onically incr
en prescript
awareness a
nificant incre
rmacy and a
creased pres
characters.
n, faxed and
ment. The te
ng the delive
lays with wr
and leverage
opiate to be
on capture r
tal‐based
ver the past
reased from
tions receive
and efficienc
ease in the
an increase i
cription fill
am
ery of
ritten
ed
e
ate
t
63
ed by
cy of
n
*Special sy
Session‐B
Poster Ti
catheteri
Poster Ty
Submissi
Resource
Primary A
Email: rb
Addition
Purpose:
chloride
solution
both ope
formulat
errors th
the pote
Methods
were ma
nursing w
reconstit
insert ins
bivalirud
flush to r
reconstit
Safe Med
errors an
formulat
considera
thawed.
reports f
par level
ymbols that w
Board # ‐ 4‐0
itle: Implem
ization labor
ype: Descrip
ion Category
es
Author: Rac
bounds4@gm
al Authors:
: The Food a
in January o
in a GALAXY
erational and
ion saves nu
at could occ
ntial of leve
s: Current st
pped from b
was observe
tuting, admin
structions, n
in vials. For
reconstitute
tute and pus
dication Prac
nd patient ha
ions was pe
ations in ana
Waste elimi
rom automa
s for each ca
2018ASProf
ere not spelled
006
entation of
ratory
ptive Report
y: Administr
chel Cordrey
mail.com
nd Drug Adm
of 2018. This
Y container. T
d regulatory
ursing time i
cur during po
raging prem
ate processe
both a nursin
d pulling biv
nistering, an
or did they f
example, on
the vial and
sh medicatio
ctices, as un
arm. In addit
rformed in a
alyzing the p
nation is cru
ated dispens
ardiac cathe
SHPMidyfessional
d‐out per the g
premixed bi
rative Practic
; Peninsula R
ministration
product is s
The use of p
standpoints
n preparatio
oint of care a
mixed bivaliru
es for bivalir
ng and phar
valirudin vial
nd charting.
follow a stan
ne nurse des
d push the bo
ons has been
labeled flush
tion, a comp
a 340b dispr
premixed pro
ucial from an
sing cabinet
terization la
yearClinlPoster
guidelines wer
ivalirudin in
ce/Managem
Regional Me
approved b
supplied as a
premixed int
s, for a varie
on of the me
admixing. Th
udin in the c
rudin utilizat
macy perspe
s from the a
In many cas
ndardized pr
scribed her w
olus dose. T
n noted as an
hes containi
prehensive f
oportionate
oduct was th
n operationa
were analyz
b.
nicalMeAbstrac
re translated i
a communit
ment/Financ
edical Cente
bivalirudin in
a frozen prem
travenous pr
ety of reason
edication, an
he purpose o
ardiac cathe
tion in the ca
ective, using
automated d
es, nursing d
rocess for re
work flow as
he use of so
n unsafe pra
ing medicati
inancial ana
e share envir
he 14 day be
al and financ
zed to deter
eetingcts
into unknown
ty‐hospital c
cial Managem
r;
n 0.9 percent
mixed, iso‐o
roducts is pr
ns. This ready
nd eliminate
of this study
eterization la
ardiac cathe
g gemba. Du
dispensing ca
did not follo
econstitution
s using a sod
odium chlorid
actice by the
ions have led
lysis of both
ronment. On
eyond use da
cial standpoi
mine approp
characters.
cardiac
ment/Huma
t sodium
osmotic, ster
referred from
y to use
s potential
y is to exami
ab.
eterization la
ring the gem
abinet,
w the packa
n of the
dium chlorid
de flushes to
e Institute fo
d to serious
h bivalirudin
ne of the key
ate once
int. Utilizatio
priate max a
n
rile
m
ne
ab
mba,
age
e
o
or
y
on
and
*Special sy
Results: A
opinion l
product i
product i
below th
Pharmac
premixed
product.
use the i
in the au
historica
health re
product t
supplied
250mg/5
Conclusio
involves
and futur
cardiac c
bivalirud
administ
working
ymbols that w
After review
eaders from
in the cardia
is slightly mo
e cost of the
cy and nursin
d product. T
It took abou
nfusion pum
tomated dis
l utilization t
ecord, smart
transition. N
in the same
50mL and 50
on: Successf
proper plan
re state proc
atheterizatio
in saves tim
ration. It als
under the re
2018ASProf
ere not spelled
wing results f
m pharmacy a
ac catheteriz
ore expensiv
e vials for ou
ng processes
he largest ba
ut a week fo
mps for both
spensing cab
to avoid bot
infusion dev
No update w
e concentrat
00mg/100mL
ful impleme
ning with af
cess map inv
on lab staff
e staff woul
o reduces th
estraint of ti
SHPMidyfessional
d‐out per the g
from the gem
and nursing
zation lab. W
ve, 340b pric
ur institution
s were re‐ma
arrier to imp
or staff to be
the bolus an
binet’s refrig
th stock outs
vices, and ot
as needed fo
ion as previo
L.
ntation of a
ffected depa
volving the f
post implem
d have spen
he potential
me to provid
yearClinlPoster
guidelines wer
mba and the
decided to i
While the wh
cing drives t
n; an estimat
apped based
plementatio
come comfo
nd infusion d
geration unit
s and wasted
ther system
or infusion p
ous state wh
premixed in
rtments. A k
front line sta
mentation ha
nt reconstitu
for errors in
de quality ca
nicalMeAbstrac
re translated i
e bivalirudin
implement t
holesale acqu
he overall co
ted savings o
d on the cha
n was lack o
ortable with
doses. Prem
ts with a suff
d product. A
s were take
pumps; the p
hen nursing
ntravenous p
key to succe
aff, including
as been very
uting and pre
n a procedur
are.
eetingcts
into unknown
financial mo
the premixe
uisition cost
ost of the pr
of 1,027 dol
ange from bi
of confidence
a new work
mixed bivalir
ficient inven
Alignment of
n into accou
premixed pr
was mixing
product, suc
ess is perform
g gemba. Fee
y positive. Pr
eparing the m
ral area whe
characters.
odel, key
d bivalirudin
of the prem
remixed pro
lars annually
valirudin via
e using a new
kflow; they n
udin was pla
ntory based
f the electron
unt during th
roduct is
on demand,
h as bivaliru
ming a curre
edback from
remixed
medication f
ere staff are
n
mixed
duct
y.
als to
w
now
aced
upon
nic
he
,
udin,
ent
m
for
*Special sy
Session‐B
Poster Ti
Poster Ty
Submissi
Resource
Primary A
Email: km
Addition
Purpose:
consumin
impleme
in order t
Methods
October
replenish
impleme
repeated
database
and the t
determin
utilized t
considere
annualize
Results: T
time per
were sca
was foun
technicia
for a tota
perceive
ymbols that w
Board # ‐ 4‐0
itle: Implem
ype: Descrip
ion Category
es
Author: Kev
mdoherty@s
al Authors:
: Improved e
ng and labor
ntation of a
to evaluate
s: The RFID t
2, 2017. Prio
hing and che
ntation proc
d for the pos
e linked to th
total numbe
ned for both
o calculate a
ed and over
ed.
The implem
iod, 410 acti
nned on dai
nd to be a to
ans of $44,10
al cost of $7,
d to enhanc
2018ASProf
ere not spelled
007
entation of
ptive Report
y: Administr
vin Doherty;
saintfrancis.
efficiency inc
r‐intensive p
simple radio
impact on e
tagging proc
or to implem
ecking drug k
cess and me
st‐implemen
he RFID scan
r of items re
pharmacist
a manpower
all time and
entation cos
ive drug kits
ily average. T
tal of 1,243
00. In compa
,520 was ob
e staff satisf
SHPMidyfessional
d‐out per the g
a radiofrequ
rative Practic
Saint Franci
com
creases over
process. An e
ofrequency
fficiency.
ess was imp
mentation, te
kits were me
easuring the
tation proce
nner includin
eplenished. T
s and techni
r cost. The in
cost savings
st was estim
were utilize
The annual m
hours for an
arison, an an
served. Alth
faction. Othe
yearClinlPoster
guidelines wer
uency taggin
ce/Managem
s Hospital;
rall quality. R
evaluation w
(RFID) taggi
plemented o
echnician an
easured by b
time of each
ess. On June
ng the numb
Total pre‐ an
icians. Base
nitial investm
s were calcu
mated at app
ed; 27 kits w
manpower c
n estimated
nnualized po
hough not m
er institution
nicalMeAbstrac
re translated i
ng system to
ment/Financ
Replenishing
was conducte
ng system to
over a weeklo
nd pharmaci
breaking dow
h step. In ea
e 1, 2018, da
ber of times e
nd post‐imp
salaries of f
ment in man
ulated. These
roximately $
were process
cost of the p
cost of both
ost‐impleme
easured, the
ns have repo
eetingcts
into unknown
o manage dru
cial Managem
g drug kits is
ed before an
o restock an
ong period b
st time requ
wn each step
arly June, thi
ta was extra
each drug ki
lementation
ull‐time emp
npower and
e calculation
$11,000. Ove
ed and 762
pre‐impleme
h pharmacist
entation time
e new proce
orted additio
characters.
ug kits and t
ment/Huma
s a time‐
nd after
d check dru
beginning on
uirements in
p in the pre‐
s method w
acted from t
it was scann
n times were
ployees wer
RFID tags we
ns were
er the study
individual it
entation proc
ts and
e of 314 hou
ess was
onal benefit
trays
n
g kits
n
‐
as
he
ned
e
re
ere
y
ems
cess
urs
s of
*Special sy
RFID tagg
when con
presence
avoided.
waste of
occurred
Conclusio
demonst
pharmac
tags, an a
processe
ymbols that w
ging includin
nfronted wit
e of items an
The recall p
soon‐to‐out
d before laun
on: The RFID
trated 75% t
cists—89% ti
annual cost
es were note
2018ASProf
ere not spelled
ng inventory
th recalls of
nnounced on
process beca
tdate items
nching the n
D tagging pro
ime and 83%
me and 93%
savings of ap
ed after impl
SHPMidyfessional
d‐out per the g
y control and
kit items. Th
n several rec
me less time
existed prio
ew process.
ocess improv
% cost saving
% cost saving
pproximatel
ementation
yearClinlPoster
guidelines wer
d drug‐recall
he new proc
calls; thus, th
e‐intensive a
r to implem
An enhance
ved time an
gs. Savings w
gs. After acco
y $17,664 is
.
nicalMeAbstrac
re translated i
manageme
cess permitte
he need to m
and more fo
entation. Op
ement to pe
d cost efficie
was especial
ounting for t
s anticipated
eetingcts
into unknown
ent. Benefits
ed pharmac
manually che
ocused. A pro
ptimization o
rmit kit trac
ency. This ev
lly pronounc
the annual c
d. Improved
characters.
were obser
y to rule out
eck all kits w
ocess to pre
of kit conten
cking is desir
valuation
ced for
cost of the R
drug recall
ved
t the
was
vent
nts
red.
RFID
*Special sy
Session‐B
Poster Ti
selected
Poster Ty
Submissi
Resource
Primary A
Email: dr
Addition
Ashley H
Victoria N
Laura Ay
Purpose:
electrica
The resu
out ways
patient c
consider
intraveno
by severa
Methods
of specifi
to be adm
aztreona
live educ
in our op
emergen
additiona
standard
of sterile
over thre
ymbols that w
Board # ‐ 4‐0
itle: Transiti
antibiotics a
ype: Descrip
ion Category
es
Author: Pau
r.paul.green@
al Authors:
alloran
Nosowicz
lor
: In Septemb
l grid and cr
lting nationa
s in which to
care or overa
ing transitio
ous push ad
al months.
s: We condu
ic antibiotics
ministered v
m, cefazolin
cation to pha
perating room
ncy departm
al training w
dized plan by
e water for in
ee to five mi
2018ASProf
ere not spelled
009
on from intr
as a clinically
ptive Report
y: Administr
ul Green; Com
@gmail.com
ber 2017, Hu
ippling one o
al shortage o
o decrease th
all costs. Wh
ning several
ministration
cted an exte
s that were b
via intraveno
n, cefepime,
armacy staff
m with no re
ent for anot
was provided
y which each
njection. Th
nutes.
SHPMidyfessional
d‐out per the g
ravenous inf
y neutral cos
rative Practic
mpleteRx / U
m
urricane Mar
of the Unite
of these fluid
heir overall u
hile our 186‐
l of our antib
n, these even
ensive review
both affecte
ous push and
cefoxitin, an
f, nurses, and
emarkable is
her one mo
to appropri
h of one gram
e total dose
yearClinlPoster
guidelines wer
fusion to intr
st savings m
ce/Managem
Upper Allegh
ria struck Pu
d States’ on
ds triggered
utilization w
‐bed rural N
biotics from
nts led us to
w of the cur
ed by the int
d decide to s
nd ceftriaxon
d providers,
ssues. The p
nth trial bef
iate staff me
m of the ant
would then
nicalMeAbstrac
re translated i
ravenous pu
easure
ment/Financ
heny Health
uerto Rico w
ly manufact
hospitals ar
without negat
ew York hos
intravenous
move up ou
rrent literatu
ravenous flu
start with an
ne. After pr
we conduct
program was
fore finally m
embers. We
ibiotic woul
n be adminis
eetingcts
into unknown
ush administ
cial Managem
System;
iping out the
turers of intr
round the co
tively impac
spital had al
s piggyback
ur implemen
ure and our r
uid shortage
n initial set o
roviding both
ted a month
s next rolled
moving facilit
e implement
d be diluted
stered via int
characters.
tration of
ment/Huma
e island’s
ravenous flu
ountry to see
cting either
ready been
infusion to
ntation time
rate of utiliz
e and approp
of five antibio
h written an
h‐long pilot s
d out in our
ty‐wide afte
ted a
d in ten millil
travenous p
n
uids.
ek
line
ation
priate
otics:
nd
study
er
liters
ush
*Special sy
Based on
had been
had trans
historica
for prepa
negative
Results:
administ
(3,694).
both to a
pharmac
appropri
shortage
No negat
administ
warmth a
has rema
mixed in
The dose
sterile wa
predicted
Conclusio
specific a
way to d
since late
has also
negative
resolutio
applicabl
ymbols that w
n the favorab
n using to ad
sitioned to, w
l norms, we
aration and n
ly impacted
During the f
ered. The m
This is a high
a higher than
cy staff to en
ate in order
.
tive clinical o
ration. Only
at the inject
ained in plac
fifty or one
es were tran
ater for inje
d utilization
on: Transitio
antibiotics fo
ecrease utili
e 2017. Whi
led to a sign
impact on c
on of the nat
le.
2018ASProf
ere not spelled
ble cost diffe
dminister the
we estimate
would save
nursing time
by the chan
first six mont
majority were
her number
n average ho
ncourage use
to conserve
outcomes ha
y one advers
ion site. The
ce with no is
hundred mi
sitioned to h
ction at a co
led to a tota
oning from in
or which goo
ization of int
ile it was not
ificant overa
clinical outco
tional shorta
SHPMidyfessional
d‐out per the g
erential betw
e antibiotics
ed that, if ou
$6,000 in on
e for adminis
nge.
ths of using
e cefazolin f
of doses tha
ospital censu
e of one of t
e intravenou
ave been cre
se reaction h
e hospital’s
sues. Prior t
illiliters of no
have each on
ost of $0.77.
al savings of
ntravenous
od safety and
travenous flu
t the primar
all cost savin
omes or wor
age and eval
yearClinlPoster
guidelines wer
ween the int
and the via
ur utilization
ne year. We
stration to e
the intraven
for surgical p
an was pred
us during the
he intraveno
us fluid bags
edited to the
has been rep
intravenous
to implemen
ormal saline
ne gram of a
The cost di
$8,811.83.
infusion to i
d efficacy da
uid bags wh
ry reason for
ngs while no
rkflow. We w
uate other a
nicalMeAbstrac
re translated i
travenous flu
ls of sterile w
remained c
e evaluated
ensure that w
nous push ro
prophylaxis (
dicted. The i
e study perio
ous push ant
which have
e change in m
ported which
s to oral med
nting the cha
e costing $1.2
antibiotic dil
fferential co
ntravenous
ata exist has
ich have rem
r implement
ot increasing
will continue
antibiotics fo
eetingcts
into unknown
uid bags of n
water for inj
consistent an
pharmacy te
workload wo
oute, 8,734 d
(3,521 doses
ncrease has
od and effor
tibiotics whe
remained o
method of in
h was noted
dication tran
ange, the an
27 and $2.47
uted in ten
oupled with
push admin
s proven to b
mained on n
ting the chan
adverse eff
e this practic
or potential
characters.
normal salin
jection that
nd followed
echnician tim
ould not be
doses were
s) or ceftriax
s been attrib
rts by the
en clinically
on national
ntravenous
as redness
nsition proce
ntibiotics we
7 respective
milliliters of
the higher t
nistration of
be an effecti
ational shor
nge, the pra
fects or havin
ce even afte
inclusion wh
e we
we
me
xone
buted
and
ess
ere
ely.
f
han
ve
rtage
ctice
ng a
er
hen
*Special sy
Session‐B
Poster Ti
at a 340B
Poster Ty
Submissi
Resource
Primary A
Email: ga
Addition
Bijan Me
Kenny Yu
Mark Cap
Kenneth
Purpose:
federal re
compreh
(GPO) Pr
WAC) co
when fin
pricing w
of real‐ti
opportun
Methods
a dashbo
accounts
WAC item
from eac
item listi
criteria: (
WAC pric
within th
ymbols that w
Board # ‐ 4‐0
itle: Optimiz
B covered en
ype: Descrip
ion Category
es
Author: Gab
abriel.guerra
al Authors:
ekoba
u
puano
Eng
: The 340B D
esources as
hensive servi
ohibition, m
ntract pricin
ancially cost
when it is low
me cost com
nities.
s: On a mont
oard generat
s from the w
m listing. On
ch respective
ng. Items ar
(1) sub‐WAC
ce savings is
he last rolling
2018ASProf
ere not spelled
010
zing purchas
ntity
ptive Report
y: Administr
briel Guerra;
Drug Pricing
far as possib
ices. Covere
may utilize th
ng in the non
t‐effective. O
wer than GPO
mparisons ca
thly basis, th
ting workboo
wholesaler, (2
n the master
e product pr
e identified
C price has at
at minimum
g 365 days. A
SHPMidyfessional
d‐out per the g
es by levera
rative Practic
; NYU Health
rg
Program wa
ble to reach
d entities (C
e Prime Ven
n‐GPO/WAC
One method
O pricing. CE
an perform a
he following
ok (DGW): (1
2) purchase
tab, a listing
icing catalog
for inclusion
t minimum $
m 10% comp
A final listing
yearClinlPoster
guidelines wer
ging sub‐wh
ce/Managem
h;
as enacted w
more eligib
CEs) subject t
ndor Program
accounts to
d of optimizin
Es utilizing sp
analyses to id
items are ex
1) product p
history for la
g of all items
g tab, purcha
n for sub‐WA
$10 savings
ared to GPO
g of items is
nicalMeAbstrac
re translated i
holesale acq
ment/Financ
with the inte
le patients a
to the Group
m's sub‐who
o maintain in
ng purchasin
plit‐billing so
dentify finan
xported and
pricing catalo
ast 365 days
s uses NDC d
ase history,
AC item listi
per package
O, and (3) the
compiled an
eetingcts
into unknown
uisition cost
cial Managem
nt of stretch
and provide
p Purchasing
olesale acqu
nventory com
ng is to utiliz
oftware with
ncially benef
d entered on
ogs for 340B
s, and (3) cu
data to quer
and the acti
ng based on
e compared
e NDC has b
nd uploaded
characters.
t contract pr
ment/Huma
hing scarce
more
g Organizatio
isition (sub‐
mpliance and
ze sub‐WAC
hout capabil
ficial
n separate ta
B, GPO and W
rrent active
ry current pr
ive sub‐WAC
n the followin
to GPO, (2)
been purchas
d to the third
ricing
n
on
d use
ities
abs in
WAC
sub‐
rices
C
ng
sub‐
sed
d‐
*Special sy
party adm
WAC acc
for contin
Results:
under W
average s
$7,460.8
was $34,
Conclusio
CEs subje
ymbols that w
ministrator s
ount if initia
nued inclusi
Purchase his
AC accounts
savings per m
1. After imp
831.53.
on: Creation
ect to the GP
2018ASProf
ere not spelled
split‐billing s
ally directed
on and are r
story from Ja
s were flagge
month achie
plementation
n of a DGW t
PO Prohibitio
SHPMidyfessional
d‐out per the g
software wh
to the GPO
removed if t
anuary 2017
ed by month
eved by sub‐
n, the averag
to analyze su
on.
yearClinlPoster
guidelines wer
ich then red
account. Ac
he inclusion
7 through Ap
h based on in
‐WAC pricing
ge savings pe
ub‐WAC pric
nicalMeAbstrac
re translated i
directs purch
ctive sub‐WA
n criteria are
pril 2018 wa
nclusion crit
g prior to im
er month ac
cing can be a
eetingcts
into unknown
hases of thes
AC items are
e no longer m
s analyzed.
teria. Of iden
mplementatio
chieved by su
a cost‐effect
characters.
se items to t
e also analyz
met.
Items purch
ntified items
on was
ub‐WAC pric
tive benefit f
the
ed
ased
s, the
cing
for
*Special sy
Session‐B
Poster Ti
large hea
Poster Ty
Submissi
Resource
Primary A
Email: el
Addition
Adrienne
Purpose:
Carolina,
significan
decrease
(ICS/LABA
spends, a
inhalers.
reduce in
fluticason
Methods
potentia
interdisc
finance p
pulmona
was ther
approve
after go‐
Subseque
inhalers i
EMR inpa
not conv
ymbols that w
Board # ‐ 4‐0
itle: Rationa
alth system
ype: Descrip
ion Category
es
Author: Edd
gutsha@sen
al Authors:
e Donaldson
: Sentara He
, with 12 hos
nt portion of
e operating b
A) inhalers s
and was con
Due to thes
npatient dru
ne‐vilantero
s: A top dow
l cost saving
iplinary team
personnel wa
ary physician
apeutically a
the intercha
live they edu
ent doses ar
in designate
atient comp
erted as a p
2018ASProf
ere not spelled
011
le and cost s
ptive Report
y: Administr
die Gutshall;
ntara.com
ealthcare is a
spitals and m
f the organiz
budgets. The
spend was id
sidered elev
se trends, th
g spend by t
ol inhaler.
wn spend ana
g opportuniti
m of pharma
as formed to
ns on the fina
acceptable.
ange. The re
ucate patien
re administe
ed area. ICS/
uter system
art of the im
SHPMidyfessional
d‐out per the g
savings of a
rative Practic
Sentara Hea
a not‐for‐pro
more. Becau
zation's oper
e inhaled cor
dentified as o
vated becau
e pharmacy
therapeutica
alysis was co
ies. Once the
acy staff, pul
o further eva
ancial oppor
Once the ph
espiratory th
nts on prope
ered by nursi
/ LABA inhal
and entered
mplementati
yearClinlPoster
guidelines wer
conversion t
ce/Managem
althcare;
ofit health sy
se pharmace
rating budge
rticosteroid/
one of the to
se of the cos
departmen
ally intercha
ompleted us
e interchang
lmonology p
aluate the o
rtunity and s
hysicians agr
herapists we
er administra
ing who are
ation therap
d new order
on. Buyers p
nicalMeAbstrac
re translated i
to fluticason
ment/Financ
ystem servin
eutical expe
et, drug spen
/long‐acting
op drug spe
st of the flut
t developed
nging the flu
ing a spend
ge opportun
physicians, re
pportunity.
surveyed the
reed, the P&
ere educated
ation with th
also encour
peutic interc
rs. Previously
purchased in
eetingcts
into unknown
ne‐vilantero
cial Managem
ng Virginia an
enditures acc
nd analysis i
g beta‐agonis
nds, top incr
ticasone‐salm
d a cost savin
uticasone‐sa
analytics to
nity was iden
espiratory th
Pharmacy fi
em to see if
&T Committe
d on use of t
he initial inh
raged to pro
change was a
y dispensed
nhalers in ad
characters.
l inhaler in a
ment/Huma
nd North
count for a
s a way to h
st inhalers
reasing drug
meterol disc
ngs initiative
almeterol to
ol to identify
ntified, an
herapy staff,
irst educated
this intercha
ee voted to
he inhaler a
alation dose
operly store
activated in
inhalers we
dvance of the
a
n
elp
g
cus
e to
y
, and
d the
ange
nd
e.
the
ere
e
*Special sy
conversio
used.
Retrospe
wholesal
Results:
impleme
these pro
a slight 4
than 4%
impleme
inhaler, u
Patients
the numb
Moving f
vilanerol
Conclusio
purchase
increased
decrease
collabora
opportun
ymbols that w
on to ensure
ective financ
er spend an
Physicians b
ntation (July
oducts comp
4.7% (‐697 un
of the saving
ntation of th
utilization of
with ICS/LAB
ber of inhale
from fluticas
once daily i
on: The ICS/
e dollars by 3
d 5.2% (+566
es nursing tim
ation betwee
nity to decre
2018ASProf
ere not spelled
e adequate s
ial monitori
alytics tool.
began orderi
y 2017 to Ma
pared to the
nits) decreas
gs. This dram
he therapeu
f the 340B/D
BA ordered
ers charged t
sone‐salmete
nhalation re
/LABA inhala
32% (‐$597,7
6). Converti
me and enco
en pharmacy
ease inpatien
SHPMidyfessional
d‐out per the g
supply. The i
ng of this ini
ng the new
ay 2018) sho
same 11 mo
se during th
matic decrea
tic interchan
DSH pricing a
increased 5.
to inpatient
erol twice da
educed nursi
ation therape
782) while th
ng from a tw
ourages pati
y, pulmonol
nt inhaler co
yearClinlPoster
guidelines wer
institutional
itiative was
inhaler in Ju
owed a 32%
onths the pr
e same 11‐m
ase in inpatie
nge is attribu
and decrease
.2% (+ 566 p
s remained
aily inhalatio
ing time, dru
eutic interch
he number o
wice daily in
ent complia
ogist and he
ost through a
nicalMeAbstrac
re translated i
14 day devi
performed u
uly 2017. The
(‐$597,782)
revious year
month timef
ent medicat
uted to enha
e in waste.
patients) from
neutral at 14
on to equally
ug waste, an
hange initiat
of patient w
haler to a on
nce. Hospit
ealth care wo
a formulary
eetingcts
into unknown
ice for both
using EMR re
e first 11 mo
) decrease in
r. Purchase v
frame, but ac
tion spend af
anced contr
m 10,782 to
4,121 to 14,
y efficacious
nd increased
tive reduced
with ICS/LABA
nce daily inh
tals should c
orkers to ass
change.
characters.
inhalers wa
eports and
onths after
n drug spend
volume show
ccounts for
fter
ract price pe
11,348 whi
026.
s fluticasone
d compliance
d the inhaler
A orders
haler also
onsider a
sess the
s
d for
wed
less
r
le
e‐
e.
*Special sy
Session‐B
Poster Ti
drug pric
Poster Ty
Submissi
Resource
Primary A
Email: an
Addition
Jackie Br
Goldina E
Purpose:
that requ
organizat
covered
health sy
Identifyin
national
Methods
expendit
purchase
orders w
fifteen o
purchase
nonfeder
outpatie
clinic pha
and com
generic a
calculate
ymbols that w
Board # ‐ 4‐0
itle: Quantif
cing program
ype: Descrip
ion Category
es
Author: And
ndrea.henry@
al Authors:
own
Erowele
: The 340B D
uires drug m
tions and co
entities to st
ystem is one
ng significan
pharmaceut
s: National d
tures combin
e history rep
were compile
utpatient fac
es for inpatie
ral hospital s
nt pharmace
armaceutica
pared to nat
and brand na
ed and trend
2018ASProf
ere not spelled
012
fying costs of
m in a county
ptive Report
y: Administr
drea Henry;
@harrisheal
Drug Discoun
manufacturer
overed entiti
tretch scarce
of those cov
nt shifts in dr
tical trends h
drug expend
ned for inpat
ort from the
ed and analy
cility expend
ent facilities
systems. Tre
eutical trend
l trends. Sp
tional trends
ame, quantit
ed by inpati
SHPMidyfessional
d‐out per the g
f high dollar
y health syst
rative Practic
Harris Healt
lth.org
nt Program i
rs to provide
es at signific
e federal res
vered entitie
rug expendit
help health s
iture trends
tient, outpat
e system wh
zed. Data fr
ditures were
were compa
ends for out
ds. Clinic ad
ecialty drug
s. The repor
ty, national
ent and out
yearClinlPoster
guidelines wer
r pharmaceu
tem
ce/Managem
h System;
s a US feder
e outpatient
cantly reduc
sources to re
es that bene
tures and pr
systems ant
were review
tient and cli
olesaler for
rom top purc
e compared t
ared to natio
tpatient facil
ministered m
s were ident
rt characteri
drug code, a
patient purc
nicalMeAbstrac
re translated i
utical expend
ment/Financ
ral governme
drugs to elig
ced prices. T
each more e
efits greatly
rescribing pa
icipate phar
wed for base
nic administ
one fiscal ye
chases for th
to national p
onal pharma
lities were c
medications
tified in top
istics include
and cost. Co
chases. Drug
eetingcts
into unknown
ditures in lig
cial Managem
ent program
gible health
The 340B pr
eligible patie
from 340B d
atterns when
rmaceutical s
eline informa
tered were e
ear and dire
hree inpatie
pharmaceut
aceutical exp
ompared to
were comp
pharmaceu
ed drugs pur
mbined tota
gs were cate
characters.
ht of a 340B
ment/Huma
m created in
care
rogram enab
ents. This co
drug pricing.
n compared
spending.
ation. Top d
evaluated. A
ect purchase
nt facilities a
tical trends.
penditures f
o national
pared to nati
tical expend
rchased by
als were
egorized by
B
n
1992
bles
ounty
.
to
drug
A
and
Top
for
onal
diture
*Special sy
specialty
classes o
Results: A
health sy
percent f
of the ph
vancomy
and amp
pegfilgra
lamivudi
Thirty sev
represen
twenty o
sectors in
penny pr
pricing a
ledipasvi
administ
provided
no 340B
Conclusio
drugs rep
inpatient
trends en
pricing. T
expendit
county h
ymbols that w
y pharmacy d
f drugs were
A total phar
ystem. Thirt
for outpatie
harmaceutica
ycin, influenz
hotericin B l
stim, trastuz
ne, intraven
ven percent
nt antimicrob
one percent f
ncluded ada
ricing of ada
nd impleme
r‐sofosbuvir
ered medica
d in an infusi
pricing avail
on: Specialty
present sixty
t expenditur
nable health
The 340B Dr
ture trends f
ealth system
2018ASProf
ere not spelled
designation
e compared
maceutical e
y‐eight perc
nt drugs. Th
al expenditu
za vaccine, t
liposome. T
zumab, elvit
ous immune
t of outpatie
bial agents w
for antimicro
limumab, in
limumab an
nted therap
r was provid
ation trends
on setting.
lable.
y drugs are a
y percent of
re for a comb
h systems to
rug Discount
for a county
m, were diffe
SHPMidyfessional
d‐out per the g
using a reco
to national
expenditure
cent of the e
here are free
ure. Top exp
rastuzumab
Top expendit
tegravir‐cobi
e globulin, in
nt expenditu
whereas for
obial agents
sulin glargin
d insulin det
peutic interch
ed free thro
were simila
Inpatient tre
a significant
the outpatie
bine total of
provide bud
t Program re
health syste
erent when c
yearClinlPoster
guidelines wer
gnized natio
trended pha
e of eighty‐fiv
xpenditure w
e programs f
penditures in
b, vasopressi
tures for out
icistat‐emtri
nfliximab, pe
ure is for on
inpatient, on
s. Top expen
ne, etanerce
temir, the he
hanges for t
ough patient
r to nationa
ends were si
portion of t
ent expendit
f forty nine p
dget project
esults in une
em. Due to 3
compared to
nicalMeAbstrac
re translated i
onal specialt
armaceutica
ve million in
was for inpa
for indigent
npatient incl
n, calcitonin
tpatient incl
icitabine, ab
ertuzumab, c
cology drug
nly twenty t
nditures iden
pt, and ledip
ealth system
hese more c
t assistance p
al because m
imilar to nat
the pharmac
ture and twe
percent. Un
ions in lieu o
expected shif
340B pricing
o national tr
eetingcts
into unknown
ty drug list. T
al spend.
n a fiscal yea
atient drugs
patients tha
lude rituxim
n, clofarabin
ude bevaciz
bacavir‐dolut
cetuximab, a
gs and twent
wo percent
ntified nation
pasvir‐sofos
m benefited
cost effectiv
program. Cl
mostly oncolo
tional trends
ceutical budg
enty eight p
derstanding
of the impac
fts in pharm
g, top expen
rends.
characters.
Therapeutic
r for a count
and sixty tw
at are not a p
ab, alteplase
e, darbepoe
umab,
tegravir‐
and rituxima
ty four perce
is oncology
nally across
buvir. Due t
from 340B
e agents, wh
linic
ogy agents w
s since there
get. Special
ercent of
g pharmaceu
ct of 340B
maceutical
ditures for a
c
ty
wo
part
e,
etin,
ab.
ent
and
all
to
hile
were
e was
ty
utical
a
*Special sy
Session‐B
Poster Ti
health‐sy
Poster Ty
Submissi
Resource
Primary A
Email: cr
Addition
Ken Max
Chris Boo
Michael
Kim Broe
Purpose:
intraveno
pharmac
automat
Additiona
been add
pharmac
automat
impact.
Methods
administ
United St
responde
Practice
and using
large size
automat
complete
ymbols that w
Board # ‐ 4‐0
itle: Post im
ystem pharm
ype: Descrip
ion Category
es
Author: Cra
raig.kimble@
al Authors:
ik
oth
Rudolph
edel‐Zaugg
: Many healt
ous (IV) auto
cy errors and
ed systems,
ally, IV admi
ded to pharm
cies prior to i
ion system i
s: An anonym
rators or ph
tates throug
ents were ta
Managemen
g additional
e hospitals.
ion technolo
e the full sur
2018ASProf
ere not spelled
013
plementatio
macy operati
ptive Report
y: Administr
ig Kimble; M
@marshall.ed
th‐system ph
omation and
d improve ac
used appro
ixture autom
macy workflo
implementa
mplementat
mous survey
armacy staff
gh targeted e
argeted using
nt, Pharmacy
databases t
A survey qu
ogy, and only
rvey. This su
SHPMidyfessional
d‐out per the g
on analysis:
ions
rative Practic
Marshall Univ
du
harmacies h
d/ or compou
ccuracy, prod
priately, wil
mation is one
ow. The goa
tion and exp
tion in term
y questionna
f that had di
email invitat
g anonymou
y Informatic
hat contain
estion was i
y those who
rvey instrum
yearClinlPoster
guidelines wer
Impact of in
ce/Managem
versity Schoo
ave implem
unding syste
ductivity, an
l aid in redu
e of the mos
l of this stud
periences re
s of quality,
aire was crea
irect superv
tions. Additi
us participat
cs, and Medi
pharmacy m
ncluded to v
o answered i
ment consist
nicalMeAbstrac
re translated i
ntravenous a
ment/Financ
ol of Pharma
ented, or ar
em in their c
nd workflow
cing errors f
st recent are
dy is to revie
ealized follow
safety, prod
ated and pro
isory roles fo
ionally, to in
ion requests
cation Safet
management
verify respon
n the affirm
ted of a tota
eetingcts
into unknown
automation s
cial Managem
acy;
re considerin
clean rooms
. Manufactu
from reachin
eas where te
ew key areas
wing intrave
ductivity, an
ovided to 35
or IV rooms
ncrease part
s and links o
ty Officer dis
t informatio
ndents had a
mative were a
l of 45 quest
characters.
systems on
ment/Huma
ng some form
to reduce
urers tout th
ng patients.
echnology ha
s assessed b
nous
d financial
54 pharmacy
across the
icipation,
on the ASHP
scussion boa
on for mid to
adopted IV
asked to
tions targeti
n
m of
at
as
y
y
ards
o
ing 4
*Special sy
key areas
informat
The surve
anonymo
Results:
having IV
10 years
installed
consistin
of autom
responde
Of those
were ach
products
of person
medicati
impleme
efficientl
impact o
Conclusio
ROI analy
financial
room ado
reduction
changes
to meet i
reduction
ymbols that w
s: quality, m
ion about th
ey was adm
ously.
Of those con
V room auto
and 60% (n=
within the p
g of at least
mated produc
ents indicate
who could p
hieved. In te
s daily throug
nnel was unc
on errors, 7
ntation. The
y and accura
n IV room o
on: A large p
ysis before IV
questions m
option decis
ns, yet few w
did not occu
increasing vo
n in purchas
2018ASProf
ere not spelled
medication sa
he responde
inistered usi
ntacted, 82 a
mation. 37%
=21) for mor
past 3 years.
10 different
cts went thr
ed they were
provide this
rms of volum
gh automati
changed pos
1% (n=10) co
e top benefit
ately though
utsourcing.
proportion o
V automatio
may suggest
sions. Most
were able to
ur as a result
olumes and
sing outsourc
SHPMidyfessional
d‐out per the g
afety, produ
nts and the
ing the Qual
attempted t
% of respond
re than 5 yea
A wide arra
t manufactu
rough a form
e unable to a
information
me, nearly 4
ion. More th
st‐implemen
ould not est
t of automat
h 70% (n=7)
of responden
on implemen
that direct c
indicated m
o identify me
t of automat
expansion y
ced product
yearClinlPoster
guidelines wer
uctivity, and
respondent
trics® survey
he survey, 4
dents (n=13)
ars. 60% (n=
ay of IV auto
urers and 2 “
mal return on
answer item
n, 82% (n=9)
3% (n=10) o
han two‐third
ntation. Alth
imate actua
tion was the
indicated th
nts indicated
ntation. A m
cost savings
anufacturer
easurable re
tion. Results
yet 70% (n=7
s.
nicalMeAbstrac
re translated i
financial im
ts’ practice s
y platform a
48% (n=39) m
) had practic
=21) of resp
omation syst
“home‐grow
n investmen
ms related to
indicated e
of facilities p
ds of respon
ough most h
al error rate c
e ability to ha
hat technolo
d their facilit
majority selec
is not a prim
rs had projec
ductions. W
s indicate au
7) indicated
eetingcts
into unknown
pact. Demo
etting was a
and data we
met inclusio
ced in the sit
ondents had
tems was im
wn” systems.
t analysis. M
o break‐even
ither limited
rocessed mo
ndents indica
had forecast
changes afte
andle increa
gy had no m
ty did not co
cted ‘do not
mary conside
cted medica
With few exce
utomation a
it has not le
characters.
ographic
also included
re recorded
n criteria of
te for more
d automatio
mplemented,
Only 22% (n
More than ha
n or fiscal ret
d or no savin
ore than 300
ated the num
ted a decrea
er
ased volume
measurable
onduct forma
know’ for th
eration for IV
ation error
eptions, staf
llows hospit
d to a direct
d.
than
on
,
n=6)
alf of
turn.
ngs
0 IV
mber
ase in
es
al
he
V
fing
tals
t
*Special sy
Session‐B
Poster Ti
within a
Poster Ty
Submissi
Resource
Primary A
Email: ja
Addition
Jennifer
Teresa tr
Shanti M
Purpose:
prescribi
ensure th
requeste
within th
hospitals
Methods
or memb
variable d
intraveno
that was
institutio
usage.
Results:
equivalen
in small h
patient d
ymbols that w
Board # ‐ 4‐0
itle: Utilizing
regional gro
ype: Evaluat
ion Category
es
Author: Jayn
yne.lepage@
al Authors:
Raltz
ronerud
Maheshwari
: With increa
ng, any reso
he safety of
ed a compari
heir institutio
s in tracking
s: Opioid pur
ber. All opioi
drugs and do
ous (IV) and
weighted an
ons as morph
Member ho
nts per patie
hospitals. Or
days in large
2018ASProf
ere not spelled
014
g purchase d
oup purchasi
tive Study
y: Administr
ne Lepage; M
@mcphs.edu
asing concer
ources or too
patients. Me
ison of opioi
ons. The GPO
and trendin
rchase data
d formulatio
osage forms
oral (PO) do
nd adjusted
hine equival
spital intrav
ent days in la
ral opioid us
hospitals, 4
SHPMidyfessional
d‐out per the g
data to comp
ng organizat
rative Practic
MCPHS Univ
u
rn about the
ols available
embers of a
id purchase
O’s aim was
g opioid util
was collect
ons were co
s equally. Me
osage forms
according to
ents per pat
enous opioi
arge hospita
age ranged
7.89 to 0.5 i
yearClinlPoster
guidelines wer
pare opioid u
tion.
ce/Managem
ersity;
e opioid epid
to evaluate
regional gro
history of bo
to develop a
ization betw
ed through t
onverted to m
ember hosp
and then be
o acuity. Hos
tient days u
d usage rang
als, 55.32 to
from 121.43
n medium h
nicalMeAbstrac
re translated i
usage betwe
ment/Financ
demic and ap
current stat
oup purchas
oth intraven
analytical be
ween acute c
the wholesa
morphine eq
ital opioid u
enchmarked
spitals were
sing graphs
ged from 1,0
2.82 in med
3 to 4.8 mor
hospitals, an
eetingcts
into unknown
een acute ca
cial Managem
ppropriate o
te of practic
sing organiza
nous and ora
enchmarking
care facilitie
aler, manufa
quivalents to
usage was se
d against a h
e compared a
to display tr
075.46 to 1.
dium hospita
phine equiv
d 53.41 2.9
characters.
are facilities
ment/Huma
opioid
ce are neede
ation (GPO)
al medication
g tools to as
s.
acturer, supp
o evaluate
eparated by
ospital statis
against like s
rends in opio
33 morphine
als and 60.55
alents per
in small
n
ed to
ns
sist
plier,
stic
sized
oid
e
5 to 2
*Special sy
hospitals
hospitals
Conclusio
trending
sized hos
surround
perform
ymbols that w
s. Hospitals a
s and make a
on: Member
of opioid us
spitals again
ding opioid p
a deeper dr
2018ASProf
ere not spelled
are able to u
appropriate
rs of the reg
sage within t
st each othe
prescribing a
ill down to m
SHPMidyfessional
d‐out per the g
use this data
changes to t
gional GPO ca
their institut
er provides a
and use. Fur
meet specific
yearClinlPoster
guidelines wer
to compare
their prescri
an benefit fr
tion. Using c
assistance to
rther, memb
c needs.
nicalMeAbstrac
re translated i
e their opioid
ibing metho
rom continu
comparative
o improve po
bers can use
eetingcts
into unknown
d use to sim
ds to decrea
uous monito
analytics to
olicies and p
e the tools cr
characters.
ilar sized
ase opioid us
ring and
o benchmark
procedures
reated to
se.
k like
*Special sy
Session‐B
Poster Ti
hospital
Poster Ty
Submissi
Resource
Primary A
Email: jo
Addition
Amy Hou
Purpose:
continuo
leadersh
many op
improvin
existing d
stakehold
Methods
held betw
identify a
divided in
to design
individua
three‐hu
pharmac
pharmac
including
added ac
were rela
efficiency
increase
ymbols that w
Board # ‐ 4‐0
itle: Applicat
ype: Descrip
ion Category
es
Author: Joh
hnlubkowsk
al Authors:
ugan
: Kaizen is a
ous improvem
ip change at
portunities e
ng provided s
departmenta
ders in desig
s: An experie
ween the fac
areas that re
nto phases.
n the improv
als with expe
ndred years
cy technician
cy managem
g nursing, su
ctivities whil
ated to inven
y to greater
inventory tu
2018ASProf
ere not spelled
015
tion of kaize
ptive Report
y: Administr
n Lubkowsk
Japanese bu
ment that is
t a mid‐sized
existed to en
service level
al functions
gning change
enced Kaizen
cilitator and
equired inter
Fundament
vements. Th
ertise in diffe
s of hospital
ns, staff phar
ent. Additio
pply chain, a
e maximizin
ntory manag
than ninety
urns by one‐
SHPMidyfessional
d‐out per the g
en philosoph
rative Practic
i; Cardinal H
om
usiness philo
sustained o
d community
nhance the o
ls. This case
and to enga
es to elimina
n facilitator
pharmacy l
rventions. B
tal to the Ka
here were th
erent areas t
pharmacy e
rmacists, clin
onally, key st
and the ope
ng value adde
gement. We
percent, de
‐third. Phase
yearClinlPoster
guidelines wer
hy to improv
ce/Managem
Health;
osophy whic
over time to
y hospital in
operational
e presents th
age all levels
ate waste an
was assigne
eadership to
Based on ide
izen approa
ree separate
to interact, a
xperience re
nical speciali
takeholders
rating room
ed and requ
e strove to im
ecrease inven
e two focuse
nicalMeAbstrac
re translated i
e pharmacy
ment/Financ
h facilitates
achieve mea
rural Virgin
efficiency of
he methods
s of pharmac
nd improve p
d to guide th
o evaluate b
entified oppo
ch is empow
e multi‐day
and plan cha
epresented.
ists, the pur
were involv
. The focus
uired activitie
mprove auto
ntory by twe
ed on person
eetingcts
into unknown
operations
cial Managem
positive cha
asurable out
ia, it was de
f the depart
utilized to a
cy staff and o
processes.
his project.
baseline oper
ortunities, th
wering those
Kaizen work
anges. In all
Participant
chasing age
ved from oth
was to elim
es. The goa
omated disp
enty‐five pe
nnel manage
characters.
in a commu
ment/Huma
ange through
tcomes. Up
termined th
tment, while
nalyze the
other key
Interviews w
rations and
he project w
e doing the w
kshops set u
l there were
ts included
nt, and
her departm
inate non‐va
ls of phase o
pensing devic
rcent, and
ement with g
unity
n
h
on
hat
e
were
was
work
p for
e over
ents,
alue
one
ce
goals
*Special sy
of clearly
processe
develop
automat
hundred
Results:
goals qui
percent t
been neg
thirty pe
purchase
increase.
increases
although
personne
medicati
simplifica
room sta
automat
still exist
Conclusio
improvin
commun
ymbols that w
y defining ro
es, reducing t
contingency
ed dispensin
percent util
Many interv
ickly. Autom
to ninety pe
gatively impa
rcent reduct
es and inven
. The decrea
s. Phase two
h continued c
el turn‐over.
ons decreas
ation. Thank
aff, and anes
ion in the op
to improve
on: The Kaiz
ng the pharm
ity hospital.
2018ASProf
ere not spelled
oles and resp
the time req
y plans with
ng work stat
lization.
ventions wer
mated dispen
rcent within
acted by dru
tion in inven
tory decreas
ase in invent
o results hav
cross‐trainin
. The time r
sed twenty‐f
ks to hospita
sthesiologist
perating roo
accuracy in
zen approach
macy departm
SHPMidyfessional
d‐out per the g
ponsibilities,
quired for m
cross trainin
ions in all op
re immediat
nsing device
n three mont
ug shortages
ntory within
se, the net e
tory should b
ve been posi
ng is required
equired for
five percent
al administra
s, we achiev
om and proce
this distribu
h to process
ment’s oper
yearClinlPoster
guidelines wer
redesigning
anual cart fi
ng. The final
perating roo
ely successf
efficiency im
ths. Over tim
s. Inventory
six months o
effect on inv
be viewed a
itive. Few ro
d to maintai
manual cart
within three
ation suppor
ved one‐hun
edural areas
ution model.
improveme
ational effic
nicalMeAbstrac
re translated i
g staffing mo
ill by twenty
l phase invo
oms and proc
ful; allowing
mproved fro
me this valu
reduction h
of intervent
entory turns
s a lead indi
oles are now
in depth of s
t fill of non‐a
e months of
rt, stakehold
dred percen
s within thre
.
ent has been
iency at this
eetingcts
into unknown
odels, standa
y‐five percen
lved implem
cedural area
us to achiev
om a baselin
e has fluctua
has been suc
ion impleme
s was only a
icator of inve
w one‐perso
staff compet
automation s
optimizatio
der input by
nt utilization
ee months. O
n highly effec
s two‐hundre
characters.
ardizing
nt, and to
mentation of
as, with one‐
ve measurab
e of eighty‐o
ated, having
ccessful with
entation. As
modest
entory turn
n dependen
tency, with
stocked
n, and proce
the operati
n of dispensi
Opportunitie
ctive at
ed fifty‐five
‐
ble
one
g
h a
s
t,
ess
ng
ng
es
bed
*Special sy
Session‐B
Poster Ti
Poster Ty
Submissi
Resource
Primary A
Email: yx
Addition
Heidi Ren
Purpose:
Sacrame
comorbid
to the ex
pharmac
sustainab
The proje
the prim
Methods
evaluatio
work for
clinics, w
2018. In
from CM
receive r
terminol
number o
emergen
location
pharmac
generatio
pharmac
ymbols that w
Board # ‐ 4‐0
itle: Financia
ype: Descrip
ion Category
es
Author: Yi S
xushi@gmail
al Authors:
ns
: Ambulatory
nto region p
dities and m
xisting role o
cist services h
bility of thes
ect objective
ary care sett
s: The institu
on designed
the three am
was complete
the primary
M and joint
eimburseme
ogy (CPT) co
of chronic co
ncy departm
of clinic visit
cist intervent
on based on
cist intervent
2018ASProf
ere not spelled
016
al impact of
ptive Report
y: Administr
hi; Sutter He
l.com
y care pharm
provide com
ultiple drug
of pharmacis
have been s
se services m
e was to eva
ting for selec
utional revie
to describe
mbulatory c
ed by Decem
y care clinics
ly see the pa
ent through
ode. Patient
onditions, nu
ent and hos
t, pharmacis
tions and pr
the visit cod
tions to calc
SHPMidyfessional
d‐out per the g
ambulatory
rative Practic
ealth;
macists (ACP
prehensive m
therapies. C
ts in this set
hown to imp
may become
luate the fin
ct high risk p
w board app
financial im
are pharmac
mber 2017. D
s, providers m
atient during
an “incident
demograph
umber of do
pitalizations
st time spent
ovider accep
ding. Costs e
ulate cost av
yearClinlPoster
guidelines wer
care pharm
ce/Managem
Ps) within Su
medication m
CMM is cond
tting in trans
prove outco
a barrier to
nancial impa
patients.
proved this m
pact of ACPs
cists, each a
Data was col
may refer pa
g the same o
t to” billing m
ic informatio
ocumented m
s in the past
t on direct p
ptance, CPT
extracted fro
voidance est
nicalMeAbstrac
re translated i
macists in prim
ment/Financ
utter Medica
managemen
ducted durin
sitional care
mes and red
further exp
act of pharm
multi‐clinic r
s in primary
ssociated w
lected betw
atients to ph
office visit. T
model utiliz
on collected
medications,
year. Additi
patient care
coding for e
om literature
timations. A
eetingcts
into unknown
mary care
cial Managem
al Foundation
nt (CMM) to
ng patient vi
manageme
duce costs, t
pansion of AC
macist provisi
retrospectiv
care. Stand
with a differe
ween January
harmacists w
These combi
ing current p
d included ag
, and numbe
onal data tr
and docume
each visit, an
e were corre
A physician s
characters.
ment/Huma
n Clinics in t
patients wit
sits in additi
nt. Although
the financial
CP‐led progr
ion of CMM
ve chart revie
ardization o
nt primary c
y and March
who may ben
ned encoun
procedural
ge, gender,
er of previou
acked includ
entation,
nd revenue
elated to
satisfaction
n
he
th
ion
h
rams.
in
ew
f
care
nefit
nters
us
ded
*Special sy
survey w
potentia
continue
Results: T
provided
spent on
equivalen
average t
patient h
The most
reimburs
391 reco
87% of re
Medicati
avoidanc
methods
avoidanc
with pha
access.
Conclusio
Pharmac
into prim
region. T
provider
positive r
establish
system fo
ymbols that w
was distribute
l impacts on
ed collaborat
Three ACPs
d for 171 pat
direct patie
nts (FTE) for
time each ph
had an avera
t common C
sement was
mmendatio
ecommenda
on reconcili
ce ranged fro
s of adding c
ce totaled $3
rmacist care
on: This proj
cist in primar
mary care tea
Three pharm
satisfaction
results of th
hment of am
or additiona
2018ASProf
ere not spelled
ed at the en
provider ef
tion with AC
collaborated
tients in com
ent care and
r all three ph
harmacist sp
age of five ch
CPT code bille
$19,126, pro
ns to both p
ations were a
ation, 2) Add
om $14,871
osts incurre
33,997 over
e, interventio
ject and eva
ry care has c
ams to provi
acists provid
ratings, and
is evaluation
bulatory car
l quality and
SHPMidyfessional
d‐out per the g
d of the eva
fficiencies, sa
Ps to utilize
d with eighte
mbined office
documenta
harmacists, w
pent on dire
hronic condit
ed was 9921
ojected over
providers/pa
accepted. Th
ded medicat
to $194,819
d by the pat
three month
ons, docume
aluation stud
contributed t
de CMM ser
ding CMM co
d potential im
n lends itself
re pharmacy
d cost impac
yearClinlPoster
guidelines wer
luation time
atisfaction w
the CMM se
een provide
e visits betw
tion average
with each co
ct patient ca
tions and to
14 followed
r three mon
tients and 2
he most com
tion, and 3)
9, with variat
tient and/or
hs. Providers
entation, an
dying the fin
to the devel
rvices within
ontributed p
mpact on im
f well to con
y services wi
ct.
nicalMeAbstrac
re translated i
e frame with
with the serv
ervices.
rs througho
ween January
ed nine hou
ontributing u
are per patie
ook an avera
by 99215 an
ths or $76,5
221 were ma
mmonly cited
Therapy cha
tion due to d
institution.
s working w
d potential
ancial impac
opment of t
n clinics stud
positive fina
mproving pat
ntinued track
thin other re
eetingcts
into unknown
h the intent t
vices, and lik
ut eight clin
y and March
rs weekly or
up to four ho
ent was 23 m
ge of thirtee
nd 99213. T
504 annualiz
ade specifica
d interventio
ange. Calcula
different cos
Projected re
with the ACPs
positive imp
ct of the Am
the pharmac
died in the Sa
ncial outcom
tient access.
king, diffusio
egions of the
characters.
to understan
kelihood of
ics. CMM w
2018. Time
r 0.2 full time
ours weekly.
minutes. Eac
en medicatio
otal
ed. ACPs ma
ally to provid
ons included
ated cost
st estimation
evenue and
s were satisf
pact on patie
mbulatory Ca
cist integrati
acramento
mes, high
The initial
on and
e Sutter Hea
nd
as
e
. The
ch
ons.
ade
ders.
d 1)
n
cost
fied
ent
re
ion
alth
*Special sy
Session‐B
Poster Ti
regional
Poster Ty
Submissi
Resource
Primary A
Email: ho
Addition
Christine
Teresa Tr
Mark Len
Jayne Lep
Purpose:
repackag
operatio
could ide
alternativ
products
drugs tha
dose rep
Methods
purchase
opportun
oral liqui
purchase
unit‐dose
commerc
compare
repackag
ymbols that w
Board # ‐ 4‐0
itle: Increasi
GPO and un
ype: Evaluat
ion Category
es
Author: Hop
ope.violette@
al Authors:
e Dash
ronerud
ney
page
: Collaborati
ging vendor
nal efficienc
entify comm
ves, that cou
s repackaged
at drive the g
ackaging ve
s: The unit‐d
e history for
nity for savin
ds. A line‐by
ed and the co
e repackagin
cial unit‐dos
ed to the rep
ging fees, to
2018ASProf
ere not spelled
017
ing operatio
it‐dose pack
tive Study
y: Administr
pe Violette;
@lahey.org
on with a re
presents a n
cy. Through t
ercially avai
uld be repac
d in‐house w
greatest cos
ndor for a th
dose repacka
all members
ngs. The pur
y‐line analys
orrespondin
ng vendor th
e products.
packaged bu
evaluate sav
SHPMidyfessional
d‐out per the g
nal efficienc
kaging vendo
rative Practic
Beverly Hos
egional group
new strategy
this type of c
lable unit‐do
ckaged into u
were also ass
st savings wh
hree‐hospita
aging vendor
s of the regi
chase histor
is was comp
ng cost of the
hen identifie
The cost‐pe
lk products c
vings opport
yearClinlPoster
guidelines wer
cy and drug c
or
ce/Managem
pital;
p purchasing
y for reducin
collaboratio
ose oral solid
unit‐dose at
sessed. The p
hen purchas
al, 340‐bed c
r performed
onal GPO to
ry was categ
pleted to ide
e commercia
d alternative
r‐dose of th
cost with the
tunities.
nicalMeAbstrac
re translated i
cost savings
ment/Financ
g organizatio
ng drug purch
n, our unit‐d
d and liquid
a significant
purpose of t
ed in bulk a
community h
d an analysis
o identify the
gorized into t
entify the tot
ally available
e bulk medic
e commerci
e unit‐dose
eetingcts
into unknown
by partneri
cial Managem
on (GPO) an
hasing costs
dose repacka
products, w
tly reduced
this study wa
nd repackag
health syste
of the previ
e hospitals w
two groups:
tal number o
e unit‐dose p
cations for t
ial unit‐dose
vendor, incl
characters.
ng with a
ment/Huma
d unit‐dose
s and increas
aging vendo
with bulk
cost. Bulk
as to identify
ged with a un
m.
ious 12‐mon
with the grea
Oral solids a
of doses
product. The
hose
e products w
uding
n
sing
or
y key
nit‐
nth
atest
and
e
was
*Special sy
Results:
savings o
These pu
products
liquid pro
$244,420
percent o
follows: G
the great
of $124,4
levels for
with the
further s
Conclusio
allowed o
significan
realized b
analysis a
efficiency
additiona
ymbols that w
Utilizing the
of $250 or gr
urchases wer
s identified d
oducts with
0. The top se
of the oral so
GPO (37 per
test savings
429. These 3
r these prod
unit‐dose re
avings and e
on: The stra
our small co
nt reduction
by decreasin
and the valu
y improvem
al significant
2018ASProf
ere not spelled
e previous 12
reater, 192 p
re a combina
demonstrate
a total savin
even liquid p
olid savings
rcent), 340B
opportunity
30 products
ucts were d
epackaging v
ease of trans
tegic collabo
ommunity he
in drug cost
ng in‐house l
ue seen in a c
ent strategy
t cost saving
SHPMidyfessional
d‐out per the g
2‐month pur
products we
ation of GPO
ed a total an
ng of $19,760
products pro
contained 5
(7 percent)
y from each a
encompasse
etermined a
vendor. The
sition.
oration with
ealth system
ts. Additiona
labor around
collaborative
y with other
gs across oth
yearClinlPoster
guidelines wer
rchase histor
re identified
O, 340B and
nual savings
0 and 178 o
oduced 80 pe
50 products.
and WAC (5
account type
ed 45 percen
and the prod
remaining li
a regional G
m with three
ally, increase
d unit‐dose
e strategy, s
members of
er institutio
nicalMeAbstrac
re translated i
ry with a mi
d by the unit
Wholesale A
s opportunit
ral solid pro
ercent of the
The breakdo
55 percent).
e were iden
nt of the tota
ducts were t
iquids and o
GPO and uni
hospitals an
ed operation
repackaging
sharing the c
f the hospita
onal settings
eetingcts
into unknown
nimum of 50
t‐dose repac
Acquisition C
ty of $264,18
oducts with a
e liquid savin
own of the s
The top 10 p
tified; the sa
al savings. M
ransitioned
oral solids we
it‐dose repa
nd 340 beds
nal efficiency
g. Based on t
cost savings
al system ma
and practice
characters.
00 doses or
ckaging vend
Cost (WAC).
80, including
a savings of
ngs, while 80
savings is as
products wit
avings consis
Monthly par
to be packa
ere assessed
ckaging ven
to uncover a
y may be
the results o
and operati
ay translate
e types.
a
dor.
The
g 14
0
th
sted
ged
d for
dor
a
of this
onal
to
*Special sy
Session‐B
Poster Ti
obstructi
Poster Ty
Submissi
Resource
Primary A
Email: m
Addition
Tam Ngu
Purpose:
healthca
disposal
that wast
pulmona
Methods
await de
of aeroso
aerosol w
canister.
canisters
inhaler st
Therapy
develope
through t
hospital‐
Results:
interchan
50 perce
month an
ymbols that w
Board # ‐ 4‐0
itle: Strategy
ive pulmona
ype: Descrip
ion Category
es
Author: Ma
ariadrakewa
al Authors:
uyen
: The minimi
re dollar. An
of partially u
te while still
ary disease (C
s: Metered d
struction pe
ol products.
waste bin an
Of the 33 ca
s was 90 per
tocked in inv
department
ed therapeut
the local Pha
wide (with t
Many positiv
nge. The mo
nt since imp
nd post‐conv
2018ASProf
ere not spelled
018
y to eliminat
ary disease (C
ptive Report
y: Administr
ria Ware; M
ization of wa
n ongoing iss
used metere
l providing e
COPD) patie
dose inhaler
er the Enviro
A pharmacis
nd evaluated
anisters eva
cent. A strat
ventory (29
t leadership
tic interchan
armacy and
the exceptio
ve trends h
onthly averag
plementation
version drug
SHPMidyfessional
d‐out per the g
te waste wit
COPD) patie
rative Practic
emorial Her
com
aste is an im
sue noted in
ed dose inha
effective resp
nt.
canisters sla
nmental Pro
st removed t
d each canist
luated, the a
tegy was dev
in total) to a
was apprise
nge which us
Therapeutic
on of anesthe
ave been no
ge drug expe
n. Pre‐conve
g costs have
yearClinlPoster
guidelines wer
th metered d
ents in an ac
ce/Managem
rmann North
mportant asp
this 250 be
aler canisters
piratory care
ated for disp
otection Age
the sequeste
ter for the a
average amo
veloped by t
a comparabl
ed of the pro
sed 6 differe
cs and Medic
esia) in Octo
oted since th
enditure for
ersion drug e
averaged $7
nicalMeAbstrac
re translated i
dose inhaler
cute care com
ment/Financ
heast Hospit
pect of good
d communit
s. This proje
e to the hosp
posal were s
ency (EPA) gu
ered caniste
amount of re
ount of med
the pharmac
e nebulized
oposal and w
ent nebulize
cal Executive
ober, 2017.
he implemen
respiratory
expenditures
7,000 per m
eetingcts
into unknown
rs (MDIs) in a
mmunity ho
cial Managem
tal;
stewardship
ty hospital in
ct was desig
pitalized chr
sent back to
uidelines reg
ers from the
emaining do
ication rema
cist to conve
solution. Th
was in full su
d solutions w
e Committe
ntation of th
products ha
s averaged $
month. Respir
characters.
adult chroni
ospital.
ment/Huma
p of the
nvolved the
gned to elim
ronic obstruc
the pharma
garding disp
designated
ses left in th
aining in the
ert each diffe
he Respirato
upport. The
was approve
es and initia
he therapeut
as decreased
$14,000 per
ratory suppl
c
n
inate
ctive
cy to
posal
he
e
erent
ory
ed
ated
tic
d by
y
*Special sy
costs hav
used. The
average
The use o
control is
increased
Pharmac
barcodes
has been
nebulizer
therapy t
Conclusio
many po
redesign
initiated
ymbols that w
ve decreased
e need for a
length of sta
of the conve
ssues noted
d because th
cy staff satisf
s to products
n impacted b
r solutions. T
treatments
on: The met
sitive outco
for a large m
at other cam
2018ASProf
ere not spelled
d due to the
erosol canis
ay (LOS) for t
ersion elimin
with the use
hey no longe
faction has i
s or replace
by the use of
There have b
on the patie
tered dose in
mes This int
multi‐hospit
mpuses thro
SHPMidyfessional
d‐out per the g
elimination
ter disposal
the COPD pa
nated concer
e of the com
er experienc
ncreased be
lost inhalers
f individually
been no rep
ents with the
nhaler to ne
erchange ha
al regional h
ughout this
yearClinlPoster
guidelines wer
n of the requ
has been el
atient has be
rns for poten
mmon caniste
e lost inhale
ecause they n
s. Barcode sc
y wrapped, m
orts of nega
e nebulized t
bulizer thera
as been adop
healthcare sy
healthcare s
nicalMeAbstrac
re translated i
uired inhaler
liminated. A
een noted si
ntial cross‐co
er. Respirato
ers and havin
no longer ha
canning com
manufacture
ative outcom
treatments.
apeutic inte
pted as part
ystem and is
system.
eetingcts
into unknown
r spacer ($4.
14 percent
ince the imp
ontaminatio
ory staff sati
ng to requisi
ave to add a
mpliance and
er barcoded,
mes or ineffe
rchange has
t of the COPD
s in the proc
characters.
67) previou
decrease in
plementation
on and infect
isfaction has
ition new on
uxiliary
d accurate b
, unit‐of‐use
ective respira
s proven to h
D clinical car
cess of being
usly
the
n.
tion
s
nes.
illing
e
atory
have
re
g
*Special sy
Session‐B
Poster Ti
Poster Ty
Submissi
Primary A
Email: sa
Addition
Matthew
Purpose:
among M
worsenin
2013 ACC
alternativ
improved
Medicare
beneficia
Methods
determin
beneficia
Results:
allowing
$360.40
up to 6 fu
dosage u
and $6.6
full mont
Conclusio
elligible H
prescribi
ymbols that w
Board # ‐ 4‐0
itle: Sacubitr
ype: Descrip
ion Category
Author: Sara
al Authors:
w Silva
: Heart failur
Medicare D b
ng, 30‐day re
CF/AHA hea
ve or replace
d outcomes,
e‐D drug‐rel
aries with HF
s: 2011‐2016
ne total claim
aries.
Sacubitril/va
for 803 claim
and $6.34 p
ull months o
units in 2016
0 per dosag
ths of therap
on: Even wit
HFrEF patien
ng life‐cycle
2018ASProf
ere not spelled
019
ril/valsartan
ptive Report
y: Cardiology
ah Alasmary
mcphs.edu
re with redu
beneficiaries
eadmission a
rt failure gui
ement for A
, even at a co
ated spendi
FrEF.
6 Medicare‐D
ms, spending
alsartan bec
ms and 45,6
er dosage u
of therapy (J
6 were 19,42
e unit ($13.2
py.
thout patien
nts received
. Failure to i
SHPMidyfessional
d‐out per the g
coverage an
y / Anticoag
y; MCPHS Un
uced left‐ven
s (40%), carry
and cardiova
idelines reco
ACEI’s/ARB’s
ost of $6,67
ng to determ
D drug relat
g and dosage
ame availab
77 total dos
nit ($12.68/
uly to Decem
26 and 1,142
20). During 2
nt‐level data,
sacubitril/va
dentify pati
yearClinlPoster
guidelines wer
nd Medicare
gulation
niversity;
ntricular (LV)
ying higher r
ascular mort
ommended s
in HFrEF pat
2/yearly (Ju
mine if sacub
ed spending
e units of sa
ble to prescri
sage units wi
day). During
mber 2015).
2,986 with an
2016, 1,619
, aggregate s
alsartan in t
ents with HF
nicalMeAbstrac
re translated i
e Part D ben
) ejection fra
risks of HF re
tality. The 20
sacubitril/va
tients. The i
ne 2018). W
bitril/valsart
g data from C
cubitril/vals
ibers and be
ith an avera
g 2015, 134 p
The total nu
n average sp
patients cou
spending da
he Medicare
FrEF early (p
eetingcts
into unknown
neficiaries; th
action (HFrE
elated admi
017 focused
alsartan as a
mplications
We undertoo
tan was pres
CMS was ev
sartan receiv
enificiaries in
ge spending
patients cou
umber of cla
pending per
uld have rec
ata show few
e‐D pool, ea
preferably in
characters.
he early yea
F) is commo
ssion, HF
updates to
a class I BR
are for grea
k a review o
scribed to
aluated to
ved by
n July of 201
g per claim o
uld have rece
aims and tot
claim of $38
eived up to
wer than 3%
rly in the
primary car
rs
on
the
atly
of
15
of
eived
tal
88
12
of
re)
*Special sy
and max
increase
ymbols that w
imize medic
in new HF re
2018ASProf
ere not spelled
al therapy in
elated diagn
SHPMidyfessional
d‐out per the g
ncluding sac
noses, HF rel
yearClinlPoster
guidelines wer
ubitril/valsa
ated morbid
nicalMeAbstrac
re translated i
artan will con
dity and mor
eetingcts
into unknown
ntribute to t
rtality.
characters.
the progress
sive
*Special sy
Session‐B
Poster Ti
retrospec
Poster Ty
Submissi
Primary A
Email: ea
Addition
Dana Bak
Mohamm
Walid Me
Purpose:
the regio
overweig
warfarin
The purp
weekly w
BMI coul
the incid
Methods
doses of
least 6 w
tertiary t
Patients
warfarin
Relevant
demogra
diabetes,
known to
(along w
TTR was
ymbols that w
Board # ‐ 4‐0
itle: Does bo
ctive cross‐s
ype: Evaluat
ion Category
Author: Ema
alhamoud@
al Authors:
kdach
med Abdulge
ekkawi
: Qatar has s
on. A recent
ght or obese
doses and a
pose of this s
warfarin dose
d affect ant
ence of thro
s: A retrospe
warfarin, de
weeks, and at
teaching hos
with missing
and/or clini
t data were c
aphics, indica
, hypertensi
o significantl
ith type/sev
calculated u
2018ASProf
ere not spelled
020
ody mass ind
sectional stu
tive Study
y: Cardiology
an Alhmoud
hamad.qa
elil
some of the
report indic
e. Evidence s
anticoagulati
study was to
e required to
icoagulation
omboemboli
ective cross s
efined as hav
ttending am
spital in Qata
g data (demo
c visits or th
collected thr
ation and du
on, renal an
ly interact w
verity of the
using Rosend
SHPMidyfessional
d‐out per the g
dex (BMI) inf
dy from Qat
y / Anticoag
; Al Wakra H
highest rate
ated that m
upporting th
ion control i
o investigate
o maintain a
n control refl
c and/or ble
sectional stu
ving a therap
bulatory ant
ar, over one
ographics, ta
hose who los
rough electr
uration of wa
d hepatic dy
with warfarin
bleeding) an
daal method
yearClinlPoster
guidelines wer
fluence warf
tar
gulation
Hospital;
es of metabo
ore than 70
he effect of
s contradict
whether a c
a stable ther
lected by me
eeding event
udy of adult
peutic INR w
ticoagulatio
e year period
arget INR), t
st follow up w
onic chart re
arfarin thera
ysfunction),
n as well as a
nd thrombos
d.
nicalMeAbstrac
re translated i
farin dosing
olic disorder
percent of Q
body mass i
ting.
correlation e
rapeutic INR
ean time in t
ts.
patients (>1
without a cha
n clinic in Ha
d (July 1st 2
those known
with the clin
eview. These
apy, target IN
tobacco use
any reported
sis were coll
eetingcts
into unknown
requiremen
rs (including
Qatar’s popu
ndex (BMI) o
exists betwe
and whethe
therapeutic
18 years old)
ange in warf
amad Gener
2016 ‐ June 3
n to have po
nic were exc
e include, pa
NR, comorb
e, the presen
d incidents o
ected.
characters.
nts? a
obesity) wit
ulation is eit
on maintena
een BMI and
er an individ
range (TTR)
) receiving st
farin dose fo
ral Hospital,
30th 2017).
or complian
luded.
atients’
idities (e.g.,
nce of drugs
of bleeding
thin
ther
ance
ual's
and
table
or at
a
nce to
*Special sy
BMI, the
categorie
was then
Results: A
61.8 kg/m
Overall, t
dose (Pe
When co
value =0.
There wa
dose (Pe
had lowe
Among 1
were rep
Conclusio
correlatio
ymbols that w
independen
es: underwe
n correlated
A total of 15
m2 (median
there was a
arson's r 0.1
omparing me
.61).
as, however,
arson's r ‐0.2
er weekly mg
159 patients,
ported with i
on: A weak p
on was obse
2018ASProf
ere not spelled
nt variable, w
ight, norma
with warfar
59 patients w
30.56 kg/m
weak positiv
186, P=0.019
ean TTR acro
, a weak neg
22). When c
g/kg warfari
, no thrombo
insignificant
positive corr
erved betwe
SHPMidyfessional
d‐out per the g
was analyzed
l weight, ove
in dose (wee
were include
2) and the m
ve correlatio
9).
oss different
gative corre
compared to
n doses req
otic events w
differences
relation exis
en BMI and
yearClinlPoster
guidelines wer
d as a contin
erweight, ob
ekly and mg
ed (57.9% m
mean TTR (±
on between
BMI catego
lation betwe
o normal BM
uirements (P
were detect
observed a
ts between
anticoagula
nicalMeAbstrac
re translated i
nuous and ca
bese, morbid
g/kg) accordi
ales). The BM
standard de
BMI and we
ories, no diffe
een BMI and
MI, morbid an
P‐value of 0.
ed. Thirteen
across differe
BMI and tot
tion control
eetingcts
into unknown
ategorical va
dly, and seve
ingly.
MI ranged b
eviation) wa
eekly warfari
erences wer
d weekly mg
nd severely o
.037 and 0.0
n incidents o
ent BMI cate
tal weekly w
l.
characters.
ariable (six B
erely obese)
between 14.3
s 78 (± 18.2)
in maintena
re observed
g/kg warfarin
obese patien
028 respectiv
of minor blee
egories (P=0
warfarin dose
BMI
) and
3 –
)
nce
(P‐
n
nts
vely).
eding
0.62).
e. No
*Special sy
Session‐B
Poster Ti
warfarin
Poster Ty
Submissi
Primary A
Email: ta
Addition
Balakesh
Raju Kon
Badr Gas
Purpose:
as well as
medicati
to achiev
quality, e
is to asse
patients
Methods
obtained
six mont
inclusion
intervent
(n equals
INRs in th
therapeu
period. S
bleeding
records,
group, fo
warfarin
ymbols that w
Board # ‐ 4‐0
itle: Clinical
ype: Evaluat
ion Category
Author: Mu
ffy.hatim@g
al Authors:
hwa Ramaiah
eri
ssar
: Warfarin is
s thromboem
ons and foo
ve and maint
efficacy, and
ess the influe
on warfarin
s: Upon the
d from all pa
hs at a tertia
n criteria wer
tion group c
s 60). Primar
he range me
utic range fo
Secondary ou
and thromb
and clinical
ollow‐ups we
drug and fo
2018ASProf
ere not spelled
021
pharmacist
tive Study
y: Cardiology
stafa Ali; Ka
gmail.com
h
s widely pres
mbolism due
ds. Internati
tain Time in
safety of th
ence of clinic
and to evalu
approval of
rticipants, a
ary care teac
re divided by
onsisted of 6
ry outcome m
ethod which
r all patients
utcome mea
boembolic ev
notes includ
ere done on
od interacti
SHPMidyfessional
d‐out per the g
intervention
y / Anticoag
rnataka Coll
scribed oral
e to its narro
ional Norma
Therapeutic
he treatment
cal pharmac
uate the cau
the instituti
prospective
ching hospit
y a simple ra
63 patients
measure wa
was calcula
s divided by
asures includ
vents. All re
ding indicatio
a daily basis
ons, monito
yearClinlPoster
guidelines wer
ns in the ma
gulation
ege of Pharm
anticoagulan
ow therapeu
alized Ratio (
c Range (TTR
t of patients
cist intervent
uses of eleva
onal review
e, randomize
al in Bangalo
andomizatio
(n equals 63
as time in the
ted by takin
the total nu
ded possible
elevant data
ons for the u
s by clinical
r INR values
nicalMeAbstrac
re translated i
nagement o
macy;
nt that pose
utic index, an
(INR) levels r
R) which is c
s on warfarin
tions in the
ated INR leve
board, and
ed, controlle
ore, India. P
on technique
3) and a cont
erapeutic ra
ng total num
umber of INR
e causes of in
were collec
use of warfa
pharmacist t
s and associa
eetingcts
into unknown
of hospitalize
es high risks
nd interactio
require a clo
onsidered th
n. The purpo
managemen
els.
an informed
ed study was
articipants w
e into two gr
trolled group
ange (TTR) by
ber of INRs w
Rs checked d
ncreased INR
cted from pa
rin. For the
to analyze s
ated risks, re
characters.
ed patients o
of hemorrha
ons with oth
ose monitori
he marker o
ose of this st
nt of hospita
d consent wa
s conducted
who met the
roups, an
p of 60 patie
y the fractio
within
during the st
R levels, and
atient medic
intervention
uspected
ecommend d
on
age
her
ing
f the
tudy
alized
as
for
e
ents
on of
tudy
d
al
n
dose
*Special sy
changes,
for both
quality, e
Results: A
Fibrillatio
Pulmona
internati
therapeu
Whereas
therapeu
Elevated
percent)
heparin,
experien
heparin,
warfarin
Hematom
Conclusio
Preventio
warfarin
effective
Impleme
ymbols that w
and lifestyle
intervention
efficacy, and
A total patie
on 66 patien
ry Embolism
onal normal
utic (20.25 p
s in the cont
utic (34.54 p
levels of INR
of increased
and 1 with a
ced elevated
and 3 with f
food interac
ma.
on: Time wit
on of many d
therapy and
ness and mi
ent the clinic
2018ASProf
ere not spelled
e cautions, a
n and the co
safety durin
ents of 123, t
nts (53.65 pe
m 18 patients
lized ratio re
ercent), sub
rolled group
ercent), sub
R were foun
d INR levels
atorvastatin
d INR levels
fluconazole)
ction, and 1
thin therape
drug reactio
d obtain bett
nimize com
al pharmaci
SHPMidyfessional
d‐out per the g
and interven
ntrolled gro
ng the hospi
the indicatio
ercent), Deep
s (14.63 per
esults were w
b‐therapeutic
p, TTR within
b‐therapeutic
nd in both gr
due to warfa
). However,
due to warf
. And 2 due
suspected a
eutic range (
ons, clinical p
ter patient c
plications. T
st interventi
yearClinlPoster
guidelines wer
ntions were m
ups was com
talization pe
ons for warfa
p Vein Throm
cent).In the
within the th
c (9.64 perce
n the therape
c (14.18 perc
oups, the in
arin interact
in the contr
farin interact
incorrect re
adverse drug
TTR) was hig
pharmacist r
clinical outco
The safety of
ion in the m
nicalMeAbstrac
re translated i
made accord
mpared for t
eriod.
arin in both
mbosis 39 pa
intervention
herapeutic r
ent), and gre
eutic range
cent), and g
tervention g
tions (3 with
rolled group
tions (7 with
enal dosage a
g reaction of
gher in the i
role can be c
omes by max
f the warfari
anagement
eetingcts
into unknown
dingly. The c
the assessm
groups were
atients (31.7
n group, the
ange (57.87
eater than 5
(43.27 perce
reater than
group had 6
h azithromyc
18 patients
h azithromyc
adjustment,
f warfarin w
ntervention
crucial in the
ximizing trea
n therapy w
of patients
characters.
collected dat
ent of the
e Atrial
7 percent), a
e TTR of the
percent), su
5 (0.32 perce
ent), supra‐
5 (2.9 perce
incidents (9
cin, 2 with
(30 percent
cin, 4 with
1 due to
hich lead to
group.
e optimizatio
atment
was ensured
on Warfarin
ta
and
upra‐
ent).
ent).
9.52
t)
on of
by
n.
*Special sy
Session‐B
Poster Ti
thrombo
Poster Ty
Submissi
Primary A
medicine
Email: fa
Addition
Steven P
Michael
Mark Mu
Daniel W
Purpose:
its introd
anticoag
are safe a
this study
patterns
following
(90+ day
Methods
administ
two year
minutes
given the
about th
diagnosis
fondapar
edoxaba
ymbols that w
Board # ‐ 4‐0
itle: Anticoa
oembolism
ype: Descrip
ion Category
Author: Fad
e;
dyallahwerd
al Authors:
an
Feehan
ungar
Witt
: Warfarin h
duction in 19
ulants (DOA
and either m
y is to descr
in a nationa
g phases of V
s)
s: A descript
ered to 907
rs. Participan
to complete
e additional
eir experien
s. Anticoagu
rinux, unfrac
n and dabiga
2018ASProf
ere not spelled
022
gulant thera
ptive Report
y: Cardiology
dy Allahwerd
as been the
954. Due to d
ACs) have bee
more effectiv
ibe the mos
al cohort of p
VTE treatme
ive study wa
patients 18
nts were invi
e. Participan
treatment c
ces as they t
lants include
ctionated he
atran). Data
SHPMidyfessional
d‐out per the g
apy utilizatio
y / Anticoag
dy; University
om
mainstay of
difficulties a
en introduce
ve or non‐inf
t common s
patients with
ent: initial (fi
as conducted
years of age
ited to comp
nts diagnose
omplexity o
transitioned
ed low‐mole
eparin, warfa
were summ
yearClinlPoster
guidelines wer
on pathways
gulation
y of Utah co
f venous thro
ssociated w
ed to the ma
ferior to war
elf‐reported
h recent VTE
rst 7 days), l
d using data
e or older wh
plete the sur
d with cance
f cancer‐rela
d from the he
ecular‐weigh
arin, and/or
marized using
nicalMeAbstrac
re translated i
s in patients
ollege of pha
omboembol
ith warfarin
arket. Studie
rfarin in VTE
d anticoagula
E who receiv
long‐term (8
a from a nati
ho experien
rvey which t
er within the
ated VTE eve
ealthcare sy
ht heparin (i.
DOACs (i.e.,
g basic descr
eetingcts
into unknown
with recent
armacy and s
lism (VTE) tr
therapy, th
es have show
E treatment.
ant therapy
ved therapy
8 to 90 days)
ional online
ced VTE eve
took approxi
e past 2 yea
ents. Patien
ystem to hom
.e., enoxapa
, rivaroxaba
riptive statis
characters.
venous
school of
reatment sin
e direct oral
wn that DOA
The purpos
utilization
during the
) or extende
survey
ent in the las
imately 45
rs were excl
ts were aske
me following
arin, daltepa
n, apixaban,
stics.
nce
l
ACs
se of
d
st
uded
ed
g VTE
rin),
,
*Special sy
Results: T
women.
pulmona
the follow
who swit
and no tr
percent r
There we
switched
receiving
5.2 perce
treatmen
to 38.1 p
anticoag
ranged fr
warfarin
Conclusio
predomi
between
not colle
even am
was com
utilizatio
ymbols that w
The mean (S
The most re
ary embolism
wing predom
tched betwe
reatment. O
received DO
ere 13 perce
d between D
g injectable t
ent and 1.5 p
nt 48.4 perce
percent of DO
ulant therap
rom 22.9 pe
and DOACs)
on: In this n
nant medica
anticoagula
cted. Use of
ong patients
mon and ma
n pathways
2018ASProf
ere not spelled
SD) age of re
ecent VTE ep
m (PE) in 18.1
minant patte
een warfarin
verall, 39 pe
ACs, 4 perce
ent patients w
OACs and 5
therapy duri
percent duri
ent of warfa
OAC patient
py beyond 90
rcent (warfa
).
ational samp
ation pathwa
ant therapy o
f injectable a
s receiving D
ay present a
will be usefu
SHPMidyfessional
d‐out per the g
espondents w
pisode was d
1 percent, a
erns: Injecta
and DOACs
ercent of pat
ent received
who switche
percent rep
ng the initia
ng 8‐90 and
rin patients
s. There wer
0 days. Aspir
arin patients
ple of recent
ay in VTE tre
options was
anticoagulan
DOACs. Aspi
an interventi
ul for other
yearClinlPoster
guidelines wer
was 52.4 (14
deep vein thr
nd both DVT
ble only, asp
, patients w
tients receiv
injectable o
ed between
ported no tre
al phase of tr
d 90+ days, r
also receive
re 65.7 perc
rin coadmin
s) to 51.4 pe
t VTE suffers
eatment follo
common al
nts was com
rin coadmin
on opportun
studies usin
nicalMeAbstrac
re translated i
4.4) years an
rombosis (D
T and PE in 1
pirin only, w
ho switched
ved warfarin
only and 9 p
warfarin an
eatments. Th
reatment wa
espectively.
ed injectable
ent patients
istration wit
rcent (patie
s warfarin th
owed by DO
though the
mon during
nistration wit
nity for phar
g these surv
eetingcts
into unknown
nd 56.7 perc
VT) in 63.8 p
18.1 percent
warfarin, DOA
d between d
‐based treat
ercent recei
d DOACs, 5
he proportio
as 39.1 perc
During the
e anticoagula
s who receiv
th anticoagu
nts switchin
herapy rema
OAC therapy.
reasons for
the first 7 d
th anticoagu
rmacists. Th
vey results e
characters.
ent were
percent,
t. We identif
ACs, patients
ifferent DOA
tment, 26
ived aspirin
percent who
on of patient
ent declinin
initial phase
ants, compa
ved extended
ulant therapy
g between
ains the
. Switching
switching w
ays of thera
ulant therap
ese medicat
xamining
fied
s
ACs,
only.
o
ts
g to
e of
ared
d
y
was
apy,
y
tion
*Special sy
Session‐B
Poster Ti
Poster Ty
Submissi
Primary A
Email: je
Addition
Purpose:
there is l
Many pro
tertiary c
the resul
health sy
determin
Methods
weight ca
protocol
during a
collected
bleeding
the proto
started o
another
These res
institutio
Results:
included
four perc
21% wer
three we
ymbols that w
Board # ‐ 4‐0
itle: Compar
ype: Evaluat
ion Category
Author: Jen
nnifer.l.bran
al Authors:
: Although w
ittle data ev
otocols inclu
care hospita
ts from an in
ystem, this w
ne if the new
s: A list of pa
ap was obta
infusion (80
2 week peri
d on the indi
complicatio
ocol was not
or discontinu
protocol, or
sults were c
on of the new
For the 110
. The avera
cent of patie
e greater th
eight groups,
2018ASProf
ere not spelled
023
rison of two
tive Study
y: Cardiology
nifer Brandt
ndt@medsta
weight‐based
valuating the
ude a weight
l, an 85 kg w
nternal regr
weight cap w
w cap was ap
atients recei
ined from th
0 units/kg bo
od following
cation, actu
ons, and the
t followed, fo
ued prior to t
if the patien
ompared to
w protocol.
kg weight ca
age weight fo
ents were les
an 110 kg.
, with increa
SHPMidyfessional
d‐out per the g
weight caps
y / Anticoag
t; MedStar W
ar.net
d heparin no
e safety and
t or dose cap
weight cap w
ession analy
was changed
ppropriate.
ving a hepar
he electronic
olus, followe
g the implem
al weight, do
formation o
or insufficie
the first ant
nt was on a d
historical da
The historic
ap analysis,
or the includ
ss than 85 kg
The distribu
asing rates o
yearClinlPoster
guidelines wer
s in an anti‐X
gulation
Washington H
omograms ha
efficacy of t
p, but there
was instituted
ysis. As part
to 110 kg.
rin infusion a
c health reco
ed by 18 unit
mentation w
osing weight
or extension
nt or missing
i‐Xa level, if
direct oral a
ata collected
cal data used
a total of 11
ded patients
g, with 25%
ution of initi
f suprathera
nicalMeAbstrac
re translated i
Xa based hep
Hospital Cen
ave been in
hese nomog
is no accept
d for the Ras
t of protoco
An evaluatio
after implem
ord. All pat
ts/kg/hr with
ere included
t, use of bol
of clotting.
g data, if the
the patient
nticoagulan
d in a similar
d an 85 kg w
16 patients w
was 91 kg (
of patients b
ial anti‐Xa le
apeutic leve
eetingcts
into unknown
parin protoc
nter;
use for mor
grams in obe
ted standard
schke‐based
l standardiza
on was unde
mentation of
tients receiv
h a goal anti
d. Informat
uses, anti‐Xa
Patients w
e heparin dr
was switche
nt prior to ini
r fashion pri
weight cap.
were identifi
range 45 – 1
between 85
evels varied b
ls as the we
characters.
col
re than 20 ye
ese patients
d. At a large
d protocol us
ation across
ertaken to
f the 110 kg
ing a standa
i‐Xa of 0.3‐0
tion was
a levels,
ere excluded
ip was not
ed to from
itiating hepa
or to the
ied with 94
153.5 kg). F
and 110 kg,
between the
ight increase
ears,
.
e,
sing
a
ard
.7)
d if
arin.
Fifty‐
, and
e
ed.
*Special sy
For patie
suprathe
26%, 32%
kg. No c
This data
conducte
analysis.
kg. The
Conclusio
protocol
skewed a
weight ca
ymbols that w
ents less than
erapeutic lev
%, and 42% f
complication
a was compa
ed in a simila
Approxima
rates of the
on: At this la
led to highe
as weights in
ap, indicatin
2018ASProf
ere not spelled
n 85 kg, the
vels were 22
for patients
ns attributed
ared to an ev
ar manner, 5
tely half of t
rapeutic lev
arge, tertiary
er rates of su
ncreased. Th
ng that the 8
SHPMidyfessional
d‐out per the g
percentage
%, 56%, and
85‐110 kg an
d to heparinw
valuation of
55 patients r
the patients
els were sim
y care hospit
upratherape
hese trends
5 kg weight
yearClinlPoster
guidelines wer
of patients
d 22%, respe
nd 0%, 38%,
were noted
the previou
receiving the
were less th
milar across b
tal, the use o
utic levels in
were not se
cap is more
nicalMeAbstrac
re translated i
with subthe
ectively. Th
, and 63% fo
during the e
s 85 kg weig
e standard p
han 85 kg an
both weight
of a 110 kg w
n obese pati
een in an ana
e appropriate
eetingcts
into unknown
erapeutic, th
hese percent
or patients g
evaluation p
ght cap. In t
protocol wer
nd half were
groups.
weight cap f
ents and be
alysis of the
e for obese p
characters.
erapeutic, a
tages change
reater than
eriod.
that evaluat
re included i
greater tha
for a heparin
came more
previous 85
patients.
and
ed to
110
tion,
n the
n 85
n
5 kg
*Special sy
Session‐B
Poster Ti
and a P2Y
intervent
Poster Ty
Submissi
Primary A
Email: rd
Addition
Jonas Old
Matias N
Deepak L
Christoph
Purpose:
(NOACs)
with BMI
informat
combine
efficacy o
therapy.”
Methods
who had
clopidog
either 11
the rates
bleeding
of death,
function
surface a
(30 to les
ymbols that w
Board # ‐ 4‐0
itle: Body m
Y12 inhibito
tion: RE‐DUA
ype: Evaluat
ion Category
Author: Raff
decater@uni
al Authors:
dgren
Nordaby
L Bhatt
her P Canno
: Knowledge
in patients w
I less than o
ion may imp
d with an an
of dabigatra
” Here, the i
s: The RE‐DU
undergone
rel or ticagre
10 mg or 150
s of the first
events or cl
, myocardial
of baseline
area): norma
ss than 35) a
2018ASProf
ere not spelled
024
ass index an
r in atrial fib
AL PCI
tive Study
y: Cardiology
faele Caterin
ich.it
n
e about effica
with extrem
r equal to 25
pact drug lev
ntiplatelet ag
n dual thera
mpact of BM
UAL PCI trial
percutaneo
elor, and asp
0 mg twice d
Internationa
linically relev
l infarction, s
BMI, dividin
al/underweig
and greater t
SHPMidyfessional
d‐out per the g
nd outcomes
brillation pat
y / Anticoag
na; Universit
acy or safety
es of body w
5 or greater
vels, and cou
gent. RE‐DU
apy with a P2
MI on outcom
randomized
us coronary
pirin for 1 to
daily (BID), e
al Society on
vant non‐ma
stroke, syste
g the popula
ght (less tha
than class I o
yearClinlPoster
guidelines wer
s of dual ant
tients under
gulation
tà degli Stud
y of non‐vita
weight or bo
than or equ
uld be of eve
AL PCI (NCT0
2Y12 inhibito
mes in RE‐DU
d 2725 patie
y interventio
o 3 months, o
ach with eit
n Thrombosi
ajor bleeding
emic emboli
ation into fo
n 25), overw
obese (great
nicalMeAbstrac
re translated i
tithrombotic
rgoing percu
di;
amin K antag
ody mass ind
ual to 35) is g
en greater re
02164864) e
or vs. a class
UAL PCI is as
nts with non
n (PCI) to tri
or to dabiga
her clopidog
s and Haem
g events, an
sm, or unpla
our subgroup
weight (25 to
ter than or e
eetingcts
into unknown
c therapy wit
taneous cor
gonist oral a
dex (BMI, inc
generally lac
elevance wh
evaluated th
sical warfari
ssessed.
nvalvular atr
iple therapy
tran dual th
grel or ticagr
mostasis (ISTH
nd the compo
anned revas
ps of BMI (al
o less than 3
equal to 35).
characters.
th dabigatra
ronary
anticoagulan
cluding patie
cking. This
hen a NOAC
he safety and
n “triple
rial fibrillatio
y with warfar
erapy with
relor. We re
H) major
osite end po
cularization
ll in kg/m2 b
30), class I ob
. Written
an
ts
ents
is
d
on
rin,
port
oint
, as a
body
bese
*Special sy
informed
by an Ins
Results:
than or e
to less th
demonst
110 mg (
than 30,
ratio[95
ratio[95
ratio[95
equals 0.
1.09]; an
vs warfar
by BMI (p
Conclusio
with atria
body ma
ymbols that w
d consent wa
stitution Rev
Median (ran
equal to 25;
han 35 and 3
trated signifi
BMI less tha
hazard ratio
percent CI] e
percent CI] e
percent CI] e
.83 [0.61‐1.1
d BMI great
rin triple the
p value for in
on: The ben
al fibrillation
ss index, inc
2018ASProf
ere not spelled
as obtained
view Board.
nge) BMI wa
1113 patien
326 patients
icantly lowe
an 25, hazard
o[95 percent
equals 0.46
equals 0.38
equals 0.70
15]; BMI 30
ter than or e
erapy. Throm
nteraction w
efit of the d
n after percu
cluding a sub
SHPMidyfessional
d‐out per the g
from all the
s 28.1 (14‐6
ts with BMI
with BMI gr
r rates of ble
d ratio[95 pe
t CI] equals 0
[0.28‐0.75];
[0.19‐0.77])
[0.46‐1.06];
to less than
qual to 35, h
mboembolic
was nonsigni
abigatran du
utaneous cor
bstantial num
yearClinlPoster
guidelines wer
patients an
6). The stud
of 25 to less
reater than o
eeding irresp
ercent CI] eq
0.54 [0.39‐0.
and BMI gre
and dabigat
BMI 25 to le
35, hazard
hazard ratio
event rates
ficant).
ual therapy v
ronary inter
mber of over
nicalMeAbstrac
re translated i
d the RE‐DU
y included 6
s than 30; 66
or equal to 3
pective of ba
quals 0.59 [0
.74]; BMI 30
eater than o
tran 150 mg
ess than 30,
ratio[95 per
[95 percent
did not diffe
vs warfarin t
vention was
rweight and
eetingcts
into unknown
UAL PCI trial
618 patients
64 patients w
35. Dual ther
aseline BMI
0.42‐0.83]; B
0 to less tha
or equal to 3
g (BMI less th
hazard ratio
rcent CI] equ
CI] equals 0
er between
triple therap
s consistent
obese patie
characters.
was approv
with BMI le
with BMI of
rapy
for dabigatr
BMI 25 to les
n 35, hazard
5, hazard
han 25, haza
o[95 percent
uals 0.67 [0.4
0.51 [0.27‐0.
the two gro
py in patient
regardless o
ents.
ed
ess
30
ran
ss
d
ard
t CI]
41‐
96]
ups
ts
of
*Special sy
Session‐B
Poster Ti
renal imp
Poster Ty
Submissi
Primary A
Email: ei
Addition
Paul Reil
Joanne v
Jeffrey W
Charles P
Purpose:
AD study
in patien
dabigatra
dabigatra
dabigatra
in patien
Methods
treated p
invasive
anticoag
boards, a
maximum
administ
divided in
(CrCl, cal
or mild, m
or equal
minute to
ymbols that w
Board # ‐ 4‐0
itle: Effectiv
pairment
ype: Evaluat
ion Category
Author: Joh
kelbj@mcm
al Authors:
ly
van Ryn
Weitz
Pollack
: Idarucizum
y, which show
ts presentin
an, idarucizu
an may accu
an reversal.
ts with and
s: RE‐VERSE
patients with
procedure w
ulation (1). T
and all patie
m reversal o
ration as me
nto groups w
culated with
moderate, o
to 50 mL pe
o less than 5
2018ASProf
ere not spelled
025
e reversal of
tive Study
y: Cardiology
n Eikelboom
master.ca
mab is license
wed rapid an
ng with sever
umab is clea
umulate in p
To examine
without ren
AD was a m
h uncontrolla
were given 5
The study pr
nts provided
f dabigatran
easured by t
with normal
h the use of
or severe ren
er minute to
50 mL per m
SHPMidyfessional
d‐out per the g
f dabigatran
y / Anticoag
m; McMaster
ed for dabiga
nd complete
re bleeding,
red primaril
atients with
this possibi
al impairme
ulticenter, p
able or life‐t
grams of in
rotocol was
d written inf
n anticoagula
the ecarin clo
renal functi
the Cockcro
nal impairme
less than 80
inute, and le
yearClinlPoster
guidelines wer
n anticoagula
gulation
r University;
atran revers
e reversal of
or in those
y by the kidn
renal impai
lity, we com
ent in the RE
prospective o
threatening
travenous id
approved by
formed cons
ation in the f
otting time o
on defined b
oft–Gault equ
ent defined b
0 mL per min
ess than 30
nicalMeAbstrac
re translated i
ation by idar
al based on
f dabigatran‐
requiring ur
neys. Theref
rment, whic
mpared the e
‐VERSE AD s
open‐label s
bleeding or
darucizumab
y all the rele
sent. The pri
first 4 hours
or diluted th
by an estima
uation) of 80
by estimated
nute, greate
mL per minu
eetingcts
into unknown
rucizumab in
the results o
‐associated
rgent surgery
fore, idaruci
ch could com
extent of dab
study.
study in whic
those requi
b for reversa
evant institut
mary endpo
s after idaruc
hrombin tim
ated creatin
0 mL per mi
d CrCl value
r than or eq
ute, respecti
characters.
n patients w
of the RE‐VE
anticoagulat
y. Like
zumab and
mpromise
bigatran reve
ch dabigatra
ring urgent
al of dabigat
tional review
oint was
cizumab
e. Patients w
ine clearanc
nute or high
s of greater
ual to 30 mL
ively.
ith
ERSE
tion
ersal
an‐
ran
w
were
ce
her,
than
L per
*Special sy
Results: A
function
(n, 127; m
severe (C
minute) r
dabigatra
and 15.0
patients
whereas
concentr
percent o
dabigatra
reversal w
as well as
Conclusio
manner w
mediated
Referenc
(1) P
analysis.
ymbols that w
At baseline,
(CrCl 110.1
median age,
CrCl 20.4 mL
renal impair
an administr
hours in pa
with norma
in patients w
rations were
of patients w
an concentra
was 100 per
s impaired r
on: Although
with declinin
d anticoagul
ce:
ollack CV, Re
N Engl J Me
2018ASProf
ere not spelled
21.5 percen
mL per minu
82 years), a
per minute
rment, respe
ration was 1
tients with s
l renal funct
with severe,
e 231, 127.5
with severe,
ations great
rcent (95 per
enal functio
h median da
ng renal func
ation regard
eilly PA, van
ed. 2017 Aug
SHPMidyfessional
d‐out per the g
nt (n, 108; m
ute); 18.1 pe
and 32.4 per
), moderate
ectively. The
4.3 hours in
severe, mod
tion, the med
, moderate a
and 69.3 ng
moderate a
er than 1000
rcent confid
on.
abigatran lev
ction, idaruc
dless of patie
Ryn J et al.
g; 377(5):431
yearClinlPoster
guidelines wer
median age, 6
ercent (n, 91
cent (n, 163
(CrCl 40.2 m
median tim
patients wi
erate and m
dian dabigat
and mild ren
per mL, res
nd mild rena
0 ng per mL.
ence interva
vels increase
cizumab app
ents' renal fu
Idarucizuma
1‐41.
nicalMeAbstrac
re translated i
68 years) of
1; median ag
3; median ag
mL per minu
me since the
th normal re
mild renal im
tran concent
nal impairme
pectively. O
al impairme
. The media
al, 100 to 10
ed in a conce
pears to effe
unction at b
ab for dabiga
eetingcts
into unknown
patients had
ge, 82 years)
ge, 78 years)
te) or mild (
reported las
enal functio
pairment, re
tration was
ent, the med
Overall, 12.1,
ent, respectiv
n maximum
00) in patient
entration‐de
ctively rever
baseline.
atran revers
characters.
d normal ren
), 25.2 perce
of patients
CrCl 61.7 m
st dose of
n, and 19.3,
espectively.
46.8 ng per
dian dabigat
2.4 and 0.6
vely, had me
percentage
ts with norm
ependent
rse dabigatr
sal ‐ full coho
nal
ent
had
L per
15.9
In
mL
ran
edian
e
mal
ran‐
ort
*Special sy
Session‐B
Poster Ti
monitori
Poster Ty
Submissi
Primary A
Email: tia
Addition
Nichole B
Ashley H
Jeff Mars
Stacy Sch
Purpose:
partial th
rivaroxab
calibrate
UFH ther
results w
frequenc
well as th
Methods
2018 thro
were inc
subseque
monitore
inhibitors
Results:
recent ad
the infus
PTT resu
ymbols that w
Board # ‐ 4‐0
itle: Impact
ng in an ant
ype: Descrip
ion Category
Author: Tia
a.hintz@asp
al Authors:
Braathen
ellerman‐Ra
shall
hoepke
: Recent lite
hromboplast
ban are direc
d with unfra
rapy, were re
with anti‐Xa l
cy of patient
he duration
s: A DUE was
ough June 1
luded if they
ently started
ed with both
s and anti‐Xa
Out of 206 p
dministratio
ion, all nine
lts indicated
2018ASProf
ere not spelled
026
of direct ora
i‐factor Xa b
ptive Report
y: Cardiology
Hintz; Aspir
pirus.org
ankin
rature sugge
tin time (PTT
ct oral facto
actionated h
ecently impl
evel monito
s receiving d
of effect the
s performed
4, 2018, afte
y received a
d on a contin
h PTT and an
a testing wh
patients that
n of an oral
patients exh
d subtherape
SHPMidyfessional
d‐out per the g
al factor‐Xa i
based protoc
y / Anticoag
us Wausau H
ests that dire
T) and anti‐fa
r‐Xa inhibito
eparin (UFH
lemented ac
oring, a drug
direct factor
eir on the an
d including p
er implemen
dose of apix
nuous UFH in
nti‐Xa levels t
hich had bee
t were starte
factor‐Xa in
hibited supr
eutic values.
yearClinlPoster
guidelines wer
nhibitors on
col
gulation
Hospital;
ect oral facto
actor Xa (an
ors that impa
H). Anti‐Xa ba
cross three c
use evaluat
‐Xa inhibitor
nti‐Xa level.
atients adm
ntation of an
xaban, edoxa
nfusion. Pat
to assess the
n calibrated
ed a continu
hibitor (4.4
atherapeuti
Approximat
nicalMeAbstrac
re translated i
n therapeuti
or‐Xa inhibit
ti‐Xa) levels
act the valid
ased protoc
community h
tion (DUE) w
rs and trans
mitted to the
n anti‐Xa mo
aban, or riva
ients receivi
e relationsh
d with UFH.
uous UFH inf
percent). At
c anti‐Xa act
tely 22 perc
eetingcts
into unknown
c unfraction
tors may im
. Apixaban, e
dity of the an
ols to maint
hospitals. Du
will further de
itioning to U
hospital fro
onitoring pro
aroxaban an
ing UFH infu
ip between
fusion, nine
t baseline an
tivity, while
ent of patie
characters.
nated hepari
pact both th
edoxaban, a
nti‐Xa level w
tain therape
ue to variabl
efine the
UFH infusion
om March 19
otocol. Patie
nd were
usions were
oral factor‐X
patients had
nd six hours
correspond
nts exhibited
n
he
and
when
utic
le
s, as
9th,
nts
Xa
d
into
ing
d a
*Special sy
therapeu
anti‐Xa le
81 secon
venous t
interpret
Conclusio
Patients
administ
on anti‐X
assess ad
anti‐Xa le
ymbols that w
utic PTT resu
evels were c
ds for acute
hromboemb
table anti‐fa
on: Direct o
who start an
ration shoul
Xa levels. Fur
dditional fac
evel, such as
2018ASProf
ere not spelled
ult on the sec
onsistently s
e coronary sy
bolism (VTE)
ctor Xa leve
ral factor‐Xa
n UFH infusi
d be monito
rther evalua
tors impacti
s renal funct
SHPMidyfessional
d‐out per the g
cond PTT an
supratherap
yndrome (AC
. The averag
l was 49.9 h
a inhibitors i
on with a re
ored with a P
tion, includi
ng the relat
ion, age, and
yearClinlPoster
guidelines wer
d 57% by th
peutic. Thera
CS) and 67 to
ge time from
ours.
mpact anti‐X
cent history
PTT for an av
ng a greater
ionship betw
d dose of dir
nicalMeAbstrac
re translated i
he third PTT,
apeutic PTT
o 95 second
m last record
Xa levels tha
y of oral fact
verage of tw
r sample size
ween direct
rect oral fac
eetingcts
into unknown
whereas th
levels were
ds for atrial f
ded oral fact
at are calibra
or‐Xa inhibit
wo days befo
e would be b
factor‐Xa in
tor‐Xa.
characters.
e correspon
defined as 6
ibrillation an
tor‐Xa dose t
ated to UFH.
tor
ore relying so
beneficial to
hibitors and
nding
67 to
nd
to an
.
olely
o
d the
*Special sy
Session‐B
Poster Ti
patients
Poster Ty
Submissi
Primary A
Email: ho
Addition
Jonas Old
Georg Ni
Deepak L
Christoph
Purpose:
balance b
Dabigatr
anticoag
dual ther
excreted
of dabiga
antithrom
Methods
fibrillatio
therapy w
therapy (
the prim
bleeding
point of d
revascula
ml/min; 5
approved
consent.
ymbols that w
Board # ‐ 4‐0
itle: Impact
with atrial fi
ype: Evaluat
ion Category
Author: Stef
ohnloser@e
al Authors:
dgren
ckenig
L Bhatt
her P Canno
: In patients
between the
an, an oral d
ulation thera
rapy vs. warf
, renal funct
atran. Here,
mbotic thera
s: The RE‐DU
on who had u
with clopido
(110 mg or 1
ary outcome
or clinically
death, myoc
arization, by
50 to less th
d by the Inst
2018ASProf
ere not spelled
027
of renal func
ibrillation un
tive Study
y: Cardiology
fan Hohnlos
m.uni‐frankf
n
with atrial f
e prevention
direct throm
apy. The RE‐
farin triple t
tion as asses
we determi
apy with dab
UAL PCI trial
undergone p
ogrel or ticag
150 mg twice
e, first Intern
relevant no
cardial infarc
y baseline cre
han 80 ml/m
titutional Re
SHPMidyfessional
d‐out per the g
ction on dua
ndergoing pe
y / Anticoag
er; Johann W
furt.de
fibrillation un
n of thrombo
bin inhibitor
‐DUAL PCI tr
herapy. As a
ssed by creat
ne the impa
bigatran and
(NCT021648
percutaneou
grelor and as
e daily) with
national Soc
on‐major ble
ction, stroke
eatinine clea
in; greater t
view Board
yearClinlPoster
guidelines wer
al antithrom
ercutaneous
gulation
Wolfgang Go
ndergoing a
osis and incr
r, provides a
rial evaluate
approximate
tinine cleara
ct of renal f
d a P2Y12 inh
864) random
us coronary i
spirin for 1 t
h clopidogrel
iety on Thro
eding event
e, systemic e
arance (less
han or equa
and all the p
nicalMeAbstrac
re translated i
botic therap
s coronary in
oethe Unive
ntithrombot
reased bleed
an alternativ
d the safety
ely 85 percen
ance could in
unction on t
hibitor in a c
mized 2725 p
intervention
o 3 months,
l or ticagrelo
ombosis and
t, and the se
embolism or
than 30 ml/
al to 80 ml/m
patients prov
eetingcts
into unknown
py with dabi
ntervention:
rsity;
tic treatmen
ding risk is cr
ve to warfari
y and efficacy
nt of dabigat
nfluence tre
the outcome
clinical settin
patients with
n (PCI) to wa
, or to dabig
or. We repor
Haemostas
condary thr
unplanned
/min; 30 to le
min). The stu
vided writte
characters.
gatran in
: RE‐DUAL PC
nt, achieving
ritical.
in for
y of dabigat
tran is renal
atment effe
es of dual
ng.
h atrial
arfarin triple
atran dual
rt the rates o
sis (ISTH) ma
ombotic end
ess than 50
udy was
en informed
CI
g a
ran
ly
ects
of
jor
d
*Special sy
Results:
Dabigatr
of creatin
creatinin
confiden
ml/ml (h
at creatin
confiden
Thrombo
Conclusio
therapy i
consisten
bleeding
more tha
ml/min.
ymbols that w
Mean (stand
an 110 mg d
nine clearan
e clearance
ce interval e
azard ratio e
nine clearan
ce interval e
oembolic eve
on: The ben
in patients w
nt regardless
was reduce
an 50 ml/min
2018ASProf
ere not spelled
dard deviatio
dual vs. warf
ce. Bleeding
of 50 to less
equals 0.49‐0
equals 0.59;
ce 30 to less
equals 0.55‐1
ent rates we
efit on bleed
with atrial fib
s of baseline
ed vs. warfar
n and simila
SHPMidyfessional
d‐out per the g
on ) baseline
farin triple th
g was lower
s than 80 ml
0.97) and wi
95 percent
s than 50 ml
1.97); p valu
ere similar be
ding reducti
brillation und
e creatinine c
rin triple the
r in patients
yearClinlPoster
guidelines wer
e creatinine
herapy had l
with dabiga
/min (hazar
ith creatinin
confidence
/min (hazar
ue of interac
etween grou
on of dabiga
dergoing pe
clearance. F
rapy in patie
s with creatin
nicalMeAbstrac
re translated i
clearance w
lower rates o
tran 150 mg
rd ratio equa
ne clearance
interval equ
rd ratio equa
tion was no
ups by creat
atran 110 mg
rcutaneous
For dabigatra
ents with ba
nine clearan
eetingcts
into unknown
was 78.0 (29.
of bleeding
g dual therap
als 0.69; 95 p
greater tha
uals 0.43‐0.8
als 1.04; 95 p
n‐significant
inine cleara
g dual vs. wa
coronary int
an 150 mg d
aseline creat
nce 30 to les
characters.
.76) ml/min.
across all lev
py with
percent
n or equal to
3); it was sim
percent
t (0.34).
nce.
arfarin triple
tervention w
ual therapy,
inine cleara
s than 50
.
vels
o 80
milar
e
was
,
nce
*Special sy
Session‐B
Poster Ti
after per
mellitus
Poster Ty
Submissi
Primary A
Email: m
Addition
Deepak B
Stefan Ho
Jur ten B
Christoph
Purpose:
cardiac a
dual anti
thrombo
subgroup
patients
atrial fibr
protecte
Methods
therapy (
mg or 15
analysis,
equals 37
diabetes
equals 46
thrombo
revascula
non‐majo
ymbols that w
Board # ‐ 4‐0
itle: Dual an
rcutaneous c
ype: Evaluat
ion Category
Author: Mic
ichmaen@r
al Authors:
Bhatt
ohnloser
erg
her Cannon
: Patients wi
and cerebral
thrombotic
oembolic eve
p analysis ev
with and wit
rillation (AF)
d against th
s: In RE‐DUA
(warfarin, cl
50 mg bid, pl
we report o
71; D150‐DA
(D110‐DAT,
60). The thro
oembolic eve
arization and
or bleeding e
2018ASProf
ere not spelled
028
tithromboti
coronary inte
tive Study
y: Cardiology
chael Maeng
m.dk
ith diabetes
events than
therapy red
ents, when c
valuated the
thout diabet
) undergoing
romboembo
AL PCI, 2725
opidogrel or
us clopidogr
outcomes in
AT, n equals
, n equals 61
omboembol
ents (myocar
d the bleedin
events as de
SHPMidyfessional
d‐out per the g
c therapy w
ervention in
y / Anticoag
g; Aarhus Un
and coronar
n patients wi
uced bleedi
compared to
effects of tr
tes, separate
g percutaneo
olic events b
AF patients
r ticagrelor a
rel or ticagre
patients wit
260 vs W‐TA
19 vs W‐TAT,
ic endpoint
rdial infarcti
ng endpoint
efined by the
yearClinlPoster
guidelines wer
ith dabigatra
patients wi
gulation
niversity Hos
ry artery dis
ithout diabe
ng events, w
o warfarin tri
reatment on
ely, in order
ous coronary
y dual versu
who had un
and aspirin; W
elor; D110‐ a
th diabetes (
AT, n equals
, n equals 60
was a comp
on, stroke, o
t was a comp
e Internation
nicalMeAbstrac
re translated i
an versus tri
th atrial fibr
spital, Aarhu
sease have a
etes. In the R
without incre
iple antithro
n thromboem
r to assess if
y interventio
us triple anti
ndergone PC
W‐TAT) or d
and D150‐DA
(D110‐DAT,
303) as wel
09; D150‐DA
posite efficac
or systemic e
posite of ma
nal Society o
eetingcts
into unknown
iple therapy
rillation and
s, Denmark;
higher risk
RE‐DUAL PCI
easing the ri
ombotic ther
mbolic and b
patients wit
on (PCI) are
thrombotic
CI were assig
dual therapy
AT). In this s
n equals 362
l as in patien
AT, n equals
cy endpoint
embolism),
ajor or clinica
on Thrombos
characters.
y with warfar
diabetes
;
of major adv
trial, dabiga
sk of
rapy. This
bleeding risk
th diabetes a
adequately
therapy.
ned to triple
(dabigatran
subgroup
2 vs W‐TAT,
nts without
503 vs W‐TA
of death,
or unplanne
ally relevant
sis and
rin
verse
atran
ks in
and
e
n 110
n
AT, n
ed
t
*Special sy
Haemost
elderly p
consent w
Results:
group ve
percent c
with 25.1
incidence
D110‐ an
56 event
D150‐DA
HR 1.05;
observed
composit
Conclusio
thrombo
with diab
reduction
diabetes,
compare
ymbols that w
tasis during f
atients from
was obtaine
In patients w
rsus 27.5 pe
confidence i
1 percent in
e of the com
nd D150‐DAT
s; HR 1.04; 9
AT groups co
95 percent
d between th
te efficacy e
on: Patients
oembolic eve
betes, the ris
n seemed le
, D110‐DAT
ed with W‐TA
2018ASProf
ere not spelled
follow‐up (m
m W‐TAT gro
ed from all pa
with diabete
ercent in the
nterval [CI],
the W‐TAT g
mposite effica
T groups com
95 percent C
mbined com
CI 0.79‐1.39
he treatmen
ndpoints.
with diabet
ents but not
sk of bleedin
ss pronounc
and D150‐D
AT.
SHPMidyfessional
d‐out per the g
mean follow‐
up outside U
atients inclu
es, the incide
e W‐TAT grou
0.35‐0.67),
group (62 vs
acy endpoin
mbined com
C, 0.75‐1.45)
mpared with
9) in patients
nt and diabet
tes and atria
bleeding aft
ng was subst
ced with D15
AT combine
yearClinlPoster
guidelines wer
‐up, 14 mon
US were exc
uded in RE‐D
ence of bleed
up (55 vs 10
and 23.8 pe
s 76 events;
nt in patients
pared with 1
, whereas it
12.3 percen
s without dia
tes subgrou
al fibrillation
ter percutan
tantially red
50‐DAT vers
ed had simila
nicalMeAbstrac
re translated i
ths). For com
luded from t
DUAL PCI stu
ding was 15
02 events; ha
ercent in the
HR 0.87; 95
s with diabet
15.1 percent
was 12.4 pe
nt in the W‐T
abetes. No s
p, for neithe
were at gre
neous corona
uced with D
us W‐TAT. A
ar rates of ov
eetingcts
into unknown
mparison wi
the analysis
dies.
.2 percent in
azard ratio [H
e D150‐DAT g
percent CI,
tes was 16.1
t in the W‐TA
ercent in the
TAT group (1
ignificant in
er the bleedi
eater risk for
ary interven
D110‐DAT bu
Among patie
verall throm
characters.
ith D150 DAT
. Informed
n the D110‐D
HR] 0.48; 95
group comp
0.62‐1.22). T
1 percent in
AT group (10
e D110‐ and
139 vs 75 ev
teraction wa
ing nor the
r
ntion. In pati
ut the risk
ents with
mbotic events
T,
DAT
5
ared
The
the
00 vs
vents;
as
ents
s
*Special sy
Session‐B
Poster Ti
prophyla
the Unite
Poster Ty
Submissi
Primary A
Email: rn
Addition
Vicki Lask
Holly Guy
Steven D
Alexande
Purpose:
preventa
discharge
efficacy/
enoxapa
approved
estimate
with acut
Methods
life‐year
(6‐14 day
decision
based on
tree stru
death, bl
health st
Costs cap
primary e
ymbols that w
Board # ‐ 4‐0
itle: Analysis
axis of venou
ed States
ype: Evaluat
ion Category
Author: W.
neuman@po
al Authors:
kier
y
Deitelzweig
er Cohen
: Venous thr
able cause of
e in nonsurg
safety of bet
rin prophyla
d for extend
d the cost‐e
te medical il
s: A cost‐effe
(QALY) gain
ys) from a U
tree structu
n primary an
cture includ
eeding and
ate Markov
ptured the tr
event compl
2018ASProf
ere not spelled
029
s of cost‐effe
us thromboe
tive Study
y: Cardiology
Richey Neum
ortola.com
romboembo
f morbidity a
gical acutely
trixaban for
axis in the Ph
ed VTE prop
effectiveness
llness who re
ectiveness a
ed for betrix
S payer pers
re was used
d secondary
ed primary e
thrombocyt
model and w
reatment an
lications. Pu
SHPMidyfessional
d‐out per the g
ectiveness o
embolism in
y / Anticoag
man; Portola
lism (VTE) in
and mortalit
ill patients r
extended V
hase 3 APEX
phylaxis in ac
s of betrixab
equire VTE p
nalysis was
xaban (35‐42
spective ove
d to estimate
y efficacy an
events and T
topenia). Aft
were at risk
nd managem
blished liter
yearClinlPoster
guidelines wer
f betrixaban
nonsurgical
gulation
a Pharmaceu
n hospitalize
ty. Studies sh
receiving sho
VTE prophyla
study. Base
cutely medic
an versus en
prophylaxis i
conducted t
2 days) comp
er a lifetime
e primary ev
d safety dat
TCs (VTE, my
ter the first t
of recurrent
ment of prim
rature identi
nicalMeAbstrac
re translated i
n compared
patients wit
uticals, Inc.;
ed acute med
how that VT
ort‐duration
axis was inve
d on the res
cally ill adult
noxaparin in
in the US.
to estimate t
pared to sta
horizon. In t
vents and tre
a from the A
yocardial inf
three month
t events and
ary events, T
ified the risk
eetingcts
into unknown
with enoxap
th acute me
dically ill pat
TE risk contin
n VTE prophy
estigated ver
sults, betrixa
ts at risk of V
n adult nonsu
the cost per
andard‐durat
the first thre
eatment com
APEX study.
farction, isch
hs, patients e
d long term c
TCs, recurre
k of recurren
characters.
parin for
edical illness
tients is a lea
nues followin
ylaxis. The
rsus standar
aban was FD
VTE. This ana
urgical patie
quality‐adju
tion enoxap
ee months, a
mplications (
The decision
hemic stroke
entered a six
complication
ent events an
nt events and
in
ading
ng
rd
A‐
alysis
ents
usted
arin
a
(TCs)
n
e,
x‐
ns.
nd
d
*Special sy
long term
Uncertai
Results:
$780 and
showed t
per patie
dominati
Conclusio
over eno
considere
at risk of
discharge
ymbols that w
m complicati
nty was exp
In the base c
d increased Q
that VTE pro
ent. Furtherm
ing enoxapa
on: In this an
oxaparin. Due
ed a cost‐eff
VTE, who re
e.
2018ASProf
ere not spelled
ions, EQ‐5D
lored throug
case analysis
QALYs of 0.0
ophylaxis wit
more, all sen
rin.
nalysis, betr
e to cost sav
fective treat
equire exten
SHPMidyfessional
d‐out per the g
utility data a
gh determin
s, betrixaban
017 per patie
th betrixaba
nsitivity anal
rixaban dem
vings per pat
tment for ad
nded VTE pro
yearClinlPoster
guidelines wer
and costs. A
istic and pro
n dominated
ent. The corr
n led to a sa
yses mainta
onstrated po
tient and un
dult nonsurg
ophylaxis fro
nicalMeAbstrac
re translated i
A 3% discoun
obabilistic se
d enoxaparin
responding
aving of $790
ained the res
otential cost
nmet need, b
ical patients
om hospitali
eetingcts
into unknown
nt rate per an
ensitivity ana
n, leading to
probabilistic
0 and a gain
sult of betrix
t savings and
betrixaban c
s with acute
zation throu
characters.
nnum was u
alysis.
o cost saving
c analysis
of 0.017 QA
xaban
d effectivene
an be
medical illn
ugh post‐
sed.
gs of
ALYs
ess
ess
*Special sy
Session‐B
Poster Ti
populatio
Poster Ty
Submissi
Primary A
Email: el
Addition
I‐Chia Lia
Paul God
Stephani
Purpose:
United St
percent w
are attrib
mortality
adequate
identify f
Methods
and elect
least 18 y
diagnosis
cohorts:
index. Fo
associati
oral and
Hazards s
Results: A
RA cohor
CV event
ymbols that w
Board # ‐ 4‐0
itle: Risk of c
on
ype: Evaluat
ion Category
Author: Elm
mor.pineda9
al Authors:
ao
dley
e Yu
: Rheumatoi
tates. Amon
within one t
butable to ca
y remains hig
ely characte
factors assoc
s: We condu
tronic medic
years if age w
s (index date
an RA cohor
or post‐index
ons betwee
injectable g
survival curv
A total of 72
rt without CV
t post‐index.
2018ASProf
ere not spelled
030
cardiovascul
tive Study
y: Cardiology
mor Pineda; B
d arthritis (R
ng patients w
o four years
ardiovascula
gh largely du
rize CV even
ciated with C
cted a retro
cal record da
with continu
e) were inclu
rt without a
x compariso
n CV events
lucocorticoid
ves were con
27 patients w
V event post
. Significant
SHPMidyfessional
d‐out per the g
lar events in
y / Anticoag
Baylor Scott
om
RA) is the mo
with RA, the
s after RA dia
ar (CV) disea
ue to CV com
nt risk in the
CV event risk
ospective coh
ata from July
uous enrollm
uded in the s
CV event po
ns, ordinary
and predict
d use, and o
nstructed fo
were include
t‐index and
differences
yearClinlPoster
guidelines wer
patients wi
gulation
& White He
ost common
risk of havin
agnosis. Ove
se. Despite r
mplications f
RA populati
k in RA patie
hort study w
y 1, 2010 thr
ment at least
study. Patien
ost‐index an
least square
ors – age, ge
opioid use. K
r time from
ed in the stu
141 patients
were observ
nicalMeAbstrac
re translated i
th rheumato
ealth;
n chronic inf
ng a myocard
er 50 percen
remarkable
from the dis
ion. The pur
ents within a
was using ph
rough March
t 6 months p
nts were pla
d a RA coho
es regressio
ender, como
aplan‐Meier
RA diagnosi
dy; 586 pati
s met inclus
ved in some
eetingcts
into unknown
oid arthritis
flammatory a
dial infarctio
t of prematu
strides in RA
ease. Few st
rpose of this
a Texas popu
armacy and
h 31, 2018. R
prior to and
aced into two
ort with a CV
n was used t
orbidity, RA
r and Cox Pr
is to CV even
ents met inc
ion for our R
baseline de
characters.
in a Texas
arthritis in th
on rises by 6
ure deaths i
A treatment
tudies
s study is to
ulation
medical cla
RA patients a
after first RA
o separate
V event post
to determin
medication
roportional
nt or censor
clusion for o
RA cohort w
emographic o
he
0
n RA
,
ims
at
A
e
use,
ship.
our
ith
or
*Special sy
clinical ch
compare
(p less th
average(
0.3[0.9];
generally
patients
TNFs (HR
Conclusio
with dec
from RA
ymbols that w
haracteristic
ed to those w
han 0.0001).
SD) Charlson
p less than 0
y had higher
on anti‐TNF
R equals 0.57
on: Our stud
reased CV ev
diagnosis co
2018ASProf
ere not spelled
cs. Patients i
without a CV
In addition,
n Comorbidi
0.0001). RA
CV event ris
s had a 43 p
73; 95% CI: 0
dy showed th
vent risk. An
ompared to n
SHPMidyfessional
d‐out per the g
n our RA co
V event with
our RA coho
ity Index sco
patients not
sk compared
percent decre
0.330‐ 0.997
hat methotr
nti‐TNF use w
no anti‐TNF
yearClinlPoster
guidelines wer
hort with a C
a mean(SD)
ort with a CV
ores than tho
t on anti‐tum
d to those on
ease in haza
; p equal to
rexate and a
was also asso
use.
nicalMeAbstrac
re translated i
CV event po
age of 70(1
V event post
ose without
mor necrosis
n anti‐TNFs
ard rate com
0.0488).
nti‐TNFs in R
ociated with
eetingcts
into unknown
ost index wer
10) years ver
t‐index date
a CV event (
s factors (an
(p equals 0.0
mpared to tho
RA patients
h a longer tim
characters.
re older
rsus 54(13) y
e had higher
(0.9[1.4] ver
ti‐TNFs)
0228). RA
ose not on a
were associ
me to CV ev
years
rsus
anti‐
ated
ent
*Special sy
Session‐B
Poster Ti
thrombo
Poster Ty
Submissi
Primary A
Medicine
Email: tp
Addition
Casey Ta
Daniel W
Michael
Mark Mu
Purpose:
embolism
substant
their acc
understa
the purp
VTE treat
Methods
experien
survey as
meet hea
your VTE
get your
VTE care
at All Diff
means “N
with pati
health in
ymbols that w
Board # ‐ 4‐0
itle: Underst
oembolism
ype: Descrip
ion Category
Author: Tim
e;
pulleyn@gm
al Authors:
k
Witt
Feehan
unger
: Venous thr
m, is a comm
ial health‐ca
ess to VTE c
anding regar
ose of this s
tment.
s: A national
ced a VTE ev
ssessed perc
althcare cost
E prescriptio
VTE care? 4
you need?
ficult” and “
Not at All Ne
ient demogr
surance; car
2018ASProf
ere not spelled
031
tanding pati
ptive Report
y: Cardiology
mothy Pulleyn
ail.com
romboembo
mon disease
are costs. Th
are, both po
ding how th
tudy is to ch
online surv
vent in the p
ceptions of V
ts related to
n medicatio
4) To what d
Questions 1
10” means “
eeded” and “
raphics inclu
re related pa
SHPMidyfessional
d‐out per the g
ent's access
y / Anticoag
n; University
lism (VTE), i
associated w
ere are man
ositively and
ese variable
haracterize p
ey was adm
past two yea
VTE care bar
o your VTE ca
ns? 3) How d
egree do yo
1‐3 (4) were
“Extremely D
“10” means
ding income
atient harms
yearClinlPoster
guidelines wer
to care barr
gulation
y of Utah Co
ncluding dee
with increase
ny factors th
negatively.
es and barrie
patient’s per
inistered to
ars. Respond
rriers by 4 qu
are? 2) How
difficult do t
ou need the s
evaluated b
Difficult”. Qu
“Extremely
e level, place
s experience
nicalMeAbstrac
re translated i
riers in the t
llege of Pha
ep vein thro
ed mortality
at may affec
Presently, t
ers affect VT
rceptions of
907 adult re
dents with c
uestions: 1)
w difficult is f
transportatio
support of o
by a 1‐to‐10 s
uestion 4 wa
Needed”. Ea
e of residenc
ed with the V
eetingcts
into unknown
treatment of
rmacy and S
ombosis or p
y, high recur
ct a patient’s
here is limit
TE patient ca
barriers enc
espondents
cancer were
How difficu
for you to m
on issues ma
others at hom
scale where
as evaluated
ach question
ce, current w
VTE episode
characters.
f venous
School of
pulmonary
rrence rates,
s perception
ed
re. Therefor
countered d
who had
excluded. T
ult is it for yo
eet costs for
ake it for yo
me to get yo
e “1” means
d where “1”
n was correl
work status,
; number of
, and
ns of
re,
uring
he
ou to
r
u to
our
“Not
ated
and
f
*Special sy
lifetime V
pathway
considere
effect of
less than
Results:
(56.7%).
Hispanic
commun
Most rep
35.4% an
prescript
Extremel
Extremel
(Transpo
Difficult a
difficulty
transport
healthca
correlate
Conclusio
past two
rated tra
in the U.S
ymbols that w
VTE events;
s. Statistical
ed continuo
the indepen
0.05.
Respondent
The sample
ethnicity (10
ity setting, h
ported VTE e
nd 2 or more
tion medicat
ly Difficult: 9
ly Difficult: 8
ortation Issue
at All: 87%, E
y with VTE m
tation issues
re primary p
ed with trans
on: Respond
years found
nsportation
S. affect app
2018ASProf
ere not spelled
patient belie
analysis wa
us variables
ndent predic
ts had a mea
was predom
0.6%) and A
had health in
events were
e by 64.6%. R
tion costs m
9% and VTE P
8%). Transpo
es: Not Diffic
Extremely D
medication co
s correlated
provider’s of
sportation is
dents in a lar
d healthcare
and home s
proximately
SHPMidyfessional
d‐out per the g
efs concerni
s conducted
for analysis
ctors on the
an age of 52.
minantly Cau
frican‐Amer
nsurance, an
DVT (63.8%
Respondents
ildly difficult
Prescription
ortation issu
cult at All: 87
ifficult: 5%).
osts and exp
with satisfa
ffice, and ho
ssues.
rge national
e costs and V
support as n
0.5‐1 in 10 p
yearClinlPoster
guidelines wer
ng VTE outc
d with SAS v
s. Linear regr
outcome va
.4 years (14.
ucasian (88.6
rican race (6
nd an incom
). A single lif
s rated mee
t (Health Car
Medication
es and home
7%, Extreme
. Meeting he
eriencing tra
ction with V
me support
online surve
VTE medicati
ot being a b
persons with
nicalMeAbstrac
re translated i
comes, and o
9.4 (Cary, N
ression was
ariables. Sign
.4 SD). The m
6%) with rep
.8%). Most w
e level betw
fetime VTE e
ting healthc
re Costs: No
n Costs: Not
e support w
ely Difficult:
ealthcare co
ansportation
VTE care, rela
. However, h
ey who had
ion costs mi
barrier to VT
h prior VTE e
eetingcts
into unknown
oral anticoag
NC). Likert sc
used to dete
nificance wa
majority wer
presentation
were living i
ween; $50,00
event was ex
care costs an
ot Difficult at
Difficult at A
were rated no
5% and Hom
sts was corr
n issues. Diff
ationship wi
home suppo
suffered a V
ldly difficult
E care. Barri
event in the
characters.
gulant thera
ale items we
ermine the
s set at p‐va
re women
n of those of
n the urban
00 to $99,00
xperienced b
nd meeting V
t All: 61%,
All: 74%,
ot difficult at
me Support:
related with
ficulty with
ith their prim
ort only
VTE event in
to meet. Th
iers to VTE c
U.S.
py
ere
alue
00.
by
VTE
t all
Not
mary
the
hey
care
*Special sy
Session‐B
Poster Ti
Poster Ty
Submissi
Primary A
Email: br
Addition
Austin Oy
Adam Go
Michael
Purpose:
than arte
higher do
kilogram
than low
purpose
than low
Methods
Adult me
included
the first m
dose into
kilogram
therapeu
Xa, or act
year, lim
therapeu
transfusi
Results: T
were 31.
ymbols that w
Board # ‐ 4‐0
itle: Evaluati
ype: Evaluat
ion Category
Author: Bra
randon.reiff@
al Authors:
yen
oetz
Erickson
: Heparin is u
erial clots, su
oses of hepa
then 18 uni
w dose hepar
of this study
w dose hepar
s: The institu
en and wom
if they rece
monitoring l
o three coho
(n equals 14
utic, defined
tivated clott
b salvage du
utic levels, ra
on. Data wa
The average
3 hours, 11.
2018ASProf
ere not spelled
032
ing the dose
tive Study
y: Cardiology
ndon Reiff; S
@jacks.sdsta
used at high
uch as a myo
arin are som
its per kilogr
rin (typically
y is to determ
rin in acute l
utional revie
en were ide
ived heparin
level. Patien
orts: 80 units
4), or no bol
as a therap
ting time. Se
uring hospita
ates of hepa
as analyzed u
e time to the
5 hours, and
SHPMidyfessional
d‐out per the g
e of heparin
y / Anticoag
South Dakot
ate.edu
her doses for
ocardial infa
etimes utiliz
ram per hou
60 units per
mine if high
imb ischemi
w board app
ntified using
n, but exclud
ts were plac
s per kilogra
us (n equals
eutic lab dra
econdary out
alization, 30
rin induced
using non‐pa
erapeutic he
d 28 hours re
yearClinlPoster
guidelines wer
in acute lim
gulation
ta State;
r venous clot
rction. Acute
zed. High do
r) is thought
r kilogram th
dose hepari
a.
proved this s
g ICD‐9/ICD‐
ded if they re
ced into coh
m or greate
s 4). The prim
aw of activat
tcomes were
day rehospi
thrombocyt
arametric te
parin levels
espectively (
nicalMeAbstrac
re translated i
b ischemia
ts, such as a
e Limb Ische
se heparin (
t to achieve
hen 12 units
in achieves b
single cente
10 codes. Sc
eceived mul
orts based o
r (n equals 1
mary endpoi
ted partial th
e all cause m
italization, n
topenia, and
sts or chi‐sq
for no bolus
(p equals 0.0
eetingcts
into unknown
venous thro
emia is an ar
(typically 80
therapeutic
s per kilogram
better thera
r retrospect
creened pati
tiple loading
on their initi
15), less than
int was time
hromboplas
mortality at 3
number of te
d receipt of p
quared tests.
s, low dose,
081). High d
characters.
omboembol
rterial clot w
units per
c levels quick
m per hour)
peutic outco
tive cohort s
ients were o
g doses befo
al heparin b
n 80 units pe
e until hepar
stin time, An
30 days and
ests before
protamine o
.
and high do
ose heparin
lism,
where
ker
. The
omes
tudy.
only
ore
olus
er
rin is
ti‐
at 1
r
ose
had
*Special sy
fewer de
cohort, b
Mortality
respectiv
with 100
equals 0.
Conclusio
ischemia
However
monitori
evaluate
ymbols that w
eaths at 30 d
but four (28%
y at 1 year fo
vely (p equal
%, 86%, and
.236).
on: The use
trended tow
r, lower dose
ng levels qu
d with a larg
2018ASProf
ere not spelled
ays compar
%) patients d
or high dose
ls 0.456). Th
d 100% for th
of high dose
wards less d
e heparin ha
icker. The cl
ger prospect
SHPMidyfessional
d‐out per the g
ed to low do
died who rec
, low dose, a
irty day reho
he no bolus,
e heparin (80
eath than lo
ad less rehos
inical signifi
tive trial.
yearClinlPoster
guidelines wer
ose. No patie
ceived low d
and no bolus
ospitalizatio
low dose, a
0 units per k
ow dose hep
spitalization
cance of the
nicalMeAbstrac
re translated i
ents died in
dose heparin
s cohorts we
on was comp
and high dos
kilogram or g
parin (less th
and achieve
ese competi
eetingcts
into unknown
the high dos
n group (p eq
ere 13%, 50%
parable amo
se cohorts re
greater) in a
an 80 units
ed therapeu
ng benefits
characters.
se heparin
quals 0.204)
%, and 25%
ng the group
espectively (
acute limb
per kilogram
tic heparin
needs to be
.
ps
p
m.
*Special sy
Session‐B
Poster Ti
stroke
Poster Ty
Submissi
Primary A
Email: m
Addition
James La
Purpose:
establish
with prov
of this pr
associate
Methods
observat
or non‐ca
years of a
2016 wit
were exc
evaluate
Secondar
experien
to analyz
Results: A
were dee
(n=21) w
After exp
45.1% (n
was used
ymbols that w
Board # ‐ 4‐0
itle: Patient
ype: Evaluat
ion Category
Author: Mic
scalese22@
al Authors:
andry
: The benefit
hed. Howeve
viders havin
roject is to e
ed with card
s: This study
ional study e
ardioemboli
age and hav
h a primary
cluded. The p
patient cha
rily, cardioem
cing a non‐c
ze patient ch
A total of 40
emed to be c
were female,
periencing a
=14) of thos
d in 18 patie
2018ASProf
ere not spelled
033
characterist
tive Study
y: Cardiology
chael Scalese
@yahoo.com
ts of statin t
er, the role o
g little evide
valuate stat
ioembolic st
was approv
evaluating p
c nature. To
ve been adm
diagnosis of
primary focu
racteristics a
mbolic strok
cardioembol
haracteristics
03 ischemic s
cardioembo
with an ave
cardioembo
se were on s
nts (75.0%)
SHPMidyfessional
d‐out per the g
tics and stati
y / Anticoag
e; Palmetto
herapy in th
of statins in s
ence to prov
in prescribin
trokes.
ved by the in
patients who
o be included
itted to the
f an acute st
us of the eva
and the use
ke patients w
ic ischemic s
s, outcome m
strokes occu
lic in origin.
erage age of
olic stroke, 7
tatin therap
whereas 5 p
yearClinlPoster
guidelines wer
in prescribin
gulation
Health Richl
he secondary
strokes with
vide support
ng patterns a
nstitutional r
o experience
d in the stud
hospital bet
troke. Patien
aluation was
of statins in
were qualitat
stroke. Desc
measures, a
urred during
Among thos
72.3 ±11.5 y
77.4% (n=24)
py prior to ad
patients (20.
nicalMeAbstrac
re translated i
ng patterns a
land;
y prevention
a cardioem
in clinical de
and identify
review board
ed an ischem
dy, patients h
tween Janua
nts experienc
s to quantita
n patients wi
tively compa
criptive stati
nd comparis
g the study p
se with a car
years, and a
) of patients
dmission. H
8%) received
eetingcts
into unknown
after an acut
n of ischemic
bolic origin
ecision‐mak
patient cha
d. This was a
mic stroke of
had to be gr
ary 2011 and
cing a hemo
atively and q
th cardioem
ared to patie
stics and T‐t
sons betwee
period, of wh
rdioembolic
mean CHA2
s received st
igh intensity
d moderate
characters.
te cardioem
c stokes is w
remains unc
king. The pur
racteristics
a retrospect
cardioembo
eater than 1
d December
orrhagic stro
ualitatively
mbolic stroke
ents
tests were u
en groups.
hich 9.2% (n=
stroke, 54.1
2DS2‐VASc o
atin therapy
y statin thera
intensity an
bolic
well
clear
rpose
ive,
olic
18
ke
es.
sed
=37)
1%
of 4.5.
y and
apy
nd 1
*Special sy
patient (4
patients
,p=0.17)
statin the
Conclusio
those wit
with card
cardioem
ymbols that w
4.2%) receiv
with a cardi
and sex (54.
erapy (77.4%
on: Patients
th a non‐car
dioembolic s
mbolic nature
2018ASProf
ere not spelled
ved low inten
oembolic str
.1% female v
% vs 99.6%, P
who experi
rdioembolic
strokes but l
e.
SHPMidyfessional
d‐out per the g
nsity. Compa
rokes were s
vs 40.2% fem
P<0.05).
enced a card
ischemic str
ess so than
yearClinlPoster
guidelines wer
ared with th
similar in av
male, p=0.10
dioembolic s
roke. Statins
patients wit
nicalMeAbstrac
re translated i
he non‐cardi
erage age (7
0) but were l
stroke were
s were used
h an ischem
eetingcts
into unknown
oembolic po
72.3 years vs
less likely to
similar in ag
in a majority
mic stroke of
characters.
opulation,
s 58.0 years
o be placed o
ge and sex to
y of patients
non‐
on
o
s
*Special sy
Session‐B
Poster Ti
Poster Ty
Submissi
Primary A
Email: m
Addition
Purpose:
presente
“spice” (a
While on
patient’s
drug use
friends w
the patie
On admis
ago. The
to his no
initially h
within no
resolved
units/L, C
initial EC
hours lat
repolariz
Repeat c
Index 5%
632 units
catheteri
significan
ECG reve
(10.3 ng/
ymbols that w
Board # ‐ 4‐0
itle: Vasospa
ype: Case Re
ion Category
Author: Mic
scalese22@
al Authors:
: A 53 year o
ed to the ED
a synthetic m
n the ground
first experie
recently. He
who were pre
ent had a rem
ssion, a CT o
patients’ on
rmal GERD s
hypotensive
ormal limits
after IV reh
CKMB <1 ng/
G showed ST
ter, his ECG w
zation.
ardiac enzym
%, Troponin 1
s/L, CKMB 52
ization. Angi
nt lesions or
ealed norma
/ml) while hi
2018ASProf
ere not spelled
034
astic myocar
eport
y: Cardiology
chael Scalese
@yahoo.com
old male with
after a poss
marijuana de
d, his legs we
ence with sp
e was appar
esent. He de
mote history
of the brain s
nly complain
symptoms. I
with a blood
with the exc
ydration. Of
/ml, Tropon
T elevation g
was read as
mes increase
1.72 ng/ml) a
2.5 ng/ml, R
iography rev
need for rev
l sinus rhyth
is othe enzy
SHPMidyfessional
d‐out per the g
rdial infarcti
y / Anticoag
e; Palmetto
h a past med
ible seizure
erivative), fe
ere observed
pice and the
ently uncon
enied any vis
y of a small r
showed an u
nt was mild c
nitial physic
d pressure o
ception of an
f note, the p
in <0.015 ng
greater than
normal sinu
ed within 6 h
and were sig
Relative Inde
vealed only n
vascularizat
hm with no a
mes had not
yearClinlPoster
guidelines wer
on following
gulation
Health Richl
dical history
episode. He
elt euphoric,
d to shake in
patient den
scious for le
sion changes
right posteri
unchanged le
chest discom
al exam reve
of 93/56 with
n elevated S
atients’ card
g/ml,) and he
n 0.08mV in
us rhythm wi
hours (CK 30
gnificantly e
x 8%, Tropo
non‐obstruc
ion. At the t
abnormalitie
t yet peaked
nicalMeAbstrac
re translated i
g use of synt
land;
significant f
e reports tha
, and procee
n a tonic‐clon
nied any alco
ess than 2 m
s or focal ne
or thalamus
esion as com
mfort describ
ealed no abn
h a heart rat
Serum creati
diac enzyme
e had a norm
leads II, III, a
ith ST elevat
03 units/L, C
levated 12 h
onin 13.5 ng/
ctive coronar
ime of the h
es. His tropo
d (CK 660 un
eetingcts
into unknown
thetic mariju
for hyperten
at he had sm
eded to lose
nic manner.
ohol, tobacco
inutes as de
eurological d
s hemorrhag
mpared to th
bed as being
normalities.
te of 71 BPM
nine of 1.59
es were nega
mal urine dr
and AVF. Wh
tion suggest
CKMB 15.5 ng
hours from a
/ml) resultin
ry artery dis
heart cathete
onin began to
its/L, CKMB
characters.
uana
nsion and GE
moked some
consciousne
This was the
o, or other il
escribed by
eficits. Of no
ge 3 years pr
he CT 3 years
g similar in na
The patient
M. All labs we
9 mg/dL, whi
ative (CK 53
ug screen. H
hen repeate
ive of early
g/ml, Relativ
admission (C
ng in cardiac
ease with no
erization, his
o normalize
55.7 ng/ml)
ERD
ess.
e
llicit
ote,
rior.
s
ature
t was
ere
ich
His
d 2
ve
CK
o
s
)
*Special sy
The patie
illicit dru
clopidog
cessation
ischemia
coronary
Probable
ymbols that w
ent was diag
g use. A non
rel 75mg da
n counseling
is supporte
y arteries. Ba
e (score =7).
2018ASProf
ere not spelled
gnosed with
ninvasive tre
ily, amlodipi
g. In this case
d chronolog
ased on the N
SHPMidyfessional
d‐out per the g
a vasospast
eatment stra
ine 10m dail
e, the role sy
gy, temporal
Naranjo nom
yearClinlPoster
guidelines wer
ic (type II) m
tegy was em
ly, and atorv
ynthetic mar
biomarker a
mogram, the
nicalMeAbstrac
re translated i
myocardial in
mployed incl
vastatin 80m
rijuana as th
and ECG tre
e causality of
eetingcts
into unknown
nfarction (M
luding aspiri
mg as well as
he culprit for
nds, and no
f spice was e
characters.
I) secondary
n 81mg daily
s illicit drug
r vasospastic
n‐obstructed
evaluated as
y to
y,
c
d
s
*Special sy
Session‐B
Poster Ti
and revie
Poster Ty
Submissi
Primary A
Email: ljs
Addition
Rachel M
Kristi Zieg
Purpose:
arrhythm
physician
Physician
of a QTc
calls, edu
intervent
prolonga
Methods
prolonga
educatio
collection
current p
patient’s
fibrillatio
assigned
QTc crite
physician
tool impl
ymbols that w
Board # ‐ 4‐0
itle: Develop
ew of physic
ype: Descrip
ion Category
Author: Lau
schulz@mer
al Authors:
Muhlenkamp
genbusch
: QTc prolon
mias, in‐parti
ns were cont
n complaint
monitoring
ucate pharm
tions and im
ation.
s: The pharm
ation. The pr
n, standardi
n. Pharmaci
potassium an
medication
on with hear
a point valu
eria point val
n for a chang
lementation
2018ASProf
ere not spelled
035
pment and im
ian feedbac
ptive Report
y: Cardiology
ra Schulz; M
cy.com
ngation cause
cular torsad
tacted if the
of phone ca
tool. This p
macists on va
mprove physi
macy clinical
rocess involv
ized docume
ists used the
nd current m
s with the p
t rate greate
ue and weigh
lue determin
ge in therapy
n and three m
SHPMidyfessional
d‐out per the g
mplementat
k
y / Anticoag
Mercy Health
ed by medic
des de pointe
QTc was > 4
ll fatigue for
roject was d
lidity of QTc
cian/pharm
team develo
ved literatur
entation tem
e QTc tool to
magnesium l
otential of Q
er than 120
hted depend
ned whethe
y. Retrospec
months after
yearClinlPoster
guidelines wer
tion of a nov
gulation
h St. Rita's M
cations has lo
es. Our insti
470 and a QT
r invalid QTc
designed to d
c warnings, s
acist commu
oped a proc
re review, Q
mplate to use
o document
evels. Addit
QTc prolongi
bpm and/or
dent on likel
r the pharm
ctive data w
r tool implem
nicalMeAbstrac
re translated i
vel tool for m
Medical Cente
ong been as
itution imple
Tc prolongin
c warnings p
decrease un
standardize
unication re
ess for scori
QTc tool deve
e in electron
the patient’
tionally, pha
ing, presenc
r in situ pace
ihood of cau
acist contin
was collected
mentation.
eetingcts
into unknown
med‐induced
er;
ssociated wit
emented a p
ng drug was
prompted the
necessary p
documentat
garding med
ing medicati
elopment, p
nic medical r
’s QTc value,
armacists do
ce of heart b
emaker. Eac
using an arrh
ued to moni
d for three m
characters.
d QTc monito
th fatal
process in w
ordered.
e developm
hysician pho
tion of QTc
dication QTc
ion induced
harmacist
record and d
, age, sex, an
cumented t
block, atrial
ch criterion
hythmia. Th
itor or conta
months prior
oring
which
ent
one
c
QTc
data
nd
he
was
he
acted
to
*Special sy
Results:
monitori
physician
pharmac
also decr
Conclusio
decrease
The proje
QTc resu
ymbols that w
Pharmacists
ng paramete
n. As a resul
cist documen
reased.
on: As a resu
ed and stand
ect helped to
lts and whe
2018ASProf
ere not spelled
s were educa
ers of patien
t of the QTc
ntation of in
ult of the im
dardization in
o improve p
n to recogni
SHPMidyfessional
d‐out per the g
ated on usin
nts with risk
c tool, physic
significant Q
mplementatio
n pharmacis
harmacists’
ze contact p
yearClinlPoster
guidelines wer
g the QTc to
for QTc pro
cian phone c
QT intervals a
on of the QT
st document
to interpret
prescribers.
nicalMeAbstrac
re translated i
ool, compute
longation an
calls decreas
and non‐sign
Tc tool, phys
tation/interv
t QTc results
eetingcts
into unknown
er documen
nd when to c
sed by 22%.
nificant drug
ician phone
vention was
s, to assess t
characters.
tation, furth
contact a
Unnecessar
g interaction
calls were
accomplishe
the validity o
her
ry
ns
ed.
of
*Special sy
Session‐B
Poster Ti
paramete
Poster Ty
Submissi
Primary A
Email: ra
Addition
Lisa Appe
Nadia Sir
Riaz Siraj
Purpose:
death an
preferred
associati
activatio
Sacubitri
from ech
which me
paramete
Methods
ejection f
sacubitri
were cur
blocker (
initiated
ARB whic
echocard
sacubitri
of cardia
ventricul
ymbols that w
Board # ‐ 4‐0
itle: Assessin
ers
ype: Evaluat
ion Category
Author: Ran
andall.sharp@
al Authors:
eddu
rajuddin
juddin
: The drug sa
d hospitaliza
d treatment
on with incr
n can be att
l inhibits the
hocardiogram
easure the i
ers.
s: A total of 4
fraction (les
l/valsartan a
rrently taking
ARB). The ot
on sacubitri
ch was appro
diogram was
l/valsartan,
c remodelin
ar ejection f
2018ASProf
ere not spelled
036
ng the impac
tive Study
y: Cardiology
ndall Sharp; S
@swosu.edu
acubitril/vals
ation from h
. Cardiac rem
reased morb
enuated by
e proteolytic
ms are comm
mpact of val
40 patients
s than 40 pe
added to exi
g an angiote
ther 25 perc
il/valsartan,
oved in 2015
s performed
with the ave
g which wer
fraction (Cal
SHPMidyfessional
d‐out per the g
ct of sacubit
y / Anticoag
Southweste
u
sartan has b
heart failure
modeling is c
bidity and mo
vasoactive p
c enzyme ne
monly used t
lsartan/sacu
in a private c
ercent) heart
sting heart f
ensin conver
cent (n equa
which is a c
5 to treat he
both prior t
erage being
re obtained
LVEF), visua
yearClinlPoster
guidelines wer
tril/valsartan
gulation
rn Oklahom
been found t
in the PARA
common in p
ortality due
peptides suc
prilysin, whi
to assess car
ubitril on spe
cardiologist’
t failure wer
failure thera
rting enzyme
ls 10) were
ombination
eart failure w
to and after
12 months a
from the ec
l left ventric
nicalMeAbstrac
re translated i
n on cardiova
a State Univ
to reduce th
ADIGM‐HF tr
patients wit
to neurohor
ch as B‐type
ich increase
rdiac remod
ecific cardiov
’s clinic with
re either swi
apy, of which
e inhibitor o
newly diagn
drug of a ne
with reduced
the patient
after the sw
hocardiogra
cular ejectio
eetingcts
into unknown
ascular rem
versity Colleg
e risk of card
rial and is no
h heart failu
rmonal activ
natriuretic p
s BNP levels
eling. Studie
vascular rem
h a history of
itched to or
h 75 percent
r an angiote
nosed with h
eprilysin inh
d ejection. A
was switche
itch. Pre‐ an
ams included
n fraction (V
characters.
odeling
ge of Pharm
diovascular
ow considere
ure and has a
vation. This
peptide (BN
s. Parameter
es are lackin
modeling
f reduced
had
t (n equals 3
ensin II recep
eart failure
ibitor and an
An
ed to
nd post‐meas
d calculated
VisLVEF), left
acy;
ed a
an
P).
rs
g
0)
ptor
and
n
sures
left
t
*Special sy
atrial vol
analyzed
and for in
significan
between
remodeli
Results: T
(cm)) in t
VisEF aft
increase
while no
cm). A sig
was foun
a larger p
CalLVEF a
associati
percent c
Conclusio
improvem
cardiovas
drug sho
showed a
more sub
supports
to furthe
ymbols that w
ume (LA), an
retrospectiv
ncreases in C
nt change. A
the percent
ing.
There was a
the LVIDd an
er the switc
(n equals 37
decrease w
gnificant (P e
nd between t
percent decr
after drug tr
on (r equals
change in Vi
on: Patients
ment in thre
scular remo
wed a defin
a statistically
bjective mea
other posit
er investigate
2018ASProf
ere not spelled
nd left ventr
vely via one
CalLVEF and
A Spearmen t
t changes as
significant (
nd a significa
h to sacubitr
7, mean 2.19
as detected
equals 0.009
the percent
rease in LVID
reatment. Th
negative 0.3
sLVEF.
with establ
ee of the fou
deling after
ite decrease
y significant
asure and ca
ive data pub
e the report
SHPMidyfessional
d‐out per the g
ricular intern
‐tail, paired
VisLVEF afte
test was also
s calculated f
(P equals 0.0
ant (P equals
ril/valsartan
9 points) in t
(P equals 0.
9) negative a
change of L
Dd was indir
here was a s
373, n equal
ished reduce
ur echocardio
taking the s
e in LVIDd an
increase wit
an be seen as
blished since
ed findings i
yearClinlPoster
guidelines wer
nal diameter
t‐tests to ev
er drug trea
o conducted
from the pre
011) decreas
s 0.015) incr
. There was
the CalLVEF
.401) in the
association (
VIDd and th
ectly associa
imilar trend
ls 15) betwe
ed ejection f
ographic par
acubitril/val
nd a trend up
th sacubitril
s a variable
e the PARAD
in large scale
nicalMeAbstrac
re translated i
r end diastol
valuate for d
tment, with
d to identify t
e‐ and post‐
se (n equals
rease (n equ
a trend (P e
after the sw
LA paramete
(r equals neg
he percent ch
ated with a h
(P equals 0.
een the perc
fraction hea
rameters co
lsartan comb
pwards in Ca
/valsartan. N
influenced b
IGM‐HF tria
e studies.
eetingcts
into unknown
le (LVIDd). D
decreases in
P less than
two‐way co
measures of
39, mean 0
als 17, 6.77
equals 0.146
witch to sacu
er (n equals
gative 0.431
hange in Cal
higher perce
.171) toward
ent change
art failure ex
mmonly ass
bination. Pa
alLVEF. Visua
Nevertheles
by operator
l and also su
characters.
Data were
LA and LVID
0.05 indicat
rrelations
f cardiac
.3 centimete
points) in th
) toward an
bitril/valsart
37, mean 0.
, n equals 36
LVEF, sugge
ent increase
d a negative
of LVIDd and
perienced a
sociated with
tients taking
ally estimate
s, VisLVEF is
bias. This da
uggests the n
Dd
ting a
ers
he
tan,
.01
6)
sting
in
d the
n
h
g the
ed EF
s a
ata
need
*Special sy
Session‐B
Poster Ti
venous t
Poster Ty
Submissi
Primary A
Email: da
Addition
Casey Ta
Daniel W
Michael
Mark Mu
Purpose:
embolism
substant
patient s
beneficia
levels of
Methods
administ
in the pa
patient s
dissatisfi
you with
majority
was prim
experien
healthca
health ca
demogra
status, an
ymbols that w
Board # ‐ 4‐0
itle: Analysis
hromboemb
ype: Evaluat
ion Category
Author: Dav
avid.webb@
al Authors:
k
Witt
Feehan
unger
: Venous thr
m is a comm
ial healthcar
atisfaction,
al to improve
patient satis
s: The institu
ered to 907
st 2 years. R
atisfaction b
ed to very sa
the care pro
of your care
marily respon
ced a VTE ev
re providers
are professio
aphics (sex, a
nd health in
2018ASProf
ere not spelled
037
s of a large U
bolism episo
tive Study
y: Cardiology
vid Webb; U
@pharm.utah
romboembo
on disease a
re costs. Litt
but improvi
ed patient ex
sfaction in a
utional revie
adult respo
Respondents
by 3 question
atisfied. Bas
ovided by th
e? 2) How lik
nsible for the
vent? 3) How
s (i.e., comm
onals) during
age, race and
surance), pa
SHPMidyfessional
d‐out per the g
U.S. national
ode
y / Anticoag
niversity of
h.edu
lism (VTE) in
associated w
le is known
ng satisfacti
xperience. T
large U.S. n
w board app
ndents who
s with cance
ns evaluated
ed on your m
he healthcar
kely would y
e majority of
w satisfied w
munications b
g your care?
d ethnicity, i
atient harms
yearClinlPoster
guidelines wer
study of pa
gulation
Utah College
ncluding dee
with increase
about the sp
on in the he
The purpose
ational sam
proved this n
provided co
r related VT
d by a 5‐poin
most recent
e provider w
ou be to rec
f your care t
were you wit
between prim
Each questi
income leve
s (i.e., misdia
nicalMeAbstrac
re translated i
tient satisfa
e of Pharma
ep vein throm
ed mortality,
pecific facto
ealthcare del
of this resea
ple of VTE p
national onl
onsent and h
E were exclu
nt Likert‐typ
VTE experie
who was prim
commend th
to friends or
th the overa
mary care d
ion was corr
el, place of re
agnosis, wro
eetingcts
into unknown
action during
cy;
mbosis or pu
, high recurr
ors contribut
livery is univ
arch is to ex
patients.
ine survey, w
had experien
uded. The su
pe scale from
ence: 1) How
marily respo
he healthcar
relatives if t
ll communic
octor, specia
related to pa
esidence, cu
ong treatmen
characters.
g a recent
ulmonary
rence rates,
ting to VTE
versally
xamine curre
which was
nced a VTE e
urvey assess
m very
w satisfied w
onsible for th
e provider w
they also
cations betw
alists, and o
atient
urrent work
nt) experien
and
ent
event
ed
were
he
who
ween
ther
ced
*Special sy
with VTE
anticoag
analysis.
the outco
Results:
percent)
of Hispan
urban co
99,000 d
was expe
responde
responsib
Respond
their care
responde
during th
VTE care
Conclusio
past 2 ye
healthca
provider
opportun
ymbols that w
episode, nu
ulant therap
Linear regre
ome variable
Respondent
. The sample
nic ethnicity
ommunity re
ollars. Most
erienced in 3
ents. Satisfac
ble for care
ents were v
e to others (
ents were on
heir care. Sat
, specifically
on: Respond
ears were so
re providers
to family an
nity for phar
2018ASProf
ere not spelled
umber of life
py pathways
ession was u
es, with P se
ts had a mea
e was predo
(10.6 perce
sidence, had
reported VT
35.4 percent
ction with th
was most co
ery likely to
(Not Likely a
nly somewha
tisfaction is
y a wrong dia
dents to a la
mewhat sat
s during trea
nd friends. V
rmacists.
SHPMidyfessional
d‐out per the g
etime VTE ev
. Likert scale
used to deter
et less than 0
an age of 52.
minantly Ca
nt) and Afric
d health insu
TE events we
t of responde
he VTE care
ommonly rat
recommend
t All: 1 perce
at satisfied w
correlated w
agnosis or tr
rge national
isfied with t
tment. They
VTE care in th
yearClinlPoster
guidelines wer
vents, patien
e items were
rmine the ef
0.05.
.4 years (14.
ucasian (88.
can‐America
urance, and
ere DVT (63
ents and 2 o
provided by
ted as some
d the healthc
ent, Extreme
with commu
with a patien
reatment, or
online surv
heir VTE car
y were very
he United St
nicalMeAbstrac
re translated i
nt beliefs con
e considered
ffect of the i
.4 SD). The m
.6 percent) w
an race (6.8
an income l
.8 percent).
or more even
y the healthc
what satisfie
care provide
ely Likely: 47
unication bet
nt perception
r delayed tre
vey who had
re and comm
likely, howe
tates can be
eetingcts
into unknown
ncerning VT
d continuous
independent
majority wer
with represe
percent). M
evel betwee
A single life
nts in 64.6 p
care provide
ed (23 perce
er primarily
7 percent). H
tween healt
n of a mistak
eatment.
suffered a V
munication b
ever, to reco
improved w
characters.
E outcomes
s variables fo
t predictors
re women (5
entation of t
ost were livi
en 50,000 to
time VTE ev
percent of
er primarily
ent).
responsible
However,
thcare provid
ke made in t
VTE event in
between the
mmend the
which presen
, and
or
on
56.7
hose
ing in
o
vent
for
ders
their
n the
eir
nts an
*Special sy
Session‐B
Poster Ti
regadeno
Poster Ty
Submissi
Primary A
Email: sa
Addition
Dustin Sp
Jennifer V
Jessica Su
Purpose:
adenosin
stress tes
intermitt
use of ad
criteria w
this study
for a resc
Methods
from pha
impleme
program
disease (
All other
adverse e
regadeno
Drug exp
restrictio
ymbols that w
Board # ‐ 4‐0
itle: Impact
oson to aden
ype: Evaluat
ion Category
Author: Sara
arah.yohey@
al Authors:
pencer
Van Cura
un
: The Americ
ne, and regad
sting. Since
tent availabi
denosine. Du
were implem
y was to eva
cue agent an
s: This study
armacologic
ntation of a
, regadenoso
COPD) or as
patients we
event data w
oson) and af
penditure for
on.
2018ASProf
ere not spelled
038
of a change
nosine in a c
tive Study
y: Cardiology
ah Yohey; M
@mwhc.com
can Society o
denoson as
2010, regad
lity of dipyri
ue to a signif
mented and a
aluate the im
nd financial i
was a single
stress agent
regadenoso
on was restr
sthma who w
ere to receiv
were collecte
fter (patients
r pharmacol
SHPMidyfessional
d‐out per the g
in preferred
community h
y / Anticoag
Mary Washin
of Nuclear C
the coronar
denoson has
idamole and
ficantly high
adenosine w
mpact of swit
impact to th
e center, ret
ts before (Fe
on formulary
ricted to use
were actively
ve an adenos
ed on 60 con
s receiving a
ogic stress a
yearClinlPoster
guidelines wer
d pharmacol
hospital
gulation
gton Health
ardiology Im
y vasodilato
been the pr
d prescriber
er acquisitio
was given pre
tching agent
he institution
trospective c
ebruary‐Mar
y restriction
e in patients
y using rescu
sine stress te
nsecutive pa
adenosine) r
agents was a
nicalMeAbstrac
re translated i
ogic nuclear
care;
maging Guide
or agents ava
referred age
perception o
on cost for re
eferred form
ts on inciden
n.
cohort study
rch 2018) an
program. Af
with severe
ue inhalers o
est. Demogr
atients both
restriction cr
also compar
eetingcts
into unknown
r stress testi
elines list dip
ailable for ph
ent at this in
of more adv
egadenoson
mulary status
nce of adver
y comparing
nd after (Apr
fter implem
e chronic obs
on the day o
raphics, com
before (pati
riteria were
red before a
characters.
ng agent fro
pyridamole,
harmacologi
stitution du
verse effects
n, restriction
s. The purpo
rse events, n
adverse eff
ril‐May 2018
entation of t
structive lun
of stress test
orbidities, a
ients receivi
implemente
nd after the
om
ic
e to
with
ose of
need
ects
8)
the
ng
ing.
and
ng
ed.
e
*Special sy
Results: A
significan
COPD co
significan
between
regadeno
patients,
who rece
expendit
of regade
Conclusio
resulted
drug exp
ymbols that w
A total of 12
nt difference
mpared tho
nt difference
the two gro
oson group e
p=0.03). In
eived regade
ture for phar
enoson restr
on: Adenosi
in less frequ
enditure.
2018ASProf
ere not spelled
20 patients (
es in patient
se who rece
e in the num
oups (52 vs.
experienced
addition, a r
enoson comp
rmacologic s
riction criter
ne is a safe a
uent reversa
SHPMidyfessional
d‐out per the g
60 per grou
demograph
eived adenos
mber of patie
58 patients,
d chest pain c
rescue agent
pared to ade
stress agents
ria.
alternative t
l agent use,
yearClinlPoster
guidelines wer
p) were eva
hics. More pa
sine (13 vs. 4
nts who exp
p=0.1), how
compared to
t was admin
enosine (16
s was decrea
to regadeno
equivalent o
nicalMeAbstrac
re translated i
luated for th
atients treat
4 patients, p
perienced at
wever signifi
o the adeno
nistered mor
vs. 7 patient
ased by 78%
son for nucl
or fewer adv
eetingcts
into unknown
his study. Th
ted with reg
p=0.03). Ther
t least one ad
cantly more
sine group (
re frequently
ts, p=0.03). T
% following im
ear stress te
verse events
characters.
here were no
adenoson h
re was no
dverse even
e patients in
(21 vs. 11
y to patients
Total drug
mplementat
esting and
s, and decre
o
ad
nt
the
s
tion
ased
*Special sy
Session‐B
Poster Ti
dapagliflo
Poster Ty
Submissi
Primary A
Email: da
Addition
Abdullah
Mustafa
Purpose:
with type
to oral hy
years old
(ED) by h
dizziness
and NPH
daily and
afebrile,
showed g
mmol/L,
implicate
and was
intraveno
patient h
for 3 hou
saline wa
units/hou
managem
bolus ins
precipita
myocard
ymbols that w
Board # ‐ 4‐0
itle: Risk of d
ozin initiatio
ype: Case Re
ion Category
Author: Dan
alkhiyami@h
al Authors:
h Shawky
Seid Ahmed
: This case re
e II Diabetes
ypoglycemic
d female with
her family wi
s for 1 day. H
insulin) to o
d Pioglitazon
normotensi
glucose valu
pH 7.26, sod
ed DKA with
started on in
ous insulin in
had a rapid r
urs, glucose
as changed t
ur. Her clinic
ment showe
ulin regimen
ting factors
ial infarction
2018ASProf
ere not spelled
039
diabetic keto
on
eport
y: Clinical To
nia Alkhiyam
hamad.qa
d Mustafa
eport illustra
s Mellitus (T2
c therapy reg
h history of T
ith complain
Her antidiabe
oral Dapaglif
e 15 mg onc
ve but tachy
ue of 306 mg
dium 131 m
positive ani
ntravenous
nfusion and
esponse to i
level droppe
to 5% dextro
cal status im
d resolve of
n. Dapagliflo
for DKA wer
n, alcohol or
SHPMidyfessional
d‐out per the g
oacidosis in
opics / Thera
mi; Hamad M
ates the pote
2DM) who a
gimen includ
T2DM for 15
nts of nausea
etic drug reg
flozin 10 mg
ce daily. On
ycardic (hear
g/dL, bicarbo
mol/L, potas
on gap of 15
normal salin
was monito
insulin infus
ed from 306
ose and norm
mproved and
the DKA. Co
ozin and othe
re ruled out
r substance a
yearClinlPoster
guidelines wer
patients wit
apeutics
edical Corpo
ential risk of
re abruptly
ding the rela
5 years was
a, vomiting,
gimen was re
once daily,
examination
rt rate: 126
onate 14 mm
ssium 4.7 m
5. The patien
ne with pota
ored after th
ion; after th
mg/dL to 14
mal saline an
lab findings
onsequently
er oral medi
as there wa
abuse. DKA w
nicalMeAbstrac
re translated i
th type II dia
oration;
f diabetic ke
switched fro
atively new a
brought to t
fatigue, poly
ecently chan
Sitagliptin‐M
n, the patien
beats per m
mol/L, keton
mol/L and c
nt was admi
ssium 20 mE
e first hour a
he infusion o
40 mg/dL. Th
nd insulin inf
s after 4 hou
y, she was dis
ications wer
as no eviden
was highly t
eetingcts
into unknown
betes mellit
etoacidosis (
om long‐term
agent Dapag
the emergen
yuria, palpit
nged from in
Metformin 5
nt was consc
minute). Bloo
es (B‐hydrox
hloride 102
tted to the m
Eq/L and con
and then ev
of 6 units/ho
he intraveno
fusion rate w
urs of startin
scharged ho
re stopped. O
ce of infecti
rigged by Da
characters.
tus upon
DKA) in pati
m insulin the
gliflozin. A 61
ncy departm
ations, and
nsulin (regula
50/1000 mg t
cious, orient
od workup
xybuterate)
mmol/L. Th
medical war
ntinuous
very 2 hours.
ur (0.1 units
ous normal
was reduced
g the
ome with bas
Other comm
on, trauma,
apagliflozin
ents
erapy
1
ment
ar
twice
ed,
5.9
is
rd
. The
s/kg)
d to 2
sal
mon
*Special sy
initiation
clinic and
inhibitors
of SGLT2
addition,
raise seru
type I Dia
reduction
are also k
ymbols that w
n and sudden
d she was co
s as Dapaglif
that are exp
, SGLT2 inhib
um ketone l
abetes Melli
n and/or dis
known risk f
2018ASProf
ere not spelled
n discontinu
omfortably c
flozin stimul
pressed in α
bitors reduce
evels. DKA a
tus but not
continuation
factors for ke
SHPMidyfessional
d‐out per the g
ation of insu
ontrolled on
late several
α‐cells in the
e the execra
associated w
as such in pa
n due to Dap
etosis.
yearClinlPoster
guidelines wer
ulin. The pat
n insulin. Sod
mechanisms
pancreas st
ation of keto
with SGLT2 in
atients with
pagliflozin in
nicalMeAbstrac
re translated i
tient was fol
dium‐Glucos
s that could
timulates glu
one bodies th
nhibitors is w
T2DM. Furt
nitiation in o
eetingcts
into unknown
lowed up in
se Cotranspo
precipitate
ucagon secre
hrough urine
well reported
thermore, in
order to avoi
characters.
the outpati
orter 2 (SGLT
DKA. Inhibit
etion. In
e which cou
d in patient w
nsulin dose
id hypoglyce
ent
T2)
tion
ld
with
emia‐
*Special sy
Session‐B
Poster Ti
heart rat
Poster Ty
Submissi
Primary A
Email: st
Addition
Matjaz F
Peter Alt
Roland B
Matthias
Purpose:
and are a
agonists
heart rat
by tiotro
confirme
Obstruct
This post
effect on
Methods
evaluate
with tiot
Initiative
patients.
electroca
and 52 u
included
ymbols that w
Board # ‐ 4‐0
itle: Long‐te
te and blood
ype: Evaluat
ion Category
Author: Stef
efan.andrea
al Authors:
lezar
ter
Buhl
s Trampisch
: Cardiovasc
associated w
and long‐ac
te and blood
pium or olod
ed tiotropium
ive Lung Dis
t hoc analysi
n heart rate
s: The 52‐we
d fixed‐dose
ropium 5 mi
for Chronic
In this post
ardiograms)
sing pre‐dos
in TONADO
2018ASProf
ere not spelled
040
rm effect of
d pressure in
tive Study
y: Clinical To
fan Andreas
ular comorb
with worse p
ting muscar
d pressure. H
daterol mon
m plus oloda
sease stage 2
s of TONADO
and blood p
eek, phase II
e tiotropium
icrogram or
Obstructive
hoc analysis
and resting
se measurem
® studies.
SHPMidyfessional
d‐out per the g
f tiotropium
chronic obs
opics / Thera
; University
‐goettingen
bidities are c
rognosis. Th
inic antagon
However, pre
notherapy on
aterol efficac
2‐4 patients
O® studies a
pressure.
I TONADO®
5 microgram
olodaterol 5
e Lung Disea
s, long‐term
blood press
ments. Inform
yearClinlPoster
guidelines wer
plus olodate
structive pul
apeutics
of Goettinge
.de
common in c
he pharmaco
nists suggest
evious studie
n heart rate
cy and safety
with chronic
assessed tiot
studies (NCT
m plus oloda
5 microgram
se 2‐4 chron
changes fro
sure (whilst s
med consen
nicalMeAbstrac
re translated i
erol fixed‐do
lmonary dise
en;
chronic obst
ology of long
ts an inheren
es demonstr
and blood p
y in Global In
c obstructive
tropium plus
T01431274
aterol 5 micr
m via the Res
nic obstructi
om baseline
sitting) were
nt was obtain
eetingcts
into unknown
ose combina
ease patient
ructive pulm
g‐acting beta
nt potential
rated no neg
pressure. TO
nitiative for
e pulmonary
s olodaterol
and NCT014
rogram, and
pimat® inha
ive pulmona
in resting he
e analyzed a
ned from all
characters.
ation therapy
ts
monary disea
a‐adrenocep
to increase
gative influe
ONADO® stud
Chronic
y disease (1)
treatment
431287)
d monothera
aler, in Globa
ary disease
eart rate (us
t weeks 12,
patients
y on
ase,
ptor
ence
dies
).
apy
al
sing
24,
*Special sy
Results: A
studies (1
patients
[less than
mmHg) w
from bas
5 microg
percent c
percent C
0.833; p,
diastolic
treatmen
Conclusio
fixed‐dos
tiotropiu
heart rat
with chro
Referenc
(1) B
versus m
ymbols that w
A total of 51
1). In this po
were analyz
n 2 beats pe
were observe
seline in hea
ram, and olo
confidence i
CI 0.601 to 1
0.5572), res
blood press
nt when com
on: There w
se combinat
m or olodat
te and blood
onic obstruc
ce:
uhl R, Malta
mono‐compo
2018ASProf
ere not spelled
163 patients
ost hoc analy
zed for blood
r minute (bp
ed from bas
rt rate for ti
odaterol 5 m
nterval (CI)
1.876; p, 0.00
spectively. S
ure were qu
mpared with
as no indica
ion of tiotro
erol monoth
d pressure fo
tive pulmon
ais F, Abraha
nents in CO
SHPMidyfessional
d‐out per the g
were rando
ysis, 3058 pa
d pressure. O
pm)] and red
eline for all
otropium 5
microgram gr
minus 0.305
001), and 0.
Similar to th
uantitatively
tiotropium
tion of an ad
opium plus o
herapy. This
or tiotropium
nary disease.
ams R et al. T
PD (GOLD 2‐
yearClinlPoster
guidelines wer
omized to re
atients were
Over 52 wee
ductions in m
treatments
microgram p
roups was 0
5 to 0.944; p
192 bpm (SE
e changes in
small and si
or olodatero
dditive effec
olodaterol tre
argues agai
m plus olodat
.
Tiotropium a
‐4). Eur Resp
nicalMeAbstrac
re translated i
ceive treatm
e analyzed fo
eks, small ch
mean blood
arms. At we
plus olodate
.319 bpm [S
, 0.3163], 1.
E, 0.327; 95
n heart rate,
imilar for tio
ol monother
ct on heart r
eatment wh
nst relevant
terol combin
and olodater
pir J. 2015 A
eetingcts
into unknown
ment in the T
or heart rate
anges in me
pressure (le
eek 52, the m
erol 5 microg
Standard erro
.239 bpm (SE
percent CI m
, changes in
otropium plu
rapy.
rate or blood
hen compare
t adverse clin
nation thera
rol fixed‐dos
pr; 45 (4):96
characters.
TONADO®
e and 3062
ean heart rat
ess than 2
mean change
gram, tiotrop
or (SE), 0.31
E, 0.325; 95
minus 0.449
systolic and
us olodatero
d pressure w
ed with eithe
nical effects
apy in patien
se combinat
69‐79.
te
e
pium
18; 95
to
d
ol
with
er
on
nts
ion
*Special sy
Session‐B
Poster Ti
comparis
Poster Ty
Submissi
Primary A
Email: na
Addition
Yana Vor
Karina Gu
Alexandr
Ana Cast
Purpose:
glucose c
clinical, d
who have
(LM) alon
Methods
Nutrition
criteria c
and had
into two
antihype
they wer
compare
characte
alpha of
Results:
Just over
househo
ymbols that w
Board # ‐ 4‐0
itle: Charact
son of lifesty
ype: Evaluat
ion Category
Author: Nim
a720@myns
al Authors:
rontsova
utierrez
ra Perez
ejon
: Just over h
control in th
dietary, exer
e achieved g
ne to those o
s: A seconda
n Examinatio
onsisted of
a hemoglob
study group
rglycemic m
re not taking
ed sociodem
ristics across
5% were use
Most of the
r 50% of part
ld income le
2018ASProf
ere not spelled
041
terization of
yle managem
tive Study
y: Clinical To
ma Ataei; No
su.nova.edu
alf of patien
e past 15 ye
rcise, and oth
glycemic con
on antihype
ary database
on Survey (N
participants
in A1C < 6.5
ps: AHT, in w
medications a
g any antihyp
ographic, be
s study grou
ed to compa
study partic
ticipants we
ess than $45
SHPMidyfessional
d‐out per the g
adults with
ment versus
opics / Thera
va Southeas
nts with type
ears. Our stu
her behavio
ntrol and to f
rglycemic tr
e analysis stu
HANES) of c
20 years of
% at the tim
which the par
at the time o
perglycemic
ehavioral, di
ups. Chi‐squa
are these pa
cipants were
re female w
k per year. T
yearClinlPoster
guidelines wer
type 2 diabe
anti‐hyperg
apeutics
stern Univer
e 2 diabetes
dy purpose
ral characte
further com
eatment (AH
udy was cond
cohorts 2005
age and old
me of examin
rticipants re
of the interv
medication
etary, diabe
are statistica
rameters.
e non‐Hispan
with no more
The average
nicalMeAbstrac
re translated i
etes and con
glycemic trea
rsity College
in the Unite
was to evalu
ristics of pat
pare those o
HT).
ducted using
5‐06 through
der that were
nation. The p
eported to be
iew and LM
s at the time
etes related f
al test and In
nic whites an
e than a high
duration of
eetingcts
into unknown
ntrolled glyc
atment
of Pharmac
ed States hav
uate the soc
tients with t
on lifestyle m
g the Nation
h 2013‐14. T
e diagnosed
population w
e taking 1 or
group, whic
e of intervie
factors and c
ndependent
nd less than
h school deg
f diabetes wa
characters.
cemia: a
y;
ve achieved
ciodemograp
type 2 diabe
managemen
nal Health an
The inclusion
with type 2
was separate
r more
ch reported
w. We
clinical
t‐test with a
65 years old
ree and a
as about 8 y
phic,
tes
nt
nd
n
2 DM
ed
that
an
d.
years
*Special sy
while a li
eight cha
insurance
circumfe
58). Heal
were gre
The A1C
obese ca
blood pre
AHT 94, L
Conclusio
mostly ov
of lower
and were
were mo
role in gl
ymbols that w
ttle over 50
aracteristics
e, if they see
rence, and L
lth insurance
eater in the A
mean was h
tegory and t
essure and L
LM 105).
on: Patients
verweight o
socioeconom
e less likely t
ore favorable
ucose contr
2018ASProf
ere not spelled
% of particip
that were st
e one doctor
LDL. The me
e (92.0% AH
AHT group. T
higher in the
the AHT gro
LDL choleste
with type 2
r obese, had
mic status. T
to be seen b
e. It seems li
ol.
SHPMidyfessional
d‐out per the g
pants had be
tatistically d
r for diabete
an age of pa
T, 84.2% LM
The AHT gro
AHT group
up showed a
erol were low
2 diabetes an
d dietary and
Those on LM
y one docto
ke other une
yearClinlPoster
guidelines wer
een diagnose
ifferent acro
es, A1C level
articipants in
M) and prescr
up was mor
(AHT 5.9%, L
a higher ave
wer in the AH
nd controlled
d sedentary
M alone were
r for diabete
explored fac
nicalMeAbstrac
re translated i
ed within th
oss study gro
, BMI, diasto
n the AHT gr
ription cove
re likely to se
LM 5.8%). B
erage (AHT 3
HT group (D
d glucose lev
times that w
e less likely t
es, but the c
ctors such as
eetingcts
into unknown
e first 5 yea
oups (p<0.05
olic blood pr
roup was hig
rage (91.6%
ee one docto
oth groups h
33, LM 31). A
BP: AHT 67.
vels were un
were not hea
to have insur
cardiovascul
s genetics m
characters.
rs. We ident
5): Age, hea
ressure, wai
gher (AHT 61
% AHT, 89.1%
or for diabet
had a BMI in
Average dias
6, LM 71.9,
nexpectedly
althy, and w
rance covera
ar risk facto
may play a big
tified
lth
st
1, LM
% LM)
tes.
n the
tolic
LDL:
were
age
rs
g
*Special sy
Session‐B
Poster Ti
patients
Poster Ty
Submissi
Primary A
Email: pe
Addition
David Ha
Benjamin
Ralf Sigm
Huib Ker
Purpose:
efficaciou
therapy t
adults wi
measure
capacity
persisten
Methods
moderat
from poo
NCT0117
microgra
GraziaTin
tiotropiu
budeson
reported
good clin
institutio
related p
ymbols that w
Board # ‐ 4‐0
itle: Forced v
with moder
ype: Evaluat
ion Category
Author: Pet
eter.frith@b
al Authors:
alpin
n van Hecke
mund
stjens
: Tiotropium
us once‐dail
to inhaled co
ith symptom
s of lung fun
(FVC) and fo
nt asthma ac
s: Lung funct
e, or mild sy
oled MezzoT
72808/NCT0
ams, or place
nA‐asthma t
m 2.5 micro
ide/equivale
d here. All cli
nical practice
onal review b
procedure.
2018ASProf
ere not spelled
042
vital capacit
ate or mild s
tive Study
y: Clinical To
er Frith; Rep
bigpond.com
m, administer
y long‐acting
orticosteroid
matic asthma
nction in adu
orced expira
cross the mil
tion data fro
ymptomatic
TinA‐asthma
1172821, re
ebo, added o
rial (mild sym
ograms, 5 mi
ent]). Howev
nical researc
e guidelines
board. All pa
SHPMidyfessional
d‐out per the g
y response t
symptomatic
opics / Thera
patriation Ge
m
red by Respi
g muscarinic
ds (ICS) with
a. Here we e
ults with mil
tory volume
ld or modera
om three Pha
asthma wer
trials (mode
eplicate 24‐w
onto ICS [400
mptomatic a
icrograms, o
ver, data fro
ch presente
and approve
atients provi
yearClinlPoster
guidelines wer
to 2.5 micro
c asthma
apeutics
eneral Hospi
imat soft‐mi
c antagonist
or without
valuated the
d or modera
e in 1 second
ate disease s
ase III clinica
re compared
erate sympt
week trials, o
0–800micro
asthma: NCT
or placebo, a
om only 2.5 m
d in this abs
ed by the ap
ded written
nicalMeAbstrac
re translated i
gram tiotrop
ital;
st inhaler, is
t (LAMA) tha
additional c
e impact of t
ate asthma.
d (FEV1) resp
severities.
al trials invo
d in this post
omatic asth
once‐daily tio
ograms bude
T01316380,
added onto I
micrograms,
stract was co
ppropriate et
informed co
eetingcts
into unknown
pium Respim
s a well‐tole
at can be use
ontroller me
treatment o
We compar
ponse in pat
lving adult p
t hoc analysi
ma:
otropium 2.
esonide/equ
12‐week tria
CS [200–400
, the US‐app
onducted acc
thics commi
onsent prior
characters.
mat in adult
rated and
ed as an add
edications in
on different
ed forced vi
tients with
patients with
is. Data were
5 microgram
ivalent]) and
al, once‐dail
0 microgram
proved dose,
cording to IC
ittee or
r to any trial
d‐on
n
tal
h
e
ms, 5
d
y
ms
, are
CH
‐
*Special sy
Results:
placebo n
placebo n
significan
0.0001 fo
asthma),
asthma a
placebo,
provided
0.0001 fo
asthma)
asthma,
Conclusio
therapy i
greater in
ymbols that w
In patients w
n equals 523
n equals 155
nt improvem
or moderate
and in troug
and 110 mL [
the addition
d significant i
or moderate
and in troug
and 98 mL [9
on: In this d
improves FE
n those with
2018ASProf
ere not spelled
with modera
3) or mild as
5), tiotropium
ments in pea
e asthma and
gh FEV1 (18
[95 percent
n of tiotropiu
improvemen
e asthma and
gh FVC (107
95 percent C
ataset, addit
V1 and FVC
h moderate a
SHPMidyfessional
d‐out per the g
ate (1042 pa
thma (309 p
m (2.5 micro
k FEV1 (0‐3h
d 159 mL [95
0 mL [95 pe
CI: 38, 182],
um 2.5 micr
nts in peak F
d 106 mL [95
mL [95 perc
CI: 13, 183],
tion of 2.5 m
in patients w
asthma, pos
yearClinlPoster
guidelines wer
tients; tiotro
patients; tiot
ograms), com
h) (223 mL [9
5 percent CI
rcent CI: 138
, P equals 0.0
ograms in p
FVC (141 mL
5 percent CI
ent CI: 62, 1
P equals 0.0
microgram ti
with modera
sibly due to
nicalMeAbstrac
re translated i
opium 2.5 m
tropium 2.5
mpared with
95 percent C
: 88, 230], P
8, 221], P les
028 for mild
atients with
L [95 percent
: 23, 188], P
152], P less t
0236 for mild
otropium Re
ate or mild a
airway rem
eetingcts
into unknown
micrograms,
micrograms
h placebo, pr
CI: 185, 262]
less than 0.
ss than 0.00
d asthma). Co
moderate o
t CI: 98, 183]
equals 0.01
han 0.0001
d asthma).
espimat to m
asthma; the
odeling and
characters.
n equals 519
s, n equals 1
rovided
, P less than
0001 for mi
01 for mode
ompared wi
or mild asthm
], P less than
119 for mild
for moderat
maintenance
impact was
hyper‐inflat
9;
54;
n
ld
erate
th
ma
n
te
e
tion.
*Special sy
Session‐B
Poster Ti
via nebu
Poster Ty
Submissi
Primary A
Email: ja
Addition
Elizabeth
Purpose:
care prov
setting, A
are regul
be unrec
administ
requiring
alternativ
patients.
Methods
with resp
after (stu
groups w
Therapeu
the same
day, or sh
The stud
were con
adrenerg
and antic
schedule
subseque
ymbols that w
Board # ‐ 4‐0
itle: Therape
lizer: impac
ype: Evaluat
ion Category
Author: Jaso
son.glick@d
al Authors:
h Gonzalez
: With the in
viders are no
Albuterol an
larly ordered
cognized and
ered by resp
g pharmacist
ves results in
s: We condu
piratory med
udy group) th
were analyze
utic duplicat
e day, long a
hort acting a
y population
nverted to b
gic agonist (L
cholinergic in
ed to receive
ently conver
2018ASProf
ere not spelled
043
eutic interch
t on the inci
tive Study
y: Clinical To
on Glick; Dig
dignityhealth
ncreasing nu
ot always aw
d ipratropiu
d in addition
d uncorrecte
piratory ther
ts to therape
n fewer insta
cted a retro
dications in h
he initiation
ed over the s
tion was def
cting agents
agents of the
n included a
udesonide n
LABA) inhale
nhalers were
e ipratropium
rted to albut
SHPMidyfessional
d‐out per the g
hange protoc
idence of the
opics / Thera
gnity Health
h.org
mber and va
ware of the i
m nebulizat
n to home re
ed, particular
rapists and n
eutically inte
ances of the
ospective eva
hospitalized
of the thera
same calend
ined as; mul
s and short a
e same class
ll patients in
neb twice da
ers were con
e converted
m every six h
terol neb eve
yearClinlPoster
guidelines wer
col of orally
erapeutic du
apeutics
‐ St. Rose Do
ariety of res
ndividual me
tion orders fo
egimen inhal
rly when diff
nurses. This
erchange all
erapeutically
aluation of t
patients. T
apeutic inter
ar months to
ltiple long ac
acting agent
s administere
nitiated on re
aily, combina
nverted to bu
to ipratropi
hours, and ar
ery six hours
nicalMeAbstrac
re translated i
inhaled med
uplication
ominican;
piratory com
edication co
ound on num
lers. Therap
ferent treat
study aims
oral inhaler
y duplicate d
the incidence
The incidenc
rchange pro
o control for
cting agents
s of the sam
ed within th
espiratory m
ation steroid
udesonide/a
ium neb eve
rformoterol
s to be given
eetingcts
into unknown
dications to
mbination pr
omponents.
merous phys
peutic duplic
ment modal
to measure
rs to nebulize
doses being a
e of therape
ce before (co
otocol were c
r seasonal va
of the same
me class give
hree hours of
medications.
d/long‐acting
arformotero
ery six hours
neb, the arf
n with the ip
characters.
administrat
roducts, hea
In the inpat
sician order
cation may o
lities are
if a protoco
ed (neb)
administere
eutic duplica
ontrol group
compared.
ariation.
e class given
n on the sam
f each other
Steroid inha
g beta‐2
l neb twice d
. If a patient
formoterol w
pratropium.
ion
alth
tient
sets
often
ol
d to
tion
) and
Both
n on
me
r.
alers
daily,
t was
was
*Special sy
Primary e
the two g
Results:
study gro
reduced
therapeu
value les
the same
steroids g
albutero
Conclusio
therapeu
reduction
ymbols that w
endpoints w
groups per p
Patients on
oup, n equal
from 1.49 d
utic duplicati
s than 0.001
e day as albu
given on the
l inhalers giv
on: Simplific
utic intercha
n of therape
2018ASProf
ere not spelled
were the num
patient stay
respiratory
s 2777). The
oses to only
ion per day o
1). Statistica
uterol, tiotro
e same day,
ven within 3
cation and cl
nge of oral i
eutically dup
SHPMidyfessional
d‐out per the g
mber of thera
and per day
medications
e incidence o
y 0.17 doses
of therapy w
ally significan
opium given
ipratropium
hours of an
larification o
nhalers to n
plicate doses
yearClinlPoster
guidelines wer
apeutically d
of therapy.
s were ident
of therapeut
(p value less
was reduced
nt reduction
on the same
m doses given
albuterol n
of physician
nebulizer age
being admi
nicalMeAbstrac
re translated i
duplicate do
ified (contro
tic duplicatio
s than 0.001
from 0.41 d
ns were also
e day as ipra
n within 3 ho
eb.
orders by a
ents resulted
nistered to
eetingcts
into unknown
oses adminis
ol group, n e
on per patie
1). The incid
doses to only
found with
atropium, tw
ours of each
pharmacist,
d in a 98 per
patients.
characters.
stered betwe
equals 2402;
nt stay was
dence of
y 0.05 doses
LABA given
wo different
h other, and
facilitated b
rcent relativ
een
s (p
on
by a
e
*Special sy
Session‐B
Poster Ti
via nebu
Poster Ty
Submissi
Primary A
Email: ja
Addition
Elizabeth
Purpose:
length of
or discha
mishand
administ
incidence
the incid
oral inha
Methods
medicati
(control g
were com
seasonal
combina
budeson
ipratropi
hours, an
every six
charged t
available
the rema
was requ
ymbols that w
Board # ‐ 4‐0
itle: Therape
lizer: impac
ype: Evaluat
ion Category
Author: Jaso
son.glick@d
al Authors:
h Gonzalez
: Oral inhale
f therapy. Pa
arge, leading
led or mispla
ration are av
e of wasted
ence of was
lers to nebu
s: We condu
ons in hospi
group) and a
mpared. Bot
variation. S
tion steroid/
ide/arformo
um neb eve
nd arformote
hours to be
to patients w
e doses were
aining doses
uired from p
2018ASProf
ere not spelled
044
eutic interch
t on the inci
tive Study
y: Clinical To
on Glick; Dig
dignityhealth
rs often con
artially used
g to waste. A
aced, increa
vailable in u
doses and in
te of a proto
ulized (neb) a
cted a retro
talized patie
after (study
th groups we
Steroid inhal
/long‐acting
oterol neb tw
ry six hours.
erol neb, the
e given with
were compa
e considered
were in exc
harmacy du
SHPMidyfessional
d‐out per the g
hange protoc
idence and c
opics / Thera
gnity Health
h.org
ntain more d
multi‐dose
Additionally,
sing waste a
nit of use pa
nhalers per p
ocol requirin
alternatives.
ospective eva
ents. The in
group) the i
ere analyzed
lers were co
g beta‐2 adre
wice daily, an
. If a patient
e arformote
the ipratrop
ared to medi
d wasted. W
ess of a full
e to mishan
yearClinlPoster
guidelines wer
col of orally
cost of waste
apeutics
‐ St. Rose Do
oses than ne
inhalers are
replacemen
and costs. C
ackaging. T
patient and
ng pharmacis
.
aluation the
ncidence and
nitiation of t
d over the sa
onverted to b
energic agon
nd anticholin
was schedu
rol was subs
pium. The to
cation dose
When multipl
unused inha
dling or misp
nicalMeAbstrac
re translated i
inhaled med
ed doses
ominican;
eeded durin
discarded u
nt inhalers a
Conversely, d
his study aim
per treatme
sts to therap
incidence o
d cost of was
the therape
ame calenda
budesonide
nist (LABA) in
nergic inhale
uled to recei
sequently co
otal available
s charted in
e inhalers fo
aler, it was a
placement o
eetingcts
into unknown
dications to
ng the averag
upon order d
re often sen
doses for ne
ms to measu
ent day, and
peutically in
of wasted res
sted medica
utic intercha
ar months to
neb twice d
nhalers were
ers were con
ve ipratropi
onverted to
e doses from
the MAR. T
or a patient w
assumed a re
of the inhale
characters.
administrat
ge hospital
discontinuat
nt when they
bulizer
ure; the
the impact
terchange a
spiratory
ation before
ange protoc
o control for
aily,
e converted
nverted to
um every six
albuterol ne
m oral inhale
The remainin
were charge
eplacement
er. Primary
ion
ion
y are
on
ll
ol
r
to
x
eb
ers
ng
ed, if
dose
*Special sy
endpoint
patient, t
Results: T
909 oral
replacem
inhaler w
0.001). C
dollars p
from 17,5
Conclusio
statistica
spent on
ymbols that w
ts were: the
the cost asso
The control
inhalers cha
ment inhalers
waste was re
Cost to repla
er patient (p
528 to 4,480
on: A therap
ally significan
wasted inha
2018ASProf
ere not spelled
number of w
ociated with
and study g
arged to any
s due to mis
educed from
ace mishand
p value less t
0, and the co
peutic interc
nt reduction
alers.
SHPMidyfessional
d‐out per the g
wasted dose
h wasted dos
roups consis
group durin
handling or
20.6 dollars
led or mispl
than 0.001).
ost of waste
change proto
s in the num
yearClinlPoster
guidelines wer
es per patien
ses, and repl
sted of 2402
ng the study
misplacing t
s to 0.55 dol
aced inhaler
The numbe
was reduce
ocol of oral i
mber of inhal
nicalMeAbstrac
re translated i
nt, the numb
laced inhale
2 and 2777 p
period, 207
the original
lars per pati
rs was reduc
er of inhaler
ed from 49,4
nhalers to n
lers wasted,
eetingcts
into unknown
ber of replac
ers.
patients, res
7 (18 percent
inhaler. Co
ient (p value
ced from 6.2
r doses wast
71 dollars to
nebulized do
, doses wast
characters.
ced inhalers
pectively. O
t) were
ost of all ora
e less than
29 dollars to
ed was redu
o 1,534 dolla
oses resulted
ed, and doll
per
Of the
l
0.06
uced
ars.
d in
ars
*Special sy
Session‐B
Poster Ti
via nebu
Poster Ty
Submissi
Primary A
Email: ja
Addition
Elizabeth
Purpose:
oral inha
inhalers,
increase
the pote
respirato
pharmac
Methods
respirato
after (stu
groups w
inhalers w
adrenerg
and antic
schedule
subseque
Respirato
treatmen
dose(s) w
administ
endpoint
ymbols that w
Board # ‐ 4‐0
itle: Therape
lizer: effect
ype: Evaluat
ion Category
Author: Jaso
son.glick@d
al Authors:
h Gonzalez
: Acquisition
lers to nebu
while respir
in respirato
ntial cost sav
ory therapist
cists to thera
s: We condu
ory medicatio
udy group) th
were analyze
were conver
gic agonist (L
cholinergic in
ed to receive
ently conver
ory therapist
nt. Nebulized
were conside
ered within
ts were tota
2018ASProf
ere not spelled
045
eutic interch
on workloa
tive Study
y: Clinical To
on Glick; Dig
dignityhealth
n costs for re
ulized doses.
ratory thera
ry therapist
vings benefi
ts and regist
apeutically in
cted a retro
ons to hospi
he initiation
ed over the s
rted to bude
LABA) inhale
nhalers were
e ipratropium
rted to albut
ts may admi
d doses docu
ered part of
one hour of
l respiratory
SHPMidyfessional
d‐out per the g
hange protoc
d of respirat
opics / Thera
gnity Health
h.org
espiratory m
Many hosp
pists are req
workload co
it. This study
ered nurses
nterchange a
ospective eva
italized patie
of the thera
same calend
esonide neb
ers were con
e converted
m every six h
terol neb eve
inister multi
umented as
the same pa
f each other
y treatments
yearClinlPoster
guidelines wer
col of orally
tory therapis
apeutics
‐ St. Rose Do
ediations m
pitals utilize
quired to adm
ould make th
y aims to me
after implem
all oral inhal
aluation of s
ents. The w
apeutic inter
ar months to
twice daily,
nverted to bu
to ipratropi
hours, and ar
ery six hours
ple medicat
administere
atient treatm
were also co
s per patient
nicalMeAbstrac
re translated i
inhaled med
sts and regis
ominican;
ay be decre
registered n
minister neb
he protocol
easure the c
menting a p
ers to nebul
staff workloa
workload bef
rchange pro
o control for
combinatio
udesonide/a
ium neb eve
rformoterol
s to be given
tions to a pat
ed within on
ment. Likew
onsidered o
t, and treatm
eetingcts
into unknown
dications to
stered nurse
ased by tran
nurses to adm
bulized dose
impractical,
changes in w
rotocol requ
lized (neb) a
ad utilized to
fore (contro
otocol was co
r seasonal va
on steroid/lo
arformotero
ery six hours
neb, the arf
n with the ip
tient during
ne hour of th
wise, any inha
one treatmen
ments per pa
characters.
administrat
es
nsitioning fro
minister
es. A percei
thus negati
workload for
uiring
alternatives.
o administer
l group) and
ompared. B
ariation. Ste
ng‐acting be
l neb twice d
. If a patient
formoterol w
pratropium.
a single pat
he previous
aler doses
nt. The prim
atient day. T
ion
om
ved
ng
r
d
oth
eroid
eta‐2
daily,
t was
was
tient
ary
The
*Special sy
secondar
per patie
Results: T
decrease
Respirato
while nu
found de
0.057), th
equals 0.
0.001). T
the study
Conclusio
a signific
number o
days pati
not proh
ymbols that w
ry endpoints
ent day, or tr
The control
e in treatmen
ory therapist
rsing treatm
ecreases in to
he number o
.58), and the
The number
y group, 3.4
on: A therap
ant increase
of treatmen
ients receive
ibitive to pro
2018ASProf
ere not spelled
s were treatm
reatments a
and study g
nts per patie
t treatments
ments per day
otal number
of respirator
e number of
of treatmen
(p value equ
peutic proto
e to combine
ts per patien
ed respirator
otocol imple
SHPMidyfessional
d‐out per the g
ments admi
dministered
roups consis
ent day was
s per day inc
y decreased
r of treatme
ry therapy tr
nursing trea
nt days per p
uals 0.11).
col converti
ed respirator
nt may parti
ry treatmen
ementation.
yearClinlPoster
guidelines wer
nistered by
d by nurses p
sted of 2402
found, 2.03
creased from
from 0.18 t
nts per patie
reatments pe
atments per
patient was
ng oral inha
ry/nursing st
ally be expla
ts. Respirat
nicalMeAbstrac
re translated i
respiratory t
per patient a
2 and 2777 p
compared t
m 1.86 to 1.9
to 0.02 (p va
ent, 11.62 ve
er patient, 1
r patient, 0.8
higher in the
lers to nebu
taff workloa
ained by a d
tory therapis
eetingcts
into unknown
therapists p
and per patie
patients resp
to 2.00 (p va
98 (p value le
lue less than
ersus 10.53
10.81 to 10.4
81 to 0.03 (p
e control gro
ulized doses
ad. The decl
ecrease in t
st workload
characters.
er patient a
ent day.
pectively. A s
alue equals 0
ess than 0.0
n 0.001). W
(p value equ
49 (p value
p value less t
oup, 3.7, ver
did not resu
ine in the
he number o
concerns we
nd
slight
0.45).
01),
We
uals
than
rsus
ult in
of
ere
*Special sy
Session‐B
Poster Ti
via nebu
Poster Ty
Submissi
Primary A
Email: ja
Addition
Elizabeth
Purpose:
hospital
discharge
misplace
available
protocol
(neb) alte
Methods
two thre
thru Febr
interchan
variation
steroid/lo
budeson
ipratropi
hours, an
every six
medicati
purchase
control fo
therapy.
ymbols that w
Board # ‐ 4‐0
itle: Therape
lizer: financ
ype: Evaluat
ion Category
Author: Jaso
son.glick@d
al Authors:
h Gonzalez
: Oral multi‐
length of the
e, leading to
d, increasing
e in unit of us
requiring ph
ernatives.
s: This was a
e month per
ruary 2018,
nge protoco
n. Steroid inh
ong‐acting b
ide/arformo
um neb eve
nd arformote
hours to be
ons docume
e price for al
or price fluc
2018ASProf
ere not spelled
046
eutic interch
cial impact
tive Study
y: Clinical To
on Glick; Dig
dignityhealth
dose inhaler
erapy. Partia
o waste. Add
g waste and
se packaging
harmacists t
a retrospecti
riods, from D
before (cont
l. The same
halers were
beta‐2 adren
oterol neb tw
ry six hours.
erol neb, the
e given with
ented on the
l items was
tuations. Pr
SHPMidyfessional
d‐out per the g
hange protoc
opics / Thera
gnity Health
h.org
rs often cont
ally used inh
ditionally, rep
costs. Conv
g. This stud
o therapeut
ve study of p
December 2
trol) and aft
e calendar m
converted t
nergic agonis
wice daily, an
. If a patient
e arformote
the ipratrop
e medication
adjusted to
rimary endp
yearClinlPoster
guidelines wer
col of orally
apeutics
‐ St. Rose Do
tain more do
halers are dis
placement in
versely, dose
dy aims to m
tically interch
patients rec
016 thru Feb
ter (study) th
onths were
to budesonid
st (LABA) inh
nd anticholin
was schedu
rol was subs
pium. The us
n administra
the current
oints were c
nicalMeAbstrac
re translated i
inhaled med
ominican;
oses than ne
scarded upo
nhalers whe
es for nebul
measure the f
hange all ora
eiving respir
bruary 2017
he initiation
selected to
de neb twice
halers were
nergic inhale
uled to recei
sequently co
sage and cos
tion record
acquisition
cost per pati
eetingcts
into unknown
dications to
eeded durin
on order disc
en they are m
izer adminis
financial imp
al inhalers to
ratory medic
7 and from D
of the thera
control for s
e daily, comb
converted to
ers were con
ve ipratropi
onverted to
st of all resp
were compa
cost as of M
ient and cost
characters.
administrat
g the averag
continuation
mishandled,
stration are
pact of a
o nebulized
cations durin
December 20
apeutic
seasonal
bination
o
nverted to
um every six
albuterol ne
piratory
ared. The
May 2018 to
t per day of
ion
ge
n or
or
ng
017
x
eb
*Special sy
Results: T
Respirato
value les
dollars to
was 58,0
Conclusio
resulted
ymbols that w
The control
ory medicati
s than 0.001
o 11 dollars
000 dollars.
on: A therap
in a significa
2018ASProf
ere not spelled
and study g
ion cost per
1). Similarly,
(p value less
peutic interc
ant cost redu
SHPMidyfessional
d‐out per the g
roups consis
treatment d
, respiratory
s than 0.001
change proto
uction in res
yearClinlPoster
guidelines wer
sted of 2402
day was redu
y medication
). Net savin
ocol convert
spiratory me
nicalMeAbstrac
re translated i
2 and 2777 p
uced from 9
n cost per pa
gs over the t
ting oral inha
edication.
eetingcts
into unknown
patients, res
.18 dollars t
atient was re
three month
alers to nebu
characters.
pectively.
to 2.47 dolla
educed from
h study perio
ulized doses
rs (p
m 32
od
s
*Special sy
Session‐B
Poster Ti
hospitaliz
Poster Ty
Submissi
Primary A
Email: br
Addition
Jessica Th
Matt Kee
Purpose:
patients
factors, i
evaluate
patients
Methods
patients
July 30, 2
July 1, 20
ketoacido
on demo
consults.
concomit
blood glu
patients
square a
Results: T
demogra
patients
documen
ymbols that w
Board # ‐ 4‐0
itle: Effect o
zed patients
ype: Evaluat
ion Category
Author: Bra
rad.hein@th
al Authors:
horburn
eler
: Insulin pum
are admitte
ncluding pat
the effect o
who continu
s: This institu
who were a
2017. This ‘P
012 to June 3
osis, admitte
ographics, do
Data was a
tant subcuta
ucose data w
with blood g
nd student t
The POST gr
aphics and b
in the POST
ntation of th
2018ASProf
ere not spelled
047
f an insulin p
s
tive Study
y: Clinical To
d Hein; Univ
hechristhosp
mps are incre
d to the hos
tient illness
of an insulin
ued them du
utional revie
dmitted and
POST’ orders
30, 2013. Pa
ed to the int
ocumentatio
lso collected
aneous insul
was compare
glucose valu
t test as app
roup had 100
lood glucose
group had c
he presence
SHPMidyfessional
d‐out per the g
pump order
opics / Thera
versity of Cin
pital.com
easingly utili
spital, the ris
and instituti
pump order
uring their ad
ew board‐ap
d continued
et group wa
atients were
tensive care
on of cognitiv
d on the adm
in as well as
ed against PR
es during th
ropriate.
0 patients an
e control wa
cognitive ass
of the insuli
yearClinlPoster
guidelines wer
set on the sa
apeutics
ncinnati;
ized in patie
sk of complic
ional unfam
rset on the s
dmission.
pproved retro
on an insulin
as compared
excluded if
unit or adm
ve assessme
ministration
s reasons for
RE data as w
he POST time
nd the PRE g
s similar bet
sessments p
n pump on t
nicalMeAbstrac
re translated i
afety and ef
nts with dia
cations is su
iliarity. The
afety and ef
ospective ch
n pump betw
d to a ‘PRE’ g
they were a
mitted to obs
ents, pump p
(both purpo
r pump inter
well as a hosp
e period. Dat
group had 86
tween the g
erformed by
the day of ad
eetingcts
into unknown
fficacy of ins
betes. When
bstantial du
purpose of t
fficacy of ins
hart review e
ween Augus
group previo
admitted in d
stetrics. Data
presence an
oseful and ac
rruptions. F
pital control
ta was analy
6 patients. B
roups. 100 p
y a nurse ev
dmission an
characters.
ulin pumps
n insulin pum
ue to many
this study w
sulin pumps
evaluated
st 1, 2016 an
ously evaluat
diabetic
a was collect
d endocrine
ccidental) of
inally, POST
l group of al
yzed with ch
Baseline
percent of
ery shift, ha
d had an
in
mp
as to
for
nd
ted
ted
e
f
T
l
hi
d
*Special sy
endocrin
respectiv
administ
0.05). Pu
to proced
control im
percent.
70 mg/dL
values gr
11.4 perc
Conclusio
insulin pu
pump pa
compare
data incl
control b
versus th
ymbols that w
nology consu
vely (p < 0.05
ration decre
mp interrup
dures and te
mproved in t
There was a
L) by 1.3 per
reater than 2
cent, p < 0.0
on: The imp
umps that a
tients impro
ed to non‐pu
uded patien
between bas
hose that com
2018ASProf
ere not spelled
ult. For the P
5 for all). The
eased substa
ptions increa
emporary co
the POST gro
also a slight d
rcent. Finally
200mg/dL as
05).
lementation
re continued
oved slightly
mp patients
ts who did n
seline insulin
me off.
SHPMidyfessional
d‐out per the g
PRE group, th
e rate of acc
antially from
ased in the P
onversion to
oup, with a
decrease in
y, 40.6 perce
s compared
n of an insuli
d in hospital
y from severa
s. There wer
not have dia
n pump patie
yearClinlPoster
guidelines wer
his was 83 pe
cidental conc
m 33 percent
POST group (
a basal‐bolu
decrease in
hypoglycem
ent of patien
to 29.2 perc
in pump ord
ized patient
al years ago,
re limitations
betes. A futu
ents who sta
nicalMeAbstrac
re translated i
ercent, 91 p
comitant su
of patients
(20 to 35 pe
us‐correction
values great
mia (defined
nts in the PO
cent for the
derset greatl
ts. Blood glu
, but was no
s to the non
ure study is
ay on the pu
eetingcts
into unknown
percent and 8
bcutaneous
down to 0 p
rcent, p < 0.
nal regimen
ter than 300
as a blood g
OST group ha
hospital con
y improved
cose contro
ot as tightly c
‐pump popu
planned to e
mp during t
characters.
86 percent,
insulin
percent (p <
05), mostly
. Blood gluco
0 mg/dL by 4
glucose less t
ad blood glu
ntrol (differe
the safety o
l for insulin
controlled w
ulation as th
evaluate glu
he hospital
due
ose
4
than
cose
ence
of
when
e
ucose
stay
*Special sy
Session‐B
Poster Ti
patients
formulat
Poster Ty
Submissi
Primary A
Email: ke
Addition
Thomas L
Purpose:
developm
(CABP). T
required
macrolid
this analy
that anti
antibiotic
Methods
was cons
omadacy
patients
Index (CC
by PSI cla
azithrom
ISPOR 22
dollars/d
study (Ko
varied fro
ymbols that w
Board # ‐ 4‐0
itle: Cost‐sav
treated with
ions, compa
ype: Evaluat
ion Category
Author: Ken
en.lapensee@
al Authors:
Lodise
: Omadacycl
ment for the
The objective
for omadac
e therapy fr
ysis was bas
biotics with
cs with IV‐on
s: A decision
structed to c
ycline treatm
of Pneumon
CI). Both PSI
ass and CCI s
mycin were o
2nd Annual I
day) for a ho
ozma CM, et
om 0 to 1,00
2018ASProf
ere not spelled
048
ving opportu
h omadacycl
ared to ceftr
tive Study
y: Clinical To
nneth LaPens
@paratekph
ine is an ora
e treatment o
e of the stud
cycline treatm
rom the hosp
ed on nume
IV and PO fo
nly formulat
n‐analytic, co
compare cos
ment (IV in h
nia Severity I
and CCI wer
score among
btained from
nternationa
spitalized pa
t al. J Med Ec
00 US dollars
SHPMidyfessional
d‐out per the g
unities amon
line, an amin
iaxone and m
opics / Thera
see; Paratek
harma.com
al (PO) and in
of patients w
dy was to ide
ment to con
pital system
erous studies
ormulations
tions like cef
ost‐minimiza
sts associate
ospital and d
Index (PSI) C
re derived fr
g hospitalize
m a previous
l Meeting. 2
atient with C
con. 2010;13
s/day.
yearClinlPoster
guidelines wer
ng hospitaliz
nomethylcyc
macrolide th
apeutics
k Pharmaceu
ntravenous
with commu
entify the ho
fer cost savi
and manage
s across vari
can shorten
ftriaxone.
ation model
d with ceftr
discharge ho
Class III or IV
rom ICD‐9 di
ed CABP pati
s MedAssets
2017; Boston
CABP was ob
3:719‐727).
nicalMeAbstrac
re translated i
zed commun
cline antibio
herapy
uticals, Inc.;
(IV) once‐da
unity‐acquire
ospital lengt
ings relative
ed care pers
ous infectio
n hospital sta
from the ho
iaxone plus
ome on PO)
V, stratified b
iagnosis cod
ents who re
s database st
n, MA). Daily
btained from
The daily co
eetingcts
into unknown
nity‐acquired
tic with IV a
aily antibioti
ed bacterial
th of stay (LO
e to ceftriaxo
spective. The
on types whic
ay relative t
ospital system
a macrolide
among hosp
by Charlson C
des. Inputs fo
eceived ceftr
tudy (LaPen
y hospital co
m a previousl
osts for omad
characters.
d pneumoni
nd oral
c that is und
pneumonia
OS) reductio
one plus a
e rationale f
ch demonst
o treatment
m perspectiv
versus
pitalized CAB
Comorbidity
or hospital L
riaxone and
see K, et al.
osts (2,273 U
ly published
dacycline we
a
der
n
for
rated
t with
ve
BP
y
LOS
US
ere
*Special sy
Results:
and IV w
perspect
of omada
2‐day ho
Conclusio
increasin
impact o
plus a ma
discharge
relative t
days with
the clinic
ymbols that w
In the MedA
ere 5 and 6
ive, omadac
acycline was
spital LOS re
on: As hospi
ngly tied to q
f shifting CA
acrolide) to
e on the equ
to ceftriaxon
h omadacycl
cal or observ
2018ASProf
ere not spelled
Assets Hospi
days, respec
cycline was c
s less than o
eduction if it
ital reimburs
quality, effici
ABP patients
inpatient IV
uivalent PO o
ne plus a ma
line IV‐to‐PO
vational trial
SHPMidyfessional
d‐out per the g
tal Database
ctively. From
cost saving w
r equal to 29
ts acquisition
sement and
iency, and co
from the cu
omadacycli
omadacyclin
crolide inpa
O transition t
arena.
yearClinlPoster
guidelines wer
e, the media
m the hospita
with a 1‐day
96 US dollar
n cost was le
antimicrobi
ost of care, t
urrent inpati
ne monothe
ne. Cost savin
tient treatm
treatment. T
nicalMeAbstrac
re translated i
an LOS for CA
al system an
hospital LOS
rs. Omadacyc
ess than or e
al stewardsh
the present
ent standard
erapy treatm
ngs may be
ment if hospi
These findin
eetingcts
into unknown
ABP patients
nd managed
S reduction
cline was co
equal to 584
hip program
study exam
d of treatme
ment with ea
realized wit
tal LOS is re
gs need to b
characters.
s in PSI Class
care
if the daily c
ost saving wi
4 US dollars.
ms are both
ined the cos
ent (ceftriax
arly hospital
h omadacyc
duced by 1 t
be validated
s III
cost
th a
st
one
cline
to 2
in
*Special sy
Session‐B
Poster Ti
acquired
moxiflox
Poster Ty
Submissi
Primary A
Email: ke
Addition
Thomas L
Rohit Mis
Kate You
Purpose:
developm
bacterial
treated p
patients
tetracycl
ratio, 0.6
The follo
omadacy
Methods
budget im
patients
and boar
cost), and
CDI was 3
adverse e
600 US d
were und
ymbols that w
Board # ‐ 4‐0
itle: Cost‐sav
pneumonia
acin: budget
ype: Evaluat
ion Category
Author: Ken
en.lapensee@
al Authors:
Lodise
stry
ng
: Omadacycl
ment as once
pneumonia
patients dev
developed C
ine antibioti
62; 95 percen
wing analys
ycline or mox
s: The econo
mpact of rep
with 5 days
rd fees, drug
d CDI advers
34,157 US d
events were
ollars/day. S
dertaken to
2018ASProf
ere not spelled
049
vings analys
a patients at
t impact mo
tive Study
y: Clinical To
nneth LaPens
@paratekph
ine is the fir
e‐daily intra
a (CABP). In a
eloped Clost
CDI. This find
ics are assoc
nt CI, 0.47‐0
is explored t
xifloxacin.
omic model w
placing the c
of moxifloxa
g acquisition
se event trea
ollars (Zhang
e considered
Scenarios wi
capture inci
SHPMidyfessional
d‐out per the g
is with use o
risk of Clost
del findings
opics / Thera
see; Paratek
harma.com
rst aminome
venous and
a phase 3 CA
tridium diffic
ding was con
ciated with lo
0.81; P less th
the manage
was develop
current strat
acin to 5 day
costs (moxi
atment; the
g S, et al. BM
. Omadacyc
ith incremen
dence uncer
yearClinlPoster
guidelines wer
of omadacyc
tridium diffic
apeutics
k Pharmaceu
ethylcycline a
oral monoth
ABP study, 2
cile infection
nsistent with
ower odds o
han .001) (Ta
ment of hos
ped using a h
egy for the t
ys of omadac
floxacin: 46
average cos
MC Infect Dis
line acquisit
ntal CDI incid
rtainty. The
nicalMeAbstrac
re translated i
cline among
cile infection
uticals, Inc.;
antibiotic in
herapy for c
percent (8 p
n (CDI), whil
h a recent m
of CDI relativ
ariq R, et al.
spitalized CA
hospital pers
treatment o
cycline. Cost
US dollars/d
st‐per‐case a
s. 2016;16(1
tion cost was
dence of mo
assumption
eetingcts
into unknown
hospitalized
n being treat
late‐stage c
community‐a
patients) of
e no omada
meta‐analysis
ve to fluoroq
CID. 2018;6
ABP patients
spective to e
of 100 hospit
ts included h
day, wholesa
attributed to
1):447). No a
s varied betw
oxifloxacin (0
was that tre
characters.
d community
ted with
clinical
acquired
moxifloxacin
acycline‐trea
s showing th
quinolones (
66(4):514‐22
treated wit
estimate the
talized CABP
hospital roo
ale acquisiti
o hospital‐on
additional
ween 300 an
0 to 12 perce
eatment wit
y‐
n‐
ated
hat
odds
2).
h
e
P
m
on
nset
nd
ent)
th
*Special sy
omadacy
potentia
Results:
cost of re
132,884
incidence
cost savi
1.5 perce
dollars/d
Conclusio
with oma
the incre
conferre
associate
approxim
required
ymbols that w
ycline has a l
l to avoid CD
For every 10
eductions in
US dollars (c
e for moxiflo
ng, the incid
ent to 8.1 pe
day).
on: The mod
adacycline c
emental incre
d cost saving
ed with hosp
mately 2 to 8
to identify C
2018ASProf
ere not spelled
ower prope
DI events lea
00 patients t
CDI rate wit
cost saving)
oxacin (0 to
dence of CDI
ercent depen
del illustrate
ompared to
ease in CDI r
gs. Use of om
pitalized CAB
8 cases of mo
CABP patien
SHPMidyfessional
d‐out per the g
nsity to indu
ading to a re
treated with
th omadacyc
depending o
12 percent).
in moxifloxa
nding on the
ed the econo
moxifloxaci
rates with m
madacycline
BP patients t
oxifloxacin‐a
ts at greates
yearClinlPoster
guidelines wer
uce CDI relat
duction in o
omadacycli
cline ranged
on the acqui
. Analysis sh
acin‐treated
e acquisition
omic impact
n. As part of
moxifloxacin
e has the pot
treated with
associated C
st risk of mo
nicalMeAbstrac
re translated i
tive to moxif
overall hospit
ine versus m
d between 52
isition cost o
owed that fo
d patients wo
n cost of oma
associated w
f the analysi
compared to
tential to red
moxifloxaci
DI per 100 p
oxifloxacin‐a
eetingcts
into unknown
floxacin and
tal costs.
moxifloxacin,
2,000 US do
of omadacyc
or omadacy
ould need to
adacycline (3
with reducti
is, the mode
o omadacyc
duce the eco
in if it can av
patients. Fut
ssociated CD
characters.
d has the
the increme
ollars and
cline and CD
cline to beco
o range betw
300 to 600 U
ons in CDI ra
el demonstra
cline that
onomic burd
void
ture studies
DI.
ental
I
ome
ween
US
ates
ates
den
are
*Special sy
Session‐B
Poster Ti
Poster Ty
Submissi
Primary A
Email: m
Addition
Sarah Au
Daniel Hi
Purpose:
surgical p
undergoi
reduction
feeding a
analysis w
common
related v
Methods
patients
men and
types of
(CV); (4)
surgery (
(1) positi
Patients
severe he
disorder,
data wer
as counts
exact tes
the Dwas
ymbols that w
Board # ‐ 4‐0
itle: Gastroin
ype: Evaluat
ion Category
Author: Ma
alesker@cre
al Authors:
urit
illeman
: Gastrointes
procedures.
ing abdomin
n in or absen
and impairs
was to evalu
major type
variables and
s: The institu
undergoing
women age
surgery inclu
total knee o
ONC). GI tra
ve bowel so
with diabeti
epatic dysfu
, and inflam
re reported a
s and propo
st or the Kru
ss, Steel, Crit
2018ASProf
ere not spelled
050
ntestinal tra
tive Study
y: Clinical To
rk Malesker
eighton.edu
stinal (GI) tra
GI dysfuncti
nal surgery. T
nce of GI pe
oral drug an
uate time req
s of surgerie
d their assoc
utional revie
select surge
ed 19 to 80 y
uded: (1) op
or hip arthro
act function
ounds; (2) pa
ic gastropare
nction (Child
mmatory bow
as medians a
rtions. Data
skal‐Wallis t
tchlow‐Flign
SHPMidyfessional
d‐out per the g
ct recovery
opics / Thera
; Creighton U
act complica
ion following
The most fre
ristalsis. Imp
nd nutrient a
quired for th
es. The seco
ciation with G
w board app
eries at an ac
years were i
en laparoto
plasty (TKNA
(GITF) was d
assage of flat
esis, end‐sta
d‐Pugh class
wel disease w
and interqua
were stratif
test based on
ner multiple
yearClinlPoster
guidelines wer
in patients u
apeutics
University;
ations are co
g surgery ha
equent post‐
pairment of
absorption. T
he return of
ondary objec
GI tract reco
proved this r
cademic me
ncluded in e
my (OL); (2)
A); (5) spinal
defined as th
tus or stool;
age renal dis
s C) or a histo
were exclude
artile ranges
fied by surgi
n data type;
comparison
nicalMeAbstrac
re translated i
undergoing s
ommon in pa
as been mos
‐operative G
GI peristalsi
The primary
normal GI fu
ctive was to
overy.
retrospectiv
dical center
each of six su
laparoscopi
l surgery (SP
he time to m
and (3) tole
sease (creati
ory of GI mo
ed from data
s while categ
cal type and
post‐hoc te
n analysis. A
eetingcts
into unknown
selected sur
atients unde
t widely stu
GI complicati
s delays resu
objective of
unction follo
evaluate pat
ve medical re
. One hundr
urgical proce
ic (LAP); (3)
PIN); and (6)
meet the follo
erance of a s
nine clearan
otility, malab
a collection.
gorical data
d compared
esting was co
negative bin
characters.
rgical proced
ergoing majo
died in patie
ions include
umption of
f this explora
owing severa
tient and su
ecord review
red consecut
edures. The
cardiothora
oncological
owing criter
solid diet.
nce < 15 ml/
bsorption
. Continuous
were report
using Fisher
ompleted wi
nomial
dures
or
ents
a
atory
al
rgery
w of
tive
cic
ia:
min),
s
ted
r’s
ith
*Special sy
regressio
recovery
Results: T
body ma
types (p <
0.001) an
CV (41 ho
p < 0.001
0.001), 1
psycholo
and TKNA
(RR = 0.9
duration
(RR = 1.0
Conclusio
surgical p
times. GI
common
clinical as
types of
ymbols that w
on model wa
time.
The 600 sub
ss index of 2
< 0.001). ON
nd TKNA (18
ours) and OL
1, respective
0 mg/day in
ogical disorde
A GITF time
94; p < 0.05),
(RR = 1.39;
08; p = 0.007
on: This data
procedures.
TF times we
among thes
ssessment is
surgery.
2018ASProf
ere not spelled
as selected t
bjects had a m
27.5 kg/m2.
NC had the lo
hours; p < 0
L (35 hours)
ely). A 6‐hou
ncreased mo
er (RR = 1.22
was lower in
, respectivel
p = 0.021).
7) and morph
a identifies t
The surgica
ere independ
se were dura
s needed to
SHPMidyfessional
d‐out per the g
o predict va
median age
GITF times
ongest medi
0.001) were
were not dif
ur increased
rphine equiv
2; p = 0.015)
n males (RR
y. SPIN GITF
ONC GITF w
hine equivale
the duration
l procedures
dently assoc
ation of intu
determine w
yearClinlPoster
guidelines wer
riables signi
of 55.0 year
were signific
ian GITF tim
associated w
fferent (p =
duration of
valent dose
) were assoc
= 0.87; p = 0
F time was as
was significan
ent dose (R
n of time for
s were assoc
iated with d
ubation and
when GI fun
nicalMeAbstrac
re translated i
ficantly asso
rs, were 49.8
cantly differ
e (72 hours)
with the sho
0.170), but
f intubation (
(RR = 1.06;
ciated with in
0.023) and m
ssociated wi
ntly higher fo
R = 1.24; p =
the return o
ciated with s
different clin
morphine e
ction norma
eetingcts
into unknown
ociated with
8% male, an
rent across t
) while LAP (
ortest GITF ti
longer than
(Rate Ratio (
p = 0.034), a
ncreased OL
morphine eq
ith increased
or increased
= 0.012).
of GITF acro
significantly
nical variable
quivalent do
alizes followi
characters.
GI tract
d had a med
the 6 surgica
(19 hours; p
ime. GITF tim
SPIN (22 ho
(RR) = 1.12;
and
L GITF time.
quivalent do
d intubation
d intubation
ss six differe
different GI
es, but most
ose. Careful
ing different
dian
al
<
me in
ours;
p <
CV
ose
n
time
ent
TF
t
*Special sy
Session‐B
Poster Ti
impacted
Poster Ty
Submissi
Primary A
Email: da
Addition
Jonathan
Peter An
Joseph C
Robert G
Purpose:
morbidit
(HRQoL)
investiga
Methods
survey of
between
AD that c
dermato
severitie
moderat
symptom
(BSA), an
patients
range 0‐3
patients
Results:
disease s
ymbols that w
Board # ‐ 4‐0
itle: Adult pa
d by their co
ype: Evaluat
ion Category
Author: Dan
aniela.myers
al Authors:
n Silverberg
derson
appelleri
Gerber
: Atopic derm
y, negatively
of patients,
ate the impa
s: Data were
f physicians
November
could be mil
logy speciali
s, including
e, severe) w
ms, presence
nd all compo
provided da
30) and Wor
provided inf
284 patients
severity asse
2018ASProf
ere not spelled
051
atients expe
ondition: resu
tive Study
y: Clinical To
niela Myers;
matitis (AD),
y impacting
their caregi
ct of AD on
e drawn from
and their ad
2014 and Fe
d at the tim
ists (n=202)
current pres
when current
e and numbe
onents of the
ata about the
rk Productivi
formed cons
s (44.7% ma
essment of m
SHPMidyfessional
d‐out per the g
eriencing mil
ults from a r
opics / Thera
Pfizer Inc;
m
, regardless
the physical
vers, and th
patients exp
m the Adelph
dult AD patie
ebruary 2015
e of data co
completed i
scription AD
t treatment w
er of acute e
e Eczema Are
eir condition
ity and Activ
sent prior to
le; mean age
mild and 554
yearClinlPoster
guidelines wer
d or modera
real‐world st
apeutics
of severity, c
l and menta
eir families.
periencing m
hi AD Diseas
ents (age ≥18
5. All patient
llection. Par
information
therapies, c
was initiated
pisodes (flar
ea and Seve
n, including D
vity Index (W
o completing
e 41.0 years
4 patients (45
nicalMeAbstrac
re translated i
ate atopic de
tudy in the U
can be assoc
l health and
The current
mild or mode
se Specific Pr
8 years) con
ts had a hist
rticipating pr
for 994 pati
clinical AD se
d and at the
res), regions
rity Index (E
Dermatology
WPAI; range 0
g self‐reporte
s) with physi
5.7% male; m
eetingcts
into unknown
ermatitis are
United State
ciated with s
health‐relat
t study was c
erate disease
rogramme, a
nducted in th
tory of mode
rimary care p
ients with A
everity asses
present visi
s affected, b
EASI). In add
y Life Qualit
0‐100) meas
ed question
cian‐reporte
mean age 39
characters.
e significant
es
significant
ted quality o
conducted t
e.
a cross‐secti
he United St
erate to seve
physicians a
D of all
ssment (mild
it, day‐to‐da
ody surface
ition, 623
ty Index (DLQ
sures. All
naires.
ed current
9.5 years) w
ly
of life
to
onal
ates
ere
nd
d,
ay
area
QI;
ith
*Special sy
moderat
BSA, 11%
physician
patients
itch (87%
were mo
acute ep
currently
therapies
result in
control c
was 4.7 f
19.9.
Conclusio
symptom
similar to
physician
disease c
ymbols that w
e AD were a
% and 15%; m
n‐reported c
experienced
% and 96%),
ost common.
isodes with
y experiencin
s on average
overall seve
ould be ach
for mild and
on: Adult AD
ms, HRQoL im
o moderate A
n and patien
control in ad
2018ASProf
ere not spelled
analyzed. Ch
mean EASI sc
chronic AD, 8
d a mean of
daily dry ski
. 80% and 68
or without d
ng an episod
e, respective
erity rating im
ieved in 56%
6.8 for mod
D patients ex
mpairment, a
AD, but in so
t data, mult
ults experie
SHPMidyfessional
d‐out per the g
aracteristics
cores, 5.4 an
81% and 84%
3.5 and 4.7 s
n (93% and 9
8% of mild a
day‐to‐day s
de. Mild and
ely. For 70%
mproving, co
% of modera
derate patien
xperiencing
and impact o
ome cases, w
iple unmet n
ncing mild a
yearClinlPoster
guidelines wer
s for mild an
nd 8.8; head
%. Outside o
symptoms d
94%), and d
nd moderat
ymptoms, w
moderate p
of moderate
onsistent wit
te patients (
nts, and corr
clinically mi
on daily life.
was worse fo
needs remai
and moderat
nicalMeAbstrac
re translated i
d moderate
and neck le
of an acute e
day‐to‐day, r
aily cracking
te patients, r
with 31% and
patients wer
e patients, c
th the physic
(and 34% of
responding W
ld AD experi
. The burden
or moderate
in, and more
te AD.
eetingcts
into unknown
e AD, respect
esions, 36% a
episode, mild
respectively,
g/raw skin (4
respectively,
d 47% patien
re receiving 2
current thera
cian’s belief
mild patien
WPAI scores
ienced poor
n of mild AD
e patients. B
e can be don
characters.
tively: mean
and 38%;
d and moder
, of which da
44% and 67%
, experience
nts, respecti
2.4 and 2.6 A
apies did no
f that better
ts). Mean D
s were 13.3 a
ly controlled
was genera
ased on
ne to improv
n
rate
aily
%)
ed
vely,
AD
t
LQI
and
d
lly
ve
*Special sy
Session‐B
Poster Ti
pharmac
Poster Ty
Submissi
Primary A
Email: ch
Addition
Li‐Wei Ch
Jessica C
Purpose:
States is
literature
considera
usefulne
instructio
to provid
Methods
people w
curriculu
viewing a
explorati
online su
Students
their con
Whitney
confiden
Results:
increased
ymbols that w
Board # ‐ 4‐0
itle: Prelimin
cy curriculum
ype: Descrip
ion Category
Author: Che
heyenne.new
al Authors:
hen
onklin
: The numbe
increasing. F
e on instruct
ations is lack
ss of the ind
onal method
de competen
s: Course ma
who are tran
m. The mate
and discussio
ion exercise,
urvey was co
s were also a
nfidence to p
U Test was
ce.
Student con
d significant
2018ASProf
ere not spelled
052
nary evaluat
m
ptive Report
y: Clinical To
eyenne New
wsome@wsu
er of transge
For many, ph
tional metho
king. The pu
dividual com
ds and also t
nt care to ind
aterial encom
sgender was
erials includ
on of a story
, a panel of p
onducted to
asked to rate
provide com
performed t
nfidence to p
ly following
SHPMidyfessional
d‐out per the g
tion of addit
opics / Thera
some; Wash
u.edu
ender and ge
harmacothe
ods about th
rpose of this
ponents of t
he effect of
dividuals wh
mpassing cu
s added to a
ed a pre‐cla
y about a pa
people who
assess stude
e how helpfu
petent care
to calculate
provide com
the interven
yearClinlPoster
guidelines wer
ion of transg
apeutics
hington State
ender divers
erapy is a par
his patient po
s study is to
the curriculu
this instruct
ho are transg
ltural, empa
third‐year c
ss video and
tient who is
identify as t
ents’ confide
ul each comp
to individua
statistical sig
petent care
ntion. The m
nicalMeAbstrac
re translated i
gender patie
e University
e patients se
rt of their ge
opulation’s s
evaluate stu
um to identif
tion on chan
gender.
athetic and m
course in a d
d handout, in
transgende
transgender,
ence before
ponent of in
als who are t
gnificance fo
to patients
median confi
eetingcts
into unknown
ent care into
College of P
eeking care
ender transit
social and m
udents’ perc
fy the most
nging studen
medical cons
doctorate of
n‐class jeopa
er, a student
, and patien
and after th
nstruction wa
transgender
or the chang
who are tra
dence level
characters.
o a doctorate
Pharmacy;
in the Unite
tion. Curren
medical
ceived
effective
nts’ confiden
siderations f
f pharmacy
ardy game,
gender iden
t cases. An
he interventi
as in changin
r. A Mann‐
ge in student
nsgender
among stud
e of
ed
nt
nce
for
ntity
ion.
ng
t
dents
*Special sy
increased
patient p
Conclusio
students
reported
pharmac
ymbols that w
d from 4/10
panel as the
on: Inclusion
’ perceived c
d as the most
cy school cur
2018ASProf
ere not spelled
to 7/10 (p<0
most helpfu
n of materia
confidence i
t helpful com
rriculums.
SHPMidyfessional
d‐out per the g
0.01). Stude
ul componen
ls on transge
in caring for
mponent and
yearClinlPoster
guidelines wer
ents rated th
nts of instruc
ender pharm
transgende
d could be c
nicalMeAbstrac
re translated i
he pre‐class v
ction.
macy care sh
r patients. T
considered fo
eetingcts
into unknown
video, jeopa
howed impro
The panel dis
or incorpora
characters.
ardy game, a
ovement in
scussion was
ation in othe
and
s
er
*Special sy
Session‐B
Poster Ti
chronic k
Poster Ty
Submissi
Primary A
Email: sw
Addition
Alain Rom
Paula Alv
David Bu
Purpose:
especiall
result in
CKD seve
treatmen
safety of
filtration
patirome
Methods
withdraw
randomiz
in AMETH
of 15 to 5
it was po
59) at ba
and grea
or more
to 16.8 g
hoc analy
potassium
ymbols that w
Board # ‐ 4‐0
itle: Effect o
kidney disea
ype: Evaluat
ion Category
Author: Stev
woods@rely
al Authors:
mero
varez
shinsky
: Hyperkalem
y those on in
arrhythmias
erity. Patirom
nt of HK in th
patiromer i
rate (eGFR)
er.
s: OPAL‐HK (
wal), single‐b
zed, open‐la
HYST‐DN, ha
59 mL per m
ossible for pa
seline. Entry
ter than 5.0
RAASi at bas
(OPAL‐HK) a
ysis, efficacy
m during the
2018ASProf
ere not spelled
053
f patiromer
se on RAAS
tive Study
y: Clinical To
ven Woods;
psa.com
mia (HK) is co
nhibitors of
s and death.
mer is a sodi
he U.S. and E
n patients a
) at baseline,
(NEJM 2015)
blind study o
abel study of
ad Type 2 dia
min per 1.73
atients to ha
y serum pota
to less than
seline and d
and 8.4 to 3
y data were
e first 4 wee
SHPMidyfessional
d‐out per the g
on serum po
inhibitors: re
opics / Thera
Relypsa;
ommon in p
the renin‐an
Normalizing
um‐free, no
E.U. In this a
cross CKD st
, enrolled in
) was a 12‐w
of 243 patien
f 304 patient
abetes melli
meters squa
ave eGFR by
assium (mEq
n 6.0 (AMETH
uring the stu
3.6 g (AMET
pooled to de
eks of patirom
yearClinlPoster
guidelines wer
otassium in
esults from O
apeutics
patients with
ngiotensin‐a
g serum pota
onabsorbed p
analysis, we
tages 3 to 5,
two previou
week, 2‐part
nts; AMETHY
ts. Eligible p
tus. For stud
ared by local
central lab t
q per L) rang
HYST‐DN). A
udies. Patiro
THYST‐DN), g
etermine the
mer treatme
nicalMeAbstrac
re translated i
hyperkalem
OPAL‐HK an
h chronic kid
ldosterone s
assium level
potassium b
evaluated th
based on es
usly publishe
(Part A, trea
YST‐DN (JAM
atients were
dy entry, pat
l lab at scree
that was less
ged from 5.1
All patients w
omer total da
given divided
e change fro
ent (primary
eetingcts
into unknown
mic patients w
nd AMETHYS
ney disease
system (RAA
ls is importa
binder indica
he pooled ef
stimated glo
ed clinical tr
atment; Part
MA, 2015) wa
e on one or
tients had to
ening; due to
s than 15 (o
1 to less than
were on stab
aily starting
d twice daily
om baseline
y endpoint in
characters.
with severe
ST‐DN
(CKD),
ASi), and ma
ant, regardle
ated for the
fficacy and
omerular
rials of
t B, randomi
as a 52‐wee
more RAASi
o have an eG
o study desi
r greater tha
n 6.5 (OPAL‐
ble doses of o
doses were
y. In this pos
in serum
n both studie
y
ess of
ized
k,
and,
GFR
gns,
an
‐HK)
one
8.4
st
es)
*Special sy
by baseli
to less th
Results: T
30, and 3
and 66 (9
5.36 (0.4
1.73 met
first 4 we
4, mean
0.92) (eG
(eGFR 30
per L at w
patients
predomi
Conclusio
suggests
stage. Th
data in th
ymbols that w
ne central la
han 30, and 3
This analysis
30 or greater
9) years; per
42) mEq per
ters squared
eeks of treat
(95 percent
GFR less than
0 or greater)
week 4 was g
discontinue
nantly mild o
on: Serum p
that patirom
he reduction
he patirome
2018ASProf
ere not spelled
ab eGFR (mL
30 or greate
s included 21
r, respective
rcent male 5
L; and mean
d, respective
tment were
Cl) serum p
n 15), ‐0.89 (
. The propor
greater than
d patiromer
or moderate
potassium re
mer was effe
in potassium
r clinical tria
SHPMidyfessional
d‐out per the g
L per min pe
er).
1, 167, and 3
ely. Baseline
7, 64, and 5
n (SD) eGFR 1
ly. Mean (SD
17.6 (8.1) g,
otassium (m
(‐0.98, ‐0.81
rtion of patie
n 82 percent
r due to relat
e in severity.
eductions we
ective in trea
m and tolera
al program.
yearClinlPoster
guidelines wer
r 1.73 mete
347 patients
characterist
9; mean (SD
11.7 (2.2), 22
D) total daily
20.1 (8.0) g
mEq per L) ch
) (eGFR 15 t
ents with se
t across eGFR
ted AEs acro
.
ere consisten
ating hyperk
ability were
nicalMeAbstrac
re translated i
rs squared)
s with eGFR
tics were me
D) potassium
2.9 (4.2), an
y prescribed
g, and 19.6 (7
hange from b
o less than 3
erum potassi
R subgroups
oss subgroup
nt across eG
kalemia in pa
consistent w
eetingcts
into unknown
subgroups (
less than 15
ean (SD) age
m 5.62 (0.46)
d 48.2 (14.0
patiromer d
7.8) g, respe
baseline was
30), and ‐0.8
ium 3.8 to le
s. Two to 5 p
ps. Gastroint
GFR subgroup
atients regar
with previou
characters.
less than 15
5, 15 to less t
e 62 (10), 65
, 5.50 (0.41)
0) mL per mi
doses during
ectively. By w
s ‐1.28 (‐1.64
80 (‐0.85, ‐0.
ess than 5.1
percent of
testinal AEs
ps, which
rdless of CKD
usly publishe
5, 15
than
(10),
), and
n per
g the
week
4, ‐
.76)
mEq
were
D
ed
*Special sy
Session‐B
Poster Ti
medical w
Poster Ty
Submissi
Primary A
Email: da
Addition
Sara Hay
Aml Ham
Purpose:
mainly d
Benzodia
second m
alcohol (C
BDZs dos
provide s
hospitaliz
Methods
Internal M
of pre‐id
pharmac
utilizatio
the avera
cumulati
complica
concomit
Results: A
recurren
duration
ymbols that w
Board # ‐ 4‐0
itle: Benzod
ward
ype: Evaluat
ion Category
Author: Dan
alkhiyami@h
al Authors:
der Ahmed
mad
: Benzodiaze
iazepam, ch
azepines (BD
major genera
CIWA‐Ar) fo
sing approac
safe and effe
zation.
s: Medicatio
Medicine wa
entified pati
cy research c
n data and p
age duration
ve BDZs dos
ations, the oc
tant disease
A total of 78
t hospitaliza
of benzodia
2018ASProf
ere not spelled
054
iazepines sa
tive Study
y: Drug Infor
nia Alkhiyam
hamad.qa
epines (BDZs
lordiazepox
DZs) are not w
al hospital in
r the sympto
ch is not stan
ective medic
n use evalua
ards betwee
ient electron
committee. W
patients’ dem
n of BDZs tre
se, use of adj
ccurrence of
e conditions
8 admissions
ations which
azepine was
SHPMidyfessional
d‐out per the g
fety and eff
rmation/Dru
mi; Hamad M
s) are the firs
ide, lorazepa
well utilized
n Qatar. Clini
om‐triggere
ndardized. A
cation therap
ation (MUE)
en May 2016
nic health re
We used des
mographics
eatment for
junctive me
f serious adv
secondary to
s, 38 patient
made the to
four days, a
yearClinlPoster
guidelines wer
ectiveness in
ug Use Evalu
edical Corpo
st line thera
am, and oth
in the mana
ical institute
d approach
Assessing BD
py thus redu
of BDZs in A
6 to Septemb
ecords by tw
scriptive stat
using Micro
AW. And the
dications fo
verse outcom
o alcohol an
s met the in
otal included
and the mea
nicalMeAbstrac
re translated i
n alcohol wi
uation
oration;
py for alcoh
ers. We hyp
agement of
es withdrawa
using BDZs i
DZs prescribin
ucing duratio
AW patients
ber 2017. A
wo pharmacis
tistics to ana
soft Excel. T
e secondary
r AW manag
mes of benz
nd nurses’ as
nclusion crite
d admission
n cumulativ
eetingcts
into unknown
thdrawal ma
hol withdraw
pothesized th
alcohol with
al assessme
is not applie
ng practices
on and cost
admitted w
retrospectiv
sts approved
alyze and pr
The primary
y outcomes w
gement, the
odiazepine t
ssessment d
eria. Three p
s number is
e BDZs dose
characters.
anagement
wal managem
hat
hdrawal in th
nt scale for
ed, and fixed
will help to
of
with AW to th
ve chart revi
d by the hos
resent BDZs
outcome wa
were mean
incidence o
treatment,
ocumentatio
patients had
42. The ave
e was 71 mg.
in
ment,
he
d
he
ew
pital
as
of AW
on.
erage
. A
*Special sy
total of 1
haloperid
requiring
tremens.
of deep s
(74%) ha
detected
Conclusio
indicate t
protocol
overall B
ymbols that w
11 patients (
dol. The inci
g the use of r
. BDZs adver
sedation tha
d at least on
d AW sympto
on: BDZs use
that there is
to optimize
DZs safety a
2018ASProf
ere not spelled
26%) require
dence of AW
restrains, ps
rse outcome
at required h
ne appropria
oms.
e led to cons
s a need for
AW manage
and effective
SHPMidyfessional
d‐out per the g
ed the use o
W complicati
sychiatry con
es found in o
holding the s
ate nurse do
siderable im
standardizin
ement. A lar
eness.
yearClinlPoster
guidelines wer
of adjunctive
ions experie
nsultation, o
one case of n
scheduled do
ocumentatio
mprovement
ng BDZs pres
rger cohort s
nicalMeAbstrac
re translated i
e medication
nced by the
one‐to‐one n
non‐arousab
ose of BDZs.
n indicating
in AW patie
scribing and
study is need
eetingcts
into unknown
ns like pheny
patients ran
nursing and d
ble sedation
Most of the
BDZs admin
ents. Results
administrat
ded to static
characters.
ytoin and
nged from
delirium
and four cas
e admission
nistration du
of this revie
tion using a
cally assess
ses
ue to
ew
*Special sy
Session‐B
Poster Ti
diabetic
Poster Ty
Submissi
Primary A
Email: dm
Addition
Purpose:
measure
both adh
diabetic
Methods
1.GMAS
Participa
were use
and frequ
deviation
of level o
square te
indicates
domains
status wi
logistic re
indicatin
regressio
to achiev
statistica
ymbols that w
Board # ‐ 4‐0
itle: The imp
patients in D
ype: Descrip
ion Category
Author: Dhf
malshayban@
al Authors:
: The purpos
the HRQoL
herence and
patients.
s: A cross‐se
to identify p
nts were rec
ed to describ
uencies wer
ns or inter qu
of medicatio
est where EQ
s no problem
but not wor
ith problems
egression w
g ‘perfect he
on where the
ve normally d
ally significan
2018ASProf
ere not spelled
055
pact of adhe
Dmmam Sau
ptive Report
y: Drug Infor
fer Alshayba
@iau.edu.sa
se of this abs
of diabetic p
HRQol and a
ctional stud
patients adhe
cruited at KF
be demograp
e used for th
uartile range
n adherence
Q‐5D health
m in domains
rse than mo
s worse than
here the res
ealth’ (1.000
e dependent
distributed r
nt. All analys
SHPMidyfessional
d‐out per the g
rence to ant
udi Arabia
rmation/Dru
n; university
a
stract is to m
patients; eva
assess the im
y using two
erence to an
FUH and PHC
phic and dise
he categoric
es were calc
e on HRQoL
states were
s of EQ‐5D; s
derate healt
n moderate
sponse varia
0) or ‘imperf
t variable, EQ
residuals. A
ses were car
yearClinlPoster
guidelines wer
tidiabetic me
ug Use Evalu
y of Imam Ab
measure the
aluate the im
mpact of adh
o types of a v
ntidiabetic d
Cs from Octo
ease charact
cal variables,
ulated for th
was assesse
e divided into
slight/mode
th in any dom
health in som
ble (EQ‐5D i
fect health’ (
Q‐5D index w
p‐value less
ried out usin
nicalMeAbstrac
re translated i
edications o
uation
bdulRahman
level of adh
mpact of soc
herence to a
validated str
drugs , .2.EQ5
ober to Jun 2
teristics of th
, while mean
he continuo
ed using thre
o three cate
rate indicate
mains; sever
me domains
index) was m
(<1.000). 3).
was transfor
than 0.05 w
ng SPSS Stat
eetingcts
into unknown
on the Quailt
n bin faisl;
herence for d
ciodemograp
anti‐diabetic
ructured que
5D to measu
2018. Descr
he patients.
ns or median
us variables
ee approach
egories (perf
es problems
re/unable in
s). 2). Using
modelled as
Using a mu
rmed using a
was consider
tistics 24.0.
characters.
ty of life (Qo
diabetic pati
phic factors o
c on HRQoL o
estionnaire:
ure the QoL
iptive statist
Percentage
ns and stand
. The associa
es: 1). Using
ect health
s in some
ndicates a he
a multiple
a binary var
ltiple linear
a cubic funct
red as
oL) of
ients;
on
of
The
tics
s
dard
ation
g chi‐
ealth
riable
tion
*Special sy
Results: A
more tha
income o
comorbid
multiple
more, an
19%, 21%
(81/189)
maintain
51%, 50%
depressio
not respo
half of pa
moderat
Conclusio
medicati
adherenc
adherenc
•The find
blood glu
general a
ymbols that w
Among the 1
an 50% had e
of 5000sar o
dity conditio
anti‐diabeti
nd 10% had p
% and 23% o
participants
ned the low m
%, 43% and 3
on, usual act
ond to some
articipants (9
e health in a
on: Patients
ons. Age is o
ce level. In c
ce.
dings indicat
ucose level a
a weak corre
2018ASProf
ere not spelled
189 particip
education of
r more. Rega
ons, 61% we
c medication
previously ad
of patients ha
s had mainta
medication a
31% were ag
tivities, mob
e domains. o
95/184) repo
any domains
found to be
one of the so
contrast, ran
te that gend
are strongly
elation betw
SHPMidyfessional
d‐out per the g
ants, half of
f high schoo
arding the c
re on oral an
ns. 48% of p
dmitted to a
ad maintain
ained high m
adherence t
greed as hav
bility, and pa
one‐fifth of p
orted as hav
s (called ‘slig
e generally h
ocio‐demogr
ndom blood
er, monthly
associated w
ween medica
yearClinlPoster
guidelines wer
f them were
ol or more, a
linical chara
nti‐diabetic m
participants h
a hospital du
ed the low m
medication a
o anti‐diabe
ving no prob
ain or discom
patients had
ving problem
ght‐moderat
highly adhere
raphic factor
glucose was
income, num
with the perf
tion adhere
nicalMeAbstrac
re translated i
male, 79% w
nd more tha
acteristics of
medications
had random
ue to diabete
medication a
adherence, a
etic drugs. Am
lem in term
mfort respec
no problem
ms in some d
e health sta
e towards th
rs which wa
s inversely p
mber of com
fect health s
nce and HRQ
eetingcts
into unknown
were older t
an half of th
f the particip
s only and 70
m glucose lev
es. The resu
adherence. I
and only 22%
mong the re
s of self‐care
tively. Five p
m in any dom
domains but
te’)
heir antidiab
s directly pr
proportionat
morbidities, a
state of diab
QoL
characters.
than 50 year
em had mon
pants, 78% h
0% were on
el of 200 or
lts show tha
In overall, 43
% (41/189) h
espondents,
e, anxiety or
participants
mains of EQ‐5
not worse t
betic
oportionate
te to the leve
and random
betic patient
rs,
nthly
ad
at
3%
had
88%,
r
did
5D
than
e with
el of
m
s. In
*Special sy
Session‐B
Poster Ti
infection
Poster Ty
Submissi
Primary A
Email: ke
Addition
Alyssa Ho
Tasha St.
Finnella M
Sara Bass
Purpose:
preventio
inapprop
mortality
The obje
of HA‐CD
Methods
patients,
retrospec
included
hospitaliz
or missin
admissio
the numb
hospitaliz
number o
analysis f
with anti
ymbols that w
Board # ‐ 4‐0
itle: Proton
s in a comm
ype: Evaluat
ion Category
Author: Kell
elly.bach@ac
al Authors:
opsicker
. John
Morgan
si
: The use of
on and treat
priate usage
y as well as d
ctive of this
DI when PPIs
s: The Institu
18 years of
ctively revie
in the study
zation. Excl
ng, patients w
ns for re‐ad
ber of patien
zation as we
of HA‐CDI ca
for the HA‐C
ibiotic classif
2018ASProf
ere not spelled
056
pump inhibi
munity teach
tive Study
y: Drug Infor
ly Bach; Alba
cphs.edu
Proton Pum
tment of acid
and long‐te
developmen
study was t
s were initiat
utional Revie
age and old
wed for the
y must have
usion criteri
with docume
mitted patie
nts with app
ell as indicat
ases when P
CDI cases det
fication.
SHPMidyfessional
d‐out per the g
tors utilizati
ing hospital
rmation/Dru
any College o
mp Inhibitors
d‐related ga
rm use of PP
t of hospital
o assess the
ted at a com
ew Board ha
der, who wer
time‐period
been admin
a consisted
entation of P
ents during t
propriate doc
ion at discha
PIs were ord
termined th
yearClinlPoster
guidelines wer
ion and hosp
ug Use Evalu
of Pharmacy
(PPIs) in clin
astrointestin
PIs has been
l acquired Cl
e appropriate
mmunity teac
as approved
re discharge
d of June 1, 2
nistered at le
of patients w
PPIs on the h
the study pe
cumented in
arge if applic
dered during
e percentag
nicalMeAbstrac
re translated i
pital acquire
uation
y and Health
nical practic
al diseases.
n associated
lostridium d
e utilization
ching hospit
this study.
ed under the
2017 to Sept
east one dos
with a home
home medic
eriod. The p
ndications fo
cable. The s
g hospitaliza
ge of patient
eetingcts
into unknown
ed Clostridiu
h Sciences;
e has greatly
Although h
with increas
difficile infec
rate of PPIs
al.
Medical reco
e hospitalist
tember 30, 2
se of a PPI du
e medication
cation list, o
rimary outco
or PPIs initia
secondary ou
ation. Additi
s ordered an
characters.
m difficile
y modified t
ighly efficac
sed hospital
tion (HA‐CD
and occurre
ords of adul
service were
2017. Patie
uring their
n list in‐prog
r subsequen
omes includ
ted during
utcome was
ionally, a sub
ntibiotics alo
the
cious,
I).
ence
t
e
nts
gress
nt
ed
the
bset
ong
*Special sy
Results: A
service, 2
outcome
documen
patients
continua
indicatio
documen
there we
concomit
Conclusio
an appro
clear asso
over‐pre
ymbols that w
After review
223 patients
e of PPIs that
nted indicati
had no docu
tion of PPIs
ns, 9 patient
nted indicati
ere three cas
tant antibiot
on: This stud
opriate indica
ociation can
scribing of P
2018ASProf
ere not spelled
wing 2,028 m
s were review
t were initiat
ions, 65 pati
umented ind
at discharge
ts with inapp
ions, and 3 p
ses of HA‐CD
tics, which in
dy observed
ation docum
n be made be
PPIs in a com
SHPMidyfessional
d‐out per the g
medical recor
wed for prim
ted during h
ents had ina
dications for
e, there were
propriate do
patients with
DI during the
ncluded fluo
that 62.3%
mented or ha
etween PPI u
mmunity teac
yearClinlPoster
guidelines wer
rds of patien
mary and sec
hospitalizatio
appropriate
PPIs. For th
e 43 patient
ocumented i
h no discharg
e study perio
oroquinolone
of patients w
ad missing d
use and HA‐
ching hospit
nicalMeAbstrac
re translated i
nts discharge
condary outc
on, 84 patien
documente
he other prim
ts with appro
ndications,
ge note. Fo
od. All three
es and ceph
who met inc
ocumentatio
‐CDI. In conc
al.
eetingcts
into unknown
ed under the
comes. For
nts had appr
d indication
mary outcom
opriate docu
36 patients
r the second
e cases of HA
alosporins.
clusion crite
on. Based o
clusion, this
characters.
e hospitalist
the primary
ropriate
s, and 74
me of
umented
with no
dary outcom
A‐CDI receive
ria did not h
on this study
study illustr
y
me,
ed
have
y, no
rates
*Special sy
Session‐B
Poster Ti
commun
Poster Ty
Submissi
Primary A
Email: cb
Addition
Ashmi Ph
Mini Varg
Rani Mad
Navin Ph
Purpose:
medicati
National
utilizes a
heparin,
the use o
Methods
record (E
continuo
the emer
demogra
coagulat
thrombo
outcome
achieved
adherenc
Results: T
hours an
ymbols that w
Board # ‐ 4‐0
itle: Retrosp
ity hospital
ype: Evaluat
ion Category
Author: Crys
boafo@hhsn
al Authors:
hilips
ghese
dduri
ilips
: The Institut
on. Correspo
Patient Safe
standardize
with an opt
of the hepar
s: This is a re
EHR). Patient
ous heparin i
rgency depa
aphics, weigh
ion panels. T
oplastin time
es were perc
d 2 consecut
ce to protoc
The study in
d mean time
2018ASProf
ere not spelled
057
pective evalu
(RETRO‐HEP
tive Study
y: Drug Infor
stal Boafo; H
nj.org
te of Safe M
ondingly, Th
ety Goals. To
ed protocol f
ion for phys
in protocol.
etrospective
ts were inclu
nfusion betw
rtment were
ht, past med
The primary
e (PTT) and m
ent of patie
ive therapeu
ol.
ncluded 285
e to 2 conse
SHPMidyfessional
d‐out per the g
uation and tr
P)
rmation/Dru
Hunterdon M
Medication Pr
he Joint Com
o help impro
for ordering,
ician‐directe
chart review
uded if they
ween July 20
e excluded f
dical history,
outcome w
mean time to
nts who ach
utic PTTs, do
patients. Me
cutive thera
yearClinlPoster
guidelines wer
racing of hep
ug Use Evalu
Medical Cent
ractices reco
mmission em
ove the safet
, monitoring
ed dosing. Th
w conducted
were at leas
017 and Janu
from this stu
heparin dos
as mean tim
o 2 consecut
hieved thera
ocumented a
ean time to
apeutic PTTs
nicalMeAbstrac
re translated i
parin infusio
uation
ter;
ognizes hepa
phasizes ant
ty of anticoa
g, and dose‐a
he purpose
d using the h
st 18 years o
uary 2018. H
udy. Data co
se and indic
me to first th
tive therape
peutic PTT, p
adverse blee
first therape
was 28 (SD=
eetingcts
into unknown
on protocol u
arin as a high
ticoagulation
agulant use,
adjusting int
of this study
hospital’s ele
of age and w
Heparin orde
llected inclu
ation, and h
erapeutic pa
eutic PTTs. Se
percent of p
eding events
eutic PTT wa
=17.04) hou
characters.
use in a
h‐alert
n safety in it
our instituti
travenous (I
y is to evalua
ectronic hea
were on a
ers received
udes patient
hematology a
artial
econdary
patients who
s, and overal
as 17 (SD=14
rs. Among t
ts
ion
V)
ate
alth
in
and
o
ll
4.12)
he
*Special sy
orders ev
(48/285)
(226/285
of patien
adherenc
non‐adhe
approxim
Conclusio
further e
to re‐eva
ymbols that w
valuated, 83
utilized phy
5) of patients
nts. Adverse
ce to protoc
erence was
mately 7.29 (
on: The stud
evaluation. B
aluate the pr
2018ASProf
ere not spelled
3 percent (23
ysician‐direc
s. Two conse
bleeding ev
ol was obse
“PTT every 6
(SD=3.03) ho
dy identified
Based on the
rotocol
SHPMidyfessional
d‐out per the g
36/285) utiliz
ted (PD) dos
ecutive ther
ents were d
rved in 11 p
6 hours,” ho
ours.
areas of no
e study resul
yearClinlPoster
guidelines wer
zed weight‐b
sing. Therap
apeutic PTTs
ocumented
ercent (31/2
wever avera
n‐adherence
ts, a multidi
nicalMeAbstrac
re translated i
based (WB)
eutic PTT wa
s were achie
in 1 percent
285) of patie
age time bet
e to the prot
sciplinary co
eetingcts
into unknown
dosing and
as achieved
eved in 57 p
t (4/285) of
ents. The gre
tween PTTs w
tocol, which
ommittee ha
characters.
17 percent
in 79 percen
ercent (168/
patients. Ov
eatest area o
was
h may warra
as been form
nt
/285)
verall
of
nt
med
*Special sy
Session‐B
Poster Ti
Poster Ty
Submissi
Primary A
Email: ja
Addition
Mohama
Diana Ma
Purpose:
overpres
of acute
associate
appropri
The stud
Steroidal
Methods
Lebanese
admitted
Steroidal
total num
endpoint
indicatio
The seco
NSAIDs. D
medicati
approved
frequenc
practices
ymbols that w
Board # ‐ 4‐0
itle: Evaluati
ype: Descrip
ion Category
Author: Jass
ssembourji@
al Authors:
ad Mahdi Far
alaeb
: Proton pum
scribed in dif
and chronic
ed with incre
ate use of P
y also target
l drugs Anti‐
s: We condu
e university
d to the follo
l drugs (NSA
mber of 115
t was evalua
n, and durat
ondary outco
Data collecte
ons, and risk
d the study d
cy/percentag
s.
2018ASProf
ere not spelled
058
ion of the pr
ptive Report
y: Drug Infor
sem Bourji; C
@gmail.com
rhat
mp inhibitors
fferent settin
ulcers. PPIs
eased risk of
PIs as a prop
ts to evaluat
Inflammato
cted a retro
hospitals fro
owing hospit
AIDs). Exclusi
patients me
ation of the a
tion in refere
ome was to e
ed included
k factors. Th
design. Data
ge and mean
SHPMidyfessional
d‐out per the g
rophylactic u
rmation/Dru
Community;
s (PPIs) are e
ngs. They ar
are often ut
f ulcer devel
phylactic me
te whether P
ry Drugs (NS
ospective mu
om October
tals and were
on criteria w
et the inclusi
appropriate
ence to Ame
evaluate the
dose and du
e Institution
a was analyze
n ± standard
yearClinlPoster
guidelines wer
use of proto
ug Use Evalu
;
effective for
e the main s
tilized with d
opment. The
easure in diff
PPIs are ade
SAIDs).
ulticenter ob
2017 to May
e prescribed
were patient
ion criteria a
use of prop
erican Societ
e appropriate
uration of PP
nal Review B
ed by the SP
d deviation (S
nicalMeAbstrac
re translated i
n pump inhi
uation
r various dise
stay of thera
drugs or dise
e aim of the
ferent popu
quately pres
bservational
y 2018. Inclu
d either prop
ts on PPI as a
and enrolled
hylactic PPI
ty of Health
e use of PPI
PI use, previ
Board (IRB) o
PSS version 2
SD) to illustr
eetingcts
into unknown
ibitors in ho
eases but ar
apy both in t
ease states t
e study was t
lation and d
scribed for p
study in five
usion criteria
phylactic PPI
a treatment
d in the study
regimen in t
System Pha
in patients p
ous medical
of the involv
22.0 and pre
rate current
characters.
spital setting
e tremendo
the managem
that are
to evaluate t
disease state
patients on N
e different
a were patie
I or Non‐
modality. A
y. The prima
terms of dos
rmacist (ASH
prescribed
l history, pre
ed centers
esented as
prescribing
gs
usly
ment
the
es.
Non‐
ents
A
ary
se,
HP).
esent
*Special sy
Results: A
patients
gender (5
vs 40.2%
Pantopra
several fa
risk facto
anticoag
represen
(73.2%, P
statistica
Conclusio
Patients
and main
targeted
recomme
process a
awarene
ymbols that w
Among 127
were given
54.6% femal
) respective
azole (39.2%
actors includ
ors criteria, i
ulation and
nted with hig
P=0.905) res
ally significan
on: This stud
were increa
nly with high
to all hospit
endations fo
across all pa
ss.
2018ASProf
ere not spelled
patients we
PPI as proph
les, 45.4% m
ly. Omepraz
%) followed b
ding if the ad
n addition th
administrati
gh percentag
pectively. Bu
nt P value <0
dy highlights
singly treate
her doses. Th
tals in differ
or PPI proper
tients throu
SHPMidyfessional
d‐out per the g
re screened
hylaxis meas
males) as wel
zole was the
by others (17
dministratio
he dose and
ion of antibi
ge as mislead
ut the result
0.01.
s the gaps ev
ed for longer
his raises the
ent medical
r utilization.
gh intervent
yearClinlPoster
guidelines wer
for appropr
sures, Patien
ll as co‐morb
most prescr
7.5%). We as
n for prophy
duration fo
otics were n
ding indicati
ts overall sho
vident in ove
r duration th
e need for co
services to o
The role of
tions that sh
nicalMeAbstrac
re translated i
riate use for
nts demogra
bidities and
ribed PPI (43
ssessed app
ylaxis as indi
or prophylax
not statistica
ion for PPI u
owed inapp
erprescribing
han recomm
ontinuous e
orient them
clinical phar
hould be imp
eetingcts
into unknown
r proton pum
phics were s
urban vs. ru
3.3%) follow
ropriateness
icated accor
is used, alth
ally significan
use (63.9 %,
ropriateness
g PPIs in Leb
mended by cl
ducational p
m about the i
rmacist may
plemented t
characters.
mp inhibitors
similar includ
ural area (59
wed by
s based on
rding to ASH
ough
nt, but
P=0.061) an
s with
banese hosp
linical guide
programs
nternationa
y facilitate th
o raise the
s, 97
ding
.8%
P
d
pitals.
lines
l
his
*Special sy
Session‐B
Poster Ti
kidney di
Poster Ty
Submissi
Primary A
Email: ba
Addition
Lama Fad
Rayane S
Purpose:
outweigh
effective
significan
higher ris
pharmac
was carri
identify t
Methods
carried o
Teaching
inclusion
was miss
impairme
square a
associate
Results:
the samp
The mea
prescribe
ymbols that w
Board # ‐ 4‐0
itle: Potentia
isease: an ob
ype: Descrip
ion Category
Author: Bah
ahia.chahine
al Authors:
ddoul
Saad
: Potentially
hing the exp
and safer a
nt health pro
sk of drug‐re
codynamics.
ied out to ex
the implicate
s: A retrospe
out on inpati
g Hospitals in
n criteria. Pat
sing. PIMs w
ent using cre
nd multiple
ed with pres
Of the 137 p
ple. The mea
n eGFR was
ed with prev
2018ASProf
ere not spelled
059
ally inapprop
bservational
ptive Report
y: Drug Infor
hia Chahine;
inappropria
ected clinica
lternative m
oblem, and p
elated toxicit
In Lebanon,
xamine the e
ed drugs and
ective data a
ents admitte
n Beirut, Leb
tients were
ere identifie
eatinine clea
logistic regr
cription of P
patients, the
an serum cre
18.74 ml/m
valence rate
SHPMidyfessional
d‐out per the g
priate medic
l study
rmation/Dru
Lebanese In
b
ate medicati
al benefits, e
medication. S
patients with
ties due to c
, limited dat
extent of PIM
d risk factors
analysis of pa
ed between
banon. Out o
excluded if t
ed using the
arance calcu
ession analy
PIMs.
e average ag
eatinine was
in/1.73 m2.
of 54.01%. A
yearClinlPoster
guidelines wer
cation presc
ug Use Evalu
nternational
on (PIM) is d
especially wh
Safe medicat
h chronic kid
changes in p
a are availab
M prescriptio
s.
atients with
January 201
of 1073 CKD
their age wa
modified Be
lated by the
ysis to deter
e was 76.39
s 4.30 mg/dl
A total of 74
A total of 56
nicalMeAbstrac
re translated i
ribing in eld
uation
University;
defined as a
hen there is
tion prescrib
dney disease
harmacokin
ble on the p
on in elderly
CKD above
16 and Janua
patients scr
as less than 6
eers’ criteria
e Cockroft–G
mine which
years. Fema
and the me
4 out of the
63 medicatio
eetingcts
into unknown
erly patient
drug carryin
evidence fo
bing in elder
e (CKD) are p
netics and
revalence of
y patients wi
the age of 6
ary 2017 at t
reened, only
65 years, and
a in patients
Gault formul
patient cha
ales account
ean BUN was
137 patient
ons were pre
characters.
s with chron
ng risks
or an equally
ly patients is
particularly a
f PIM. This s
ith CKD and
65 years was
two Univers
y 137 met th
d if chart da
with renal
a. We used
racteristics w
ted for 54%
s 69.20 mg/d
ts had a PIM
escribed amo
nic
y
s a
at
tudy
to
s
sity
e
ta
chi
were
of
dl.
M
ong
*Special sy
the 137 p
(322/563
Histamin
ranitidine
for the n
10.55% (
prescript
[95% con
(95% CI,
(95% CI,
(95% CI,
Conclusio
confirms
Increasin
prescript
ymbols that w
patients with
3) of all med
ne‐2 recepto
e representi
ext largest c
34/322) of t
tions were le
nfidence inte
0.14–0.67)].
1.11–2.35)]
0.95–3.00)].
on: PIMs we
that physici
ng awarenes
tions.
2018ASProf
ere not spelled
h an average
ications pre
r antagonist
ng the most
category of P
total PIMs. T
ess likely if th
erval (CI): 0.0
. PIM prescr
and if the re
.
ere prescribe
ians are not
s on PIMs in
SHPMidyfessional
d‐out per the g
e four medic
scribed were
ts accounted
t commonly
PIMs with 34
The opioid an
he patient w
09–1.46]} an
iptions were
eason for ho
ed for more
aware of PI
n Lebanese h
yearClinlPoster
guidelines wer
cations per p
e potentially
d for 42.54%
prescribed m
4.16% (110/3
nalgesic tram
was in stage G
nd if admitte
e more likely
ospital admis
than half of
Ms, which in
hospitals mig
nicalMeAbstrac
re translated i
patient (rang
y inappropri
% (137/322) o
medication.
322) followe
madol accou
G4 CKD {adj
ed to the inte
y if the patie
ssion was no
f elderly CKD
ncreases dru
ght reduce t
eetingcts
into unknown
ge 1–9). Ove
ate.
of the total P
Anticoagula
ed by antico
unted for 8.6
usted odds
ensive care
ent was fema
on‐renal dise
D patients in
ug‐related p
he frequenc
characters.
erall, 57%
PIMs with
ants account
nvulsants
69% of PIMs.
ratio (AOR):
unit [AOR: 0
ale [AOR: 1.6
ease [AOR: 1
this study. T
roblems.
cy of PIM
ted
. PIM
0.11
0.31
62
1.69
This
*Special sy
Session‐B
Poster Ti
Poster Ty
Submissi
Primary A
Email: ju
Addition
Ashmi Ph
Rani Mad
Mini Varg
Navin Ph
Purpose:
the safe
anticoag
direct ora
emphasiz
encourag
anticoag
Methods
rivaroxab
medical r
included
Decembe
maternit
included
concomit
anticoag
based on
literature
anticoag
encompa
ymbols that w
Board # ‐ 4‐0
itle: Review
ype: Evaluat
ion Category
Author: Just
stin.ch.degu
al Authors:
hilips
dduri
ghese
ilips
: The Joint C
use of medic
ulant therap
al anticoagu
zes the need
ge optimal u
ulant utilizat
s: This was a
ban. A retros
record. This
if they were
er 2017, and
y unit were
patient dem
tant medica
ulant manag
n comparison
e. The prima
ulants utiliza
assing dosing
2018ASProf
ere not spelled
060
of oral antic
tive Study
y: Drug Infor
tin Deguzma
uzman@gma
ommission N
cations and
py. Trends in
ulants over th
d to develop
use. This stud
tion in an in
a medication
spective cha
study was e
e 18 years of
d received at
excluded. A
mographics,
tions, timing
gement, blee
ns to approv
ary endpoint
ation during
g, transition
SHPMidyfessional
d‐out per the g
coagulant us
rmation/Dru
an; Hunterdo
ail.com
National Pat
highlight the
n prescribing
he more trad
p institutiona
dy’s objectiv
patient setti
n use evaluat
art review wa
exempt by th
f age or olde
t least one d
report of el
initial dosing
g of switchin
eding events
ved labeling,
t was the inc
a patient’s
ing to or fro
yearClinlPoster
guidelines wer
se in a comm
ug Use Evalu
on Medical C
tient Safety G
e goal to red
g have shifte
ditional oral
al guidelines
ve is to asses
ing.
tion assessin
as conducte
he institution
er, admitted
ose of a stud
igible patien
g, dose adju
ng between a
s, and throm
, tertiary ref
cidence of ov
hospital stay
om other ant
nicalMeAbstrac
re translated i
munity hospi
uation
Center;
Goals emph
duce harm a
d toward an
l anticoagula
s for the dire
ss appropria
ng use of api
ed using the
nal review b
to the instit
dy medicatio
nts was gene
stments, ren
anticoagulan
mbotic event
ferences, gui
verall appro
y. This was a
ticoagulants
eetingcts
into unknown
ital
asize the ne
ssociated w
n increased u
ant, warfarin
ect oral antic
teness of di
ixaban, dabi
institution’s
board. Patien
tution from
on. Patients
erated and d
nal function
nts, timing o
ts. Appropri
idelines, and
priateness o
a composite
, and timing
characters.
eed to impro
with
utilization of
n. This
coagulants to
rect oral
igatran, and
s electronic
nts were
August to
admitted to
data collecte
, weight,
of periopera
ateness was
d peer review
of direct oral
endpoint
g of
ove
f the
o
o the
ed
tive
s
wed
l
*Special sy
anticoag
bleeding
encompa
Results: T
acting or
percent)
anticoag
inapprop
anticoag
managem
direct act
a parente
anticoag
(19/35) o
dose adju
(28/40), f
Rivaroxa
compare
instances
Conclusio
majority
a parente
managem
major fin
prescribe
ymbols that w
ulants aroun
events, rela
ass the prim
Three hundr
ral anticoagu
and dabigat
ulant use wa
priate use (n
ulants (44.29
ment (27.14
ting oral ant
eral anticoag
ulant was in
of the time a
ustment ma
followed by
ban had the
ed to dabigat
s of bleeding
on: Though
of instances
eral anticoag
ment of anti
ndings is req
er order set
2018ASProf
ere not spelled
nd procedur
ated thromb
ary endpoin
red and thirt
ulant was ap
tran (7.53 pe
as considere
=140), a maj
9 percent), f
percent). Pa
ticoagulant 5
gulant overl
appropriate
and 45.24 pe
de up a maj
indication (
e highest rate
tran (8 perce
g and no inst
the direct ac
s, higher rate
gulant to a d
coagulation
uired. Such a
and clinical
SHPMidyfessional
d‐out per the g
es. Seconda
otic events,
t. Descriptiv
ty two patie
ixaban (68.3
ercent). Ove
ed complete
jority was du
followed by
arenteral an
57.41 percen
apped with
ely held prior
ercent (19/4
ority of the
22.5 percen
e of inappro
ent, 2/25) an
tances of th
cting oral an
es of subopt
direct oral an
. Further ana
analysis will
pathway.
yearClinlPoster
guidelines wer
ry endpoint
and aforem
ve statistics w
nts were inc
37 percent),
erall, 63.86 p
ly appropria
ue to inappr
dosing (28.5
ticoagulants
nt (62/108) o
direct acting
r to and rest
2) of the tim
instances of
t, 9/40) and
opriate renal
nd apixaban
rombosis.
nticoagulants
timal utilizat
nticoagulant
alysis on the
guide devel
nicalMeAbstrac
re translated i
s included th
mentioned in
were used to
cluded. The
followed by
percent (212
ate. Of the to
ropriate tran
57 percent) a
s were inapp
of the time.
g oral antico
tarted after
me, respectiv
f inappropria
drug intera
dose adjust
(6.17 perce
s were mana
tion were se
t and during
e gaps in wo
lopment and
eetingcts
into unknown
he incidence
dividual fact
o analyze th
most comm
y rivaroxaba
/332) of dire
otal instance
nsitions to o
and periproc
propriately t
There were
oagulant. A d
a procedure
vely. Inappro
ate dosing a
ctions (7.5 p
tment (15 pe
ent, 14/227).
aged approp
en when tra
periproced
rkflow contr
d implement
characters.
es of recorde
tors that
he results.
only used di
n (24.96
ect acting or
es of
r from other
cedural
transitioned
21 cases wh
direct acting
e 54.29 perce
opriate rena
t 70 percent
percent, 3/4
ercent, 12/8
. There were
priately in a
ansitioning fr
ural
ributory to t
tation of a
ed
irect
ral
r
to a
here
oral
ent
l
t
0).
80)
e 17
rom
these
*Special sy
Session‐B
Poster Ti
interactio
Poster Ty
Submissi
Primary A
Email: cc
Addition
Yi‐Yen Ch
Yueh‐Chi
Chia‐Lin
Yuh‐Lih C
Purpose:
with an e
contraind
serious h
interactio
medical c
This stud
physician
use.
Methods
prescript
medical c
2014 we
prescript
prescript
reviews o
about pa
from Jan
ymbols that w
Board # ‐ 4‐0
itle: Prevale
on in an amb
ype: Evaluat
ion Category
Author: Chia
chsu6@vght
al Authors:
hen
ing Chou
Chou
Chang
: Concomita
elevated risk
dicated the c
hypoglycemi
on alert was
center. How
dy aimed to i
ns’ response
s: A retrospe
tion databas
center in Tai
re included.
tions in resp
tions, and m
of electronic
atients who c
uary 2007 to
2018ASProf
ere not spelled
061
nce and clin
bulatory sett
tive Study
y: Drug Infor
a‐Chen Hsu;
pe.gov.tw
nt use of rep
k of hypoglyc
concomitant
c episodes in
s implement
wever, prescr
investigate t
s to the inte
ective observ
e and inform
iwan. Prescr
We manual
onse to the
edication hi
c medical ch
concomitant
o Septembe
SHPMidyfessional
d‐out per the g
ical consequ
ting
rmation/Dru
Departmen
paglinide wit
cemia. The E
t use of thes
n patients us
ed into com
riptions invo
the prevalen
eraction aler
vational stud
mation from
riptions invo
ly reviewed
alert by com
story. Furth
arts. We col
t use of repa
r 2015.
yearClinlPoster
guidelines wer
uences of co
ug Use Evalu
nt of Pharma
th gemfibro
European Me
se two drugs
sing them at
puterized ph
olving these t
nce of repagl
rts, and the c
dy was perfo
an alert and
lving repagl
all alert and
mparing alert
ermore, we
lected blood
aglinide and
nicalMeAbstrac
re translated i
ontraindicate
uation
acy, Taipei V
zil may incre
edicinal Prod
s in 2003 acc
t the same t
hysician ord
two drugs a
linide‐gemfi
clinical conse
ormed using
d logging sys
inide or gem
d confirmed
t prescriptio
conducted a
d glucose da
gemfibrozil
eetingcts
into unknown
ed repaglinid
Veterans Gen
ease in repa
ducts Evalua
cording to 5
time. This dr
der entry sys
re still presc
brozil intera
equences of
g a compute
stem in a ter
mfibrozil thro
any individu
ons logged, f
a case series
ata and relat
at the same
characters.
de‐gemfibro
neral Hospit
glinide expo
ation Agency
reports of
ug‐drug
tem in 2004
cribed recent
action,
f concomitan
rized ambula
rtiary care
ough 2007 to
ual changes
final
s study base
ted informat
e medical ce
ozil
tal;
osure,
y
4 at a
tly.
nt
atory
o
of
ed on
tion
nter
*Special sy
Results:
gemfibro
received
(72.1%, 4
reduced
accepted
repaglini
repaglini
gemfibro
hypoglyc
Conclusio
are not r
interactio
result in
ensure d
ymbols that w
During the 8
ozil were pre
332 prescrip
44/61) patie
in 2 prescrip
d alerts, gem
de was shift
de was canc
ozil concomit
cemic events
on: Medical
are in clinica
on alerts. Ex
hypoglycem
rug safety.
2018ASProf
ere not spelled
8‐year study
escribed for 9
ptions with r
nts were ove
ptions (0.64%
mfibrozil was
ted to anoth
celed in 5 (22
tantly. Over
s (1.41 event
prescription
al practice. P
xposure of th
mia. Concomi
SHPMidyfessional
d‐out per the g
period, 101
9,197 patien
repaglinide‐
erridden. In
%, 2/310) wi
shifted to a
er oral antid
2.7%, 5/22).
the entire 1
ts/1,000 pat
ns involving
Physicians us
hese contrai
itant use of
yearClinlPoster
guidelines wer
1,422 prescri
nts. A total o
gemfibrozil
respond to
ith override
nother lipid
diabetic drug
A total of 4
14,198‐day o
tient‐days) w
contraindica
sually overro
ndicated dru
repaglinide
nicalMeAbstrac
re translated i
iptions invol
of 61 (0.66%
interaction.
alerts, the d
alert. Amon
‐lower drug
g in 8 (36.4%
8 patients u
observation
were detecte
ated repagli
ode the cont
ug‐drug inte
and gemfibr
eetingcts
into unknown
lving repagli
, 61/9,197)
Of these, 31
daily dose of
ng the 22 pre
in 9 (40.9%,
%, 8/22) and
sed repaglin
time, 8 patie
ed.
nide‐gemfib
traindicated
eraction wou
rozil should
characters.
nide or
patients
10 alerts for
f gemfibrozil
escriptions w
, 9/22),
gemfibrozil
nide and
ents with 20
brozil interac
d drug‐drug
uld certainly
be avoided t
r 44
was
with
or
0
ction
to
*Special sy
Session‐B
Poster Ti
real‐wor
Poster Ty
Submissi
Primary A
Email: ei
Addition
Kathryn S
Rich Glik
Keith Hin
Setareh W
Purpose:
teriparat
Methods
medical a
or DMAB
and inclu
at index
index dat
between
defined a
index dat
Results:
identifica
cohort w
respectiv
females (
were ost
respirato
ymbols that w
Board # ‐ 4‐0
itle: Charact
ld setting: a
ype: Evaluat
ion Category
Author: Erik
al Authors:
Starzyk
lich
nes
Williams
: To identify
tide (TPTD), o
s: A propriet
and pharma
B. The OM1 D
udes over 35
date and a p
te was defin
May 1, 201
as patients w
te.
Overall, 241
ation period
was 4.47 year
vely, was 69.
(95.3%, 86.7
eoarthritis (
ory diseases
2018ASProf
ere not spelled
062
terizing patie
US linked cl
tive Study
y: Drug Infor
k Imel; Indian
u
and charact
or denosum
tary data por
cy claims wa
Data Cloud c
5 million pati
prescription
ned as the da
7 and May 7
with no reco
11 ABL, 8613
. The media
rs. Mean age
.6 (10.57), 69
7%, and 91.6
46.1%), gast
(COPD: 19.7
SHPMidyfessional
d‐out per the g
ents initiatin
aims and EM
rmation/Dru
na Universti
terize patien
ab (DMAB)
rtal containi
as used to id
covers appro
ients with lin
or fill of one
ate of the in
7, 2018 (the
rded treatm
3 TPTD, and 8
n duration o
e (±standard
9.3 (11.09),
6%; p<0.001)
trointestinal
7% and asthm
yearClinlPoster
guidelines wer
ng abalopara
MR database
ug Use Evalu
y School of M
nts initiating
in a real‐wo
ng electroni
dentify patie
oximately 20
nked claims
e or more of
itial prescrip
identificatio
ment with the
83115 DMA
of pre‐index
d deviation, S
and 72.1 (10
). Overall, th
disorders (4
ma: 12.5%).
nicalMeAbstrac
re translated i
atide, teripar
e analysis
uation
Medicine;
treatment w
rld setting.
ic medical re
ents new to t
00 million pa
and EMR da
f ABL, TPTD o
ption or fill fo
on period). N
e same drug
B patients w
historical da
SD) for ABL,
0.18), with a
he most prev
45.6%), type
Both ABL‐ a
eetingcts
into unknown
ratide, or de
with abalopa
ecords (EMR
treatment w
atients in the
ata. Patients
or DMAB we
or ABL, TPTD
New/recent
g in the 12 m
were new to
ata per patie
TPTD, and D
a greater pro
valent como
e 2 diabetes
and TPTD‐ tre
characters.
enosumab in
aratide (ABL
R) and links t
with ABL, TPT
e US with cla
≥18 years o
ere included
D or DMAB;
users were
months prior
therapy in t
ent in the stu
DMAB cohor
oportion bei
rbid conditio
(19.8%), and
eated patien
n a
L),
to
TD,
aims
of age
. The
to
the
udy
rts,
ng
ons
d
nts
*Special sy
had lowe
DMAB‐tr
respectiv
received
medicati
glucocort
treated p
and 15.8
Conclusio
demogra
ymbols that w
er mean com
reated patien
vely, having
bisphospho
ons prior to
ticoids prior
patients resp
% for ABL‐, T
on: Patients
aphic charact
2018ASProf
ere not spelled
morbidity sco
nts, with 33%
a score of ≥2
onate(s), sele
treatment i
r to their ind
pectively; p<
TPTD‐ and D
initiating AB
teristics and
SHPMidyfessional
d‐out per the g
ore as assess
%, 36%, and
2 (p<0.001).
ective estrog
nitiation. Ad
ex date (46.
<0.001) with
DMAB‐ treate
BL, TPTD, an
d comorbidit
yearClinlPoster
guidelines wer
sed by the C
45% of ABL
Overall, 17.
gen receptor
dditionally, 4
5%, 50.8%, 4
16.0% curre
ed patients r
nd DMAB sho
ties prior to t
nicalMeAbstrac
re translated i
harlson Com
L, TPTD, and
.4%, 2.2% an
r modulator
45.8% of all p
45.2% for AB
ently on gluc
respectively
owed some
treatment in
eetingcts
into unknown
morbidity Ind
DMAB patie
nd 20.0% of
s, or other o
patients had
BL‐, TPTD‐ a
cocorticoids
y; p<0.001).
differences
nitiation.
characters.
dex compare
ents,
patients
osteoporosis
d exposure t
nd DMAB‐
(12.6%, 19.
in clinical an
ed to
s
o
6%,
nd
*Special sy
Session‐B
Poster Ti
with type
Poster Ty
Submissi
Primary A
Informat
Email: m
Addition
Ayae Suz
Koichiro
Akinori H
Purpose:
do not st
metform
inhibitors
diabetes
several s
prescribi
well as th
Methods
Hospital
with T2D
who star
from elec
endocrin
teneliglip
simulate
change t
algorithm
patients
ymbols that w
Board # ‐ 4‐0
itle: The imp
e 2 diabetes
ype: Evaluat
ion Category
Author: Ma
tion;
akiko@pobo
al Authors:
zuki
Atsuda
Hayashi
: Unlike guid
tate which a
min exhibits b
s, DPP‐4 inh
mellitus (T2
tudies have
ng patterns
he impact of
s: The study
(KUH), Japa
DM at KUH b
ted oral hyp
ctric medica
nologist and
ptin, and me
d patients e
he selection
m were: HbA
not to be in
2018ASProf
ere not spelled
063
pact of imple
mellitus in a
tive Study
y: Drug Infor
kiko Iwasaw
ox.com
delines from
nti‐diabetic
better HbA1c
ibitors are o
2DM) in Japa
reported th
of oral hypo
f implement
was approv
n. We first c
etween Janu
poglycemic m
l records. A
a pharmacis
etformin. To
nrolled in th
n of initial the
A1c between
itiated on in
SHPMidyfessional
d‐out per the g
ementation
an academic
rmation/Dru
wa; Kitasato U
the America
agents shou
c‐lowering e
often prescri
an because o
at metformi
oglycemic ag
ation of a m
ved by the In
onducted a
uary 1 and D
monotherapy
medication
st. Medicatio
examine the
he retrospec
erapy and in
n 6.5 and 10.
sulin therap
yearClinlPoster
guidelines wer
of a medicat
c teaching ho
ug Use Evalu
University Sc
an Diabetes
uld be used a
effects than d
bed for pati
of the low in
in has been
gents (OHA)
medication al
stitutional R
retrospectiv
December 31
y were inclu
algorithm w
ons included
e impact of i
tive chart re
nfluence dru
.0 percent, n
py. Patients l
nicalMeAbstrac
re translated i
tion algorith
ospital in Jap
uation
chool of Pha
Association
as first line t
dipeptidyl p
ents newly d
ncidence of s
underused.
in drug‐naïv
lgorithm.
Review Boar
ve chart revi
1, 2016. Pati
uded in the s
was then dev
d in the algor
implementa
eview to see
ug costs. Incl
negative test
lacking an in
eetingcts
into unknown
hm for drug‐
pan.
armacy, Divis
, Japanese c
therapy. Alth
peptidase‐4 (
diagnosed w
side effects.
This study e
ve patients w
rd of Kitasato
iew of drug‐
ients older t
study. Data w
veloped by a
rithm were s
ation of the a
if using the
usion criteri
t result for u
nitial HbA1c
characters.
naïve patien
sion of Drug
clinical guide
hough
(DPP‐4)
with type 2
Moreover,
examined th
with T2DM, a
o University
naïve patien
han 20 year
was collecte
an
sitagliptin,
algorithm, w
algorithm w
ia for the
urine ketone
value and re
nts
g
elines
e
as
nts
s
d
we
would
e, and
esults
*Special sy
of renal a
therapy i
dialysis p
females,
from me
their esti
Results: A
the study
26.7±8.3
than 50 m
inhibitors
(11.1 per
(42.2 per
(13.3 per
(2.2 perc
algorithm
were cha
therapy.
per patie
3,501 – ‐
switching
Conclusio
inhibitors
the algor
percent o
dosage a
DPP‐4 inh
impairme
appropri
ymbols that w
and liver fun
if they did no
patients, crea
and medica
tformin ther
imated glom
A total of 63
y (mean age
kg/m2; mea
mL/min/1.73
s, 8 (12.7 pe
rcent) were
rcent) were
rcent) were
cent) was pre
m, 27 (42.9 p
anged from o
No patients
ent between
5,658) by sw
g from OHA
on: By retro
s, while 11.1
rithm, appro
of patients c
djustment b
hibitors; the
ent. The resu
ate initial th
2018ASProf
ere not spelled
nction tests w
ot meet the
atine value g
al conditions
rapy were ca
merular filtra
3 patients wh
: 64.2±14.0
an HbA1c: 7
3 m2 was 92
ercent) were
on biguanid
prescribed s
prescribed l
escribed vild
percent) wer
other OHA t
s were categ
pre‐ and po
witching from
to sitagliptin
spective cha
1 percent sta
oximately 70
could be trea
based on the
erefore, sitag
ults of the si
herapy and r
SHPMidyfessional
d‐out per the g
were exclud
following ex
greater than
for which m
ategorized in
tion rate (eG
ho started o
years; 61.9 p
.7±1.0 perce
2.1 percent.
on sodium
es (metform
sitagliptin, 13
inagliptin, 6
dagliptin. As
re changed f
o sitagliptin,
orized using
ost‐utilizatio
m OHA to m
n.
art review, 7
arted on me
percent of t
ated by metf
e degree of r
gliptin is reco
imulation sh
educe drug
yearClinlPoster
guidelines wer
ed. Patients
xclusion crit
n or equal to
metformin is
nto sitaglipti
GFR).
oral hypoglyc
percent mal
ent). The pro
Of the 63 pa
glucose cotr
min). Of the p
3 (28.9 perc
(13.3 perce
a result of s
from other O
, and 17 (27
g teneligliptin
n of the algo
etformin, an
71.4 percent
tformin. Wh
the initial th
formin. Alth
renal impair
ommended
howed that u
costs.
nicalMeAbstrac
re translated i
s were categ
eria: patient
o 1.3 mg/dL f
contraindic
in or tenelig
cemic mono
es, 38.1 per
oportion of p
atients, 45 (7
ransporter‐2
patients pre
ent) were p
nt) were pre
simulating 63
OHA to metf
.0 percent) e
n. The differ
orithm was ‐
nd ‐279 JPY (
of drug‐naïv
hen selecting
herapy would
ough tenelig
ment, it is m
for patients
using the alg
eetingcts
into unknown
orized into m
ts older than
for males an
cated. Patien
gliptin therap
otherapy wer
rcent female
patients with
71.4 percent
2 (SGLT2) inh
scribed DPP
rescribed te
escribed sax
3 patients us
formin, 19 (3
exhibited no
rence of mo
‐4,359 Japan
(‐1,260 – ‐3,
ve patients s
g an initial th
d change an
gliptin does
more expens
s without sev
gorithm coul
characters.
metformin
n 75 years ol
nd 1.2 mg/dL
nts excluded
py dependin
re enrolled i
es; mean BM
h eGFR grea
t) were on D
hibitors, and
P‐4 inhibitors
eneligliptin, 6
xagliptin, and
sing the
30.2 percent
o change of
nthly drug c
nese yen (JPY
948) by
started on D
herapy base
d more than
not require
ive than oth
vere renal
ld promote
ld,
L for
g on
nto
MI:
ter
DPP‐4
d 7
s, 19
6
d 1
t)
ost
Y) (‐
DPP‐4
d on
n 50
her
*Special sy
Session‐B
Poster Ti
disease
Poster Ty
Submissi
Primary A
Email: jm
Addition
Manami
Motoki N
Yasuyo M
Mitsuhik
Purpose:
caused b
hyperins
diabetes
NAFLD/N
establish
for NAFL
we have
liver dise
Methods
Universit
chronic l
Hospital
based on
liver from
absence
from me
SGLT2 in
ymbols that w
Board # ‐ 4‐0
itle: Multi‐fa
ype: Evaluat
ion Category
Author: Koic
m‐kkataoka@
al Authors:
Okamoto
Nishida
Morita
o Miyamura
: Nonalcoho
by overeating
ulinemia, an
. Drug thera
NASH, such a
hed. On the o
D patients w
examined th
eases.
s: This retros
ty Medical S
iver disease
could contin
n medical ch
m the medica
of concomit
dical charts.
hibitor adm
2018ASProf
ere not spelled
064
aceted effect
tive Study
y: Drug Infor
chi Kataoka;
@kochi‐u.ac.j
a
lic fatty liver
g and lack of
nd affected p
py encompa
as diabetes a
other hand,
with concom
he multiple e
spective stud
chool. We e
who started
nue taking m
arts. We ext
al charts as t
tant medicat
In addition,
inistration to
SHPMidyfessional
d‐out per the g
ts of SGLT2 i
rmation/Dru
Kochi Medi
jp
r disease (NA
f exercise. T
patients are
asses agents
and dyslipide
SGLT2 inhib
mitant diabet
effects of SG
dy’s protoco
xtracted 71
d treatment
more than 3
tracted sex,
the backgro
tions, clinica
, changes of
o 3 months a
yearClinlPoster
guidelines wer
inhibitor in d
ug Use Evalu
ical School H
AFLD) / nona
hey accomp
very likely to
s for lifestyle
emia, no def
itors are exp
tes. In condu
GLT2 inhibito
ol was appro
patients wit
with SGLT2
months betw
age, diabete
und of the p
al laboratory
HbA1c, bod
after admini
nicalMeAbstrac
re translated i
diabetic pati
uation
Hospital;
alcoholic ste
pany obesity,
o suffer from
e diseases ac
finitive drug
pected to be
ucting clinica
ors in diabet
oved by the e
th type2 diab
inhibitor at
ween Augus
es history, pr
patient. In ad
y data were r
dy weight, an
istration we
eetingcts
into unknown
ients with m
eatohepatis
, dyslipidem
m other dise
ccompanied
therapy has
e therapeuti
al research o
tic patients w
ethics comm
betes with m
Kochi Medic
st 2014 and J
resence or a
ddition, the
retrospectiv
nd ALT from
re calculate
characters.
metabolic live
(NASH) are
mia, and
eases such as
by
s yet been
cally effectiv
on NAFLD/NA
with metabo
mittee of Koc
metabolic
cal School
January 201
absence of fa
presence or
vely extracte
the start of
d, and
er
s
ve
ASH,
olic
chi
8
atty
r
d
f
*Special sy
correlatio
were exa
In order t
multivari
sulfonylu
objective
Results:
administ
significan
HbA1c an
correlatio
was not a
medicati
Conclusio
and hypo
is genera
may not
and liver
hypergly
ymbols that w
ons between
amined by de
to investigat
iate analysis
urea (SU), DP
e variables o
HbA1c, body
ration comp
ntly decrease
nd body wei
on was foun
a significant
on against a
on: It was su
oglycemic ac
ally thought t
correlate wi
function im
cemia and in
2018ASProf
ere not spelled
n changes of
etermining t
te the influe
as explanat
PP4 inhibitor
f HbA1c, bo
y weight and
pared to base
ed 3 months
ght change,
nd between A
explanatory
any effects o
uggested tha
ction. On the
to be involv
ith weight lo
mprovement
nsulin resista
SHPMidyfessional
d‐out per the g
f HbA1c and
the correlati
ence of the ty
tory variable
r (DPP4I), GL
dy weight an
d BMI signifi
eline. In live
s after admin
ALT and we
ALT and HbA
y variable fo
of hypoglycem
at there is a
e other hand
ed in weight
oss. In this st
effect sugge
ance improv
yearClinlPoster
guidelines wer
body weigh
ion coefficie
ype of conco
es of no com
LP‐1 recepto
nd ALT impr
cantly decre
r function, A
nistration. N
eight change
A1c change.
r the presen
mic depress
correlation
d, liver funct
t loss by dru
tudy, the cor
ested improv
vement.
nicalMeAbstrac
re translated i
ht, HbA1c an
nt, respectiv
omitant drug
mbination dru
or agonist (G
rovement.
eased from 1
ALT, AST, γG
No correlatio
e in each cor
The effect o
nce or absen
ion, weight
between live
tion improvin
gs, but liver
rrelation bet
vement of liv
eetingcts
into unknown
nd ALT, body
vely.
g, we condu
ug, insulin p
GLP‐1), thiazo
1 month afte
TP and FIB‐4
on was found
relation, but
of concomita
nce and type
loss and ALT
er function i
ng effect of
function im
tween hypo
ver function
characters.
y weight and
ucted
reparation,
olidine (TZD
er
4index were
d between
t a positive
ant medicati
e of concomi
T improveme
improving ac
SGLT2 inhib
mproving acti
glycemic eff
n by
d ALT
), as
e
ions
itant
ent.
ction
itor
ion
fect
*Special sy
Session‐B
Poster Ti
Poster Ty
Submissi
Primary A
Email: yo
Addition
Ana Loza
Cristina M
Rubén Pa
Belén Ro
Purpose:
the clopi
The aim o
Clopidog
Methods
2018 in a
clopidog
electroni
clinical re
blood tes
events id
subseque
adverse e
discontin
Paclitaxe
Results:
mean ag
were car
dosing at
ymbols that w
Board # ‐ 4‐0
itle: Interact
ype: Evaluat
ion Category
Author: Yoa
oarfh@gmai
al Authors:
ano
Martínez‐Mú
ampín
odríguez
: Paclitaxel is
dogrel meta
of the study
grel.
s: A retrospe
a tertiary hos
rel were inc
ic medical re
elevance of t
sts (Hb, neut
dentified by t
ent to the co
events (AE) w
nuation rate
el’ SPC.
Seven patie
e of 65 year
boplatin+pa
t 175 mg/m2
2018ASProf
ere not spelled
065
tion betwee
tive Study
y: Drug Infor
ar Labeaga; H
l.com
úgica
s mainly elim
abolite acyl‐β
y is to assess
ective observ
spital. All pa
luded. To ide
ecord and th
the interacti
trophil coun
the physicia
ombined adm
was analyse
due to AE. T
nts were tre
s old and EC
aclitaxel 50 m
2 and 200 m
SHPMidyfessional
d‐out per the g
n placitaxel
rmation/Dru
HOSPITAL UN
minated by C
β‐D‐glucuron
the clinical
vational stud
atients who w
entify the pa
he chemothe
ion, age, reg
nt, platelets,
n were extra
ministration
d according
These rates w
eated with pa
COG perform
mg/m2 week
mg/m2) and p
yearClinlPoster
guidelines wer
and clopido
ug Use Evalu
NIVERSITARI
CYP2C8 in th
nide. This ca
relevance of
dy was perfo
were admin
atients who
erapy databa
gimen, paclit
etc), ECOG
acted from t
of clopidog
to the crite
were compa
aclitaxel and
mance status
kly (n=2), car
paclitaxel 10
nicalMeAbstrac
re translated i
grel: relevan
uation
IO DE CABU
he liver, whic
an lead to inc
f the interac
ormed betw
istered a com
were treate
ase were che
taxel dose, c
performanc
the clinical r
grel and pacl
ria NCI‐CTCA
ared with AE
d clopidogre
s of 1. The th
rboplatin+pa
00 mg/m2 w
eetingcts
into unknown
nce in clinica
EÑES‐ASTUR
ch is strongly
creased pac
ction betwee
ween January
mbination o
ed with both
ecked. In ord
cumulative p
e status and
records prior
itaxel. The in
AE, including
Es’ frequency
el concomita
herapeutic re
aclitaxel eve
eekly (n=3).
characters.
al practice
RIAS;
y inhibited b
litaxel toxici
en Paclitaxe
y 2014 and A
of paclitaxel
drugs, the
der to asses
paclitaxel do
d any advers
r and
ncidence of
g the
y described
ntly, with a
egimens use
ery 3 weeks
Each patien
by
ity.
l and
April
and
s the
se,
e
on
ed
(n=2,
nt
*Special sy
was adm
drug use
normal fo
Accordin
during th
thrombo
the SPC,
None of t
dose or s
hematolo
experien
performa
Conclusio
clinically
observed
limitation
patients
ymbols that w
ministered 7 c
d that could
or all the pa
g to clinical
he study per
ocytopenia a
respectively
the patients
skip/postpon
ogical toxicit
ced periphe
ance status c
on: Drug‐dru
relevant inc
d during the
ns (interindi
analised).
2018ASProf
ere not spelled
cycles, with
d influence C
tients.
implications
iod vs 28% o
nd six anem
y).
s required tre
ne a course o
ty (of any gr
eral sensory
changed dur
ug interactio
creased risk
study period
vidual variab
SHPMidyfessional
d‐out per the g
an average c
CYP2C8 was c
s, three patie
on the SPC),
mia (14% and
eatment dis
of treatmen
ade) was de
neuropathy
ring co‐admi
on between
of neuropat
d. Neverthe
bility, differe
yearClinlPoster
guidelines wer
cumulative d
clopidogrel.
ents experie
only one gra
64% during
continuation
t. According
eveloped in 1
(0% vs 25‐8
inistration o
clopidogrel
thy or neutro
less, further
ent regimen
nicalMeAbstrac
re translated i
dose of 1036
Blood cell c
enced neutro
ade 3. One p
g the study p
n due to AEs
g to the phys
100% of the
85% accordin
only in one ca
and paclitax
openia, acco
r research is
s and doses
eetingcts
into unknown
6 mg of pacl
ounts at bas
openia and l
patient deve
period vs 11%
s, neither re
sician’s evalu
cases, but n
ng to the SPC
ase, worsen
xel was not a
ording to the
needed due
of paclitaxe
characters.
litaxel. The o
seline were
leucopenia (
eloped
% and 86% o
duce paclita
uation,
none
C). The ECOG
ing from 1 t
associated w
e low rate of
e to study
el used and f
only
(43%
on
axel
G
o 2.
with a
f AE
few
*Special sy
Session‐B
Poster Ti
anticoag
Poster Ty
Submissi
Primary A
Email: no
Addition
Ahmad S
Marwan
Mariam D
Michelle
Purpose:
nonvalvu
Dabigatr
These ag
of antico
including
Lebanon
the appro
Methods
one outp
2018. Pat
were inc
receiving
medical h
source of
including
Appropri
indicatio
and acco
ymbols that w
Board # ‐ 4‐0
itle: Medicat
ulants
ype: Evaluat
ion Category
Author: Nou
oura.m.mak
al Authors:
Sinno
Akel
Dabbous
Cherfan
: Direct oral
ular atrial fib
an was intro
gents offer so
oagulant effe
g lack of clini
, therefore w
opriateness
s: We condu
patient depa
tients who p
luded in the
g an oral info
history and c
f the prescri
g dose, frequ
iate indicatio
ns, while ap
ording to the
2018ASProf
ere not spelled
066
tion utilizati
tive Study
y: Drug Infor
ura Makki; L
anticoagula
brillation (NV
oduced in 20
ome advanta
ect and fewe
ical experien
we conducte
of DOACs us
cted a cross
rtment of a
presented to
study if the
ormed conse
concurrent m
bed DOAC, p
uency, durat
on was base
propriate do
e FDA’s recom
SHPMidyfessional
d‐out per the g
on evaluatio
rmation/Dru
ebanese Int
om
nts (DOACs)
VAF) and ven
011, followed
ages compa
er drug‐drug
nce. Studies
ed this medi
se and their
s‐sectional d
university h
o the commu
ey were takin
ent, we gath
medication u
perceived or
tion of use a
d on the Foo
osing regime
mmendation
yearClinlPoster
guidelines wer
on and presc
ug Use Evalu
ernational U
) are approv
nous thromb
d by rivaroxa
red to warfa
interactions
evaluating t
cation utiliza
prescribing
escriptive st
hospital in Be
unity pharm
ng any of da
ered socio‐d
use. In addit
r documente
nd administ
od and Drug
en was defin
ns. Drug‐Dru
nicalMeAbstrac
re translated i
cribing patte
uation
University;
ed for preve
boembolism
aban in 2013
arin such as
s but their u
the use of DO
ation evalua
patterns.
tudy in comm
eirut, Lebano
acies or the
bigatran, riv
demographic
tion, patient
ed indication
ration with
g Administra
ned in relatio
ug interactio
eetingcts
into unknown
erns of direc
ention of thr
(VTE). In Le
3 and apixab
lack of routi
use is subject
OAC’s are la
ation (MUE)
munity phar
on, from Jan
outpatient
varoxaban or
c informatio
ts were aske
n of use, dos
respect to m
tion (FDA) a
on with the i
ons were ide
characters.
t oral
rombosis in
banon,
ban in 2016.
ine monitori
t to challeng
acking in
to determin
rmacies and
nuary to Apr
department
r apixaban. A
on, self‐repo
d about the
sing regimen
meals.
approved
indication of
ntified.
both
ing
ges
ne
in
ril
t
After
rted
n
f use
*Special sy
Statistica
as mean
categoric
and Fishe
value of 0
Lebanese
Results: A
(57.4%) w
whom, 6
a low risk
payers, 4
23 (20%)
followed
indicatio
respectiv
most app
and 92.1
and choic
associate
inapprop
Conclusio
was an o
Inapprop
encounte
efforts sh
thorough
regarding
ymbols that w
al analysis w
± standard d
cal variables
er exact test
0.05 was co
e Internation
A total of 11
were males.
7 (94.4%) ha
k of bleeding
43 (39%) had
by private i
by dabigatr
n, duration,
vely. At least
propriate cri
7% respectiv
ce of the DO
ed with appr
priately than
on: This MU
verall appro
priateness w
ers had at le
hould be imp
h patient edu
g recommen
2018ASProf
ere not spelled
as conducte
deviation (SD
. To determ
ts were used
nsidered sta
nal Universit
15 patients w
The most co
ad a high ris
g shown by A
d their medic
nsurance. R
ran and apix
and dose/fr
t one inappr
terion was a
vely). There
OAC. Multiva
ropriate DOA
self‐payers
E revealed t
opriate use w
was mostly se
ast one inap
plemented t
ucation at th
nded dosing
SHPMidyfessional
d‐out per the g
ed using SPSS
D) for quant
ine factors a
d when appli
atistically sig
ty approved
were include
ommon indi
k of stroke s
ATRIA score
cations cove
ivaroxaban w
aban (33% a
requency we
opriate crite
administratio
was no stat
ariable analy
AC use; patie
(adjusted O
that in a con
with regards
een in the do
ppropriate c
to improve t
he time of D
and duratio
yearClinlPoster
guidelines wer
S version 22
titative varia
associated w
icable as we
nificant. The
the study.
ed. The mea
cation was s
seen by CHA
less than 4.
ered by the N
was the mos
and 10.5% of
ere seen in 1
erion was en
on of DOAC
istical differ
ysis found th
ents having c
OR 0.26; 95%
venient sam
to indicatio
ose and freq
riterion, sug
he appropri
OAC initiatio
on.
nicalMeAbstrac
re translated i
.0. Descripti
ables or freq
with appropr
ll as logistic
e institution
n ± SD age w
stroke proph
A2DS2VASc s
Among all p
National Soc
st commonly
f patients re
10.4%, 20.9%
ncountered i
with respec
rence betwe
at medicatio
coverage we
% CI 0.091 – 0
mple of patie
on, duration
quency. Mor
ggesting that
ate use of D
on and impr
eetingcts
into unknown
ive analyses
uency and p
riateness of u
regression m
al review bo
was 71 ± 10.5
hylaxis in NV
core ≥2 and
patients, 47
cial Security
y prescribed
espectively).
% and 42.6%
in 68 (59.1%
ct to time an
en patients’
on cost cove
ere less likel
0.737; p=0.0
ents receivin
and adminis
e than half o
t quality imp
DOACs; such
roved prescr
characters.
were report
percentage f
use, chi‐squa
models. A P‐
oard at the
51 years and
VAF (61.7%),
45 (63.4%)
(41%) were
Fund (NSSF)
d DOAC (56.5
Inappropria
% of the patie
%) patients. T
d meals (96
’ characteris
erage was
y to use DOA
011).
g DOACs, th
stration.
of the
provement
as providing
riber educati
ted
for
are
‐
d 66
of
had
self‐
) and
5%),
ate
ents,
The
.5%
tics
AC
here
g
ion
*Special sy
Session‐B
Poster Ti
inhibitors
Poster Ty
Submissi
Primary A
Email: m
Addition
Faten Aw
Nathalie
Sylvia Saa
Jihan Saf
Purpose:
associate
cancer as
evaluate
relatively
Methods
among Le
Internati
pancreat
from hos
to the pa
in the stu
patient d
multivari
pancreat
deemed
Results: T
500 cont
ymbols that w
Board # ‐ 4‐0
itle: Case co
s (DPP4I) in
ype: Evaluat
ion Category
Author: Ma
aryline.man
al Authors:
wada
Lahoud
ade
fwan Saade
: Pancreatic
ed with this d
ssociated wi
the risk of t
y a new class
s: A retrospe
ebanese dia
onal Univers
tic cancer ca
spitals and c
ancreas or th
udy. Pre‐esta
demographic
iable analyse
tic cancer wh
statistically
The study in
rols (mean a
2018ASProf
ere not spelled
067
ntrol study a
Lebanon
tive Study
y: Drug Infor
ryline Manso
nsour1@gma
cancer is on
disease are
ith incretin b
this type of c
s of oral anti
ective case‐c
betic patien
sity approve
ses were rec
linics in a 1:4
hose who we
ablished que
cs, comorbid
es were cond
hile adjustin
significant.
ncluded 625
age 61.8 ± 30
SHPMidyfessional
d‐out per the g
about the ris
rmation/Dru
our; Lebane
ail.com
ne of the dea
long‐term d
based therap
cancer with d
idiabetic me
control study
nts. The Instit
ed the study
cruited from
4 ratio. Patie
ere on a DPP
estionnaires
dities, labora
ducted to as
g for potent
patients of w
0.2 years). T
yearClinlPoster
guidelines wer
sk of pancre
ug Use Evalu
se Internatio
adliest malig
iabetes and
pies is contro
dipeptidyl p
edications.
y was condu
tutional Rev
protocol in
m multiple ho
ents with an
P4‐inhibitor
were then f
atory values
ssess the rel
tial confound
whom 125 c
The bivariate
nicalMeAbstrac
re translated i
eatic cancer w
uation
onal Univers
gnancies wor
smoking. Si
oversial, we
eptidase‐4 (
ucted betwee
view Board o
December 2
ospitals acro
ny type of ca
for less than
filled via a m
and medica
ationship be
ders. A p‐val
cases (mean
e analysis ide
eetingcts
into unknown
with dipepti
sity;
rldwide. Risk
nce, the risk
conducted
(DPP‐4) inhib
en January a
of the Leban
2017. Recent
oss Lebanon
ncer that ha
n one year w
medical chart
ations. Bivari
etween DPP4
lue less than
age 67.9 ± 1
entified mul
characters.
idyl peptidas
k factors
k of pancreat
this study to
bitors that a
and April 20
ese
tly diagnose
while contr
as metastasi
were not incl
t review cov
iate and
4‐inhibitors
n 0.05 was
11.1 years) a
tiple signific
se‐4
tic
o
re
18
ed
ols
zed
uded
vering
and
and
cant
*Special sy
differenc
more hyp
statistica
physical
(aOR=0.4
(aOR=4.3
cancer w
with vilda
Conclusio
and panc
prevalen
conducte
ymbols that w
ces between
pertensive, a
ally significan
activity [adju
46), history o
38) and sodiu
were higher w
agliptin (aOR
on: This case
creatic cance
ce of pancre
ed to allow g
2018ASProf
ere not spelled
cases and c
and had a lo
nt associatio
usted odd's
of diabetes (
um‐glucose
with rapid ac
R=0.16) than
e control stu
er, particular
eatic cancer
generalizatio
SHPMidyfessional
d‐out per the g
controls, cas
onger history
on between p
ratio (aOR)=
(aOR=1.12),
co‐transpor
cting (aOR=7
n sitagliptin
udy suggests
rly with vilda
with insulin
on of the res
yearClinlPoster
guidelines wer
es being less
y of diabetes
pancreatic c
=0.37], hype
DPP4‐inhibi
rter‐2 inhibit
7.56) than lo
(aOR=0.53).
s a protectiv
agliptin. It fu
therapy. La
sults.
nicalMeAbstrac
re translated i
s physically
s. The multiv
cancer risk an
rtension (aO
tors (aOR=0
tors (aOR=0.
ong acting (a
e associatio
urther emph
rger prospe
eetingcts
into unknown
active, less d
variable ana
nd the follow
OR=2.28), dy
0.33), insulin
.14). The odd
aOR=2.95) in
n between D
hasizes the in
ctive studies
characters.
dyslipidemic
lysis showed
wing factors
yslipidemia
therapy
ds of pancre
nsulin and low
DPP4‐inhibit
ncreased
s should be
c,
d a
s:
eatic
wer
tors
*Special sy
Session‐B
Poster Ti
Poster Ty
Submissi
Primary A
Email: ja
Addition
Andrea H
Goldina E
Purpose:
autoimm
was adde
authoriza
Gastroen
dose rou
purchase
review w
Methods
patients
utilizatio
Systems
for use, p
authoriza
Results:
male and
years of a
percent g
neurolog
Arthritis.
respirato
ymbols that w
Board # ‐ 4‐0
itle: Cost sav
ype: Evaluat
ion Category
Author: Jacq
cqueline.mi
al Authors:
Henry
Erowele
: Infliximab i
mune disease
ed to a coun
ation progra
nterology, De
nding proto
es are appro
was conducte
s: A retrospe
receiving Inf
n report for
department
physician spe
ation approv
One hundre
d fifty‐five pe
age. Thirty‐e
gastroentero
gy. The top in
The adverse
ory infection
2018ASProf
ere not spelled
068
vings initiativ
tive Study
y: Drug Infor
queline Milt
lton@harris
s an anti‐TN
es such as Cr
nty health sy
am in an effo
ermatology
col to reduc
ximately 2 m
ed to evalua
ective electro
fliximab from
infliximab fo
t. The report
ecialty, dose
val and effica
d and ninety
ercent (105/
eight percen
ology, five p
ndications w
e reactions i
, abdominal
SHPMidyfessional
d‐out per the g
ves for inflix
rmation/Dru
on‐Brown; H
health.org
NF‐alpha inhi
rohn’s diseas
stem formu
ort to contro
and Neurolo
ce waste whe
million dollar
te appropria
onic chart re
m January 20
or this time
t characteris
e, adverse dr
acy.
y patients w
/190) were f
nt (72/190) o
ercent (10/1
were Crohn’s
included bac
pain and hy
yearClinlPoster
guidelines wer
ximab use in
ug Use Evalu
Harris Health
ibitor indicat
se, Ulcerativ
lary over a d
ol cost. It is re
ogy services
en utilizing a
rs annually d
ate use and a
eview was co
016 to May
frame was o
stics included
rug reaction
were reviewe
female. The
of the prescr
190) dermat
s disease, Ulc
cterial infect
ypersensitivi
nicalMeAbstrac
re translated i
a county ho
uation
h System;
ted for the t
ve Colitis and
decade ago r
estricted to
. The hospita
agents such
despite thes
adherence t
onducted on
2017. An inp
obtained fro
d the patien
, prior thera
ed, forty‐five
average age
ribers were r
tology and tw
cerative coli
tion, active T
ity reactions
eetingcts
into unknown
ospital syste
treatment of
d Rheumato
restricted to
Rheumatolo
al system im
as infliximab
e cost saving
to the curren
n one hundr
patient and
om the intern
nt’s demogra
apy, TB test s
e percent (85
e of the patie
rheumatolog
wo percent (
itis and Rheu
TB or TB rein
s. Prior thera
characters.
m
f numerous
oid arthritis.
o a prior‐
ogy,
mplemented
b. Infliximab
gs initiatives
nt guidelines
ed and nine
outpatient
nal Informat
aphics, indica
status, prior
5/190) were
ents was 44
gy; fifty‐five
(3/190)
umatoid
nfection,
apy for the
It
a
b
s. A
s.
ty
tion
ation
r
*Special sy
dermato
percent e
for gastro
etanerce
methotre
inflixima
treatmen
efficacy w
hundred
Conclusio
measure
the prior
Executive
appropri
original i
400,000
ymbols that w
logy indicati
each among
oenterology
ept prior to in
exate were t
b discontinu
nt, loss of ins
with inflixim
percent wh
on: Inflixima
s have been
r authorizatio
e Board app
ate indicatio
nfliximab be
dollars with
2018ASProf
ere not spelled
ions include
other agent
y indications
nfliximab th
the only prio
uation were
surance or in
ab therapy.
ile complian
ab remains a
n employed.
on guideline
roved using
ons. The bios
eing the last
the biosimi
SHPMidyfessional
d‐out per the g
d topical ste
ts. Azathiop
. Patients m
erapy for rh
or agents fai
pregnancy, d
neffectivene
Compliance
nce with the
a top purcha
The review
es. The Pharm
step‐therap
similar, Inflix
choice for u
lar switch an
yearClinlPoster
guidelines wer
eroids, adalim
rine and me
ost often fai
eumatology
led for neur
death, ADE,
ess. Seventy‐
e with the pr
dose round
se for a cou
revealed tha
macy and Th
py with a tria
ximab‐dyyb
use. There is
nd additiona
nicalMeAbstrac
re translated i
mumab and
esalamine we
iled methotr
y indications
ology indica
antibodies,
‐nine percen
rior authoriz
ing protoco
nty health s
at there is co
herapeutics
al of adalimu
was added t
a potential
al cost saving
eetingcts
into unknown
methotrexa
ere the top t
rexate, adali
. Mycophen
ations. The re
non‐compli
nt of the pat
zation criteri
l was only fif
ystem altho
omplete com
Committee
umab for up
to the formu
annual cost
gs with adali
characters.
ate at sixty
two prior ag
imumab and
nolate and
easons for
ance, TB, HC
tients showe
a was one
fty‐six perce
ough cost sav
mpliance wit
and Medica
to 12 weeks
ulary with th
savings of
imumab use
gents
d
CV
ed
ent.
vings
th
l
s for
he
e.
*Special sy
Session‐B
Poster Ti
Poster Ty
Submissi
Primary A
Email: ja
Addition
Goldina E
Andrea H
Purpose:
Services
cause ort
There are
conducte
within th
dispense
Methods
utilizatio
Informat
high risk
medicati
obtained
Results: T
three hu
their resp
thousand
HRM pre
eleven an
percent w
during th
ymbols that w
Board # ‐ 4‐0
itle: Curtailin
ype: Evaluat
ion Category
Author: Jacq
cqueline.mi
al Authors:
Erowele
Henry
: High‐Risk M
(CMS) as ha
thostatic hyp
e 12,676 pat
ed to identify
he system. U
ed to this pat
s: An outpat
n report fro
tion Systems
medication
ons. The uni
d from the w
There were
ndred and e
pective time
d nine hundr
escriptions d
nd the lowes
were on two
he same time
2018ASProf
ere not spelled
069
ng the use o
tive Study
y: Drug Infor
queline Milt
lton@harris
Medications
ving a highe
potension le
tients 65 yea
y all patient
ltimately th
tient popula
ient utilizati
m August 20
s departmen
received, di
it cost of the
wholesaler.
two thousan
eighty‐nine in
e frames. The
red and elev
ispensed du
st was fiftee
o different H
e frame. The
SHPMidyfessional
d‐out per the g
of high risk m
rmation/Dru
on‐Brown; H
health.org
(HRMS) are
er safety risk
eading to fal
ars of age or
s in this age
e goal is to e
tion.
on report fr
017 to Janua
nt. The repor
spensing loc
e high risk m
nd six hundr
npatients 65
ere were tw
ven outpatie
uring this tim
en. Nineteen
HRMS and les
e top five HR
yearClinlPoster
guidelines wer
medications i
ug Use Evalu
Harris Health
identified b
in individua
ls, decline in
r older in a c
range who w
enhance safe
om August 2
ary 2018 wer
rt characteri
cation, autho
medication as
red and twen
5 years of ag
wenty‐nine di
ent prescript
me period fro
n percent of t
ss than one
RMS dispens
nicalMeAbstrac
re translated i
in the elderl
uation
h System;
by the Cente
als 65 years o
n drug cleara
county healt
were dispen
ety by decre
2017 to Apri
re obtained
stics include
orizing phys
s well as the
nty‐five outp
ge or older w
ifferent HRM
tions. The hig
om one locat
the outpatie
percent was
sed in the ou
eetingcts
into unknown
y at a count
rs for Medic
of age or old
ance or hear
h system. A
nsed one or
easing the nu
il 2018 and a
from the int
ed patient de
sician, altern
e formulary a
patients and
who received
MS dispense
ghest numb
tion was sev
ents were on
s on greater
utpatient set
characters.
y health sys
care & Medic
der. They ma
rt anomalies
review was
more HRMS
umber of HR
an inpatient
ternal
emographic
ative
alternative w
d one thousa
d a HRM with
d from two
er of outpat
ven hundred
n one HRM,
than two H
tting were
tem
caid
ay
s.
S
RMS
s,
was
and
hin
tient
d and
two
RMS
*Special sy
cycloben
eight diff
seven un
and one
greater t
digoxin, d
Conclusio
avoided;
Each of t
this shift
electroni
can then
ymbols that w
nzaprine, hyd
ferent HRMS
nits dispense
percent was
han two diff
diphenhydra
on: The use
however de
he high risk
is negligible
ic health rec
select an al
2018ASProf
ere not spelled
droxyzine, ni
S dispensed
ed during tha
s on two diff
ferent HRMS
amine, ketor
of HRMS in
ecreasing the
medications
e to the heal
cord with all
ternative if t
SHPMidyfessional
d‐out per the g
itrofurantoin
to inpatient
at time fram
ferent HRMS
S. The top fiv
rolac, metho
patients 65
eir exposure
s have a safe
th system. It
of the availa
they deem it
yearClinlPoster
guidelines wer
n, meclizine
ts from four
me. Nine perc
S. Less than
ve HRMS dis
ocarbamol a
years of age
e to the elde
er alternativ
t was recom
able alternat
t appropriat
nicalMeAbstrac
re translated i
and amitrip
thousand on
cent of the in
one percent
spensed in t
nd prometh
e and older i
erly can subs
ve available a
mmended to
tives to assis
te for their p
eetingcts
into unknown
ptyline. Ther
ne hundred
npatients w
t of inpatien
he inpatient
hazine.
in many case
stantially imp
and the cost
add an HRM
st physicians
patient.
characters.
e were twen
and ninety
ere one HRM
ts were on
t area were
es cannot be
prove safety
t associated
M alert to the
s. The physic
nty‐
M
e
y.
with
e
cian
*Special sy
Session‐B
Poster Ti
inpatient
Poster Ty
Submissi
Primary A
Email: am
Addition
Malak Re
Nathalie
Razan M
Purpose:
care syst
reviews,
use of m
the drugs
evaluate
guideline
additiona
Methods
utilizatio
and rura
institutio
were sca
older) th
hypersen
sheet wa
guideline
utilizatio
analyzed
ymbols that w
Board # ‐ 4‐0
itle: Retrosp
ts in Lebanes
ype: Evaluat
ion Category
Author: Am
mani.mjaled
al Authors:
eda
Lahoud
hanna
: Albumin is
em if used in
where they
edication, p
s, and decre
the pattern
es for inpatie
al health cos
s: This is a six
n. The study
l (north and
onal review b
nned from J
at have rece
nsitivity, seve
as used to as
es. It was com
n, and labor
using statis
2018ASProf
ere not spelled
070
pective study
se hospitals
tive Study
y: Drug Infor
ani Moujalle
40.am@gm
an expensiv
nappropriat
can improve
reventing ad
easing unnec
of albumin
ents in Leban
st of albumin
x months ob
y was condu
south: one s
board appro
January 2017
eived albumi
ere anemia,
ssess various
mposed of fo
ratory param
tical packag
SHPMidyfessional
d‐out per the g
y investigatin
rmation/Dru
ed; Lebanese
ail.com
ve drug whic
ely. Pharma
e the quality
dverse react
cessary med
use (indicat
nese hospita
n when used
bservational
cted in five d
site each) re
oval from the
7 till January
in during the
or at risk of
s factors abo
our fields (p
meters) and f
e for social s
yearClinlPoster
guidelines wer
ng the adher
ug Use Evalu
e Internation
ch imposes r
cists play an
y of care for
tions of drug
ication costs
ion, frequen
als. Seconda
d inappropria
retrospectiv
different ho
egions in Leb
e centers inc
y 2018 to inc
eir hospital a
f volume ove
out knowled
atient demo
filled by the
science (SPS
nicalMeAbstrac
re translated i
rence to gui
uation
nal Universit
elatively add
n important
patients by
gs, improving
s. Hence, the
ncy, and dur
ry objective
ately.
ve hospital‐b
spital sites i
banon. Resea
cluded in the
clude all pat
admission. P
erload were
ge, practice
ographics, ad
investigator
SS) version 2
eetingcts
into unknown
delines in us
ty;
ditional load
role in drug
preventing
g the overal
e present stu
ration) and a
e was to dete
based resea
n urban (Be
archers obta
e study. Hos
ients (eighte
Patients with
excluded. A
and adhere
dmission de
rs at each sit
2. Means, st
characters.
sing albumin
d on the hea
utilization
inappropria
l effectivene
udy aimed t
adherence to
ermine
rch on drug
irut: Three s
ained
pital records
een years or
h albumin
A data collect
ence to album
tails, albumi
te. Data was
tandard
n for
lth
te
ess of
o
o
sites)
s
r
tion
min
in
s
*Special sy
deviation
than 0.05
Results: A
mainly p
patients
inapprop
misuse (7
versus ot
strong co
than 0.00
other un
albumin
was 52 p
insignific
Conclusio
of album
appropri
essential
among a
concerni
ymbols that w
ns, percenta
5.
A total of 19
rescribed in
received alb
priate use. A
78 percent)
ther indicati
orrelation wa
01). Higher a
its (P equals
administrati
ercent matc
ant (P equal
on: The find
min should be
ate use of al
to set guide
ll healthcare
ng indicatio
2018ASProf
ere not spelled
ges and p va
93 patients w
the intensiv
bumin appro
mong the la
and the adh
ons (P less t
as noted bet
adherence w
s 0.034). Also
ion (P less th
ching with gu
ls 0.629).
ings of this s
e taken into
lbumin and t
eline standa
e team perso
n, frequency
SHPMidyfessional
d‐out per the g
alues were u
with mean a
ve care unit (
opriately for
tter, malnut
herence to gu
han 0.001).
tween adhe
was present s
o, albumin b
han 0.001). F
uidelines. Th
study reveal
consideratio
to minimize
rds within e
onnel about
y and duratio
yearClinlPoster
guidelines wer
used. For all
ge 64.1 ± 19
(ICU) with 75
its indicatio
trition was t
uideline was
Mean serum
rence to gui
significantly
blood levels s
For cirrhosis
he cost of ina
ed that the
on in Lebane
any possible
ach hospital
the importa
on.
nicalMeAbstrac
re translated i
analysis, sig
9.1 years we
5.1 percent.
n and only 2
he most pre
s significantl
m albumin w
delines and
y in the inten
significantly
s patients, th
appropriate
percentage
ese hospitals
e additional
l and to mai
ance of adeq
eetingcts
into unknown
gnificance wa
re included.
. Seventy fou
26 percent h
evalent reaso
y lower in m
was 2.5 g/dL
albumin blo
nsive care un
differed bef
he duration o
albumin uti
of inapprop
s. Thus, to e
cost on pub
ntain contin
quate drug u
characters.
as set at P le
Albumin wa
ur percent o
had
on for album
malnutrition
± 0.6; and a
ood levels (P
nit (ICU) vers
fore and aft
of albumin u
ilization was
priate utilizat
nhance the
blic health, it
nuous aware
utilization
ess
as
of the
min
P less
sus
er
use
s
tion
t is
ness
*Special sy
Session‐B
Poster Ti
a commu
Poster Ty
Submissi
Primary A
Email: m
Addition
Purpose:
euvolem
medicati
high cost
of this st
guideline
Methods
were adm
restrictiv
severe hy
symptom
water res
the perce
collected
serum so
hyponatr
were use
Results:
patients
restrictiv
therapies
percent (
ymbols that w
Board # ‐ 4‐0
itle: Assessm
unity hospita
ype: Evaluat
ion Category
Author: Mic
fpoole2003@
al Authors:
: Conivaptan
ic or hyperv
ons utilized
t, restrictive
udy is to ass
es.
s: This retros
ministered c
ve guidelines
yponatremia
ms attributed
striction, fur
entage of co
d included da
odium conce
remia sympt
ed for analys
During the t
were follow
ve criteria fo
s. In addition
(16 out of 20
2018ASProf
ere not spelled
071
ment of adhe
al
tive Study
y: Drug Infor
chelle Poole;
@yahoo.com
n, a vasopres
olemic hypo
in the inten
guidelines w
sess utilizatio
spective cha
onivaptan fr
s for conivap
a (defined as
d to hyponat
rosemide diu
onivaptan or
ays of coniva
entration at i
toms, and th
sis.
two‐year tim
wed by a nep
r severe hyp
n, of those r
0) had no sy
SHPMidyfessional
d‐out per the g
erence to res
rmation/Dru
; Cleveland C
m
ssin antagon
onatremia, h
sive care un
were created
on of coniva
art review inc
rom January
ptan approva
s serum sod
tremia not r
uresis, saline
ders in com
aptan therap
initiation of
herapy prior
me frame 23
hrologist. Th
ponatremia w
eceiving con
mptoms doc
yearClinlPoster
guidelines wer
strictive guid
ug Use Evalu
Clinic Medin
nist typically
has historica
it (ICU) at ou
d to judiciou
ptan and to
cluded all ad
y 2015 throu
al at order e
ium less tha
esponsive to
e infusion or
pliance with
py, urine osm
conivaptan
to conivapt
patients we
hree patient
with sympto
nivaptan and
cumented in
nicalMeAbstrac
re translated i
delines for c
uation
a Hospital;
utilized as a
lly been liste
ur institution
usly utilize th
review adh
dult patients
ugh Decembe
ntry include
an 120 millim
o other stan
r demeclocyc
h the restrict
molarity, uri
use, listed h
an administ
ere administe
ts (13 percen
oms, and tre
d not meetin
n the medica
eetingcts
into unknown
conivaptan a
a second line
ed in the top
n. Due to th
his medicatio
erence to re
s admitted t
er 2016. Est
ed admission
moles per lite
dard therap
cline). Prima
tion criteria.
ne sodium c
hyponatremi
ration. Desc
ered conivap
nt) met the d
atment failu
ng restriction
al record, 40
characters.
administratio
e treatment
p ten most c
is medicatio
on. The purp
estrictive
o the ICU wh
ablished
n into the ICU
er), and
pies (such as
ary endpoint
Selected da
concentratio
ia diagnosis,
criptive statis
ptan and all
defined
ure with oth
n criteria, 80
0 percent (8 o
on at
for
ostly
on’s
pose
ho
U,
free
t was
ata
on,
,
stics
er
0
out
*Special sy
of 20) ha
no inpati
savings o
followed
Conclusio
establish
ymbols that w
d serum sod
ient treatme
of approxima
during this
on: This stud
hed restrictio
2018ASProf
ere not spelled
dium greate
ent for their
ately $25,00
time frame.
dy demonstr
on criteria fo
SHPMidyfessional
d‐out per the g
r than 119 m
hyponatrem
0 could have
rated the ne
or conivaptan
yearClinlPoster
guidelines wer
millimoles pe
mia prior to c
e been actua
eed for physi
n administra
nicalMeAbstrac
re translated i
er liter, and
conivaptan a
alized if rest
ician and ph
ation.
eetingcts
into unknown
15 percent (
administratio
triction crite
harmacist ad
characters.
(3 out of 20)
on. A cost
ria were
herence to
had
*Special sy
Session‐B
Poster Ti
analysis o
Poster Ty
Submissi
Primary A
Email: rw
Addition
Yesha Pa
Laura Ko
Lara Ellin
Purpose:
their man
Drug Info
informat
number o
characte
recomme
seeking g
Methods
electroni
requests
Descripti
American
for short
these rec
Results: A
requests
(21.9%; n
electroly
ymbols that w
Board # ‐ 4‐0
itle: Shortag
of affected d
ype: Evaluat
ion Category
Author: Rya
wrodrig@uic
al Authors:
tel
ppen
nger
: Drug shorta
nagement to
ormation Gro
ion requests
of requests a
rize the sho
endations pr
guidance on
s: Data on re
ically. Text‐m
to be scree
ive analyses
n Hospital Fo
age manage
commendat
A total of 15
occurred in
n=33), and 2
te, caloric, a
2018ASProf
ere not spelled
072
ge‐related re
drugs and re
tive Study
y: Drug Infor
an Rodriguez
c.edu
ages remain
o ensure opt
oup (DIG) is
s from client
are related t
rtage‐relate
rovided, and
manageme
equests rece
mining funct
ned, and ma
were perfor
ormulary Se
ement, types
ions.
51 shortage‐
2013 (43.0%
2016 (11.9%;
and water ba
SHPMidyfessional
d‐out per the g
equests rece
esources sup
rmation/Dru
z; University
n a significan
timal patien
a fee‐for‐se
t hospitals a
to drug shor
d requests r
d identify use
nt of drug sh
eived by the
ions in Micr
anual review
rmed to repo
rvice (AHFS)
s of recomm
‐related drug
%; n=65) and
; n=18). Mos
alance agent
yearClinlPoster
guidelines wer
ived by a dr
pporting reco
ug Use Evalu
of Illinois at
t problem in
t care. The U
ervice drug in
nd health sy
rtage manag
received by o
eful drug inf
hortages.
UIC DIG bet
osoft Excel i
w identified t
ort frequenc
) drug class,
mendations, a
g informatio
d decreased
st requests w
ts (15.2%; n=
nicalMeAbstrac
re translated i
ug informat
ommendatio
uation
t Chicago Co
n healthcare
University of
nformation c
ystems throu
gement. The
our center, d
formation re
ween 2013
identified pr
those confirm
cies of reque
requests rec
and informa
on requests w
in number i
were related
=23); autono
eetingcts
into unknown
ion center: a
ons for mana
ollege of Pha
e, and presen
f Illinois at C
center that a
ughout the U
purpose of
describe the
esources for
and 2016 we
resumably sh
med to be sh
ests for each
ceiving reco
ation resourc
were identif
in 2014 (23.
d to AHFS cla
omic drugs (
characters.
a descriptive
agement
rmacy;
nt challenge
Chicago (UIC)
accepts drug
United State
our study is
e manageme
pharmacist
ere collected
hortage‐rela
hortage‐rela
h drug and
mmendatio
ces supporti
fied. Most
2%; n=35), 2
asses of
(12.6%; n=19
e
es in
)
g
es. A
to
ent
s
d
ated
ated.
ns
ng
2015
9);
*Special sy
and card
affected
A recomm
frequent
different
(60.2%; n
website (
Conclusio
center w
cardiovas
majority
alternativ
necessar
drug info
pharmac
guidance
ymbols that w
iovascular d
were, respe
mendation w
t was use of
t information
n=74) and th
(41.5%; n=5
on: Request
were most co
scular agent
of shortage
ve agent. Th
rily reflect na
ormation res
cists may ben
e.
2018ASProf
ere not spelled
rugs (11.9%
ectively, sodi
was provided
an alternativ
nal resource
he American
1).
ts for drug sh
ommonly rela
ts, which ma
‐related req
he identified
ational drug
sources supp
nefit from a
SHPMidyfessional
d‐out per the g
%; n=18). Wit
ium chloride
d for 81.5%
ve drug (76.
categories a
Society of H
hortages rec
ated to drug
ay predomin
uests were r
decrease in
shortage tre
ported recom
more comp
yearClinlPoster
guidelines wer
thin these ca
e (n=8), phen
of requests
4%; n=94). R
and were m
Health‐Syste
ceived by a n
g classes of e
antly affect
recommend
n shortage‐re
ends, and sh
mmendation
rehensive re
nicalMeAbstrac
re translated i
ategories, th
ntolamine (n
(n=123), am
Recommend
ostly derive
em Pharmaci
nationally‐se
electrolyte, a
critically ill a
ded to be ma
elated reque
hould be furt
ns for shorta
esource prov
eetingcts
into unknown
he drugs mos
n=10), and p
mong which t
dations were
d from prim
ists (ASHP) D
erving drug i
autonomic, a
and surgical
anaged by us
ests over tim
ther explore
age managem
viding shorta
characters.
st frequently
papaverine (n
the most
e informed b
mary literatur
Drug Shortag
nformation
and
populations
sing an
me may not
ed. Numerou
ment; thus,
age‐specific
y
n=8).
by 15
re
ges
s. A
us
*Special sy
Session‐B
Poster Ti
cross‐sec
Poster Ty
Submissi
Primary A
Email: 11
Addition
Hady Jab
Bahia Ch
Purpose:
because
defined a
somatose
data exis
the patte
their asso
Methods
across al
with neu
question
informat
medicati
monthly
Question
Results: T
females.
40‐49 ye
cervical o
spinal co
ymbols that w
Board # ‐ 4‐0
itle: Pattern
ctional study
ype: Descrip
ion Category
Author: Tare
1230825@st
al Authors:
bado
ahine
: Neuropath
of the heter
as pain arisin
ensory syste
st on the rate
erns of presc
ociated adve
s: This is an o
l Lebanese g
ropathic pai
naire. The p
ion, past me
ons used, dr
cost). Pain d
nnaire (SF‐M
Three hundr
Most patien
ars (25.3 pe
or lumbar ra
rd injury (13
2018ASProf
ere not spelled
073
s of prescrib
y
ptive Report
y: Drug Infor
ek Selman; L
tudents.liu.e
ic pain is a c
rogeneity of
ng as a direc
em. Drugs to
es and patte
cribing neuro
erse effects.
observationa
governorates
in disorder w
parameters e
edical history
rug classes, d
description w
MPQ).
red and sixty
nts diagnose
rcent). The m
diculopathy
3.9 percent)
SHPMidyfessional
d‐out per the g
bing neuropa
rmation/Dru
Lilies Pharma
edu.lb
common chr
its etiologie
ct consequen
o treat neuro
erns of use in
opathic pain
al study that
s between Ja
were include
evaluated we
y, type of ne
doses, physi
was evaluate
y patients w
ed with neur
most commo
y (42.8 perce
and post he
yearClinlPoster
guidelines wer
athic pain dr
ug Use Evalu
acy;
onic pain co
es, symptom
nce of a lesio
opathic pain
n Lebanon. T
n drugs in the
t was condu
anuary and
ed in the stu
ere demogra
europathic p
cians’ specia
ed according
ere included
ropathic pain
on neuropat
ent) followed
erpetic neura
nicalMeAbstrac
re translated i
rugs in the L
uation
ondition that
ms and under
on or disease
are highly p
This study w
e Lebanese
cted at 30 c
May 2018. A
dy. Data wa
aphic profile
pain disorder
alty, duratio
g to Short‐Fo
d in this stud
n disorders r
thic pain dis
d by diabetic
algia (9.4 pe
eetingcts
into unknown
ebanese com
t can be cha
rlying mecha
e affecting t
prescribed; h
was conducte
community
ommunity p
Adult patien
s collected b
e of patients
r and drug d
on of treatme
orm McGill P
dy of whom
resided in th
order encou
c neuropath
ercent). Twen
characters.
mmunity: a
llenging to t
anisms. It is
the
however, lim
ed to evaluat
pharmacies
pharmacies
ts diagnosed
by interview
s, geographic
data (numbe
ent and its
Pain
55 percent w
he age group
untered was
y (26.1 perc
nty‐three
treat,
mited
te
and
d
w
c
r of
were
p of
ent),
*Special sy
percent o
prescribe
more dru
identified
neurolog
used dru
without a
than six m
with time
reported
Conclusio
Polythera
however
ymbols that w
of patients u
ed class (87 p
ugs, with pre
d. The presc
gists (16.1 pe
gs without a
a prescriptio
months. Am
e. Eighty per
d adverse eff
on: Pregaba
apy is usuall
r, it was asso
2018ASProf
ere not spelled
used monoth
percent). Se
egabalin plus
ribing physic
ercent), endo
a prescriptio
on (40 perce
ong those u
rcent report
fect was sed
lin is first lin
y needed to
ociated with
SHPMidyfessional
d‐out per the g
herapy of wh
venty‐seven
s nonsteroid
cians were p
ocrinologists
on. Post‐herp
nt of cases).
sing neurop
ed having ex
ation (40.6 p
ne treatment
o alleviate ne
higher risk o
yearClinlPoster
guidelines wer
hich antiepil
n percent of
dal anti‐infla
primarily ort
s (15.6 perce
petic neuralg
. Thirty‐six p
pathic pain d
xperienced a
percent) foll
t of neuropa
europathic p
of adverse e
nicalMeAbstrac
re translated i
leptics were
patients use
mmatory dr
thopedics (3
ent), wherea
gia was the m
percent had
rugs, 31.7 p
adverse effe
lowed by we
athic pain dis
pain and imp
vents versus
eetingcts
into unknown
the most fr
ed combinat
rugs the mos
6.7 percent)
as 16.5 perc
major etiolo
been taking
ercent incre
ects. The mo
eight gain (3
sorders in Le
prove patien
s monothera
characters.
equently
tions of two
st frequently
), followed b
ent of patie
ogy treated
the drug fo
eased the do
ost common
1.7 percent)
ebanon.
nts’ quality o
apy.
or
y
by
nts
r less
ose
).
of life,
*Special sy
Session‐B
Poster Ti
Poster Ty
Submissi
Primary A
Center;
Email: na
Addition
Seon‐You
Youn‐Joo
Hyokeun
Purpose:
osteopor
drugs, te
utilized a
Program
utilizatio
and Asse
mineral d
Methods
who had
First, pat
the appro
treatmen
after the
Results: T
osteopor
appropri
inapprop
was prop
ymbols that w
Board # ‐ 4‐0
itle: Validity
ype: Evaluat
ion Category
Author: Ock
ahee316@gm
al Authors:
ung Min
o Jung
n Jeong
: Owing to th
rosis and ost
riparatide, a
after the dru
since Decem
n in this hos
essment. It a
density (BM
s: This retros
been prescr
tients who h
opriateness
nt were asse
administrat
The reimbur
rotic fracture
ateness of te
priately presc
perly prescri
2018ASProf
ere not spelled
074
of utilizatio
tive Study
y: Drug Infor
k Yoon; Depa
mail.com
he recent em
teoporotic fr
a unique syn
g was prove
mber, 2016.
spital by the
lso makes a
D) before an
spective stud
ribed for ter
ad been adm
of age, dise
essed by com
tion of teripa
rsement crit
es and a T‐sc
eriparatide a
cribed due t
bed, satisfyi
SHPMidyfessional
d‐out per the g
n and effica
rmation/Dru
artment of C
mergence of
racture have
nthetic anabo
ed for reimb
This study a
reimbursem
n assessmen
nd after adm
dy, utilizing
riparatide at
ministered w
ase name an
mparing bone
aratide.
teria for terip
core of BMD
administrati
to their ages
ng the reim
yearClinlPoster
guidelines wer
cy of teripar
ug Use Evalu
Clinical Pharm
f rapidly‐agin
e sharply inc
olic agent of
ursement by
attempts to e
ment criteria
nt of the the
ministration o
the electron
this hospita
with teripara
nd prescript
e mineral de
paratide are
D test of ‐2.5
on showed t
s being less t
bursement c
nicalMeAbstrac
re translated i
ratide prescr
uation
macy, Veter
ng society, th
creased. Acco
f parathyroid
y Korea Nati
examine the
, set forth b
erapeutic eff
of teriparatid
nic health re
al from Marc
atide at this h
ion duration
ensities (BM
e sixty‐five ye
5 or less. The
that 18 out
than 65 year
criteria rega
eetingcts
into unknown
ription
ans Health S
he number o
ordingly, am
d hormone,
ional Health
e appropriat
y Health Ins
ficacy by me
de.
cord, evalua
ch 2013 to D
hospital wer
n. Then, the
Ds) and T‐sc
ears or olde
e assessmen
of 281 patie
rs. A total of
rding osteop
characters.
Service Med
of patients w
mong various
has been
Insurance
eness of dru
urance Revi
asuring the
ated 281 pat
December 20
re evaluated
efficacies of
cores before
r, two or mo
t of the
ents were
118 patient
porosis or
ical
with
s
ug
ew
bone
tients
017.
d for
f
e and
ore
ts
*Special sy
osteopor
met the l
assessme
change a
patients
observed
increase,
a mean B
BMD incr
femur an
Conclusio
investiga
pharmac
administ
duration
monitori
intervent
ymbols that w
rotic fracture
less‐than‐24
ent of treatm
after teripara
had an incre
d in 2 patien
, while 5 rev
BMD increas
rease of 0.05
nd lumbar re
on: The sign
ation. This st
cologic indica
ration, and o
. Furthermo
ng adverse r
tion by phar
2018ASProf
ere not spelled
es. The mea
4‐months cri
ment effect o
atide admini
eased BMD;
ts. Regardin
ealed a BMD
se of 0.12±0.
5±0.07 g/cm
egions.
ificant thera
udy was abl
ation by con
of (2) this sy
re, this inve
reactions of
rmacists.
SHPMidyfessional
d‐out per the g
n duration o
teria of Hea
of teriparati
istration. Th
One patient
g the proxim
D decrease d
.15 g/cm² (1
m² (13.6%). B
apeutic effec
e to establis
ducting time
ynthetic para
stigation ha
patients adm
yearClinlPoster
guidelines wer
of teriparatid
lth Insuranc
de was carri
e results of
t showed no
mal femur, a
despite terip
7.3%), while
BMD increase
ct of teripara
sh the neces
ely BMD tes
athyroid age
s developed
ministered w
nicalMeAbstrac
re translated i
de administr
ce Review an
ied out by m
lumbar tests
o change; an
mong 24 su
paratide trea
e the proxim
e was appar
atide could b
ssity of (1) at
sts before an
ent administ
d a basis for t
with teripara
eetingcts
into unknown
ration was 3
nd Assessme
making an an
s showed th
d a BMD de
bjects, 19 sh
atment. The
mal femur rev
rent in both
be verified b
ttaining and
nd after terip
ration for an
the manage
atide, which
characters.
3 months, wh
ent. The
nalysis of BM
at 21 out of
crease was
howed a BM
lumbar sho
vealed a me
the proxima
by this
accurate
paratide
n adequate
ement system
necessitate
hich
MD
f 24
MD
wed
an
al
m for
es an
*Special sy
Session‐B
Poster Ti
Poster Ty
Submissi
Primary A
Email: m
Addition
Abdelaziz
Purpose:
program
Saudi Ata
Methods
adherenc
(from Se
emergen
Adheren
observed
date visib
the patie
Results:
complian
duration
57%). Th
at the be
Collectio
reached
Septemb
Conclusio
hospital
ymbols that w
Board # ‐ 4‐0
itle: Impact
ype: Evaluat
ion Category
Author: Mo
maljamal@h
al Authors:
z Galdigoun
: The aim of
(ASP) in the
abia using se
s: A pilot stu
ce to the app
ptember 20
ncy, critical c
ce to the sel
d to evaluate
ble, indicatio
ent prescribe
Considering
nce; howeve
. There was
e indication
eginning (Sep
n of specime
in 93% of th
ber. About 93
on: The stud
improves th
2018ASProf
ere not spelled
075
of antimicro
tive Study
y: Infectious
hammed Alj
hotmail.com
the study w
e improveme
elected antim
dy was cond
propriate ad
17 to Februa
are and gen
lected antim
e appropriat
on shown, ap
ed the right a
the docume
er, variations
improveme
for the anti
ptember); ho
ens for cultu
e cases by F
3% patients
dy concluded
e appropriat
SHPMidyfessional
d‐out per the g
obial steward
s Disease / H
jamal; King S
m
was to evalua
ent of appro
microbial ste
ducted to ev
dherance to
ary 2018) we
eral surgica
microbial stew
te initiation c
ppropriate s
antibiotic do
entation of t
s was noticed
nt noticed o
biotic therap
owever grad
ure and sens
February alth
in average r
d that having
te prescribin
yearClinlPoster
guidelines wer
dship on app
HIV
Salman Milit
ate the impa
opriate antib
ewardship q
valuate ASP w
antibiotic th
e randomly r
l and medica
wardship qu
criteria for a
specimen ob
ose to be ad
the start dat
d on the doc
on last two m
py was show
dually increa
sitivity at the
hough starte
received the
g an antimic
ng of antibio
nicalMeAbstrac
re translated i
propriate ini
tary Hospita
act of the an
biotic prescri
uality indica
where it was
herapy stand
reviewed 85
al patients re
uality indicat
antibiotic the
btained prior
ministered a
te of therapy
cumentation
month (Janua
wn only on 4
ased to reach
e time of init
ed with a pe
e antibiotic d
crobial stewa
otics and col
eetingcts
into unknown
itiation of an
l;
tmicorbial s
bing at a ma
ators.
s noticed flu
dards. Over 6
54 medicatio
eceiving ant
tors was pro
erapy (start
r to therapy
at the right i
y initiation w
n of the anti
ary 66.9% an
49% of the o
h 66% on Fe
tiating empi
rcentage of
dose at the r
ardship prog
laboration w
characters.
ntibiotic the
tewardship
ajor hospital
uctuation in
6 month per
on orders of
tibiotic thera
ospectively
date visible,
imitation, a
intervals).
we reached 1
biotic therap
nd February
rders review
bruary.
rical therapy
59% on
ight interval
gram (ASP) i
with all
rapy
l in
riod
apy.
, stop
nd
100%
py
wed
y
l.
n the
*Special sy
healthca
team. Th
were imp
educatio
Further e
ASP. ASP
hospital.
ymbols that w
re professio
e antimicro
plemented t
nal program
evaluative st
P software w
2018ASProf
ere not spelled
nal can furth
bial steward
o improve a
m, feedback a
tudies are re
was suggeste
SHPMidyfessional
d‐out per the g
her influenc
dship quality
dherence to
and continuo
equired to ev
d to oversee
yearClinlPoster
guidelines wer
e the effecti
y indicators w
o ASP. These
ous commun
valuate the e
eing the real
nicalMeAbstrac
re translated i
iveness of th
were improv
e include req
nications wit
effectivenes
ltime overal
eetingcts
into unknown
he an antibio
ving overtim
quiring autho
th prescribe
ss of these st
l use of antim
characters.
otic steward
e. Strategies
orisation,
ers and nurse
trategies on
microbials in
ship
s
es.
the
n the
*Special sy
Session‐B
Poster Ti
tertiary c
Poster Ty
Submissi
Primary A
Email: du
Addition
Alhanouf
Anhar Al
Nada Alh
Dhafer A
Purpose:
common
undergon
with othe
the mult
evaluate
A.bauma
Methods
2017 and
collected
pneumon
were exc
A.bauma
predispo
A.bauma
Results: T
patients,
tigecyclin
ymbols that w
Board # ‐ 4‐0
itle: Evaluati
care hospita
ype: Evaluat
ion Category
Author: Dua
uaa.alsulaim
al Authors:
f Almalaihi
zaydi
hamad
Alshayban
: Acinetobac
pathogens
ne significan
er organism
i drug resista
the used th
annii among
s: This is retr
d to Dec 201
d from medic
nia infection
cluded. The p
annii pneumo
se the patie
annii pneumo
There were
65% were m
ne (63%). Ot
2018ASProf
ere not spelled
076
ion of Acinet
l in Saudi Ar
tive Study
y: Infectious
aa Alsulaima
cter bauman
of nosocom
nt taxonomic
s. A study in
ance‐ A.bau
erapy, lengt
critically ill p
rospective c
17. Institutio
cal charts. A
n caused by A
primary outc
onia infectio
nts to A.bau
onia infectio
71 patients
males. The m
ther tested a
SHPMidyfessional
d‐out per the g
tobacter bau
abia
s Disease / H
an; King Faha
com
nnii (A.baum
ial pneumon
c alterations
U.S. showe
mannii was
th of hospita
patients at a
hart review
nal review b
ll patients a
A. baumann
come is to sp
on. Secondar
umannii pne
on among IC
included in
mean length
antibiotics at
yearClinlPoster
guidelines wer
umannii pne
HIV
ad University
annii) has be
nia. Through
s leading to h
d that amon
more than 8
al stay and m
a tertiary ca
study condu
board approv
dmitted to t
ii were inclu
pecify the m
ry outcomes
umonia and
U patients a
the study w
of stay was
t our institut
nicalMeAbstrac
re translated i
eumonia am
y Hospital;
een identifie
hout the tim
high antimic
ng patients w
80%. The pu
mortality rate
re hospital i
ucted over o
ved this stud
the intensive
uded. Immun
most commo
s are to eval
d report the
at our institu
ith a mean a
55 days. Th
tion were al
eetingcts
into unknown
mong criticall
ed as one of
e, this bacte
crobial resist
with A.baum
rpose of this
e of pneumo
n Saudi Arab
one year, bet
dy. Patient in
e care unit (I
nocomprom
n antibiotic
uate the risk
mortality ra
ution.
age of 55 ye
e most sens
l under 20%
characters.
y ill patients
f the most
erium has
tance compa
mannii infect
s study is to
onia caused
bia.
tween Janua
nformation
ICU) with
mised patient
used to trea
k factors
te of
ars old. Of t
itive agent w
of sensitivit
s in a
ared
ions,
by
ary
ts
at
hose
was
ty,
*Special sy
our instit
sodium w
therapy w
risk facto
days (84%
infection
Conclusio
caused b
including
Further s
outcome
ymbols that w
tution howe
was the mos
was used in
or for A.baum
%) and mec
s (55%), the
on: This stud
by A.bauman
g implement
studies shou
es.
2018ASProf
ere not spelled
ver does not
t used agent
42% of the p
mannii pneu
hanical vent
e 14‐day mor
dy demonstr
nnii among IC
ting antimicr
ld be done t
SHPMidyfessional
d‐out per the g
t test for col
t (55%) for s
patients com
umonia in ou
tilation (73%
rtality rate w
rates the po
CU patients.
robial stewa
to assess suc
yearClinlPoster
guidelines wer
listimethate
such infectio
mpared to 13
ur ICU patien
%). Most of t
was 46.15%.
or outcome
Further imp
rdship and w
ch implemen
nicalMeAbstrac
re translated i
e sodium sen
ons, colistime
3% as mono
nts were use
he patients
s associated
provement s
wise use of b
ntations and
eetingcts
into unknown
nsitivity. Coli
ethate sodiu
therapy. The
e of antibioti
died before
d with pneum
should be co
broad spectr
d its relation
characters.
istimethate
um combina
e most ident
cs in the pas
resolution t
monia infect
onsidered
rum antibiot
ship to patie
tion
tified
st 90
their
tion
tics.
ent
*Special sy
Session‐B
Poster Ti
stewards
Poster Ty
Submissi
Primary A
Email: di
Addition
Paulo Fe
Alexandr
Purpose:
related to
As medic
help opti
stewards
Stewards
of this st
intervent
outcome
Methods
Novembe
ASP EPIC
categorie
duplicate
2015 to J
and and
was the t
intervent
square a
periods.
ymbols that w
Board # ‐ 4‐0
itle: Impact
ship report i
ype: Evaluat
ion Category
Author: Dia
andrade@m
al Authors:
rnandes
ra Perez
: Clostridium
o antibiotic
cation exper
imize antibio
ship report u
ship Program
udy was to e
tions on loca
es.
s: A pharmac
er 2016. It in
C report (AER
es 1) target o
e coverage 6
July 2017. Th
the post inte
the percent
tions. Secon
nd independ
An alpha lev
2018ASProf
ere not spelled
077
of implemen
n the incide
tive Study
y: Infectious
na Andrade;
mhs.net
m difficile inf
exposure. M
ts, pharmac
otic therapy
using the Inf
m recommen
evaluate the
al healthcare
cist driven a
nvolved daily
R) that flagge
organism, 2)
6) protected
he pre interv
ervention tim
of HA CDIs a
dary outcom
dent t test w
vel of five pe
SHPMidyfessional
d‐out per the g
nting a phar
nce of healt
s Disease / H
; Memorial H
ections (CDI
Moreover, CD
ists have be
and reduce
ectious Dise
ndations in o
e effect of AS
e associated
ntibiotic ste
y pharmacis
ed potential
) bug drug m
antimicrobi
vention time
me period fr
at our facility
mes were len
were used to
ercent was u
yearClinlPoster
guidelines wer
macist drive
hcare associ
HIV
Hospital We
) in hospital
DI increases
come essen
adverse effe
eases Society
order to imp
SP Epic Repo
C. difficile i
wardship se
t review of t
patients elig
mismatch, 3)
al. Our stud
e period was
rom Novemb
y pre and po
ngth of stay
compare ou
used for all o
nicalMeAbstrac
re translated i
en interventi
iated clostrid
st;
lized patient
mortality ra
tial in the su
ects. Our ins
y of America
prove antibio
ort (AER) gui
nfection rat
ervice was in
the steward
gible for an
de escalatio
dy time perio
s from Septe
ber 2016 to
ost stewards
and numbe
utcomes acr
of the compa
eetingcts
into unknown
ion antimicr
dium difficil
ts are known
ates and eco
urveillance o
stitution imp
a (IDSA) Anti
otic utilizatio
ided pharma
es and othe
nitiated at ou
ship alerts g
intervention
on 4) drug la
od was from
ember 2015
July 2017. P
ship report g
r of days on
ross pre and
arisons.
characters.
robial
e infections
n to be close
nomic burde
of antibiotics
plemented a
biotic
on. The obje
acist
r healthcare
ur facility in
generated by
n based on 5
ab mismatch
m September
to October 2
Primary outc
guided
antibiotics.
post time
ely
en.
s to
a
ctive
e use
y the
5
h 4)
r
2016
ome
Chi
*Special sy
Results:
males co
respectiv
and post
ASP patie
intervene
(p equals
13.22 ve
mean nu
8.209 (m
Conclusio
HA CDIs,
Furtherm
stay that
led interv
significan
produce
ymbols that w
In the pre in
ompared to 5
vely (p equal
groups resp
ent’s interve
ed patients.
s 0.235). The
rsus 10.52 d
mber of day
mean differen
on: Pharmac
but may be
more, there w
may amoun
ventions pla
ntly influenc
savings.
2018ASProf
ere not spelled
ntervention g
54.9 percent
l 0.269). The
pectively. In
ened. In the
The percent
e mean lengt
ays (mean d
ys on antibio
nce minus 1.
cist interven
extrapolate
was a signific
nt to a cost s
y a crucial ro
e appropriat
SHPMidyfessional
d‐out per the g
group there
tage vs. 45.1
e mean age w
the prior to
post AER, th
t of HA CDI w
th of stay in
difference m
otics in the p
.3954, p less
ntions resulte
ed to an ann
cant reducti
savings over
ole in succes
te antibiotic
yearClinlPoster
guidelines wer
were 52.9 p
1 percentage
was 66 versu
the AER, the
here were 24
was decreas
the pre and
minus 2.695,
pre and post
s than 0.005)
ed in a non s
ual 1,450,00
on in the nu
3,000 dolla
ssful antimic
c prescribing
nicalMeAbstrac
re translated i
percentage f
e in the post
us 67.2 yo (p
ere were 16
4 HA CDIs ca
sed from 1.5
d post implem
p less than 0
AER implem
).
statistical re
00 dollars in
umber of ant
rs per patien
crobial stewa
g habits, imp
eetingcts
into unknown
females and
t interventio
p equal 0.46
6 cases of HA
ases amongs
percentage
mentation o
0.005) respe
mentation w
eduction of 0
medical cos
tibiotic days
nt admission
ardship prog
proved qualit
characters.
47.1 percen
n group
1) for the pr
A CDI in the 1
st the 2316 A
e to 1 percen
of the AER w
ectively. The
as 9.604 ver
0.5 percenta
st avoidance
s and length
n. Pharmaci
grams and
ty of care an
ntage
re
1059
ASP
ntage
was
rsus
ge in
e.
of
st
nd
*Special sy
Session‐B
Poster Ti
procalcit
Poster Ty
Submissi
Primary A
Email: as
Addition
Sara Utle
Cassandr
Purpose:
agents, p
highly sp
respirato
determin
commun
Methods
an ICD‐10
long‐term
onset. Su
equals 17
inpatient
total LOT
using the
panels (R
results le
atypical c
followed
Results:
discharge
ymbols that w
Board # ‐ 4‐0
itle: Duratio
onin
ype: Descrip
ion Category
Author: Sah
skarian@mu
al Authors:
ey
ra Gibbes
: In an effort
procalcitonin
ecific to non
ory tract infe
ne the length
ity‐acquired
s: A list of all
0 code of J18
m care, or nu
ubjects were
78) and thos
t length of th
T for those d
e medication
RP) were rev
ed to early d
coverage. PC
by discharg
Mean durat
ed with pres
2018ASProf
ere not spelled
078
n of therapy
ptive Report
y: Infectious
hand Askaria
usc.edu
t to decrease
n was made
n‐localized b
ections (LRTI
h of stay and
d pneumonia
l antibiotics
8.9 for pneu
ursing facilit
e categorized
se without (n
herapy (LOT
ischarged o
n administra
viewed. RP w
iscontinuati
CT was class
ge prescriptio
ion of total t
scriptions fo
SHPMidyfessional
d‐out per the g
y in commun
s Disease / H
n; South Car
e the duratio
available at
bacterial infe
s), when clin
d overall dur
a (CAP), and
orders for p
umonia was
y were exclu
d into those
n equals 239
), added to t
n antibiotics
tion records
was determin
on of antibio
ified as guid
ons, or led to
therapy was
r antibiotics
yearClinlPoster
guidelines wer
nity‐acquired
HIV
rolina Colleg
on of therap
our instituti
ections. It off
nical uncerta
ration of the
to identify w
patients adm
obtained. Pa
uded to limit
with discha
9). Inpatient
the day supp
s. For those w
s. Orders for
ned to guide
otics, or if ne
ing DOT if le
o a decrease
s determined
, and greate
nicalMeAbstrac
re translated i
d pneumoni
ge of Pharma
py and unnec
ion. Procalci
fers aid in di
ainty prevail
erapy for pat
whether pro
mitted from J
atients adm
t population
rge prescrip
length of st
ply of the pr
without DCP
r procalciton
e duration of
egative pane
evels less tha
e in inpatien
d to be great
er than 4 day
eetingcts
into unknown
a (CAP) and
acy, MUSC c
cessary use
itonin is a se
iagnoses of
s. This study
tients admitt
ocalcitonin h
January to A
itted from a
n sample to c
ptions (DCP)
ay (LOS) wa
escriptions t
P, the LOT w
nin (PCT) and
f therapy (D
els led to ter
an 0.25 ng/m
nt DOT.
ter than 7 d
ys in those w
characters.
the role of
campus;
of antimicro
erum biomar
lower
y was aimed
ted with
had played a
April of 2018
nother hosp
community‐
for antibioti
s used as th
to determin
was determin
d respiratory
OT) if positiv
rmination of
ml were not
ays in patien
without. Ord
obial
rker
d to
role.
with
pital,
ics (n
e
e
ned
y
ve
f
nts
ers
*Special sy
for proca
cases. Th
correspo
instances
inpatient
were det
Conclusio
the popu
These fin
antimicro
decision
ymbols that w
alcitonin (n e
here were 66
onding PCT le
s of DCP wer
t stay, but no
termined to
on: Lack of c
ulation pool,
ndings may s
obial stewar
making and
2018ASProf
ere not spelled
equals 302) w
6 orders for
evels falling
re identified
ot within 24
guide durat
consistency
raising conc
suggest a ne
rdship practi
increasing a
SHPMidyfessional
d‐out per the g
were determ
continuation
below 0.25
d where PCT
hours prior
ion of thera
in interpreta
cerns with re
ed to increa
ces. Pharma
appropriate
yearClinlPoster
guidelines wer
mined to guid
n of antibiot
ng/mL; of w
was ordered
to discharge
py more oft
ation of PCT
egards to co
se prescribe
acist have a p
interpretati
nicalMeAbstrac
re translated i
de DOT in le
tics upon dis
which 25 wer
d at some po
e. Respirato
en than PCT
levels were
ost and bene
er education
potential to
on of serum
eetingcts
into unknown
ess than 15 p
scharge, des
re below <0.
oint during t
ory panels (n
T in both gro
e frequently
efit to overal
n and utilizat
offer aid in
m biomarkers
characters.
percent of al
pite
10 ng/mL. 8
the length o
equals 214)
oups.
observed ac
l patient car
tion of effect
antibiotic
s.
ll
81
f
)
cross
re.
tive
*Special sy
Session‐B
Poster Ti
critical ac
Poster Ty
Submissi
Primary A
Email: m
Addition
Erin Doxt
Katherine
Purpose:
Commiss
the state
less than
(CDC) Co
of ASPs i
assess th
stewards
Methods
related to
impleme
devised a
pharmac
prospect
pharmac
focused o
tracking f
days a w
duplicati
escalatio
antimicro
ymbols that w
Board # ‐ 4‐0
itle: Implem
ccess hospit
ype: Descrip
ion Category
Author: Me
eghan.aslan
al Authors:
tater
e Shea
: Current reg
sion Antimic
e of Californi
50% of CAH
ore Elements
n CAHs pose
he impact of
ship interven
s: This was a
o antimicrob
ntation of a
a plan to enh
cist to provid
tive audit str
cy staff traini
on antimicro
form and int
eek during p
on, de‐escal
on, and intrav
obial interve
2018ASProf
ere not spelled
079
entation of
al
ptive Report
y: Infectious
ghan Aslania
nian@gmail.
gulatory req
robial Stewa
a antimicrob
Hs had imple
s of Hospital
e unique cha
a pharmacis
ntions and C
a single cente
bial steward
prospective
hance stewa
de drug expe
rategy. The
ing and educ
obial stewar
tervention t
pharmacy op
lation, dose
venous to o
entions per 1
SHPMidyfessional
d‐out per the g
an antimicro
s Disease / H
an; Ridgecre
com
uirements fo
ardship Med
bial steward
emented all
Antimicrob
allenges, incl
st prospectiv
CDC Core Ele
er, retrospec
ship before
e audit strate
ardship servi
ertise, guidan
developmen
cation which
dship as we
racking syste
perating hou
optimization
ral conversio
1000 patient
yearClinlPoster
guidelines wer
obial stewar
HIV
est Regional
or critical ac
dication Man
ship require
7 of the Cen
ial Stewards
luding limite
ve audit stra
ment compl
ctive study a
(Jan17‐Mar
egy. The ant
ices within t
nce regardin
nt and educa
h consisted o
ll as develop
em. Pharma
urs and focus
n (e.g., rena
on. To dete
t days and in
nicalMeAbstrac
re translated i
rdship prosp
Hospital;
ccess hospita
nagement St
ements. A r
nters for Dise
ship Program
ed resources
ategy within
liance.
assessing ph
17) and afte
timicrobial s
he CAH whic
ng tracking a
ation phase
of 12‐hours
pment and im
acist interve
sed on the f
l dose adjus
ermine the im
ntervention
eetingcts
into unknown
pective audit
als (CAHs) in
tandard MM
recent surve
ease Contro
ms (ASPs). Im
s. Investigato
a CAH on an
harmacist int
er (Apr17‐Ma
stewardship
ch included
and reportin
(Nov16‐Mar
of continuin
mplementat
entions were
following: th
stment), ther
mpact of the
acceptance
characters.
t strategy in
clude The Jo
M.09.01.01 an
ey found tha
l and Preven
mplementat
ors sought to
ntimicrobial
terventions
ar18)
committee
appointing a
g, and to lea
r17) include
ng education
tion of a pat
e performed
erapeutic
rapy initiatio
e interventio
rates were
a
oint
nd
at
ntion
ion
o
a
ad a
d
n
ient
7
on or
on,
*Special sy
collected
(Sep 201
Results:
intervent
from 50%
Stewards
impleme
Conclusio
strategy
Antimicro
days, and
ymbols that w
d pre and po
6) and after
Post‐implem
tions per 100
%), respectiv
ship Program
nting the pr
on: Impleme
in a CAH res
obial Stewar
d enhanced
2018ASProf
ere not spelled
st implemen
the interven
mentation, th
00 patient d
vely. Compli
ms increased
rospective au
entation of a
sulted in enh
rdship Progr
intervention
SHPMidyfessional
d‐out per the g
ntation. CDC
ntion (Mar 2
here was a 6
days (50.5 fro
ance with th
d from 29% t
udit strategy
a lead pharm
hanced comp
rams, increa
n acceptance
yearClinlPoster
guidelines wer
C Core Elem
2018).
635% and 52
om 6.9) and
he CDC’s Cor
to 100% afte
y.
macist and a
pliance with
sed antimicr
e rates.
nicalMeAbstrac
re translated i
ent complia
2% increase
interventio
re Elements
er appointing
pharmacist‐
h the CDC’s C
robial interv
eetingcts
into unknown
nce was ass
in antimicro
n acceptanc
of Hospital
g a lead pha
‐led prospec
Core Elemen
ventions per
characters.
essed befor
obial
ce rates (76%
Antimicrobi
armacist and
ctive audit
nts for Hospit
1000 patien
e
%
ial
d
tal
nt
*Special sy
Session‐B
Poster Ti
experien
Poster Ty
Submissi
Primary A
Email: pr
Addition
Purpose:
annually
hospitals
their clin
and prov
care hosp
Rico. This
with van
Methods
pharmac
the rotat
dose adju
with infe
Therapeu
vancomy
(based o
panel, ev
based on
with the
monitori
impact o
function;
number,
ymbols that w
Board # ‐ 4‐0
itle: Impact
ce (APPE) on
ype: Descrip
ion Category
Author: Pris
riscilla.ayalac
al Authors:
: The two ph
. Although o
s that do are
ical workloa
vide this pha
pital develo
s report des
comycin dru
s: Collaborat
cist develope
tion included
ustment, an
ectious disea
utic, Infectio
ycin. The van
n weight and
valuation of
n pharmacok
preceptor, t
ng‐related in
f these reco
; allergies; d
types and a
2018ASProf
ere not spelled
080
of an antimi
n a vancomy
ptive Report
y: Infectious
scilla Ayala; C
harmacy sch
only certain h
e expected to
ad. To fulfill t
rmacy servic
oped the first
cribes the im
ug monitorin
ting with the
ed the first A
d student tra
tibiogram de
se physician
on Control an
ncomycin dru
d renal func
renal functio
kinetic calcu
the student
nterventions
mmendatio
iagnosis; do
cceptance r
SHPMidyfessional
d‐out per the g
icrobial stew
ycin drug mo
s Disease / H
Comprehens
edu
ools in Puert
hospitals ma
o include An
the practice
ce offering a
t ASP APPE a
mpact of an A
ng.
e School of P
ASP APPE. Im
aining and re
evelopment
n, and shado
nd ASP Com
ug monitorin
tion), determ
on, trough re
lation, and e
provided rec
s were docu
ns, data coll
se per proto
ates of reco
yearClinlPoster
guidelines wer
wardship‐foc
onitoring ser
HIV
sive Pharma
to Rico grad
ay employ a
ntimicrobial S
obligation t
at the facility
available in t
ASP APPE on
Pharmacy, U
mplemented
esponsibilitie
, culture and
owing or acti
mittees. Th
ng service co
mining the n
esult evalua
evaluation o
commendat
mented in t
ected includ
ocol (based o
mmendatio
nicalMeAbstrac
re translated i
cused advanc
rvice
acy Services;
duate less th
full‐time clin
Stewardship
to train futur
y, the clinica
the public p
n pharmacy
niversity of
in a second
es in pharma
d sensitivity
ive participa
e students r
onsisted of e
need for a tr
tion, recom
f culture res
tions to the p
the pharmac
ded patient d
on weight an
ns made to
eetingcts
into unknown
ced pharma
an 100 phar
nical pharma
p Program (A
re pharmaci
al pharmacis
harmacy sch
intervention
Puerto Rico
ary care hos
acokinetic e
results eval
ation on the
reviewed all
evaluating d
ough or bas
mendation o
sults. After c
physician. A
cy record. To
demographi
nd renal fun
physicians.
characters.
cy practice
rmacists
acist, the
ASP) initiativ
sts in this ar
t of a second
hool of Puert
ns associate
, a clinical
spital in 2017
evaluation, re
uation, roun
Pharmacy a
patients on
ose per prot
ic metabolic
of a new dos
clinical revie
ll vancomyc
o evaluate th
ics; renal
ction); and t
ves in
rea,
dary
to
d
7,
enal
nds
nd
tocol
c
se
ew
in
he
the
*Special sy
Results:
There we
percent b
vancomy
the imple
were doc
increase
as neede
recomme
recomme
calculatio
pharmac
culture re
acceptan
percent (
acceptan
Conclusio
strategie
In additio
experien
ymbols that w
From July 20
ere 247 adul
between 18‐
ycin monitor
ementation
cumented du
of 164 perce
ed and order
endations w
endations w
on with 100
cokinetic calc
esults with 1
nce, five disc
(1/1) accept
nce.
on: Pharmac
es as was dem
on, pharmac
ces and inte
2018ASProf
ere not spelled
017 through
t patients ev
‐64 years old
ring‐related
of the ASP A
uring the firs
ent. A total o
red by the cl
were made w
were: three fo
percent (3/3
culation with
100 percent
continuation
ance and on
cy students c
monstrated
cy students h
erest in hosp
SHPMidyfessional
d‐out per the g
December 2
valuated. Th
d and 45 per
intervention
APPE, while 7
st six month
of 173 troug
inical pharm
with 62 perce
or dose redu
3) acceptanc
h 51 percent
(5/5) accept
s with 80 pe
ne initiation
can make a
with the inc
have an opp
pital pharma
yearClinlPoster
guidelines wer
2017, five st
he demograp
rcent more t
ns were docu
741 vancom
hs of the APP
ghs and 112
macist per pr
ent (38/61) a
uction based
ce; 43 for do
t (22/43) acc
tance; three
ercent (4/5)
of and addit
difference in
crease in dru
ortunity to g
cy as a pote
nicalMeAbstrac
re translated i
tudents part
phics were: 5
than 64 year
umented in
mycin monito
PE; this repre
basic metab
rotocol. A to
acceptance.
d on trough l
ose increase
ceptance; fiv
e for de‐esca
acceptance,
tional antibio
n the fulfillm
ug monitorin
gain exposu
ntial career
eetingcts
into unknown
ticipated in t
51 percent f
rs old. A tot
the six‐mon
oring‐related
esents an in
bolic panels
otal of 61 pha
These pharm
level and ph
s based on t
ve therapy c
alation with
, one escalat
otic with 10
ment of an in
ng and relate
re to real‐wo
choice.
characters.
the ASP APP
female, 55
tal of 280
th period be
d interventio
tervention
were identif
armacy
macy
harmacokine
trough level
change based
67 percent (
tion with 10
0 percent (1
nstitution’s A
ed intervent
orld pharma
E.
efore
ons
fied
etic
and
d on
(2/3)
0
1/1)
ASP
ions.
acy
*Special sy
Session‐B
Poster Ti
tazobact
Poster Ty
Submissi
Primary A
Email: gl
Addition
Charlie H
Mary An
Purpose:
methicill
vancomy
cefepime
with high
adequate
available
of AKI in
the comb
Methods
commun
until Dec
care pati
vancomy
was AKI i
1.5‐fold,
hospital
Results: A
criteria.
cefepime
ymbols that w
Board # ‐ 4‐0
itle: Risk of a
am compare
ype: Evaluat
ion Category
Author: Glo
oriahcheng@
al Authors:
Huang
ne Renette J
: The most c
in‐resistant
ycin and an a
e. Some stud
her rates of n
ely‐powered
e evidence is
patients rec
bination of c
s: This retros
ity‐based te
cember 31, 2
ents who m
ycin and pipe
incidence be
or 0.3 mg/d
length of sta
A total of 52
The vancom
e group (n=6
2018ASProf
ere not spelled
081
acute kidney
ed to those o
tive Study
y: Infectious
ria Cheng; C
@gmail.com
Jose
ommon em
Staphylococ
antipseudom
dies suggest
nephrotoxic
d studies com
often confli
ceiving the c
cefepime and
spective coh
eaching hosp
2017, the oc
et the inclus
eracillin‐tazo
etween the t
dL, over the p
ay and day o
25 patients w
mycin and pip
66) had simil
SHPMidyfessional
d‐out per the g
y injury in pa
on vancomy
s Disease / H
Comprehens
piric antibio
ccus aureus
monal beta‐la
vancomycin
ity, compare
mparing rate
icting. This r
ombination
d vancomyc
hort study w
pital located
currence rat
sion criteria
obactam, or
two groups,
patient’s bas
of AKI onset a
were review
peracillin‐taz
ar baseline c
yearClinlPoster
guidelines wer
atients on co
ycin and cefe
HIV
ive Pharmac
tic regimen
(MRSA) and
actam, usua
n and pipera
ed with vanc
es of acute k
research pro
of piperacil
in in a comm
as conducte
in Long Bea
tes of AKI we
and receive
vancomycin
which was d
seline renal
after antibio
ed. Out of 5
zobactam gr
characterist
nicalMeAbstrac
re translated i
oncomitant v
epime at a co
cy Services;
administere
Pseudomon
ally either pip
cillin‐tazoba
comycin and
kidney injury
oject seeks to
lin‐tazobact
munity hosp
ed at College
ach, Californi
ere analyzed
d either a co
n and cefepim
defined as th
function. Se
otic initiation
525 patients
roup (n=263
ics such as a
eetingcts
into unknown
vancomycin
ommunity h
ed for covera
nas aerugino
peracillin‐ta
actam may b
d cefepime.
y (AKI) are la
o investigate
am and vanc
ital setting.
e Medical Ce
ia. From Jan
d and compa
ombination t
me. The prim
he increase
econdary end
n.
s, 329 patien
3) and vanco
age, gender,
characters.
and piperac
ospital
age of
osa includes
zobactam o
be associated
Well‐contro
cking and
e the inciden
comycin ver
enter, a 221‐
uary 1, 2015
ared in acute
therapy of
mary endpoi
in creatinine
dpoints inclu
nts met inclu
mycin and
baseline se
cillin‐
s
r
d
olled,
nce
rsus
‐bed
5
e
int
e by
uded
usion
rum
*Special sy
creatinin
percent i
vancomy
Patients
and pipe
non‐AKI g
12.36 an
occurren
slightly e
Conclusio
between
was asso
ymbols that w
e and use of
in the vanco
ycin and cefe
who develo
racillin‐tazo
groups, resp
d 7.81 days
nce during an
earlier AKI on
on: The resu
patients wh
ociated with
2018ASProf
ere not spelled
f other neph
omycin and p
epime group
ped AKI requ
bactam, the
pectively. Fo
in the AKI an
ntibiotic the
nset compar
ults of this st
ho received
a longer len
SHPMidyfessional
d‐out per the g
hrotoxic age
piperacillin‐t
p. This differe
uired a longe
e average len
r vancomyci
nd non‐AKI g
rapy was ex
red to the VC
tudy suggest
VPT compar
gth of stay.
yearClinlPoster
guidelines wer
nts. Overall
azobactam g
ence was no
er length of
ngth of stay w
in and cefep
groups, resp
amined, pat
C group (Day
t there is no
red with VC.
nicalMeAbstrac
re translated i
, the occurr
group comp
ot statisticall
stay in both
was 9.8 and
pime, the ave
pectively. Wh
tients in the
y 5 vs 6.2, re
difference i
In both gro
eetingcts
into unknown
ence of AKI
pared to 21.2
ly significant
h groups. For
d 6.9 days fo
erage length
hen the first
VPT group e
espectively).
in occurrenc
ups, develop
characters.
was 22.05
21 percent in
t (P=0.7604)
r vancomyci
r the AKI and
h of stay was
t day of AKI
experienced
ce of AKI
pment of AK
n the
.
n
d
s
a
KI
*Special sy
Session‐B
Poster Ti
the inpat
Poster Ty
Submissi
Primary A
Email: cc
Addition
Iris Tam
Tahira W
Pamela H
Matthew
Purpose:
United St
The purp
patients
Methods
purpose
column I
ICD‐9 cod
Mapping
costs and
estimate
analyses
Results:
hospitaliz
hospitaliz
Q1‐Q3 20
Q1‐Q3 20
survived
ymbols that w
Board # ‐ 4‐0
itle: Econom
tient hospita
ype: Evaluat
ion Category
Author: Cou
coles@bluep
al Authors:
Wangnoo
Hawn
w Gitlin
: Bloodstrea
tates (US). T
pose of this s
with BSI and
s: Data from
of this study
CD‐9 codes
des using th
gs file. Hospit
d length of s
d overall an
were perfor
Overall, 2,52
zation was e
zations were
015, and a m
015, the me
through hos
2018ASProf
ere not spelled
082
mic burden o
alization: ana
tive Study
y: Infectious
urtney Coles
pathsolution
m infections
They represe
study was to
d sepsis‐rela
the 2015 U
y. BSI and se
outlined in t
e Centers fo
talization de
tay (LOS) as
d stratified b
rmed using t
28,695 admi
estimated as
e costly with
mean cost of
an cost was
spital discha
SHPMidyfessional
d‐out per the g
f bloodstrea
alysis of 201
s Disease / H
; BluePath S
s.com
s (BSI) and se
ent the most
o evaluate th
ted hospital
S National In
epsis‐related
the literatur
or Medicare
emographics
sociated wit
by whether
the primary
issions were
s 7.1 percent
h a mean cos
f $23,449 ov
$22,503 wit
arge and $35
yearClinlPoster
guidelines wer
am infection
15 National I
HIV
Solutions;
epsis are on
t significant c
he economic
izations in t
npatient Sam
d hospitalizat
e. Relevant
and Medica
s, characteris
th BSI and se
the patient w
and primary
e observed in
t of all hospi
st of $23,968
erall and a m
th a mean LO
5,827 with a
nicalMeAbstrac
re translated i
among thos
npatient Sam
e of the lead
cause of dea
c burden ass
he US.
mple (NIS) w
tions were id
ICD‐10 code
id Services (
stics, and ou
epsis‐related
was discharg
y or seconda
n 2015. BSI a
italizations.
8 overall and
mean LOS of
OS of 9.3 day
mean LOS o
eetingcts
into unknown
se who surv
mple
ding causes
ath in the inp
ociated with
was used to a
dentified us
es were then
(CMS) Gener
utcomes incl
d hospitaliza
ged alive or
ary diagnosis
and sepsis‐re
BSI and seps
d a mean LO
f 9.0 days fo
ys among th
of 9.6 days a
characters.
vive or die du
of death in t
patient setti
h mortality i
achieve the
ing any diag
n mapped to
ral Equivalen
luding the m
ations were
not. Sensitiv
s columns.
elated
sis‐related
OS of 9.3 day
r Q4 2015. F
hose who
mong those
uring
the
ing.
n
gnosis
o the
nce
mean
vity
ys for
For
e who
*Special sy
died duri
8.9 days
died. The
surviving
per day o
those sur
percent.
Conclusio
study sug
higher to
with pati
reduce m
ymbols that w
ing the hosp
among thos
e cost per da
g was $2,377
of 85%. For Q
rviving was $
on: Using na
ggest that BS
otal and per
ients not dis
mortality and
2018ASProf
ere not spelled
pitalization. F
se who surviv
ay overall fo
7 and among
Q4 2015, the
$2,453 and a
ationally‐rep
SI and sepsis
day costs. T
charged aliv
d thus indire
SHPMidyfessional
d‐out per the g
For Q4 2015
ved and $36
r Q1‐Q3 201
g those dying
e cost per da
among those
presentative
s‐related ho
here is an in
ve. There is a
ctly reduce
yearClinlPoster
guidelines wer
, the mean c
6,237 with a
15 was $2,58
g was $4,399
ay overall wa
e dying was
inpatient ho
spitalization
ncreased cos
a considerab
the econom
nicalMeAbstrac
re translated i
cost was $21
mean LOS o
88 while the
9, represent
as $2,675 w
$4,632, rep
ospitalizatio
ns that result
st and longer
ble need for
mic burden o
eetingcts
into unknown
1,962 with a
of 9.4 days a
cost per day
ting an incre
hile the cost
resenting an
n data, the r
t in in‐hospit
r lengths of
better treat
n hospitals.
characters.
a mean LOS o
mong those
y among tho
ase in the co
t per day am
n increase of
results of th
tal death inc
stay associa
tment option
of
e who
ose
ost
mong
f 89
e
cur
ted
ns to
*Special sy
Session‐B
Poster Ti
(MRSA) m
Poster Ty
Submissi
Primary A
Pharmac
Email: m
Addition
Jacob Pa
Purpose:
concentr
Although
loading d
began ad
MIC tren
administ
values.
Methods
administ
unless th
vancomy
been col
intervent
Septemb
evaluate
the first p
and was
evaluate
to determ
vancomy
ymbols that w
Board # ‐ 4‐0
itle: Impact
minimum inh
ype: Descrip
ion Category
Author: Ma
cy;
fcrader@ua
al Authors:
inter
: A commun
rations (MIC
h the Infectio
doses for ser
dministering
ds. The obje
ering loadin
s: Since Dece
ered a loadi
he patient ha
ycin MIC valu
lected. Retr
tion (January
ber 2016) pe
d was mean
positive MRS
determined
d was vanco
mine if any c
ycin usage. A
2018ASProf
ere not spelled
083
of vancomyc
hibitory con
ptive Report
y: Infectious
rsha Crader;
ams.edu
ity hospital
) for vancom
ous Diseases
riously ill pat
loading dos
ective of eva
g doses in a
ember 2013
ng dose at 2
ad already re
ues for MRSA
rospective da
y 2011 to No
riods. No in
vancomycin
SA culture fr
via an auto
omycin usage
change in va
An interrupt
SHPMidyfessional
d‐out per the g
cin loading d
centrations
s Disease / H
; University o
reported a t
mycin with m
s Society of A
tients, a pha
ses in all adu
aluating this
ll adult vanc
, any patient
25 milligrams
eceived the f
A was evalua
ata for all in
ovember 20
npatient data
n MIC values
rom any spe
mated broth
e defined as
ncomycin M
ted time seri
yearClinlPoster
guidelines wer
doses on me
HIV
of Arkansas
trend of incr
methicillin re
America guid
armacist‐man
ult patients r
dosing prac
comycin pati
t 18 years an
s per kilogra
first dose. T
ated after ap
patients wa
13) and post
a was exclud
s for MRSA b
ecific patient
h dilution ins
s mean days
MIC values co
ies analysis w
nicalMeAbstrac
re translated i
ethicillin resi
for Medical
easing minim
sistant Stap
delines only
naged pharm
receiving van
ctice change
ients impact
nd older rec
am with a ma
The effect of
pproximatel
s collected e
t‐interventio
ded from rev
before and a
t was include
strument. T
of therapy (
ould be cont
with Newey‐
eetingcts
into unknown
istant staphy
Sciences Co
mum inhibit
hylococcus a
y recommend
macokinetic
ncomycin du
e was to dete
ted MRSA va
ceiving vanco
aximum dos
f loading dos
ly three year
each month
on (Decemb
view. The pr
after the inte
ed during ea
The seconda
(DOT) per 10
tributed to a
‐West stand
characters.
ylococcus au
ollege of
tory
aureus (MRS
d vancomyc
dosing serv
ue to worsen
ermine if
ancomycin M
omycin has b
se of 2 gram
ses on
rs of data ha
during the p
er 2013 to
rimary endp
ervention. O
ach calendar
ry endpoint
000 patient d
a reduction i
dard errors fo
ureus
SA).
in
vice
ning
MIC
been
s
ad
pre‐
point
Only
r year
days
n
or
*Special sy
coefficien
months a
Results: V
patients
vancomy
(1.64 vs.
intervent
intervent
vancomy
(62.86 vs
during th
during th
Conclusio
the imple
vancomy
days.
ymbols that w
nts was cond
as the time s
Vancomycin
except for tw
ycin MIC for
1.65; p equa
tion period (
tion (coeffic
ycin DOT per
s. 63.03; p eq
he pre‐interv
he post‐inter
on: A signific
ementation
ycin MIC cou
2018ASProf
ere not spelled
ducted, whic
series interv
n MIC values
wo patients
MRSA when
als 0.94). Th
(coefficient e
ient equals ‐
r 1000 patien
quals 0.92).
vention perio
rvention per
cant decreas
of loading d
uld not be co
SHPMidyfessional
d‐out per the g
ch was estim
al.
for MRSA fr
who had M
n comparing
e mean vanc
equals 0.007
‐0.007, p eq
nt days for t
The mean v
od (coefficie
riod (coeffici
se in the van
oses in all a
ontributed to
yearClinlPoster
guidelines wer
mated by ord
rom 2011 to
ICs of 0.5. T
the pre‐inte
comycin MIC
7; p less than
uals 0.006).
he pre‐inter
vancomycin
ent equals ‐0
ent equals
ncomycin M
dult patients
o a decrease
nicalMeAbstrac
re translated i
dinary least‐
o 2016 were
There was no
ervention an
C for MRSA
n 0.001) and
There was
rvention and
DOT per 100
0.315; p equ
equals ‐0.06
IC for MRSA
s receiving v
e in vancomy
eetingcts
into unknown
‐squares reg
reported as
o difference
nd post‐inter
increased du
d then decre
no differenc
d post‐interv
00 patient d
uals 0.005) b
66, p equals
A was demon
vancomycin.
ycin DOT per
characters.
ression and
s 1 or 2 for a
in the mean
rvention per
uring the pre
eased post‐
ce in mean
vention perio
ays decreas
but was cons
0.574).
nstrated afte
. The chang
r 1000 patie
ll
n
riods
e‐
ods
ed
stant
er
ge in
ent
*Special sy
Session‐B
Poster Ti
piperacil
Poster Ty
Submissi
Primary A
Email: sh
Addition
Cristen W
Shimeng
Puja Triv
Joseph R
Purpose:
with an i
an antibi
cause AK
is not un
nephroto
incidence
our comm
Methods
Novembe
combina
or more
(CrCl) of
report us
increase
observed
assessed
disease k
patient d
ymbols that w
Board # ‐ 4‐0
itle: Evaluati
lin‐tazobact
ype: Evaluat
ion Category
Author: She
hela.delosrey
al Authors:
Whittaker
Liu
edi
eilly
: The combin
ncreased fre
otic similar t
KI. At AtlantiC
common, ye
oxicity with t
e of AKI in pa
munity hosp
s: This retros
er 2016 and
tion with PIP
days. Patien
less than 20
sing Cerner D
of 0.5 millig
d within 7 da
utilizing pu
known as RIF
demographic
2018ASProf
ere not spelled
084
ion of the de
am with con
tive Study
y: Infectious
ela Delos Rey
yes@atlanti
nation of pip
equency of a
to vancomyc
Care Region
et there is a
this combina
atients rece
pital.
spective eva
March 2018
P‐TAZO. Pati
nts were exc
0 milliliters p
Discern Expl
grams per de
ays of the stu
blished crite
FLE Criteria.
cs, past med
SHPMidyfessional
d‐out per the g
evelopment
ncomitant va
s Disease / H
yes; AtlantiC
care.org
peracillin‐taz
acute kidney
cin used for
al Medical C
paucity of p
ation. The pu
iving PIP‐TA
aluation inclu
8 who were
ients include
luded if they
er minute (m
orer. Any ca
eciliter (mg/d
udied antibi
eria for renal
Medical rec
dical history,
yearClinlPoster
guidelines wer
of acute kid
ancomycin o
HIV
Care Regiona
zobactam (P
y injury (AKI)
gram‐positiv
Center (ARM
ublished dat
urpose of th
ZO with con
uded patient
ordered eith
ed in this stu
y had a base
mL/min). Su
ases of AKI w
dL) or a 50 p
otic combin
l risk, injury,
cords were r
prior history
nicalMeAbstrac
re translated i
dney injury in
or telavancin
al Medical Ce
PIP‐TAZO) an
) in hospitali
ve infection
MC), the use o
ta regarding
his evaluatio
ncomitant va
ts admitted
her vancomy
udy received
eline calculat
bjects were
were defined
percent incre
ation. Neph
, failure, loss
reviewed an
y of AKI, lev
eetingcts
into unknown
n patients re
n
enter;
nd vancomyc
zed patients
s and has be
of telavancin
g the develop
n is to comp
ancomycin o
to ARMC be
ycin or telav
d the drug co
ted creatinin
identified fr
d by a serum
ease from ba
rotoxicity or
s, and end‐st
nd data colle
el of treatm
characters.
eceiving
cin is associa
s. Telavancin
een reported
n with PIP‐T
pment of
pare the
or telavancin
etween
vancin in
ombination f
ne clearance
rom a gener
m creatinine (
aseline when
r AKI was als
tage renal
ection includ
ent acuity, C
ated
n is
d to
AZO
in
for 3
e
ated
(SCr)
n
so
ed
CrCl,
*Special sy
laborato
determin
documen
indicated
developm
approval
Results:
patients
vancomy
ranged fr
AKI. Ther
characte
infusion
of therap
groups. T
percent)
increase
within 10
groups 3
Conclusio
PIP‐TAZO
given as
recomme
occurren
ymbols that w
ry results, an
ned by study
nted, vancom
d. Statistical
ment of AKI
for this eva
Fifty‐eight p
being femal
ycin and PIP‐
rom 0.7 to 1
re were no s
ristics. All pa
and the ave
py was simila
Ten of 58 pa
in the telava
above 2 mg
0 days. Seve
of 5 patient
on: The deve
O with telava
an extended
endations in
nce of AKI wi
2018ASProf
ere not spelled
nd urine out
y investigato
mycin trough
analysis was
between the
luation.
patients with
e (51.7 perc
‐TAZO arm a
1.5 mg/dL, an
statistically s
atients recei
rage telavan
ar between t
tients devel
ancin group
/dL (maximu
n of the 10 A
ts had telava
elopment of
ancin and PIP
d infusion an
n this evaluat
th these ant
SHPMidyfessional
d‐out per the g
tput. Also re
ors. The dose
h levels, as w
s performed
e 2 groups. T
h an average
cent) met inc
and 28 in the
nd 9 of 58 pa
significant di
ived PIP‐TAZ
ncin dose wa
the vancomy
oped AKI, 5
(p‐value of
um of 2.4 m
AKI cases inv
ancin or vanc
f AKI appear
P‐TAZO in ou
nd telavancin
tion. Additio
tibiotic comb
yearClinlPoster
guidelines wer
corded was
es and durat
well as evalu
d to compare
The institutio
e age of 56 ye
clusion crite
e telavancin
atients (15.5
fferences ob
ZO 3.375 gra
as 7.5 milligr
ycin (4.8 day
(16.7 percen
0.999). Only
g/dL) and pa
volved conco
comycin disc
rs to be the s
ur populatio
n dosing was
onal studies
binations.
nicalMeAbstrac
re translated i
the use of c
tion of study
uating for ren
e baseline ch
onal review
ears (range
ria. Thirty pa
and PIP‐TAZ
5 percent) ha
bserved betw
ms every 8
rams per kilo
ys) and telav
nt) in the va
y 1 case in ea
atients all re
omitant nep
continued w
similar when
on. It is notew
s lower than
are warrant
eetingcts
into unknown
concurrent n
y antibiotics
nal dose adj
haracteristic
board at AR
27 to 79 yea
atients were
ZO arm. The
ad a docume
ween study
hours as a 4
ogram. The a
vancin (4.3 d
ncomycin gr
ach study ar
eturned to th
phrotoxins, a
when AKI dev
n comparing
worthy that
n the manufa
ted to furthe
characters.
nephrotoxins
were
ustments w
cs and the
RMC granted
ars) with 30
e included in
baseline SC
ented histor
group basel
4 hour exten
average dura
days) study
roup and 5 (
rm had a SCr
heir baseline
and in both s
veloped.
g vancomycin
PIP‐TAZO w
acturer
er examine t
s as
hen
d
n the
r
ry of
ine
ded
ation
(17.9
r
e
study
n and
was
the
*Special sy
Session‐B
Poster Ti
difficile in
Poster Ty
Submissi
Primary A
Temple;
Email: m
Addition
Jon Herri
Esther Yi
Kiumars
Purpose:
College o
patients
recomme
available
regarding
opioid po
outcome
Methods
identified
no opioid
were adm
equivalen
administ
endpoint
CDI seve
analyses
values of
ymbols that w
Board # ‐ 4‐0
itle: Evaluati
nfections
ype: Evaluat
ion Category
Author: Mo
onica.t.do@
al Authors:
ington
Zolfaghari
: The 2010 In
of Gastroent
with Clostrid
endations ar
e since 2010,
g antimotilit
opulation ca
es.
s: Using data
d patients w
d group (NO
ministered a
nts (OMEs) p
ered an ave
t was differe
rity based o
were condu
f less than 0.
2018ASProf
ere not spelled
085
ing the impa
tive Study
y: Infectious
nica Do; Bay
@gmail.com
nfectious Dis
terology guid
dium difficile
re based on
, the 2018 ID
ty use. Opioi
n be used to
a retrospecti
with a first tim
G) and the o
n average o
per day whil
rage of more
ence in lengt
n the 2010 I
ucted with SA
.05 were con
SHPMidyfessional
d‐out per the g
act of opioid
s Disease / H
ylor Scott &
seases Socie
delines both
e infections
poor and low
DSA guidelin
ds have a cl
o examine th
ively collecte
me diagnosis
opioid group
f less than o
e hospitalize
e than 10 m
th of stay (LO
DSA classific
AS version 9
nsidered sta
yearClinlPoster
guidelines wer
s on length
HIV
White Healt
ety of Americ
recommend
(CDIs) to pre
w quality ev
e no longer
ass effect of
he possible l
ed from the
s of CDI. Dat
p (OG). Patie
or equal to 1
ed. Patients
g of OMEs p
OS). Seconda
cation and re
9.4 software
tistically sig
nicalMeAbstrac
re translated i
of stay in pa
th ‐ Scott & W
ca (IDSA) an
d the avoida
event comp
vidence. Give
contains for
f decreasing
ink between
institution’s
ta were cate
ents were pla
0 milligrams
were placed
per day while
ary endpoint
ecurrence w
(SAS Institu
nificant.
eetingcts
into unknown
atients with
White Medic
d the 2017 A
ance of antim
lications, bu
en the limite
rmal recomm
peristalsis. T
n antimotilit
s electronic
egorized into
aced into the
s (mg) of ora
d into the OG
e hospitalize
ts included d
within ninety
te, Cary, No
characters.
Clostridium
cal Center –
American
motility agen
ut these
ed evidence
mendations
Therefore, t
ty use and w
records, we
o two groups
e NOG if the
al morphine
G if they we
ed. The prim
differences i
y days. Statis
orth Carolina
nts in
the
worse
s: the
ey
ere
mary
in
stical
a). P
*Special sy
Results: A
in the OG
day in th
average
significan
28.89% p
also simi
Conclusio
LOS or in
ymbols that w
A total of 11
G. The media
e OG (p < 0.
LOS was 5.6
nt (p=0.98).
p=0.66) infec
lar between
on: Based on
nfluence CDI
2018ASProf
ere not spelled
12 patients w
an opioid us
0001). The N
in the NOG
Rates of sev
ctions were
n the NOG an
n this small
severity. Fu
SHPMidyfessional
d‐out per the g
were include
e was 0 ± 0.4
NOG consist
and 5.58 in
vere (49.25%
similar betw
nd OG (23.88
retrospectiv
uture prospe
yearClinlPoster
guidelines wer
ed in this stu
4 OMEs per
ed of older p
the OG, wh
% vs. 42.22%,
ween the NO
8% vs. 17.78
ve analysis, it
ctive studies
nicalMeAbstrac
re translated i
udy with 79 p
day in the N
patients (73
ich was foun
, p=0.46) an
OG and the O
8%, p=0.49).
t appears op
s are needed
eetingcts
into unknown
patients in t
NOG and 36
± 18 vs. 59
nd to be not
d complicat
OG. Recurren
pioid use ma
d to confirm
characters.
he NOG and
± 40 OMEs p
± 20). The
t statistically
ed (32.87% v
nce rates we
ay not increa
m these findi
d 45
per
y
vs.
ere
ase
ngs.
*Special sy
Session‐B
Poster Ti
within a
Poster Ty
Submissi
Primary A
Email: aly
Addition
Heidi Cla
Erika Ditt
Purpose:
measure
continue
represen
experien
Committ
UTIs to b
assess w
antibiotic
Methods
Board. Th
was a ret
2016 and
urine cul
March 20
neutrope
treatmen
Results: A
reviewed
percent i
ymbols that w
Board # ‐ 4‐0
itle: Impact
community
ype: Evaluat
ion Category
Author: Alys
yssad@bapt
al Authors:
rke
tmar
: Treatment
s to reduce
e to rise and
nt a growing
ce, local res
ee at Baptis
be used as gu
hether this p
c use.
s: This study
he study con
trospective c
d October 20
tures after i
018. Patient
enia, acute b
nt algorithm
A total of 50
d during pha
in phase II) a
2018ASProf
ere not spelled
086
of a urinary
hospital
tive Study
y: Infectious
ssa Donadio
tisthealth.ne
algorithms a
costs while i
therapeutic
public healt
istance patt
t Health Sou
uidance for e
pathway is a
was approv
nsisted of tw
chart review
017. Phase II
mplementat
s were exclu
bacterial pro
was used to
0 patients we
se II. The ma
and had a dia
SHPMidyfessional
d‐out per the g
tract infecti
s Disease / H
; Baptist Hea
et
are often im
improving p
options rem
th concern. B
erns, and co
uth Florida a
empiric antib
an effective s
ved by the B
wo phases an
w of admitted
I was a prosp
tion of the U
uded from th
ostatitis, or a
o determine
ere reviewe
ajority of pa
agnosis of se
yearClinlPoster
guidelines wer
on treatmen
HIV
alth South F
mplemented
atient outco
main limited,
Based on the
onsensus gui
pproved an
biotic therap
stewardship
aptist Health
nd included p
d patients di
pective revie
UTI treatmen
he study if th
another coex
appropriate
d during pha
tients were
evere and/o
nicalMeAbstrac
re translated i
nt pathway o
lorida;
within healt
omes. As ant
, urinary tra
e institution
idelines, the
evidence‐ba
py. The purp
p effort to pr
h South Flor
patients at l
iagnosed wi
ew of admitt
nt pathway b
hey had a di
xisting infect
eness of ant
ase I of the s
female (74
or complicate
eetingcts
into unknown
on antimicro
thcare instit
tibiotic resis
ct infections
al formulary
e Pharmacy a
ased treatm
pose of this s
romote appr
rida Institutio
east 18 year
th a UTI bet
ted patients
between Jan
agnosis of fe
tion. Adhere
ibiotic thera
study while
percent in p
ed UTI (44 p
characters.
obial prescri
utions as
tance rates
s (UTIs)
y, clinical
and Therape
ment pathway
study was to
ropriate
onal Review
rs of age. Ph
ween Novem
s with positiv
nuary 2018 a
ebrile
ence to the U
apy.
50 patients
phase I vs. 64
ercent in ph
bing
eutics
y for
o
w
hase I
mber
ve
and
UTI
were
4
hase I
*Special sy
vs. 46 in
percent a
from 7.8
6.7 days.
Conclusio
antimicro
as well as
and redu
ymbols that w
phase phase
after implem
days to 6.7
on: Impleme
obial agents
s length of s
uce healthca
2018ASProf
ere not spelled
e II). Approp
mentation of
days, and av
entation of a
. Additionall
tay. Pharma
re costs by p
SHPMidyfessional
d‐out per the g
priate empiri
f the UTI trea
verage durat
a UTI treatm
ly, this pathw
acists are we
promoting p
yearClinlPoster
guidelines wer
c antimicrob
atment path
tion of antib
ment pathwa
way reduced
ell equipped
pathway adh
nicalMeAbstrac
re translated i
bial use incre
hway. Averag
biotic therap
y improved
d average du
to further im
erence and
eetingcts
into unknown
eased from
ge length of
py decreased
appropriate
uration of an
mprove pati
antimicrobi
characters.
30 percent t
f stay decrea
d from 8 day
e empiric use
ntibiotic ther
ent outcom
al de‐escalat
to 58
ased
ys to
e of
rapy
es
tion.
*Special sy
Session‐B
Poster Ti
Lebanese
Poster Ty
Submissi
Primary A
Email: fa
Addition
Antonios
Etwal Bo
Purpose:
health ou
been inc
of any as
prevalen
institutio
infection
use of an
Methods
access to
2017. We
test to in
logistic re
potentia
stay. We
infection
conjunct
Results: A
infection
years. Th
ymbols that w
Board # ‐ 4‐0
itle: The pre
e teritary ho
ype: Descrip
ion Category
Author: Mia
ragemia@g
al Authors:
s Darcy
u Raad
: People with
utcomes ava
reasing, so s
ssociation be
ce of all type
on in Lebano
s among sch
ntipsychotics
s: We exami
o medical rec
e calculated
nvestigate bi
egressions r
l confounde
e classified in
s and gastro
ivitis and on
Among 344
s (systemic &
he most prev
2018ASProf
ere not spelled
087
valence of a
ospital
ptive Report
y: Infectious
a Farage; Leb
mail.com
h schizophre
ailable to the
special guide
etween the t
es of infectio
on. The secon
hizophrenic
s.
ned risk of in
cords of a te
the odds ra
variate asso
un to exami
rs such as ag
nfections as
ointestinal in
nychomycosi
schizophren
& local). 50.
valent infect
SHPMidyfessional
d‐out per the g
all types of in
s Disease / H
banese Inter
enia have no
e general po
elines for the
two diseases
ons among s
ndary object
patients incl
nfection in r
ertiary health
tios and 95%
ociations and
ne the stren
ge, use of an
systemic (u
nfections) an
is).
nic patients,
6 % of patie
ions were re
yearClinlPoster
guidelines wer
nfections am
HIV
rnational Un
ot fully taken
opulation and
e prevention
s. The main
schizophren
tive is to ass
luding age, c
relation to sc
h care hospi
% confidence
d student t‐t
ngth and pre
ntipsychotics
pper respira
nd local infec
51.1 % of th
ents who dev
espiratory in
nicalMeAbstrac
re translated i
mong schizop
niversity;
n advantage
d therefore
n of infection
objective of
ic patients r
sess factors t
comorbiditie
chizophrenia
tal from Dec
e intervals u
est to analyz
ecision of the
s, smoker, a
atory tract, p
ctions (skin a
he patients d
veloped infe
nfections (68
eetingcts
into unknown
phrenic patie
from the im
their risk of
ns might be
f this study is
esiding in a
that increase
es, length of
a based on r
cember 201
using Pearso
ze continuo
e association
lcohol intake
pneumonia,
and soft tiss
developed a
ections aged
8.75 %), urin
characters.
ents residing
mprovement
infections h
needed in c
s to assess t
tertiary
e risk of
f stay, and th
retrospective
6 till Decem
n’s chi‐squa
us data. Bina
ns controllin
e and length
urinary trac
sue infection
ll type of
more than 5
ary tract
g in a
s in
have
ase
he
he
e
ber
re
ary
ng for
h of
t
ns,
55
*Special sy
infection
at the ins
and soft
more tha
neverthe
compare
who is ta
2.890). In
infection
Haloperid
4.411) (1
Conclusio
one terti
among sc
are at hig
patients
that the
patients
should be
ymbols that w
s (17.6%), a
stitution of l
tissue infect
an 10 years.
eless, patient
ed to local in
aking Zuclop
n addition, p
s (95 % CI 1.
dol or Chlor
1.089‐3.826)
on: This stud
ary institutio
chizophrenic
gher risk to d
who are res
risk of syste
taking Zuclo
e undertake
2018ASProf
ere not spelled
nd soft tissu
ess than 10
tions (P valu
No significa
t taking Zucl
fections, 95
entixol has 1
patient who
.002‐3.811).
promazine h
respectively
dy assessed
on. More stu
c patients in
develop syst
iding in the
mic infectio
openthixol o
en to preven
SHPMidyfessional
d‐out per the g
ue infections
years had m
e <0.02) com
nt differenc
lopenthixol h
% CI (1.389‐
1.786 the od
is taking Ola
As for loca
has 2 times t
y.
the prevalen
udies are wa
Lebanon. N
temic infecti
institution f
ns in particu
r Olanzapine
t infections
yearClinlPoster
guidelines wer
s (15.3 %). Pa
more risk to d
mpared to pa
e in patients
has 3.4 time
‐9.277).As fo
dds of having
anzapine has
l infections,
the odds of h
nce of infect
arranted to r
Nevertheless
ions compar
or less than
ular respirato
e. Our findin
among thes
nicalMeAbstrac
re translated i
atients who
develop GI in
atients with
s taking anti
es the odds o
or the type o
g respiratory
s 1.954 the o
data showe
having local
tions among
reflect the p
s, this study s
red to local i
10 years. In
ory infection
ngs suggest t
se patients.
eetingcts
into unknown
had mean d
nfection ( P
mean durat
psychotics a
of having sys
of systemic i
y infections
odds of havi
ed that patie
infections 9
g schizophre
revalence of
showed that
nfections es
n addition, th
ns was highe
that special c
characters.
duration of s
value <0.008
tion of stay o
and infection
stemic infect
infection, pa
(95 % CI 1.1
ng respirato
ent taking
95 % CI (1.04
nic patients
f infections
t these patie
specially am
his study sho
er among
consideratio
stay
8)
of
ns
tions
atient
03‐
ory
47‐
in
ents
ong
owed
ons
*Special sy
Session‐B
Poster Ti
outpatie
Poster Ty
Submissi
Primary A
Email: af
Addition
Shannon
Michelle
Purpose:
outpatie
in childre
duration
treatmen
published
Methods
twelve ye
January 1
antimicro
Watchfu
prescript
in the 20
managem
Results: A
patients
exclusion
presence
antibiotic
dosing w
ymbols that w
Board # ‐ 4‐0
itle: Evaluati
nt setting
ype: Descrip
ion Category
Author: Aus
farnstrom@b
al Authors:
Short
Wessling
: The rate of
nt setting. A
en. Appropri
reduces ant
nt failure. Th
d guidelines
s: This was a
ears of age o
1st, 2017 an
obial regime
l waiting wa
tion. Approp
013 American
ment of acut
A total of 24
prescribed a
n were follow
e of tympano
c was prescr
was utilized in
2018ASProf
ere not spelled
088
ion of antibi
ptive Report
y: Infectious
stin Farnstro
brodstone.o
f inappropria
Acute otitis m
iate drug sel
tibiotic misu
he purpose o
for acute ot
a retrospecti
or less who w
d December
en (i.e. agent
s defined as
priateness of
n Academy o
te otitis med
44 patients w
an antibiotic
w‐up appoin
ostomy tube
ribed in 55.8
n 43.9 perce
SHPMidyfessional
d‐out per the g
otic prescrib
s Disease / H
om; Cardinal
org
ate antibiotic
media is one
ection with
use which lim
of this study
titis media a
ve evaluatio
were prescri
r 31st, 2017.
t, dosing, du
s a diagnosis
f drug select
of Pediatrics
dia.
were identifi
c and 36 pati
ntments to e
es. The avera
8 percent (11
ent (68/155)
yearClinlPoster
guidelines wer
bing for acut
HIV
Health Inno
c use is repo
of the most
an adequate
mits the spre
was to eval
at a rural out
on in an outp
ibed an antib
. Data collec
ration), and
of acute oti
ion, dosing,
s clinical prac
ied within th
ients being e
evaluate reso
age age was
16/208) of p
of patients
nicalMeAbstrac
re translated i
te otitis med
ovative Deliv
orted to be a
t common in
e weight‐ba
ead of resista
uate prescri
tpatient clin
patient clinic
biotic for ac
cted included
d documenta
itis media w
and duratio
ctice guideli
he pre‐specif
excluded. Th
olution of ac
3.31 years (
atients. App
and the dur
eetingcts
into unknown
dia in childre
very Solution
as high as 50
ndications fo
sed dose an
ance and the
bing compli
ic.
c of patients
ute otitis me
d patient ag
ation of “wat
without issuin
on was asses
ne on the di
fied time pe
he most com
cute otitis m
(± 3.11). An
propriate we
ration of the
characters.
en in a rural
ns;
0 percent in
or antibiotic
d recomme
e risk of
ance with
s who were
edia betwee
e, weight,
tchful waitin
ng an antibio
ssed as outli
iagnosis and
eriod with 20
mmon reason
edia and the
appropriate
eight‐based
rapy prescri
the
use
nded
en
ng.”
otic
ned
d
08
ns for
e
e
bed
*Special sy
was appr
inapprop
80‐90 mg
or failure
Conclusio
common
often app
acute oti
ymbols that w
ropriate in 9
priate prescr
g/kg/day) an
e to first‐line
on: Antibiot
ly inconsiste
propriate. O
tis media w
2018ASProf
ere not spelled
6.1 percent
ribing include
nd the select
e agents. The
ic selection
ent with cur
Opportunities
ithin the out
SHPMidyfessional
d‐out per the g
(171/178) o
ed too low o
tion of azithr
ere were two
and dosing f
rent nationa
s exist for op
tpatient sett
yearClinlPoster
guidelines wer
of regimens.
of an amoxic
romycin or c
o cases of w
for acute oti
al guidelines
ptimizing an
ting.
nicalMeAbstrac
re translated i
The most co
cillin dose (i.
cefdinir with
watchful wait
itis media in
while antib
timicrobial t
eetingcts
into unknown
ommon caus
e. below the
hout a docum
ting identifie
n an outpatie
iotic duratio
therapy for t
characters.
se of
e recommen
mented aller
ed.
ent setting w
ons were mo
the treatme
nded
rgy
were
ost
nt of
*Special sy
Session‐B
Poster Ti
Poster Ty
Submissi
Primary A
Email: fa
Addition
Lisa Dum
Lauren W
Kasey Bra
Gerald D
Purpose:
Antimicro
settings.
inpatient
these init
impleme
Methods
two heal
discharge
support f
practice
protocol.
prescribi
between
number o
hours, an
Results:
guideline
group co
ymbols that w
Board # ‐ 4‐0
itle: Evaluati
ype: Evaluat
ion Category
Author: Lau
al Authors:
mkow
Wolf
andt
eYoung
: Antimicrob
obial stewar
While many
t and emerg
tiatives in ur
nting a phar
s: A retrospe
th system‐af
e. In April 20
from UC pro
agreement a
. The primar
ng (defined
the Pre‐ASP
of patients w
nd hospital a
300 patients
e‐concordan
mpared to t
2018ASProf
ere not spelled
089
ion of a pha
tive Study
y: Infectious
ren Fay; Me
edu
bial resistanc
rdship initiat
y programs h
ency depart
rgent care (U
rmacist‐led a
ective quasi‐
ffiliated UC
015, the hea
oviders, impl
allowing for
ry outcome o
as the comb
P and Post‐A
who required
admission w
s were includ
t prescribing
the Pre‐ASP
SHPMidyfessional
d‐out per the g
rmacist‐led
s Disease / H
ercy Health S
ce is one of t
tives have be
have demon
tment (ED) s
UC) sites. Th
antimicrobia
‐experiment
sites with po
lth system's
emented em
pharmacist‐
of this study
bination of a
ASP groups. S
d follow‐up,
ithin 30 day
ded in the st
g for all diag
group (41.3%
yearClinlPoster
guidelines wer
urgent care
HIV
Saint Mary's;
the most ser
egun to expa
strated pha
ettings, ther
is study aim
al stewardsh
al study was
ositive urine
s infectious d
mpiric therap
‐led culture
y was to com
appropriate a
Secondary o
time to foll
s between g
tudy (Pre‐AS
gnoses was s
% vs. 53.3%,
nicalMeAbstrac
re translated i
antimicrobi
;
rious threats
and from ac
rmacist‐led
re is a paucit
med to determ
hip program
s conducted
e or wound c
diseases and
py guideline
follow‐up vi
mpare guidel
agent, dose,
outcomes inc
ow‐up, UC o
groups.
SP n=150, Po
significantly
, p=0.037). G
eetingcts
into unknown
al stewardsh
s to public h
cute care to a
stewardship
ty of literatu
mine the im
(ASP) in the
evaluating p
culture resul
d ED pharma
es and a colla
ia a steward
ine‐concord
, and duratio
cluded comp
or ED revisits
ost‐ASP n=15
improved in
Guideline‐co
characters.
hip program
ealth.
ambulatory
p successes i
ure exploring
pact of
UC setting.
patients from
ts following
acists, with
aborative
ship‐focused
dant antibiot
on of therap
paring the
s within 72
50). Total
n the Post‐AS
oncordant
m
care
in
g
m
d
tic
py)
SP
*Special sy
antibiotic
74%, p=0
was requ
(p=0.07),
hours, p<
(p=1.0) w
Conclusio
guideline
ymbols that w
c selection im
0.287) and d
uired for 27 (
, however m
<0.001). The
within 72 hou
on: A pharm
e‐concordan
2018ASProf
ere not spelled
mproved in
uration (61%
(18%) patien
median time t
ere were no
urs or hospit
macist‐led urg
t antimicrob
SHPMidyfessional
d‐out per the g
the Post‐ASP
% vs. 65%, p
nts in the Pre
to follow‐up
differences
tal admissio
gent care AS
bial prescrib
yearClinlPoster
guidelines wer
P group (51%
=0.283) wer
e‐ASP group
p call was lon
between gro
ns within 30
SP was assoc
ing.
nicalMeAbstrac
re translated i
% vs. 68%, p
re similar be
p vs. 16 (10.7
nger in the P
oups in UC (
0 days (p=0.7
ciated with s
eetingcts
into unknown
p=0.01) while
tween grou
7%) in the Po
Post‐ASP gro
p=1.0) and E
723).
significantly
characters.
e dose (70 %
ps. Follow‐u
ost‐ASP grou
oup (71 vs. 3
ED revisits
improved
% vs.
up
up
8
*Special sy
Session‐B
Poster Ti
Poster Ty
Submissi
Primary A
Email: la
Addition
Wafaa Ab
Victoria L
Lisa Pete
Margaret
Purpose:
improvin
multidisc
identify a
Methods
multidisc
patients
The team
phleboto
inflamma
sepsis ra
meets cr
antibiotic
antibiotic
Pharmac
and prov
order ver
Monthly
improvem
antibiotic
ymbols that w
Board # ‐ 4‐0
itle: Sepsis r
ype: Evaluat
ion Category
Author: Lam
ma.kanawat
al Authors:
bou‐Zeinedd
Ly
ers
t Breakenrid
: Timely iden
ng patient ca
ciplinary sep
and treat pa
s: This study
ciplinary sep
with sepsis o
m consists of
omists. Patie
atory respon
pid response
iteria. Pharm
c regimen, d
cs to the pat
cists also rec
vide necessa
rification, an
team meeti
ment to iden
c administra
2018ASProf
ere not spelled
090
apid respon
tive Study
y: Infectious
ma Kanawati
ti@medstar.
dine
dge
ntification an
are and patie
sis rapid res
tients in sep
received ins
sis rapid res
outside the
f physicians,
ents were ide
nse syndrom
e team to fu
macists’ role
doses and fre
tient’s nurse
ommend se
ry drug infor
nd antibiotic
ings and dat
ntify issues a
ation and pat
SHPMidyfessional
d‐out per the g
se team per
s Disease / H
; MedStar W
.net
nd treatmen
ent outcome
sponse team
psis in a time
stitutional re
sponse team
intensive ca
nurses, adv
entified thro
me criteria an
urther evalua
includes ev
equencies, v
e, and facilita
quence of a
rmation. Ob
cs administra
a analysis ar
and impleme
tient outcom
yearClinlPoster
guidelines wer
rformance im
HIV
Washington H
nt of patients
es. The obje
m with contin
ely manner.
eview board
m to improve
re units. Pha
anced pract
ough the elec
nd signs of e
ate the patie
aluation of t
verification o
ation of time
ntibiotic adm
bjective data
ation. Morta
re conducted
ent correctiv
mes.
nicalMeAbstrac
re translated i
mprovement
Hospital Cen
s in sepsis o
ctive of this
nuous perfor
d approval. O
e early identi
armacists jo
tice clinicians
ctronic med
nd organ dy
ent and initia
the patient,
of antibiotic
ely antibiotic
ministration
collected in
ality rate was
d for continu
ve actions in
eetingcts
into unknown
t initiative
nter;
r septic shoc
study was t
rmance imp
Our hospital
ification and
ined the tea
s, pharmacis
dical record f
ysfunction. T
ate therapy,
recommend
orders, time
c administra
, verify drug
nclude time o
s analyzed m
uous perform
n order to str
characters.
ck are critica
to form a
rovement to
formed a
d treatment
am in April 2
sts, and
for systemic
This alerted t
, if the patie
dation of
ely delivery o
ation.
g compatibili
of order ent
monthly.
mance
rengthen tim
al for
o
of
017.
the
nt
of
ity,
try,
mely
*Special sy
Results: T
from 6 to
pharmac
order an
median t
49.5) min
over a on
problems
administ
charting
SD to 15.
Conclusio
for ident
antibiotic
ymbols that w
The number
o 40 per mon
cist intervent
d verificatio
times for firs
nutes, respe
ne year perio
s with intrav
ration, drug
of administr
.9 percent ±
on: A multid
ifying patien
cs.
2018ASProf
ere not spelled
r of patients
nth, average
tion was 8.1
n was 6.0 ±
st dose antib
ctively. Ove
od. Identifie
venous line a
shortages, d
ration times
2.63 SD afte
disciplinary s
nts with seps
SHPMidyfessional
d‐out per the g
evaluated b
e 18.7 ± 13 S
± 3.3 SD pe
4.4 SD and 3
biotic admin
erall there w
d issues lead
access, time
drug incomp
. The averag
er pharmacis
sepsis rapid r
sis and assur
yearClinlPoster
guidelines wer
by pharmacis
SD. Average
r month. Th
3 (range 1‐6)
istration we
was improvem
ding to a del
to draw blo
patibility, de
ge mortality
sts’ participa
response tea
ring appropr
nicalMeAbstrac
re translated i
sts has incre
e number of
he mean and
) minutes, re
re 51.8 ± 23
ment in time
lay in antibio
ood cultures
elayed alert n
rate decrea
ation in the
am that incl
riate and tim
eetingcts
into unknown
eased over a
patients tha
d median tim
espectively.
3.8 SD and 34
e to antibiot
otic adminis
before antib
notification,
sed from 18
sepsis rapid
udes pharm
mely adminis
characters.
a one year pe
at required
me for antibi
The mean a
4.1 (range 1
tic administr
tration inclu
biotic
and incorre
8 percent ± 2
response te
macists is use
stration of
eriod
iotic
and
5‐
ration
ude
ect
2.61
eam.
ful
*Special sy
Session‐B
Poster Ti
expendit
hospital
Poster Ty
Submissi
Primary A
Email: eu
Addition
Ihab Ibra
Howard S
Tamar Be
Purpose:
tens of th
year. App
program
other pu
of a dive
resistanc
Long Isla
Methods
approach
pharmac
pharmac
prospect
disease‐s
daptomy
the instit
record, p
committe
nursing, w
ymbols that w
Board # ‐ 4‐0
itle: Impact
tures, bacter
ype: Evaluat
ion Category
Author: Eug
ugene.kolom
al Authors:
ahim
Sussman
erger
: Increasing
housands of
propriate an
s is recomm
blished guid
rse set of an
ce, and Clost
nd.
s: Implemen
h which inclu
cist participa
cist‐driven in
tive antibioti
specialized p
ycin, linezolid
tution’s antim
performs ann
ee, consistin
which meet
2018ASProf
ere not spelled
091
of antimicro
rial resistanc
tive Study
y: Infectious
gene Kolomiy
miyets@gma
antimicrobia
f lives that co
ntibiotic use
ended by th
delines. This
ntimicrobial s
tridium diffic
tation of an
uded around
tion in inter
ntravenous‐t
ic review and
physicians. R
d, ceftarolin
microbial fo
nual antibiog
ng of represe
s twice wee
SHPMidyfessional
d‐out per the g
obial steward
ce, and Clost
s Disease / H
yets; St. Jose
il.com
al resistance
osts the Unit
through imp
he Centers fo
study was d
stewardship
cile incidenc
antimicrobi
d‐the‐clock p
rdisciplinary
to‐oral conve
d restriction
Restricted an
e, and tigecy
rmulary. The
gram analys
entatives fro
kly. The com
yearClinlPoster
guidelines wer
dship progra
tridium diffic
HIV
eph Hospita
e is a loomin
ted States h
plementatio
or Disease Co
esigned to a
p interventio
e at a 200‐b
ial stewards
pharmacist‐a
rounds in th
ersions using
n of a limited
ntimicrobials
ycline, amon
e hospital al
es and creat
om medicine
mmittee eval
nicalMeAbstrac
re translated i
am impleme
cile incidenc
l ‐ CHSLI;
g public hea
ealthcare in
n of interdis
ontrol’s Cor
assess the im
ons on antibi
bed commun
hip program
assisted dos
he hospital’s
g automatic
d number of
s included th
ng others wh
so impleme
ted an antim
e, pharmacy,
luates all pat
eetingcts
into unknown
entation on a
ce at a subur
alth threat th
dustry billio
sciplinary ste
e Elements a
mpact of the
iotic expend
nity hospital
m consisted o
e optimizati
s critical care
substitution
antibiotics t
he carbapene
hich constitu
nted an elec
microbial ste
, infection p
tients on res
characters.
antibiotic
rban commu
hat has claim
ons of dollars
ewardship
and numero
e implement
ditures, bacte
in suburban
of a multimo
ion, clinical
e unit, daily
n protocols,
to infectious
ems,
ute 30 perce
ctronic medi
wardship
revention an
stricted
unity
med
s per
ous
ation
erial
n
odal
s
ent of
ical
nd
*Special sy
antibiotic
therapy a
hospital’
place ove
stewards
cleaning
stewards
difficile r
Results:
per 1000
pharmac
policies,
total of $
expenses
decrease
expenses
decrease
Clostridiu
Staphylo
to first‐li
resistanc
cephalos
increase
carbapen
study pe
Conclusio
preventin
infection
that inclu
successfu
spending
among co
ymbols that w
cs as well as
and makes i
s electronic
er a period b
ship, the hos
policies and
ship perform
rates, and su
During the p
0 patient day
cist in the cri
and the esta
$260,000 in s
s and usage
ed by 63 perc
s decreased
ed by 75 perc
um difficile r
coccus aure
ne therapies
ce for Acinet
sporins and a
in extended
nems, and an
riod.
on: Antimicr
ng unnecess
s and preve
uded a partn
ul implemen
g, decreased
ommon path
2018ASProf
ere not spelled
those patie
nterventions
medical rec
between Jun
spital also in
d implement
mance metric
usceptibility t
period betwe
ys had decre
tical care un
ablishment o
savings betw
decreased b
cent, Daptom
by 74.9 perc
cent from 18
rates decrea
us and Ente
s. Among gra
tobacter bau
aztreonam w
d‐spectrum b
nti‐gram‐po
robial stewa
sary or inapp
nting antimi
nership betw
ntation of thi
incidence o
hogens.
SHPMidyfessional
d‐out per the g
nts who hav
s to prescrib
ord. Implem
ne 2014 and
stituted pol
ing changes
cs assessed i
trends of co
een January
eased by 39.1
nit, establish
of the antim
ween Januar
by 71.5 perce
mycin expen
cent. Betwe
8.12 to 4.36
ased by 42%
rococcus fae
am‐negative
umanii with m
with Klebsiel
beta‐lactama
sitive agents
rdship is an
propriate an
icrobial resis
ween clinical
is program t
of Clostridium
yearClinlPoster
guidelines wer
ve received g
bers. All inte
mentation of
February 20
icies to targe
to contact i
include chan
mmon bacte
2015 and A
1 percent, w
ing stricter p
icrobial stew
y 2015 and
ent over the
nses decreas
en 2012 and
cases per 10
alone. Betw
ecalis have r
e pathogens,
most antibio
la and Esche
ase strains. R
s have rema
essential an
timicrobial u
stance to an
and nonclin
that contribu
m difficile an
nicalMeAbstrac
re translated i
greater than
rventions ar
the antimic
016. In addit
et Clostridiu
isolation pro
nges in antib
erial pathog
April 2018, to
which occurr
pharmacist‐
wardship com
December 2
e 3‐year peri
sed by 43.3 p
d 2017, Clost
0,000 patien
ween 2012 an
remained sta
, there has b
otics and an
erichia coli. T
Resistance t
ined relative
nd effective
utilization, re
tibiotics. An
nical departm
uted to a de
nd maintaine
eetingcts
into unknown
n five days of
re document
crobial stewa
tion to antim
um difficile b
ocedures. An
biotic expens
gens.
otal antibiot
ed after add
driven antib
mmittee. Th
2017. Total C
od. Tigecycl
percent and
tridium diffi
nts. Between
nd 2017, sen
able and hig
been fluctua
increase of
This trend is
o piperacilli
ely unchang
program in r
educing Clos
n interdiscipl
ments had re
crease in an
ed stable res
characters.
f antimicrob
ted in the
ardship took
microbial
by modifying
ntimicrobial
ses, Clostrid
ic expenditu
ding a clinica
biotic review
his resulted i
Carbapenem
ine expense
linezolid
cile rates ha
n 2016 and 2
nsitivities of
hly suscepti
tions in
resistance t
s driven by a
n‐tazobacta
ed during th
reducing and
stridium diff
inary appro
esulted in a
ntibiotic
sistance patt
bial
k
g
ium
ures
al
w
n a
m
es
ad
2017,
ble
o
n
m,
he
d
ficile
ach
terns
*Special sy
Session‐B
Poster Ti
morbimo
Poster Ty
Submissi
Primary A
Email: yo
Addition
Ana Loza
Aitor Aya
Rubén Pa
Beatriz F
Purpose:
improvem
complica
infectiou
associate
Methods
between
IE was co
transtho
Variables
methicill
infection
analyzed
Enfermed
therapy:
1. Empiri
MRSA: C
2. Target
NV: Cloxa
ymbols that w
Board # ‐ 4‐0
itle: Infectio
ortality
ype: Evaluat
ion Category
Author: Yoa
oarfh@gmai
al Authors:
ano
astuy
ampín
ernández
: Infective en
ments in its
ations.The ai
s endocardi
ed.
s: Retrospec
August‐201
onsidered on
racic echoca
s gather wer
in–resistant
(NV/PV). Th
according t
dades Infecc
ical treatme
loxacillin+Da
t treatment w
acillin. In cas
2018ASProf
ere not spelled
092
us endocard
tive Study
y: Infectious
ar Labeaga; H
l.com
ndocarditis (
managemen
m of the stu
tis (IE) by St
tive observa
14 and Marc
nce diagnose
ardiography.
re: demogra
or methicill
he degree of
o the conse
ciosas y Micr
nt for suspic
aptomycin
with diagnos
se of allergic
SHPMidyfessional
d‐out per the g
ditis by staph
s Disease / H
HOSPITAL UN
(IE) by Staph
nt, IE remain
udy is to ana
aphylococcu
ational study
h‐2017. All p
ed after bloo
.
phic data, e
in‐susceptib
f adequacy o
nsus docum
robiologia C
cion of IE by
sis of IE eith
c to beta‐lac
yearClinlPoster
guidelines wer
hylococcus a
HIV
NIVERSITARI
hylococcus a
ns associated
lyze the ade
us aureus (SA
y realized ov
patients with
od culture‐po
mpirical/tar
ble SA (MRSA
of the antim
ent publishe
línica) in 201
MSSA or MR
er by MSSA
tams (T‐MSS
nicalMeAbstrac
re translated i
aureus: adeq
IO DE CABU
ureus (SA) is
d with high m
equacy of an
A) and to ass
ver a period
h suspected
ositive for SA
get antimicr
A/MSSA), na
icrobial regi
ed by the SE
15, which re
RSA: E‐MSSA
or MRSA eit
SA‐NV‐A): D
eetingcts
into unknown
quacy of trea
EÑES‐ASTUR
s a deadly d
mortality an
ntibiotic trea
sess morbid
of 2 years a
IE were incl
A and transe
robial treatm
ative/prosthe
men in EI by
EIMC (Socied
ecommends
A: Cloxacillin
ther in PV or
aptomycin+
characters.
atment and
RIAS;
isease. Desp
d severe
atment in
ity and mort
nd 7 months
luded. Defin
esophageal o
ment (E/T),
etic valve
y SA was
dad de
the followin
n±Daptomyc
r NV: T‐MSSA
+Fosfomycin.
pite
tality
s,
nitive
or
ng
cin. E‐
A‐
. T‐
*Special sy
MSSA‐PV
Daptomy
To determ
in patien
cultures)
mortality
Results:
73% of w
The adeq
MRSA 25
Cloxacilli
100% (1/
associate
Average
surgery w
hospital a
Conclusio
still being
treatmen
EI is asso
disease a
mortality
ymbols that w
V: Cloxacillin
ycin+Rifamp
mine morbid
ts who com
, cardiac sur
y.
Fifteen patie
whom were m
quacy of the
5% (1/4), T‐M
n), T‐MSSA‐
/1) and T‐MR
ed). The deg
hospital stay
was required
admission.
on: Due to t
g discussed,
nt of IE by SA
ociated with
at an early st
y and its seri
2018ASProf
ere not spelled
+Rifampicin
icin+Gentam
dity and mo
pleted antib
rgery perfor
ents were tr
men.
antimicrobi
MRSA‐NV 0%
NV‐A 100%
RSA‐PV 0% (
ree of adequ
y was 47 day
d; 56% (5/9)
he low degr
it would be
A.
a high morb
tage with th
ous complic
SHPMidyfessional
d‐out per the g
+Gentamicin
micin.
rtality in the
biotic treatm
med as cons
eated for su
ial treatmen
% (0/4, becau
(1/1), T‐MSS
0/1, because
uacy to the c
ys. Of the 9
had emboli
ree of adequ
convenient
bidity and mo
e most appr
cations.
yearClinlPoster
guidelines wer
n. T‐MRSA‐N
ese patients,
ment (betwee
sequence of
uspicion of IE
nt was the fo
use in all Dap
SA‐PV 0% (0/
e neither Rif
consensus d
patients wit
c complicati
uacy register
to establish
ortality, so it
ropriate anti
nicalMeAbstrac
re translated i
NV: Cloxacill
, the variable
en 4 and 6 w
IE, embolic
E by SA with
ollowing: E‐M
ptomycin wa
/2, because
fampicin nor
document wa
h definite IE
ions and 44%
red and the f
h a protocol
t is necessar
imicrobial re
eetingcts
into unknown
in+Daptomy
es gather we
weeks after n
complicatio
an average
MSSA 100% (
as associate
Daptomycin
r Gentamicin
as 33%.
E by SA: 33%
% (4/9) died
fact that opt
in our hospi
ry to detect
egimen to re
characters.
ycin. T‐MRSA
ere: hospital
negative blo
ons and
age of 76 ye
(2/2 patient
d with
n was in all),
n was
% (3/9) cardia
during their
timal treatm
tal for the
and treat th
educe its
A‐PV:
l stay
od
ears,
s), E‐
,
ac
r
ment
he
*Special sy
Session‐B
Poster Ti
born bet
Poster Ty
Submissi
Primary A
Universit
Email: m
Addition
Darby Ro
Nadia Na
Todd Lee
Purpose:
rates for
guideline
(babyboo
United St
populatio
among b
Methods
patients
patients
characte
concomit
history, r
data and
rate for b
characte
was appr
ymbols that w
Board # ‐ 4‐0
itle: Sustaine
ween 1945 a
ype: Evaluat
ion Category
Author: Mic
ty of Illinois a
michell@uic
al Authors:
osenfeld
abulsi
e
: Direct‐actin
hepatitis C v
es recomme
omers), rega
tates were b
on is unrepo
abyboomers
s: Investigato
who started
who started
ristics, inclu
tant medica
regimen, and
means/stan
babyboomer
ristics; rates
roved by the
2018ASProf
ere not spelled
093
ed virologic
and 1965
tive Study
y: Infectious
chelle Martin
at Chicago C
c.edu
ng antiviral (
virus (HCV) t
nd a one‐tim
ardless of tra
born within t
orted. The o
s treated wit
ors perform
d HCV treatm
d dual‐DAA r
ding age, ge
tions; and H
d lab values.
ndard deviat
r patients. T
s were comp
e institutiona
SHPMidyfessional
d‐out per the g
response ra
s Disease / H
n; University
College of Ph
(DAA) regim
treatment. I
me HCV scree
ansmission r
this birth co
objective of t
th DAAs at a
ed a retrosp
ment from Ja
egimens we
ender, race/e
HCV‐related d
. Data were
tions for con
he secondar
pared using c
al review bo
yearClinlPoster
guidelines wer
tes after hep
HIV
y of Illinois H
harmacy;
ens offer hig
n addition to
ening for all
risk. It is est
hort. Howev
this study is
an urban aca
pective coho
anuary 1, 20
ere included.
ethnicity, bo
data includin
described w
ntinuous dat
ry endpoints
chi‐square te
ard.
nicalMeAbstrac
re translated i
patitis C viru
Hospital and
gh sustained
o risk‐based
patients bo
imated that
ver, real‐wo
to describe
ademic med
ort study of t
14 to Decem
. Data collec
ody mass ind
ng stage of d
with counts/p
ta. The prima
s were SVR r
ests and SAS
eetingcts
into unknown
us treatment
Health Scien
d virologic re
d HCV screen
orn between
75% of the
orld data on
and compar
ical center.
the electron
mber 1, 2017
ction include
dex (BMI), co
disease, HCV
percentages
ary endpoin
rates by pati
S software. T
characters.
t in patients
nces System
esponse (SVR
ning, nationa
1945 and 1
patients in t
this patient
re HCV SVR r
ic records of
7. Babyboom
ed baseline
omorbidities
V treatment
s for categor
t was the SV
ent
This research
m /
R)
al
965
the
rates
f
mer
s, and
ical
VR
h
*Special sy
Results:
were 63
years, an
24 perce
percent h
psychiatr
The inten
up and 1
protocol.
versus 89
versus 92
naïve pat
history o
0.005). S
insurance
Conclusio
this supp
Among t
experien
patients
were see
progress
explored
ymbols that w
Of the 822 p
percent mal
nd BMI of 29
nt treatmen
hepatocellul
ric illness. S
nt‐to‐treat S
5 patients w
. The SVR ra
9 percent in
2 percent in
tients versus
f HCC (94 pe
VR rates did
e (p greater
on: Most of
ports the nat
hese patient
ced patients
in this diver
en in HCC pa
ion to cirrho
as no publis
2018ASProf
ere not spelled
patients trea
le, 64 percen
.3 kg/m2. Th
nt‐experienc
lar carcinom
ixty‐six perc
VR rate was
who discontin
tes differed
cirrhotic pat
males, p eq
s 87 percent
ercent in non
d not differ b
than 0.05).
the HCV‐tre
tional estima
ts, treatmen
s, non‐cirrho
se patient p
tients in this
osis to allow
shed literatu
SHPMidyfessional
d‐out per the g
ated for HCV
nt black, 41
he populatio
ed, 11 perce
ma (HCC); 4 p
ent were tre
s 86 percent
nued treatm
by presence
tients, p less
ual to 0.012
t in treatmen
n‐HCC patie
by race/ethn
eated patien
ates of baby
nt‐naïve pati
otic patients
opulation. H
s population
for increase
ure addresse
yearClinlPoster
guidelines wer
V, 602 (73 pe
percent Med
on was, 93 p
ent post‐tran
percent HIV,
eated with le
(518/602). E
ment, the SV
e of cirrhosis
s than 0.000
28), treatmen
nt‐experienc
nts versus 8
icity, obesity
ts at the urb
boomer pre
ents had hig
had signific
HCC typically
n. These resu
ed SVR rates
es this in the
nicalMeAbstrac
re translated i
ercent) were
dicaid‐insure
percent geno
nsplant. Com
30 percent
edipasvir/so
Excluding th
R rate was 9
s (98 percen
01), gender (
nt history (9
ced patients
2 percent in
y, diabetes,
ban medical
evalence amo
gher SVR rat
cantly higher
y develops in
ults support
s. Gender dif
e DAA era.
eetingcts
into unknown
e babyboome
ed, had a m
otype 1,50 p
morbidities i
diabetes; an
ofosbuvir±rib
he 33 patient
94 percent (5
t in non‐cirr
97 percent i
96 percent in
s, p equal to
n HCC patien
psychiatric
center were
ong HCV‐inf
es than trea
r SVR rates t
n cirrhosis; lo
HCV treatm
fferences ca
characters.
ers. The pat
ean age of 6
ercent cirrh
ncluded 6
nd 25 percen
bavirin.
ts lost‐to‐fol
518/554) pe
rhotic patien
in females
n treatment‐
0.0002), and
nts, p equal t
illness, or
e babyboom
fected patien
atment‐
han cirrhoti
ow SVR rate
ment prior to
n be further
ients
60.5
otic,
nt
llow‐
er
nts
‐
d
to
mers;
nts.
c
s
r
*Special sy
Session‐B
Poster Ti
hospital w
Poster Ty
Submissi
Primary A
Email: dh
Addition
Tania Ku
Bella Koh
Densie D
Michael
Purpose:
infection
negative
disease (
carbapen
utilizatio
the form
A medica
Methods
imipenem
30, 2016
gender, m
associate
analysis w
carbapen
thus was
Results: T
steady ve
ymbols that w
Board # ‐ 4‐0
itle: Evaluati
with antibio
ype: Evaluat
ion Category
Author: Dha
hara.mehta@
al Authors:
pferman
hn
Dong
Blumenfeld
: Carbapene
s in patients
bacteria. A
ID) physician
nem was sw
n quarterly
ulary switch
ation use eva
s: A list of all
m between O
was identifi
meropenem
ed culture an
was used to
nems betwe
s exempt fro
Twenty‐four
ersus forty‐f
2018ASProf
ere not spelled
094
ing the incre
tic utilizatio
tive Study
y: Infectious
ara Mehta; B
@bellevue.n
ms are broa
s with risk fa
t our institu
n and subse
itched from
using the de
h but also rev
aluation was
l patients 18
October 1, 2
ied from the
or imipenem
nd sensitivity
determine t
en the two q
m institution
r patients re
four patients
SHPMidyfessional
d‐out per the g
ease in carba
n monitorin
s Disease / H
Bellevue Hos
nychhc.org
ad spectrum
actors for, hi
tion, carbap
quent review
imipenem t
efined daily d
vealed an in
s performed
8 years of ag
2015 to Dece
e hospital’s m
m dose and
y data, indic
the statistica
quarters. Th
nal board re
eceived carba
s when carba
yearClinlPoster
guidelines wer
apenem use
g by the ant
HIV
spital Center
antibiotics r
story of, or e
penem use re
w by the ASP
to meropene
dose metric.
crease in ca
d to assess th
e and older
ember 30, 20
medical reco
frequency, r
cation of use
al difference
e study was
eview.
apenems in
apenem usa
nicalMeAbstrac
re translated i
in a large, t
tibiotic stew
r;
reserved for
evidence of
equires appr
P. In Decem
em. The ASP
. Review of u
rbapenem u
his increase.
with an ord
015 and Oct
ord. The data
renal functio
e and etiolog
e in the num
s deemed a q
4th quarter
age peaked (
eetingcts
into unknown
ertiary care,
wardship prog
r treatment o
multidrug r
roval by an i
mber 2015, th
P monitors a
utilization da
usage in four
er for merop
tober 1, 2016
a collected i
on, duration
gy of infectio
mber of patie
quality impro
2015 when
(p=0.011) in
characters.
, metropolit
gram (ASP)
of serious
esistant gram
infectious
he preferred
ntimicrobial
ata confirme
rth quarter 2
penem or
6 to Decemb
ncluded: age
n of therapy,
on. Chi‐squa
ents on
ovement stu
utilization w
4th quarter
an
m
d
ed
2016.
ber
e,
red
udy
was
r
*Special sy
2016. Of
meropen
duration
2016. ID
93% (41/
(36/37) o
(16/24) o
an identi
cefepime
de‐escala
narrower
develope
the two s
Conclusio
quarter 2
a longer
carbapen
of patien
spectrum
and revie
ymbols that w
f the patient
nem during 2
of therapy i
approval an
/44) of patie
of patients w
of patients in
fied pathoge
e in 2015. In
ation of ther
r spectrum a
ed an advers
study period
on: Evaluatio
2015 demon
duration of
nems were u
nts with docu
m agent was
ew was perfo
2018ASProf
ere not spelled
ts that receiv
2015 contras
in 2015 was
nd / or consu
nts in 2016.
were dose ad
n 2015 versu
en had an or
n 2016, 54%
rapy once se
agents, 11%
se reaction t
ds.
on of the inc
nstrated a lar
antibiotic co
used for app
umented res
feasible, it t
ormed by th
SHPMidyfessional
d‐out per the g
ved carbape
sted with 89
11.5 days (r
ult was obtai
Among all
djusted appr
us 64% (28/4
rganism that
(15/28) had
ensitivities b
(3/28) expir
o optimal th
crease in car
rger number
ourses. In‐de
ropriate ind
sistant patho
took place in
he ID consult
yearClinlPoster
guidelines wer
enems, 46%
9% (39/44) o
range 1‐42 d
ined in all pa
patients req
ropriately. A
44) of patien
t was resista
d documente
ecame avail
red before c
herapy. The
rbapenem u
r of patients
epth review
ications. Th
ogens and w
n a timely ma
t service as r
nicalMeAbstrac
re translated i
(11/24) of p
of patients in
days) vs. 7.3
atients (24/2
quiring renal
An organism
nts in 2016. A
ant to pipera
ed resistant
able, 14% (4
ulture result
sources of i
se in 4th qu
s on carbape
of utilization
he increased
when de‐esca
anner. Rena
required by o
eetingcts
into unknown
patients rece
n 2016. The
days (range
24) in 2015 c
dose adjust
was identifi
All 16 patien
acillin‐tazoba
pathogens,
4/28) did not
ted, and 3%
infections va
arter 2016 c
enem therap
n confirmed
d use was du
alation to a n
al dosing was
our hospital
characters.
eived
average
1‐32 days) i
compared to
tments, 97%
ed in 67%
nts (100%) w
actam or
18% (5/28)
t respond to
(1/28)
aried betwee
compared to
py as oppose
that
e to treatme
narrower
s appropriat
protocols.
in
o
%
with
had
o
en
o 4th
ed to
ent
te
*Special sy
Session‐B
Poster Ti
disease d
Poster Ty
Submissi
Primary A
Email: yu
Addition
Helen Le
Purpose:
(IFD) in a
undergoi
trial dem
suspensio
has since
The purp
AML and
Methods
Adult pat
induction
transition
IFD in AM
compare
antifunga
chemoth
within 10
for Resea
disease. T
(PP) grou
or posaco
fluconazo
ymbols that w
Board # ‐ 4‐0
itle: Efficacy
during chem
ype: Evaluat
ion Category
Author: Yuu
uumiyazaw@
al Authors:
e
: Posaconazo
acute myelog
ing induction
monstrating i
on form of p
e been devel
pose of this s
d MDS patien
s: The institu
tients hospit
n chemother
ned from or
ML and MDS
ed to posaco
al agents or
herapy. The p
00 days of in
arch and Tre
The primary
ups, where t
onazole (n e
ole (n equals
2018ASProf
ere not spelled
095
y of posacona
otherapy‐in
tive Study
y: Infectious
umi Miyazaw
@gmail.com
ole is one of
genous leuke
n or re‐induc
ts superiorit
posaconazol
loped with im
study was to
nts undergoi
utional revie
talized betw
rapy for AM
al fluconazo
patients. A
nazole recip
were diagno
primary outc
nitiation of c
eatment of C
y outcome w
he ITT includ
equals 23), w
s 9) or posac
SHPMidyfessional
d‐out per the g
azole delaye
duced neutr
s Disease / H
wa; UC Irvine
f the recomm
emia (AML)
ction chemo
ty over othe
e. The delay
mproved bio
o compare th
ing induction
w board exe
ween Novem
L or MDS we
ole to posaco
cohort of flu
pients. Patien
osed with IF
come invest
hemotherap
Cancer were
was analyzed
ded all patie
while the PP
conazole (n e
yearClinlPoster
guidelines wer
ed‐release ta
ropenia
HIV
e Health;
mended age
and myelod
otherapy. Ho
r azole agen
yed‐release (
oavailability
he efficacy o
n chemothe
empted this
ber 2014 an
ere reviewed
onazole DR a
uconazole re
nts were exc
D within 30
igated was t
py. Criteria d
used to cate
in both the
ents who init
group includ
equals 13) d
nicalMeAbstrac
re translated i
ablet for pre
nts to preve
dysplastic syn
owever, ther
nts, and it wa
(DR) tablet f
and more co
of posaconaz
rapy at an a
study as a q
nd Decembe
d. In August
as the prefer
ecipients pri
cluded if the
days prior to
the rate of p
defined by th
egorize IFD a
Intent‐To‐T
tially receive
ded patients
during the st
eetingcts
into unknown
evention of i
ent invasive f
ndrome (MD
re has been
as performe
formulation
onsistent ph
zole DR to flu
cademic me
quality impro
r 2017 for in
2016, the in
rred agent fo
or to this tra
ey received o
o initiation o
proven or pro
he European
as proven or
Treat (ITT) an
ed fluconazo
s who remai
udy period.
characters.
nvasive fung
fungal disea
DS) patients
only one clin
d using the
of posacona
harmacokine
uconazole in
edical center
ovement pro
nduction or r
nstitution
or preventio
ansition was
other system
of
obable IFD
n Organizatio
r probable
nd Per‐Proto
ole (n equals
ned on
Secondary
gal
se
nical
oral
azole
etics.
n
r.
oject.
re‐
on of
s
mic
on
ocol
15)
*Special sy
endpoint
reasons f
than 0.05
Results:
patients
group (p
percent)
0.017). T
fluconazo
fluconazo
was swit
for adver
group we
associate
and 15.4
agent of
one patie
stay of 17
Conclusio
proven o
Although
antifunga
of posaco
during in
remain o
significan
ymbols that w
ts included t
for switch in
5 defined to
In the ITT an
(26.7 percen
equals 0.01
in the fluco
The most com
ole group wi
ole and posa
ched most c
rse events fo
ere hyperbil
ed with IFD i
percent, res
interest. Of
ent in the flu
7 days.
on: While th
or probable I
h fluconazole
al agents du
onazole DR a
nduction or r
on the antifu
nce of this st
2018ASProf
ere not spelled
types of IFD,
n antifungal a
detect signi
nalysis of the
nt) in the flu
8). In the PP
nazole coho
mmon type o
ith candidem
aconazole gr
commonly fo
ollowed by s
irubinemia,
n the flucon
spectively, in
the patients
uconazole gr
he sample siz
FD in the po
e appears be
ring hospita
as an effecti
re‐induction
ngal agent o
tudy.
SHPMidyfessional
d‐out per the g
mortality an
agents. Data
ificance.
e primary ou
uconazole gr
P analysis, pr
ort compared
of IFD was a
mia. The rate
roups, at 60
or suspected
suspected IF
persistent n
nazole and p
n the subgro
s who were
roup was rea
ze of this stu
osaconazole
etter tolerat
lization in bo
ve prophyla
chemothera
of interest an
yearClinlPoster
guidelines wer
nd readmiss
a are express
utcome, prov
oup compar
roven or pro
d to 0 patien
spergillus pn
e of antifung
percent at 4
d IFD, while p
D. Adverse e
nausea, and Q
osaconazole
oup of patien
discharged o
admitted for
udy was sma
DR group co
ed and a lar
oth groups,
ctic antifung
apy. Larger s
nd aid in fur
nicalMeAbstrac
re translated i
sion with IFD
sed as perce
ven or proba
red to 0 pati
obable IFD oc
nts in the po
neumonia ex
gal switch oc
43.5 percent
posaconazol
events obser
QT prolonga
e DR groups
nts who rem
on fluconazo
r possible IF
all, there wa
ompared to
ge proportio
the results o
gal agent in
studies will y
rther determ
eetingcts
into unknown
D, and freque
entage with
able IFD occ
ents in the p
ccurred in 4
osaconazole
xcept for on
ccurred freq
t, respective
le was switc
rved in the p
ation. Morta
occurred in
mained on th
ole or posac
D, with inpa
s a lower inc
the fluconaz
on of patien
of this study
AML and M
yield more p
mining the cl
characters.
ency and
p value of le
urred in 4
posaconazol
patients (44
group (p eq
e patient in
uently in bo
ely. Fluconaz
hed most of
posaconazol
ality possibly
22.2 percen
he antifunga
onazole DR,
tient length
cidence of
zole group.
ts switched
y support the
DS patients
patients who
inical
ess
e
4.4
uals
the
oth
zole
ften
e
y
nt
l
only
of
e use
o
*Special sy
Session‐B
Poster Ti
increased
Commiss
Poster Ty
Submissi
Primary A
Email: am
Addition
John Hor
Renuga V
Purpose:
associate
acquired
all hospit
of the CD
TeleStew
to the tra
Methods
project, t
Infectiou
hospital s
services,
review p
impleme
pharmac
and/or d
Results: A
pathogen
stewards
ymbols that w
Board # ‐ 4‐0
itle: TeleStew
d antimicrob
sion Standar
ype: Descrip
ion Category
Author: Ash
mouser@hm
al Authors:
rne
Vivekananda
: Antimicrob
ed with redu
infections, a
tals have AS
DC’s core ele
wardship serv
aditional ASP
s: Hardin Me
the hospital
us Disease ph
stewardship
enabling off
atient cases
nted rapid b
cists and eva
e‐escalation
After the im
n detection,
ship increase
2018ASProf
ere not spelled
096
wardship se
bial stewards
rds for Antim
ptive Report
y: Infectious
hleigh Mouse
mh.net
an
bial stewards
uced hospita
and decreas
Ps, almost 6
ements. The
vices in com
P model tha
emorial Hosp
had implem
hysicians and
p programs.
f‐site Infecti
and make s
blood pathog
luated with
n of antibioti
mplementatio
average mo
ed from 100
SHPMidyfessional
d‐out per the g
rvices in com
ship interve
microbial Ste
s Disease / H
er; Hardin M
ship program
l‐acquired C
sed hospital
60 percent of
purpose of t
mbination wit
t includes on
pital is a 300
mented a pha
d had not ye
During the
ous Disease
stewardship
gen detectio
the primary
ic therapy.
on of TeleSte
onthly pharm
to 329. In a
yearClinlPoster
guidelines wer
mbination w
ntions and i
wardship
HIV
Memorial Hos
ms (ASPs) ha
Clostridium d
costs. Altho
f US hospita
this project
th rapid bloo
n‐site Infect
0‐bed hospit
armacist‐led
et met all sev
project, the
physicians t
recommend
on, which wa
y care team f
ewardship se
macist interv
ddition, the
nicalMeAbstrac
re translated i
with rapid blo
mproved co
spital;
ave been doc
difficile infec
ugh The Join
ls have ASPs
was to evalu
od pathogen
ious Disease
tal in Elizabe
d ASP, howev
ven of the C
hospital imp
that are exp
dations remo
as immediat
for clinically
ervices in co
ventions rela
program re
eetingcts
into unknown
ood pathoge
ompliance w
cumented in
ction rates, r
nt Commissi
s that don’t
uate the imp
n detection a
e physicians.
ethtown, KY.
ver did not e
CDC’s core el
plemented T
perienced wi
otely. The h
tely reported
y appropriate
ombination w
ated to antim
educed avera
characters.
en detection
ith Joint
n literature t
reduced hos
ion requires
meet all sev
pact of
as an alterna
.
Prior to the
employee
ements of
TeleSteward
th ASPs to
hospital also
d to clinical
e adjustmen
with rapid b
microbial
age days of
n
to be
spital‐
that
ven
ative
e
dship
nts
lood
*Special sy
antibiotic
average
reduced
CDC’s co
Conclusio
ASP signi
improved
rapid blo
infectiou
Commiss
ymbols that w
c therapy pe
length of st
by 50 perce
re elements
on: The add
ificantly incr
d readmissio
ood detect m
s disease ph
sion requirem
2018ASProf
ere not spelled
er 1000 patie
ay was redu
nt. TeleStew
s of hospital
ition of Tele
reased pharm
on rates and
may provide a
hysicians. Te
ments for a s
SHPMidyfessional
d‐out per the g
ent days by 2
ced from 5.2
wardship ser
stewardship
eStewardship
macist’s inte
length of st
an alternativ
leStewardsh
stewardship
yearClinlPoster
guidelines wer
26 percent.
24 to 4.93 d
vices also en
p programs.
p services an
erventions, d
tay. TeleStew
ve to traditio
hip services c
p program.
nicalMeAbstrac
re translated i
For patients
days and 30
nabled comp
nd rapid bloo
decreased ov
wardship ser
onal ASPs in
can assist w
eetingcts
into unknown
s with bacter
day readmis
pliance with
od detection
verall antibio
rvices in com
areas witho
ith fulfillmen
characters.
remia, the
ssion rates w
all seven of
n to an exist
otic use and
mbination w
out on‐site
nt of the Joi
were
f the
ing
ith
nt
*Special sy
Session‐B
Poster Ti
Poster Ty
Submissi
Primary A
Email: Jn
Addition
Katy Wrig
Charles A
Katherine
Purpose:
difficile in
central n
Center of
analytics
less than
making it
levofloxa
infection
Methods
length of
levofloxa
March of
use to wh
preferred
pharmac
entry ord
antibiotic
impleme
new colle
new HA‐
ymbols that w
Board # ‐ 4‐0
itle: Impact
ype: Evaluat
ion Category
Author: Jam
nichols@Cov
al Authors:
ght
Ashley
e Shea
: Use of fluo
nfection (CD
ervous syste
f Oak Ridge,
benchmark
80% agains
t unsuitable
acin restrictio
(HA‐CDI) ra
s: This was a
f stay before
acin restrictio
f 2016, a lev
hen no othe
d agents. Im
cist intervent
der sets, and
c therapy gu
nted simulta
ection and te
CDI cases. Le
2018ASProf
ere not spelled
097
of a levoflox
tive Study
y: Infectious
mes Nicholso
vHlth.com
roquinolone
DI), and deve
em effects, p
levofloxacin
k. Additiona
st many gram
for empiric
on program
ates.
a single cente
e (Mar 2015
on program
ofloxacin re
er suitable al
mplementati
tion, remova
d removal of
uidelines. Ad
aneously wit
esting proto
evofloxacin
SHPMidyfessional
d‐out per the g
xacin restrict
s Disease / H
on; Cardinal H
es has been
elopment of
peripheral n
n utilization
lly, levofloxa
m‐negative o
therapy. Inv
on utilizatio
er, retrospec
5‐Feb 2016) a
. Prior to M
striction wa
ternatives w
on of the res
al of levoflox
f levofloxacin
dditional infe
th the restri
ocols, care pr
utilization as
yearClinlPoster
guidelines wer
tion program
HIV
Health at Me
associated w
serious adve
europathy).
was identifi
acin suscept
organisms, in
vestigators s
on, length of
ctive study c
and after (M
arch 2016, l
s implement
were availab
striction pro
xacin from v
n from first‐l
ection preve
ction and in
rovider educ
s defined by
nicalMeAbstrac
re translated i
m on utilizat
ethodist Me
with increase
erse reactio
During 201
ed as above
ibility per th
ncluding E. c
sought to ass
f stay, and ho
comparing le
Mar 2016‐Feb
evofloxacin
ted which co
le or there w
ogram consis
various comp
line status in
ention (IP) m
cluded new
cation, and r
y days of the
eetingcts
into unknown
ion in a com
edical Center
ed bacterial
ns (e.g., ten
15 at Method
e the Cardina
he hospital a
coli and P. ae
sess the imp
ospital‐acqu
evofloxacin u
b 2018) imp
was non‐res
onsisted of c
was presenc
sted of presc
puterized pr
n the institut
methods for C
room clean
root cause a
erapy per 10
characters.
mmunity hos
r of Oak Ridg
resistance,
dinopathy,
dist Medical
al Health dat
ntibiogram
eruginosa,
pact of a
uired C. diffic
utilization an
lementation
stricted. In
criteria allow
e of an aller
criber educa
escriber ord
tion’s empir
CDI were
ing protocol
nalyses on a
00 patient d
pital
ge;
C.
l
ta
was
cile
nd
n of a
wing
rgy to
ation,
der
ric
ls,
all
days
*Special sy
(DOT/100
were ass
1000 PD
Healthca
Results: T
PD [(131
p=0.003]
groups in
Conclusio
reducing
restrictio
infection
ymbols that w
00 PD) and l
essed pre‐ a
(cases/1000
re Safety Ne
The hospita
.4 ± 16.5) vs
post‐implem
n the top 10
on: Impleme
levofloxacin
on program m
prevention
2018ASProf
ere not spelled
ength of sta
and post‐imp
0 PD) were id
etwork (NHS
l experience
. (22.0 ± 7.3
mentation.
DRGs [(6.7 ±
entation of a
n utilization
may be an e
methods.
SHPMidyfessional
d‐out per the g
ay in days (LO
plementatio
dentified by
SN) definitio
ed a significa
); p<0.001] a
No differenc
± 3.3) vs. (6.
a levofloxaci
without sign
ffective met
yearClinlPoster
guidelines wer
OS) for the t
n. HA‐CDI ra
trained IP p
n.
nt reduction
and HA‐CDI
ce was obse
7 ± 3.1); p=N
n restriction
nificantly im
thod for red
nicalMeAbstrac
re translated i
top 10 Diagn
ates as defin
practitioners
n in mean (±
cases/1000
erved in the
NS].
n program w
pacting leng
ucing HA‐CD
eetingcts
into unknown
nosis‐Related
ned by numb
using the N
± SD) levoflox
PD [1.0 + 0.
mean (± SD)
was an effect
gth of stay. A
DI when imp
characters.
d Groups (DR
ber of cases
National
xacin DOT/1
6) vs. (0.4 +
) LOS betwee
tive strategy
A levofloxac
plemented w
RGs)
per
1000
0.3);
en
y for
cin
with
*Special sy
Session‐B
Poster Ti
nasal pol
pneumon
Poster Ty
Submissi
Primary A
Email: pi
Addition
Christoph
Jonathan
Kerry Ma
Purpose:
of pneum
all inpati
results. H
predomi
high nega
purpose
on the du
Methods
study. Th
on order
MRSA th
October
result (or
alternate
hours of
duration
intensive
(VARD) a
ymbols that w
Board # ‐ 4‐0
itle: Impact
lymerase ch
nia
ype: Evaluat
ion Category
Author: Lilia
mentellilian
al Authors:
her Fronczek
n Grey
arr
: Methicillin‐
monia. Guide
ents who m
However, res
nant organis
ative predict
of this study
uration of an
s: The institu
he protocol a
sets for pne
erapy for pn
2017 to Mar
r possibly no
e indication f
admission w
in days. Sec
e care unit (I
and C. difficil
2018ASProf
ere not spelled
098
of a pharma
ain reaction
tive Study
y: Infectious
ana Pimente
k
‐resistant St
elines recom
eet risk crite
spiratory cul
sm. Studies s
tive value in
y is to evalua
nti‐MRSA th
utional revie
allowed pha
eumonia. Inp
neumonia be
rch 2018 (po
o PCR if in pr
for MRSA co
were exclude
condary outc
CU) length o
e infections
SHPMidyfessional
d‐out per the g
acist‐driven m
ordering pr
s Disease / H
el; Mease Co
com
aphylococcu
mmend initia
eria, followe
ltures are di
show MRSA
determinin
ate the impa
erapy in hos
w board app
rmacists to o
patients grea
etween Octo
ost‐protocol
re‐protocol g
overage, com
ed. The prim
comes includ
of stay (LOS)
, cost of ant
yearClinlPoster
guidelines wer
methicillin‐r
rotocol on th
HIV
untryside Ho
us aureus (M
ting empiric
d by de‐esca
fficult to col
nasal polym
g negative M
act of a phar
spitalized pa
proved this m
order MRSA
ater than 18
ober 2015 to
group) were
group). Inpa
mplicated pu
mary outcom
ded total ant
, rates of va
i‐MRSA ther
nicalMeAbstrac
re translated i
esistant stap
he duration o
ospital;
MRSA) contin
c therapy wit
alation of an
llect and ma
merase chain
MRSA respira
rmacist‐drive
atients with p
multi‐center
A nasal PCR,
8 years of ag
o March 201
e included if
tients with a
ulmonary inf
e was reduc
tibiotic ther
ncomycin as
rapy, numbe
eetingcts
into unknown
phylococcus
of antibiotic
nues to be a
th anti‐MRS
ntibiotics bas
ay not produ
n reaction (P
atory cultur
en MRSA na
pneumonia.
r, retrospect
and pre‐sele
ge receiving e
16 (pre‐proto
f they had a
a severe bet
fection, or de
ction in anti‐
rapy duration
ssociated re
er of doses a
characters.
s aureus (MR
c therapy for
common ca
A antibiotics
sed on cultu
uce a
PCR) assay ha
e results. Th
sal PCR prot
tive cohort
ected the as
empiric anti
ocol group) o
negative PC
ta‐lactam all
eath within
‐MRSA thera
n, hospital a
nal dysfunct
and drug leve
RSA)
r
ause
s for
ure
as a
he
tocol
say
‐
or
CR
ergy,
48
apy
and
tion
els
*Special sy
per patie
would yie
between
Student’s
analyzed
medians
Results: A
group an
protocol
to 4.5) to
0.001). T
3.9 to 9.5
equals 0.
infection
and level
discontin
post‐prot
not diffe
Conclusio
significan
or patien
ymbols that w
ent, and prot
eld 80 perce
groups. Par
s t test and M
using chi‐sq
with interqu
A total of 12
nd N equals 6
led to a med
o 1.3 days (IQ
There was a m
5) to 4.8 day
.027). There
s, or reducti
ls ordered p
nuation of an
tocol group,
r between g
on: Impleme
nt reduction
nt safety.
2018ASProf
ere not spelled
tocol compli
ent power an
rametric and
Mann–Whit
quare test or
uartile range
28 patients w
65 in the pos
dian reducti
QR 0.8 to 1.9
median redu
ys (IQR 3.1 to
was no diffe
ion in cost d
er patient. T
nti‐MRSA the
, however tim
groups.
enting a pha
in anti‐MRS
SHPMidyfessional
d‐out per the g
iance. For th
nd two‐sided
d non‐param
ney U test, r
r Fisher’s exa
es (IQR) or a
were include
st‐protocol g
on of 1.6 da
9) in the pre
uction of 5.4
o 7.5) in the
erence in ho
espite a sign
Time from p
erapy based
me from PC
armacy‐drive
SA antibiotic
yearClinlPoster
guidelines wer
he primary o
d alpha of 0.
metric contin
respectively.
act test, as a
s numbers a
ed in this stu
group. Imple
ays in empiri
‐ and post‐p
4 days in tota
pre‐ and po
ospital or ICU
nificant redu
presentation
d on a negati
R result to a
en MRSA nas
c duration w
nicalMeAbstrac
re translated i
outcome, 64
.05 to detect
nuous data w
. Differences
appropriate.
and percenta
udy, N equals
ementing a M
c MRSA the
protocol grou
al antibiotic
ost‐protocol
U LOS, incide
uction in the
n to PCR orde
ive PCR resu
nti‐MRSA th
sal PCR orde
ithout comp
eetingcts
into unknown
participants
t a differenc
were analyze
s in proporti
. Data are ex
ages, as app
s 63 in the p
MRSA nasal
rapy, from 2
ups respecti
therapy, fro
groups resp
ence of VAR
e median num
ering and ra
ult were imp
herapy disco
ering protoco
promising cli
characters.
s in each gro
ce of 2 days
ed using
ions were
xpressed as
propriate.
pre‐protocol
PCR orderin
2.9 days (IQR
ively (P less t
om 6.2 days
pectively (P
D or C. diffic
mber of dos
te of
roved in the
ontinuation d
ol led to a
inical outcom
oup
ng
R 1.3
than
(IQR
cile
es
e
did
mes
*Special sy
Session‐B
Poster Ti
fluoroqu
Poster Ty
Submissi
Primary A
Email: ch
Addition
Arielle Ru
Jonathan
Ryan Dun
Purpose:
an effect
In additio
resistanc
alert stat
UTIs shou
antimicro
treatmen
Methods
a 687 bed
suspecte
The cont
fluoroqu
intervent
initiative
antimicro
driven an
fluoroqu
of UTIs. S
escalatio
ymbols that w
Board # ‐ 4‐0
itle: Impact
inolones in t
ype: Evaluat
ion Category
Author: Chr
hristine.price
al Authors:
uff
n Grey
nn
: Current uri
tive treatme
on, empirica
ce rates to Es
ting these sid
uld be limite
obial stewar
nt of UTIs.
s: The institu
d not‐for‐pr
ed or confirm
rol group in
inolone anti
tion group in
includes a f
obial treatm
ntimicrobial
inolones pre
Secondary o
on, length of
2018ASProf
ere not spelled
099
of an antimi
the treatme
tive Study
y: Infectious
ristine Price;
nary tract in
nt for UTIs, s
al treatment
scherichia co
de effects ca
ed. The purp
rdship initiat
utional revie
ofit commun
med UTI and
cludes patie
microbial st
ncludes patie
fluoroquinol
ment cystitis a
stewardship
escribed and
utcomes inc
stay, treatm
SHPMidyfessional
d‐out per the g
icrobial stew
nt of urinary
s Disease / H
Morton Pla
org
nfection (UT
should be re
with a fluor
oli. In 2016,
an be disabli
pose of this s
tive to decre
w board app
nity teaching
prescribed a
ents prescrib
tewardship i
ents after th
one restricti
algorithm, C
p interventio
d overall day
clude empiri
ment failures
yearClinlPoster
guidelines wer
wardship init
y tract infect
HIV
nt Mease He
I) guidelines
eserved due
roquinolone
the Food an
ing and pote
study is to ev
ease the ove
proved this r
g hospital. A
an antibiotic
bed antibioti
nitiative (Au
he initiative (
ion and pres
Cerner indica
ons. The two
ys of therapy
c and final a
s and antibio
nicalMeAbstrac
re translated i
tiative to dec
tions in hosp
ealth Care;
s discuss tha
to the prop
may not be
nd Drug Adm
entially perm
valuate the
rall use of fl
retrospectiv
A total of 11
c for more th
cs for the tre
ugust 2016 to
(August 201
scribing guid
ation and sto
o primary ou
y for fluoroq
antibiotic pre
otic related a
eetingcts
into unknown
crease the u
pitalized pat
t fluoroquin
pensity for co
favorable d
ministration
manent, ther
impact of a
uoroquinolo
ve cohort stu
16 adult patie
han 24 hour
eatment of
o December
17 to Decem
de, physician
op dates, an
utcomes wer
uinolones in
escribed, an
adverse eve
characters.
use of
tients
nolones, alth
ollateral dam
due to local
issued a saf
refore use in
pharmacist‐
ones in the
udy perform
ents with a
s were enro
UTI before t
r 2016) and t
ber 2017). T
n education,
d pharmacis
re the numb
n the treatm
tibiotic de‐
nts, includin
hough
mage.
fety
n
‐led
ed at
olled.
the
the
The
st
ber of
ment
ng
*Special sy
Clostridiu
treatmen
number f
therapy.
nominal
Whitney
Results: T
groups. F
statistica
the prim
significan
therapy i
statistica
empiric a
(P equals
escalatio
failure, C
Conclusio
statistica
treatmen
improved
educatio
had simil
treatmen
are need
resistanc
ymbols that w
um difficile.
nt group wo
fluoroquino
Statistical a
data, two sa
test for nom
There were
For the prim
ally significan
ary endpoin
nt 41 percen
in the interv
ally significan
antibiotic fro
s 0.03). Ther
on within 48
Clostridium d
on: This pha
ally significan
nt of UTIs. Th
d significant
n, Cerner in
lar findings t
nt of UTIs, ho
ed to determ
ce rates.
2018ASProf
ere not spelled
For the prim
uld yield 80
lones prescr
nalysis perfo
ample t‐test
minal and co
no significan
ary endpoin
nt reduction
t of fluoroqu
nt reduction
vention grou
nt difference
om 72 perce
re were no d
hours, avera
difficile or ot
armacy‐led a
nt reduction
he percenta
ly. Key succ
dication sto
to other stud
owever, the
mine the eff
SHPMidyfessional
d‐out per the g
mary outcom
percent pow
ribed and a 9
ormed were
for continuo
ontinuous va
nt difference
nt of fluoroq
from 40 per
uinolone ove
from a total
p (P equals 0
e in the perc
nt in the con
differences in
age duration
ther antibiot
antimicrobia
in the overa
ge of patien
cesses to this
p dates and
dies looking
re are limite
fects of these
yearClinlPoster
guidelines wer
mes, it was de
wer to detec
90 percent p
Pearson Ch
ous variable
riables (non
es in baselin
uinolone reg
rcent to 17 p
erall days of
l of 110 days
0.015). For
entage of pa
ntrol group t
n the other s
n of all antib
tic related ad
l stewardshi
all use of and
ts prescribe
s initiative in
pharmacist
at antimicro
ed studies in
e initiatives
nicalMeAbstrac
re translated i
etermined t
ct a 20 perce
power to det
i‐Square tes
s (normally
n‐normally d
e demograp
gimens pres
percent of p
f therapy, th
s in the cont
secondary e
atients presc
to 90 percen
secondary e
biotic therap
dverse even
ip initiative w
d overall day
ed an approp
ncluded fluo
intervention
obial stewar
hospitalized
on uropatho
eetingcts
into unknown
hat 58 patie
ent differenc
tect a 1.7 da
st or Fisher's
distributed
istributed da
phics betwee
cribed, ther
patients (P eq
ere was a st
trol group to
endpoints, th
cribed an ap
nt in the inte
ndpoints of
y, length of
ts.
was associat
ys of fluoroq
priate empir
oroquinolone
ns. Data fou
rdship initiat
d patients. F
ogen antimi
characters.
ents per
ce for the
ay reduction
s Exact test f
data) or Ma
ata).
en the two
e was a
quals 0.013)
tatistically
o 45 days of
here was a
ppropriate
ervention gr
antibiotic de
stay, treatm
ted with a
quinolones i
ic antibiotic
e restrictions
nd in this st
tives for the
Future studie
crobial
in
for
nn‐
). For
oup
e‐
ment
n the
also
s,
udy
es
*Special sy
Session‐B
Poster Ti
Poster Ty
Submissi
Primary A
Email: ra
Addition
Thomas W
Purpose:
of Ameri
be assoc
reporting
antimicro
organism
assess th
fluoroqu
Methods
susceptib
Vigilanz C
the study
assessed
quarter o
Dosage (
moxiflox
test. Fina
was com
differenc
compare
Results:
patient d
ymbols that w
Board # ‐ 4‐1
itle: Reducin
ype: Evaluat
ion Category
Author: Ang
atlangh@isu.
al Authors:
Wadsworth
: Guidelines
ca recomme
iated with a
g of antimicr
obial stewar
ms that are s
he implemen
inolone usag
s: Cascade re
bilities were
Clinical Phar
y period. To
during the f
of 2018 (inte
DDD) per 10
acin were in
ally, to adjus
pared to tot
ce in fluoroq
ed to the pre
Fluoroquino
days. This de
2018ASProf
ere not spelled
100
ng fluoroquin
tive Study
y: Infectious
gharad Ratlif
.edu
for antimicr
end impleme
high risk of
robial suscep
rdship progra
usceptible to
ntation of su
ge.
eporting rule
suppressed
rmacist Work
assess the e
first quarter
ervention pe
000 patient d
ncluded in th
st for potent
tal antibiotic
uinolone DD
e‐interventio
olone usage f
ecreased to 2
SHPMidyfessional
d‐out per the g
nolone usag
s Disease / H
ff; UAA/ISU C
robial stewa
enting interv
Clostridium
ptibility test
am elected t
o narrower‐
ppression ru
es were revi
in our elect
kflow was us
efficacy of th
r of 2017 (pr
eriod). Fluoro
days. All pre
he study. Dat
ial differenc
c use per 100
DD per 1000
on period.
for the pre‐i
27.51 DDD p
yearClinlPoster
guidelines wer
e by partner
HIV
College of P
rdship progr
ventions to r
difficile infe
results. As a
to suppress
spectrum ag
ules for fluor
ewed. Wher
tronic health
sed to collec
his intervent
e‐interventi
oquinolone
scriptions fo
ta for each m
ces in total a
00 patient d
patient day
intervention
per 1000 pat
nicalMeAbstrac
re translated i
ring with the
harmacy;
rams from th
reduce the u
ection as we
a result of th
fluoroquino
gents. This st
roquinolone
re appropria
h record (Epi
ct data regar
tion, fluoroq
on period) a
usage was re
or levofloxac
month was c
ntibiotic usa
ays. Our pri
ys during the
n period was
ient days du
eetingcts
into unknown
e microbiolo
he Infectiou
use of antibi
ell as implem
hese recomm
olone suscep
tudy was co
e susceptibili
ate, fluoroqu
ic) starting in
rding antibio
uinolone us
as compared
ecorded as D
cin, ciproflox
compared us
age, fluoroq
mary endpo
e interventio
s 39.05 DDD
uring the inte
characters.
ogy lab
s Disease So
otics known
menting casca
mendations,
ptibilities for
onducted to
ity reporting
uinolone
n January 20
otic usage du
age was
d to the first
Defined Dail
xacin and
sing a studen
uinolone use
oint was a
on period as
per 1000
ervention pe
ociety
n to
ade
our
g on
018.
uring
ly
nt’s t
e
eriod
*Special sy
(p=0.164
of 29.56
decrease
(p=0.188
Conclusio
29.56 pe
significan
the three
Additiona
was relat
antibiotic
spectrum
ymbols that w
41). An absol
percent was
ed from 2.49
8). This was a
on: Followin
rcent. While
nt with a lon
e month stud
ally, this dec
tively stable
c usage sugg
m antibiotics
2018ASProf
ere not spelled
ute differen
s detected. A
9 percent of
a relative de
ng this interv
e not statisti
nger study pe
dy period. It
crease was is
. While outs
gests that pr
.
SHPMidyfessional
d‐out per the g
nce of 11.54
As compared
total antibio
crease of 28
vention, fluo
cally signific
eriod. This d
t did not req
solated in flu
ide of the sc
roviders sele
yearClinlPoster
guidelines wer
DDD per 10
d to total an
otic usage to
8.03 percent
oroquinolone
cant, this dec
ecrease in u
uire any pat
uoroquinolo
cope of this s
ected other,
nicalMeAbstrac
re translated i
00 patient d
tibiotic usag
o 1.79 percen
t.
e usage decr
crease does
usage was im
tient or prov
one usage as
study, the m
potentially l
eetingcts
into unknown
days and a re
ge, fluoroqu
nt of total an
reased in ou
show a tren
mmediate an
vider‐specific
s our total an
maintenance
less toxic an
characters.
elative differ
inolone usag
ntibiotic usa
ur facility by
nd that may
nd sustained
c interventio
ntibiotic usa
e of total
nd narrower
rence
ge
age
be
d over
ons.
ge
*Special sy
Session‐B
Poster Ti
care, tea
Poster Ty
Submissi
Primary A
Email: le
Addition
Rebecca
Cynthia D
Cara Fan
Purpose:
addition
an antim
monitori
antibiotic
Clostridio
microbio
lastly, pro
formulat
Methods
committe
to measu
prescribi
indicatio
repeated
overall u
card was
appropri
common
patients
ymbols that w
Board # ‐ 4‐1
itle: Implem
ching hospit
ype: Descrip
ion Category
Author: Leo
onor.rojas@
al Authors:
Jayakumar
Derouin
ning
: Valley Hosp
to alarming
icrobial stew
ng and decr
c utilization
oides difficile
ota transplan
omoting phy
ed to track r
s: The ASP se
ee, including
ure appropri
ng patterns
ns were con
d incidences.
tilization for
s created and
ate use indic
indications
on fluoroqu
2018ASProf
ere not spelled
101
entation of
tal: three ye
ptive Report
y: Infectious
onor Rojas; V
@uhsinc.com
pital Medica
rates of Gra
wardship pro
easing the in
by 20 perce
e infection (
nts; developi
ysician educ
resistance pa
ervice emplo
g ID physicia
ate use of a
for these an
ntacted, offe
. Days of the
r each drug.
d distributed
cations and
. In addition
inolone ther
SHPMidyfessional
d‐out per the g
an antimicro
ars later
s Disease / H
Valley Hospit
m
al Center’s ov
am‐negative
ogram (ASP)
nappropriate
nt, the year
CDI) rate by
ing clinical p
ation and pr
atterns.
oyed various
ans, develop
ntibiotics. T
ntimicrobials
red alternat
erapy (DOT)
To target flu
d to medical
on the oppo
to this educ
rapy on a da
yearClinlPoster
guidelines wer
obial stewar
HIV
tal Medical C
verutilizatio
bacterial re
in 2015. Th
e utilization
prior to ASP
y 50 percent
pathways for
rospective fe
s interventio
ed and agre
he ASP phar
s. Prescriber
tive treatme
per a 1000 p
uoroquinolo
staff. These
osite side an
cational prog
aily basis to p
nicalMeAbstrac
re translated i
rdship progra
Center;
n of broad s
esistance, led
e goals of th
of antimicro
P initiation; r
as well as im
r common in
eedback. Bia
ons to accom
ed on appro
rmacist track
rs who devia
ent options, a
patient days
one prescribi
e cards have
alternative
gram, the AS
prospectivel
eetingcts
into unknown
am (ASP) in
spectrum an
d to the imp
he ASP servic
obials, decre
reducing hos
mplementing
nfectious dis
annual antib
mplish these
opriate use c
ked and doc
ated from ap
and monitor
s was calcula
ing, a lamina
e one side ill
treatment o
SP pharmac
ly intervene
characters.
a 300‐bed, a
tibiotics in
plementation
ce included
easing specif
spital‐onset
g fecal
ease states;
biograms we
goals. The A
criteria by w
umented
pproved
red for pote
ated to track
ated pocket
ustrating
options table
ist reviewed
on switchin
acute
n of
fic
; and
re
ASP
which
ntial
k
size
e for
d
g to
*Special sy
alternativ
services c
CDI were
gastroen
for patie
infectiou
resistanc
Results: T
the ASP s
aztreona
days has
Overall u
respectiv
from 201
by 32 pe
testing m
date. Res
Escherich
Similarly,
three bro
resistanc
Enteroco
Conclusio
utilizatio
decrease
present d
positive r
the incre
intervent
ymbols that w
ve agents. E
conducted b
e targeted an
terology, an
nts with rec
s disease sta
ce rates.
Three years
service in 20
m, ertapene
decreased b
usage of the
vely, from 20
14 to 2017. T
rcent from 2
methodology
sistance dec
hia coli and K
, meropenem
oad‐spectrum
ce of methici
occus faecium
on: The Vall
n of antimic
ed and eleve
date. Gram‐
resistance p
eased Gram‐
tions.
2018ASProf
ere not spelled
fforts to red
by the ASP p
nd intervene
nd infection c
urrent CDI.
ates were al
of data hav
015. The yea
em, merope
by 58, 46, 94
carbapenem
014 to 2017.
The incidenc
2016 to 2017
y. The hospit
reased for s
Klebsiella pn
m‐resistant
m antimicro
illin‐resistan
m have incre
ey Hospital
crobials durin
n fecal micr
negative res
atterns have
positive resi
SHPMidyfessional
d‐out per the g
duce hospita
harmacist a
ed on a daily
control staff
Laminated c
so distribute
e been colle
r 2014 was u
nem, ciprofl
4, 27, 31, and
ms and fluoro
. Furthermo
ce of hospita
7. Previous y
tal has condu
pecific Gram
neumoniae h
Pseudomon
bials exhibit
nt Staphyloco
eased by 23
Medical Cen
ng its first th
obiota trans
sistance patt
e trended up
istance is be
yearClinlPoster
guidelines wer
l‐onset CDI
nd residents
y basis. Joint
f created a p
cards detaili
ed. Lastly, an
ected, analyz
used as the
oxacin, and
d 80 percent
oquinolones
re, overall a
al onset CDI
years were n
ucted 11 fec
m‐negative p
have decreas
as aeruginos
ting over 90
occus aureus
and 6 perce
nter’s ASP se
hree‐year pe
splants have
terns have sh
p recently. F
eing investiga
nicalMeAbstrac
re translated i
involved nur
s. Antibiotics
ly, the ASP c
protocol for f
ng evidence
ntibiograms
zed, and rep
baseline for
levofloxacin
t, respective
s decreased
ntibiotic use
per a 1000
not included
cal microbiot
pathogens: c
sed by 100 a
sa has decre
percent sen
s and vanco
ent, respectiv
ervice has su
eriod. Hospit
e been perfo
hown a sign
urther trend
ated in orde
eetingcts
into unknown
rsing and ph
s deemed to
committee,
fecal microb
e‐based trea
were formu
ported since
r comparison
n DOT per a
ely, from 201
by 31 and 4
e decreased
patient days
due to diffe
ta transplan
carbapenem
and 81 perce
eased by 86
nsitivity rate
mycin‐resist
vely.
uccessfully d
tal‐onset CD
rmed at the
ificant decre
ding and inv
er to institute
characters.
hysician in‐
o be high‐risk
biota transpl
tment on se
ulated to tra
the inceptio
n. Daptomyc
1000 patien
14 to 2017.
47 percent,
by 10 perce
s has decrea
erences in CD
ts to presen
‐resistant
ent, respecti
percent, wit
. Recently,
tant
ecreased
I rates have
e facility to
ease while G
estigation in
e targeted
k for
lants
everal
ck
on of
cin,
nt
ent
ased
DI
nt
ively.
th
also
Gram‐
nto
*Special sy
Session‐B
Poster Ti
patients
Poster Ty
Submissi
Primary A
Email: ju
Addition
Jose Dryj
Norman
Lisa Rosa
Christine
Purpose:
setting, w
followed
unnecess
pathogen
difficile in
to provid
usage to
resistant
Methods
financial
and an a
started o
antifunga
program
Disease c
was colla
physician
intervent
ymbols that w
Board # ‐ 4‐1
itle: Implem
ype: Descrip
ion Category
Author: Jud
dy.l.san@kp
al Authors:
janski
Jung
a
e Balekian
: According t
with up to 70
over one ye
sary or inapp
ns, increases
nfections. T
de Infectious
optimize pa
bacteria.
s: This is a de
support we
ntimicrobial
on 01/01/20
al, and antiv
. Prospectiv
consultation
aboration be
ns, and nursi
tions (appro
2018ASProf
ere not spelled
102
entation of
ptive Report
y: Infectious
y San; Kaise
p.org
to the CDC, a
0% of reside
ear. Studies
propriate. In
s adverse dr
The objective
s Disease sup
atient outcom
escriptive st
re secured,
stewardshi
16. Kaiser P
viral agents i
ve chart revi
n and educat
etween ASP
ing home sta
ove, change,
SHPMidyfessional
d‐out per the g
an antimicro
s Disease / H
r Permanent
antibiotics a
ents receivin
have shown
nappropriate
ug events, a
e is to imple
pport and pr
mes, minimi
udy. To imp
nursing hom
p team for n
Permanente
n the Kaiser
ew with inte
tion were pr
pharmacists
aff in manag
discontinue
yearClinlPoster
guidelines wer
obial stewar
HIV
te ‐ Woodla
are frequent
g one or mo
n that 40‐75
e antimicrob
and creates c
ment an ant
romote appr
ze adverse e
plement the
mes were vis
nursing hom
nursing hom
Woodland H
ervention an
ovided to nu
s, Infectious
ging patients
e, and initiate
nicalMeAbstrac
re translated i
rdship progra
nd Hills Med
ly prescribed
ore courses o
% of antibio
bial use incre
collateral da
timicrobial s
ropriate evid
events, and
program, le
ited, key sta
es was creat
me patients w
Hills service
nd feedback
ursing home
Diseases ph
s’ antimicrob
e) were trac
eetingcts
into unknown
am for nursi
dical Center;
d in the nurs
of systemic a
otics prescrib
eases select
amage such a
stewardship
dence‐based
decrease th
eadership co
akeholders w
ted. The pro
who were o
area were i
was conduc
e physicians
hysicians, nu
bial regimen
cked and rep
characters.
ing home
;
sing home
antibiotics w
bed are
ion of resist
as Clostridiu
program (AS
d antimicrob
e selection o
ommitment a
were identifi
ogram was
n antimicrob
ncluded in t
cted. Infecti
and staff. T
rsing home
ns. ASP
ported quart
when
ant
um
SP)
bial
of
and
ed,
bial,
he
ous
There
terly.
*Special sy
Readmiss
pneumon
pre‐imple
Results:
were app
consulted
were cha
number o
51208, 4
and 2017
3), C. diff
reduction
hospital c
readmiss
2017 com
cost of p
Conclusio
clinical a
readmiss
nursing h
to be det
stewards
ymbols that w
sions from n
nia, urinary t
ementation
In 2016, ASP
proved, 303
d 1040 patie
anged, 126 w
of patients w
6239, and 4
7: Sepsis (50
ficile colitis (
n in hospital
cost savings
sions with in
mpared to 20
rogram ope
on: The Anti
nd financial
sions. The p
home physic
termined. T
ship in the n
2018ASProf
ere not spelled
nursing hom
tract infectio
benchmark
P consulted 1
were chang
ent antimicro
were discont
were 1465, 1
5023, respe
, 38, and 25
(3, 1, and 0),
l readmissio
in 2016 com
fection‐rela
015. The tot
rations.
imicrobial St
outcomes w
rogram was
cians. The im
he program
ursing home
SHPMidyfessional
d‐out per the g
es for the fo
on, C. difficil
.
1125 patien
ed, 173 wer
obial regime
tinued, and 4
1495, and 13
ctively. Rea
), pneumoni
, and cellulit
ns with infec
mpared to 20
ted diagnose
tal cost savin
tewardship P
with lower ra
well‐receive
mpact on ant
can serve a
es.
yearClinlPoster
guidelines wer
ollowing pres
le colitis, and
t antimicrob
re discontinu
ens, of those
45 were init
378, respect
dmission dia
ia (20, 9, and
is (1, 0, and
ction‐related
015. There w
es resulting
ngs were est
Program sho
ate of infecti
ed by all par
timicrobial r
s a best prac
nicalMeAbstrac
re translated i
set target di
d cellulitis) f
bial regimen
ued, and 43
e regimens: 6
iated. In 20
tively; total l
agnoses wer
d 2), urinary
1), respectiv
d diagnoses
was a 65% r
in 338 days
timated to b
owed a signi
ion‐related d
rticipants inv
resistance an
ctice model
eetingcts
into unknown
iagnoses (se
from 2015 w
s, of those r
were initiate
612 were ap
15, 2016, an
ength of sta
re as follows
y tract infect
vely. There
resulting in
eduction in
of hospital c
be more tha
ficant positi
diagnoses fo
volved, parti
nd collateral
for antimicr
characters.
psis,
were used as
regimens: 60
ed. In 2017,
pproved, 257
nd 2017, tota
ay in days we
s in 2015, 20
ion (10, 11,
was a 30%
160 days of
hospital
cost savings
n 5 times th
ve impact o
or hospital
icularly our
l damage is y
robial
s the
06
, ASP
7
al
ere
016,
and
f
in
e
n
yet
*Special sy
Session‐B
Poster Ti
Poster Ty
Submissi
Primary A
Email: ju
Addition
Cassandr
Kristi Kup
Purpose:
antibiotic
to encou
enters th
restrictio
evaluate
purchase
Methods
purchase
between
approved
May 201
pharmac
database
January 2
evaluate
spectrum
drug or w
product n
utilizatio
reflective
purchase
ymbols that w
Board # ‐ 4‐1
itle: Does ut
ype: Descrip
ion Category
Author: Just
stinjtsantos@
al Authors:
ra Miller
per
: Although th
c utilization
rage the res
he market, it
on status and
the impact
es and utiliza
s: This was a
es and utiliza
2014 and 2
d Septembe
7) and Tygac
ceutical distr
e ((Clinical D
2015 to Mar
d independe
m of antibact
were a chara
name, trade
n data was m
e of inpatien
es were exclu
2018ASProf
ere not spelled
103
tilization incr
ptive Report
y: Infectious
tin Santos; V
@gmail.com
he primary g
and decreas
striction of h
t creates com
d potentially
of generic a
ation.
a retrospecti
ation for ant
017. Three d
r 2014), Ave
cil (tigecyclin
ribution data
ata Base ‐ Re
rch 2018. Ge
ently for eac
terial activity
acteristic of t
e size, total u
measured ba
nt utilization
uded. A pai
SHPMidyfessional
d‐out per the g
rease when
s Disease / H
Vizient, Inc;
m
goals of an a
se antibiotic
high cost dru
mpetition an
y lead to incr
pproval of p
ve study tha
ibacterial dr
drugs were i
elox (moxiflo
ne, approved
a feeds and a
esource Ma
eneric and br
ch drug. They
y to evaluate
the category
units, individ
ased on days
only. Non‐s
red t‐test wa
yearClinlPoster
guidelines wer
a brand nam
HIV
antibiotic ste
resistance,
ugs. When th
nd results in
reased utiliz
previously br
at evaluated
rugs that rec
included in t
oxacin; oral a
d May 2017)
antibiotic ut
nager (CDB/
rand name p
y were also
e if trends o
y/class. Purc
dual acquisiti
s of therapy
systemic ant
as used to d
nicalMeAbstrac
re translated i
me antibiotic
ewardship pr
ASPs may in
he generic v
lower drug
ation. The p
rand name a
the relation
ceived their
the analysis:
approved Fe
). Purchase d
tilization dat
/RM) (Vizien
purchasing a
compared to
bserved wer
chase data fi
ion cost and
y per 1000 pa
tibiotics (e.g
etermine a s
eetingcts
into unknown
c goes gener
rogram (ASP
ntentionally
version of th
prices which
purpose of th
antibacterial
nship betwe
first generic
: Cubicin (da
ebruary 2014
data was ag
ta was derive
t, Inc.)) for t
and utilizatio
o drugs with
re unique to
elds evaluat
d aggregate s
atient days a
g. topical) an
significant d
characters.
ric?
P) are to imp
include polic
e medicatio
h may ease A
his study wa
drugs on to
en drug
c drug appro
aptomycin,
4, IV approve
gregated fro
ed from a la
the period o
on trends we
h a similar
o the individu
ted included
spend. Antib
and was
nd 340b
difference
prove
cies
n
ASP
s to
otal
oval
ed
om
rge
f
ere
ual
d
biotic
*Special sy
between
underlyin
Results: A
centers a
quarter o
while uti
trends fo
measure
Q3/16 an
ciproflox
were obs
were obs
decreasin
Conclusio
daptomy
remained
vancomy
and utiliz
ciproflox
Continue
evaluate
ymbols that w
the utilizati
ng event, wi
A total of 13
and 39.4% w
of generic av
lization duri
or daptomyc
d. For moxif
nd Q1/18 (40
acin and lev
served (p= 0
served begin
ng in Q1/15
on: Varying
ycin, vancom
d relatively s
ycin) and tige
zation for flu
acin and lev
ed monitorin
d to determ
2018ASProf
ere not spelled
ion and purc
th a one‐tail
32 hospitals
were commu
vailability (Q
ng the same
in were sim
floxacin, the
0.6% and 29
vofloxacin ut
.004 and 0.0
nning in Q1/
and was ind
magnitudes
mycin, and tig
stable for da
ecycline dur
uoroquinolon
vofloxacin co
ng of generic
ine if these t
SHPMidyfessional
d‐out per the g
chasing mea
led p‐value o
were includ
nity hospita
Q3/16) to the
e comparison
ilar to linezo
largest decr
9.5%, respect
tilization afte
008, respect
17. Overall p
dependent o
of reductio
gecycline aft
aptomycin (a
ing the perio
nes appeare
orresponded
c and brand
trends conti
yearClinlPoster
guidelines wer
ns before an
of 0.025 indi
ed. Approxim
ls. Total pur
e most recen
n periods inc
olid and vanc
rease in purc
tively; p>0.0
er the Food
ively). For ti
purchases de
of generic sta
n in overall q
ter generic a
alone and wh
od after gen
ed to be a cla
d to the FDA
name antibi
inue.
nicalMeAbstrac
re translated i
nd after gen
icating signif
mately 60.6%
rchases for d
nt quarter (Q
creased by 6
comycin dur
chases and u
025). Howev
and Drug Ad
gecycline, d
ecreased by
atus.
quarterly pu
availability.
hen compar
neric availabi
ass effect an
fluoroquino
iotic utilizati
eetingcts
into unknown
eric availabi
ficance.
% were acad
daptomycin,
Q1/18) decre
6% (p>0.025
ring the time
utilization oc
ver, a signific
dministratio
eclines in to
y 19.2%, but
urchases we
However, ut
red to linezo
ility. Change
nd significant
olone warnin
ion and purc
characters.
ility, or othe
demic medic
, from the fi
eased by 36.
5). Utilization
e period
ccurred betw
cant decreas
n (FDA) war
otal purchase
utilization b
re observed
tilization
lid and
es in purcha
t declines in
ng in July 20
chases shoul
er
cal
rst
.6%,
n
ween
se in
ning
es
began
for
ses
n
16.
ld be
*Special sy
Session‐B
Poster Ti
infection
Poster Ty
Submissi
Primary A
Email: m
Addition
Jassem B
Purpose:
Infection
causative
Methods
between
with eith
were pre
correspo
abscess m
microbio
suprapub
50 ml spe
isolated w
Results: A
the Pus o
The vario
(33.03%)
Pus deriv
most freq
In a seco
as well as
ymbols that w
Board # ‐ 4‐1
itle: Microbi
s and urinar
ype: Descrip
ion Category
Author: Mo
ohammad.s
al Authors:
Bourji
: The aim of
ns (DFI) and U
e pathogens
s: A retrospe
January 201
her Diabetic f
egnancy and
onded to cur
material, or
ological evalu
bic aspirate
ecimen. The
was determ
A total of 25
of DFI patien
ous pathoge
), followed b
ved from DF
quent uropa
nd step, E. c
s from all th
2018ASProf
ere not spelled
104
iological pro
ry tract infec
ptive Report
y: Infectious
hammad Se
serhane.93@
this study w
Urinary Trac
.
ective, open‐
17 and April
foot infectio
lactation. M
ettage of th
aspiration o
uation was d
being collect
e type of bac
ined by the V
54 samples (
nts) were scr
ns detected
by E.coli (27.5
I patients .H
athogens.
coli isolates,
e PUS samp
SHPMidyfessional
d‐out per the g
ofile and esch
ctions among
s Disease / H
hane; Comm
@gmail.com
was to charac
ct infections
‐label, contr
2018 analyz
on (DFI) or U
Materials use
e base of the
f material th
done by obta
ted in a ster
cteria and th
Vitek machi
145 issued f
reened for th
in the cultu
52%) were t
owever, E. c
derived from
les issued fr
yearClinlPoster
guidelines wer
herichia coli
g Lebanese
HIV
munity;
cterize the b
and to asses
rolled study
zing 254 pat
rinary tract
ed for microb
e ulcer after
hrough the i
aining a clea
rile wide‐mo
e in vitro an
ne method.
from the urin
he contained
res are show
the two mos
coli (73.10%)
m 56 sample
rom the DFI
nicalMeAbstrac
re translated i
resistance p
patients
bacterial pro
ss the antibi
was perform
tients (adults
infection (U
biological ev
r debrideme
nfected skin
n‐catch mid
outh leak‐pro
ntimicrobial s
ne of UTI pa
d pathogens
wn and Stap
st common o
)and Klebsie
es issued fro
patients, we
eetingcts
into unknown
patterns in d
ofile of Diabe
iotic sensitiv
med at Raee
s >18 years o
UTI). Main ex
valuation for
ent, needle a
n and deep t
dstream spec
oof containe
susceptibilit
atients and 1
s and antibio
hylococcus c
organisms id
ella (11.03%)
om the urine
ere screened
characters.
diabetic foot
etic foot
vity of the
hospital
old) present
xclusion crite
r pathogen i
aspiration of
issues. UTI
cimen or a
er to hold ab
ty of the E.co
109 derived f
otic sensitivit
coag. Negat
dentified in t
) were the tw
e of UTI patie
d for antibiot
t
ted
eria
n DFI
f the
bout
oli
from
ty.
ive
he
wo
ents
tic
*Special sy
sensitivit
antibiotic
(Ertapen
antibiotic
were the
resistanc
the cases
Conclusio
present n
different
ymbols that w
ty using Anti
c efficacy in
em, Merope
cs for E. coli
e least effect
ce to fluoroq
s. The MIC re
on: We show
not only in U
t antibiotics.
2018ASProf
ere not spelled
biogram and
both UTI an
enem and Im
eradication
tive antibioti
quinolones (e
esults were
wed in this s
UTIs but also
SHPMidyfessional
d‐out per the g
d MIC assays
d DFI sampl
mipenem) fo
in both infe
ics to eradic
especially cip
in accordanc
study that E.
o in DFIs. Mo
yearClinlPoster
guidelines wer
s. The Antib
es was not s
llowed by am
ections, whil
ate E. coli. O
profloxacin a
ce with the A
coli is amon
oreover, E. co
nicalMeAbstrac
re translated i
iogram resu
significantly
mikacin wer
e ceftazidim
On the other
and levoflox
Antibiogram
ng the most
oli showed s
eetingcts
into unknown
lts revealed
different. Ca
re the most e
me, cefepime
r hand, the i
xacin) was ar
m data.
common ba
significant re
characters.
that the
arbapenems
effective
e and bactrim
ncidence of
round 50% o
acterial spec
esistance to
s
m
of
ies
*Special sy
Session‐B
Poster Ti
regulator
Poster Ty
Submissi
Primary A
Email: ka
Addition
Jennifer V
Oscar Gu
Purpose:
impleme
Antibioti
with bed
roughly a
a small a
AS consu
and after
Methods
hospital a
after form
areas for
dissemin
was com
SARAA.
collected
impleme
Results: T
(present)
complian
ymbols that w
Board # ‐ 4‐1
itle: Impact
ry complianc
ype: Descrip
ion Category
Author: Kat
ate.shea@ca
al Authors:
VanCura
uzman
: The most r
ntation of th
c Stewardsh
sizes less th
a 45% varian
nd rural hos
ultation and
r formation o
s: This was a
and critical a
mation of SA
r ASP implem
ation of ASP
pleted by 26
Responses o
d. The workg
ntation surv
Twenty‐six C
) with regula
nce increase
2018ASProf
ere not spelled
105
of a small an
ce
ptive Report
y: Infectious
herine Shea
ardinalhealth
ecent Nation
he Centers f
hip (AS) Prog
han or equal
nce compare
spital AS allia
resources. I
of SARAA.
a multi‐site s
access hospi
ARAA. SARA
mentation, c
P resources t
6 hospitals b
of present, n
group focuse
vey results.
CAHs comple
atory elemen
d from 58%
SHPMidyfessional
d‐out per the g
nd rural hosp
s Disease / H
; Cardinal He
h.com
nal Healthca
or Disease C
grams report
to 50 were
ed to genera
ance (SARAA
Investigators
urvey assess
itals antimic
AA consisted
ollaboration
to assist with
before (Dec1
ot present,
ed on key dr
eted the sur
nts (68%+22
(+22) to 83%
yearClinlPoster
guidelines wer
pital antimic
HIV
ealth, Innov
are Safety Ne
Control and P
ted less than
compliant w
l acute care
A) was estab
s sought to a
sing complia
robial stewa
of bi‐month
n with two in
h achieving
16‐June17) a
partially pre
rivers of low
rvey. In gene
2 vs 38%+19)
% (+16) whe
nicalMeAbstrac
re translated i
crobial stewa
ative Delive
etwork surv
Prevention C
n 50% of crit
with all 7 ele
or larger ho
blished Dece
assess regul
ance with 18
ardship prog
hly meetings
nfectious dis
regulatory c
and after (Ju
esent, unkno
w compliance
eral, a 78% in
) was experi
en combining
eetingcts
into unknown
ardship allia
ry Solutions
ey regarding
Core Elemen
tical access a
ements. This
ospitals. To
mber 2016 t
atory compl
8 regulatory
grams (ASPs)
s regarding k
seases pharm
compliance.
l17‐May 201
own, or exem
e based on p
ncrease in co
enced. Add
g present an
characters.
ance on
;
g
nts of Hospit
and hospital
s demonstra
bridge this g
to provide e
liance before
elements fo
) before and
key regulato
macists, and
An ASP surv
18) formatio
mpt were
pre‐
ompliance
ditionally,
nd partially
tal
s
ated
gap,
xpert
e
or
d
ory
vey
on of
*Special sy
present r
with lead
training,
identified
for leade
multidisc
and phar
three nee
included
use of an
Conclusio
antimicro
Impleme
resource
ymbols that w
responses in
dership supp
monitoring,
d by the ASP
ership suppo
ciplinary com
rmacist lead
eds (identifi
: competenc
ntibiotics, an
on: A standa
obial stewar
entation of a
s and suppo
2018ASProf
ere not spelled
n the post gr
port, presenc
, tracking, an
P. In the pos
ort, presence
mmittee, coo
ers, multidis
ed as greate
cy‐based edu
nd the ASP d
ardized surv
rdship suppo
small and r
ort which res
SHPMidyfessional
d‐out per the g
oup. The la
ce of a writt
nd reporting
st group, gre
e of a written
ordination w
sciplinary pro
er than 25%
ucation of h
emonstratin
ey identified
ort within th
ural hospita
sulted in a si
yearClinlPoster
guidelines wer
rgest percen
en policy an
g for the ASP
eater than 75
n policy and
with relative
otocols, doc
replying “no
ospital perso
ng improvem
d gaps in pra
e small and
l antimicrob
gnificant inc
nicalMeAbstrac
re translated i
ntage increa
nd procedure
P, and taking
5% complian
procedure,
interdiscipli
cumentation
ot present”)
onnel, ASP d
ment in prop
actice and re
rural hospit
bial stewards
crease in reg
eetingcts
into unknown
se in presen
e, competen
g action on o
nce (present
presence of
nary membe
n of ASP activ
within the p
documents e
per antibiotic
ecognized a c
als in our co
ship alliance
gulatory com
characters.
nt response w
ncy‐based
opportunities
t) was identi
f a
ers, physicia
vities. The t
post group
evidence‐bas
c.
critical need
ohort.
e provided AS
mpliance.
was
s
fied
an
top
sed
d for
SP
*Special sy
Session‐B
Poster Ti
analysis i
Poster Ty
Submissi
Primary A
Email: sh
Addition
Brandon
Purpose:
patients,
combina
hospitals
than 100
of P‐T, bo
utilized t
Methods
of Findla
between
generate
further a
72 hours
of the pa
health re
patient w
demogra
daily BUN
vancomy
grams of
concentr
ymbols that w
Board # ‐ 4‐1
itle: Risk of n
in a commun
ype: Evaluat
ion Category
Author: Bra
hinn@findlay
al Authors:
Soltesz
: Piperacillin
has been sh
tion with va
s. The purpo
0 bed) comm
oth as mono
o develop h
s: This retros
y Institution
Jan. 1, 2015
ed by the hos
nalysis: child
(or 12 dose
atients were
ecord was re
who met stu
aphics, reaso
N and serum
ycin serum c
f P‐T and van
ration of at l
2018ASProf
ere not spelled
106
nephrotoxic
nity hospital
tive Study
y: Infectious
dley Shinn; T
y.edu
‐tazobactam
hown to be a
ncomycin. M
ose of this st
munity hospit
otherapy and
ospital‐spec
spective, qu
nal Review B
5 and June 3
spital’s IT de
dren (less th
es) of P‐T, an
excluded du
eviewed and
dy inclusion
on for admis
m creatinine
oncentratio
ncomycin ad
east 0.3 mg/
SHPMidyfessional
d‐out per the g
ity with the
l
s Disease / H
The Univers
m (P‐T), a com
associated w
Most of thes
tudy was to d
tal who suffe
d in combina
cific guidelin
antitative, e
oard (#1152
30, 2015 wer
epartment.
han 18 years
d patients w
ue to P‐T cou
a standardi
criteria. Th
sion, presum
concentratio
ns, microbio
ministered.
/dL at any ti
yearClinlPoster
guidelines wer
use of piper
HIV
ity of Findlay
mmonly pre
with acute ki
se studies ha
determine t
er an episod
ation with va
es to reduce
experimenta
2). Hospitaliz
re identified
The followin
), pregnant w
with end‐stag
urses that w
zed data col
e following
med or docu
ons, white b
ology results
AKI was de
me during P
nicalMeAbstrac
re translated i
racillin‐tazob
y College of
escribed anti
dney injury
ave been do
he number o
de of nephro
ancomycin.
e the risk of A
l study was a
zed patients
via a drug u
ng patients (
women, tho
ge renal dise
were less tha
llection form
information
mented infe
blood cell an
s, all concom
fined as an i
P‐T therapy.
eetingcts
into unknown
bactam: retr
Pharmacy;
biotic in hos
(AKI), both a
one in larger,
of patients i
otoxicity follo
This inform
AKI within t
approved by
s who were i
use evaluatio
(N=53) were
ose who rece
ease receivin
n 72 hours.
m was compl
n was collect
ection site, a
d platelet co
mitant antibio
increase in s
Each data s
characters.
rospective
spitalized
alone and in
, tertiary car
n a small (le
owing initiat
ation will be
he hospital.
y the Univer
initiated on
on report
e excluded fr
eived less th
ng dialysis.
Each electr
leted for eac
ted: patient
admission an
ounts,
otics, and to
serum creati
set was
n
re
ess
tion
e
rsity
P‐T
rom
an
Most
onic
ch
nd
otal
inine
*Special sy
independ
consensu
Results: A
study po
the avera
the time
each pat
patients
of 41 pat
of 8 of 29
vancomy
creatinin
serum cr
creatinin
therapy.
Conclusio
hospitaliz
underrep
increases
risk of de
who initi
nephroto
medicati
ymbols that w
dently review
us was reach
A total of 70
pulation con
age length o
of hospital a
ient was 21.
(21.4%) exp
tients (17.1%
9 patients (2
ycin therapy
e concentra
reatinine bet
e of 0.3 mg/
on: These re
zed patients
presented in
s the risk of
eveloping AK
ate P‐T (with
oxicity. This
on safety pr
2018ASProf
ere not spelled
wed by each
hed.
0 patients m
nsisted of 40
of hospital st
admission w
4, and 29 pa
erienced on
%) experienc
27.6%) exper
. Upon hosp
ation than at
tween 0.01 a
/dL or greate
esults confirm
s and that th
n previous st
AKI in patien
KI vs. P‐T mo
h or without
information
rogram.
SHPMidyfessional
d‐out per the g
h investigato
et inclusion
0 males (57.1
ay was 9.1 d
was 1.56 mg/
atients (41.4
e episode of
ced an episod
rienced an e
pital discharg
t the time of
and 0.29 mg
er. No study
m studies th
his also occu
udies. Thes
nts receiving
onotherapy.
t vancomyci
n will be utili
yearClinlPoster
guidelines wer
or and discre
criteria and
1%), the ave
days, the ave
/dL, the aver
4%) received
f AKI with or
de of AKI wh
episode of AK
ge, 50 patien
f admission,
g/dL, and 8 p
y patients re
hat suggest P
rs in commu
e results als
g P‐T. Patien
These resul
n), especially
ized to furth
nicalMeAbstrac
re translated i
epancies wer
were includ
erage study p
erage serum
rage numbe
d concomitan
r without th
hile receiving
KI while rece
nts (71.4%)
12 patients
patients (11.
equired any f
P‐T increases
unity hospita
o confirm th
nts on dual t
lts support c
y in patients
her enhance
eetingcts
into unknown
re discussed
ded in the da
patient age w
m creatinine c
r of P‐T dose
nt vancomyc
e use of van
g P‐T monot
eiving dual P
had a lower
(17.1%) had
8%) had an
form of rena
s the risk of
al patients w
hat vancomy
therapy had
close monito
s at higher ri
the hospita
characters.
until a
ata analysis.
was 70.4 yea
concentratio
es received b
cin. Fifteen
ncomycin. Se
therapy; a to
P‐T plus
serum
d an increase
increased se
al replaceme
AKI in
who have bee
ycin further
a 61% incre
oring of patie
isk of
l’s ongoing
The
ars,
on at
by
even
otal
ed
erum
ent
en
eased
ents
*Special sy
Session‐B
Poster Ti
impleme
Poster Ty
Submissi
Primary A
Email: sh
Addition
Jenna Co
Todd Leo
David Co
James Ne
Purpose:
(IDSA), a
stewards
including
hospital,
Green, O
year of th
and phar
Methods
(#1188).
the elect
were gat
intervent
of metho
therapy d
Results:
following
tazobact
ymbols that w
Board # ‐ 4‐1
itle: Assessm
ntation in a
ype: Evaluat
ion Category
Author: Bra
hinn@findlay
al Authors:
onner
opold
omshaw
elson
: Due to wid
long with m
ship program
g three backg
a pharmacy
Ohio in Janua
he program
rmacist inter
s: This study
This study p
tronic medic
thered from
tion data we
ods recogniz
de‐escalatio
Overall, from
g targeted an
am, cefepim
2018ASProf
ere not spelled
107
ment of an a
community
tive Study
y: Infectious
dley Shinn; T
y.edu
espread ant
any other or
ms (ASPs) in
ground stud
y‐managed A
ary 2017. Th
through ana
rvention acti
was approv
population c
al record be
WCH data b
ere collected
ed by the ID
n, earlier dis
m 2016 to 20
ntimicrobial
me, levofloxa
SHPMidyfessional
d‐out per the g
ntimicrobial
hospital
s Disease / H
The Univers
timicrobial re
rganizations
all healthcar
ies that asse
ASP was initi
he purpose o
alysis of chan
ivities.
ved by the U
consisted of
etween Janu
bases utilizin
d and assess
DSA to impro
scontinuatio
017, there w
agents: imip
acin, ciproflo
yearClinlPoster
guidelines wer
stewardshi
HIV
ity of Findlay
esistance, th
, encourage
re settings.
essed the pr
ated at Woo
of this study
nges in antim
niversity of
all WCH inp
ary 1 and De
ng only patie
ed via chart
ove and redu
on, and time
was an 8% de
penem/cilas
oxacin, vanco
nicalMeAbstrac
re translated i
p program o
y College of
he Infectious
es establishm
Following a
re‐ASP usage
od County H
is to assess
microbial us
Findlay Insti
patients who
ecember 31,
ent de‐identi
review. Thi
uce antimicr
ly conversio
ecrease in to
statin, mero
omycin, and
eetingcts
into unknown
one year afte
Pharmacy;
s Disease So
ment of antim
multiyear p
e of antibiot
Hospital (WC
the effectiv
age rates, a
itutional Rev
o had an anti
, 2017. Cost
ified aggrega
is program u
obial usage,
on of IV to or
otal grams ut
penem, pipe
linezolid. W
characters.
er
ociety of Ame
microbial
planning proc
ics within th
CH) in Bowlin
eness of the
ntibiotic cos
view Board
ibiotic order
t and usage
ate data. Cli
utilized a var
, including
ral therapy.
tilized of the
eracillin‐
When adjust
erica
cess,
he
ng
e first
sts,
red in
data
inical
riety
e
ed
*Special sy
for gram
2017. Th
linezolid.
this is dir
savings a
to $7.34
tazobact
program
comforta
per mont
intervent
Conclusio
evidence
recomme
antibiotic
savings o
increased
coming y
objective
ymbols that w
s utilized pe
he largest us
. Overall, an
rectly attribu
are due to th
in 2017. Mo
am and vanc
became inc
able in formu
th) were ma
tions (60.2%
on: A pharm
ed by the 80.
endations re
c use and lim
occurred bet
d as the yea
years as both
es of the ASP
2018ASProf
ere not spelled
r 1000 patie
sage decreas
ntibiotic cost
utable to the
he ASP. Tota
onth‐by‐mon
comycin we
creasingly eff
ulating and m
ade through
%) focused on
macist‐manag
.2% accepta
esulted in de
mit the selec
tween May a
r progressed
h pharmacist
P.
SHPMidyfessional
d‐out per the g
ent‐days, the
ses occurred
ts decreased
e ASP, more
al antibiotic c
nth analysis
re highest in
fective as th
making inter
the ASP and
n therapy de
ged ASP pro
nce rate for
e‐escalation
ction of resis
and Decemb
d. It is expec
ts and provi
yearClinlPoster
guidelines wer
ere was an o
d with cefepi
d by $10,417
detailed ana
costs per pa
shows that
n the last six
e year progr
rventions. A
d 158 (80.2%
e‐escalation.
gram in a co
ASP recomm
of therapy,
stant organis
ber, suggesti
cted that thi
ders becom
nicalMeAbstrac
re translated i
overall decre
ime, levoflox
7 from 2016
alysis sugges
atient‐day de
reductions i
months of 2
ressed and p
A total of 197
%) were acce
.
ommunity ho
mendations.
intervention
sms. Over $
ng the effec
is ASP will be
e more com
eetingcts
into unknown
ease of 5.6%
xacin, vanco
to 2017. W
sts that 60‐7
ecreased fro
in the use of
2017, sugges
pharmacists
7 recommen
epted. The m
ospital was w
. More than
ns most likel
9,000 of the
ctiveness of t
ecome more
mfortable wit
characters.
from 2016 t
omycin, and
While not all o
70% of these
om $8.13 in 2
f piperacillin
sting the
became mo
ndations (16
majority of t
well receive
n half of thos
y to reduce
e annual cost
the program
e effective in
th the goals
to
of
e
2016
n‐
ore
6.4
hese
d, as
se
t
m
n
and
*Special sy
Session‐B
Poster Ti
Poster Ty
Submissi
Primary A
Email: ni
Addition
Janet Fisc
Brittany
Brady Div
Nicole Ra
Purpose:
the popu
allergy ra
leading t
and side
this instit
antibiotic
Methods
to July 20
Data coll
until the
antibiotic
compare
analysis w
outcome
Results:
indeterm
which ha
with a co
ymbols that w
Board # ‐ 4‐1
itle: Cost‐be
ype: Evaluat
ion Category
Author: Nich
cholas.skibb
al Authors:
cher
Elgersma
veley
asmussen
: Penicillin is
ulation repor
ate is around
o the avoida
effects. The
tution to det
c costs.
s: Data was c
016. Testing
ected includ
end of July
cs costs for i
ed to actual a
was perform
es of subsequ
PAST reveal
minate tests.
ad an immed
ost of perfor
2018ASProf
ere not spelled
108
nefit of inpa
tive Study
y: Infectious
holas Skibba
ba@sanfordh
s one of the
rt a penicillin
d 1 percent.
ance of beta
e purpose of
termine tim
collected on
g was physic
ded antibioti
2016. Actua
initial and su
alternative a
med to deter
uent and pre
ed 170 (85 p
129 of the
diate allergic
ming the tes
SHPMidyfessional
d‐out per the g
atient pharm
s Disease / H
a; Sanford US
health.org
most comm
n allergy, ho
A penicillin
‐lactam anti
f this study w
e requireme
n the first 20
ian ordered
ics prior to P
al antibiotic
ubsequent co
antibiotic cos
rmine the pr
eceding cost
percent) neg
170 were ch
c reaction. In
st at 16,708.
yearClinlPoster
guidelines wer
macist admin
HIV
SD Medical
on patient‐r
wever when
allergy labe
ibiotics, whic
was to review
ent and cost‐
0 patients th
and pharma
PAST and aft
costs were c
ost savings.
sts for prece
imary outco
t savings. A
gative, 23 (11
hallenged wi
nitial antibio
.00 dollars.
nicalMeAbstrac
re translated i
nistered pen
Center;
reported alle
n allergy test
el may alter
ch may caus
w penicillin
‐benefit, if a
hat received
acist admini
ter PAST, inc
compared to
Estimated a
eding cost sa
ome of initia
time study w
1.5 percent)
ith a beta‐la
otics cost sav
Subsequent
eetingcts
into unknown
icillin allergy
ergies. Abou
ting is emplo
provider ant
se increased
allergy skin
any, based so
d PAST from
stered to ad
cluding readm
o estimated
antibiotic co
avings. A co
l cost saving
was also per
) positive an
ctam antibio
vings were 1
t antibiotics
characters.
y skin testing
ut 10 percen
oyed, the tru
tibiotic choic
antibiotics
testing (PAS
olely on
December 2
dult inpatien
missions, up
alternative
osts were
st‐benefit
gs and secon
rformed.
d 7 (3.5 perc
otic, none of
15,995.62 do
treatment c
g
nt of
ue
ces
costs
ST) in
2013
nts.
p
ndary
cent)
f
ollars
cost
*Special sy
savings w
cost savi
perform.
Conclusio
admissio
grow wit
ymbols that w
were 17,851
ngs were ca
.
on: The use
n but with s
th time. PAS
2018ASProf
ere not spelled
.94 dollars.
lculated to b
of PAST in t
subsequent a
ST was also a
SHPMidyfessional
d‐out per the g
Preceding c
be 17,139.56
his specific i
admissions.
able to be co
yearClinlPoster
guidelines wer
ost savings w
6 dollars. PA
nstitution re
As would b
ompleted wi
nicalMeAbstrac
re translated i
were 12,197
AST on avera
ealized cost
e predicted
thin a reaso
eetingcts
into unknown
7.67 dollars.
age took 45.
savings not
cost savings
onable amou
characters.
Total realiz
4 minutes to
on the initia
s will continu
unt of time.
zed
o
al
ue to
*Special sy
Session‐B
Poster Ti
care hosp
Poster Ty
Submissi
Primary A
Email: ja
Addition
Katherine
Jennifer V
Purpose:
Standard
hospital d
resource
optimiza
Disease C
program
of a mero
Methods
before (S
optimiza
gram eve
and Ther
nursing,
upon ord
9:00am t
meropen
per 1000
Results:
meropen
ymbols that w
Board # ‐ 4‐1
itle: Implem
pital
ype: Evaluat
ion Category
Author: Jam
mie.stocker@
al Authors:
e Shea
Van Cura
: As of Janua
d MM09.01.0
designation
s for implem
tion is a reco
Control and
s to improve
openem dos
s: This was a
September –
tion protoco
ery 8‐hour d
rapeutics Co
case manag
der entry du
to 3:00pm o
nem doses a
0 patient day
Post‐implem
nem 500 mg
2018ASProf
ere not spelled
109
entation of
tive Study
y: Infectious
mie Stocker; C
@cardinalhe
ary 1st, 2017
01 for accred
for The Join
menting anti
ommended
Prevention
e antibiotic u
se optimizat
a single cente
– December
ol in a 45‐be
osing regime
mmittee an
ement, phys
ring pharma
n Saturdays.
dministered
ys (DDD/100
mentation, ro
was experie
SHPMidyfessional
d‐out per the g
a meropene
s Disease / H
Cardinal Hea
ealth.com
7, hospitals a
ditation. Lon
nt Commissio
biotic stewa
strategy by
(CDC) Core E
use. The pur
ion protocol
er, retrospec
2017) and a
d LTAC. A m
ens to 500 m
d implemen
sicians, and
acy open hou
. A retrospec
d as well as u
00PD).
oughly a 27%
enced [75%
yearClinlPoster
guidelines wer
em dose opt
HIV
alth;
are required
ng‐term acut
on. LTACs ar
ardship and c
national gui
Elements of
rpose of this
l in an LTAC.
ctive study c
fter (May 20
eropenem d
mg every 6 h
ted in May 2
pharmacists
urs, 8:00am
ctive chart r
utilization, w
% increase in
(9/12) vs 59
nicalMeAbstrac
re translated i
imization pr
to meet the
te care hosp
re often chal
clinical phar
delines as w
Hospital An
study was t
.
comparing m
018) implem
dose optimiz
hours was ap
2018. Educa
s. The dose o
to 4:30pm M
review was p
which was de
n the numbe
% (35/59)].
eetingcts
into unknown
rotocol in a l
e Antimicrob
pitals (LTACs
llenged with
rmacy protoc
well as the Ce
tibiotic Stew
to evaluate t
meropenem
mentation of
zation for co
pproved by t
ation was pro
optimization
Monday thro
performed to
efined as def
er of patient
Additionally
characters.
ong‐term ac
bial Steward
) fall under t
h limited
cols. Dose
enters for
wardship
the effective
utilization
a dose
onversion of
the Pharmac
ovided to
n was perfor
ough Friday,
o determine
fined daily d
ts administe
y, a 39%
cute
dship
the
eness
1
cy
med
, and
e
ose
red
*Special sy
reduction
correspo
(+386.38
Conclusio
decrease
gram dos
ymbols that w
n in mean (+
onded to a 15
8)].
on: Impleme
e in DDD/100
ses of merop
2018ASProf
ere not spelled
+SD) merope
5% decrease
entation of a
00PD and an
penem.
SHPMidyfessional
d‐out per the g
enem DDD/1
e in mean (+
a meropene
n increase in
yearClinlPoster
guidelines wer
1000 PD occu
SD) monthl
m dose opti
the number
nicalMeAbstrac
re translated i
urred [96 vs
y expenditu
mization pro
r of patients
eetingcts
into unknown
s 156.5(+62.5
re [$1,606.6
otocol in a L
s receiving 5
characters.
5)] which
60 vs $1,889
LTAC resulted
00 mg versu
.90
d in a
us 1
*Special sy
Session‐B
Poster Ti
carbapen
Poster Ty
Submissi
Primary A
Email: ita
Addition
Pamela H
Shawn H
Courtney
Matthew
Purpose:
are incre
clinical a
(QALY) lo
aminogly
purpose
plazomic
head clin
Methods
health sy
model in
(85.7 per
subseque
mortality
estimate
included
treatmen
plazomic
based on
ymbols that w
Board # ‐ 4‐1
itle: Health e
nem‐resistan
ype: Evaluat
ion Category
Author: Iris
am@achaog
al Authors:
Hawn
einey
y Coles
w Gitlin
: Bloodstrea
asing with a
nd economi
ost per CRE B
ycoside, for t
of this study
cin‐based ve
nical trial evi
s: A determi
ystem perspe
corporated
rcent and 46
ent treatme
y (7.1 percen
a daily prob
treatment d
nt regimens
cin or colistin
n wholesale a
2018ASProf
ere not spelled
110
economic va
nt enterobac
tive Study
y: Infectious
Tam; Achao
gen.com
m infections
an estimated
c burden is s
BSI patient h
the potentia
y was to dev
rsus colistin‐
dence
nistic decisio
ective assum
clinical effic
6.7 percent f
nts and exte
nt and 40 pe
bability of de
duration obs
and duratio
n‐based regi
acquisition c
SHPMidyfessional
d‐out per the g
alue of plazo
cteriaceae b
s Disease / H
ogen, Inc.;
s (BSI) due to
d rise from 1
significant w
hospitalizatio
al treatment
velop an eco
‐based regim
on tree mod
ming 3 perce
acy from a P
for plazomic
ended hospit
ercent for pla
eath during t
served in the
n of treatme
mens. Econo
cost, therape
yearClinlPoster
guidelines wer
omicin versu
loodstream
HIV
o carbapene
.2 percent in
with about $6
on. The econ
of BSI due t
nomic mode
mens in the t
del was desig
ent annual di
Phase 3 trial
in and colist
talization da
azomicin and
the hospital
e clinical tria
ents among
omic inputs
eutic drug m
nicalMeAbstrac
re translated i
s colistin in t
infections: a
em‐resistant
n 2001 to 4.
66,000 and 1
nomic value
to CRE has y
el to estimat
treatment o
gned with a
iscounting o
including ba
tin, respectiv
ays. Addition
d colistin, re
ization perio
al as well as a
those failing
included ho
management
eetingcts
into unknown
the treatme
a cost‐effect
t Enterobact
2 percent in
1 quality‐adj
of plazomic
et to be det
te the cost‐e
of CRE BSI us
lifetime hor
on efficacy a
acteremia cl
vely) to infor
nally, 28‐day
espectively) w
od. Other cli
assumptions
g initial ther
ospital‐specif
t, and cost p
characters.
ent of
tiveness ana
teriaceae (CR
n 2011. The
justed life ye
cin, an
ermined. Th
effectiveness
sing the head
izon from a
nd costs. Th
learance at D
rm the risk o
y all‐cause
was used to
nical inputs
s on subsequ
apy on eithe
fic treatmen
per day in the
alysis
RE)
ear
he
s of
d‐to‐
e
Day 5
of
uent
er
nts
e
*Special sy
hospital
inputs in
economi
adjusted
effective
analyses
and the t
Results:
regimen,
willingne
calculate
incremen
of plazom
QALY gai
the down
resulting
findings w
hospital d
Conclusio
effective
pay thres
ymbols that w
(analysis of
cluded futur
c burden of
to 2017 USD
ness ratio (I
were perfor
total costs o
Based on a r
, it was estim
ess to pay th
ed with plazo
ntal QALY ga
micin prices,
ned. From a
nstream cos
in cost savin
were robust
day.
on: From a l
versus colis
sholds of $5
2018ASProf
ere not spelled
National Inp
re healthcar
those patien
D). The prim
CER) defined
rmed from t
f the hospita
range of ass
mated that p
resholds of $
omicin versu
ain for plazom
the ICER wa
a hospital pe
ts of subseq
ngs to the ho
t to the key d
ifetime heal
stin for the t
0,000 to $15
SHPMidyfessional
d‐out per the g
patient Samp
e costs ($10
nts surviving
mary model o
d as the cost
he hospital
alization per
umed treatm
plazomicin is
$50,000 to $
us colistin wa
micin versus
as estimated
erspective, p
quent treatm
ospital. Sens
drivers inclu
lth system p
reatment of
50,000 per Q
yearClinlPoster
guidelines wer
ple database
0,137 per yea
g the CRE BS
outcomes inc
t per QALY g
perspective
riod only.
ment costs fo
cost‐effecti
$150,000 pe
as about 5 ye
s colistin of 1
d to range fr
lazomicin es
ments and th
sitivity and s
ding mortali
erspective,
f CRE BSI wit
QALY gained
nicalMeAbstrac
re translated i
e, $2,770 per
ar) to captur
SI infection h
cluded the i
gained. Addit
including th
or a plazom
ive and well
er QALY gain
ears resultin
1.38 years. B
om about $9
stimated tre
e associated
scenario ana
ity, treatme
plazomicin i
th an ICER w
.
eetingcts
into unknown
r day). Othe
re the post‐d
hospitalizatio
ncremental
tional outco
he cost per d
icin‐based tr
within acce
ed. The tota
ng in a disco
Based on an
9,000 to abo
eatment cost
d extended l
alyses demon
nt cost, and
s estimated
well within a
characters.
r economic
discharge
on (all costs
cost‐
omes and
death avoide
reatment
ptable
al life expect
unted
assumed ra
out $17,000
ts were offse
length of sta
nstrated the
cost per
to be cost‐
willingness t
ed
tancy
nge
per
et by
ay
e
to
*Special sy
Session‐B
Poster Ti
complica
Poster Ty
Submissi
Primary A
Email: ita
Addition
Pamela H
Shawn H
Courtney
Matthew
Purpose:
common
selection
treatmen
aminogly
infection
of this st
plazomic
evidence
Methods
hospital‐
incorpora
the test o
percent a
subseque
rates pos
Mortality
and 7.2 p
duration
ymbols that w
Board # ‐ 4‐1
itle: Health e
ated urinary
ype: Evaluat
ion Category
Author: Iris
am@achaog
al Authors:
Hawn
einey
y Coles
w Gitlin
: Complicate
infections t
n in the man
nt failures fr
ycoside bein
s, including
udy was to d
cin versus me
e.
s: A determi
perspective
ated clinical
of cure time
and 70.1 per
ent treatme
st discharge
y was based
percent trea
observed in
2018ASProf
ere not spelled
111
economic va
tract infecti
tive Study
y: Infectious
Tam; Achao
gen.com
ed urinary tr
that can resu
agement of
om empiric
g developed
those due to
develop an e
eropenem in
nistic decisio
assuming 3
efficacy fro
point for the
rcent for pla
nts and exte
(1.8 percent
on publishe
tment failur
n the clinical
SHPMidyfessional
d‐out per the g
alue of plazo
ons includin
s Disease / H
ogen, Inc.;
act infection
ult in inpatie
cUTI/AP can
treatment a
d for the trea
o multidrug‐
economic m
n the treatm
on tree mod
percent ann
m the Phase
e microbiolo
zomicin and
ended hospit
t and 7.9 pe
ed literature
res. Other cli
trial and ass
yearClinlPoster
guidelines wer
omicin versu
ng acute pye
HIV
ns (cUTI), inc
ent hospitaliz
n result in ad
and the risk o
atment of cU
‐resistant (M
odel to estim
ment of cUTI/
del was desig
nual discoun
e 3 registrati
ogically mod
d meropenem
talization da
rcent for pla
assuming 1
inical inputs
sumptions o
nicalMeAbstrac
re translated i
s meropene
lonephritis:
cluding acute
zations. Inap
dditional hea
of relapse. P
UTI and othe
MDR) Entero
mate the cos
/AP using th
gned with a
nting on effic
ional trial inc
ified intent‐
m, respectiv
ays. Addition
azomicin and
.8 percent a
include the
on subseque
eetingcts
into unknown
em in the tre
cost‐effectiv
e pyeloneph
ppropriate a
althcare bur
Plazomicin is
er serious ba
bacteriacea
st‐effectiven
he head‐to‐h
lifetime hor
cacy. The mo
cluding clini
‐to‐treat pop
vely) to infor
nal data inclu
d meropene
mong treatm
use of the t
ent treatmen
characters.
eatment of
veness analy
hritis (AP), ar
antibiotic
rden due to
s an
acterial
e. The purpo
ness of
ead clinical
izon from a
odel
cal cure rate
pulation (81.
rm the risk o
uded relapse
em, respectiv
ment succes
treatment
nt regimens
ysis
re
ose
trial
es at
.7
of
e
vely).
sses
and
*Special sy
duration
inputs we
wholesal
average c
outcome
quality‐a
alternate
of the mo
Results: A
healthca
a range o
about $2
treatmen
clinical cu
costs for
Conclusio
versus m
threshold
plazomic
hospitaliz
ymbols that w
among thos
ere specific
e acquisition
cost per day
es included t
djusted life
e outcome. S
odel to unce
Assuming a
re costs was
of assumed p
22,000 while
nt costs eval
ure rates an
plazomicin.
on: From a l
meropenem f
d of $50,000
cin is estimat
zed with cUT
2018ASProf
ere not spelled
se failing init
to the hospi
n cost, thera
y in the hosp
he incremen
year (QALY)
Sensitivity an
ertainty in m
range of pla
s estimated t
plazomicin p
meropenem
uated for pl
d clinical rel
ifetime hosp
for the treat
0 to $150,00
ted to be co
TI/AP infecti
SHPMidyfessional
d‐out per the g
tial therapy
ital‐perspect
apeutic drug
pital. All cost
ntal cost‐effe
gained. The
nd scenario
model inputs.
azomicin trea
to be about
prices, the co
m was estim
azomicin, th
apse resulte
pital perspec
ment of cUT
0 per QALY g
st‐competiti
ions.
yearClinlPoster
guidelines wer
on either pla
tive and incl
g manageme
s were adjus
ectiveness ra
e cost per cli
analyses we
.
atment cost
$14,000 to a
ost per clinic
ated at abou
he benefits o
ed in offsetti
ctive, plazom
TI/AP with an
gained. In ad
ive to merop
nicalMeAbstrac
re translated i
azomicin or
uded treatm
ent, and othe
sted to 2017
atio (ICER) d
nical cure w
ere performe
s, the ICER w
about $23,0
cal cure rang
ut $21,000.
of plazomicin
ing most of t
micin is calcu
n ICER well w
ddition, the
penem for th
eetingcts
into unknown
meropenem
ment costs b
er hospital c
7 USD. The p
defined as th
was also estim
ed to assess
without inclu
000 per QALY
ged from abo
Despite high
n versus me
the estimate
ulated to be
within a will
cost per clin
he treatmen
characters.
m. Economic
ased on
costs using a
primary mod
he cost per
mated as an
the robustn
uding future
Y gained. Ac
out $20,000
her assumed
ropenem on
ed treatmen
cost‐effectiv
ingness to p
nical cure fo
nt of patient
c
n
del
ness
e
ross
0 to
d
n
nt
ve
pay
r
s
*Special sy
Session‐B
Poster Ti
patients
Poster Ty
Submissi
Primary A
Email: hu
Addition
Alicia Lic
Michelle
Purpose:
antiviral
increased
based re
cirrhosis,
Investiga
based).
Methods
study. Inv
with IFN‐
academic
collected
fibrosis s
prior trea
HCC‐spec
and date
based re
each coh
treatmen
variables
baseline
ymbols that w
Board # ‐ 4‐1
itle: De novo
treated with
ype: Evaluat
ion Category
Author: Han
underw@uic
al Authors:
hvar
Martin
: Opposing f
(DAA) hepat
d rate of de
gimens were
, but new DA
ators will ass
s: The institu
vestigators r
‐ or DAA‐bas
c medical ce
d included pa
tage, and Ch
atment histo
cific data inc
e of de novo
gimens were
hort. The sec
nt. Clinical ch
s, and means
characterist
2018ASProf
ere not spelled
112
o hepatocell
h oral direct‐
tive Study
y: Infectious
nnah Underw
c.edu
indings in th
titis C virus t
novo hepato
e safe to use
AA regimens
sess de novo
utional revie
reviewed ele
sed regimen
enter betwee
atient age at
hild‐Turcotte
ory, HCV trea
cluded prior
or recurrent
e excluded. T
condary outc
haracteristic
s with stand
tics of the tw
SHPMidyfessional
d‐out per the g
ular carcino
‐acting antiv
s Disease / H
wood; Unive
he literature
treatment (H
ocellular (HC
e in non‐cirrh
s are also saf
o and recurre
w board app
ectronic med
s under the
en June 1, 20
t initiation o
e‐Pugh class
atment regim
HCC treatm
t HCC. Patie
The primary
come was su
cs were desc
ard deviatio
wo groups w
yearClinlPoster
guidelines wer
ma (HCC) an
viral and inte
HIV
ersity of Illino
yield uncert
HCV) treatm
CC) or HCC re
hotic patien
fe to use in p
ent HCC rate
proved this s
dical records
care of the
009 and Ma
f HCV treatm
s in cirrhotic
men, dates a
ment history,
nts who wer
y outcome w
ustained viro
cribed with c
on for contin
ere done wi
nicalMeAbstrac
re translated i
nd HCC recu
erferon‐base
ois at Chicag
tainty wheth
ent regimen
ecurrence. H
ts and patie
patients wit
es by HCV re
single cente
s of patients
clinical phar
rch 1, 2017.
ment, gende
patients. HC
and duration
date of com
re treated w
was HCC occu
ologic respon
counts and p
uous variab
ith t‐tests fo
eetingcts
into unknown
rrence in he
ed regimens
go;
her or not di
ns are associ
Historic inte
ents with com
h decompen
egimen type
r, retrospect
s who starte
rmacist at an
Baseline pa
er, race/ethn
CV‐specific d
n of therapy
mplete radio
with both IFN
urrence or re
nse (SVR) aft
percentages
les. Compar
or continuou
characters.
epatitis C viru
irect‐acting
ated with an
rferon (IFN)‐
mpensated
nsated cirrho
(IFN‐ or DAA
tive cohort
d HCV treat
n urban
atient data
nicity, genot
data included
y, and lab va
logic respon
N‐ and DAA‐
ecurrence in
ter HCV
for categori
risons betwe
s variables a
us
n
‐
osis.
A‐
ment
ype,
d
lues.
nse,
n
ical
een
and
*Special sy
chi squar
version 9
Results:
49 perce
total of 2
the IFN g
groups; i
percent v
years (int
diagnose
versus 1.
was 3.2 a
(58/96) i
percent (
Conclusio
increased
cirrhotic
to IFN‐ba
of HCC re
ymbols that w
re or Fisher’s
9 software.
Inclusion cri
nt (289/595
20 cases of H
group, and 2
t was diagno
versus 1 per
terquartile r
ed in 3 patien
9 percent, p
and 1.7 year
n the IFN gro
(514/595) in
on: De novo
d compared
patients we
ased regime
ecurrence w
2018ASProf
ere not spelled
s exact tests
teria were m
) of the DAA
HCC were dia
percent (11
osed in no p
cent, p value
range 2.3–3.
nts in the IFN
p value equa
rs, respective
oup achieve
n the DAA gro
o and recurre
to IFN‐base
ere treated w
ns. This stud
with DAA regi
SHPMidyfessional
d‐out per the g
s for categor
met by 894 p
A group were
agnosed afte
1/595) in the
atients in th
e equal to 0
5). De novo
N group vers
l to 0.41). Ti
ely (interqua
d SVR at 24
oup achieve
ent HCC in p
ed regimens
with DAAs, w
dy further su
imens. This s
yearClinlPoster
guidelines wer
rical variable
patients. 26
e cirrhotic at
er HCV treat
e DAA group
e IFN group
.32). Time t
HCC also did
sus 11 patie
ime to de no
artile range 0
weeks after
ed SVR at 12
atients treat
in this patie
which have a
upports seve
study is limit
nicalMeAbstrac
re translated i
es. Data were
percent (25
t baseline (p
tment comp
. HCC recurr
versus 6 pa
to recurrenc
d not differ
nts in the DA
ovo HCC in t
0.4–5.5 vers
r HCV treatm
weeks.
ted with DA
nt populatio
a more tolera
eral studies t
ted by its re
eetingcts
into unknown
e analyzed w
5/96) of the
p value less t
letion: 3 per
rence did no
atients in the
e in the DAA
between gro
AA group (3
he IFN versu
sus 1.3–2.7).
ment comple
AA regimens
on. A larger
able safety p
that found n
trospective
characters.
with Stata
IFN group ve
than 0.001).
rcent (3/96)
ot differ betw
e DAA group
A group was
oups; it was
.1 percent
us DAA grou
73 percent
etion, and 86
was not
proportion o
profile comp
o increased
design.
ersus
A
in
ween
p (0
2.8
ps
6
of
pared
risk
*Special sy
Session‐B
Poster Ti
disease t
Poster Ty
Submissi
Primary A
Email: to
Addition
Edward G
Hongyua
John Flah
Anuj Gag
Purpose:
transplan
dysfunct
calcineur
post‐ope
infection
fumurate
Methods
greater c
1:1 to eit
efficacy a
pre‐spec
(BMD), c
assessme
Results:
characte
eGFRCKD
baseline
ymbols that w
Board # ‐ 4‐1
itle: Evaluati
treated with
ype: Evaluat
ion Category
Author: Toa
oan.vo@gilea
al Authors:
Gane
n Wang
herty
ggar
: chronic hep
ntation (OLT
ion seconda
rin inhibitors
erative cortic
with tenofo
e (TDF) due t
s: In this Pha
chronic kidne
ther receive
analysis was
ified second
hanges in se
ent (Chromiu
51 patients
ristics includ
D‐EPI 52mL/m
surface area
2018ASProf
ere not spelled
113
ion of renal
tenofovir al
tive Study
y: Infectious
an Vo; Gilead
ad.com
patitis B (CH
T) worldwide
ry to periop
s; osteoporo
costeroids. In
ovir alafenam
to its improv
ase 2 study (
ey disease a
TAF 25 mg Q
the percent
dary safety e
erum creatin
um‐ EDTA Re
were random
ded: mean a
min/1.73m2
a corrected G
SHPMidyfessional
d‐out per the g
and bone an
lafenamide i
s Disease / H
d Sciences;
B) remains a
e. Common c
perative rena
osis is also ob
n this setting
mide (TAF) m
ved renal an
NCT0286254
nd receiving
QD or contin
t of patients
ndpoints we
nine (sCr), es
enal Scan; C
mized and tr
ge 60 years,
2 with 53% o
GFRCr‐EDTA
yearClinlPoster
guidelines wer
nd safety in
in post liver
HIV
a leading ind
complication
al injury and
bserved seco
g, antiviral p
may have ad
nd bone safe
48), liver tra
g antiviral pr
nue their TD
s who mainta
ere changes
stimated GFR
r‐EDTA) ove
reated at a s
, 75% males,
of patients w
A was 58 mL/
nicalMeAbstrac
re translated i
patients wit
transplanta
dication for o
ns following
postoperat
ondary to pr
prophylaxis t
vantages ov
ety profile.
ansplant reci
rophylaxis w
F containing
ained viral s
in hip and s
R by CKD‐EP
er 48 weeks.
single site in
, 53% Pacific
with <50mL/m
/min/1.73m
eetingcts
into unknown
th CHB and c
tion
orthotopic li
OLT include
ive nephroto
reoperative
to prevent re
ver tenofovir
ipients with
with TDF were
g regimen. T
uppression a
pine bone m
PI formula an
New Zealan
c Islander an
min/1.73m2
2. The medi
characters.
chronic kidne
iver
e renal
oxicity from
malnutrition
ecurrent HB
r disoproxil
stage 2 or
e randomize
The primary
at Week 24.
mineral dens
nd direct GF
nd. Baseline
nd mean bas
2. The media
an interval s
ey
n and
V
ed
Key
sity
R
seline
an
since
*Special sy
transplan
tacrolimu
Week 12
were no
arm com
sCr levels
eGFRCKD
week 12.
the time
Conclusio
high rate
function
ymbols that w
ntation was
us and 29% r
to date, all
treatment d
mpared to the
s (median ch
D‐EPI (media
. Complete d
of the prese
on: Early aft
e of renal dys
were observ
2018ASProf
ere not spelled
approximate
remained on
patients (25
discontinuati
e TDF arm. S
hange in mg/
an change in
data includin
entation.
ter switching
sfunction, vi
ved.
SHPMidyfessional
d‐out per the g
ely 9 years. S
n long‐term
5 in TAF; 22 i
ions and ser
Switching to
/dL: ‐0.07 fo
mL/min/1.7
ng changes i
g from TDF t
iral suppress
yearClinlPoster
guidelines wer
Seventy‐six
prednisone.
in TDF arm)
rious adverse
TAF treatme
or TAF vs. ‐0.
73m2: 2.7 fo
n bone para
o TAF in a liv
sion is maint
nicalMeAbstrac
re translated i
percent of p
. Of the 47 p
maintained
e events we
ent resulted
.02 for TDF;
or TAF vs. 0.8
ameters at w
ver transpla
tained while
eetingcts
into unknown
patients wer
patients that
viral suppre
re numerica
d in a trend t
p=0.09) and
8 for TDF; p=
week 24 will
nt recipient
e smaller cha
characters.
re maintaine
t have reach
ession. There
ally lower in
toward impr
d improved
=0.14) as ear
be available
population
anges in rena
ed on
ed
e
TAF
roved
rly as
e at
with
al
*Special sy
Session‐B
Poster Ti
stewards
Poster Ty
Submissi
Primary A
Email: kn
Addition
Jessica W
Purpose:
thorough
exposure
drug eve
1000 pat
anti‐infec
Methods
and anti‐
reviews r
lacked a
daily revi
process c
symptom
pharmac
note was
workflow
collected
ongoing
monitori
reduction
ymbols that w
Board # ‐ 4‐1
itle: Utilizing
ship program
ype: Descrip
ion Category
Author: Kris
nziegenbusc
al Authors:
Walles
: :Antimicrob
h review to r
e leads to inc
nts, and hos
tient days m
ctive agents
s: Days of th
‐infective ag
revealed a la
formal antim
iew of antim
change requ
ms of an activ
cist, educatio
s implement
w. Retrospec
d for TCU for
data collecti
ng the most
n in DOT per
2018ASProf
ere not spelled
114
g days of the
m on a transi
ptive Report
y: Infectious
sti Ziegenbus
bial use in th
reduce unne
creased risk
spital readm
etric reveale
for the enti
erapy per 10
ent. Our tra
ack of stop d
microbial rev
microbials on
ires the pha
ve infection,
on was provi
ted to ensure
ctive data fo
r 2017. Prosp
ion as part o
t utilized IV a
r 1000 patie
SHPMidyfessional
d‐out per the g
erapy per 10
ition of care
s Disease / H
sch; Mercy H
om
he long‐term
ecessary anti
for resistan
missions. Ana
ed an overal
re institutio
000 patient
ansition of ca
dates for ant
view process
n all TCU pat
armacist to r
, and culture
ided to all ph
e all pharma
r both oral a
pective data
of a perform
and oral anti
nt days.
yearClinlPoster
guidelines wer
000 patient d
unit
HIV
Health St. Rit
m care settin
imicrobial da
ce, clostridiu
lysis of our i
l 20% increa
n from 2016
days for 201
are unit (TCU
ti‐infective a
s for TCU ad
ients was de
eview all an
e results. Du
harmacists.
acists were c
and intraven
was collect
ance improv
i‐infectives t
nicalMeAbstrac
re translated i
days to furth
ta's Medical
g or at trans
ays of thera
um difficile a
institution’s
ase in DOT p
6 to 2017.
17 was analy
U) became a
gents upon
missions. A
eveloped an
ti‐infective a
ue to lack of
Additionally
compliant w
nous (IV) DOT
ted from Jan
vement proj
to determine
eetingcts
into unknown
her develop a
l Center;
sitions of car
py. Extende
associated d
days of the
per 1000 pat
yzed by both
an area of fo
transfer. Ph
A policy and p
d implemen
agent indica
a dedicated
y, a standard
ith the proc
T per 1000 p
uary 2018 to
ject. In addi
e if our inter
characters.
an antimicro
re requires a
ed antimicro
diarrhea, adv
rapy (DOT) p
ient days for
h hospital un
ocus after ch
harmacy also
procedure fo
nted. This
ations, signs
antimicrobi
dized pharm
edure and
patient days
o May 2018
tion, we are
rventions sh
obial
a
obial
verse
per
r oral
nit
hart
o
or
and
ial
acy
was
with
e
ow a
*Special sy
Results:
patients
patient d
oral DOT
infective
amoxicill
IV 37 per
Conclusio
1000 pat
without a
care facil
enhance
ymbols that w
Pharmacists
and proper
days has dec
T per 1000 pa
agents; we
in‐clavulana
rcent; merop
on: Surveilla
tient days m
affecting pat
lity. Continu
ment requir
2018ASProf
ere not spelled
s were educa
documentat
reased on av
atient days h
have seen t
ate 17 perce
penem IV 55
ance of antim
ay help redu
tient outcom
ued area of i
ring a stop da
SHPMidyfessional
d‐out per the g
ated on the
tion of the in
verage by 53
has been ob
he following
nt; cephalex
5 percent; va
microbial ste
uce unneces
mes, especia
mprovemen
ate on all an
yearClinlPoster
guidelines wer
procedure f
ntervention.
3 percent. I
served. Am
g reductions
xin 25 percen
ancomycin IV
ewardship pr
sary exposu
lly on transf
nt includes a
nti‐infective
nicalMeAbstrac
re translated i
or antimicro
. As a result
n addition, a
ong the targ
in DOT per
nt; ciproflox
V 42 percent
rograms util
ure to antimi
fer to a trans
a future elec
agents at tra
eetingcts
into unknown
obial review
t, TCU IV DO
a 25 percent
geted oral an
1000 patien
xacin 25 perc
t.
lizing days o
icrobials and
sition care u
tronic medic
ansitions of
characters.
for all TCU
OT per 1000
t reduction i
nd IV anti‐
nt days:
cent; ceftriax
f therapy pe
d decrease c
unit or extern
cal record
care.
n
xone
er
ost
nal
*Special sy
Session‐B
Poster Ti
emergen
Poster Ty
Submissi
Primary A
Services
Email: au
Addition
Megan P
Jakea Joh
Karen Mi
Cody Cha
Purpose:
increasin
are nece
risk facto
screening
of similar
emergen
referred
Methods
schedule
Clinic. Tw
appointm
ED scree
ongoing
excluded
complete
schedule
therapy;
ymbols that w
Board # ‐ 4‐1
itle: Referra
ncy departm
ype: Evaluat
ion Category
Author: Aut
Department
utumn.zucke
al Authors:
eter
hnson
iller
astain
: Hepatitis C
ngly recogniz
ssary to com
or‐based scre
g models on
r programs.
ncy departm
to HCV trea
s: We condu
ed appointm
wo cohorts w
ment betwee
ning program
HCV care or
d. The prima
ed in the CoC
ed appointm
initiation of
2018ASProf
ere not spelled
115
l source mat
ent referrals
tive Study
y: Infectious
tumn Zucker
t;
erman@vum
(HCV) is a k
zed. Innovat
mbat the epi
eening, ther
n the HCV ca
We examin
ent (ED)‐init
tment from
cted a single
ent in the Va
were analyze
en Septembe
m between
who had no
ry outcome
C. Steps in th
ent); evalua
f therapy; co
SHPMidyfessional
d‐out per the g
tters: hepati
s
s Disease / H
rman; Vande
mc.org
nown epide
ive screenin
demic. Whil
re is growing
scade of car
ned CoC com
tiated univer
traditional s
e‐center, co
anderbilt Un
ed: patients
er 2015 and
December 2
ot been deem
was CoC pro
he CoC inclu
tion (i.e., co
ompletion of
yearClinlPoster
guidelines wer
itis C cascad
HIV
erbilt Univer
mic, with ch
g strategies
e current gu
g interest in
re (CoC) is ne
mpletion rate
rsal HCV scre
sources.
hort study o
niversity Me
referred thr
July 2016; a
2016 and Ap
med lost to f
ogression, de
uded: referra
ompletion of
f therapy; an
nicalMeAbstrac
re translated i
e of care for
rsity Medica
hronic diseas
to best iden
uidelines adv
universal sc
eeded to ade
es among pa
eening prog
of patients w
dical Center
rough traditi
and patients
ril 2018. Pat
follow‐up at
efined as th
al; linkage to
f labs and im
nd achievem
eetingcts
into unknown
r traditional
l Center, Spe
se and acute
ntify undiagn
vocate for ag
reening. Eva
equately ass
tients referr
ram, compa
with chronic
r (VUMC) Inf
onal source
s referred th
tients curren
t the time of
e number of
o care (i.e., a
maging); pres
ment of a sus
characters.
versus
ecialty Pharm
e infections
nosed diseas
ge cohort an
aluation of s
sess the imp
red from an
ared to patie
HCV with a
fectious Dise
s with an
rough the V
ntly receiving
f analysis we
f stages
attendance a
scription of
tained virolo
macy
se
nd
uch
pact
ents
eases
VUMC
g
ere
at
ogic
*Special sy
response
Additiona
care. Chi
cohorts.
by cohor
boomer a
disorder,
multidisc
Results:
tradition
patients
p=.003) t
cohort (2
(33%) co
the ED co
occurred
cohort, w
patients
progress
p=0.020)
Medicaid
Conclusio
screening
the baby
insurance
completi
between
hinges on
ymbols that w
e. Baseline d
al demograp
‐square test
Using multiv
rt (traditiona
age group),
, alcohol abu
ciplinary pro
Overall, 369
al cohort. Am
(22% vs. 5%
than the trad
2% vs. 41%, p
mpleted all
ohort (7%) v
d between re
with only 27%
in the tradit
ion was high
), and lower
d insurance (
on: In this si
g program v
y‐boomer ag
e. In both un
on rates tha
referral and
n ensuring li
2018ASProf
ere not spelled
emographic
phic, health,
ts were cond
variate linea
al vs. ED refe
and social a
use, illicit dru
viders and w
9 patients me
mong all pat
, p<0.001), a
ditional refe
p<0.001), am
CoC stages a
versus traditi
eferral and li
% of ED pati
tional cohort
her in baby b
among patie
(β=‐0.26, p<
ngle center
aried signific
e cohort, mo
nivariate and
an those refe
d linkage to
nkage to car
SHPMidyfessional
d‐out per the g
c data were c
and social c
ducted to co
ar regression
erral), patien
nd health ch
ug use). Both
were treated
et inclusion
tients referr
and fewer pa
rral cohort.
mong patien
across cohor
ional (56%).
inkage to ca
ents attendi
t. In the mul
boomers (β=
ents in the E
0.001).
cohort stud
cantly from
ore uninsure
d multivariat
erred throug
care. Optim
re after refe
yearClinlPoster
guidelines wer
collected for
characteristi
mpare demo
n, we tested
nt demograp
haracteristic
h cohorts re
d based on H
criteria—18
ed to care, t
atients in th
Lower preva
ts linked to
rts, but com
Across coho
re; however
ing an initial
tivariate ana
=0.22, p=0.00
ED cohort (β
y, patients r
traditional r
ed patients,
te analyses,
gh traditiona
izing the imp
erral for HCV
nicalMeAbstrac
re translated i
r all patients
cs were mea
ographic cha
whether Co
phics (i.e., ge
s (i.e., HIV d
eceived care
HCV therape
83 in the ED c
the ED coho
e baby‐boom
alence of HIV
care. One‐th
pletion rate
orts, the larg
r, this was m
l scheduled v
alysis of pat
03) and pati
=‐0.27, p<0.
referred thro
referral sour
and fewer p
the ED coho
al methods,
pact of unive
V treatment.
eetingcts
into unknown
s at time of r
asured for p
aracteristics
oC progressio
ender, ethnic
diagnosis, psy
from the sa
utic guidelin
cohort and 1
rt had more
mer age gro
V was also s
hird of refer
s were signi
gest drop wi
more pronou
visit compar
ients linked
ients with H
.001) and th
ough a unive
rces, with few
patients with
ort had lowe
with the larg
ersal ED scre
characters.
referral.
patients linke
s between
on was pred
city, baby‐
ychiatric
me
nes.
186 in the
uninsured
up (38% vs.
een in the E
red patients
ficantly lowe
thin the CoC
nced in the
red to 77% o
to care, CoC
IV (β=0.18,
ose with
ersal ED
wer patients
h commercia
er CoC
gest drop se
eening prog
ed to
icted
53%,
ED
s
er in
C
ED
of
C
s in
al
een
rams
*Special sy
Session‐B
Poster Ti
extended
Poster Ty
Submissi
Primary A
Email: jd
Addition
Jayne Pa
Barry Qu
Thomas O
Alice Chu
Purpose:
pharmac
concentr
local ana
proprieta
to reduce
effective
011 and
clinical tr
Methods
Board‐ap
primary u
mesh pla
HTX 011
bupivaca
same pro
remained
treatmen
correlatio
ymbols that w
Board # ‐ 4‐1
itle: Pharma
d‐release, no
ype: Evaluat
ion Category
Author: Jose
al Authors:
wasauskas
art
Ottoboni
u
: The curren
cokinetic‐pha
rations and r
lgesic with b
ary 72‐hour
e local inflam
ness of bupi
PD activity,
rials across d
s: The PK‐PD
pproved, ran
unilateral fir
acement. Eac
via instillatio
aine) or salin
oprietary for
d in the hosp
nt and receiv
on between
2018ASProf
ere not spelled
116
acokinetic‐ph
on‐opioid an
tive Study
y: Pain Mana
eph Dasta; S
utexas.edu
tly available
armacodyna
reduction of
bupivacaine
extended‐re
mmation ass
ivacaine). W
represented
different sur
D relationship
ndomized, bl
rst metatarsa
ch patient p
on (bunione
e placebo. I
rmulation an
pital for prot
ved opioids a
the plasma
SHPMidyfessional
d‐out per the g
harmacodyn
nalgesic HTX
agement / P
Self‐employe
e liposomal f
amic (PK‐PD)
postoperat
as the activ
elease (ER) f
sociated with
We compared
d by pain red
gical models
p of bupivac
linded, Phas
al bunionect
rovided info
ectomy: 60 m
n addition, a
nd dose (HTX
tocol‐specifi
as rescue m
concentrati
yearClinlPoster
guidelines wer
namic relatio
‐011
Palliative Car
ed;
formulation
) relationship
ive pain. HTX
e ingredient
ormulation.
h surgery (w
d the rate of
duction com
s.
caine was ev
e 2 dose‐fin
tomy or unil
ormed conse
mg bupivacai
an active con
X‐002) was i
ied assessme
edication fo
on of bupiva
nicalMeAbstrac
re translated i
onship obser
re
of bupivaca
p between p
X‐011 is an i
t and low‐do
The additio
which lowers
absorption
pared to sal
valuated in tw
ding trials in
lateral open
ent and at th
ine; hernior
ntrol of ER b
ncluded in e
ents of pain
or pain contr
acaine and p
eetingcts
into unknown
rved with th
ine has not s
plasma bupiv
investigation
ose meloxica
on of meloxic
s pH and can
of bupivaca
ine placebo
wo Institutio
n patients un
inguinal he
he end of sur
rhaphy: 200
bupivacaine
each study. P
intensity fo
rol, when req
pain control
characters.
e investigati
shown a
vacaine
nal, non‐opio
am in a
cam is desig
n reduce the
ine from HT
, in two Pha
onal Review
ndergoing
rniorrhaphy
rgery receive
0 mg
alone in the
Patients
r 72 hours p
quested. A
was analyze
ional
oid
ned
TX‐
se 2
y with
ed
e
post‐
ed by
*Special sy
plotting t
intensity
windowe
intent‐to
including
Results: T
103 salin
patients
Demogra
administ
differenc
time. In c
received
numeric
or HTX‐0
011. Pati
significan
placebo (
surgical m
Conclusio
consisten
product H
extended
different
ymbols that w
the rate of a
scores over
ed worst obs
o‐treat popu
g blood draw
The analysis
e placebo p
vs 13 HTX‐0
aphic charac
ered into th
ce in pain sco
contrast, no
HTX‐011 un
rating scale
02 (p=0.033
ents who re
ntly lower AU
(p=0.0180) o
models, desp
on: The resu
nt PK‐PD cor
HTX‐002. HT
d release of
t doses in tw
2018ASProf
ere not spelled
absorption o
r 72 hours be
servation car
lation was e
ws at numero
s included: in
atients unde
02 patients
cteristics wer
e surgical sit
ore and the
correlation
ndergoing bu
(NRS) for pa
33), despite H
eceived 200 m
UC0‐72 for t
or HTX‐002 (
pite differen
ults suggest e
rrelation. Th
TX‐011 also
bupivacaine
wo different s
SHPMidyfessional
d‐out per the g
f bupivacain
etween salin
rried forwar
mployed. Fu
ous timepoin
n the first stu
ergoing a bu
vs 60 saline
re comparab
te, there wa
calculated r
was seen w
unionectomy
ain intensity
HTX‐002 hav
mg of HTX‐0
the NRS of p
(p=0.0333). T
nces in vascu
evidence for
is correlatio
demonstrat
e and meloxi
surgical mod
yearClinlPoster
guidelines wer
ne against th
ne placebo a
rd (wWOCF)
ull PK profile
nts through
udy, 52 HTX‐
unionectomy
placebo pat
ble within ea
s a high deg
ate of absor
ith the singl
y exhibited s
than those
ving a simila
011 after und
ain intensity
Thus, the re
ularity and a
r HTX‐011 as
n was not de
ted prolonge
cam. These
dels of varyin
nicalMeAbstrac
re translated i
he difference
and treatme
imputation
es were obta
72 hours.
‐011 patient
y; in the seco
tients under
ach study. W
gree of corre
rption of bup
e agent prod
significantly
who receive
r bupivacain
dergoing he
y than those
sults were c
natomical sp
s the first ER
emonstrate
ed analgesic
results were
ng vascularit
eetingcts
into unknown
e in the curv
nt groups. A
method in t
ained in all p
ts vs 23 HTX
ond study, 1
rgoing a hern
When HTX‐01
elation betw
pivacaine fro
duct HTX‐00
lower AUC0
ed saline pla
ne release pr
rniorrhaphy
e who receiv
consistent ac
pace.
R bupivacain
d with the s
activity con
e replicated
ty.
characters.
ve of pain
A conservativ
the modified
patients,
‐002 patient
16 HTX‐011
niorrhaphy.
11 was
een the
om HTX‐011
02. Patients w
0‐72 of the
cebo (p=0.0
rofile to HTX
y also showe
ed saline
cross both
e to show a
ingle agent
sistent with
with two
ve
d
ts vs
over
who
0003)
X‐
d
the
*Special sy
Session‐B
Poster Ti
lumbar r
Poster Ty
Submissi
Primary A
Email: ha
Addition
Tarek Se
Bahia Ch
Purpose:
are comm
in relievi
measure
in neurop
treatmen
question
Methods
across Le
pain trea
demogra
treatmen
additiona
a compa
included
change in
pain scor
criteria in
Patients
and PGIC
(group A
ymbols that w
Board # ‐ 4‐1
itle: Self asse
adiculopath
ype: Descrip
ion Category
Author: Had
adi_jabado@
al Authors:
lman
ahine
: Spinal diso
mon causes
ng radiculop
s treatment
pathic pain p
nt efficacy us
naires.
s: This is an o
ebanon. All a
atments wer
aphics, clinic
nt for two ar
al items rega
rison of the
a score from
n activity an
re on SAT wa
ncluded subj
were follow
C follow up v
) or a combi
2018ASProf
ere not spelled
117
essment of n
y in Lebanon
ptive Report
y: Pain Mana
di Jabado; Al
@outlook.co
rders, includ
of neuropat
pathy induce
‐related imp
patients. The
sing the SAT
observationa
adult patient
e screened.
al data, SAT
reas (pain re
arding (1) wh
study treatm
m 1 (no chan
d symptoms
as moderate
jects with ot
wed up at we
versions. Stu
nation of tw
SHPMidyfessional
d‐out per the g
neuropathic
n
agement / P
l Rafah Phar
m
ding cervical
thic pain. The
ed pain. The
provements
e purpose of
T II and patie
al prospectiv
ts diagnosed
Subjects we
and PGIC sc
elief; impact
hether the p
ment to prev
nge) to 7 (gre
s related to p
e, severe or v
ther pain co
eeks 4, 8, and
dy subjects
wo or more d
yearClinlPoster
guidelines wer
pain treatm
Palliative Car
macy;
or lumbar r
ere is a lack
Self‐Assessm
in pain and
f this study i
ent global im
ve study car
d with radicu
ere interview
cores. The SA
on activity l
patient woul
vious treatm
eat deal bet
pain. Patient
very sever (g
nditions and
d 12 to asses
were receiv
drugs (nonst
nicalMeAbstrac
re translated i
ment among
re
radiculopath
of evidence
ment of Trea
impacts and
is to assess t
mpression of
rried out in 3
ulopathy and
wed at basel
AT items inc
evel and qua
d undergo t
ments for pai
ter) of how
ts were inclu
greater or eq
d those with
ss response
ving either pr
teroidal anti‐
eetingcts
into unknown
patients wit
hy due to dis
e about med
atment vers
d impression
the pharmac
change (PG
30 communi
d receiving p
ine (first pha
cluded asses
ality of life)
the treatmen
in. The PGIC
the patient
uded only if
qual to zero
cognitive im
to treatmen
regabalin m
‐inflammato
characters.
th cervical o
c compressi
ication effic
ion II (SAT II
ns of treatme
cological
IC)
ty pharmaci
pharmacolog
armacy visit
sments afte
and two
nt again, and
evaluation
can describe
their baselin
). Exclusion
mpairment.
nt by filling S
onotherapy
ory drug (NSA
or
on
acy
)
ent
ies
gical
t) for
r
d (2)
e the
ne
SAT
AID),
*Special sy
Vitamin B
change in
Results:
48.5 year
characte
pain” fol
impact” f
5.62 in gr
PGIC has
responde
33.3% re
respectiv
does the
responde
Conclusio
neuropat
and qual
ymbols that w
B complex, a
n SAT‐II and
138 patients
rs. Group A w
ristics were
low up item
follow up ite
roup A versu
been repor
ed “yes, pro
sponded “ye
vely. In Grou
study treatm
ed as such in
on: Anticonv
thic pain ach
ity of life wh
2018ASProf
ere not spelled
and topical a
PGIC from b
s were includ
was compos
not significa
mean in Gro
em mean in
us 4.97 in gr
ted in 61.5%
bably” to a q
es, definitely
up A, 50 % of
ment compa
n group B.
vulsant mon
hieved 20‐30
hile combina
SHPMidyfessional
d‐out per the g
agents) (grou
baseline to w
ded in this s
sed of 52 sub
antly differen
oup A was 0
group A was
oup B (P=0.0
% of group A
question if th
y”, whereas
f patients re
ared to othe
notherapy in
0% improvem
ation treatm
yearClinlPoster
guidelines wer
up B). The pr
week 12.
tudy of who
bjects and g
nt between
0.54 versus ‐0
s 3.62 versus
034). “Bette
and 39% of
hey would li
37% and 10
sponded “ve
er treatment
the manage
ment in pain
ents failed t
nicalMeAbstrac
re translated i
rimary effica
om 57.1% we
roup B of 86
the two gro
0.2 in group
s ‐0.2 in grou
r and definit
f group B. In
ike to receiv
0.3% respond
ery much be
ts you have r
ement of rad
n relief and i
to achieve an
eetingcts
into unknown
acy endpoin
ere females.
6. The SAT II
oups. At wee
p B (P=0.037)
up B (P<0.01
te pain impr
Group A, 45
ve the treatm
ded as such
etter” to a qu
received, wh
diculopathy
mpact of pa
ny response
characters.
t was the m
. Mean age w
baseline
ek 12, the “SA
), the “SAT
1). PGIC was
rovement” o
5.8% of patie
ment again a
in group B,
uestion how
hereas 23.4%
induced
ain on activit
e.
ean
was
AT
s
on
ents
and
w
%
ties
*Special sy
Session‐B
Poster Ti
of Aetna
Poster Ty
Submissi
Primary A
Email: sh
Addition
Amiee Ka
Arun Tiw
Rajesh M
Simon Da
Purpose:
are assoc
to opioid
fundame
procedur
Methods
18 years
who und
Decembe
arthropla
resection
required
variables
square a
Results: A
on the ty
were inc
equals 13
ymbols that w
Board # ‐ 4‐1
itle: Use of o
fully insured
ype: Descrip
ion Category
Author: Ajay
harmaa32@a
al Authors:
ang
wari
Mehta
agenais
: Opioids are
ciated with b
ds before sur
ental to unde
res.
s: This was a
or older in A
erwent 10 c
er 31, 2016:
asty (TSA), lu
n, hernia rep
at least 2 m
s were summ
nalysis.
A total of 95
ype of postsu
luded in the
3,999), follow
2018ASProf
ere not spelled
118
opioids befo
d commercia
ptive Report
y: Pain Mana
y Sharma; H
aetna.com
e the current
burdensome
rgery can lea
erstanding t
a retrospecti
Aetna fully in
common elec
total knee a
umbosacral f
pair, vertical
months befor
marized as co
5,125 patien
urgical analg
analyses. Th
wed by CS (1
SHPMidyfessional
d‐out per the g
re and after
al and Medic
agement / P
ealthagen O
t standard o
e and costly
ad to prolon
he use of op
ve analysis o
nsured comm
ctive surgica
arthroplasty
fusion (LF), c
sleeve gastr
re and at lea
ounts (perce
ts met eligib
gesia used (e
he most com
10,569), TKA
yearClinlPoster
guidelines wer
r common el
care populat
Palliative Car
Outcomes‐Di
of care to ma
adverse eve
ged use afte
pioids before
of medical a
mercial heal
al procedure
(TKA), total
cesarean sec
rectomy (VS
st 12 month
ent) and pro
bility criteria
eg, neuraxial
mmon surgic
A (10,341), h
nicalMeAbstrac
re translated i
lective surgic
tions
re
ivision of Ae
anage acute
ents. There a
er surgery. R
e and after c
nd pharmac
lth plans or M
es between J
hip arthrop
ction (CS), hy
G), and chol
hs after the d
portions we
a; 64,251 (68
l/regional/lo
cal procedur
hysterectomy
eetingcts
into unknown
cal procedur
etna;
postsurgica
are concerns
Real‐world d
common ele
cy claims for
Medicare Ad
January 1, 20
lasty (THA),
ysterectomy
lecystectom
date of surg
ere compare
8 percent) ha
ocal analgesi
re was chole
y (9,542), he
characters.
res: An analy
l pain, but t
s that exposu
ata are
ctive surgica
patients ag
dvantage pla
014, and
total should
y, colorectal
my. Coverage
ery. Categor
d using chi‐
ad informati
ia, opioids) a
cystectomy
ernia repair
ysis
hey
ure
al
ed
ans
der
e was
rical
ion
and
(n
*Special sy
(8,996), T
Overall, 1
63,390 (9
prescript
days pos
days pres
proportio
the highe
days pos
(LF: 79 vs
Conclusio
adult pat
received
within th
long‐term
approach
Funded b
ymbols that w
THA (5,950),
13,356 patie
99 percent)
tion within 3
tsurgery. LF
surgery (45
on of patien
est (48 perce
tsurgery wa
s 59 percent
on: Use of p
tients under
opioids at t
he first 60 da
m health and
hes aimed at
by Pacira Pha
2018ASProf
ere not spelled
, colorectal r
ents (21 perc
had a claim
30 days posts
had the hig
percent), wh
ts with pres
ent) for 31 to
s significant
t; TKA: 25 vs
prescription o
going electiv
he time of s
ays after surg
d economic c
t minimizing
armaceutica
SHPMidyfessional
d‐out per the g
resection (4,
cent) filled a
for intraope
surgery, and
hest proport
hile CS had t
cription opio
o 60 days po
ly higher in
13 percent;
opioids befo
ve surgical p
urgery, and
gery. More r
consequenc
g the use of o
als, Inc.
yearClinlPoster
guidelines wer
,220), LF (3,0
n opioid pre
erative opioid
d 11,750 (18
tion of patie
the lowest (3
oids in the 3
ostsurgery. T
patients rec
; each, P les
ore surgery w
procedures. A
a substantia
research is n
ces of periop
opioids for p
nicalMeAbstrac
re translated i
091), VSG (1
escription wi
ds, 28,319 (4
percent) co
ents with pre
3 percent). T
30 days posts
The proporti
eiving opioid
ss than 0.05)
was common
Almost all pa
al proportion
needed to un
perative opio
postsurgical
eetingcts
into unknown
1,711), and T
ithin 30 days
44 percent)
ontinued to d
escription op
TKA had the
surgery (77
ion of opioid
ds within 30
).
n among a la
atients unde
n continued
nderstand th
oid use and t
analgesia.
characters.
TSA (1,625).
s presurgery
filled an opi
do so 31 to 6
pioids within
highest
percent); LF
d use in the 3
0 days presu
arge cohort
ergoing surg
to use them
he short‐ an
to evaluate
y;
ioid
60
n 30
had
30
rgery
of
gery
m
d
*Special sy
Session‐B
Poster Ti
Poster Ty
Submissi
Primary A
Email: be
Addition
Robin Bre
Caprice T
Julianna
Purpose:
under th
value to
medicati
potentia
adherenc
ambulato
Methods
ambulato
Cross Blu
Inspira M
2017 (10
paired t‐t
addition
Disease t
Pharmac
algorithm
into two
should be
patients
ymbols that w
Board # ‐ 4‐1
itle: Optimiz
ype: Descrip
ion Category
Author: Jod
al Authors:
ennan
Torrance
Filluzzi
: For many d
e supervisio
patient care
on reconcilia
l to utilize th
ce rates and
ory setting t
s: In Februar
ory setting. P
ue Shield pat
Medical Grou
0‐1‐2017 t0 1
test explore
to adherenc
to evaluate i
cy Technician
m, provider/
groups, Pha
e managed b
with 8 or mo
2018ASProf
ere not spelled
119
zing patient c
ptive Report
y: Pharmacy
y Beach; Ins
org
decades, hea
on of Pharma
e, and reduce
ation in the
hem in the a
the ability o
o optimize p
ry 2018, a Ph
Prior to the
tients; that r
up Primary C
12‐31‐2017)
d the effect
ce, the Pharm
f they are el
n receive pat
nurse referr
armacy Care
by the Pharm
ore prescrip
SHPMidyfessional
d‐out per the g
care by utiliz
y Technicians
pira Health
althcare syst
acists in hosp
e costs. Sinc
inpatient an
mbulatory s
of a Pharmac
patient care.
harmacy Tec
hire, the Pha
responsibilit
Care Provide
and Quarte
of a Pharma
macy Techn
ligible for ca
tients to car
ral and from
and Chronic
macy Techni
tions. A one
yearClinlPoster
guidelines wer
zing a pharm
s: Competen
Network;
tems have ut
pitals to incr
ce Pharmacy
nd emergenc
setting. The p
cy Technicia
.
chnician was
armacist foll
y thereafter
r, had an ad
r One 2018
acy Technici
ician also rev
are managem
re manage th
the payer. T
c Kidney Dise
ician, giving
e‐tail, paired
nicalMeAbstrac
re translated i
macy techini
ncies/Develo
tilized the ro
rease the eff
y Technician
cy departme
purpose of t
an to suppor
s hired to su
lowed adhe
r shifted. 69
herence rat
(1‐1‐2018 to
an on patien
views patien
ment. Both t
hrough an id
To monitor p
ease. All Ch
the Pharma
t‐test was c
eetingcts
into unknown
cian in ambu
opment/Oth
ole of Pharm
ficiency of P
ns have been
ents, this stu
this study is
rt the Pharm
pport a Phar
rence for all
Horizon pat
e for both Q
o 3‐31‐2018)
nt’s adheren
nts with Chr
the Pharmac
dentification
performance
hronic Kidney
cist more tim
conducted to
characters.
ulatory setti
her
macy Technic
harmacists,
n effective in
udy explores
to evaluate
macist in an
rmacist in th
Horizon Blu
tients who se
Quarter Four
). One tail,
nce rates. In
onic Kidney
cist and
n/attrition
e, cases are
y Disease ca
me to spend
o assess if th
ngs
cians
add
n
the
the
he
ue
ee an
r
spilt
ases
d on
here
*Special sy
was a sig
compare
Results: T
the 3‐mo
October
(2,249 m
Pharmac
and after
number o
less case
more min
Conclusio
work wit
the Phar
ymbols that w
gnificant diff
ed the past fo
There was a
onth timespa
2017 to Janu
inutes) with
cy Technician
r the Pharma
of cases that
s in the mon
nutes with e
on: Pharmac
h patients in
macist can m
2018ASProf
ere not spelled
erence in th
our months.
n overall 1.4
an. However
uary 2018, t
h the sum of
n. We did no
acy Technici
t the Pharm
nths with the
each patient
cy Technicia
n all settings
maximize the
SHPMidyfessional
d‐out per the g
e four mont
.
4% increase
r, the increa
he Pharmac
these patie
ot find a sign
an (p=0.07),
acist was ab
e Pharmacy
.
ns have the
s. By utilizing
eir clinical ex
yearClinlPoster
guidelines wer
ths prior to t
in adherenc
se was not s
cist had more
nts compare
nificant diffe
, but there w
ble to see (p=
Technician,
clinical back
g the Pharm
xpertise pro
nicalMeAbstrac
re translated i
the Pharmac
ce rates amo
significant w
e cases (515
ed to the fou
rence in the
was a signific
=0.05). Even
the Pharma
kground in m
macy Technic
viding optim
eetingcts
into unknown
cy Technicia
ong Horizon
with a p value
5 cases) and
ur months w
e time that w
cant differen
n though, the
acist spent o
medication a
cian in ambu
mal patient c
characters.
ns arrival
patients dur
e of 0.14. Fro
spent more
with the
was spent be
nce in the
e Pharmacis
n average 5
adherence to
ulatory settin
care.
ring
om
time
efore
t saw
.15
o
ngs,
*Special sy
Session‐B
Poster Ti
Poster Ty
Submissi
Primary A
Email: ja
Addition
Cara Roz
Purpose:
and incre
machine
although
pharmac
pharmac
utilized t
goal.
Methods
twelve h
the urgen
without p
started t
soft go‐li
were req
the hour
pharmac
able to m
in standa
National
multiple
the telep
April 201
ymbols that w
Board # ‐ 4‐1
itle: Increase
ype: Descrip
ion Category
Author: Jam
mesfurr@ho
al Authors:
ell
: A critical ac
ease safety b
s (ADMs). T
h the expecta
cy departme
cy is closed. T
o maintain q
s: The emerg
undred med
ncy of drug a
prior review
hat requires
ve to turn o
quired to com
s of 1730 to
cy departme
meet the qui
ard of care, t
ly Certified p
facilities. T
pharmacist o
18.
2018ASProf
ere not spelled
120
ed emergen
ptive Report
y: Pharmacy
mes Furr; Pip
otmail.com
ccess hospita
by turning of
They also set
ation of the
nt is not ope
This poster w
quick order t
gency depar
dication orde
administrati
w by the phar
s a pharmaci
ff the overri
mplete the r
0700, remo
nt is closed.
ck order tur
telepharmac
pharmacy te
TSS were give
of the pendin
SHPMidyfessional
d‐out per the g
cy departme
y Technicians
elinrx;
al in Washin
ff nursing ov
t a goal of 15
emergency
en 24/7, tele
will demonst
turn around
tment (ED) a
ers each mo
on in the ED
rmacist (ove
ist review of
de function
review of the
ote telepharm
A quick ass
naround tim
cy support sp
echnicians w
en view only
ng orders. D
yearClinlPoster
guidelines wer
ent order pr
s: Competen
ngton state s
verride privil
5 min turnar
staff is 10 m
epharmacist
trate how re
and suppor
at Mason Ge
nth verified
D, medicatio
erride). In Ap
f all ED medi
of the ADM
e ED orders w
macist take
sessment sho
me due to the
pecialists (TS
orking remo
y access to p
ata collected
nicalMeAbstrac
re translated i
ocessing by
ncies/Develo
sought to im
leges to thei
round time (T
minutes or le
s are utilized
emote telep
rt the hospit
eneral Hosp
by after hou
ns can be re
pril 2017, a p
ication orde
MS began in A
within five t
over the ord
owed that te
eir high wor
SS) were rec
otely to assis
pending orde
d and review
eetingcts
into unknown
using remot
opment/Oth
mprove qualit
ir automated
TAT) for STA
ss. Since the
d overnight
harmacy sup
tal patient sa
ital has an a
urs telephar
emoved from
patient safet
rs prior to ad
April 2017. P
to fifteen mi
der review w
elepharmac
rkload. To av
cruited to he
st telepharm
ers from the
wed are from
characters.
te support s
her
ty patient ca
d dispensing
AT orders
e hospital
when the
pport staff is
afety initiativ
verage of
macists. Due
m the ADMs
ty initiative
dministratio
Pharmacists
nutes. Betw
while the on‐
ists were no
void a decre
elp. TSS are
macists servin
e ED and not
m April 2017
taff
are
g
s
ve
e to
was
on. A
ween
‐site
ot
ease
ng
ified
7 to
*Special sy
Results: T
Mason G
being 5 t
during th
entered
pending
telepharm
order has
for the p
and regim
pharmac
anticoag
the expe
Conclusio
administ
integratio
the after
thorough
Mason G
telepharm
administ
ymbols that w
The average
General Hosp
o 10 minute
he second ph
by the ED pr
orders. This
macists revie
s to be revie
atient. Phar
mens with th
cist intervent
ulation reco
ctations of t
on: The pati
ration prior
on of the tel
r hours telep
hly prior to a
General. A q
macist mak
ration safety
2018ASProf
ere not spelled
e order turna
pital during t
es. This was
hase of the p
rescriber. Th
s process res
ewed 20 ord
ewed by a ph
rmacists are
he prescribe
tions include
mmendatio
the hospital
ent safety in
to a pharma
lepharmacy
pharmacists.
administratio
uick turnaro
es this work
y.
SHPMidyfessional
d‐out per the g
around time
the first pha
below TAT e
project to all
he TSS would
sulted in a T
ders each ho
harmacist be
able to ask
er prior to th
ed renal adju
ns. The turn
ED and phar
nitiative was
acist review
support staf
Emergent o
on. This has
ound time an
kflow a consi
yearClinlPoster
guidelines wer
e by a teleph
se of the pro
expectations
low the TSS
d immediate
TATof less th
our. Having t
efore admin
questions o
e drug being
ustment, kin
n around tim
rmacy staff.
s executed su
in the ED ha
ff improved
orders were
now becom
nd complete
ideration for
nicalMeAbstrac
re translated i
armacist for
oject was 12
s of the ED s
to have acc
ely notify th
han 4 minut
the requirem
istration ens
n drug allerg
g administer
netic dosing
me of less tha
uccessfully a
as improved
order review
prioritized t
me the new s
e review of e
r other facili
eetingcts
into unknown
r processing
2 minutes wi
staff. A chan
cess to pend
he pharmacis
es. On avera
ment that a
sures the dr
gies and clar
red by the n
and monito
an 4 minutes
and the prev
patient safe
w and turna
to ensure th
tandard of c
each ED orde
ities seeking
characters.
ED orders a
ith the goal
nge was mad
ing orders
sts of the
age, the
medication
ug is approp
rify drug dos
urse. Other
ring as well
s has exceed
vention of dr
ety. The
around time
hey are revie
care for the
er by a
g to improve
at
de
priate
ses
as
ded
rug
by
ewed
ED at
drug
*Special sy
Session‐B
Poster Ti
Poster Ty
Submissi
Primary A
Email: m
Addition
Marci Kn
James M
Purpose:
pharmac
who acce
training.
specifica
validatio
responsib
responsib
hospital
Methods
the rules
rules stat
has an as
Carolina
States De
the North
compete
technicia
proficien
accuracy
completi
measure
ymbols that w
Board # ‐ 4‐1
itle: Implem
ype: Descrip
ion Category
Author: Mic
ichelle.porte
al Authors:
norr
undy
: A validation
cists from dr
ept the valid
Allowing the
lly medicatio
n technician
bilities. Thro
bility and ac
pharmacy.
s: Before imp
s and regulat
tes that a ph
ssociate’s de
community
epartment o
h Carolina B
ency to be co
ans are requ
ncy in practic
y rate in chec
on of the co
and quality
2018ASProf
ere not spelled
121
entation of
ptive Report
y: Pharmacy
chelle Porter
er@conehea
n technician
ug distributi
dation techn
e validation
ons being de
n role provid
ough the aut
countability
plementatio
tions from th
harmacy tec
egree in pha
college syst
of Education,
oard of Phar
ompleted pr
ired to score
cal tasks. Fo
cking no less
ompetency e
assurance p
SHPMidyfessional
d‐out per the g
a pharmacy
y Technicians
r; Cone Heal
alth.com
program in
on to provid
ician role m
technician t
elivered to a
es an additio
thority of the
y for stocking
on of the vali
he North Car
hnician may
rmacy techn
em, regiona
, or accredit
rmacy. A ph
ior to being
e 90% on the
or the initial v
s than 1,500
exam, the ph
process need
yearClinlPoster
guidelines wer
validation t
s: Competen
th‐Moses Co
an acute ca
de more clin
ust have req
to check med
utomated d
onal incentiv
e state boar
g and prepac
idation tech
rolina Board
y validate if t
nology, confe
al accrediting
ed by ASHP,
armacy man
placed into
e assessmen
validation, t
doses acros
harmacy tech
d to be in pla
nicalMeAbstrac
re translated i
echnician pr
ncies/Develo
one Hospita
are hospital c
ical interven
quisite educa
dications fill
dispensing ca
ve by expan
d, the valida
ckaging func
nician progr
d of Pharmac
the following
erred by an
g agencies re
, PTCB‐certif
nager develo
the validatio
nt questions
he technicia
ss a minimum
hnician can
ace. Safety m
eetingcts
into unknown
rogram
opment/Oth
l;
can be used
ntions. Pharm
ation and pr
led by anoth
abinets. The
ding their ro
ation technic
ctions in an a
ram, Moses
cy (21 NCAC
g criteria is m
institution w
ecognized by
fication; and
oped the did
on role. Vali
and demon
an must atta
m of five aud
begin check
measures us
characters.
her
to redirect
macy techni
roper superv
her technicia
e creation of
oles and
cian accepts
acute care
Cone review
46.1418). T
met: technic
within the N
y the United
d registered
dactic trainin
dation
strate
in a 99.8%
dits. Upon
king. A safet
sed at Moses
cians
vised
an,
f the
s
wed
The
cian
orth
d
with
ng
y
s
*Special sy
Cone inc
automat
administ
assuranc
technicia
Results:
and wast
94% of m
cartless),
for the p
patient c
Conclusio
capable p
provides
pharmac
pharmac
ymbols that w
lude: barcod
ed dispensin
ration. All m
e process, a
an’s work.
In a 12 mon
te were decr
medications a
, with a 99.8
harmacist(s)
care possible
on: With pro
partners in t
career deve
cists to focus
cy technician
2018ASProf
ere not spelled
de scanning
ng cabinets,
medication er
pharmacist
th window,
reased. The
are located i
8% accuracy
) more time
e.
oper safegua
the medicati
elopment op
s on optimal
n to validate
SHPMidyfessional
d‐out per the g
all medicatio
and bedside
rrors are rep
t performs ra
with two va
validation te
in the autom
checking rat
to perform
ards, pharm
ion dispensin
pportunity fo
patient care
stocking an
yearClinlPoster
guidelines wer
on into and
e barcode sc
ported as ad
andom unan
lidation tech
echnician ch
mated dispen
te (documen
clinical func
acy technici
ng process. T
or pharmacy
e. The result
d prepackag
nicalMeAbstrac
re translated i
out of the c
canning med
dverse drug e
nnounced au
hnicians, me
hecks 80% of
nsing cabine
nted by the m
ctions to pro
ans have est
The validatio
y technicians
ts show that
ging function
eetingcts
into unknown
arousels, wh
dication at ti
events. For t
udits on the
edication err
f the medica
ets for the un
monthly aud
ovide the bes
tablished th
on technicia
s. The progra
t it is ideal fo
ns in an acut
characters.
hen refilling
me of
the quality
validation
rors, stock o
ation fills (87
nits that are
dits). This all
st optimal
emselves as
an program
am allows th
or a qualified
te care hosp
the
uts,
7‐
e
lows
s
he
d
ital.
*Special sy
Session‐B
Poster Ti
Corporat
Poster Ty
Submissi
Primary A
Email: da
Addition
Sara Mah
Palli Abd
Rasha El
Purpose:
pharmac
Office (C
opportun
in Qatar.
Council P
knowledg
Methods
pharmac
hospitals
educatio
program
efficient
is how th
measure
skills of t
commerc
Results: A
pharmac
ymbols that w
Board # ‐ 4‐1
itle: Impact
tion, Qatar
ype: Descrip
ion Category
Author: Dan
alkhiyami@h
al Authors:
hmoud
ulrouf
Anany
: In a changi
cists and pha
PPD) at Ham
nities that se
Being accre
Pharmacy Ed
ge and daily
s: A cross‐se
cists and pha
s in Qatar. Th
nal activities
. In this stud
CPD system
he impact of
d by: indicat
he speaker,
cial bias.
A total of 12
cy technician
2018ASProf
ere not spelled
122
of continuou
ptive Report
y: Profession
nia Alkhiyam
hamad.qa
ng and incre
armacy techn
mad Medical
erves the con
edited by Qa
ducation (AC
y practice of
ctional surve
armacy techn
he survey co
s, impact of
dy, two secti
is implemen
this system
ting learning
time and ve
26 responses
ns. The majo
SHPMidyfessional
d‐out per the g
us professio
nalism and C
mi; Hamad M
easingly com
nicians. The
Corporation
ncept of pro
atar Council
CPE), HMC is
pharmacy p
ey was deve
nicians curre
onsisted of a
the CPD pro
ons were re
nted across
was measu
g objectives
enue of activ
s were collec
rity of the re
yearClinlPoster
guidelines wer
nal pharmac
Career Devel
edical Corpo
mplex profess
Continuous
n (HMC) is k
ofessional de
of Healthca
seeking to m
professionals
eloped based
ently practic
total of 13 q
ocess and att
ported in th
a large healt
red. The qua
and coverin
vities, assess
cted, 80% w
espondents
nicalMeAbstrac
re translated i
cy developm
lopment
oration;
sion, lifelong
Pharmacy P
een on prov
evelopment
re Practition
measure the
s.
d on literatu
cing at Hama
questions w
titudes towa
he methodol
thcare entity
ality of educ
g them com
sment metho
were pharma
agreed that
eetingcts
into unknown
ment at Ham
g learning is
Professional
viding efficie
for pharmac
ners and the
e impact of C
ure review. P
ad Medical C
which assesse
ards the imp
ogy. The firs
y such as HM
cational activ
mprehensivel
od and being
cist and 20%
t CPD has po
characters.
ad Medical
essential fo
Developme
ent CPD
cy professio
e American
CPD on
Participants w
Corporation
ed quality of
plemented
st is how an
MC. The seco
vities were
y, presentat
g free of
% were
ositively
or
ent
nals
were
f
ond
tion
*Special sy
impacted
(75%) an
hand, som
changes
to educa
lack of re
activities
Conclusio
program
and antic
outcome
ymbols that w
d their know
d has encou
me (7.5%) re
in the applic
tion at 61%.
elevant topic
s such as wo
on: Pharmac
in HMC. Cu
cipated barr
es which is a
2018ASProf
ere not spelled
wledge (81%)
uraged them
espondents
cation proce
. This was fo
cs (17%). In
rkshops.
cists and pha
rrently, the
iers to CPD.
plan in prog
SHPMidyfessional
d‐out per the g
), increased
to pursue f
reported tha
ess. Participa
ollowed by: a
addition, m
armacy tech
CPPD Office
It is importa
gress in affili
yearClinlPoster
guidelines wer
their confide
urther learn
at the CPD p
ants reported
accessibility
any suggest
hnicians have
has implem
ant to measu
ation with A
nicalMeAbstrac
re translated i
ence and pe
ning opportu
process is no
d that lack o
(41%), cost
ed to provid
e positive at
mented a pla
ure the impa
ACPE.
eetingcts
into unknown
erformance i
unities (79%
ot smooth w
of time is the
of participat
de more app
ttitudes towa
n to overcom
act of CPD o
characters.
in daily prac
%). On the ot
which led to s
e biggest bar
tion (32%) a
plication base
ards the CPP
me the curre
n healthcare
tice
ther
some
rrier
nd
ed
PD
ent
e
*Special sy
Session‐B
Poster Ti
Poster Ty
Submissi
Primary A
Email: hb
Addition
Hussam K
Shorouq
Laila Jam
Najwa Al
Purpose:
graduatin
other) re
residency
pharmac
clinical p
postgrad
describe
Methods
pharmac
pharmac
phone ap
was valid
data colle
using Exc
Results: A
1) reside
the natio
(R1 & R2
ymbols that w
Board # ‐ 4‐1
itle: Current
ype: Evaluat
ion Category
Author: Hus
bakhsh@hot
al Authors:
Kutbi
Alessa
mjoom
shamrani
: The numbe
ng through n
esidency pro
y training pr
cy residency
harmacy is a
uate year‐tw
the post‐res
s: A survey s
cy residency
cy in Saudi A
pplications a
dated by a fa
ection was d
cel Microsft
A total of 48
ncy training
onal program
), and 16 ph
2018ASProf
ere not spelled
123
t status of re
tive Study
y: Profession
ssain Bakhsh
tmail.com
er of residen
national (Sau
gram. In Sau
rogram (R1 a
program in
a third‐year
wo(PGY‐2) p
sidency clini
tudy with 24
training, eit
rabia. This q
and social me
aculty memb
done via fou
2013.
8 responses
, and 13 hav
ms,19 pharm
armacists ha
SHPMidyfessional
d‐out per the g
esidency‐trai
nalism and C
h; King Abdu
ncy‐trained p
udi) residenc
udi, the gene
and R2) that
the United S
pharmacy re
pharmacy res
cal pharmac
4 questions
her national
questionnair
edia. The su
ber in the fac
rth‐year pha
were receive
ve completed
macists have
ave the Saud
yearClinlPoster
guidelines wer
ned pharma
Career Devel
laziz Univers
pharmacists
cy programs
eral clinical p
is qualifying
States. On th
esidency pro
sidency prog
cy practice in
was sent to
lly or interna
e was built e
rvey was act
culty of phar
armacy stud
ed. Of them
d (PGY‐2) re
completed t
di certificate
nicalMeAbstrac
re translated i
acists in Saud
lopment
sity;
is increasing
s or through
pharmacy di
g the postgra
he Other han
ogram (R3) t
gram. The pu
n Saudi Arab
all pharmac
ationally and
electronicall
tive for one
rmacy at Kin
ents. The da
,16 pharmac
esidency trai
the general c
e in clinical p
eetingcts
into unknown
di Arabia
g in Saudi Ar
internation
iploma is a t
aduate year
nd, Saudi ce
that is qualif
urpose of th
bia.
cists who had
d currently p
y and distrib
month. The
ng Abdulaziz
ata analysis w
cists have co
ning in the U
clinical phar
pharmacy (R
characters.
rabia, either
al (USA and
wo‐year
‐one (PGY‐1
rtificate in
fying the
he study is to
d completed
practicing cli
buted throug
e questionna
University.
was then do
ompleted (P
United State
rmacy diplom
3). Seventee
by
1)
o
d
inical
gh
aire
The
one
GY‐
es. In
ma
en
*Special sy
pharmac
their are
after com
cardiolog
Conclusio
of traine
for more
ymbols that w
cist work in a
a of specialt
mpleting resi
gy, organ tra
on: The curr
d pharmacis
training op
2018ASProf
ere not spelled
academic ho
ty. Interestin
idency train
ansplant, and
rent status o
sts who prov
portunities i
SHPMidyfessional
d‐out per the g
ospitals. Also
ngly the mos
ing. The top
d infectious
of post‐resid
vide direct p
is highly dem
yearClinlPoster
guidelines wer
o, 75 % of the
st of them ha
three specia
diseases.
ency trainin
atient care.
manded in Sa
nicalMeAbstrac
re translated i
em are prac
ave work ex
alties respon
g is promisin
Increasing t
audi Arabia
eetingcts
into unknown
ticing clinica
perience of
nding to this
ng by increa
the residency
characters.
al pharmacy
1 to 5 years
s survey are
sing the num
y‐training sit
in
mber
tes
*Special sy
Session‐B
Poster Ti
Poster Ty
Submissi
Primary A
Health Sc
Email: ev
Addition
Suzanne
Charnicia
Batoul Se
Levita Hi
Purpose:
interest t
with sign
degrees w
of this st
these mo
Methods
approved
PM grou
open for
question
This stud
Results:
responde
44 perce
practiced
worked i
non‐reta
ymbols that w
Board # ‐ 4‐1
itle: Perceive
ype: Evaluat
ion Category
Author: Eva
ciences, LIU
vangelina.be
al Authors:
Soliman
a Huggins
enhaji‐Tomz
dayat
: The extent
to the pharm
nificant press
were award
udy are to 1
oms felt disc
s: A Faceboo
d as a memb
p members
60 days. Th
s. The stress
dy was IRB ap
Ninety‐three
ents graduat
nt had one o
d in retail ph
n retail felt m
il moms (63
2018ASProf
ere not spelled
124
ed stress an
tive Study
y: Profession
ngelina Berr
Pharmacy;
errioscolon@
a
and determ
macy profess
sures from a
ed to wome
1) determine
criminated a
ok Pharmacis
ber of this gr
were then in
e survey inc
s‐related sur
pproved.
e pharmacis
ted greater t
or more chil
harmacy, 25
more upset
percent ver
SHPMidyfessional
d‐out per the g
d discrimina
nalism and C
rios‐Colon; A
@liu.edu
minants of jo
sion over the
a wide variet
en pharmacis
e stress level
gainst in the
st Moms (PM
roup, moms
nvited to com
luded stress
rvey questio
st moms resp
than 5 years
dren less tha
percent in h
because of s
rsus 28 perce
yearClinlPoster
guidelines wer
ation among
Career Devel
Arnold & Ma
b satisfactio
e last decade
ty of sources
sts, many of
s amongst w
e workplace.
M) group wa
were screen
mplete a pilo
s, discrimina
ns were der
ponded to th
s ago. Most (
an 5 years o
hospital and
something t
ent p=0.001
nicalMeAbstrac
re translated i
working ph
lopment
arie Schwart
on have been
es. Pharmac
s. In 2016, 6
f who were a
working phar
.
as founded 2
ned through
ot 18 questi
tion, and de
rived from a
he survey. T
(81 percent)
old. Fifty‐eigh
12 percent
hat happene
15). Retail ph
eetingcts
into unknown
armacist mo
z College of
n topics of co
cy practice is
1 percent of
also mothers
rmacist mom
2017. In orde
h a series of q
on online su
emographic‐
previously p
he majority
) had at least
ht percent o
in academia
ed at work c
harmacist mo
characters.
oms
Pharmacy &
onsiderable
s often faced
f PharmD
s. The objec
ms 2) ascerta
er to be
questionnai
urvey which
‐related
published st
(82 percent
t two childre
of responden
a. Moms who
compared to
oms also fel
&
d
tives
ain if
res.
was
udy.
t) of
en;
nts
o
o
t
*Special sy
more ner
likely tha
them (48
question
vs more t
discrimin
Conclusio
non‐reta
pharmac
significan
educatin
educatio
incorpora
ymbols that w
rvous or stre
an non‐retail
8 percent ve
naires when
than 5 years
nation.
on: Pharmac
il counterpa
cist moms is
nt role in the
g pharmacy
n should inc
ate life man
2018ASProf
ere not spelled
essed about
l mothers to
rsus 15 perc
n we compar
s ago. There
cist moms w
arts. These fi
warranted.
e future of th
students ab
clude coping
agement tec
SHPMidyfessional
d‐out per the g
work (70 pe
o feel difficul
cent, p=0.00
red the phar
were no sig
working in re
ndings sugg
Women hav
he professio
bout stress in
g skills, partic
chniques tha
yearClinlPoster
guidelines wer
ercent versu
ties were pi
1). We foun
rmacist mom
gnificant find
tail report h
est a larger
ve become a
on. These res
n their upco
cularly for fe
at foster a h
nicalMeAbstrac
re translated i
s 49 percent
ling up so hi
d no differe
ms who grad
dings regardi
higher stress
survey to de
a major force
sults highligh
ming career
emale stude
ealthy work
eetingcts
into unknown
t, p=0.0014)
igh they cou
nces in any
duated less t
ing workplac
levels comp
etermine str
e in pharmac
ht the impor
rs. Pharmacy
nts, and may
k‐life balance
characters.
) and were m
uld not overc
of the stress
han 5 years
ce
pared to the
ress perceive
cy and play a
rtance of
y curricular
y also
e in moms.
more
come
s
ago
ir
ed by
a
*Special sy
Session‐B
Poster Ti
healthca
Poster Ty
Submissi
Primary A
Email: ya
Addition
Farah Zu
Susan M
Teckenbr
Mariamo
Purpose:
within a
by promo
outcome
“learn” in
patient‐c
pharmac
Methods
assemble
Pharmac
establish
open pos
From the
develope
Training
and to de
similar p
were fina
Committ
ymbols that w
Board # ‐ 4‐1
itle: Implem
re system
ype: Descrip
ion Category
Author: Yan
anela.lozano
al Authors:
beri
itchelson
rock Amand
o Oyebanjo
: To explain
multi‐hospit
oting confid
es through in
n a classroom
centered pha
cy.
s: Represent
ed to develo
cy Technician
hed from this
sitions and t
ese figures, t
ed to justify
Coordinator
etermine the
rograms, tui
alized in rega
ee develope
2018ASProf
ere not spelled
125
entation of
ptive Report
y: Profession
nela Lozano;
o@leehealth
a
the process
tal health sy
ence, leader
nterdisciplina
m environm
armacies to
tatives from
op program f
n Education
s cohort. An
he number o
technician tu
program ne
r. Additional
e number of
ition cost wa
ards to a 1 y
ed an applica
SHPMidyfessional
d‐out per the g
a pharmacy
nalism and C
Lee Health;
.org
taken to de
stem. The g
rship, and pr
ary medicat
ent, “practic
improve a st
Human Res
framework u
and Training
n internal rev
of technician
urnover rate
ed and to es
ly, these figu
f classes offe
as establishe
year work co
ation proces
yearClinlPoster
guidelines wer
technician t
Career Devel
sign and imp
goal of the p
rofessional s
ion managem
ce” through
tudent’s kno
ources and p
using the AS
g Programs a
view was co
ns hired by t
es were calcu
stablish fund
ures were us
ered per yea
ed as $3800
ommitment i
ss along with
nicalMeAbstrac
re translated i
training prog
lopment
plement a p
rogram is to
skills in orde
ment. The m
simulated la
owledge and
pharmacy ad
HP Accredita
as a guide. A
nducted to d
the health‐sy
ulated and a
ding for hirin
sed to proje
ar, as well as
per student
in lieu of tuit
h criteria for
eetingcts
into unknown
gram within
harmacy tec
o prepare fut
er to optimiz
manner in w
abs, and “do
d skills in the
dministratio
ation Standa
An Advisory
determine t
ystem from
a business pl
ng a Pharma
ect future wo
s class size. U
t and studen
tion paymen
r admission,
characters.
a multi‐hos
chnician pro
ture technic
e patient
which is to
o” in actual
e area of
on were
ards for
Committee
he number o
2015‐2016.
an was
cy Technicia
orkforce nee
Upon review
nt agreemen
nt. The Advis
including a
spital
gram
cians
was
of
an
eds,
w of
ts
sory
*Special sy
prescree
Program
experien
faculty w
was appr
class of 7
Results:
interview
were cho
graduate
remained
location.
were cho
begun ex
open, at
2018.
Conclusio
hospital
graduatin
of the tra
system’s
committe
and train
quality ca
ymbols that w
ning mathem
advertising
tial compon
was establish
roved, recru
7 students co
Enrollment w
w process, ni
osen through
ed from the p
d within the
The second
osen to start
xperiential tr
this time the
on: The imp
healthcare s
ng technicia
aining progra
administrat
ed to runnin
n as well as m
andidates.
2018ASProf
ere not spelled
matics exam
was initiate
nents based o
hed and a stu
itment and
ommenced i
was opened
ineteen cand
h this proces
program. All
health syste
d round of en
t in February
raining on si
ere are twen
lementation
system was a
ns who are r
am was achi
tive support
ng a successf
marketing th
SHPMidyfessional
d‐out per the g
mination and
d, a propose
on ASHP Acc
udent trainin
hiring of a p
in Septembe
with the cri
didates appl
ss to start th
l seven stud
em and two
nrollment ha
y 2018. This
te at the dif
nty applican
n of a pharm
a successful
ready to fulf
ieved throug
to establish
ful program,
he program w
yearClinlPoster
guidelines wer
criteria for
ed curriculum
creditation S
ng manual w
rogram coo
er, 2017.
iteria of pass
ied in the fir
he class in Se
ents success
were hired
ad fifteen ap
cohort is cur
fferent locat
ts. This coho
macy technici
initiative th
fill the needs
gh a coordin
a new prog
, preceptors
within and o
nicalMeAbstrac
re translated i
successful p
m combining
Standards w
was authored
rdinator was
sing a math
rst round. A
eptember 20
sfully registe
as pharmacy
pplicants. Ou
rrently in th
ions. Enrollm
ort is schedu
ian training
at provides
s of the heal
nated effort t
gram, a prog
who were e
outside of th
eetingcts
into unknown
program com
g didactic, si
was develope
d. Once the
s completed
exam and g
total of seve
017. In the fi
ered with BO
y technician
ut of those c
e second se
ment for the
uled to start
program wit
a pool of we
lth system. I
that include
ram coordin
eager and w
e health sys
characters.
mpletion.
imulation an
ed, teaching
business pla
d and the firs
going throug
en candidat
irst cohort, 1
OP, five
s at an outs
andidates, s
mester and
e next cohort
class in July
thin a multi‐
ell trained,
Implementa
ed the health
nator who w
illing to teac
stem to find
nd
an
st
h an
es
100%
ide
six
has
t is
y
‐
tion
h
was
ch
*Special sy
Session‐B
Poster Ti
practice
Poster Ty
Submissi
Primary A
Email: te
Addition
Jason Gu
Cynthia G
Purpose:
inclusion
Educatio
prepares
standard
team‐bas
interprof
pilot to p
to prepa
Methods
Participa
enhance
moderat
and cont
bowl and
teams we
Students
and phys
time at t
position.
rounds w
ymbols that w
Board # ‐ 4‐1
itle: Preparin
using the fo
ype: Descrip
ion Category
Author: Sha
ernullo@find
al Authors:
uy
Goodwin
: The World
n into curricu
n mandates
s students to
dized, reliabl
sed practice
fessional com
provide stud
re them for
s: The ethics
ting health c
their applic
ors. Teams w
tact informat
d could choo
ere compris
s and faculty
sician assista
he opening
Judges scor
won and scor
2018ASProf
ere not spelled
126
ng pharmac
rmat of an in
ptive Report
y: Profession
ron Ternullo
dlay.edu
Health Orga
ulums for all
s the incorpo
o provide fut
e, efficient,
in four com
mmunication
ents with an
APPEs and f
s quiz bowl w
care disciplin
ability to all
were assigne
tion for thei
ose to prepa
ed of studen
y from pharm
ant program
round and h
red each ma
res in individ
SHPMidyfessional
d‐out per the g
cy students t
nterdisciplin
nalism and C
o; University
anization adv
health care
oration of m
turistic healt
and equitab
mpetency are
n practices,
n opportunit
future practi
was modeled
nes submitte
participatin
ed and stude
r teammate
re together
nts from mu
macy, sonogr
s participate
had 3 minute
tch and the
dual rounds.
yearClinlPoster
guidelines wer
to respond t
nary ethics q
Career Devel
y of Findlay C
vocates for i
students. Th
meaningful IP
th care that
ble. IPE focus
eas: values/e
and interpro
ty to apply e
ce.
d on the Nat
ed health‐ca
g specialties
ents receive
s approxima
if they desir
ltiple discipl
raphy, and n
ed. Teams re
es to read th
winning tea
A survey ev
nicalMeAbstrac
re translated i
to ethical dil
uiz bowl
lopment
College of Ph
interprofess
he Accredita
PE into pharm
is evidence‐
ses on devel
ethics, roles/
ofessional te
thical princi
tional High S
are focused c
s. Faculty ac
d the poten
ately 2 week
red but this w
lines and ha
nuclear imag
eceived their
he case and d
ams were de
valuating the
eetingcts
into unknown
emmas enco
harmacy;
sional educa
ation Counci
macy school
‐based, patie
oping stude
/ responsibil
eamwork. W
ples within a
School Ethics
cases and ed
ted as judge
tial ethical c
ks before the
was not man
d 6‐8 team m
ging, occupa
r actual case
determine t
etermined by
e Quiz Bowl
characters.
ountered in
tion (IPE)
il for Pharma
l curriculums
ent‐centered
ent skills for
lities,
We designed
a format of
s Bowl.
dited them t
es and
case scenario
e actual quiz
ndatory. All
members.
tional thera
es for the firs
heir ethical
y combining
was distribu
acy
s. IPE
d,
this
IPE
to
os
z
py,
st
uted
*Special sy
to all stu
scale and
IPE. Desc
discipline
discipline
Results:
students
that the
participa
informat
of studen
occupatio
physician
and appr
and sugg
identified
in ethics
cases had
care disc
Conclusio
they mus
to and du
IPE progr
who grad
environm
common
positive a
ymbols that w
dents who p
d two short‐a
criptive stat
e are being c
es.
Seventy‐sev
participated
quiz bowl w
te was wort
ion on the a
nts agreed th
onal therapy
n assistant a
reciated the
gestions for f
d by student
didactics, an
d been deve
iplines, som
on: For heal
st be provide
uring their a
rams can be
duate with t
ment. Studen
ethical issu
and the prog
2018ASProf
ere not spelled
participated.
answer ques
istics were u
compared to
ven students
d and return
as a good fo
thwhile. Add
application o
hat we shou
y and pharm
nd imaging s
interdiscipli
future progr
ts included s
nd more pre
eloped and a
e students f
th care prov
ed with oppo
dvanced pra
formidable
he skills nec
nt attitudes t
es encounte
gram will be
SHPMidyfessional
d‐out per the g
. The survey
stions. The
used to evalu
o determine
s signed‐up t
ned evaluativ
ormat for IPE
ditionally, 77
of ethical prin
uld repeat th
macy student
students. Stu
inary approa
rams than ot
scheduling, p
eparatory co
adjusted to b
felt that they
viders to coll
ortunities as
actice rotatio
but equally
essary to wo
toward the o
ered within t
e continued i
yearClinlPoster
guidelines wer
consisted o
survey evalu
uate overall
if any signif
to participat
ve surveys (9
E and 76% be
7% of studen
nciples to th
e ethics quiz
ts were mor
udents gene
ach. Physicia
ther disciplin
preparation
ntact with fa
be universall
y were not a
laborate effe
s students to
ons. The bar
formidable
ork in a patie
opportunity
their profess
in spring 201
nicalMeAbstrac
re translated i
of four quest
uated the stu
effectivene
ficant differe
e in the Ethi
92%). Overa
elieved that
nts agreed th
heir future h
z bowl the fo
e positive in
erally felt the
an assistant s
nes. Opportu
for students
aculty and fe
ly applicable
applicable to
ectively and
o collaborate
rriers and log
are the pote
ent‐centered
y to participa
sional practi
19.
eetingcts
into unknown
tions using a
udent’s perc
ss of the IPE
ences exist b
ics Quiz Bow
all, 88% of st
t the time th
hat they lear
ealth care p
ollowing spr
n their respo
e event was
students had
unities for im
s not concur
ellow teamm
e to all partic
o their practi
improve he
e with other
gistics aroun
ential benef
d collaborat
ate in an IPE
ce were ove
characters.
5‐point Like
ceptions of t
E and scores
between
wl. Seventy‐o
tudents agre
ey used to
rned worthw
practice and
ring. In gene
onses than
well organiz
d more critic
mprovement
rrently involv
mates. Altho
cipating hea
ice.
ealth outcom
r disciplines
nd developin
its to studen
tive health ca
focused on
erwhelmingl
ert
the
by
one
eed
while
75%
eral,
zed
cisms
t
ved
ough
lth
mes,
prior
ng
nts
are
y
*Special sy
Session‐B
Poster Ti
postgrad
Poster Ty
Submissi
Primary A
Email: tu
Addition
Eli Philips
Stefanos
Jenny Mu
David Sch
Purpose:
students
placeme
interview
candidat
of availab
time acro
obtaining
Methods
pharmac
This surv
professio
week dur
organizat
which stu
leadersh
througho
acceptan
assessed
ymbols that w
Board # ‐ 4‐1
itle: Impact
uate trainin
ype: Evaluat
ion Category
Author: Tuc
uckerward25
al Authors:
s
Torkos
ullakary
hnee
: As competi
have attem
nt in these p
w itself is oft
e’s level of i
ble literature
oss various m
g an initial in
s: An anonym
cy students a
vey assessed
onal years of
ring the P1 t
tions, and no
udents work
ip positions
out the P1 to
nce rates for
. Student da
2018ASProf
ere not spelled
127
of student in
g programs
tive Study
y: Profession
cker Ward; B
ition for pos
mpted to dive
positions is o
en determin
nvolvement
e on this top
modalities d
nterview for
mous survey
at a single in
each studen
f pharmacy s
to P4 years i
on‐pharmac
ked, the num
held within
o P4 years. T
both reside
ata was divid
SHPMidyfessional
d‐out per the g
nvolvement
in a graduat
nalism and C
Biogen;
m
stgraduate re
ersify their ti
often related
ned solely by
t during thei
pic, this stud
uring pharm
a postgradu
y, composed
stitution du
nts’ time allo
school. The s
n the follow
cy organizati
mber of phar
these organ
The number
ency and fello
ded into 3 gr
yearClinlPoster
guidelines wer
on attainme
ting class of
Career Devel
esidency and
ime and effo
d to interview
y application
r profession
dy was design
macy school t
uate position
of 45 quest
ring their we
ocation amo
survey asses
wing activitie
ons. Also re
rmacy organ
nizations, an
of applicatio
owship prog
roups: those
nicalMeAbstrac
re translated i
ent of an init
P4 pharmac
lopment
d fellowship
orts during p
w performa
n materials, w
al years of p
ned to evalu
to see if this
n.
tions, was ad
eeklong boa
ong various a
ssed average
s: paid work
corded in th
izations invo
d involveme
ons and inte
grams for ea
e who applie
eetingcts
into unknown
tial interview
cy students
p positions in
pharmacy sc
nce, attainm
which largel
pharmacy sc
uate how stu
s directly cor
dministered
ard preparat
activities du
e number of
k, profession
he survey wa
olved with,
ent with rese
erviews as w
ach applicant
d to residen
characters.
w for
ncreases,
hool. While
ment of the i
ly depict a
hool. Due to
udents alloca
rrelated with
to graduatin
ion program
ring the
f hours spen
nal pharmacy
as the setting
the number
earch activit
ell as the
t was also
ncy or fellow
nitial
o lack
ated
h
ng
m.
t per
y
g in
r of
ties
wship
*Special sy
program
the profe
fellowshi
quantifie
those wh
that may
Results: A
applied f
to both).
(75.4 per
percent)
greater t
interview
approxim
years com
Regardin
percent o
more pos
residency
for postg
position
Conclusio
candidat
fellowshi
not only
members
leadersh
results, s
environm
ymbols that w
s and/or ent
essional year
ip and/or re
ed and subse
ho were not.
y have occur
A total of 23
for postgrad
Among app
rcent) for res
residency a
han 3.5 com
ws. Of those
mately 30 pe
mpared to 1
ng leadership
of all applica
sition(s) dur
y applicants
graduate pro
and 29 (42.0
on: This stud
e’s chance o
ip programs
be correlate
ship and inc
ip roles with
students sho
ment to be co
2018ASProf
ere not spelled
try level pos
rs of pharma
sidency prog
equently com
. Trends in d
red.
37 graduatin
uate training
plicants, 71 w
sidency prog
pplicants wh
mpared to 4 (
who attaine
rcent of resi
7.6 percent
p roles withi
ants offered
ing the P2 a
that did not
ograms, 38 w
0 percent) at
dy suggests t
of being offe
. Among oth
ed to achievi
reased level
hin these org
ould continue
onsidered st
SHPMidyfessional
d‐out per the g
itions. To de
acy school co
gram, the st
mpared betw
data were as
ng PharmD st
g (21 for fell
were offered
grams. Six (2
ho received
(23.5 percen
ed at least on
idency appli
of residency
n profession
at least one
nd/or P3 ye
t receive any
were offered
ttained a res
that there a
ered an inter
her factors, t
ing a higher
l of involvem
ganizations a
e to seek ad
trong candid
yearClinlPoster
guidelines wer
etermine if a
orrelates to
udents data
ween those w
sessed betw
tudents com
owship prog
d interviews:
28.5 percent
an interview
nt) residency
ne interview
cants perfor
y applicants
nal pharmacy
e interview (
ar compared
y interviews
d positions: 9
sidency posi
re multiple v
rview during
the likelihoo
GPA but als
ment in profe
and participa
ditional opp
dates for the
nicalMeAbstrac
re translated i
a students’ le
being offere
a within each
who were of
ween groups
mpleted this
grams, 69 fo
: 19 (90.5 pe
t) fellowship
w had a Grad
y applicants
w, 26.3 perce
rmed resear
who did not
y organizatio
residency or
d to approxi
. Of those of
9 (42.9 perce
tion.
variables tha
g the applica
od of attainin
o to other a
essional pha
ation in rese
portunities o
ese increasin
eetingcts
into unknown
evel of activ
ed an interv
h of these gr
ffered an int
to evaluate
survey. Eigh
or residency
ercent) for fe
p applicants a
de Point Ave
who did not
ent of fellow
rch during th
t receive any
ons, approx
r fellowship)
mately 37 p
ffered at lea
ent) attained
at may influ
tion process
ng an intervi
ctivities incl
armacy orga
earch. Based
outside the a
ngly competi
characters.
vity througho
iew for a
roups was
terview and
e any correla
hty four stud
programs an
ellowship an
and 23 (44.2
erage (GPA)
t receive any
wship and
he P3 and/or
y interviews
imately 50
) held one or
percent of
ast one inter
d a fellowsh
ence a
s for residen
iew appears
uding
nizations,
d on these
academic
itive position
out
ations
dents
nd 6
nd 52
2
y
r P4
s.
r
rview
ip
ncy or
to
ns.
*Special sy
Session‐B
Poster Ti
Poster Ty
Submissi
Primary A
Email: pa
Addition
Moza Al
James M
Derek Ste
Purpose:
disease a
Pregnant
products
pregnant
as nutriti
potentia
drug inte
Methods
trimester
birth, adm
East Scot
clinic for
question
pregnant
health an
during pr
modalitie
Medicine
product i
Compreh
ymbols that w
Board # ‐ 4‐1
itle: Potentia
ype: Descrip
ion Category
Author: Pall
abdulrouf@h
al Authors:
Hail
cLay
ewart
: Women are
and mainten
t women are
s to treat pre
t women use
ional supple
l for herb‐dr
eractions and
s: Data asses
r (18–21 we
mitted to th
tland were c
their mid tr
naire was te
t and postpa
nd medicatio
regnancy ; a
es considere
es and Healt
interaction w
hensive Data
2018ASProf
ere not spelled
128
al risk of her
ptive Report
y: Women's
ivalappila A
hamad.qa
e the major
nance of hea
e routinely p
edominantly
e HNP to tre
ments to aid
rug interactio
d their poten
ssing the use
eks) scan (n
e postnatal
combined. Q
imester scan
ested for fac
artum wome
on use durin
nd demogra
ed as herbal
hcare‐Produ
with prescrib
abase. Data w
SHPMidyfessional
d‐out per the g
rb‐drug inter
Health
bdulrouf; Ha
users of her
lth, and this
prescribed m
y pregnancy
eat pregnanc
d fetal devel
ons (HDIs) in
ntial clinical
e of CAM co
=332) and w
unit (n=557
Questionnaire
n or on the p
e and conte
en. The ques
ng pregnancy
aphics . To he
or natural p
ucts Regulat
bed medicin
were coded
yearClinlPoster
guidelines wer
ractions dur
amad medic
rbal and natu
s widespread
medicines wh
related cond
cy related pr
opment. Th
n pregnant w
significance
llected from
women, with
) at the Roya
es were give
postnatal wa
nt validity b
stionnaire co
y ; use of CA
elp participa
roducts a ch
ory Agency .
nes was asse
and entered
nicalMeAbstrac
re translated i
ring pregnan
cal corporati
ural product
d use also ex
hile self‐med
ditions. App
roblems such
e aim of this
women and
e.
m women att
hin the first 2
al Aberdeen
en to wome
ard following
by a panel of
ontained fou
AM therapies
ants to ident
heck list was
. The potent
ssed using t
d into an SPS
eetingcts
into unknown
ncy: a cross‐s
on;
ts (HNP) for
xtends into p
dicating with
roximately 4
h as nausea
s study was
to explore p
tending for t
24 hours foll
n Maternity H
en attending
g delivery. T
f healthcare
ur sections co
s ; attitudes
tify correctly
s provided fr
tial for herba
he Natural M
SS 22.0 data
characters.
sectional sur
r treatment o
pregnancy.
h herbal natu
40% of UK
and vomitin
to assess th
possible herb
their mid‐
owing a live
Hospital, No
the antenat
The
professiona
omprising:
toward CAM
y the produc
rom the
al and natur
Medicines
abase.
rvey
of
ural
ng or
e
b‐
e
orth‐
tal
ls,
M use
cts or
ral
*Special sy
Descripti
was used
products
Health Se
Results: T
reported
prescript
12). A tot
those tak
HNP (Ran
the pote
and enha
Almost a
and only
potentia
antidiabe
hormona
anti‐eme
Conclusio
unaware
which ha
Almost h
minerals
identified
concurre
potentia
ymbols that w
ive statistics
d to test the
s; p<0.05 wa
ervice North
The survey w
d the use of a
tion medicin
tal of 91 diff
king prescrip
nge 1‐12). Th
ntial to incre
ance matern
all were rate
one minor (
l for interact
etic agents (
al therapies
etics (1).
on: In the U
that they ar
ave the pote
half of pregn
and almost
d in an eight
ent use of HN
l risks.
2018ASProf
ere not spelled
were used t
associations
s considered
h of Scotland
was complet
at least one
es, 44.9% (1
ferent presc
ption medici
hirty‐four he
ease the risk
nal/fetal CNS
ed as modera
(ondansetro
tion with HN
5), hypnotic
(2, preventio
K, HNPs are
re using her
ntial to inter
ant women
half of thes
th of the stu
NPs and pres
SHPMidyfessional
d‐out per the g
to analyse th
s between a
d statistically
d Research E
ted by 889 r
prescription
181) also rep
ription medi
nes, 44.9% (
erb‐drug inte
k of postpart
S depression
ate (93.9%),
on and cham
NP were anti
s and anxiol
on of miscar
used by alm
bal medicine
ract with pre
in this study
e used HNPs
dy cohort. H
scription me
yearClinlPoster
guidelines wer
he data and
ge, educatio
y significant
thics Comm
espondents
n medicine, e
ported concu
icines were
(181) also re
eractions we
tum haemor
n.
one as a po
omile). The
thrombotic
ytics (4), op
rriage), proto
most half of p
es. While ma
escribed me
y were presc
s. Potential m
Healthcare p
edicines duri
nicalMeAbstrac
re translated i
provide res
on and the u
. Received e
ittee.
(73% respo
excluding vit
urrent use o
reported by
eported conc
ere identifie
rrhage, alter
otentially ma
prescribed d
agents (7), a
iate analges
on pump inh
pregnant wo
any HNPs co
edication eith
cribed medic
moderate to
rofessionals
ing pregnanc
eetingcts
into unknown
pondent pro
use of herba
ethic approva
nse rate). 45
tamins. Of th
f at least on
y respondent
current use o
d in 23 (12.7
r maternal ha
ajor (ginger a
drug classes
antihyperten
sics (4), NSAI
hibitors (1),
omen, althou
ontain active
her directly
cines exclud
o severe HDI
s should be a
cy is commo
characters.
ofile. Chi‐sq
l or natural
al from Nati
5.3% (403)
hose taking
e HNP (Rang
ts using HNP
of at least o
7%) women
aemodynam
and nifedipin
with the
nsive agents
IDs (3),
insulin (1) an
ugh most are
e ingredients
or indirectly
ing vitamins
Is were
aware that t
on and carrie
uare
onal
ge 1‐
Ps. Of
ne
with
mics,
ne)
s (6),
nd
e
s,
y.
s and
he
es
*Special sy
Session‐B
Poster Ti
practice
Poster Ty
Submissi
Primary A
Email: m
Addition
Tarek Jen
Razan M
Purpose:
countries
modalitie
mammog
thus allow
treatmen
breast ca
Methods
cancer sc
rural (fou
informed
employe
administ
current d
version o
question
supervisi
infant de
cancer sc
medical h
was used
ymbols that w
Board # ‐ 4‐1
itle: Multi‐ce
in hospital e
ype: Evaluat
ion Category
Author: Ma
icha_z1991@
al Authors:
nani
hanna
: Breast canc
s as well as t
es which are
graphic imag
wing patient
nts. The aim
ancer screen
s: The study
creening me
ur sites) and
d consents w
d at the incl
rative office
diagnosis of
of the validat
naire was co
on of the re
elivery, healt
creening mo
help. For dat
d. Standard d
2018ASProf
ere not spelled
129
enter prospe
employed Le
tive Study
y: Women's
ha Zeitouni;
@hotmail.co
cer is the mo
the Middle E
e Self Breast
ging are pow
ts a better c
of this study
ning method
was a seven
thods. Rese
urban (two
were signed b
uded center
ers, cleaning
breast cance
ted Breast C
omprised of
esearchers. T
th habits, pa
odalities, atti
ta input and
deviation, 95
SHPMidyfessional
d‐out per the g
ective study
ebanese wom
Health
Self employ
om
ost common
East and Nor
Examination
werful tools t
hance at com
y was to ass
s among hos
n months, m
archers obta
sites) region
by all partici
rs as nurses,
services or o
er were excl
Cancer Aware
75 question
The question
tient and fa
itude toward
d analysis SPS
5 percent co
yearClinlPoster
guidelines wer
of breast ca
men
yed;
nly diagnosed
rth Africa (M
n (SBE), Clin
that help wit
mplete remi
ess the know
spital emplo
ulticenter, p
ained IRB ap
ns. Informat
ipants. Wom
physicians,
others, were
uded. Asses
eness Meas
ns and was s
nnaire includ
mily history,
ds breast can
SS (statistica
onfidence int
nicalMeAbstrac
re translated i
ancer screen
d cancer in w
MENA) region
ical Breast E
th the early
ission using
wledge, attit
oyed Lebane
prospective t
pproval from
tion sheets w
men aged 20
pharmacists
e included. P
ssment was d
ure (CAM) q
elf‐complete
ded sections
, breast canc
ncer screeni
al package fo
terval and P
eetingcts
into unknown
ning knowled
women livin
n. Breast can
Examination
detection o
the least ag
tude and pra
ese women.
trial concern
m six differen
were distribu
years or old
s, accountan
Patients with
done using a
questionnair
ed by partic
about: dem
cer knowled
ing and barr
or social scie
value were
characters.
dge, attitude
g in Western
ncer screeni
(CBE) and
of the disease
gressive
actice (KAP)
ned with bre
nt hospitals i
uted and
der and
nts,
h history or
a modified
e. The
ipants unde
mographic da
dge, breast
riers to seeki
ence) version
calculated.
e and
n
ng
e,
of
east
n
r the
ata,
ing
n 21
Chi‐
*Special sy
square te
participa
Results: A
Seventy e
correlatio
and age g
question
knowledg
question
Chi‐squa
correlatio
women i
method w
undergon
hence no
women f
percent)
Conclusio
the empl
breast ca
and at th
breast ca
barriers t
ymbols that w
est, T‐test an
nts. For all a
Among two
eight percen
on between
groups (p =0
s (out of 7) r
ge. Whereas
s (out of 14)
re studies of
on (p >0.05)
n our study
was CBE (sev
ne mammog
ot requiring
from underg
and fear of
on: Lebanes
loying hospit
ancer, and th
he correct fre
ancer screen
that prevent
2018ASProf
ere not spelled
nd ANOVA te
analysis, sign
hundred dis
nt of the par
educationa
0.001). Arou
regarding kn
s only 41 pe
) regarding k
f individual q
. Despite ha
had low leve
venty nine p
graphic scree
mandatory m
going screen
visiting a ph
se women re
tals have a r
he benefits s
equency. He
ning and imp
ts them from
SHPMidyfessional
d‐out per the g
ests were us
nificance wa
stributed qu
rticipants we
l level and a
nd 62 perce
nowledge of
rcent of the
knowledge o
questions w
ving good kn
els of practic
percent). On
ening, due to
mammograp
ing were em
hysician (app
equire more
responsibility
screening mo
ealth care pr
prove their a
m seeking me
yearClinlPoster
guidelines wer
sed for comp
s set at p < 0
estionnaires
ere employe
ge groups (p
nt of the pa
symptoms;
participants
of risk factor
ith work sta
nowledge ab
ce. The most
ly twenty on
o the fact th
phy. The mo
mbarrassmen
proximately f
awareness c
y in highligh
odalities pro
ofessionals
ttitude towa
edical help.
nicalMeAbstrac
re translated i
parisons bet
0.05.
s, 104 femal
d in the med
p =0.0001) a
rticipants an
implying ad
s answered c
rs, implying p
tus/educatio
bout breast
t commonly
ne percent o
hat participa
ost common
nt of visiting
fifty seven p
campaigns. T
hting the dan
ovide when
need to enc
ards the pra
eetingcts
into unknown
tween differ
es complete
dical field. T
and between
nswered cor
dequate sym
correctly 7 o
poor risk fac
on level sho
cancer scree
y practiced s
of the partici
nts’ mean a
barriers tha
a physician
percent).
The Ministry
ngers of late
practiced in
courage wom
ctice by limi
characters.
ent subsets
ed the study
here was a c
n work statu
rrectly 4 or m
mptoms
or more
ctors knowle
owed no
ening metho
creening
ipants had
ge was 32 ye
at prevented
(sixty one
y of Health a
diagnosis o
the right wa
men to parta
iting all poss
of
y.
clear
s
more
edge.
ods,
ears,
d
and
f
ay
ake in
sible
*Special sy
Session‐B
Poster Ti
pulmona
Poster Ty
Submissi
Primary A
Email: br
Addition
Craig Bak
Purpose:
inhaler te
disease (
contribut
increased
opportun
clinic to i
and impr
Methods
on medic
pharmac
with med
member
nurse pra
to the CO
referrals
medicati
educatio
plans and
addition
healthy l
following
ymbols that w
Board # ‐ 7‐0
itle: Clinical
ary disease (C
ype: Descrip
ion Category
Author: Brit
ritt.cummins
al Authors:
ker
: National da
echnique to
COPD). Subo
ting factors t
d morbidity
nity for impr
identify and
roving clinica
s: In January
cation mana
cist‐nurse pra
dical decisio
of the team
actitioner fo
OPD Clinic co
is a transitio
on review/r
n, emphasis
d tools to op
to medicatio
ifestyle choi
g outcomes w
2018ASProf
ere not spelled
001
and financia
COPD) clinic
ptive Report
y: Ambulato
tt Cummins;
s@memoria
ata shows hi
increased m
optimal choi
to high rates
and mortalit
rovement. P
implement
al outcomes
y 2016, the p
gement and
actitioner te
n‐making re
m emphasizes
ocusing on ph
ome from bo
ons‐of‐care c
econciliation
s on proper i
ptimize med
on managem
ices, dietary
were measu
SHPMidyfessional
d‐out per the g
al outcomes
– 2 years of
ory Care
Pharmacy S
lohio.com
igh correlatio
morbidity an
ices related
s of hospital
ty. High adm
harmacy pro
clinical strat
for patients
pharmacy im
d healthy life
eam. Patient
eached throu
s medication
hysical exam
oth primary
clinic. Medic
n, titration o
nhaler techn
ication adhe
ment, the cli
counseling,
ured at basel
yearClinlPoster
guidelines wer
for a multid
f experience
Systems Inc (
on linking m
d mortality f
to lifestyle,
admissions
mission rates
oposed and
tegies aimed
s with this di
mplemented
estyles. Patie
ts are seen b
ugh close clin
n monitoring
mination and
care and spe
cation mana
of medicatio
nique, imple
erence, and f
nical team e
exercise, an
line for each
nicalMeAbstrac
re translated i
disciplinary c
e
(Memorial H
medication no
from chroni
exercise, an
and emerge
s for COPD w
developed a
d at reducing
isease.
a multidiscip
ents are man
by both team
nical collabo
g, managem
d clinical asse
ecialty provi
gement focu
ns, patient m
ementation o
financial ass
emphasizes e
nd pulmonar
h patient and
eetingcts
into unknown
chronic obst
Hospital);
on‐adherenc
c obstructiv
nd smoking a
ency room v
were identifi
a multidiscip
g hospital ad
plinary COPD
naged by a c
m members a
oration. The
ment and edu
essment. Pa
iders. Anoth
uses on com
medication a
of customize
sistance asse
educating pa
ry rehabilita
d tracked th
characters.
ructive
ce and poor
e pulmonary
are also
visits and
ed as an
plinary COPD
dmission rat
D clinic to fo
clinical
at every visit
pharmacist
ucation with
atient referr
her source fo
mprehensive
and disease
ed medicatio
essment. In
atients abou
tion, The
roughout a 2
r
y
D
es
ocus
t
the
als
or
on
ut
2
*Special sy
year peri
have quit
Results: T
patient m
(2.43/pat
compare
referral.
stopped
Based on
financial
and the n
volumes.
admissio
Conclusio
along wit
disease e
treatmen
cornersto
medicati
managem
working
improvem
ymbols that w
iod: hospital
t smoking, M
This evaluat
management
tient). Hosp
ed with what
The rate of e
smoking inc
n manageme
benefit of $
net financial
. The financi
ns and eme
on: A compr
th intervent
exacerbation
nt failure wit
ones of ther
on aspects o
ment and ad
in collaborat
ments in clin
2018ASProf
ere not spelled
l admission a
Medication in
tion involved
t (equivalent
pital admissio
t these patie
emergency r
creased from
ent of 40 pat
905,740 dol
benefit is p
al benefit is
rgency room
rehensive ap
ions focused
ns. Medicatio
th COPD. M
rapy. The bes
of their thera
dherence sho
tion with ph
nical outcom
SHPMidyfessional
d‐out per the g
and emerge
nterventions
d 40 patients
t of 38 patie
on rates dec
ents experien
room visits d
m 19% at bas
tients during
llars per yea
rojected to
largely deriv
m visits.
pproach to o
d on healthy
on non‐adhe
edication ad
st care plan
apy. A more
ould be a top
hysicians and
mes for COPD
yearClinlPoster
guidelines wer
ncy room vis
s were also t
s over the 2
ent years). Th
creased by 7
nced during
decreased by
seline to 47%
g this 2‐year
r. The COPD
be $1.63 mi
ved from co
optimizing m
y lifestyle imp
erence is a f
dherence an
often fails w
e comprehen
p priority for
d midlevel pr
D.
nicalMeAbstrac
re translated i
sit rates, pe
tracked as w
year period
here were 1
72% during t
the 12 mon
y 27%. The p
% after smok
period, the
D clinic curre
llion per yea
ost savings w
medication us
proved clinic
requent con
nd effective i
when patient
nsive approa
r health care
roviders can
eetingcts
into unknown
rcentage of
well as financ
resulting in
173 medicati
he clinic’s fi
nth period pr
percentage o
king cessatio
COPD Clinic
ently manage
ar based on
with reduced
sage and ad
cal outcome
ntributing fac
inhaler tech
ts struggle w
ach to medic
e organizatio
n achieve sig
characters.
patients wh
cial metrics.
441 months
on interven
rst two year
rior to their
of patients w
on interventi
c achieved a
es 72 patien
present
d hospital
herence in C
es and reduc
ctor to
nique are
with carrying
cation
ons. Pharma
nificant
ho
s of
tions
rs
who
ions.
net
ts
COPD
ced
g out
acists
*Special sy
Session‐B
Poster Ti
of experi
Poster Ty
Submissi
Primary A
Email: br
Addition
Craig Bak
Purpose:
morbidit
exercise,
and eme
admissio
proposed
strategie
patients
Methods
to focus
pharmac
with med
member
nurse pra
to the He
for referr
medicati
educatio
adherenc
clinical te
exercise,
each pat
ymbols that w
Board # ‐ 7‐0
itle: Clinical
ence
ype: Descrip
ion Category
Author: Brit
ritt.cummins
al Authors:
ker
: National da
y and morta
and stress c
rgency room
n rates for h
d and develo
es aimed at r
with heart f
s: In the fall
on medicati
cist‐nurse pra
dical decisio
of the team
actitioner fo
eart Failure C
rals is a tran
on review/r
n, implemen
ce, and finan
eam emphas
and cardiac
ient and trac
2018ASProf
ere not spelled
002
and financia
ptive Report
y: Ambulato
tt Cummins;
s@memoria
ata shows hi
ality from he
can also sign
m visits and i
heart failure
oped a multi
reducing hos
ailure.
of 2014, the
on managem
actitioner te
n‐making re
m emphasizes
ocusing on ph
Clinic come f
sitions‐of‐ca
econciliation
ntation of cu
ncial assistan
sizes educat
c rehabilitati
cked throug
SHPMidyfessional
d‐out per the g
al outcomes
ory Care
Pharmacy S
lohio.com
igh correlatio
eart failure. S
nificant cont
increased m
were identi
idisciplinary
spital admiss
e pharmacy i
ment and he
eam. Patient
eached throu
s medication
hysical exam
from both p
are clinic. Me
n, titration o
ustomized m
nce assessm
ing patients
on,. The foll
hout a 3 yea
yearClinlPoster
guidelines wer
for a multid
Systems Inc (
on between
Suboptimal c
ributing fact
orbidity and
fied as an op
heart failure
sion rates an
implemente
ealthy lifesty
ts are seen b
ugh close clin
n monitoring
mination and
primary care
edication ma
of medicatio
medication p
ent. In addit
about healt
lowing outco
ar period: ho
nicalMeAbstrac
re translated i
disciplinary h
(Memorial H
n medication
choices relat
tors to high
d mortality f
pportunity f
e clinic to id
nd improving
ed a multidis
yles. Patients
by both team
nical collabo
g, managem
d clinical asse
and specialt
anagement
ns, patient m
lans and too
tion to medi
thy lifestyle
omes were m
ospital admi
eetingcts
into unknown
heart failure
Hospital);
n non‐adhere
ted to lifesty
rates of hos
rom this dise
for improvem
entify imple
g clinical out
ciplinary He
s are manag
m members a
oration. The
ment and edu
essment. Pa
ty providers
focuses on c
medication a
ols to optimi
ication mana
choices, die
measured at
ssion rates,
characters.
clinic – 3 ye
ence and
yle, diet,
pital admiss
ease. High
ment. Pharm
ement clinica
tcomes for
eart Failure C
ed by a clini
at every visit
pharmacist
ucation with
atient referr
s. Another so
comprehens
and disease
ze medicatio
agement, th
tary counse
t baseline fo
percentage
ears
sions
macy
al
Clinic
cal
t
the
als
ource
sive
on
he
ling,
or
of
*Special sy
patients
percent o
rate.
Results: T
613 clinic
by 71% d
prior to t
improved
62% of p
beta‐bloc
convertin
from 51%
benefit o
associate
Conclusio
failure pa
exacerba
failure w
care plan
more com
priority f
providers
ymbols that w
at less than
of patients o
The clinic m
c visits. Hosp
during the cl
their referra
d to 56% of
atients were
cker. This im
ng enzyme in
% to 88%. Du
of $1.57 milli
ed with redu
on: A compr
atients along
ations of this
with heart fai
n often fails w
mprehensive
for health pr
s can achiev
2018ASProf
ere not spelled
or equal to
on an angiot
anaged 70 p
pital admissi
inic’s first th
l. At baselin
patients bei
e receiving a
mproved for
nhibitor and
uring this 3‐y
ion dollars d
uced hospita
rehensive ap
g with health
s disease. M
lure. Medica
when patien
e approach t
roviders. Pha
ve significant
SHPMidyfessional
d‐out per the g
their goal w
ensin conve
patients with
ion rates for
hree years co
ne, 19% of pa
ng at their g
an angiotens
patients see
d 95.7 % for b
year period,
during this ti
l admissions
pproach to o
hy lifestyles
Medication no
ations are a
nts struggle w
to medicatio
armacists wo
t improveme
yearClinlPoster
guidelines wer
weight, perce
rting enzym
h heart failur
r patients see
ompared wit
atients were
goal weight.
sin convertin
en in the hea
beta‐blocke
the Heart F
me. The fina
s.
optimizing m
improved cl
on‐adherenc
cornerstone
with carryin
on managem
orking in col
ents in clinic
nicalMeAbstrac
re translated i
entage of pat
me inhibitor,
re over the t
en in the He
th what thes
e at their goa
At baseline
ng enzyme in
art failure cli
rs. Medicati
ailure Clinic
ancial largely
medication us
linical outco
ce is a frequ
e of therapy
g out medic
ment and adh
laboration w
cal outcomes
eetingcts
into unknown
tients on a b
and medicat
three‐year p
eart Failure c
se patients e
al weight. O
prior to refe
nhibitor and
inic to 74% f
on adherenc
achieved a
y derived fro
sage and ad
omes and red
uent factor in
for heart fa
cation aspect
herence sho
with physicia
s for heart fa
characters.
beta‐blocker
tion adhere
period involv
clinic decrea
experienced
ver time this
erral to the c
85% were o
for angioten
ce increased
net financia
om cost savi
herence in h
duced
n treatment
ilure. The be
ts of therapy
ould be a top
ans and midl
ailure.
r, and
nce
ving
sed
s
clinic,
on a
sin
d
l
ngs
heart
est
y. A
p
level
*Special sy
Session‐B
Poster Ti
and clinic
Poster Ty
Submissi
Primary A
Email: br
Addition
Craig Bak
Purpose:
an estim
to errors
readmiss
this 97‐b
disease,
develope
admissio
Methods
nurse pra
complexi
1) 70% o
treatmen
prescript
primary a
inadequa
transition
multidisc
pharmac
to initiate
follow‐up
ymbols that w
Board # ‐ 7‐0
itle: Clinical
c
ype: Descrip
ion Category
Author: Brit
ritt.cummins
al Authors:
ker
: Poorly coor
ated $12‐44
, complicatio
sion rates fo
ed hospital w
16.2% for pn
ed a multidis
n rates and
s: A multidis
actitioner te
ity/risk patie
f patients do
nt failures, re
tions not fille
and specialt
ate care coo
ns of care pr
ciplinary hos
cist and nurs
e care coord
p at 48 hour
2018ASProf
ere not spelled
003
and financia
ptive Report
y: Ambulato
tt Cummins;
s@memoria
rdinated car
4 billion per y
ons, treatme
r chronic dis
were 24.8%
neumonia, a
sciplinary tra
improve clin
ciplinary tra
eam was imp
ents from ho
on’t take me
eadmissions
ed in a timel
y providers,
rdination is
rogram invo
spital rounds
e practitione
dination, and
s; 4) transiti
SHPMidyfessional
d‐out per the g
al outcomes
ory Care
Pharmacy S
lohio.com
re transitions
year. Poor t
ent failures,
seases have
for heart fa
and 15.5% fo
ansition of ca
nical outcom
nsition of ca
plemented in
ospital to ho
edications pr
s, progressio
ly manner po
lab monitor
a major fact
lves: 1) phar
s to identify
er meet with
d schedule p
ons clinic vis
yearClinlPoster
guidelines wer
for a multid
Systems Inc (
s from hosp
transitions o
and falls. In
typically ran
ilure, 20.3%
or all causes
are program
mes following
are program
n 2015 to op
me. Opport
roperly‐ non
on of chronic
ost‐discharg
ring, and dia
tor in treatm
rmacist and
patients at e
h patients to
post‐ dischar
sit (compreh
nicalMeAbstrac
re translated i
disciplinary t
(Memorial H
itals to othe
often result i
recent year
nged from 20
% for chronic
between 20
m to impleme
g hospital di
m and clinic w
ptimize the t
unities for im
n‐adherence
c diseases, a
ge,3) patient
agnostic test
ment failures
nurse practi
elevated risk
o identify ne
rge transition
hensive med
eetingcts
into unknown
transitions o
Hospital);
er care settin
n negative o
rs, 30‐day ho
0‐30%. Read
obstructive
011‐2014. In
ent strategie
ischarge.
with a clinica
transition of
mprovemen
is a major f
nd adverse e
ts often fail t
ting after dis
s and readm
itioner parti
k for readmi
eeds, clinical
ns clinic visit
dication
characters.
f care progr
ngs or home
outcomes re
ospital
dmission rat
pulmonary
2015, pharm
es to reduce
al pharmacis
moderate‐h
t included:
actor in
events, 2)
to follow‐up
scharge, 4)
issions. The
cipation in
ssion; 2) the
financial ris
t; 3) telepho
am
cost
lated
es at
macy
e re‐
t‐
high
p with
e
sks,
one
*Special sy
review/r
schedulin
Results:
transition
for these
the disea
all cause
3‐ year b
savings f
visits gen
expense
related in
Additiona
initiate o
Conclusio
30‐day h
readmiss
approach
financial
levels, ph
to home.
exist with
rehabilita
ymbols that w
econciliation
ng primary/s
Between Ap
ns of care pr
e patients wa
ase) during t
readmission
aseline perio
rom decreas
nerated $135
are factored
nterventions
ally there we
or were being
on: A compr
ospital read
sions resultin
h to care coo
outcomes. C
hysicians, an
. Based on re
h other care
ation facilitie
2018ASProf
ere not spelled
n, patient ed
specialty pro
pril 2015 and
rogram and
as 4% for the
he 3‐year pe
n rate over t
od. The tran
sed readmis
5,000 in reve
d‐in was app
s to correct i
ere 331 time
g medically
rehensive m
mission rate
ng in improv
ordination d
Clinical phar
nd case mana
esults obser
transitions
es.
SHPMidyfessional
d‐out per the g
ducation, fin
oviders, and
d September
clinic visits.
e same disea
eriod prior to
the 30‐mont
nsitions of ca
sions and av
enue. The n
proximately $
issues with d
ely intervent
untreated o
ultidisciplina
es to 4% (du
ved clinical o
uring care tr
rmacists wor
agers can ac
ved with thi
involving th
yearClinlPoster
guidelines wer
ancial assist
care coordi
r 2017 there
During this t
ase (compar
o establishin
th period wa
are program
voidance of g
net financial
$1.5 million
drug therapy
tions to corr
r undertreat
ary transitio
e to same di
outcomes an
ransitions is
rking in colla
chieve signifi
is project, sim
e emergenc
nicalMeAbstrac
re translated i
tance, clinica
nation).
e were 803 p
time overall
red with a ra
ng the transi
as 7% as com
and clinic a
government
l benefit afte
. Pharmacist
y (2.77 per p
rect situation
ted.
ons of care p
isease) and
nd reduced c
key to achie
aboration wi
icant improv
milar opport
cy room, exte
eetingcts
into unknown
al exam, foll
patients com
30‐day read
ange 20‐25%
itions of care
mpared to 15
chieved a $1
t imposed pe
er salaries an
ts initiated 2
patient, 2.31
ns in which p
rogram and
7% for all‐ca
cost. A comp
eving optima
ith patients
vement in pa
tunities for i
ended care f
characters.
ow‐up tests
mpleting the
dmission rat
% (depending
e program. T
5.5% during
1.7 million
enalties. Clin
nd other
2224 medica
1 per visit).
patients faile
clinic decre
ause
prehensive
al clinical an
and family,
atient transi
improvemen
facilities, an
,
tes
g on
The
the
nic
ation
ed to
ased
d
mid‐
itions
nt
d
*Special sy
Session‐B
Poster Ti
federally
Poster Ty
Submissi
Primary A
Email: je
Addition
Don Klep
Corey Pa
Purpose:
Uniform
efforts de
percent o
to descri
an A1c in
percent i
Methods
2 diabete
month ti
nine perc
informat
medicati
insulin in
pharmac
between
percent)
to predic
equal to
ymbols that w
Board # ‐ 7‐0
itle: Charact
y qualified he
ype: Evaluat
ion Category
Author: Jess
ssica.downe
al Authors:
pser
z
: A primary c
Data System
edicated to
of our diabe
be characte
n the last thr
in the last ye
s: A retrospe
es who were
me period (A
cent within t
ion with res
on regimen
njectables, th
cists during t
the two gro
were condu
ct factors tha
9 percent) o
2018ASProf
ere not spelled
004
teristics of ad
ealth center
tive Study
y: Ambulato
sica Downes
care, federal
m requireme
improving A
tic populatio
ristics of pat
ree months a
ear.
ective chart
e seen within
August, Sept
the precedin
pect to race
including th
he number o
he study pe
oups (A1c les
ucted using t
at influence
or not. This w
SHPMidyfessional
d‐out per the g
dults with a
ory Care
s; University
du
lly qualified
ents for diab
A1c lowering
on having an
tients from t
and who hav
review was
n the clinic a
tember, and
ng 12 month
e, sex, age, in
he number o
of encounter
riod, and ch
ss than or eq
t‐tests and c
whether a p
was approve
yearClinlPoster
guidelines wer
history of u
of Nebraska
health cente
etics with A1
g, our annual
n A1c greate
this organiza
ve also had a
performed o
and had an A
d October 20
hs. Data was
nsurance sta
f oral antidia
rs with provi
ange in weig
qual to nine
hi square an
patient is mo
ed by the loc
nicalMeAbstrac
re translated i
ncontrolled
a Medical Ce
er reports an
1c greater th
l data has st
er than nine
ation with ty
at least one
of adults age
A1c value rec
017) and also
collected in
atus, and pri
abetic medic
iders, diabet
ght over the
percent and
nalysis. Regr
ore likely to
cal institutio
eetingcts
into unknown
type 2 diabe
enter College
nnual data b
han nine per
tayed stagna
percent. Thi
ype 2 diabete
A1c greater
ed 19‐75 yea
corded with
o had an A1c
ncluding basi
mary langua
cations, insu
tic educator
e study perio
d A1c greate
ression mode
reach A1c go
nal review b
characters.
etes within a
e of Pharma
based on
rcent. Despi
ant with abo
is research a
es who have
r than nine
ars old with
in a three‐
c greater tha
ic demograp
age, diabete
ulin, and non
rs or clinical
od. Comparis
er than nine
els were util
oal (less tha
board.
a
cy;
te
ut 30
aims
e had
type
an
phic
s
n‐
sons
lized
n or
*Special sy
Results: A
period an
(uncontr
the two g
percent)
source be
insurance
less than
past year
starting A
lower tha
significan
compare
percent)
Conclusio
were con
uncontro
predictor
a year ag
ymbols that w
A total of 30
nd 45 percen
olled). There
groups with
(p equals 0.
etween the
e, and five p
or equal to
r (28.9 perce
A1c for patie
an those wit
nt more pati
ed to those w
(p less than
on: There w
ntrolled vers
olled were ta
r of patients
go.
2018ASProf
ere not spelled
06 patients w
nt (n equals
e were no st
the majority
6652). Mea
groups: 65 p
percent were
nine percen
ent) compar
ents achievin
th an uncont
ents with an
with an A1c l
0.01).
as not a sign
sus uncontro
aking metfor
s being unco
SHPMidyfessional
d‐out per the g
were review
140) of thes
tatistically si
y being whit
n age was 51
percent wer
e commercia
nt (controlle
ed to those
ng an A1c les
trolled A1c (
n uncontrolle
less than or
nificant diffe
olled. Statisti
rmin compa
ntrolled was
yearClinlPoster
guidelines wer
ed who had
se patients h
gnificant dif
te (85 percen
1 years old.
e uninsured
ally insured (
d) were mor
who were u
ss than or eq
10.2 percen
ed A1c were
equal to nin
erence amon
ically signific
red to those
s their basel
nicalMeAbstrac
re translated i
an A1c with
had an A1c g
fferences in
nt) followed
There were
, 30 percent
(p equals 0.9
re likely to h
uncontrolled
qual to nine
nt versus 11.
e more likely
ne percent (8
ng race, sex,
cant more p
e who were c
ine A1c and
eetingcts
into unknown
hin the three
greater than
race, age, or
d by African A
no differenc
t had federa
9026). Patie
have been di
(p equal 0.0
percent wa
1 percent). S
y to be takin
82 percent v
or age amo
atients who
controlled. T
if they were
characters.
e‐month stu
nine percen
r sex betwee
American (6
ces in payer
lly funded
nts with an A
iagnosed in t
0441). The
s significant
Statistically
g metformin
versus 44
ng those wh
were
The biggest
e diagnosed
dy
nt
en
6
A1c
the
tly
n
ho
over
*Special sy
Session‐B
Poster Ti
payment
Poster Ty
Submissi
Primary A
Email: aly
Addition
Robert A
Indu Lew
Jennifer S
Samanth
Purpose:
Reauthor
MACRA c
Payment
unnecess
prescribe
Centers f
members
demonst
Methods
gaps was
2018 (Jan
appointm
commun
method o
recomme
by a com
Pharmac
visit, dep
ymbols that w
Board # ‐ 7‐0
itle: Evaluati
t system with
ype: Evaluat
ion Category
Author: Alys
yssa.gallipan
al Authors:
Adamson
w
Sternbach
ha Williams
: Congress im
rization Act
combines m
t System. Acc
sary costs, b
ers may rece
for Medicare
s of teams a
trating outco
s: A report o
s retrieved. P
nuary 1 to M
ment in the f
icated and i
of communi
endation on
mbination of
cist intervent
pending on p
2018ASProf
ere not spelled
005
ion of pharm
hin an accou
tive Study
y: Ambulato
ssa Gallipani
mplemented
(MACRA) wh
easures into
countable ca
ut add to pr
eive paymen
e and Medic
nd provide u
omes from p
of potential p
Patients with
March 31, 20
first quarter
ntervened b
cation. Pres
ly, as per pr
chart alert,
tion occurre
prescriber av
SHPMidyfessional
d‐out per the g
macist interv
untable care
ory Care
i; RWJBarna
rg
d the Medica
hich utilizes
o one reimbu
are organiza
rescriber wo
nt bonuses if
caid Services
unique pers
pharmacist in
patient reco
h a schedule
18) were inc
of 2018 wer
by pharmacis
cribers in pr
escriber req
electronic m
d between o
vailability. O
yearClinlPoster
guidelines wer
vention on cl
organizatio
bas Health;
are Access a
quality mea
ursement pr
ations (ACO)
rk load. ACO
f benchmark
(CMS) ackn
pectives to f
ntervention
rds with ide
ed visit with
cluded in thi
re excluded.
st to prescri
ractice one w
uest. Prescr
message, and
one and seve
ne week afte
nicalMeAbstrac
re translated i
losure of qu
on (ACO)
Fairleigh Dic
nd Children’
asurements t
rogram calle
aim to fulfil
Os achieve p
ks of perform
nowledged th
fulfill these m
are limited.
ntified comm
their prescr
is analysis. P
. Potential g
ber via the p
were interve
ribers in prac
d in‐person r
en days prio
er the visit, t
eetingcts
into unknown
ality gaps in
ckinson Univ
’s Health Ins
to drive ince
d the Merit‐
ll measurem
performance
mance stand
hat pharmac
measures. St
mercial qual
riber in the f
Patients with
aps in care w
prescribers’
ened by in‐pe
ctice two we
recommend
or to the pat
the pharma
characters.
a merit bas
versity;
surance Prog
entive payme
‐based Incen
ments to prev
e scores whe
ards are me
cists are inte
tudies
ity measure
irst quarter
hout a sched
were
preferred
erson
ere interven
ation.
ient’s sched
cist perform
sed
gram
ents.
ntive
vent
ere
et.
egral
e
of
duled
ed
uled
med a
*Special sy
retrospec
closed pr
measure
determin
Results: A
care, yiel
and two,
patients
aged 50‐
years wit
aged 18‐
incomple
quality m
mammog
19% of co
differenc
Conclusio
closure o
outpatie
percent o
on reimb
ymbols that w
ctive chart r
roperly by th
gaps succes
ne whether o
A total of 59
lding a total
respectively
aged 18 yea
75 years (28
th diabetes (
85 years (7%
ete eye exam
measure gaps
grams, 63%
olonoscopie
ce in quality
on: Pharmac
of quality me
nt office pra
of benchmar
bursement a
2018ASProf
ere not spelled
review to ass
he prescribe
ssfully closed
or not metho
9 patients m
of 75 gaps i
y. All potent
ars and older
8%); 3) hemo
(11%); 4) blo
%); 5) incom
m in patients
s were close
of hemoglob
es, and 0% of
measure ga
cist expertis
easurements
actices may a
rks met. Mo
fter addition
SHPMidyfessional
d‐out per the g
sess whethe
r. The prima
d by any typ
od of comm
et the inclus
n care. A tot
tial quality g
r (47%); 2) in
oglobin A1c
ood pressure
plete mamm
s aged 18‐75
ed after phar
bin A1c, 60%
f eye exams
ps filled bet
e of chronic
s which drive
assist practic
ore research
n of pharma
yearClinlPoster
guidelines wer
r or not the
ary outcome
e of pharma
unication af
sion criteria
tal of 38 and
aps included
ncomplete c
greater than
e reading gre
mogram in w
5 years with
rmacist inter
% of blood p
were comp
ween practi
disease stat
e incentive p
ces in receiv
is needed to
cy services.
nicalMeAbstrac
re translated i
quality mea
e was the pe
acist interve
ffects closur
and had at l
d 37 gaps we
d: 1) incomp
olorectal ca
n eight perce
eater than 1
women aged
diabetes (2%
rvention. A t
ressure, 40%
leted or bro
ces.
te managem
payments. A
ving paymen
o assess the
eetingcts
into unknown
asure gap wa
rcent of com
ntion. We a
e of these m
least one po
ere open in p
plete depress
ncer screeni
ent in patien
140/90 mmH
50‐74 years
%). Overall, 4
total of 100%
% of depress
ught to goal
ment provide
Addition of a
t bonuses by
cost avoida
characters.
as assessed
mmercial qua
lso aim to
measures.
otential gap i
practices on
sion screen
ing in patien
nts aged 18‐
Hg in patient
s (5%); 6)
40% of total
% of
sion screenin
l. There was
es value to
pharmacist
y increasing
nce and effe
and
ality
in
e
in
nts
75
ts
l
ngs,
s no
t to
ect
*Special sy
Session‐B
Poster Ti
after disc
Poster Ty
Submissi
Primary A
Email:
Addition
Robert M
Joe Gonz
Purpose:
of opioid
Methods
outpatie
patients’
primary g
amount,
the use o
Adenoide
United St
postoper
ibuprofe
it is impo
througho
opioid pa
for over a
Results:
pateint c
two wee
ymbols that w
Board # ‐ 7‐0
itle: Pharma
charge
ype: Descrip
ion Category
Author: Log
al Authors:
Moneypenny
zaga
: Evaluate th
d prescribing
s: This discri
nt pediatric
attested us
goal is to de
with an ove
of the Ameri
ectomies are
tates each y
rative levels
n. As no con
ortant to foll
out their pai
ain control fo
a half million
Chart studie
complication
ks after surg
2018ASProf
ere not spelled
006
acists role in
ptive Report
y: Ambulato
an Sanders;
y
he role of the
g.
ptive study o
Tonsillectom
e and result
termine whi
erall endpoin
can Academ
e one of the
ear. (1) The
of pain, con
nsensual pai
ow up with
n managem
or the durat
n children un
es were utiliz
ns. Telephon
gery to asses
SHPMidyfessional
d‐out per the g
pain manag
ory Care
West Virgin
e pharmacis
of WVU Med
my with or w
ting unintent
ich pain med
nt of trying t
my of Pediatr
most comm
e outpatient
ntrolled by a
in managem
patients/car
ent. Detecti
tion prescrib
nder fifteen
zed to deter
e survey wa
ss trends suc
yearClinlPoster
guidelines wer
gement of pe
nia University
t after disch
dicine’s pain
without Aden
tional overp
dications are
o reduce exc
rics PDSA Cy
monly perfor
surgery is as
combinatio
ment regime
regivers to u
ng a recurrin
bed, can decr
years old na
mine which
s conducted
ch as medica
nicalMeAbstrac
re translated i
ediatric patie
y Health Sys
harge for the
n manageme
noidectomy
prescribing o
e being pres
cessive disp
cle. Tonsille
rmed surgeri
ssociated wi
n of opioids
exists, espec
understand t
ng correlatio
rease the am
ationwide.(1
medication
d by Pharma
ation counse
eetingcts
into unknown
ents after to
stem;
e monitoring
ent strategie
aims to und
of opioid med
cribed, inclu
ensing of na
ctomies and
ies for pedia
ith moderat
s, acetamino
cially in rela
the individua
on of patient
mount of op
1)
s were presc
acists and Ph
eling, overal
characters.
onsillectomy
g and educat
es following
derstand the
dications. Th
uding dosage
arcotics thro
d
atrics in the
e‐severe
ophen and
tion to dura
al use of opi
ts not requir
ioids dispen
cribed as we
harmacy Inte
l pain
y
tion
e
he
e and
ugh
tion,
ioids
ring
sed
ell as
erns
*Special sy
satisfacti
medicati
Conclusio
to thirty
amount o
over 12,0
departm
as Medic
handout,
ymbols that w
ion, amount
on refills.
on: Patients
days. Forty
of Lortab, w
000 ml of Lo
ental change
cation Regim
, emphasizin
2018ASProf
ere not spelled
of medicati
, on average
percent of p
hile pain sat
rtab prescri
es to a maxi
men Standard
ng the use of
SHPMidyfessional
d‐out per the g
on leftover,
e, received 4
patients had
tisfactory sco
bed to patie
mum day su
dization as w
f acetamino
yearClinlPoster
guidelines wer
complicatio
42 doses of L
d a remainde
ores average
ent. First qua
upply for pat
well as a disc
phen and ib
nicalMeAbstrac
re translated i
ons of medic
Loratab rang
er of greater
ed 4.5/5. Th
arter of stud
teints of sev
charge pharm
uprofen ove
eetingcts
into unknown
cation use, a
ging from a t
r than half th
is equates to
y immediate
en days. Act
macists’ edu
er Lortab, ha
characters.
nd need for
two day sup
he prescribe
o an excess
ely led to
tion Plans su
ucation and
ave been uti
r
ply
d
of
uch
lized.
*Special sy
Session‐B
Poster Ti
Poster Ty
Submissi
Primary A
Email: tim
Addition
Pirneeka
Kathy Za
Nathan S
Judy Che
Purpose:
incidence
induced
urticarial
occurs in
reported
ultimatel
reactions
may be d
causes of
A 76‐yea
and 3 aft
hyperlipi
fluticason
estradiol
patient h
presente
below th
and warm
was perf
C‐reactiv
ymbols that w
Board # ‐ 7‐0
itle: Associat
ype: Case Re
ion Category
Author: Tim
m.hudd@mc
al Authors:
Chugh
iken
Samuels
eng
: Allergic cut
e of less tha
cutaneous r
l lesions. Wa
n an estimate
d within 5 da
ly lead to ski
s from less s
due to the ac
f these adve
r old Caucas
ter a recent d
demia, hype
ne nasal spr
0.5mg daily
has no know
ed to her prim
e left eye. P
mth in the V
ormed and d
ve protein of
2018ASProf
ere not spelled
007
ted unilatera
eport
y: Ambulato
mothy Hudd;
cphs.edu
taneous reac
n 0.1 percen
eactions hav
arfarin induc
ed 1 in 10,00
ys of taking
in necrosis.
erious skin e
ctive ingredi
erse reaction
sian female w
diagnosis of
ertension, os
ay daily, ato
y, calcium ca
n drug, food
mary care ph
hysical exam
1 and V2 trig
deemed unr
f 28mg/L, an
SHPMidyfessional
d‐out per the g
al facial swe
ory Care
MCPHS Univ
ctions in pat
nt in the liter
ve been repo
ced skin necr
00 patients e
warfarin an
Practitioner
eruptions. C
ent itself, or
ns remain un
was initiated
paroxysmal
steopenia, a
orvastatin 10
arbonate 500
d, or dye alle
hysician with
m revealed s
geminal ner
remarkable.
nd an elevate
yearClinlPoster
guidelines wer
elling and ski
versity;
tients on wa
rature. Neve
orted includ
rosis is a mo
exposed to w
d may progr
rs should dis
Cutaneous re
r certain exc
nclear.
d on warfari
l atrial fibrill
nd allergic r
0 mg daily, m
0mg twice d
ergies. One w
h a headach
ignificant lef
ve distributi
Abnormal la
ed white blo
nicalMeAbstrac
re translated i
in rash in a p
rfarin are ra
ertheless, va
ding vesicula
ore serious d
warfarin. Re
ress to hemo
stinguish the
eactions to o
cipients such
n 5 mg daily
ation. Her p
rhinitis. Othe
metoprolol su
aily, and bio
week after st
e, facial rash
ft‐sided faci
ion. A comp
aboratory fin
ood cell coun
eetingcts
into unknown
patient on w
are and repo
arious types
r, maculopa
dermatologic
d, painful pl
orrhagic blis
ese more ser
oral formula
h as dye. Alb
y with a goal
past medical
er medicatio
uccinate 12.
otin 200mcg
tarting warf
h, and fluid a
al erythemia
uterized tom
ndings includ
nt of 15,000/
characters.
warfarin
orted at an
of warfarin‐
pular, and
c condition t
aques have
sters, ulcers,
rious cutane
tions of war
eit, precise
INR betwee
history inclu
ons included
.5mg daily,
daily. The
arin, the pat
accumulatio
a, tendernes
mography sc
ded an eleva
/µL. The
‐
that
been
and
eous
rfarin
en 2
uded
tient
on
ss,
can
ated
*Special sy
patient’s
medicati
day meth
diphenhy
and rash
with imp
following
symptom
“probabl
warfarin
aware of
why thes
ymbols that w
INR was 2.2
on regimen.
hylprednisol
ydramine 25
subsided. T
provement. T
g warfarin di
ms were fully
y” induced b
and allergic
f this potent
se adverse re
2018ASProf
ere not spelled
2 and warfar
. The primar
one‐taperin
5mg every ev
he patient c
The INR fell b
iscontinuatio
y resolved. N
by warfarin.
dermatolog
ial adverse e
eactions occ
SHPMidyfessional
d‐out per the g
rin was note
ry care physi
g regimen, c
vening for th
continued to
below 2 and
on, the patie
Naranjo algo
This case re
gic reactions
effect. Furth
cur.
yearClinlPoster
guidelines wer
d as the only
cian discont
cetirizine 10
he next wee
o report inter
apixiban 5 m
ent returned
orithm produ
eport furthe
s. Although r
er studies a
nicalMeAbstrac
re translated i
y recent cha
tinued the w
mg every m
k. One week
rmittent ery
mg twice da
d to the clini
uced a score
er supports t
rare, it is imp
re necessary
eetingcts
into unknown
ange to the p
warfarin and
orning, and
k later, the f
ythemia and
aily was initia
c for follow‐
e of 5 indicat
the associati
portant for p
y to fully asc
characters.
patient’s
prescribed a
acial swellin
pruritus, bu
ated. Two w
‐up. Her
ting the rash
on between
providers to
certain how,
a 6‐
ng
ut
weeks
h was
n
be
and
*Special sy
Session‐B
Poster Ti
setting
Poster Ty
Submissi
Primary A
Email: c_
Addition
Jered Arq
Purpose:
San Joaq
patients
care clini
this study
between
pharmac
Methods
phases. T
CHF betw
related IC
CHF‐relat
readmiss
who did
provider
Patients
California
study wa
versus th
after a pa
pharmac
ymbols that w
Board # ‐ 7‐0
itle: Role of
ype: Evaluat
ion Category
Author: Ying
al Authors:
quiette
: Congestive
uin General
being readm
ic and chang
y was to ass
patients se
cist intervent
s: This was a
The retrospe
ween July 1,
CD‐10 codes
ted admissio
sion rates we
not. All patie
within the S
were exclud
a Departmen
as the differe
hose who did
atient’s first
cists in the C
2018ASProf
ere not spelled
008
pharmacists
tive Study
y: Ambulato
g Wu Liu; Sa
cific.edu
e heart failur
Hospital (SJ
mitted for CH
ged the form
ess the impa
en in the ne
tions was als
a single‐cent
ective phase
2016 and Ju
s within the
ons. During t
ere compare
ents who we
SJGH system
ded if they w
nt of Correct
ence in 30‐d
d not. Secon
clinic visit, t
HF clinic, an
SHPMidyfessional
d‐out per the g
s in reducing
ory Care
n Joaquin G
re (CHF) cost
GH) felt tha
HF. In respon
mat into a mu
act of the ne
w clinic and
so assessed.
er observati
of this stud
une 30, 2017
admissions d
the prospect
ed between
ere 18 years
m, and diagno
were less tha
tions and Re
ay readmiss
dary endpoi
the number
d the length
yearClinlPoster
guidelines wer
g heart failur
eneral Hosp
ts the nation
t there was
nse, SJGH mo
ultidisciplina
ew clinic form
those who w
onal study w
y consisted
7. CHF admis
database. T
tive phase (J
patients wh
of age or ol
osed with he
n 18 years o
ehabilitation
ions betwee
ints included
and type of
h of hospital
nicalMeAbstrac
re translated i
re readmissi
pital;
n 30.7 billion
a significant
oved the CH
ary team bas
mat on hear
were not. Th
with retrosp
of a review
ssions were
This served t
July 1, 2017
ho attended
lder, oversee
eart failure w
of age or we
n (CDCR). The
en patients w
d the numbe
f interventio
stay (LOS) f
eetingcts
into unknown
ons in the co
n dollars eac
t increase in
HF clinic into
sed clinic. Th
rt failure rea
he specific im
ective and p
of all admiss
identified by
o establish a
to February
the CHF clin
en by a prim
were include
re in the cus
e primary en
who attende
er of admiss
ns performe
for exacerba
characters.
ommunity
h year. In 20
the number
the primary
he purpose o
admission ra
mpact of
prospective
sions related
y searching C
a baseline fo
y 28, 2018) t
nic versus tho
mary care
ed in the stu
stody of the
ndpoint of th
ed the CHF c
ions before
ed by
tions.
017,
r of
y
of
tes
d to
CHF‐
or
he
ose
dy.
his
clinic
and
*Special sy
Results: A
period. T
for 908 h
a total of
been see
accounte
average
two 30‐d
30‐day re
patients
admissio
made du
period, 5
(NYHA) f
Conclusio
improvin
patients
their first
their NYH
ymbols that w
A total of 21
Twenty of th
hospital days
f 127 admiss
en in the clin
ed for 91 tot
LOS of 5.7 d
day readmiss
eadmissions
who had at
ns after a pa
ring the pro
50 percent of
unctional cla
on: Pharmac
ng patient ou
who attende
t clinic visit.
HA functiona
2018ASProf
ere not spelled
18 CHF‐relat
ese admissio
s with an ave
sions, which
nic and 22 pa
al admission
ays. Patients
sions, 24 hos
was not sig
least one cli
atient’s first
ospective pha
f the patient
ass.
cists working
utcomes. Wh
ed the clinic
Patients see
al class.
SHPMidyfessional
d‐out per the g
ed admissio
ons were 30
erage LOS of
were attrib
atients had a
ns, three 30‐
s who had a
spital days, a
nificantly dif
inic visit the
clinic visit (2
ase 157 invo
ts had an im
g in a multid
hile there wa
c showed a s
en in the clin
yearClinlPoster
guidelines wer
ns were ide
0‐day readm
f 4.2 days. D
utable to 10
at least one c
‐day readmis
t least one c
and an avera
fferent betw
re was a sign
29 versus 7,
olved a CHF
mprovement
disciplinary C
as no signific
ignificant de
nic also had a
nicalMeAbstrac
re translated i
ntified durin
issions. The
During the pr
02 patients. E
clinic visit. P
ssions, 479 h
clinic visit ac
age LOS of 3
ween groups
nificant decr
P=0.002). O
medication.
in their New
CHF clinic pla
cant differen
ecrease in CH
a shorter LO
eetingcts
into unknown
ng the retros
218 admissi
rospective p
Eighty patie
Patients not
hospital day
ccounted for
3.4 days. The
s (P=0.160).
rease in the
Of the 329 in
By the end
w York Heart
ay an import
nce in 30‐da
HF‐related a
OS and an im
characters.
spective rev
ions account
hase there w
nts had neve
seen in clini
ys, and an
r 36 admissio
e difference
In the group
number of
terventions
of the study
t Association
tant role in
y readmissio
admissions a
mprovement
iew
ted
were
er
c
ons,
in
p of
y
n
ons,
after
in
*Special sy
Session‐B
Poster Ti
populatio
Poster Ty
Submissi
Primary A
Universit
Email: m
Addition
Yu‐Han C
Nadia Na
Todd Lee
Purpose:
virologic
elbasvir/
DAA regi
elbasvir/
elbasvir/
of elbasv
Methods
Investiga
with elba
medical c
ethnicity
informat
regimen;
also colle
Pearson’
Secondar
ymbols that w
Board # ‐ 7‐0
itle: Hepatit
on at an urb
ype: Evaluat
ion Category
Author: Mic
ty of Illinois a
michell@uic
al Authors:
Chen
abulsi
e
: The direct‐
response (S
/grazoprevir
mens. Sever
/grazoprevir
/grazoprevir
vir/grazoprev
s: This retros
ators reviewe
asvir/grazop
center. The
y, body mass
ion includin
; and lab res
ected. The d
s chi‐square
ry endpoints
2018ASProf
ere not spelled
009
is C virus tre
an academic
tive Study
y: Ambulato
chelle Martin
at Chicago C
c.edu
acting antiv
SVR) rates fo
had the low
ral payers ad
over other D
treatment is
vir treatmen
spective coh
ed the elect
revir from Ja
investigator
index (BMI)
g stage of liv
ults. Data o
data were an
e test. The pr
s included ev
SHPMidyfessional
d‐out per the g
eatment with
c medical ce
ory Care
n; University
College of Ph
iral combina
r hepatitis C
west advertis
djusted form
DAA regimen
s lacking. Th
nt at a divers
hort study w
ronic medica
anuary 28, 2
s collected b
), concurren
ver disease,
on document
nalyzed using
rimary endp
valuation of
yearClinlPoster
guidelines wer
h elbasvir/gr
enter
y of Illinois H
harmacy;
ation of elba
C virus (HCV)
sed wholesal
mulary cover
ns, yet exten
e purpose o
se urban aca
as approved
al records of
2016 to Dece
baseline cha
t medication
previous HC
ted medicat
g descriptive
oint was the
SVR rates b
nicalMeAbstrac
re translated i
razoprevir in
Hospital and
asvir/grazopr
) treatment.
le acquisitio
age to mand
nsive real‐wo
of this study
ademic medi
d by the inst
f patients w
ember 1, 201
racteristics
ns, and com
CV treatmen
tion adheren
e statistics, F
e percent of
by baseline p
eetingcts
into unknown
n a diverse p
Health Scien
revir offers h
From 2016
n cost of the
date use of
orld data on
is to evaluat
ical center.
itutional rev
ho started H
17 at an urb
including ag
orbidities; a
t history, cu
nce and adve
Fisher’s exac
f patients wh
patient chara
characters.
patient
nces System
high sustaine
to mid‐2017
e available H
n SVR rates w
te the SVR ra
view board.
HCV treatme
ban academi
ge, gender,
and HCV‐spe
urrent HCV
erse events w
ct test, and
ho achieved
acteristics.
m /
ed
7,
HCV
with
ates
ent
c
ecific
were
SVR.
*Special sy
Results:
percent r
populatio
(standard
the popu
were on
were pos
had hepa
Adheren
treatmen
headache
The over
the SVR r
age, obes
interactio
not achie
Conclusio
SVR rate
transplan
demogra
regimen
insurance
ymbols that w
Sixty‐four pa
received elb
on was 58 pe
d deviation e
ulation, 56 p
dialysis, 48 p
st‐transplant
atocellular c
ce data show
nt. Adverse
es during tre
rall SVR rate
rate was 98
sity, genotyp
ons, (p value
eve SVR.
on: Treatme
in this diver
nt patients a
aphics, yet co
offers a succ
e prior to th
2018ASProf
ere not spelled
atients start
asvir/grazop
ercent male
equal to 8.3)
ercent had g
percent had
t, 38 percen
arcinoma (H
wed that 23
events inclu
eatment. No
was 94 perc
percent per
pe, treatmen
e greater tha
ent with the
rse patient p
and a high pr
onclusions a
cessful treat
e availability
SHPMidyfessional
d‐out per the g
ed HCV trea
previr and 9
, 80 percent
), and a base
genotype 1a
Medicaid in
t had diabet
HCC). Fifty‐th
percent of p
uded a 10‐pe
o patients dis
cent. After e
protocol. S
nt history, in
an 0.05). On
low‐cost DA
population w
roportion of
cross group
tment option
y of a new lo
yearClinlPoster
guidelines wer
atment with
percent also
t African Am
eline BMI of
, 91 percent
nsurance, 38
tes, 23 perce
hree percent
patients rep
ercent rate o
scontinued t
xcluding the
SVR rates did
nsurance, co
e Caucasian
AA regimen o
which include
f cirrhotic pa
s are limited
n for HCV pa
ower‐cost pa
nicalMeAbstrac
re translated i
elbasvir/gra
o received ri
merican, had
30 (standar
t were treat
8 percent we
ent had psyc
t had drug‐d
orted 1 or m
of fatigue an
treatment.
e 3 patients
d not differ b
omorbidities
patient, the
of elbasvir/g
ed off‐label
atients. The S
d due to the
atients and w
angenotypic
eetingcts
into unknown
azoprevir. Ni
ibavirin. The
a mean age
rd deviation
ment‐naïve,
ere cirrhotic,
chiatric illnes
drug interact
more missed
nd 3‐percent
who were lo
by stage, cirr
, adherence
e only patien
grazoprevir a
treatment o
SVR rates di
small numb
was used wi
c regimen.
characters.
inety‐one
e patient
of 62.3 yea
equal to 8.4
, 34 percent
, 17 percent
ss, and 3 pe
tions at base
dose(s) dur
t rate of
ost‐to‐follow
rhosis, gend
, or drug‐dru
nt with HCC,
achieved a h
of post‐
d not differ
bers. This
dely by Med
rs
4). In
t
rcent
eline.
ring
w‐up,
er,
ug
did
high
by
dicaid
*Special sy
Session‐B
Poster Ti
Poster Ty
Submissi
Primary A
Email: m
Addition
Rani Mad
Ashmi Ph
Mini Varg
Navin Ph
Purpose:
Incorpora
has been
is not inv
determin
Methods
by home
medicati
conjunct
pharmac
deemed
pharmac
documen
pharmac
Results:
conjunct
and 3 we
Patients
medicati
ymbols that w
Board # ‐ 7‐0
itle: Implem
ype: Evaluat
ion Category
Author: Mic
tmauri@buf
al Authors:
dduri
hilips
ghese
ilips
: Medication
ating a phar
n shown to d
volved in the
ne the impac
s: This study
health staff
on errors. In
ion with hom
cists to perfo
to be partic
cist. Data wil
nted medica
cy personnel
Initial phase
ion with nur
ere final visit
had an aver
on discrepan
2018ASProf
ere not spelled
010
entation of
tive Study
y: Ambulato
chael Mauri;
ffalo.edu
n errors have
rmacist in th
decrease the
e home healt
ct of pharma
was granted
f for patients
nitial phase o
me health nu
orm a medica
ularly high r
l be collecte
tion list and
.
e of data coll
rse home vis
ts in which th
age of 14 m
ncies noted.
SHPMidyfessional
d‐out per the g
pharmacy se
ory Care
Hunterdon
e the potent
e medicatio
e number of
th program
acy on medic
d expedited
s determine
of patient da
urses. Secon
ation reconc
isk of medic
ed prospectiv
what patien
lection inclu
sits. Four of t
he patient w
edications li
. The most c
yearClinlPoster
guidelines wer
ervices in a h
Medical Cen
tial to cause
n reconciliat
potentially d
at our institu
cation recon
IRB approva
d by nurse o
ata collectio
ndary phase
ciliation and
cation errors
vely regardin
nt is actually
ded 9 patien
these were
was discharg
sted and 6.1
ommon type
nicalMeAbstrac
re translated i
home health
nter;
significant h
tion process
dangerous e
ution. The o
nciliation in t
al. Pharmacy
or physician
n consists of
will include
update med
s will be eligi
ng medicatio
y taking and
nts seen by p
new admiss
ed from the
1 medical pr
e of discrepa
eetingcts
into unknown
h program
harm to pati
s during tran
errors. Curre
objective of
this setting.
y services w
to be at hig
f patients se
patients co
dication list.
ible for a ho
on discrepan
intervention
pharmacy se
ions, 2 were
e home healt
roblems. The
ancy was me
characters.
ents.
nsitions of ca
ently, pharm
this study is
ill be consul
h risk of
een in
ntacted by
. Patients
me visit by a
ncies betwee
ns performe
ervices in
e routine visi
th program.
ere were 23
edication
are
acy
s to
ted
a
en
ed by
its,
*Special sy
missing f
longer ta
included
and drug
Conclusio
medicati
clinical si
the wron
Continue
and reso
ymbols that w
from list (n=1
aking medica
clarifying th
g information
on: The maj
ons not note
ignificance o
ng dose or us
ed pharmaci
lving these m
2018ASProf
ere not spelled
12) followed
ation on list
he aforemen
n question r
ority of the
ed on docum
of these disc
sing wrong d
st involveme
medication e
SHPMidyfessional
d‐out per the g
d by wrong d
(n=2). There
ntioned discr
esponses (n
discrepancie
mented lists.
repancies is
directions ce
ent in the ho
errors.
yearClinlPoster
guidelines wer
directions (n
e were 35 ph
repancies in
=5).
es noted we
. These were
unclear, ho
ertainly have
ome health s
nicalMeAbstrac
re translated i
=5), wrong d
harmacy inte
addition to
re those ass
e typically ov
wever, the i
e the potent
setting may
eetingcts
into unknown
dose (n=4), a
erventions p
medication
sociated with
ver‐the‐coun
ncidences o
ial to cause
be beneficia
characters.
and patient
performed, w
counseling
h patients ta
nter drugs. T
of patients ta
harm.
al in identify
no
which
(n=7)
aking
The
aking
ying
*Special sy
Session‐B
Poster Ti
powder i
Poster Ty
Submissi
Primary A
Email: pm
Addition
Tanya Ilia
Kathy Za
Purpose:
inhaler, f
powder i
Health, a
cost‐savi
combina
current i
patients’
from one
Methods
12 years
inhaler w
prospect
diagnosis
therapy,
12 weeks
compara
savings.
Results:
patients
ymbols that w
Board # ‐ 7‐0
itle: Clinical
nhaler in as
ype: Evaluat
ion Category
Author: Pat
mccarthy255
al Authors:
adis
iken
: A generic in
fluticasone p
nhaler (MDP
a multi‐site a
ngs initiative
tion inhalers
nhaler to co
clinical resp
e of its comp
s: The Institu
of age or old
were include
tive chart rev
s of asthma.
increased d
s. Secondary
tive switch r
In total, 413
meeting inc
2018ASProf
ere not spelled
011
response to
thma patien
tive Study
y: Ambulato
rick McCarth
nhaled cortic
propionate/s
PI) is the firs
ambulatory c
e for patient
s. The initiat
mparable do
ponse to gen
petitors.
utional Revie
der who we
d in the stud
view. Patien
The primary
ose of ICS/LA
y endpoints
rates at sites
3 patient cha
lusion criter
SHPMidyfessional
d‐out per the g
o generic flut
nts managed
ory Care
hy; Lahey He
m
costeroid/lo
salmeterol, h
st generically
care organiz
ts with asthm
tive includes
oses of the g
neric fluticas
ew Board at
re switched
dy. Their ast
ts were excl
y endpoint w
ABA, oral co
included ext
s with and w
arts have bee
ria. 61.2% of
yearClinlPoster
guidelines wer
ticasone pro
d at an ambu
ealth;
ong‐acting be
has recently
y available IC
ation, the cl
ma currently
s switching c
generic inha
sone propion
MCPHS Univ
from a bran
hma contro
luded if they
was worsene
orticosteroid
tending the
without a clin
en reviewed
f patients we
nicalMeAbstrac
re translated i
opionate/sal
ulatory care
eta agonist (
y been appro
CS/LABA com
linical pharm
y controlled
clinically app
ler. Current
nate/salmet
versity has a
nd‐name ICS
l on the gen
y had a diagn
ed asthma c
d therapy, or
primary out
nical pharma
d for inclusio
ere female a
eetingcts
into unknown
meterol mu
practice sett
(ICS/LABA) c
oved. The m
mbination in
macy team h
using brand
plicable patie
ly, there is li
erol MDPI w
approved th
S/LABA inhal
eric inhaler
nosis of COP
ontrol requi
r hospitalizat
tcome to 24
acist, and an
on into the st
and the aver
characters.
ltidose, dry‐
ting
combination
ultidose, dry
nhaler. At At
as instituted
d‐name ICS/L
ents from th
ittle data on
when switche
is study. Pat
er to the ge
was assesse
PD with no
iring change
tion at or be
weeks,
nnual cost‐
tudy with 21
age age was
‐
n
y
trius
d a
LABA
eir
ed
tients
neric
ed via
e in
efore
19
s
*Special sy
49.9 year
switched
patients,
CI 12.0%
therapy d
the 186 p
total site
that were
Conclusio
generic f
weeks. S
healthca
and more
generic f
ymbols that w
rs. An additi
d back to the
35 had a ch
to 22.4%) w
due to worse
patients who
es at Atrius H
e made occu
on: Roughly
fluticasone p
ignificant co
re systems.
e cost‐saving
fluticasone p
2018ASProf
ere not spelled
onal 16 pati
eir previous i
hange in ther
within 12 we
ened asthm
o were not s
Health, 13 ha
urred at site
83% of pati
propionate/s
ost‐savings a
Clinical phar
gs. More dat
propionate/s
SHPMidyfessional
d‐out per the g
ents were e
inhaler for re
rapy due to
eks. Of 25 p
a control (32
switched bac
ave a clinical
s with a clin
ents who we
salmeterol M
re associate
rmacists wer
ta is needed
salmeterol.
yearClinlPoster
guidelines wer
xcluded from
easons othe
worsened a
atients follo
2.0%). Total
ck to their pr
l pharmacist
ical pharmac
ere switched
MDPI mainta
ed with maki
re associate
d to show the
nicalMeAbstrac
re translated i
m the prima
er than wors
sthma contr
owed for 36 w
projected y
revious inha
t on‐site. 171
cist (78.1%).
d from bran
ained approp
ing this switc
d with highe
e long‐term
eetingcts
into unknown
ary endpoint
ened asthm
rol (17.2% of
weeks, 8 ha
early saving
aler was $58
1 of the 219
.
d‐name ICS/
priate asthm
ch for both p
er rates of p
effects of sw
characters.
t as they wer
a control. O
f patients –
d a change i
gs for switchi
1,628. Of 32
total switch
/LABA inhale
ma control fo
patients and
atients switc
witching to
re
f 203
95%
n
ing
2
hes
ers to
or 12
d
ched
*Special sy
Session‐B
Poster Ti
Poster Ty
Submissi
Primary A
Email: ka
Addition
Amy Kno
Shelby G
Purpose:
maintain
5.7 millio
patients
on the na
can be ef
multidisc
improvem
Methods
including
were hel
role with
directed
pharmac
these pat
To suppo
pharmac
responsib
patient's
providing
Documen
updated
ymbols that w
Board # ‐ 7‐0
itle: Implem
ype: Descrip
ion Category
Author: Kay
ayla.m.mcint
al Authors:
oblock
audet
: Heart failur
n adequate b
on adults in t
will die with
ational econ
ffectively ma
ciplinary app
ments in clin
s: From Augu
g pharmacy s
d to establis
hin the clinic
medication
cy interventio
tients. In Jan
ort the pharm
cist responsib
bilities at the
chart, inter
g any additio
ntation of ph
clinic docum
2018ASProf
ere not spelled
012
entation of
ptive Report
y: Ambulato
yla McIntyre;
tyre@gmail.
re is a chron
blood circula
the United S
hin 5 years o
nomy with an
anaged thro
proach to ma
nical outcom
ust to Decem
staff, physici
sh the goals
included me
therapy, ass
ons we expe
nuary 2018,
macy compo
bilities and e
e outpatient
viewing the
onal educati
harmacist's i
ment as well
SHPMidyfessional
d‐out per the g
pharmacy se
ory Care
; Baptist Hos
.com
nic, progress
tion needed
States have h
f initial diag
n annualized
ugh medicat
anaging this
mes.
mber 2017, b
ians, nurse p
and workflo
edication re
sessing barri
ected to imp
the outpatie
onent of the
expectations
t heart failur
patients, m
on prior to t
intervention
as in the M
yearClinlPoster
guidelines wer
ervices in an
spital;
ive condition
d to sustain p
heart failure
nosis. Heart
d cost estima
tion therapi
patient pop
biweekly me
practitioners
ow of the ou
conciliation,
iers to care,
pact the hosp
ent heart fai
clinic, the in
s were amen
re clinic. The
aking recom
the patient l
ns and recom
edKeeper H
nicalMeAbstrac
re translated i
n outpatient
n in which th
physiologica
e and an esti
t failure plac
ated to be $
es and lifest
pulation has
eetings with
s, and other
tpatient hea
, recommen
and patient
pitalization a
ilure clinic st
npatient tran
nded to inclu
e expectatio
mmendations
eaving the a
mmendation
ub database
eetingcts
into unknown
heart failur
he heart is u
al function.
mated one h
ces a heavy f
30.7 billion.
tyle modifica
been shown
multidiscipl
healthcare
art failure cli
ndations for g
t education.
and readmis
tarted seein
nsitions of c
ude outpatie
ns included
s to the prov
appointment
ns were to be
e.
characters.
e clinic
unable to
Approximat
half of the
financial bur
This conditi
ations. A
n to provide
linary group
professiona
inic. Pharma
guideline‐
Through the
ssion rates fo
g patients.
are (TOC)
ent
reviewing th
vider, and
t.
e detailed on
tely
rden
ion
ls,
acy's
ese
or
he
n the
*Special sy
Results:
evaluate
A total of
intervent
medicati
The base
heart fail
was 14.5
estimate
heart fail
$146,310
The outp
week wit
services t
Conclusio
clinic wa
readmiss
apprecia
the phar
relations
the near
ymbols that w
Data was co
d.
f 52 interven
tions includi
ons.
eline heart fa
lure readmis
8% (14/96).
d to be $14,
lure readmis
0 with an ext
patient heart
th further ex
to the clinic.
on: Overall,
s shown to b
sion rates to
ted during t
macy service
hips. Billing
future.
2018ASProf
ere not spelled
ollected from
ntions accep
ng titration
ailure 30‐day
ssion rate fo
The mean p
,631 accordi
ssions during
trapolated a
t failure clini
xpansion of t
.
the implem
be effective,
below natio
he study pe
es added to
codes are b
SHPMidyfessional
d‐out per the g
m January 3,
pted by prov
of medicatio
y readmissio
or patients w
per‐patient c
ng to a rece
g the study p
annual cost a
ic has now e
the inpatien
entation of
, providing c
onal and org
riod. Provide
the heart fa
eing validate
yearClinlPoster
guidelines wer
2017 to Ma
viders were d
ons, initiatio
on rate for B
who were see
cost of a hea
ent publicatio
period, there
avoidance of
expanded fro
t transitions
pharmacy se
ontinuity of
ganizational
er feedback
ailure clinic w
ed with the
nicalMeAbstrac
re translated i
rch 30, 2017
documented
on of medica
aptist Healt
en in the clin
art failure re
on. Based on
e was an est
f $585,240.
om two days
s of care pro
ervices in an
f care and de
rates with su
validated th
with improve
hopes of bil
eetingcts
into unknown
7 with a tota
d with the m
ations and ho
h Care is 25.
nic during th
elated hospit
n an estimat
timated cost
s per week t
ogram to con
n outpatient
ecreased hos
ubstantial co
he important
ed provider‐
ling for phar
characters.
al of 96 patie
most common
old/stop
.69%. The 30
he study per
talization is
ted 10 avoid
t avoidance
o five days p
ntinue to pro
heart failure
spital
ost avoidanc
t contributio
‐pharmacy
rmacy servic
ents
n
0‐day
iod
ded
of
per
ovide
e
ce
ons
ces in
*Special sy
Session‐B
Poster Ti
Delphi co
Poster Ty
Submissi
Primary A
Email: gr
Addition
Charmain
Kathleen
Purpose:
patients
cardiovas
are also a
clinicians
operatio
safe use
techniqu
Methods
survey‐b
from acro
SGLT‐2 in
asked to
initial pre
included
bone min
infection
agreeme
in additio
rated the
prescribe
ymbols that w
Board # ‐ 7‐0
itle: Best pra
onsensus pro
ype: Evaluat
ion Category
Author: Lau
recheckle@v
al Authors:
ne Rocheste
n Pincus
: Sodium‐glu
with type 2
scular outco
associated w
s need to res
nalize the re
and monito
e.
s: The institu
ased study.
oss the Unit
nhibitors we
freely comm
escribing and
hyperkalem
neral density
s, and a bro
ent with the
on to modifi
e importance
ed SGLT‐2 in
2018ASProf
ere not spelled
013
actices for sa
ocess
tive Study
y: Ambulato
ren Pamulap
vcu.edu
er‐Eyeguokan
ucose co‐tran
diabetes me
omes in patie
with serious
spond to the
ecommenda
ring of SGLT
utional revie
A panel of h
ed States fa
re selected f
ment on mon
d for minimi
mia, acute kid
y, leg and fo
ad category
statements
ed statemen
e of the stat
hibitors. In r
SHPMidyfessional
d‐out per the g
afe use of SG
ory Care
pati; Virginia
n
nsporter 2 (S
ellitus (T2DM
ents with ath
adverse effe
e emerging s
tions. This st
T‐2 inhibitors
w board at t
healthcare pr
miliar with t
for a four‐ro
nitoring para
izing and ma
dney injury,
ot amputati
for other ad
formulated
nts from rou
ements in re
round 4, pan
yearClinlPoster
guidelines wer
GLT‐2 inhibit
a Commonw
SGLT‐2) inhi
M) in terms o
heroscleroti
ects. Given t
safety data,
tudy aimed
s in patients
the Universi
rofessionals
the care for
ound Delphi
ameters, act
anaging spec
diabetic ket
ons, hypote
dverse event
from round
und 2, procee
educing the
nelists select
nicalMeAbstrac
re translated i
tors develop
wealth Unive
bitors have
of A1c reduc
c cardiovasc
the increased
but little gui
to develop a
with T2DM
ty of Maryla
(nurses, ph
patients wit
process. In r
tions, or con
cific adverse
toacidosis, fr
ension, urina
ts. In round
1. Statemen
eded to rou
adverse eve
ted if the sta
eetingcts
into unknown
ped from an
ersity School
demonstrat
ction and red
cular disease
d use of SGL
idance exists
a list of best
through use
and, Baltimo
armacists, a
th T2DM and
round 1, pan
nsiderations
e events. The
ractures due
ary tract infe
2, panelists
nts with a st
nd 3, in whic
ent rate in p
atements sh
characters.
expert pane
of Pharmac
ted efficacy i
duction in
e. However,
LT‐2 inhibito
s on how to
practices fo
e of the Delp
ore approved
and physician
d the use of
nelists were
for appropr
e adverse ev
e to decrease
ections, genit
indicated th
rong consen
ch panelists
atients
ould be
el
cy;
in
, they
rs,
or the
phi
d this
ns)
riate
vents
ed
tal
heir
nsus,
*Special sy
considere
medicati
medicati
Results: A
practice
statemen
concepts
concept
concepts
patients
practice
safe med
pertained
infection
preventio
medicati
physical
Conclusio
can be ut
with T2D
ymbols that w
ed a best pr
on use, or if
on use.
A 15‐membe
participated
nts describin
s that were g
areas. Roun
s were deem
prescribed a
statements
dication use.
d to managi
s. There we
on or manag
on use prim
exam compo
on: A list of
tilized by clin
DM.
2018ASProf
ere not spelled
actice specif
f the stateme
er interprofe
d in the Delp
ng safe use o
grouped by t
d 3 included
med by the p
a SGLT‐2 inh
specific to S
Fifty‐four p
ng and/or p
re no best p
gement of le
arily focused
onents, and
best practic
nicians to gu
SHPMidyfessional
d‐out per the g
fic to SGLT‐2
ent should n
essional pan
hi consensu
of SGLT‐2 inh
the investiga
d 217 individ
anel to be cr
ibitor. In rou
GLT‐2 inhibi
percent of th
reventing hy
ractice state
eg and foot a
d on medica
patient edu
e statement
uide the safe
yearClinlPoster
guidelines wer
2 inhibitors,
not be consid
nel with an a
s process. In
hibitors. The
ators into 15
dual concept
ritical to or l
und 4, panel
itors and 25
e best pract
ypotension,
ements spec
amputations
ation historie
ucation.
ts was devel
e use and mo
nicalMeAbstrac
re translated i
a best pract
dered as a b
average of 17
n round 1, pa
ese statemen
50 questions
ts from roun
likely to redu
lists came to
statements
tice stateme
urinary trac
cific to SGLT‐
s. The genera
es, past med
oped using t
onitoring of
eetingcts
into unknown
tice for gene
best practice
7.9 years of
anelists subm
nts represen
s related to t
d 2, and 148
uce adverse
o a consensu
as general b
ents for SGLT
ct infections,
‐2 inhibitors
al best pract
dical history
the Delphi m
SGLT‐2 inhib
characters.
eral safe
for safe
diabetes‐re
mitted 440
nted 351 uni
the different
8 of these
event rates
us on 37 bes
best practice
T‐2 inhibitor
, and genital
s for the
tices for safe
consideratio
method, whi
bitors in pat
lated
que
t
s for
t
es for
s
l
e
ons,
ch
tients
*Special sy
Session‐B
Poster Ti
health ce
Poster Ty
Submissi
Primary A
Email: co
Addition
Jessica D
Don Klep
Purpose:
with alm
lowering
stagnant
have had
year, in a
equal to
Methods
records o
health ce
(August,
percent w
obtaining
indicate
weight ch
to nine p
square a
Results:
criteria.
on avera
ymbols that w
Board # ‐ 7‐0
itle: Prescrib
enter
ype: Evaluat
ion Category
Author: Cor
orey.paz@un
al Authors:
ownes
pser
: A primary c
ost half of th
in this popu
. This resea
d an A1c in th
an effort to i
nine percen
s: The institu
of adult patie
enter with ty
September,
within one y
g pertinent p
level of diab
hanges. Pre
percent) and
nd t‐tests.
Of the 327 p
Patients wit
ge (2.17) co
2018ASProf
ere not spelled
014
bing patterns
tive Study
y: Ambulato
rey Paz; Univ
nmc.edu
care, federal
he patients b
ulation the p
rch highlight
he past thre
dentify tren
nt or an A1c g
utional revie
ents (ages 1
ype 2 diabet
October 20
year of the re
patient infor
betes contro
escribing pat
uncontrolle
patient medi
th an A1c les
mpared to t
SHPMidyfessional
d‐out per the g
s of patients
ory Care
versity of Ne
lly qualified
being uninsu
percentage o
ts prescribin
ee months, w
ds that may
greater than
w board app
9‐75 years o
es who have
017) and who
eporting dat
rmation inclu
l, medicatio
terns for pat
ed (A1c great
ical records
ss than or eq
hose with a
yearClinlPoster
guidelines wer
s with type 2
ebraska Med
health cente
ured. Despit
of patients w
ng patterns f
who have als
y describe wh
n nine perce
proved this r
of age) seen
e had an A1c
o have previ
te were revie
uding demo
n regimen, i
tients who w
ter than nin
that were re
qual to nine
n A1c above
nicalMeAbstrac
re translated i
2 diabetes fr
dical Center;
er serves a d
te efforts de
who are unco
for patients
so been unco
hy a patient
nt.
retrospectiv
at the prima
c within a th
iously had an
ewed. Chart
graphic info
nteractions
were contro
e percent) w
eviewed, 30
percent use
e nine percen
eetingcts
into unknown
rom a federa
diverse patie
edicated to i
ontrolled ha
with type 2
ontrolled wi
reaches an
ve cohort stu
ary care, fed
hree‐month t
n A1c greate
t review con
ormation, lab
with provid
lled (A1c les
were compa
6 patients m
ed slightly fe
nt (2.32) but
characters.
ally qualified
ent populatio
mproving A1
s remained
diabetes wh
thin the pas
A1c less tha
udy. Medica
derally qualif
time period
er than nine
nsisted of
b values to
ers in clinic,
ss than or eq
red using ch
met the inclu
wer medicat
t the differe
d
on
1c
ho
st
an or
al
fied
and
qual
hi
usion
tions
nce
*Special sy
was not s
were sign
percent),
percent)
not diffe
percent v
Conclusio
uncontro
correlate
patients
medicati
to goal. A
success.
ymbols that w
statistically s
nificantly mo
, basal insuli
. Very few p
r significantl
versus six pe
on: In a fede
olled A1c in t
e with patien
struggling to
ons, these in
Additional r
2018ASProf
ere not spelled
significant (p
ore likely (p
in (60 percen
patients in th
ly between t
ercent, p equ
erally qualifi
the past yea
nt attainmen
o attain A1c
nterventions
esearch is ne
SHPMidyfessional
d‐out per the g
p equals 0.16
less than 0.0
nt versus 22
his sample w
those with a
uals 0.65).
ed health ce
r, medicatio
nt of goal A1
goal seem t
s alone do n
eeded to be
yearClinlPoster
guidelines wer
6). In partic
01) to be tak
2 percent) an
were prescrib
an A1c above
enter popula
on prescribin
1c (less than
to be approp
ot seem to b
etter underst
nicalMeAbstrac
re translated i
ular, patient
king metform
nd bolus insu
bed a GLP‐1
e nine perce
ation of type
ng patterns d
or equal to
priately pres
be adequate
tand factors
eetingcts
into unknown
ts with an un
min (82 perc
ulin (34 perc
agonist and
ent and those
e 2 diabetes
do not appe
nine percen
scribed addit
e for getting
leading to t
characters.
ncontrolled
cent versus 4
cent versus 1
d, as such, it
e below (eig
patients wit
ar to positiv
nt). While
tional diabet
some patie
treatment
A1c
44
12
did
ght
th an
vely
tes
nts
*Special sy
Session‐B
Poster Ti
centers
Poster Ty
Submissi
Primary A
Email: ro
Addition
Alexa Va
Victoria W
Junan Li
Ashley Ba
Purpose:
documen
project a
improve
United St
engaged
specifica
2016.
Methods
pharmac
invitation
Systems
multiple
years bei
models, p
reimburs
outcome
and futur
2018. Su
ymbols that w
Board # ‐ 7‐0
itle: Assessin
ype: Evaluat
ion Category
Author: Jen
al Authors:
lentino
Williams
allard
: The effectiv
nted, but ha
ims to serve
because of t
tates. The p
with FQHCs
lly assessing
s: This IRB ex
cists practicin
n sent to the
Pharmacists
choice, fill‐i
ing studied,
pharmacist a
sement mod
es were track
re plans for
mmary stati
2018ASProf
ere not spelled
015
ng the lands
tive Study
y: Ambulato
nifer Rodis;
edu
veness of ph
s yet to be e
e as evidence
the leadersh
purpose of th
s to provide
g clinical pha
xempt, cross
ng in FQHCs
e Midwest C
s’ Connect p
n, and open
types of clin
access to the
dels for phar
ked for phar
pharmacy se
stics were re
SHPMidyfessional
d‐out per the g
cape of clini
ory Care
The Ohio Sta
harmacist int
evaluated in
e that the AS
hip and clinic
his project is
care for und
armacy servi
s‐sectional s
to participa
linicians Net
latform. Th
‐ended ques
nical pharma
e electronic
macist servi
rmacist servi
ervices. The
eported by s
yearClinlPoster
guidelines wer
cal pharmac
ate Universi
terventions
Federally Q
SHP Founda
cal skills of p
s to determi
derserved pa
ces offered t
tudy recruit
te in an onli
twork and th
e voluntary,
stions on clin
acy services
health reco
ces, use of c
ces, success
survey was
study group
nicalMeAbstrac
re translated i
cy services in
ity College o
on patient c
Qualified Hea
tion’s vision
pharmacists”
ne how pha
atient popula
to patients o
ted represen
ine survey (Q
hrough the A
, 32‐item sur
nical pharma
(CPS) offere
rd, funding f
collaborative
ses and chall
open from O
for continuo
eetingcts
into unknown
n federally q
of Pharmacy;
care outcom
alth Centers
n that “patie
” is a reality
rmacists are
ations acros
of FQHCs be
ntatives from
QualtricsTM
American So
rvey gathere
acist covera
ed, medicatio
for pharmac
e practice ag
lenges in sta
October 201
ous data as
characters.
qualified hea
;
mes is well
(FQHCs). Th
nt outcome
for FQHCs in
e currently
ss the countr
etween 2013
m FQHCs and
) via email
ociety of Hea
ed data thro
ge over the
on access
cist positions
greements, i
arting service
17 to Februa
means and
alth
his
s
n the
ry,
3 and
d
alth‐
ugh
four
s,
f
es,
ary
*Special sy
standard
Categoric
Results:
(46/61) i
(33/72) r
year. Com
hyperten
medicati
CPS were
medicati
percenta
according
41.7%. O
site, 10 r
and 10 d
and cash
44.4% of
indicated
Conclusio
patient a
as a refe
managem
developm
intervent
Data Syst
assess th
ymbols that w
d deviations
cal data was
Seventy two
ndicated CP
reported tha
mmonly repo
nsion (65.2%
on reviews (
e: funding (3
on access, 6
age of sites in
g to whethe
Of the 46 res
eported fun
eclined to re
/self‐pay. 7
f respondent
d interest in
on: This stud
access to clin
rence for he
ment provide
ment of prac
tions in FQH
tem (UDS) o
he impact of
2018ASProf
ere not spelled
if normally d
s reported by
o participant
S are curren
at they are a
orted CPS w
%), anticoagu
(69.6%). Cha
30), personn
61.1% of resp
ndicating ph
er they were
spondents th
ding by a co
espond. The
76% of partic
ts (32/72) no
future resea
dy demonstr
nical pharma
ealth centers
ed by pharm
ctice‐based r
Cs. Anothe
outcomes be
pharmacists
SHPMidyfessional
d‐out per the g
distributed o
y study grou
ts from 21 st
ntly provided
nticipating t
were chronic
ulation (56.5%
allenges tha
el/staffing (2
pondents (44
harmacists h
on‐site, disp
hat offer CPS
ollege of pha
e most comm
cipants (26/3
oted use of c
arch collabo
rates the cur
acy services
s looking to e
macists. Resu
research net
r future dire
tween FQHC
s on these m
yearClinlPoster
guidelines wer
or as median
up as counts
tates respon
d for their pa
the developm
disease man
%), hyperlip
t were ident
27), and lack
4/72) report
ave electron
pensing, or p
S, 17 indicat
armacy, 6 rep
mon reimbu
34) reported
collaborative
rations.
rrent engage
in communit
expand their
ults also pro
tworks that e
ection of this
Cs that offer
measures.
nicalMeAbstrac
re translated i
ns and inter‐
and frequen
nded to the s
atients, and
ment of add
nagement fo
pidemia (56.5
tified with re
k of resource
ted 340b ph
nic health re
providing CP
ed a pharma
ported a pos
rsement mo
d tracking ou
e practice ag
ement of ph
ty health ce
r service‐off
ovide the fou
examine the
s study is the
r CPS to thos
eetingcts
into unknown
‐quartile ran
ncies (%).
survey. 75%
45.8% of res
itional CPS w
or diabetes (
5%) and com
egard to imp
es (26). In te
armacy cont
ecord access
PS and range
acist positio
sition co‐fun
odels were 3
utcomes for
greements.
harmacists in
nters. Resu
ferings to inc
undation for
e impact of p
e compariso
se FQHCs tha
characters.
ges otherwi
% of respond
spondents
within the ne
(71.7%),
mprehensive
plementing n
erms of
tracts. The
varied
ed from 2.8%
n funded by
nded by both
340b revenue
CPS services
23 responde
n FQHCs and
lts could ser
clude medica
r the
pharmacist
n of Uniform
at do not to
se.
ents
ext
e
new
% to
y the
h,
e
s.
ents
d
rve
ation
m
*Special sy
Session‐B
Poster Ti
classes
Poster Ty
Submissi
Primary A
Email: ns
Addition
Jamie Hu
Lauren D
Roger Pr
Clyde Sch
Purpose:
pharmac
insight in
to captur
system o
increase
support i
practice.
Methods
a diabete
class focu
Nutrition
Every cla
speak on
fitness co
to the to
and/or fu
slippers,
blood glu
ymbols that w
Board # ‐ 7‐0
itle: Improvi
ype: Descrip
ion Category
Author: Nat
scheinb@su
al Authors:
uff
Donohue
itchard
hechter
: Pharmacist
cy diabetes v
n diabetes se
re and educa
of support. G
self‐empow
in improving
s: A pharmac
es education
used on diffe
n, exercise an
ss included
n a related to
oach. At the
pics being co
unded by a r
toothbrushe
ucose meter
2018ASProf
ere not spelled
016
ng diabetes
ptive Report
y: Ambulato
taliya Schein
.edu
ts play a cruc
visits at a pri
elf‐managem
ate more pa
Group diabet
werment. Thi
g diabetes se
cy team spe
n series cons
erent aspect
nd sleep; Tre
a “Doc‐Talk”
opic, and a 3
end of ever
overed in th
research gra
es, diabetes
rs, plate‐met
SHPMidyfessional
d‐out per the g
self‐manage
ory Care
berg; Shena
cial role in d
mary care c
ment skills. G
tients simul
tes classes im
s service wa
elf‐managem
cializing in d
sisting of 5, 2
ts of diabete
eatment; Co
” where a he
30‐minute ex
ry class, patie
e respective
nt from She
supply orga
thod plates,
yearClinlPoster
guidelines wer
ement via p
andoah Univ
iabetes edu
linic consiste
Group diabet
taneously an
mprove glyce
as created to
ment skills fo
diabetes edu
2‐hour classe
es self‐mana
omplications
ealthcare pro
xercise sessi
ents were pr
e classes. Giv
nandoah Un
anizers, pedo
and lunch b
nicalMeAbstrac
re translated i
harmacist ru
versity;
cation and m
ently identif
tes educatio
nd provide t
emic contro
o provide an
or patients b
ucation in a p
es, meeting
agement: Int
s; and Health
ovider from
on led by a p
rovided with
veaways we
niversity. Ite
ometers, exe
boxes. Patien
eetingcts
into unknown
un diabetes
managemen
fied patients
on classes all
them with an
l, patient att
additional a
belonging to
primary care
every other
troduction to
h maintenan
the practice
professional
h free giveaw
re donated
ms included
ercise resista
nts were rec
characters.
education g
nt. Individual
s with poor
ow practitio
n additional
titudes, and
avenue of
a primary ca
e clinic desig
r week. Each
o diabetes;
nce for diabe
e was invited
l health and
ways that re
by vendors
d pillboxes,
ance bands,
ruited via
group
l
oners
are
gned
h
etes.
d to
elated
*Special sy
provider
diagnose
than eigh
Results: T
of 5 tota
past the
and one
one othe
patients
treatmen
As part o
lower the
extremel
responde
format a
apprecia
Conclusio
providing
provides
supportiv
glucose l
develop
who com
setting.
ymbols that w
and pharma
ed or had chr
ht percent w
Two pharma
l classes. A t
first class. O
patient with
er patient mi
were asked
nt of hypogly
of the refresh
e glycemic in
ly positive. T
ed to the “D
nd indicated
ted receivin
on: A pharm
g diabetes se
a comprehe
ve environm
evels in a su
and implem
mplete this p
2018ASProf
ere not spelled
acy diabetes
ronic poorly
were contact
acy diabetes
total of fiftee
One patient w
hdrew due to
issed two cla
refresher qu
ycemia and/
her question
ndex of vario
They appreci
oc‐Talk” and
d that they w
g the inform
macist led dia
elf‐managem
ensive appro
ment for aski
ustainable w
ent an addit
rogram and
SHPMidyfessional
d‐out per the g
s clinic referr
controlled d
ed and invit
s education c
en patients e
withdrew fro
o cost. One p
asses due to
uestions rela
/or glycemic
ns, patients w
ous meals. O
iated the ph
d exercise co
would have l
mation and s
abetes educa
ment skills to
oach to teac
ng question
ay. As a res
tional suppo
would be in
yearClinlPoster
guidelines wer
rals. Additio
diabetes wit
ed to enroll
classes were
enrolled in t
om the prog
patient miss
o lack of tran
ating to prev
goals and w
were also ab
Overall, patie
armacist‐led
omponents o
iked for the
upport for im
ation group
o patients w
hing self‐ma
s and explor
ult of patien
ort group cla
nterested in
nicalMeAbstrac
re translated i
nally, patien
th a hemoglo
.
e run every o
he program
gram due to
sed one class
nsportation.
viously taugh
were able to
ble to identif
ent percepti
d format of t
of the classe
program to
mproving th
class progra
with poor dia
anagement s
ring ways to
nt feedback,
ss that will m
continuing t
eetingcts
into unknown
nts who wer
obin A1c lev
other week,
; two patien
lack of perce
s session du
Throughout
ht skill‐sets s
correctly re
fy multiple s
ons of the p
the sessions
es. Patients l
o last longer
eir diabetes
am is an exce
betes insigh
skills and cre
improve pa
the pharma
meet quarte
to receive su
characters.
e newly
vel of greate
each consis
nts did not at
eived benefi
e to travel, a
t the program
such as
call the answ
strategies to
program wer
s and positiv
iked the gro
because the
s manageme
ellent mean
ht. This progr
eates a
tients’ blood
acy team wil
erly for patie
upport in a g
r
ting
ttend
it,
and
m,
wers.
re
ely
oup
ey
ent.
s to
ram
d
l
ents
group
*Special sy
Session‐B
Poster Ti
internati
Poster Ty
Submissi
Primary A
Email: ss
Addition
Ashley W
Purpose:
revealed
Non‐adh
therapeu
employe
were not
subthera
determin
therapeu
Methods
of patien
Patients
complian
The prim
Results: A
in the an
anticoag
patient g
compare
demogra
complian
ymbols that w
Board # ‐ 7‐0
itle: Associat
onal normal
ype: Evaluat
ion Category
Author: Step
eyse@kaleid
al Authors:
Woodruff
: Previous in
that patient
erence with
utic INR resu
d: increased
t seen in the
apeutic INRs
ne if non‐adh
utic INR valu
s: As part of
nts receiving
were groupe
nt (<4 missed
mary outcom
A total of 90
alysis. Forty
ulation clinic
groups. Ther
ed to 194 (40
aphics were
nt group wer
2018ASProf
ere not spelled
017
tion betwee
lized ratio (IN
tive Study
y: Ambulato
phanie Seyse
dahealth.org
ternal asses
ts receiving
warfarin th
lts. In an at
d pillbox usa
erapeutic INR
needed to b
herence to a
es.
an institutio
warfarin ma
ed in accord
d appointme
e was the to
0 patients we
y‐five were c
c visits. Ther
re were 309
0 percent) in
similar betw
re older with
SHPMidyfessional
d‐out per the g
en anticoagu
NR) result
ory Care
e; Buffalo Ge
g
ssments of a
warfarin had
erapy was fo
tempt to im
age and coun
R results. It
be investigat
anticoagulat
on supported
anaged by th
dance with th
ents/year) o
otal number
ere manage
categorized
re were a tot
(56 percent
n the non‐co
ween groups
h a mean [St
yearClinlPoster
guidelines wer
lation clinic
eneral Medi
pharmacist
d INRs that w
ound to be t
prove thera
nseling time
was determ
ted. The cur
ion clinic ap
d, continuou
he anticoagu
heir attenda
r non‐compl
of therapeu
d by the ant
as complian
tal of 1031 I
t) therapeut
mpliant grou
with the exc
tandard Dev
nicalMeAbstrac
re translated i
visit compli
ical Center;
t‐run anticoa
were therap
the most com
apy adherenc
. Despite th
mined that ot
rrent assessm
pointments
us quality as
ulation clinic
ance at antic
liant (>= 4 m
utic INRs.
ticoagulation
nt and 45 we
NR results fr
ic INR result
up, p less th
ception of a
viation(SD)] a
eetingcts
into unknown
ance and th
agulation clin
peutic 57‐63%
mmon reaso
ce several m
hese changes
ther modifia
ment was un
would corre
surance pro
c in 2017 wa
coagulation c
missed appoi
n clinic in 20
ere non‐com
rom 2017 ac
ts in the com
an 0.0001. B
ge. Patients
age in years
characters.
erapeutic
nic have
% of the tim
on for non‐
modalities we
s, improvem
ble reasons
ndertaken to
elate with no
ogram, a revi
as conducted
clinic visits;
intments/ye
017 and inclu
pliant with
cross both
mpliant group
Baseline
s in the
of 68 (14)
me.
ere
ments
for
o
on‐
iew
d.
ear).
uded
p
*Special sy
compare
of warfar
equals 0.
Conclusio
to other
clinic atte
ymbols that w
ed to 56 (11)
rin therapy b
.9538.
on: Non‐adh
aspects of c
endance.
2018ASProf
ere not spelled
, p less than
between com
herence to c
are. Additio
SHPMidyfessional
d‐out per the g
0.0001, how
mpliant and
linic appoint
nal interven
yearClinlPoster
guidelines wer
wever there
non‐compli
tments may
ntions may b
nicalMeAbstrac
re translated i
was no diffe
ant patients
y reveal a lar
be required t
eetingcts
into unknown
erence in m
s, 7.5 (5.3) ve
ger problem
to improve a
characters.
ean (SD) len
ersus 7.5 (5.
m with adher
anticoagulat
ngth
.6), p
rence
ion
*Special sy
Session‐B
Poster Ti
to premix
Poster Ty
Submissi
Primary A
Email: m
Addition
Sylvia Ba
Rachel W
Barbara F
Jillian Ho
Purpose:
appointm
clean roo
To shift s
infusion
were pre
decreasin
Methods
and analy
that wor
day of th
starting i
schedule
days afte
before th
day one o
orders ut
orders be
pharmac
ymbols that w
Board # ‐ 7‐0
itle: Reducin
x continuing
ype: Descrip
ion Category
Author: Ma
ark_sudol@
al Authors:
rtel
Wolfberg
Fine
offman
: There is a c
ment and to
om operates
some drug p
only appoint
epared earlie
ng overall m
s: A Premix W
ytics and pro
k off of daily
e patient inf
n January 20
ed infusion o
er the first in
he patient’s
of that cycle
tilizing a con
efore premix
cist also indic
2018ASProf
ere not spelled
018
ng infusion w
g oncology m
ptive Report
y: Ambulato
rk Sudol; Da
@dfci.harvard
considerable
when their
s at above th
reparations
tments was
er in the day
medication tu
Working Gro
ocess improv
y infusion en
fusion appo
018 looking
only appointm
nitial treatme
infusion app
e. Pharmacis
ntinuing orde
xing and prio
cated on the
SHPMidyfessional
d‐out per the g
wait time for
medications.
ory Care
na Farber Ca
d.edu
e amount of
medications
he maximum
to off‐peak
conducted a
y and prior to
urnaround ti
oup was form
vement lead
ncounters on
intment. On
at preparing
ments. Cont
ent day. The
pointment si
sts along wit
er log sheet.
or to patient
e patient lab
yearClinlPoster
guidelines wer
r patients wi
ancer Institu
delay betwe
s are availab
m capacity re
hours a pre
at Dana‐Farb
o a patient’s
me.
med which c
ds. The imple
nly allows m
ne of the six
g specific co
tinuing order
ese medicati
ince they on
h infusion n
. Pharmacist
ts arriving fo
el their infus
nicalMeAbstrac
re translated i
ith infusion o
ute;
een patients
ble. During p
esulting in ba
mix pilot inv
ber Cancer I
s infusion ap
consisted of
ementation
edications t
infusion floo
ntinuing ord
rs include m
ons can be p
nly depend o
urses identif
ts validated t
or their infus
sion appoint
eetingcts
into unknown
only appoint
s arriving to
peak hours o
acklog in dru
volving patie
nstitute (DF
ppointment w
pharmacy le
of a new co
o be dispens
ors participa
der medicati
medications f
prepared ah
on clinical inf
fied patients
the list and v
sion appoint
tment time
characters.
tments: a pi
infusion for
of infusion, t
ug preparatio
ents with
CI). Medicat
with the goa
eads, nurse l
omputer syst
sed on the s
ated in the p
ons ahead o
for subseque
head of time
formation fr
s on continu
verified the
tment. The
so they can
lot
their
he
on.
tions
al of
leads
tem
same
ilot
of
ent
rom
uing
be
*Special sy
prepared
extracted
prepared
Decembe
Results: T
baseline
baseline,
(Decemb
63% (Ma
prepared
baseline,
(Decemb
(March),
orders to
patient’s
administ
checks.
Conclusio
earlier in
infusion
medicati
medicati
patients
treatmen
ymbols that w
d in order an
d from the p
d before the
er 2017) and
The percent
months of S
, the percent
ber). During t
rch), and 60
d before infu
, the percent
ber). During
and 69% (A
o be prepare
infusion ap
ered to the
on: The pilot
n the day wit
appointmen
ons for sam
on turnarou
overall expe
nt.
2018ASProf
ere not spelled
nd prior to th
patient’s elec
infusion app
d implement
tage of mont
September‐D
tages were 1
the pilot mo
0% (April). In
usion appoin
tages were 3
pilot months
pril). Compa
ed earlier in t
pointment t
patient once
t was succes
th a higher p
nt time. Ther
e day appoin
und time. By
erience impr
SHPMidyfessional
d‐out per the g
he patient’s
ctronic healt
pointment t
tation of the
thly continu
December 20
18% (Septem
onths, the pe
n addition, th
ntment time
38% (Septem
s, the percen
ared to base
the day and
time. As a re
e the nurse c
ssful in shifti
percentage o
re was an inc
ntments dur
decreasing
roved during
yearClinlPoster
guidelines wer
infusion app
th record. Th
ime were co
e premix pilo
ing orders p
017 to pilot
mber), 46% (
ercentages w
he percentag
was increas
mber), 54% (
ntages were
line, the pre
a higher pe
sult, the me
completed t
ing continuin
of medicatio
crease in eff
ring peak ho
the overall m
g their visit t
nicalMeAbstrac
re translated i
pointment. C
he percentag
ompared bet
ot (January‐A
prepared bef
months of J
(October), 2
were 44% (Ja
ge of continu
sed from bas
(October), 3
e 67% (Janua
emix pilot sh
rcentage of
edications w
their patient
ng medicatio
ns ready bef
ficiency in th
ours thereby
medication t
o the infusio
eetingcts
into unknown
Continuing o
ges of contin
tween basel
April 2018).
fore 8am inc
anuary‐Apri
7% (Novemb
anuary), 77%
uing orders
seline to pilo
7% (Novemb
ary), 83% (Fe
hifted more c
orders prep
ere readily a
t assessment
on order pre
fore the pat
he cleanroom
y, decreasing
turnaround
on clinic on d
characters.
order data w
nuing orders
line (Septem
creased from
l 2018. At
ber), and 30
% (February)
that were
ot months. A
ber), 40%
ebruary), 65
continuing
pared before
available to
ts and clinica
eparation to
tient’s sched
m to prepare
g the overall
time, the
day of
were
s
mber‐
m
0%
),
At
%
e the
be
al
o
duled
e
*Special sy
Session‐B
Poster Ti
(CRAVES
Poster Ty
Submissi
Primary A
Email: ivy
Addition
Karen Lin
Thao Ngu
Purpose:
Beach He
the diffe
help with
two chan
also com
examined
continue
Methods
study pe
for the g
Referred
between
(TCI) and
were no
baseline
demogra
tobacco‐
number o
nicotine
hospitaliz
ymbols that w
Board # ‐ 7‐0
itle: Counse
)
ype: Evaluat
ion Category
Author: Ivy
y.tonnu‐mih
al Authors:
ng
uyen
: The use of
ealthcare Sy
rent tobacco
h improving
nges 1/in the
pared the q
d hospitaliza
ed using toba
s: This is an I
riod was De
roup clinics.
patients to
2016 – 201
d Patient Alig
intervention
characterist
aphic charact
use characte
of previous q
replacemen
zation and m
2018ASProf
ere not spelled
019
ling referrals
tive Study
y: Ambulato
Tonnu‐Miha
tobacco am
stem, pharm
o cessation c
quit rates. W
e clinic struc
uit rates bet
ations and m
acco.
Institutional
cember 1, 2
Index date
group tobac
7 (Group 2);
gned Care Te
n(s) made by
tics, or no sh
teristics (age
eristics (num
quit attempt
t therapy, b
mortality. Ab
SHPMidyfessional
d‐out per the g
s and abstin
ory Care
ara; VA Long
v
ong Veteran
macists are t
clinic setting
We aimed to
ture and 2/
tween the d
mortality in V
Review Boa
013 to May
defined as t
cco cessatio
; and the ind
eam (PACT) w
y the tobacc
how to clinic
e, gender, ra
mber of cigar
ts, reason fo
upropion, va
bstinence (or
yearClinlPoster
guidelines wer
ence for vet
g Beach Heal
ns is one of t
obacco cess
gs. Evaluatio
o assess the q
different ps
ifferent indi
Veterans wh
ard approved
31, 2014 an
he date the
n programs
dividual clini
were include
o cessation
appointmen
ace, body ma
rettes per da
or relapse), p
arenicline), a
r quit) was id
nicalMeAbstrac
re translated i
terans enrol
lthcare Syste
the hardest
sation provid
ns of these c
quit rates in
sychologists
vidual‐patie
o achieved a
d, retrospec
nd Decembe
pharmacist
between 20
cs: tobacco
ed. Patients
clinic pharm
nt. Collected
ass index, co
ay, number o
pharmacoth
and 6‐month
dentified by
eetingcts
into unknown
led in smoki
em;
habits to bre
ders who ma
clinics provid
n the group c
supporting t
ent clinics. La
abstinence v
ctive chart re
r 1, 2016 to
first counse
013 – 2014 (G
cessation in
s were exclu
macist provid
d data includ
omorbidities
of years of t
erapies (diff
h post index
y electronic m
characters.
ng cessation
eak. At VA Lo
anage patien
de insights t
clinics follow
the clinic. W
astly, we
versus those
eview study.
May 31, 201
eled the pati
Group 1) an
dividual clin
uded if there
ders, missing
ded: baseline
s), baseline
tobacco use,
ferent forms
x date quit ra
medical reco
n
ong
nts in
that
wing
We
e who
The
17
ent.
d
nic
e
g of
e
,
s of
ates,
ord
*Special sy
notes exp
designati
utilized w
Results:
compose
respectiv
the comp
mental h
no statist
12.77 for
therapy w
replacem
compare
the secon
tobacco a
Conclusio
between
psycholo
The grou
compare
compare
who did
ymbols that w
plicitly statin
ion was cons
when approp
213 out of 3
ed the four c
vely). Baselin
parative gro
health diagno
tically signifi
r Group 1 vs
was predom
ment therapy
ed to TCI. For
ndary outco
at 6 months
on: Data sug
the compar
ogy provider.
up clinic coho
ed to the ind
ed to the PAC
not quit at 6
2018ASProf
ere not spelled
ng that patie
sidered did n
priate.
353 screened
cohorts (39, 4
ne demograp
ups except f
osis in Group
icant differe
. Group 2; a
minantly pres
y was prescr
r all cohorts,
me, the tren
than those
ggest that 6
rative cohor
. There was
orts seemed
ividual clinic
CT providers
6 months tha
SHPMidyfessional
d‐out per the g
ent had been
not quit. De
d patients m
47, 64 and 6
phic charact
for there we
p 2 compare
nces in quit
nd 9.38 vs. 9
scribed in th
ribed more in
, the main m
nd for hospit
that did not
months quit
ts despite th
s also no diff
d to use more
c cohorts, an
s. Finally, th
an those wh
yearClinlPoster
guidelines wer
n abstinent a
scriptive sta
met the inclus
63 patients f
eristics reve
ere statistica
ed to Group
rates betwe
9.52 for TCI v
e group clin
n the individ
motive for qu
talizations w
t quit.
t rate was no
he change in
ference in q
e dual nicoti
nd the TCI pr
e trend for h
o did quit.
nicalMeAbstrac
re translated i
at 6‐month p
atistics, chi‐s
sion and exc
for Group 1,
ealed no stat
lly significan
1 (53.19 vs.
een the relev
vs. PACT). D
ics while mo
dual clinics a
uitting tobac
was lower in
ot statistical
n clinic struct
uit rate betw
ine replacem
roviders use
hospitalizati
eetingcts
into unknown
post index d
quared, and
clusion criter
Group 2, TC
tistical differ
ntly more pa
2.56 percen
vant compa
Dual nicotine
onotherapy
and more so
cco was heal
patients wh
lly significan
tures and ch
ween the ind
ment therap
d more dua
ons was hig
characters.
date. Missing
d t tests were
ria and
CI and PACT,
rences betw
atients with
nt). There we
risons (17.95
e replaceme
nicotine
in PACT clin
lth concerns
ho had quit
tly different
hange in
dividual clini
y formulatio
l therapy
her in patien
g this
e
ween
ere
5 vs.
nt
nic
s. For
t
ics.
ons
nts
*Special sy
Session‐B
Poster Ti
cessation
Poster Ty
Submissi
Primary A
Email: ka
Addition
Erica Ma
Jocelyn G
Heidi Mc
Purpose:
also on t
confiden
pharmac
impleme
tobacco c
Methods
“statewid
knowledg
survey w
Preventio
and Inter
A tobacc
additiona
best prac
of a toba
pharmac
electroni
toolkit re
ymbols that w
Board # ‐ 7‐0
itle: Knowle
n services
ype: Descrip
ion Category
Author: Kar
al Authors:
rtin
Good
cClelland
: The negativ
he healthcar
ce in provid
cists to assist
ntation tool
cessation se
s: PSW elect
de survey”) t
ge in provid
were develop
on and Cont
rvention; Pfi
o cessation
al expertise
ctices and op
acco cessatio
cist confiden
ically to 19 W
eview to asse
2018ASProf
ere not spelled
020
dge, confide
ptive Report
y: Ambulato
i Trapskin; P
rg
ve effects of
re system. T
ing tobacco‐
t in the deve
kit to increa
ervices.
ronically dis
to pharmaci
ing tobacco
ped and revie
trol Program
zer; and PSW
advisory gro
in providing
pportunities
on service im
ce and know
Wisconsin ph
ess for impro
SHPMidyfessional
d‐out per the g
ence, and mo
ory Care
Pharmacy So
f tobacco use
To understan
‐cessation se
elopment of
ase pharmac
stributed a st
ist members
cessation se
ewed by the
m; University
W.
oup was also
g services pra
s was solicite
mplementati
wledge in ser
harmacists fo
oved confide
yearClinlPoster
guidelines wer
otivations of
ociety of Wis
e are multifo
nd pharmaci
ervices, thre
a comprehe
cists’ knowle
tatewide sur
s of PSW to a
ervices (“ser
e Wisconsin
of Wisconsi
o formed to e
acticing in va
ed from the
on toolkit. T
rvice provisi
or review. A
ence and kn
nicalMeAbstrac
re translated i
f pharmacist
consin;
old on patie
sts’ percept
ee surveys w
ensive tobac
edge and con
rvey (herein
assess pharm
rvices”). The
Department
in‐Madison C
engage Wisc
arious settin
advisory gro
The intent of
on. Once dr
A survey was
nowledge in
eetingcts
into unknown
ts in providi
nts’ health a
ions, knowle
were adminis
cco cessation
nfidence in p
nafter referre
macists’ con
questions o
t of Health S
Center for T
consin pharm
ngs. Informat
oup to assist
f the toolkit
rafted, the to
s collected p
service prov
characters.
ng tobacco
and lives, bu
edge, and
stered to
n
providing
ed to as
fidence and
of the statew
Services, Tob
Tobacco Rese
macists with
tion regardi
t in the draft
is to increas
oolkit was se
rior to and p
vision after
ut
wide
bacco
earch
h
ng
ting
se
ent
post
*Special sy
toolkit re
question
Results:
believe t
is their p
or neutra
with pati
Most pha
agreeme
believed
addition
said they
The resp
respectiv
provision
knowledg
percent t
62 perce
Conclusio
to their p
are motiv
financial
tobacco c
order. Th
about to
educatin
tobacco c
ymbols that w
eview (herei
s were deve
135 respons
obacco cess
rofessional r
al. Patients a
ients and fee
armacists wo
ent and more
little or no r
of reimburs
y would prov
onse rate fo
vely. After to
n. Pharmacis
ge of metho
to 59 percen
nt to 71 per
on: Pharmac
patients and
vated and en
sustainabilit
cessation se
he implemen
bacco cessat
g on tobacco
cessation se
2018ASProf
ere not spelled
nafter referr
eloped and r
ses were rec
ation couns
responsibilit
asking for he
eling that pa
ould provide
e would thro
reimbursem
ement woul
vide services
or the pre‐su
oolkit review
st comfort le
ods for financ
nt; and comf
cent.
cists believe
are interest
ngaged. To s
ty models m
ervices throu
ntation of a t
tion service
o cessation,
ervices, and m
SHPMidyfessional
d‐out per the g
red at as “pr
eviewed by
ceived throug
eling is an ap
ty to provide
elp is the larg
atients are n
e services if t
ough a statew
ent is availa
ld increase t
s if Medicaid
rvey and po
w, pharmacis
evels with co
cial sustaina
fort with mo
it is their re
ted in invest
support thes
must be impr
ugh a collabo
toolkit with
provision de
financial su
motivationa
yearClinlPoster
guidelines wer
re‐survey” a
Pfizer and P
gh the state
ppropriate s
e, and 94 pe
gest motivat
ot engaged
they could a
wide standin
ble for servi
their motivat
d reimbursem
ost‐survey w
sts improved
ounseling im
ability of serv
otivational in
esponsibility
ting their tim
se profession
roved. Pharm
orative pract
supplement
emonstrated
stainability m
l interviewin
nicalMeAbstrac
re translated i
nd “post‐sur
PSW.
ewide survey
service to pr
rcent were i
tor to provid
in their quit
attain a colla
ng order. Six
ice provision
tion to prov
ment was av
as high at 63
d confidence
proved from
vice provisio
nterviewing t
to provide t
me and expe
nal services,
macists show
tice agreeme
tal, non‐med
d improved
models for p
ng technique
eetingcts
into unknown
rvey”, respe
y; 88 percent
rovide, 89 pe
interested, v
de services.
t attempt we
aborative pra
xty percent o
n, 68 percen
ide services,
vailable.
3 percent an
e and knowle
m 80 percent
on improved
techniques i
tobacco cess
rtise to help
, scope of pr
w interest in
ent or a stat
dication rela
pharmacist
pharmacist‐p
es.
characters.
ectively). The
t of pharma
ercent believ
very interest
Limited time
ere barriers.
actice
of pharmaci
t said the
, and 80 per
nd 47 percen
edge in serv
t to 88 perce
d from 35
improved fro
sation servic
p patients wh
ractice and
providing
tewide stand
ted informa
confidence i
provided
e
cists
ve it
ted,
e
sts
rcent
nt,
ice
ent;
om
ces
ho
ding
ation
in
*Special sy
Session‐B
Poster Ti
hepatitis
Poster Ty
Submissi
Primary A
Email: lis
Addition
Babafunl
Sarah Yo
Purpose:
hepatitis
and Infec
in these
The hepa
agreeme
patients
history to
Methods
reviewed
hepatitis
documen
pharmac
hepatitis
series or
Results:
hepatitis
and 15 p
immune
complete
ymbols that w
Board # ‐ 7‐0
itle: Pharma
C
ype: Descrip
ion Category
Author: Lisa
sa.m.woolard
al Authors:
lola Davis
o
: Hepatitis B
C is recomm
ctious Diseas
patients.
atology clinic
ent and mana
on hepatitis
o identify ca
s: Following
d patients to
B core antib
nted hepatit
cist for susce
B surface a
did not sero
Between No
C in our clin
atients initia
pre‐referral
ed vaccinatio
2018ASProf
ere not spelled
021
acist driven h
ptive Report
y: Ambulato
a Woolard; K
screening a
mended by t
se Society of
cal pharmac
ages all of th
s C treatmen
re gaps and
referral for
o determine
body status.
is B serologi
eptible patie
ntibody who
oconvert aft
ovember 1, 2
nic. Three hu
ated vaccina
(by exposur
ons did not s
SHPMidyfessional
d‐out per the g
hepatitis B sc
ory Care
Kaiser Perma
and vaccinat
the American
f America (ID
ist at our ins
he education
nt. Additiona
to determin
hepatitis C t
hepatitis B s
The pharm
ies or incom
nts. Suscept
o had not co
er vaccinatio
2014 and De
undred eight
ation withou
re or vaccina
seroconvert
yearClinlPoster
guidelines wer
creening and
anente;
ion of susce
n Associatio
DSA) based o
stitution wo
n, pharmaco
ally, the pha
ne the need
treatment, t
surface antig
macist ordere
plete serolo
tible patient
mpleted the
on completio
ecember 31,
ty‐eight pati
t prior scree
ation comple
. Eight‐eight
nicalMeAbstrac
re translated i
d/or vaccina
ptible patien
n for the Stu
on evidence
rks under a
otherapy, an
armacist revi
for recomm
he hepatolo
gen, hepatit
ed screening
ogies. Vaccin
ts were defin
e recommen
on.
2017, 495 p
ents were sc
ening. Of the
etion). Howe
t of the 92 p
eetingcts
into unknown
ation in patie
nts initiating
udy of Liver
e of hepatitis
collaborativ
d laboratory
iews patient
mended vacc
ogy clinical p
is B surface
g for patients
nes were ord
ned as those
nded three‐d
patients wer
creened prio
ese 403 patie
ever, five pa
atients who
characters.
ents treated
g therapy for
Disease (AA
s B reactivat
ve practice
y monitoring
ts’ immuniza
inations.
harmacist
antibody, an
s with no
dered by the
e with a neg
dose vaccina
re treated fo
or to referra
ents, 202 we
atients who
o were not
for
r
SLD)
ion
g for
ation
nd
ative
ation
or
al,
ere
*Special sy
previous
patients
been com
remainin
series on
incomple
Conclusio
to the sc
out of 49
and/or h
pharmac
treated f
ymbols that w
ly screened
were determ
mpleted or is
ng 21 patient
nce treatmen
ete series pr
on: Overall,
reening of a
95 patients t
ave complet
cist intervent
for hepatitis
2018ASProf
ere not spelled
or vaccinate
mined to be
s currently in
ts, 19 started
nt ended. Th
ior to referr
pharmacist
n additional
reated for h
ted the thre
tions, there
C.
SHPMidyfessional
d‐out per the g
ed were scre
immune, an
n progress fo
d vaccinatio
he pharmacis
al.
involvemen
l 88 patients
epatitis C du
e‐dose vacc
was a reduc
yearClinlPoster
guidelines wer
eened by the
nd 65 remain
or 44 of the
n during tre
st also comp
t during hep
s after referr
uring the stu
ination serie
ction in susce
nicalMeAbstrac
re translated i
e pharmacist
ned suscepti
65 suscepti
atment, how
pleted vaccin
patitis C trea
ral. With the
udy period h
es for hepati
eptibility rat
eetingcts
into unknown
t. Twenty‐th
ible. Vaccina
ble patients
wever did no
nation for 57
atment at ou
e pharmacist
have docume
itis B. Based
tes for hepat
characters.
hree of these
ation series h
. Of the
ot complete
7 patients w
ur institution
t’s oversight
ented immu
on our
titis B in pat
e
has
their
with
n led
t, 402
nity
ients
*Special sy
Session‐B
Poster Ti
managem
Poster Ty
Submissi
Primary A
Email: se
Addition
Fouad Sa
Nathalie
Marwan
Mariam D
Purpose:
point in t
condition
there is l
pharmac
knowledg
present w
Methods
commun
represen
commun
a questio
included
and ques
outcome
advising
pharmac
advice an
ymbols that w
Board # ‐ 7‐0
itle: Knowle
ment of low
ype: Evaluat
ion Category
Author: Sara
e.rafeim@ho
al Authors:
akr
Lahoud
Akel
Dabbous
: Low back p
their life. In
n, and to rei
ittle specific
cy to people
ge and repo
with acute o
s: This is a m
ity pharmac
ntative numb
ity pharmac
onnaire. The
demograph
stions about
e was to dete
people who
cists’ recomm
nd care prov
2018ASProf
ere not spelled
022
dge and pra
back pain: a
tive Study
y: Chronic /
ah Moustafa
otmail.com
pain is a com
Lebanon, co
nforce advic
c information
presenting w
rted practice
or chronic low
multi‐center c
cies across Le
ber of pharm
cy were cons
questionna
hic questions
treatment t
ermine the k
presented w
mendation a
vided to pati
SHPMidyfessional
d‐out per the g
ctice of Leba
a cross sectio
Managed Ca
a; Ghaith Ph
mmon disord
ommunity ph
ce given by o
n about the
with back pa
e of Lebanes
w back pain.
cross‐section
ebanon. The
macies in all d
sidered eligib
ire was desi
s about the r
to reflect an
knowledge a
with low bac
bout educat
ents presen
yearClinlPoster
guidelines wer
anese comm
onal study
are
armacy;
er affecting
harmacists c
other health
quality of ca
ain. The purp
se communi
.
nal study co
e selection o
districts of L
ble, and tho
gned for sel
respondent,
d characteri
and reported
ck pain. The
tion needed
ting with ba
nicalMeAbstrac
re translated i
munity pharm
about 80 pe
can be consu
care profess
are provided
pose of this
ity pharmac
nducted in a
of participant
Lebanon. Pha
se who wish
f‐completio
questions t
ize the natu
d practice of
secondary o
in order to
ck pain. Dat
eetingcts
into unknown
macists in th
ercent of peo
ulted to advi
sionals. In th
d in the com
study is to d
ists advising
a representa
ts was done
armacists w
hed to partic
n by the pha
hat assessed
re of practic
f the commu
outcome wa
improve the
ta is express
characters.
he self‐
ople at some
ce about thi
he literature,
munity
determine th
g people who
ative numbe
e by choosing
orking at a
cipate comp
armacist and
d the knowle
ce. The prima
unity pharma
as to assess t
e quality of
ed as freque
e
is
,
he
o
er of
g a
leted
d
edge,
ary
acists
the
ency,
*Special sy
and evalu
regressio
Results: T
response
knowledg
knowledg
week see
0.020 an
compare
the oral t
the most
complex
pharmac
experien
postgrad
the secon
educatio
Conclusio
pain, yet
educatio
quality o
to suppo
ymbols that w
uation of pri
on.
This cross‐se
e of 320 com
ge about low
ge (48.3 per
em to demo
d 0.007 resp
ed to local pa
therapy, NSA
t prescribed
was the mo
cists referred
ce referred
uate studies
ndary outco
nal program
on: Commun
major gaps
n about low
f advice. Fur
ort evidence
2018ASProf
ere not spelled
imary and se
ectional stud
mmunity pha
w back pain
rcent). Those
nstrate bett
pectively). O
atch and loca
AIDs were th
NSAID (29 p
ost prescribe
d patients to
at most (OR
s referred le
me assessm
ms about low
nity pharma
still exist, pa
w back pain is
rther researc
based self m
SHPMidyfessional
d‐out per the g
econdary ou
dy was appro
rmacists wa
(51.7 percen
e with more
er knowledg
ral therapy w
al cream (58
he most pres
percent), wh
d combinati
o the physicia
R equals 2.85
ss patients t
ment, 87.2 pe
w back pain m
cists in Leba
articularly in
s needed to
ch would be
management
yearClinlPoster
guidelines wer
utcomes utili
oved by the
as analyzed.
nt) was sligh
years of exp
ge (Odds rat
was the mos
8 percent ve
scribed med
ile a combin
ion. Moreov
an once nee
56, P equals
to physicians
ercent of the
managemen
anon express
n terms of th
improve kno
e useful to as
t of back pai
nicalMeAbstrac
re translated i
ized analysis
institutiona
The number
htly higher th
perience and
io [OR] equa
st prescribed
rsus 15 and
dications (42
nation of dic
ver, 73.1 per
eded. Those
0.039), whe
s (OR equals
e pharmacist
t.
sed accepta
he quality of
owledge, an
ssess commu
in.
eetingcts
into unknown
s of chi‐squa
al review boa
r of pharmac
han those w
d more hour
al 0.146 and
d dosage for
27 percent
2 percent). D
clofenac and
rcent of the
with less tha
ereas, those
s 0.484, P eq
ts agreed th
ble knowled
f advice. Hen
nd thus prov
unity pharm
characters.
are and logis
ard. The
cists with go
ith poor
rs of practice
4.603; P eq
rm for back
respectively
Diclofenac wa
vitamin B
participating
an five years
with
quals 0.04). F
at they need
dge about ba
nce, more
ide better
macists attitu
tic
ood
e per
ual
pain
y). In
as
g
s of
For
d
ack
udes
*Special sy
Session‐B
Poster Ti
adherenc
Poster Ty
Submissi
Primary A
Email: ts
Addition
Dominiq
Lisa Deal
Melody T
Scooter P
Purpose:
increased
was integ
address n
clinical o
objective
precisely
evaluate
HF patien
Methods
novel dig
high‐touc
included
ingestion
digital ve
ingestion
and phys
included
below 80
ymbols that w
Board # ‐ 7‐0
itle: Impact
ce and hosp
ype: Evaluat
ion Category
Author: Tab
alam@chris
al Authors:
ue Medaglio
Tran
Plowman
: Suboptima
d healthcare
grated into a
nonadheren
utcomes am
e adherence
y to address
s the real‐w
nts.
s: Medicare
gital medicin
ch pharmaci
DigiMedsTM
n, and a mob
ersions of the
n. Clinical ph
siology data
patient and
0%. Ingestion
2018ASProf
ere not spelled
023
of a novel, p
ital utilizatio
tive Study
y: Chronic /
bassum Salam
tianacare.or
o
l medication
e utilization.
an intensive,
ce and prov
mong HF pati
data, enabl
missed or in
orld impact
HF patients
ne program (
ist‐led care m
M (medicatio
bile applicati
eir HF medic
armacists m
from the we
d provider ou
n adherence
SHPMidyfessional
d‐out per the g
pharmacist‐l
on in heart fa
Managed Ca
m; Christiana
rg
n adherence
A novel digi
, high‐touch
vide a mediu
ients. The DM
ing patients
ncorrect dose
of the DMP
were identif
(DMP), Prote
managemen
ons with ing
ion. After inf
cations. The
monitored pa
earable patc
utreach, and
e (number of
yearClinlPoster
guidelines wer
ed digital m
ailure patien
are
a Care Healt
in patients
ital medicine
pharmacist
m for optim
MP captures
, caregivers,
es and optim
on medicat
fied in hospi
eus Discover
nt program a
estible sens
formed cons
index date w
atients’ adhe
ch through a
d patient cou
f ingestions
nicalMeAbstrac
re translated i
edicine prog
nts
th System;
with heart f
e program (D
t‐led care ma
mizing medica
s and shares
, and provide
mize medica
ion adheren
ital or ambu
r®, was integ
and offered t
ors), a wear
sent, these H
was the date
erence, med
secure web
unseling whe
recorded/nu
eetingcts
into unknown
gram on me
failure (HF) i
DMP), Prote
anagement
al decision‐m
s (with patie
ers to interv
tion therapi
nce and hosp
ulatory clinic
grated into a
to these pat
rable patch c
HF patients w
e of first sch
dication takin
b portal. Inte
en adherenc
umber of sch
characters.
dication
s associated
eus Discover
program to
making and
nt permissio
vene more
ies. This ana
pital utilizati
settings. A
an intensive,
tients. The D
confirming
were started
heduled
ng behaviors
erventions
ce dropped
heduled dos
d with
®,
on)
lysis
on in
,
DMP
d on
s,
ses),
*Special sy
and patie
hospital
Results: A
period of
psychiatr
allowed f
common
comorbid
days was
complete
DMP pro
Conclusio
pharmac
and optim
confirma
workflow
ymbols that w
ent‐reported
utilization an
A total of 29
f 165 ± 46 da
ric comorbid
for intervent
ly reported
dity taking p
s lower post‐
ed a satisfac
ovided accur
on: These re
cist care man
mize clinical
atory impact
w efficiency.
2018ASProf
ere not spelled
d reasons fo
nd patient s
9 patients us
ays (age 75 ±
dity). Mean i
tions to be t
reasons for
precedence (
‐index (0.03,
tion survey
ate informat
eal‐world da
nagement pr
outcomes.
of DMP on
SHPMidyfessional
d‐out per the g
r nonadhere
atisfaction w
sed the DMP
± 14 years [m
ngestion ad
targeted to p
nonadheren
(n = 6). Mean
, 1 visit total
(n=10), 90%
tion to their
ta suggest th
rograms can
Future contr
clinical outc
yearClinlPoster
guidelines wer
ence were as
were evaluat
P for 77 ± 19
mean ± SD];
herence wa
patients who
nce were low
n CHF‐relate
l) vs pre‐inde
% found the D
r care team.
hat DMP uti
enable time
rolled studie
comes, healt
nicalMeAbstrac
re translated i
ssessed. Also
ted.
(mean ± SD
65% male; 7
s 79.7 ± 15.4
o were nona
w health lite
ed hospital v
ex (0.45, 13
DMP easy to
lization in co
ely, targeted
es and real‐w
thcare resou
eetingcts
into unknown
o, 30‐day pr
D) days, with
72% Caucasi
4%. Integrat
adherent. Th
racy (n = 8)
visits per pat
visits total).
o use and 80
ombination
d adherence
world analys
urce utilizatio
characters.
re‐ vs post‐in
a follow‐up
ian; 41% wit
tion of the D
he most
and a
tient within
. Of those w
% agreed th
with high‐to
e interventio
ses should as
on, and
ndex
p
th a
MP
30
ho
he
ouch
ons
ssess
*Special sy
Session‐B
Poster Ti
Poster Ty
Submissi
Primary A
Email: rs
Addition
Purpose:
related to
Departm
facilities
for monit
audits on
Methods
pharmac
after (Jan
of 2017,
strategy
entry and
treatmen
and appr
antimicro
indicatio
evaluate
post‐imp
Results:
roughly 1
intervent
review (1
(5%), dos
ymbols that w
Board # ‐ 7‐0
itle: Impact
ype: Descrip
ion Category
Author: Rob
huminski@g
al Authors:
: As of Janua
o antimicrob
ment of Healt
have an ant
toring the u
n pharmacist
s: This was a
cist antibiotic
nuary 1, 201
the antimicr
for pharmac
d weekly bas
nt guidelines
roved. To pr
obial stewar
n, duration,
the impact
plementation
Post‐implem
18 times the
tion types (%
16%), potent
se adjustme
2018ASProf
ere not spelled
024
of a pharma
ptive Report
y: Chronic /
bert Shumins
gsrh.org
ary 1st, 2017
bial steward
th and the C
ibiotic stewa
se of antibio
t interventio
a retrospecti
c interventio
8 through M
robial stewa
cist audit of
sed on a com
s and an intr
repare for in
rdship educa
culture/sen
of the audit
n.
mentation, p
e pre‐implem
%) included:
tial drug‐dru
nt performe
SHPMidyfessional
d‐out per the g
acist‐led anti
Managed Ca
ski; Good Sh
7 The Joint C
ship within
enter for Me
ardship prog
otics. Invest
ons.
ve study of t
ons before (J
May 31, 2018
rdship sub‐c
all prescribe
mputer‐gene
ravenous to
nterventions
ation. Pharm
nsitivity matc
program, p
harmacist a
mentation ba
indication v
ug interactio
ed (2%). The
yearClinlPoster
guidelines wer
ibiotic audit
are
hepherd Reh
Commission
nursing care
edicare Serv
gram that in
igators soug
two LTC faci
January 1, 20
8) implemen
committee o
ed antimicro
erated list. T
oral antibiot
, all pharma
macists revie
ch, and pote
harmacist in
ntibiotic inte
aseline (22 v
verification (
ns (16%), alt
e Pennsylvan
nicalMeAbstrac
re translated i
program at
habilitation H
requires ele
e centers. Ad
vices require
cludes antib
ght to assess
ilities (159 to
017 through
ntation of an
of Infection C
obials which
To assist wit
tic conversio
cists comple
ewed antibio
ential conver
nterventions
erventions p
vs. 1.25). Th
60%), cultur
ternative an
nia Departm
eetingcts
into unknown
two long te
Hospital;
ments of pe
dditionally, t
e that long te
biotic protoc
s the impact
otal beds) co
h December
n audit progr
Control deve
included rev
th implemen
on policy we
eted 12‐hou
otic orders fo
rsion to oral
s were asses
per quarter i
e breakdow
re and sensit
ntibiotic reco
ent of Healt
characters.
rm care faci
erformance
the Pennsylv
erm care (LT
cols and syst
of antibiotic
omparing
31, 2017) an
ram. At the
eloped a
view upon o
ntation, emp
ere develope
rs of basic
or appropria
alternatives
sed pre‐ and
increased by
n of pharma
tivity drug m
ommendatio
th reviewed
lities
vania
TC)
tems
c
nd
e end
order
piric
ed
ate
s. To
d
y
acy
match
on
*Special sy
intervent
complian
Conclusio
intervent
ymbols that w
tion data du
nt with CMS
on: A pharm
tions within
2018ASProf
ere not spelled
ring an unan
antibiotic st
macist‐led an
a LTC settin
SHPMidyfessional
d‐out per the g
nnounced A
tewardship e
ntibiotic audi
g.
yearClinlPoster
guidelines wer
pril 2018 vis
expectations
it program in
nicalMeAbstrac
re translated i
sit and deem
s.
ncreased an
eetingcts
into unknown
med Good Sh
ntibiotic stew
characters.
hepherd
wardship
*Special sy
Session‐B
Poster Ti
stable ty
Poster Ty
Submissi
Primary A
Email: ivy
Addition
Renee Ca
Catherin
Stephani
Eddie (Sh
Purpose:
strategie
uncontro
complica
patient b
how bloo
eight Vet
inapprop
Methods
retrospec
30, 2017
prescript
identified
or hypog
laborato
rate (eGF
first and
moderat
interest w
ymbols that w
Board # ‐ 7‐0
itle: Correlat
pe 2 diabete
ype: Evaluat
ion Category
Author: Ivy
y.tonnu‐mih
al Authors:
astillo
e Lo
e Wong
hinn) Wong
: Per Americ
es is self‐mon
olled blood g
ations. Howe
burden and i
od glucose te
terans Affair
priate test st
s: The VA Lo
ctive databa
. Veterans w
tion for test
d. Patients w
glycemia, hyp
ry results su
FR) above 20
last A1c test
e ad high ba
were patient
2018ASProf
ere not spelled
025
tion of clinic
es in a Veter
tive Study
y: Chronic /
Tonnu‐Miha
can Diabetes
nitoring of b
glucose fluct
ever, recent
ncreased he
est strips we
rs (VA) hospi
rip usage.
ng Beach He
ase review st
who had typ
strip from V
were exclude
perosmolari
ggested tha
00 ml/min) d
t result date
ased on mea
t demograph
SHPMidyfessional
d‐out per the g
cal outcomes
rans Health A
Managed Ca
ara; VA Long
v
s Association
lood glucose
tuations, wh
studies have
ealthcare cos
ere utilized i
itals. We als
ealthcare Sys
tudy. The stu
pe 2 diabetes
VA pharmacy
ed if they ha
ty, or diabet
t the record
during the st
es, respective
n daily usag
hics (age, ge
yearClinlPoster
guidelines wer
s with glucos
Administrati
are
g Beach Heal
n guidelines,
e (SMBG) at
ich can resu
e also shown
sts. The purp
n stable type
so evaluate t
stem institu
udy period w
s with record
y, and cared
d diagnoses
tes secondar
s were error
tudy period.
ely. Test stri
ge over all pr
ender, race,
nicalMeAbstrac
re translated i
se test strip
on Hospitals
lthcare Syste
part of the
home. This
ult in serious
n that over‐t
pose of this
e 2 diabetic
the costs ass
tional review
was from Oc
d of stable A
for by VA pr
s of uncontro
ry to pregna
rs (e.g. estim
The index d
p frequency
rescriptions
body mass i
eetingcts
into unknown
dispensing
s Network
em;
disease stat
is importan
micro‐ and
testing can l
study was to
veterans in
sociated wit
w board app
ctober 1, 201
A1c, filled at
rimary care
olled type 2
ancy), decea
mated glome
dates were d
y was catego
filled days. P
ndex, baseli
characters.
in patients w
te managem
t in prevent
macrovascu
ead to incre
o determine
a network o
th perceived
proved this
15 to Septem
least one
provider we
diabetes (hy
sed, or
erular filtrati
defined as th
orized as low
Predictors of
ine A1c, base
with
ment
ing
ular
eased
e
of
d
mber
ere
yper
ion
he
w,
f
eline
*Special sy
eGFR, an
kidney di
test strip
usage by
9.4 was u
Results: A
the avera
reported
(5.3) was
moderat
significan
disease, f
users, so
significan
A1c (betw
predictor
percent o
while abo
quantity.
spent du
Conclusio
the study
SMBG te
frequenc
characte
hospitals
on test st
improvem
result in
ymbols that w
nd antidiabet
isease and fo
p use. Secon
y calculating
utilized. Stat
A total of 25
age age of 6
d, and Asian
s a combinat
e to low‐fre
ntly more lik
foot ulcer an
me demogra
ntly associat
ween first an
rs included h
of patients w
out 10 perce
. These two
e to perceiv
on: Anti‐dia
y veteran po
sting were c
cy testing to
ristics were
s appeared t
trip dispensi
ments. Ident
significant c
2018ASProf
ere not spelled
tic regimen)
oot ulcers).
ndary endpo
the potentia
tistical signif
5,696 vetera
8 years. Mo
(66.3, 12.4,
tion of Nativ
quency user
kely to be a m
nd antidiabe
aphic charac
ed with high
nd last index
heart failure
who were no
ent of patien
groups cont
ved inapprop
betic regime
opulation. Sig
comorbiditie
low frequen
found to be
o adhere to
ing, with two
tification an
ost savings.
SHPMidyfessional
d‐out per the g
and comorb
Primary end
int assessed
al cost avoid
ficant was se
ns was inclu
ost patients w
11.8 and 4.2
ve American,
rs, patients w
moderate‐fre
etic regimes.
cteristics sho
h‐user. Thos
x dates) was
, kidney dise
ot on any an
nts on oral m
tributed to t
priate testing
ens have a ro
gnificant cha
es associated
ncy testing, s
predictors o
the guidanc
o hospitals t
d discontinu
yearClinlPoster
guidelines wer
bidities (myo
dpoint asses
the cost fro
dance based
et at 0.05.
uded in the a
were Caucas
2 percent, re
, Native Haw
with the follo
equency tes
. When com
owed to be t
se character
s also a pred
ease, and an
tidiabetic m
medications u
the estimate
g at the eigh
obust associ
aracteristics
d. However,
some patien
of high‐frequ
ce set forth b
that may hav
uation of ina
nicalMeAbstrac
re translated i
ocardial infa
ssed the fact
om perceive
on prescrip
analysis. 95.
sian, followe
espectively),
waiian and M
owing chara
ster: heart fa
mparing high
the predicto
ristics were a
ictor of test
ntidiabetic re
medications w
used more t
ed total cost
ht VA sites d
iation with S
associated
when comp
nt demograp
uency tester
by the Veter
ve some opp
ppropriate t
eetingcts
into unknown
arction, hear
tors predicte
d inappropr
tion filled. S
.99 percent
ed by African
the remain
Multi‐race. W
acteristics we
ailure, stroke
‐frequency t
ors that were
age, race. A
strip usage.
egimens. Fin
were prescri
than recomm
t of 145,000
uring the stu
SMBG testing
with moder
paring betwe
phic and outc
r. Furthermo
rans Health A
portunities f
test strip dis
characters.
rt failure, str
ed frequency
iate test stri
STATA versio
were mail w
n American,
ing percenta
When compa
ere statistica
e, kidney
to low‐frequ
e statistically
lso, change
. Other
nally, about
bing test str
mended dail
dollars per y
udy period.
g frequency
ate‐frequen
een high‐
come
ore, the eigh
Administrat
for
spensed cou
roke,
y of
ip
on
with
Not‐
age
aring
ally
uency
y
in
20
rips,
y
year
in
cy
ht VA
ion
ld
*Special sy
Session‐B
Poster Ti
disease (
Poster Ty
Submissi
Primary A
Email: es
Addition
Kiumars
Karen Ra
Paul God
Purpose:
access fo
with valu
and cont
many chr
purpose
overall h
(IDS).
Methods
and elect
1, 2014 t
greater t
1, 2014 t
as propo
patient, w
with a ra
medicati
the mean
pre/post
ymbols that w
Board # ‐ 7‐0
itle: Impact
COPD) medi
ype: Evaluat
ion Category
Author: Esth
stheryi917@
al Authors:
Zolfaghari
ascati
dley
: Value‐base
or medicatio
ue rather tha
tain health c
ronic condit
of this study
ealth care u
s: We condu
tronic medic
through Dec
han 18 with
through Dec
rtion of days
was measur
ndom effect
on adherenc
n change in
analysis of h
2018ASProf
ere not spelled
026
of a value‐b
ication adhe
tive Study
y: Chronic /
her Yi; Baylo
@gmail.com
ed insurance
ns deemed o
an cost, VBID
are spend. L
ions such as
y is to evalua
tilization for
cted a retro
cal record da
ember 31, 2
at least two
ember 31, 2
s covered (P
ed every mo
ts segmente
ce both imm
pre‐interven
healthcare u
SHPMidyfessional
d‐out per the g
ased insuran
erence and h
Managed Ca
or Scott and W
design (VBI
of higher va
D delivers a m
Long‐term m
s COPD and e
ate the impa
r select COP
ospective coh
ata from com
2017. The VB
o pharmacy
2017 were en
PDC) or the n
onth during t
ed regression
mediately and
ntion versus
utilization (co
yearClinlPoster
guidelines wer
nce design o
health care u
are
White Healt
D) reduces o
lue relative t
means to sim
medication us
effective in r
act of reduce
D medicatio
hort study u
mmercially in
BID was impl
claims for se
nrolled in th
number of d
the study pe
n analysis as
d longitudin
post‐interve
ombined ou
nicalMeAbstrac
re translated i
on chronic ob
utilization
th;
or waives co
to their cost
multaneousl
se is the ma
reducing adv
ed copays on
ons in an inte
sing pharma
nsured patie
lemented on
elected COP
e study. Me
ays of medic
eriod. An int
ssessed the i
nally over tim
ention healt
utpatient and
eetingcts
into unknown
bstructive p
ost sharing a
ts. By alignin
ly improve h
instay of tre
verse health
n medicatio
egrated deliv
acy claims, m
ents in the ID
n April 1, 201
D medicatio
edication adh
cation availa
errupted tim
mpact of th
me. Paired t‐
th care utiliz
d inpatient v
characters.
ulmonary
nd increases
ng cost shari
health outco
eatment for
h outcomes.
n adherence
very system
medical claim
DS from Janu
16. Patients
ons from Jan
herence, def
able to each
me series de
e VBID on C
‐tests compa
ation. A sub
visits) for
s
ng
mes
The
e and
ms
uary
aged
uary
fined
sign
OPD
ared
bset
*Special sy
patients
before an
Results:
age of 44
beta ago
36%). On
continue
patients
no signifi
impleme
Conclusio
adherenc
medicati
but the im
ymbols that w
who had 6 m
nd after the
We identifie
4 years and w
nist/corticos
n average, th
ed to increas
who had 6 m
icant differe
ntation of th
on: The imp
ce and overa
ons. Overall
mpact on cli
2018ASProf
ere not spelled
months of pr
implementa
ed 1,177 pat
were more l
steroid com
he PDC was a
e by an aver
months of pr
ence in the a
he VBID (7.5
lementation
all stability in
, health care
inical outcom
SHPMidyfessional
d‐out per the g
re‐intervent
ation of the
ients that m
ikely to be fe
bination me
about 2.6% (
rage of 0.3%
re‐intervent
verage num
54 vs 7.47).
n of the VBID
n trends dur
e utilization
mes and spe
yearClinlPoster
guidelines wer
ion and post
VBID.
met the inclus
emale (68%)
edications (n
(p=0.01) hig
% (p < 0.05) p
ion and post
ber of visits
D was associ
ring the post
was compar
ending requir
nicalMeAbstrac
re translated i
t‐interventio
sion criteria
). The major
n=810; 69%)
her after the
per month af
t‐interventio
per patient
ated with im
t‐interventio
rable before
res further e
eetingcts
into unknown
on adherenc
. Patients ha
rity of patien
and corticos
e interventio
fter the inte
on adherenc
before and
mproved me
on period fo
e and after th
evaluation.
characters.
ce was evalu
ad an averag
nts were tak
steroids (n=
on and
ervention. 13
ce demonstr
after the
edication
r COPD
he intervent
uated
ge
ing
429;
31
rated
tion,
*Special sy
Session‐B
Poster Ti
IV to PO
Poster Ty
Submissi
Primary A
Email: al
Addition
Bayan Da
Maha Al‐
Purpose:
therapy o
reports o
Saudi Ara
pharmac
hospital a
easily inc
King Abd
Methods
eligible fo
approved
months (
was mad
age and f
follow up
Pharmac
campaign
generate
more of t
on hospit
orders w
ymbols that w
Board # ‐ 7‐0
itle: Practice
therapy usin
ype: Evaluat
ion Category
Author: Alaa
aa‐babonji@
al Authors:
arwesh
‐Alawi
: There is inc
of certain dr
on pharmaci
abia. This wa
cist‐managed
at Saudi Ara
corporated i
ulaziz Unive
s: This is a pr
or the switch
d by pharma
(pre‐interven
de to generat
full patients
p the interve
cists training
n took place
ed list of acti
the selected
tal switch fro
were sent for
2018ASProf
ere not spelled
027
e developme
ng electronic
tive Study
y: Clinical Se
a Babonji; Ki
@hotmail.co
creasing awa
rugs with cer
st‐managed
as designed
d switch from
bia to impro
nto a daily p
ersity Hospit
rospective q
h from IV to
acy and ther
ntion phase)
te a filtered
profile whic
entions.
, educationa
e on go‐live d
ve IV orders
d IV guideline
om IV to PO
investigatio
SHPMidyfessional
d‐out per the g
ent: impleme
c identificati
ervices Mana
ing Abdulazi
m
areness on e
rtain medica
switch from
to impleme
m IV to PO p
ove patient’s
practice. This
al.
quasi‐experim
PO and incl
apeutics com
) and 5 mon
list of active
ch can be ex
al interventio
date, April 15
s of adult me
e drugs afte
guideline a
on through t
yearClinlPoster
guidelines wer
entation of p
on at a terti
agement
iz University
early switch f
al conditions
m IV to PO th
nt and evalu
program at 1
s quality of l
s research w
mental study
usion and ex
mmittee. IV
ths (post‐int
e selected IV
ported on e
on to health
5, 2018. Pha
edical and su
r 48 hours o
nd their clin
he system to
nicalMeAbstrac
re translated i
pharmacist‐
iary academ
y Hospital;
from intrave
s or focused
herapy and n
uate practice
1002‐bed pu
ife and facili
was approved
y. Guideline
xclusion crit
delivered or
tervention p
V orders in se
xcel sheet to
h care provid
armacists ex
urgical in‐pa
of IV therapy
ical judgmen
o the orderi
eetingcts
into unknown
managed ea
ic hospital
enous (IV) to
on antibioti
no reports w
e and outcom
blic tertiary
itate implem
d by ethics c
list of 17 IV
teria were cr
rders were c
phase). syste
elected unit
o easily docu
ders and awa
port an elec
tients who r
y and review
nt for eligibi
ng doctor to
characters.
arly switch fr
o oral (PO)
ics alone. lim
were found fr
mes of
academic
mentation to
committees
medication
reated and
collected for
em enhancem
s showing d
ument and
areness
ctronically
received 1 o
w the list base
ility. Eligible
o switch to th
rom
mited
rom
o be
of
s
r 5
ment
iet,
r
ed
he
*Special sy
oral form
action. P
excel she
Results: T
patients
recomme
orders el
meeting
Of these
were alre
alternativ
not renew
(3%) orde
weren’t e
medicati
Conclusio
educatio
as a team
clinical co
PO form.
assuring
professio
encourag
ymbols that w
mulation if ap
harmacist’s
eet on a daily
Total of 608
of which we
endations w
igible to swi
the inclusio
recommend
eady switche
ve was out o
wed, 5 (1%)
ers were sw
eligible but w
ons upon di
on: Pharmac
nal lectures
m and on phy
onditions. Th
. Using elect
continuous
onals is nece
gement to in
2018ASProf
ere not spelled
ppropriate w
intervention
y basis for fo
84 patients w
ere collected
were made by
itch to PO m
n criteria.
dations, 36 (
ed without p
of stock, 29 (
patients de
itched to an
were switch
scharge and
cist‐manage
and awaren
ysician’s awa
here was a s
ronic identif
implementa
essary for suc
nteract and e
SHPMidyfessional
d‐out per the g
which will au
ns and physi
ollow up.
were collecte
d and analyze
y pharmacis
medications w
9%) orders w
pharmacist’s
(7%) orders
ceased, 4 (1
nother PO m
ed by orderi
d only 24 (6%
d switch fro
ness campaig
areness on u
significant nu
fication ensu
ation of the p
ccess of the
education to
yearClinlPoster
guidelines wer
utomatically
cian’s action
ed from the
ed in the po
ts, of these
while 304 (54
were accept
s interventio
were discon
%) orders sw
edication, 6
ing physician
%) IV orders c
m IV to PO p
gn had posit
using PO for
umber of IV
ures timely c
program. Eff
program wh
o improve th
nicalMeAbstrac
re translated i
hold the ord
ns were doc
pre‐implem
ost‐implemen
recommend
4%) were IV
ted and impl
on, 3 (1%) or
ntinued, 102
witched to a
(2%) orders
n ,16 (4%) or
continued ti
program usi
tive impleme
m wheneve
medications
conversion a
fective colla
hich can be i
he understan
eetingcts
into unknown
der till the d
umented on
entation ph
ntation phas
dations, 260
V orders excl
lemented, 1
rders weren’
2 (26%) orde
another IV m
s pharmacist
rders were s
ill patient wa
ng electroni
enting a cha
r appropriat
s eligible for
and saves ph
boration am
improved by
nding of eac
characters.
octor takes
n the exporte
ase. 321
se. 564
(46%) were
uded for no
117 (30%) or
’t switched a
rs expired a
medication, 1
t thought
switched to
as discharge
ic identificat
nge of pract
te for patien
r the switch
harmacist’s t
mong healthc
y active
h profession
an
ed
IV
t
ders
as PO
nd
10
PO
ed.
tion,
tice
nt’s
to
time
care
n.
*Special sy
Session‐B
Poster Ti
formular
Poster Ty
Submissi
Primary A
Email: kv
Addition
Jane McC
Juliana C
Purpose:
in hepati
restrictio
Sof/Vel t
sofosbuv
AASLD/ID
staging a
study ass
Sof/Vel, S
Methods
different
authoriza
assessed
formular
was not i
compare
assess th
Results:
fibrosis o
(52%) sta
ymbols that w
Board # ‐ 7‐0
itle: Improve
ries one year
ype: Descrip
ion Category
Author: Kels
vande33@ui
al Authors:
Cullough
han
: The advent
tis C virus (H
ons for treatm
o HCV genot
vir/velpatasv
DSA guidelin
nd include S
sesses the 50
Sof/Vel/Vox
s: An online
t researchers
ation (PA) fo
for inclusio
ry agents for
included on
ed to previou
he availability
Fifty states w
of F3, F2, or F
ates have no
2018ASProf
ere not spelled
028
ed patient ac
r later in 201
ptive Report
y: Clinical Se
sey Bridgem
ic.edu
t of pan‐gen
HCV) treatm
ment varied
types 2 and
vir/voxilapre
nes recomme
Sof/Vel and G
0 state Med
x and/or Gle/
search was
s reviewed t
orms betwee
n of Sof/Vel
r all six genot
the PDL or P
usly collected
y and access
were include
F1 was foun
o fibrosis res
SHPMidyfessional
d‐out per the g
ccess to HCV
18
ervices Mana
man; Universi
otypic direct
ent. Since th
across state
3. Additiona
evir (Sof/Vel/
end individu
Gle/Pib as fi
icaid formul
/Pib as prefe
conducted f
he most rec
en 6/1/2018
, Sof/Vel/Vo
types. If the
PA form, it w
d data on st
sibility of DA
ed in our res
d in 9 (18%)
trictions in 2
yearClinlPoster
guidelines wer
V treatment
agement
ity of Illinois
t acting anti
he FDA appr
e Medicaid p
al DAAs appr
/Vox) and gl
uals receive t
rst line agen
aries for HC
erred agents
for all 50 Uni
cently update
and 6/11/2
ox, and Gle/P
state had n
was labeled “
ate PDLs fro
AA treatmen
sults. To qua
, 12 (24%) o
2018 compa
nicalMeAbstrac
re translated i
: DAA inclus
s at Chicago
virals (DAAs
oved sofosb
plans. Many
roved in 201
ecaprevir/pi
treatment re
nts for treatm
CV treatment
s.
ited States’
ed preferred
018. Each st
Pib as prefer
ot yet appro
“non‐formul
om June 201
ts.
alify for DAA
or 3 (6%) stat
red to 9 (18
eetingcts
into unknown
sion across st
College of P
s) initiated a
buvir/velpata
states (38%
17 include
ibrentasvir (
egardless of
ment naïve
t eligibility a
Medicaid se
d drug lists (
tate Medica
rred, non‐pr
oved the DA
lary.” The fin
7 and betwe
A approval, a
tes, respecti
8%) of states
characters.
tate Medica
harmacy;
paradigm sh
asvir (Sof/Ve
%) restricted
(Gle/Pib).
Metavir fibr
patients. Th
and inclusion
ervices. Two
PDL) and pr
id program w
referred, or n
AA for use or
ndings were
een states to
minimum
ively. Twent
in 2017. Th
aid
hift
el),
rosis
is
n of
ior
was
non‐
it
e
o
ty‐six
irty‐
*Special sy
two (64%
genotype
states do
states (9
(6%) do n
(34%) an
genotype
Based on
recomme
recomme
Conclusio
vastly im
HCV trea
Medicaid
diagnosis
Gle/Pib,
Improved
system a
ymbols that w
%) and 13 (26
es. Two state
o not include
2%). One sta
not include G
d non‐prefe
e 2, where it
n these data,
endations. T
ended Sof/V
on: Patient a
proved sinc
atment now
d programs h
s for eligibilit
expanding a
d access to p
nd improve
2018ASProf
ere not spelled
6%) states li
es (6%) restr
e Sof/Vel on
ate includes
Gle/Pib on fo
erred in 21 st
t is non‐pref
, all 50 state
This is a vast
Vel for all gen
access to DA
e the approv
relies less he
have lifted m
ty. In additio
access to age
pan‐genotyp
patients’ qu
SHPMidyfessional
d‐out per the g
st Sof/Vel as
rict Sof/Vel a
formulary. N
Gle/Pib as a
ormulary. So
tates (42%).
erred. Sof/V
es include pr
improveme
notypes or u
AAs, which p
val of Sof/Ve
eavily on fib
minimum fib
on, 32 progr
ents that yie
pic DAAs will
uality of life.
yearClinlPoster
guidelines wer
s preferred o
as a preferre
Notably, Gle
a non‐prefer
of/Vel/Vox is
One state li
Vel/Vox was
eferred drug
nt from one
use in genoty
provide the h
ef. Compare
brosis staging
rosis restrict
ams include
ld the greate
likely decre
nicalMeAbstrac
re translated i
or non‐prefe
ed agent for
e/Pib is prefe
rred agent fo
s preferred f
sts Sof/Vel/
not on form
gs consisten
e year ago, w
ypes 2, 3, 5,
highest level
ed to previou
g. Instead, a
tions and on
e Sof/Vef on
est sustaine
ease disease
eetingcts
into unknown
erred, respec
genotypes 2
erred for all
or all genoty
for all genot
/Vox for all g
mulary in 10 s
t with AASL
where only 1
and 6.
s of virologi
us criteria, q
n increased
nly require c
their PDL an
d virologic r
burden on t
characters.
ctively, for a
2 and 3. Five
genotypes i
ypes, and 3 s
types in 17 s
genotypes ex
states (20%)
D/IDSA
15 states (30
c response,
ualification
number of
hronic HCV
nd 46 includ
response.
the healthca
all
e
n 46
states
tates
xcept
).
0%)
for
e
are
*Special sy
Session‐B
Poster Ti
bedside d
Poster Ty
Submissi
Primary A
Email: co
Addition
Laura Bu
Julia Chis
Purpose:
2014. Ho
assessme
personne
to addres
bedside m
Methods
team wh
team use
discharge
pharmac
email, fly
The TS‐P
electroni
insurance
Barriers i
for appro
alerted t
to dispen
bedside a
ymbols that w
Board # ‐ 7‐0
itle: Advanci
delivery
ype: Descrip
ion Category
Author: Sara
oxsa@umkc.
al Authors:
tkievich
sholm
: Discharge m
owever, over
ent of the di
el barriers. T
ss discharge
medication d
s: The Transi
ich included
ed plan, do,
e workflow.
cy staff, case
yers, meetin
MLs targete
ic health rec
e coverage,
identified w
opriate inter
hrough the E
nse the disch
and docume
2018ASProf
ere not spelled
029
ing the role
ptive Report
y: Clinical Se
ah Cox; Univ
.edu
medication b
r time utiliza
scharge med
The purpose
e medication
deliveries.
ition Special
d pharmacy l
study, act (P
The new dis
managers,
gs and/or pr
ed patients a
cord (EHR). T
and enroll p
ere commun
rventions. O
EHR at whic
harge medic
ented the co
SHPMidyfessional
d‐out per the g
of pharmacy
ervices Mana
versity of Mi
bedside deliv
ation decline
dication bed
of this proje
n bedside de
ist ‐ Patient
leaders, TS‐P
PDSA) cycles
scharge wor
nurses, and
resentations
t high risk fo
Their goal wa
patients in th
nicated with
nce the pati
h time, they
ations. The T
mpletion of
yearClinlPoster
guidelines wer
y technician
agement
ssouri Kansa
very was im
ed and turna
dside deliver
ect was to im
livery barrie
Medication
PMLs, and in
to enhance
kflow and TS
physicians t
s.
or readmissi
as to identify
he discharge
h a pharmaci
ent had disc
y communica
TS‐PML deliv
f delivery in t
nicalMeAbstrac
re translated i
s to improve
as‐City Scho
plemented a
around time
ry program i
mplement an
ers and incre
Liaison (TS‐
nformation t
e the role and
S‐PML role w
through vari
on based on
y adherence
e medication
ist, case man
charge order
ated with th
vered the m
the EHR.
eetingcts
into unknown
e discharge
ol of Pharma
at University
increased. A
dentified bo
n advanced t
ease the rate
‐PML) was d
technology s
d design its
was commun
ous platform
n a score cal
e barriers, pr
n bedside de
nager, and/o
rs placed the
e hospital re
medications t
characters.
medication
acy at MU;
y Hospital in
An internal
oth process a
technician r
e of discharg
eveloped by
support. The
fit within th
nicated with
ms including
culated by t
rescription
elivery servic
or social wor
e TS‐PML wa
etail pharma
to the patien
n
and
ole
ge
y a
e
e
h
he
ce.
rker
as
acy
nt’s
*Special sy
Data was
included
bedside d
patients
deliverie
Results:
High risk
14% of th
of the tim
October
Conclusio
other dis
delivery s
patients
discharge
and turn
ymbols that w
s assessed m
rate of all d
delivery for
visited by th
s.
Baseline dis
patients int
he time, com
me, compare
2017 at 4.35
on: Advance
sciplines with
service. Alth
are present.
e medication
around time
2018ASProf
ere not spelled
monthly from
ischarge me
patients visi
he TS‐PML, a
charge beds
terviewed by
mpared with
ed with a ba
5 hours and
ed technician
hin the healt
hough numb
. The progra
n delivery ra
e.
SHPMidyfessional
d‐out per the g
m September
edication bed
ted by the T
and turnarou
side medicat
y the TS‐PML
a baseline o
seline of 36%
declined to
ns in collabo
th‐system ha
ers have imp
m will conti
ates, numbe
yearClinlPoster
guidelines wer
r 2017 throu
dside delive
TS‐PML, rate
und time for
tion delivery
L received d
of 6% and ha
%. Bedside m
2.5 hours by
oration with
ave enhance
proved, add
nue to use P
r of patients
nicalMeAbstrac
re translated i
ugh February
ries, rate of
e of medicati
r all discharg
y rates increa
ischarge me
ad medicatio
medication t
y February 2
hospital ret
ed the disch
itional oppo
PDSA cycles
s with medic
eetingcts
into unknown
y 2018. Met
discharge m
ions in hand
ge medicatio
ased from 12
edication bed
ons in hand
turnaround t
2018.
ail pharmac
arge medica
ortunities to
to further im
cations in ha
characters.
rics assessed
medication
d at discharg
on bedside
2.2% to 21.8
dside delive
at discharge
time peaked
y staff as we
ation bedsid
deliver to
mprove
nd at discha
d
e for
86%.
ry
e 48%
d in
ell as
e
arge,
*Special sy
Session‐B
Poster Ti
initiative
Poster Ty
Submissi
Primary A
Email: vic
Addition
Nicole Bo
Julie Just
Joseph K
P. Brando
Purpose:
higher re
medicati
a hospita
compone
delivery,
Methods
prospect
would co
Patients
house su
each of t
stewards
appropri
receive m
provided
within on
adherenc
being hig
ymbols that w
Board # ‐ 7‐0
itle: Implem
on Clostridi
ype: Evaluat
ion Category
Author: Vict
ctoria.hethe
al Authors:
ookstaver
to
ohn
on Bookstav
: Outpatient
ecurrence ra
on access an
al discharge
ents includin
patient edu
s: The Institu
tive impleme
omplete anti
discharged t
upply were e
he four com
ship team wa
ate therapy
medication d
d by a pharm
ne week of d
ce (if applica
ghest). Secon
2018ASProf
ere not spelled
030
entation of
ium difficile
tive Study
y: Clinical Se
toria Hether
erington@pa
ver
t manageme
tes, potentia
nd adherenc
transitions o
ng antimicro
ucation, and
utional Revie
entation stud
ibiotic thera
to a facility w
xcluded. The
mponents of
as alerted to
based on in
delivery to th
macist from t
discharge wa
able) and pat
ndary outco
SHPMidyfessional
d‐out per the g
a comprehe
infection ma
ervices Mana
rington; Palm
almettohealt
ent of Clostri
ally due to m
ce. The purp
of care (TOC
bial steward
post dischar
ew Board ap
dy. Patients
py for CDI as
with direct m
e primary ou
the TOC bun
o positive C.
stitutional g
he bedside w
he institutio
as conducted
tient satisfa
mes include
yearClinlPoster
guidelines wer
ensive transit
anagement
agement
metto Health
th.org
dium difficil
modifiable fa
ose of this s
) bundle ser
dship interve
rge follow‐u
pproved this
aged 18 yea
s an outpati
medication a
utcome was
ndle beginni
difficile Tox
guidelines. P
with disease
onal outpatie
d to assess m
ction with th
e service imp
nicalMeAbstrac
re translated i
tions of care
h Richland;
e infection (
actors includ
study is to as
rvice that int
ention, conc
p.
single‐instit
ars and olde
ent were eli
administratio
successful i
ng in Decem
xin B PCR and
rior to disch
state and m
ent pharmac
medication a
he service (L
plementation
eetingcts
into unknown
e stewardshi
(CDI) is asso
ding treatme
ssess the im
tegrates fou
cierge bedsid
tution, multi
r, diagnosed
igible for enr
on provided
mplementat
mber 2017. T
d evaluated
harge, the pa
medication e
cy. A follow‐
and follow‐u
Likert scale,
n cost analys
characters.
ip bundle
ciated with
ent selection
plementatio
r key
de medicatio
i‐centered,
d with CDI w
rollment.
from an in‐
tion (Y/N) of
The antimicr
the patient
atient would
ducation
‐up phone ca
up appointm
1 to 5, with
sis, patient
n,
on of
on
who
f
robial
for
d
all
ment
5
*Special sy
satisfacti
were use
Results: A
for exclu
prescript
median d
4 compo
complete
patients.
prior to d
service b
time of t
reported
patients
prescript
percent.
Conclusio
system a
impleme
expansio
ymbols that w
ion with TOC
ed to analyze
Among 133
sion was dis
tions for ora
duration of t
nents were
ed in 50.8 pe
The most co
discharge at
bundle per pa
he call, 87 p
d any medica
had addition
tions per pat
on: The imp
ddresses sev
ntation cost
on.
2018ASProf
ere not spelled
C service, an
e service‐rel
patients eva
scharge to a
l vancomyci
therapy rem
completed s
ercent of pat
ommon reas
off‐site cam
atient. Patie
ercent of pa
ation‐related
nal medicati
tient. Among
lementation
veral barrier
ts and long t
SHPMidyfessional
d‐out per the g
d 30‐ and 90
ated outcom
aluated, 63 p
rehabilitatio
n (74.6 perc
aining at dis
successfully
tients; and a
son for an in
mpuses. An a
ent satisfacti
atients repor
d problems.
ons filled, av
g evaluable
n of a TOC st
rs to success
term impact
yearClinlPoster
guidelines wer
0‐day CDI re
mes.
patients wer
on or nursing
cent), 6.3 pe
scharge was
in 38.1 perc
at least 2 of t
ncomplete b
verage of 82
on with the
rted antibiot
In addition t
veraging 2.3
patients (n e
tewardship b
sful CDI treat
on recurren
nicalMeAbstrac
re translated i
ecurrence rat
re included.
g facility. Of
rcent were d
10.0 days (i
cent of patie
the 4 were c
undle was m
2 minutes w
service was
tic adherenc
to the CDI an
34 (standard
equals 60), 3
bundle at a m
tment at ho
nt CDI will be
eetingcts
into unknown
tes. Descript
The most co
f the patient
discharged o
nterquartile
ents; at least
completed in
missed medi
was spent fac
s 4.8 on a 5.0
ce, and 2.4 p
ntibiotic, 44
deviation 2
30‐day recur
multi‐campu
ospital discha
e valuable to
characters.
tive statistic
ommon reas
s with
on a taper. T
e range 8‐12
3 of the 4 w
n 87.3 perce
cation delive
cilitating the
0 scale. At th
percent patie
.8 percent o
.11)
rrence was 5
us hospital
arge. The
o support se
cs
son
The
). All
were
ent of
ery
he
ents
of
5
rvice
*Special sy
Session‐B
Poster Ti
Poster Ty
Submissi
Primary A
Email: yv
Addition
Zach McC
Melinda
Jon Herse
Heidi Ma
Purpose:
initiative
contracts
costs, 3)
institutio
value ove
Methods
identifies
health ca
these chr
disease,
and phar
challenge
is patient
missing,
establish
program
services a
ymbols that w
Board # ‐ 7‐0
itle: Populat
ype: Evaluat
ion Category
Author: Yve
vholman@lh
al Authors:
Call McCall
Muller
en
ahoney
: Care Suppo
. CSR provid
s. The purpo
enhance the
on can meet
er volume.
s: CSR patien
s members a
are costs, an
ronic condit
diabetes or
rmacist. An
es to improv
t‐specific. U
taken but no
hed collabora
, patients wo
and improve
2018ASProf
ere not spelled
031
tion health s
tive Study
y: Clinical Se
tte Holman;
hs.org
ort Resource
des populati
ose of the CS
e patient exp
the demand
nts are selec
at risk for fut
d whose hea
ions: asthma
heart failure
assessment
ving health a
Using drug us
ot needed, o
ative drug th
ork to modif
e health outc
SHPMidyfessional
d‐out per the g
ervice: utiliz
ervices Mana
; Legacy Hea
es (CSR) is at
on managem
SR program a
perience, 4)
ds of a rapid
cted for the p
ture emerge
alth care usa
a, chronic ob
e. Patients a
is complete
are identified
se review, m
or dose adju
herapy mana
fy their heal
comes.
yearClinlPoster
guidelines wer
zing care sup
agement
alth;
the heart o
ment service
are to 1) imp
enhance the
ly transform
program usi
ency departm
age can be im
bstructive pu
are assigned
ed with the p
d, and a care
medications a
stments nee
agement agr
th behaviors
nicalMeAbstrac
re translated i
pport resour
f our institu
es to patient
prove popul
e provider e
ming health c
ng a data dr
ment and in
mpacted. Pa
ulmonary di
a nurse cas
patient's inp
e plan is dev
are identifie
eded. Pharm
reements. W
s to reduce t
eetingcts
into unknown
rces to impro
tion's Care T
ts covered b
ation health
experience s
care system
riven predict
patient utiliz
atients must
sease, coron
e manager o
ut, goals are
veloped. The
d that may b
macists work
While enrolle
their need fo
characters.
ove care
Transformat
y risk based
h, 2) reduce
o that the
that prioriti
tive model t
zation, high
t have one o
nary artery
or health coa
e selected,
e pharmacist
be indicated
within
ed in the CS
or health ca
tion
zes
hat
f
ach,
t role
d but
R
re
*Special sy
Results:
coaches)
managem
times mo
Among d
percent v
Reduced
to the pa
reduction
expenses
million d
Patient e
Ninety pe
personal
Provider
their pra
Conclusio
also redu
disease s
program
ymbols that w
Population h
focus on ca
ment. Amon
ore likely tha
diabetic patie
vs 89 percen
cost: Emerg
atient startin
n in ED visits
s for CSR pat
ollars to the
experience: S
ercent of pa
goals.
experience:
ctice and pa
on: The CSR
ucing utilizat
states being
s such as CS
2018ASProf
ere not spelled
health: The
re gap closu
ng patients e
an non‐CSR p
ents, CSR me
nt) to have re
gency room
ng in the pro
s and 31 per
tients declin
e health syste
Survey data
tients repor
: Seventy fou
atients.
program is
tion and cost
taken on. A
R will becom
SHPMidyfessional
d‐out per the g
clinical team
ures such as
eligible for co
patients (76
embers wer
eceived a he
(ED) and inp
ogram to 1 ye
rcent reducti
ed by 32 pe
em for the m
assessing pa
rted they cou
ur percent o
improving th
t. Program e
As our health
me even mor
yearClinlPoster
guidelines wer
m (pharmaci
colorectal sc
olorectal can
percent vs 6
e 2.5 times m
emoglobin A
patient utiliz
ear after pro
ion in inpati
rcent. This e
managemen
atient satisfa
uld positivel
of providers r
he experienc
expansion is
h system con
re vital.
nicalMeAbstrac
re translated i
sts, nurse ca
creening and
ncer screeni
63 percent)
more likely t
A1c screening
zation was m
ogram initiat
ent visits. Ad
equates to a
t of 182 mem
action post‐e
y affect thei
reported the
ce of our pa
s planned wi
ntinues to tr
eetingcts
into unknown
ase manager
d chronic dis
ing, CSR pati
to have rece
than non‐CS
g.
measured fro
tion. We fou
dditionally, m
n annual sav
mbers.
enrollment w
ir own healt
e program w
tients and p
ith new lives
ransition to v
characters.
rs and healt
sease state
ients were 1
eived an exa
SR patients (9
om 1 year pr
und a 24 per
monthly me
vings of one
was measur
h and had se
was valuable
providers, wh
s and additio
value based
h
1.8
am.
95
rior
rcent
edical
ed.
et
to
hile
onal
care,
*Special sy
Session‐B
Poster Ti
specialty
Poster Ty
Submissi
Primary A
Email: ke
Addition
Jenna Gia
Oliver Go
Daniel Lo
Aaron W
Purpose:
annually
ownersh
reminder
adherenc
impact o
medicati
satisfacti
Methods
from Nov
institutio
both gro
the chron
human im
from the
group (n=
came at
did not re
proportio
ymbols that w
Board # ‐ 7‐0
itle: Impact
y chronic dise
ype: Evaluat
ion Category
Author: Kell
elly.mathew
al Authors:
anninoto
oal
ok
Wilkerson
: Per Mcmul
due to patie
ip rates are
rs presentin
ce, persisten
f SMS remin
on. Seconda
ion for susta
s: This retros
vember 1, 20
onal review b
ups were ag
nic specialty
mmunodefic
specialty ph
=555) receiv
no cost to p
eceive any S
on of days co
2018ASProf
ere not spelled
032
of short mes
eases at a sp
tive Study
y: Clinical Se
ly Mathews;
len et al. (2
ent lack of a
at an all‐tim
g as an inexp
nce and outc
nders on a pa
ary objective
ainability of t
spective, cha
016 through
board from t
ge of 18 year
y disease stat
ciency virus (
harmacy for
ved bi‐direct
atients if the
SMS reminde
overed (PDC
SHPMidyfessional
d‐out per the g
ssaging serv
pecialty phar
ervices Mana
Avella Spec
m
015), health
dherence an
me high in the
pensive and
comes. The p
atient’s adhe
es were to m
the program
art review ev
h November,
the Universit
rs old or olde
tes self‐adm
(HIV), and in
at least 3 m
tional text m
ey had an un
ers. Adheren
C). Duration
yearClinlPoster
guidelines wer
ice (SMS) te
rmacy
agement
cialty Pharm
hcare costs a
nd not taking
e United Sta
simple‐to‐u
primary obje
erence rate
measure the
m.
valuated pat
, 30 2017 an
ty of Arizona
er by the sta
ministered m
nflammatory
months (at le
message dose
nlimited text
nce was mea
of therapy w
nicalMeAbstrac
re translated i
echnology in
acy;
are estimate
g medication
ates, with sh
use opportun
ective of this
to a self‐adm
duration of
tient record
nd was grant
a in Tucson,
art of the stu
edications f
y conditions,
ast 1 month
e and/or refi
t plan. The n
asured utiliz
was calculate
eetingcts
into unknown
patient out
d at $105‐29
n as prescrib
ort messagi
nity to impro
s study was t
ministered s
therapy and
s at a specia
ted exempt s
AZ. Inclusio
udy period, r
for cancer, h
, and receivi
h for hepatiti
ill reminders
non‐SMS gro
ing refill rec
ed utilizing r
characters.
comes with
90 billion
bed. Cell pho
ng service (S
ove medicat
to evaluate
specialty
d patient
alty pharmac
status from
on criteria fo
receiving on
epatitis C,
ing medicati
is C). The SM
s. The progra
oup (n=17,33
ords to calcu
refill records
one
SMS)
tion
the
cy
the
r
e of
on
MS
am
35)
ulate
s. The
*Special sy
SMS grou
thereafte
independ
percenta
Results: A
significan
diseases
96.5% fo
the non‐S
patients
PDC for h
(P=0.92).
the non‐S
days, P<0
inflamma
group co
grade of
Conclusio
and infla
significan
patients
with ease
the utiliz
ymbols that w
up received
er. Continuo
dent t‐test. C
ages. P<0.05
A total of 17
nt difference
(P<0.001). T
r the SMS gr
SMS group a
was 95.7% f
hepatitis C p
. Median du
SMS group f
0.001), hepa
atory condit
mpleted the
A or B for he
on: The SMS
mmatory co
ntly prolonge
with cancer
e of use and
ation of SMS
2018ASProf
ere not spelled
satisfaction
ous variables
Categorical a
was conside
7,890 patien
e in age betw
The median
roup (P<0.00
and 91.9% fo
for the non‐S
patients was
uration of th
for all group
atitis C (106 v
ions (162 vs
e satisfaction
elpfulness in
S program w
onditions and
ed duration
, HIV, hepat
helpfulness
S in a broade
SHPMidyfessional
d‐out per the g
survey via t
s were repor
and binary v
ered statistic
ts were eval
ween groups
PDC for HIV
01). The med
or the SMS g
SMS group a
100.0% for t
erapy was s
s: patients r
vs 101 days,
160 days, P
n survey and
n managing t
was associate
d significant
of therapy w
itis c and inf
s was found
er patient po
yearClinlPoster
guidelines wer
ext 60 days
rted as medi
variables wer
cally signific
luated. For b
s was identif
patients wa
dian PDC for
group (P=0.2
and 95.8% fo
the non‐SM
ignificantly g
eceiving me
P<0.001), H
P<0.001). Fif
d 93% of tho
their health
ed with impr
ly improved
which may le
flammatory
with the SM
opulation w
nicalMeAbstrac
re translated i
post enrollm
ans then co
re reported
ant.
baseline cha
fied in oncol
as 94.63% fo
r inflammato
23). The me
or the SMS g
S group and
greater in th
edications fo
HIV (396 vs 3
fty‐two perc
ose patients
and ease of
roved adher
d adherence
ead to impro
conditions. A
MS program.
ithin special
eetingcts
into unknown
ment, then e
mpared with
as frequenc
aracteristics,
ogy and infl
or the non‐SM
ory patients
dian PDC for
group (P=0.7
d 100.0% for
he SMS grou
or oncology (
389, P<0.05),
cent of patie
rated the pr
f use.
ence in pati
in HIV patie
oved clinical
A high patie
Further stud
lty chronic d
characters.
every 6 mont
h the
cies and
only a
ammatory
MS group an
was 90.4% f
r oncology
79). The med
the SMS gro
p compared
(340 vs 266.5
, and
nts in the SM
rogram a let
ents with ca
ents. It also
l outcomes i
ent satisfacti
dies can vali
diseases.
ths
nd
for
dian
oup
d to
5
MS
ter
ancer
n
on
idate
*Special sy
Session‐B
Poster Ti
on hospit
Poster Ty
Submissi
Primary A
Email: sn
Addition
Carrie Kr
Heather
Hannah D
Alan Zillic
Purpose:
all‐cause
Methods
Midwest
pharmac
patient w
the patie
educatio
design w
outpatie
thirteen
observat
period w
days afte
regressio
TOC prog
baseline
ymbols that w
Board # ‐ 7‐0
itle: Evaluati
tal readmiss
ype: Evaluat
ion Category
Author: Ma
nyderme@p
al Authors:
ekeler
Jaynes
Davis
ch
: To measure
readmission
s: In 2015, a
ern acute ca
cist reviews t
with their pri
ent to confirm
n/interventi
was used to e
nt clinics we
PCPs (interv
ion period) a
were included
er discharge.
on models w
gram and 30
healthcare u
2018ASProf
ere not spelled
033
ing the effec
sions
tive Study
y: Clinical Se
rgie Snyder;
urdue.edu
e the effect
n.
pharmacist‐
are hospital.
the patient’s
imary care p
m receipt of
ions as need
evaluate the
ere matched
vention coho
and discharg
d in the usua
. The primar
were construc
0‐day readm
utilization. T
SHPMidyfessional
d‐out per the g
cts of a mult
ervices Mana
Purdue Uni
of a pharma
‐initiated tra
At the time
s medication
physician (PC
f all discharg
ded to ensur
program. D
on patient p
ort) received
ge patients s
al care coho
ry outcome
cted to evalu
issions. Mod
This evaluatio
yearClinlPoster
guidelines wer
tidisciplinary
agement
versity Colle
acist‐initiated
ansitions of c
e of discharg
n action plan
CP) is schedu
ge medicatio
re optimal ph
uring progra
panel size an
d the program
seen by the
rt. Patients i
was 30‐day
uate the ass
dels controll
on was appr
nicalMeAbstrac
re translated i
y transition c
ege of Pharm
d transitions
care program
e, the transi
n, ensures a
uled within 1
ons, and prov
harmacothe
am impleme
nd clinic loca
m from 9/20
other 12 PC
in both coho
all‐cause re
sociation bet
ed for patie
roved by the
eetingcts
into unknown
care manage
macy;
s of care pro
m began at a
ition of care
follow‐up vi
14 days of di
vides
erapy. A retro
entation, 25
ation. Discha
015 – 6/2016
Ps during th
orts were fo
admissions.
tween patie
nt demogra
e institutiona
characters.
ement progr
ogram on 30
a medium si
(TOC)
isit for the
ischarge, cal
ospective co
PCPs from 4
arged patien
6 (our study
he same time
llowed for 9
Logistic
nt receipt of
phics and
al review bo
ram
‐day
zed
lls
ohort
4
nts of
e
0
f the
oard.
*Special sy
Results: A
the usua
were rea
controllin
Further a
physician
Conclusio
all‐cause
ymbols that w
A total of n=
l care cohor
admitted fro
ng for co‐var
analyses will
ns within clin
on: A pharm
readmission
2018ASProf
ere not spelled
= 492 patien
t. Among int
m the usual
riates (p=0.0
examine th
nics.
macist‐initiat
ns.
SHPMidyfessional
d‐out per the g
ts received t
tervention p
care cohort
002), (odds
e influence
ed transition
yearClinlPoster
guidelines wer
the TOC inte
patients, 9%
t. This differe
ratio: 2.01, 9
of patient cl
ns of care pr
nicalMeAbstrac
re translated i
ervention an
were readm
ence was sta
95% confide
lustering wit
rogram was
eetingcts
into unknown
nd n=379 we
mitted in 30 d
atistically sig
ence interval
thin physicia
effective in
characters.
ere followed
days vs. 15%
gnificant afte
l: 1.28‐3.16)
ans and
reducing 30
in
%
er
.
0‐day
*Special sy
Session‐B
Poster Ti
Poster Ty
Submissi
Primary A
Email: ka
Addition
Dallas Sc
Andrew D
Tejal Pat
Purpose:
must ma
acetamin
its oral e
develope
parenter
acetamin
This anal
appropri
Methods
generate
were rev
demogra
duration
concomit
surgical a
Descripti
Complian
use, the
contraind
agents. P
ymbols that w
Board # ‐ 7‐0
itle: Parenta
ype: Evaluat
ion Category
Author: Kar
aren.trenkle
al Authors:
hepers
DeSio
el
: Pharmacy r
nage medica
nophen beca
quivalent. To
ed to ensure
ral formulati
nophen into
ysis was und
ateness of o
s: Electronic
ed. The EMR
viewed. Key
aphics; lengt
; acetamino
tant analges
and medical
ive statistics
nce with hos
patient mus
dication to r
Perioperativ
2018ASProf
ere not spelled
034
al acetamino
tive Study
y: Clinical Se
en Trenkler;
represents 1
ation cost/b
ame availabl
o address th
e rational use
on exceeds
surgical mu
dertaken to
order sets in
Medical Rec
Rs of all adul
data eleme
h of stay; dia
ophen indica
sics; and abil
indications,
were used t
spital guideli
t have met a
rectal route a
vely, acetam
SHPMidyfessional
d‐out per the g
ophen use an
ervices Mana
; Mount Sina
10‐20% of th
benefit witho
e as a paren
his potential
e. Subseque
oral by over
lti‐modal an
determine c
managing p
cord (EMR)
t patients fo
nts were ext
agnosis and,
ation, order
lity to tolera
, mean or m
to interpret
ines was eva
all of the fol
and a contra
inophen is li
yearClinlPoster
guidelines wer
nalysis at a c
agement
ai Hospital, C
he typical ho
out comprom
nteral formu
budgetary i
ently, the co
r six hundred
nalgesia orde
compliance w
parenteral ac
reports of pa
or whom par
tracted from
, if a surgica
detail and n
ate oral/rect
medians dete
the results.
aluated. For
lowing crite
aindication t
isted on pre‐
nicalMeAbstrac
re translated i
community t
Chicago;
spital budge
mising clinica
ulation at con
mpact, hosp
ost disparity
d‐fold. With
er sets, its us
with hospita
cetaminophe
arenteral ac
renteral acet
m the EMR in
l procedure,
number of d
al routes. Re
ermined, and
r compliance
ria: contrai
to non‐stero
‐operative a
eetingcts
into unknown
teaching hos
et. Hospital p
al outcomes
nsiderably g
pital guidelin
widened su
recent integ
se necessari
al guidelines
en use.
cetaminophe
taminophen
ncluding pat
, surgical dia
oses admini
esults were d
d ranges det
e with guide
indication to
oidal anti‐inf
and post‐ope
characters.
spital
pharmacists
s. In 2010,
reater cost t
nes were
uch that the
gration of
ly expanded
and
en usage we
n was dispen
ient
agnosis and
stered;
delineated b
tailed.
lines of gene
o oral route,
lammatory
erative orde
than
d.
ere
nsed
by
eral
r
*Special sy
sets, whi
indicatio
inclusion
(within 2
use for su
and post
delineate
Institutio
Results:
during Q
perioper
Acetamin
average
Of the 11
five preo
only. Pre
appropri
94%) rec
postoper
Thirty‐fiv
the hosp
were adm
two (28%
routine a
provided
of genera
Conclusio
for gener
perioper
administ
patients
differenc
orally pre
consisten
acetamin
ymbols that w
ch cite that
ns to oral ro
n of analgesic
24 hours of s
urgical patie
operative) a
ed based on
onal Review
One hundre
Quarter IV of
atively (96%
nophen was
number of d
13 periopera
operatively, t
eoperative a
ate. On ave
eived only o
ratively for a
ve patients w
ital postope
mitted, forty
%) received g
acetaminoph
d to varying d
al surgery.
on: Analysis
ral use are st
ative use ide
ered intraop
can receive
ce in post‐op
eoperatively
nt provision
nophen orall
2018ASProf
ere not spelled
the intraven
oute; pre‐che
cs; prescribe
urgery) was
ents was deli
and by surge
surgery typ
Board appro
d seventeen
2017. One
%) and four (4
used appro
doses per pa
ative patient
two both pre
and immedia
erage, 1.2 do
one dose. O
a period long
were dischar
eratively. Ev
y‐nine ( 62%
gabapentin p
hen orally su
degrees base
of data dem
tringent; thu
entified opp
peratively. A
a preoperat
perative pain
y vs. intraven
of broader m
ly and increa
SHPMidyfessional
d‐out per the g
nous route is
ecking is not
ers have pref
based on co
ineated by t
ery type. Pro
e.
oved.
n (117) adul
hundred thi
4) received a
priately, per
tient was tw
ts, ninety‐nin
eoperatively
ate postoper
oses were ad
One patient
ger than the
rged the day
aluating the
) received no
postoperativ
ubsequent to
ed on surger
monstrated a
us, medical u
ortunities fo
Although th
tive dose ora
n scores whe
nously intrao
multi‐modal
ased non‐ste
yearClinlPoster
guidelines wer
s to be limite
t used on the
ference. Ap
ontra‐indicat
he operative
ovision of m
t patients re
rteen (113)
acetaminoph
r institution
wo.
ne (88%) rec
y and postop
rative period
dministered
received int
patient had
y of surgery;
e multi‐moda
on‐steroidal
vely. Twenty
o intravenou
ry type: 45%
appropriate
use represen
or improvem
e IV formula
ally. A recent
en patients w
operatively.
analgesia w
eroidal and
nicalMeAbstrac
re translated i
ed to those
e order sets
ppropriatene
tion to oral
e setting (pr
multi‐modal a
eceived acet
received ace
hen for med
guidelines, f
ceived aceta
peratively, a
d use (within
per patient
travenous ac
d contraindic
eighty (80)
al analgesia
l anti‐inflam
y‐three (23)
us dose(s).
% of obstetri
use for med
nted only 4.2
ment: most a
ation is requ
t publication
were admini
Another are
with an emph
/or gabapen
eetingcts
into unknown
patients wit
for either ro
ess of periop
route. Ac
reoperative,
analgesia wa
taminophen
etaminophe
dical indicati
for all medic
minophen in
nd seven po
n 24 hours o
(range 1 to 9
cetaminophe
cation to the
) patients we
aspect: of th
matory agen
of the 80 (2
Multi‐moda
ics/gynecolo
dical indicati
2%. Convers
acetaminoph
uired intraop
n demonstra
istered aceta
ea for impro
hasis on con
ntinoid use,
characters.
th contra‐
oute or the
perative use
cetaminoph
intraoperat
as detailed a
intravenous
n
ons (4%).
cal patients;
ntraoperativ
ostoperative
f surgery) w
9); most (10
en routinely
e oral route.
ere admitted
he eighty wh
nts and twen
29%) receive
al analgesia w
ogical versus
ons. Guideli
sely, analysis
hen (86%) w
peratively, m
ated no
aminophen
ovement is th
ntinuation of
if appropria
en
tive
and
sly
the
vely,
ly
was
06 or
y
d to
ho
nty‐
ed
was
s 20%
ines
s of
as
many
he
f
te.
*Special sy
Session‐B
Poster Ti
and the b
Poster Ty
Submissi
Primary A
Email: hu
Addition
Fadia Sha
Magaly R
Purpose:
utilizing c
medicati
clinical p
pharmac
need to i
pharmac
clinical p
Methods
version o
pharmac
then revi
multiple‐
participa
visited ty
pharmac
examined
forth sec
with app
additiona
expectat
ymbols that w
Board # ‐ 7‐0
itle: Prelimin
barriers to u
ype: Evaluat
ion Category
Author: Huy
uyen.vu@cn
al Authors:
aya
Rodriguez de
: The study i
clinical phar
ons dispens
harmacy ser
cists has not
nvestigate t
cists to prom
harmacy ser
s: The institu
of the survey
cists, and pha
ised followin
‐choice ques
nts’ patient
ypes of phar
cists provide
d their perce
ction investig
licable ques
al thoughts a
ions of phar
2018ASProf
ere not spelled
035
nary results
tilizing phar
tive Study
y: Clinical Se
yen Vu; Calif
nsu.edu
e Bittner
nvestigates
macy service
ing to comp
rvices remai
yet been ad
the barriers t
mote the cap
rvices.
utional revie
y was based
armacy stud
ng the feedb
stions and 3
demograph
macies. The
and recorde
eption of, co
gated the ba
tions. The la
about the ba
rmacists. Usi
SHPMidyfessional
d‐out per the g
of a nationa
rmacy servic
ervices Mana
fornia North
the public’s
es. Pharmac
lex disease s
ns low. Desp
dequately stu
to utilizing p
abilities of p
w board gra
on publishe
dents. The su
back of 36 pa
open‐ended
hic informati
second sect
ed what serv
onfidence an
arriers to uti
ast section c
arriers to uti
ng Survey M
yearClinlPoster
guidelines wer
al public surv
es
agement
state Univer
perception
cist roles and
state manag
pite this, the
udied nation
pharmacy se
pharmacists
anted exemp
ed literature
urvey was te
articipants. T
d questions.
on, frequenc
tion investig
vices the pub
nd trust in, a
lizing pharm
omprised of
ilizing pharm
Monkey Audi
nicalMeAbstrac
re translated i
vey on the p
rsity College
of pharmac
d responsibil
gement. How
e general pu
nwide. There
ervices and t
and to incre
ption status
and the inp
est‐launched
The revised s
The first sec
cy of visiting
gated their k
blic had utili
and advantag
macy services
f free text co
macists and p
ience Servic
eetingcts
into unknown
erception of
e of Pharmac
cists and the
lities have e
wever, patie
blic’s percep
efore, there
he public’s p
ease patient
for this stud
ut of researc
d for 3 month
survey conta
ction collect
g a pharmac
knowledge o
ized. The thi
ges of pharm
s. The Likert
omments to
personal vie
e, the surve
characters.
f pharmacist
cy;
barriers to
xpanded fro
nt utilization
ption of
is a pressing
perception o
enrollment
dy. The initia
chers,
hs in 2017 a
ained 47
ted the surve
y, and most
f what servi
ird section
macists. The
scale was u
record any
ws and
y was
ts
om
n of
g
of
in
al
nd
ey
ces
sed
*Special sy
distribute
people w
informat
roles, an
Likert sca
Results: A
Member
identified
participa
month (2
clinical se
had actu
trusted p
thought t
or strong
medicati
multiple‐
regarding
services f
training o
Conclusio
public’s p
Pharmac
professio
this, pha
and prov
ymbols that w
ed nationwi
who were at
ion of the pa
d the barrie
ale question
A total of 21
s of all 50 U
d themselve
nts utilized c
27.64 percen
ervices besid
ally utilized
pharmacists
that pharma
gly agreed w
ons. The ma
‐choice ques
g the pharm
from other h
of pharmacis
on: The prel
perception o
cists must ta
onals about t
rmacists can
viding consul
2018ASProf
ere not spelled
de between
least 18 yea
articipants w
rs to utilizing
s and the fre
145 people w
.S. states too
s as female
chain pharm
nt). Although
des dispensi
the addition
to fill their p
acists were a
with the state
ain barriers t
stions and th
macy services
healthcare p
sts.
iminary resu
of pharmacis
ke more init
their capabi
n better prom
ltation on th
SHPMidyfessional
d‐out per the g
April and M
ars old. For p
was analyzed
g pharmacy
ee text comm
with an aver
ok part in th
(51.33 perce
macies (48.63
h the majori
ng medicatio
nal services t
prescriptions
accessible. H
ement that t
to utilizing cl
he free text c
s by pharmac
professionals
ults of the su
sts and the im
tiative to edu
lities and the
mote the we
heir proper u
yearClinlPoster
guidelines wer
May 2018 and
preliminary d
d. Their perc
clinical serv
ments.
age age of 4
e survey. M
ent) and non
3 percent), a
ty believed t
ons and pro
that pharma
s correctly, a
However, on
the pharmac
linical pharm
comments in
cists and oth
s, and a lack
urvey identif
mportant cli
ucate the ge
e rigid traini
ellness of pa
uses
nicalMeAbstrac
re translated i
d collected o
data analysis
ceptions of p
vices were de
48.10 years o
ost of the su
n‐Hispanic W
and most vis
that pharma
viding couns
acists offer. T
and most of
ly 22.29 per
cists should b
macy service
ncluded the
her health ca
of understa
fy the differe
inical service
eneral public
ing that they
tients beyon
eetingcts
into unknown
over 2000 re
s, the demog
pharmacists,
etermined t
old answere
urvey’s parti
White (74.36
sited a pharm
acists could
sel, very few
The participa
them (abou
rcent of part
be able to p
es identified
lack of adve
are professio
anding about
ences betwe
es that phar
c and even o
y must unde
nd dispensin
characters.
esponses fro
graphic
, pharmacist
hrough the
d the survey
icipants
6 percent). M
macy once a
provide diffe
w participant
ants genera
ut 80.41 perc
icipants agre
rescribe
through the
ertisement
onals, comp
t the rigid
een the gene
macists offe
other healthc
ergo. By doin
ng medicatio
om
t
y.
Most
erent
ts
lly
cent)
eed
e
eting
eral
er.
care
ng
ons